[CLS] O
the O
systematic O
availability O
of O
im O
can O
be O
determined O
by O
comparison O
of O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
versus I-PK
time I-PK
curves I-PK
. O
[SEP] O
[CLS] O
the O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
values O
for O
micro O
##cid O
s O
##r O
and O
formulation O
f O
##3 O
were O
124 O
##7 O
##8 O
± O
104 O
. O
21 O
ng O
/ O
m O
##l O
h O
##− O
##1 O
and O
121 O
##45 O
± O
87 O
. O
32 O
ng O
/ O
m O
##l O
h O
##− O
##1 O
, O
respectively O
. O
[SEP] O
[CLS] O
slow O
in O
v O
##it O
##ro O
release O
of O
im O
from O
the O
products O
micro O
##cid O
s O
##r O
and O
f O
##3 O
formulation O
##s O
may O
be O
responsible O
for O
the O
decreased O
au B-PK
##c I-PK
values O
when O
compared O
to O
the O
reported O
conventional O
dos O
##age O
forms O
[ O
19 O
] O
. O
[SEP] O
[CLS] O
the O
average O
value O
of O
the O
individual O
and O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
ratio I-PK
at O
95 O
% O
confidence O
limit O
( O
0 O
. O
8 O
– O
1 O
. O
25 O
) O
was O
within O
acceptable O
limits O
for O
bio O
##e O
##qui O
##valent O
products O
[ O
19 O
] O
. O
[SEP] O
[CLS] O
in O
order O
to O
obtain O
in O
v O
##it O
##ro O
- O
in O
v O
##ivo O
correlation O
, O
drug O
absorption O
profiles O
were O
compared O
for O
micro O
##cid O
s O
##r O
and O
formulation O
f O
##3 O
using O
the O
cumulative B-PK
fraction I-PK
of I-PK
the I-PK
drug I-PK
absorbed I-PK
in O
v O
##ivo O
against O
cumulative B-PK
fraction I-PK
of I-PK
the I-PK
drug I-PK
dissolved I-PK
in O
v O
##it O
##ro O
up O
to O
8 O
h O
. O
from O
the O
study O
it O
was O
noticed O
that O
both O
products O
showed O
an O
adequate O
correlation O
. O
[SEP] O
[CLS] O
currently O
accepted O
criteria O
in O
the O
us O
for O
bio O
##e O
##qui O
##valence O
for O
most O
dos O
##age O
forms O
require O
that O
the O
mean O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
the O
test O
dos O
##age O
forms O
should O
be O
within O
80 O
– O
120 O
% O
of O
the O
reference O
dos O
##age O
form O
using O
90 O
% O
confidence O
interval O
. O
[SEP] O
[CLS] O
the O
observed O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
##val O
##ues O
for O
micro O
##cid O
s O
##r O
and O
formulation O
f O
##3 O
were O
126 O
##32 O
± O
132 O
. O
12 O
ng O
/ O
m O
##l O
. O
h O
##− O
##1 O
and O
124 O
##5 O
##2 O
± O
96 O
. O
32 O
ng O
/ O
m O
##l O
. O
h O
##− O
##1 O
which O
does O
not O
show O
any O
significant O
statistical O
difference O
between O
the O
products O
. O
[SEP] O
[CLS] O
however O
, O
rapid B-PK
##mu I-PK
##co I-PK
##ci I-PK
##lia I-PK
##ry I-PK
clearance I-PK
in O
nasal O
cavity O
is O
a O
major O
h O
##ur O
##dle O
. O
[SEP] O
[CLS] O
the O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
the O
serum O
concentration O
of O
25 O
( O
oh O
) O
d O
up O
to O
day O
28 O
[SEP] O
[CLS] O
a O
one O
- O
compartment O
model O
with O
an O
absorption B-PK
la I-PK
##g I-PK
- I-PK
time I-PK
( I-PK
t I-PK
##lag I-PK
) I-PK
best O
described O
the O
data O
. O
[SEP] O
[CLS] O
the O
final O
model O
included O
age O
( O
adult O
; O
aged O
) O
on O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
, O
apparent B-PK
elimination I-PK
rate I-PK
( I-PK
k I-PK
##e I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
t B-PK
##lag I-PK
; O
sex O
( O
female O
; O
male O
) O
on O
k B-PK
##e I-PK
/ I-PK
f I-PK
, O
and O
breed O
( O
be O
##ag O
##le O
; O
mixed O
- O
breed O
) O
on O
v B-PK
##d I-PK
/ I-PK
f I-PK
. O
addition O
of O
the O
co O
##var O
##iate O
##s O
to O
the O
model O
explained O
78 O
% O
of O
the O
inter O
##ind O
##iv O
##idal O
var O
##iability O
( O
ii O
##v O
) O
in O
v B-PK
##d I-PK
/ I-PK
f I-PK
, O
36 O
% O
in O
k B-PK
##e I-PK
/ I-PK
f I-PK
, O
and O
24 O
% O
in O
t B-PK
##lag I-PK
, O
respectively O
. O
[SEP] O
[CLS] O
the O
recovery O
rates O
of O
different O
groups O
were O
similar O
, O
which O
indicated O
that O
there O
was O
no O
relationship O
between O
concentration O
and O
recovery O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
t B-PK
##lag I-PK
was O
longer O
, O
whereas O
v B-PK
##d I-PK
/ I-PK
f I-PK
and O
k B-PK
##e I-PK
/ I-PK
f I-PK
were O
lower O
in O
aged O
compared O
to O
adult O
animals O
; O
in O
female O
aged O
dogs O
k B-PK
##e I-PK
/ I-PK
f I-PK
was O
lower O
than O
in O
male O
aged O
dogs O
; O
however O
, O
the O
differences O
were O
of O
low O
magnitude O
. O
[SEP] O
[CLS] O
this O
study O
was O
conducted O
in O
order O
to O
character O
##ize O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
oral O
##ly O
administered O
c O
##ep O
##hale O
##xin O
to O
healthy O
adult O
and O
aged O
dogs O
, O
using O
a O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
approach O
. O
[SEP] O
[CLS] O
different O
disposition O
of O
c O
##ep O
##hale O
##xin O
may O
be O
expected O
in O
aged O
dogs O
. O
[SEP] O
[CLS] O
finally O
, O
the O
average O
fluorescent O
- O
counts O
in O
each O
experiment O
were O
compared O
with O
non O
- O
trans O
##fected O
cells O
. O
[SEP] O
[CLS] O
when O
the O
per O
##fusion O
rate O
was O
1 O
. O
5 O
μ O
##l O
/ O
min O
, O
the O
average O
recover O
##ies O
measured O
by O
in O
##cre O
##ment O
and O
de O
##cre O
##ment O
method O
were O
47 O
. O
22 O
##± O
##1 O
. O
97 O
% O
and O
49 O
. O
48 O
##± O
##2 O
. O
25 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
two O
hundred O
and O
eighty O
- O
six O
c O
##ep O
##hale O
##xin O
plasma O
concentrations O
obtained O
from O
previous O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
were O
used O
. O
[SEP] O
[CLS] O
after O
a O
wash O
##out O
period O
of O
1 O
week O
, O
the O
next O
cycle O
of O
administration O
was O
carried O
out O
. O
[SEP] O
[CLS] O
each O
of O
the O
les O
##ion O
r O
##oi O
’ O
s O
and O
background O
r O
##oi O
’ O
s O
mean O
counts O
were O
used O
as O
p O
##ois O
##son O
distribution O
mean O
values O
. O
[SEP] O
[CLS] O
the O
e O
##ff O
##lux O
transfer B-PK
constant I-PK
k I-PK
##out I-PK
was O
calculated O
as O
0 O
. O
05 O
min O
##− O
##1 O
, O
equal O
to O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, I-PK
brain I-PK
of O
13 O
. O
8 O
min O
. O
[SEP] O
[CLS] O
a O
two O
- O
part O
, O
phase O
i O
, O
random O
##ized O
, O
five O
- O
period O
crossover O
trial O
in O
healthy O
adults O
( O
aged O
18 O
– O
55 O
years O
) O
was O
conducted O
to O
determine O
the O
dose O
- O
proportional O
##ity O
of O
five O
doses O
of O
f O
##ent O
##any O
##l O
sub O
##ling O
##ual O
spray O
( O
100 O
, O
200 O
, O
400 O
, O
600 O
, O
and O
800 O
μ O
##g O
) O
under O
fast O
##ed O
conditions O
( O
part O
a O
) O
, O
and O
determine O
the O
effects O
of O
temperature O
and O
p O
##h O
in O
the O
oral O
cavity O
on O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
f O
##ent O
##any O
##l O
after O
administration O
of O
f O
##ent O
##any O
##l O
sub O
##ling O
##ual O
spray O
200 O
μ O
##g O
( O
part O
b O
) O
. O
55 O
a O
total O
of O
53 O
subjects O
( O
38 O
female O
, O
15 O
male O
) O
were O
enrolled O
in O
part O
a O
and O
14 O
subjects O
( O
3 O
female O
, O
11 O
male O
) O
were O
enrolled O
in O
part O
b O
. O
subjects O
withdrew O
due O
to O
positive O
urine O
drug O
screen O
( O
n O
= O
2 O
) O
, O
positive O
urine O
alcohol O
screen O
( O
n O
= O
1 O
) O
, O
and O
withdrawal O
of O
consent O
( O
n O
= O
9 O
) O
. O
[SEP] O
[CLS] O
the O
reliability O
of O
the O
ex O
##po O
##nent O
##ial O
fitting O
procedure O
for O
half B-PK
- I-PK
life I-PK
calculations O
was O
assessed O
using O
mon O
##te O
car O
##lo O
simulation O
of O
error O
propagation O
. O
[SEP] O
[CLS] O
a B-PK
##0 I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
values O
were O
fitted O
for O
every O
time O
series O
, O
and O
mean O
and O
standard O
de O
##viation O
##s O
of O
the O
fitted O
parameters O
were O
calculated O
. O
[SEP] O
[CLS] O
[UNK] O
the O
p O
##k O
model O
predict O
##s O
the O
concentrations O
of O
l O
##y O
##25 O
##10 O
##9 O
##24 O
for O
various O
doses O
of O
the O
drug O
. O
[SEP] O
[CLS] O
the O
p O
##k O
/ O
p O
##d O
model O
predict O
##s O
the O
c O
##d O
##34 O
+ O
cell O
response O
to O
repeated O
l O
##y O
##25 O
##10 O
##9 O
##24 O
dos O
##ing O
. O
[SEP] O
[CLS] O
sample O
size O
was O
the O
size O
of O
the O
respective O
r O
##oi O
. O
[SEP] O
[CLS] O
the O
a O
##ero O
##si O
##l O
suspension O
thus O
obtained O
was O
freeze O
dried O
to O
remove O
water O
by O
sub O
##lim O
##ation O
methods O
. O
[SEP] O
[CLS] O
10 O
, O
000 O
random O
numbers O
for O
all O
three O
imaging O
time O
points O
were O
generated O
, O
and O
le O
##ven O
##berg O
- O
ma O
##r O
##qua O
##rd O
##t O
non O
##linear O
fit O
was O
performed O
for O
all O
10 O
, O
000 O
time O
series O
generated O
. O
[SEP] O
[CLS] O
the O
micro O
##em O
##ul O
##sion O
containing O
solid O
ads O
##or O
##bent O
was O
prepared O
as O
described O
in O
spray O
drying O
method O
. O
[SEP] O
[CLS] O
this O
allowed O
us O
to O
assess O
the O
reliability O
of O
the O
a B-PK
##0 I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
values O
. O
[SEP] O
[CLS] O
choosing O
op O
##ti O
##mum O
imaging O
times O
, O
as O
stated O
above O
, O
will O
provide O
more O
reliable O
a B-PK
##0 I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
data O
. O
[SEP] O
[CLS] O
the O
study O
was O
designed O
as O
a O
single O
‐ O
center O
, O
5 O
‐ O
part O
study O
in O
healthy O
subjects O
to O
compare O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
single O
and O
multiple O
doses O
of O
the O
up O
##ada O
##ci O
##tin O
##ib O
er O
formulation O
with O
the O
i O
##r O
formulation O
under O
fast O
##ing O
conditions O
, O
to O
evaluate O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
safety O
, O
and O
to O
##ler O
##ability O
of O
multiple O
doses O
of O
the O
er O
formulation O
, O
and O
to O
assess O
the O
effect O
of O
a O
high O
‐ O
fat O
meal O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
er O
formulation O
. O
[SEP] O
[CLS] O
geometric O
mean O
f O
##xi O
##ii O
t B-PK
##rough I-PK
level I-PK
was O
0 O
. O
17 O
i O
##u O
/ O
m O
##l O
. O
geometric O
terminal B-PK
half I-PK
- I-PK
life I-PK
was O
13 O
. O
7 O
days O
. O
[SEP] O
[CLS] O
sixty O
patients O
were O
exposed O
to O
r O
##f O
##xi O
##ii O
- O
a O
##2 O
; O
their O
median O
age O
was O
26 O
. O
0 O
years O
( O
range O
: O
7 O
. O
0 O
– O
77 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
the O
precision O
( O
c O
##v O
% O
) O
did O
not O
exceed O
20 O
% O
for O
ll O
##o O
##q O
and O
15 O
% O
for O
the O
other O
concentrations O
, O
which O
prove O
the O
close O
##ness O
of O
the O
measurements O
. O
[SEP] O
[CLS] O
the O
quality O
of O
images O
was O
assessed O
using O
a O
3 O
- O
point O
scale O
( O
poor O
, O
fair O
, O
and O
good O
) O
. O
[SEP] O
[CLS] O
re O
##comb O
##ina O
##nt O
factor O
x O
##ii O
##i O
- O
a O
##2 O
( O
r O
##f O
##xi O
##ii O
- O
a O
##2 O
) O
was O
developed O
for O
prop O
##hyl O
##ax O
##is O
and O
treatment O
of O
bleed O
##s O
in O
patients O
with O
con O
##gen O
##ital O
f O
##xi O
##ii O
a O
- O
subunit O
deficiency O
. O
[SEP] O
[CLS] O
a O
##gi O
##lent O
bond O
el O
##ute O
c O
##18 O
, O
50 O
mg O
per O
1 O
m O
##l O
cartridges O
were O
from O
a O
##gi O
##lent O
( O
sa O
##nta O
c O
##lar O
##a O
, O
ca O
) O
. O
[SEP] O
[CLS] O
we O
also O
know O
that O
medium O
energy O
co O
##lli O
##mat O
##ors O
have O
about O
10 O
mm O
resolution O
as O
compared O
to O
0 O
. O
1 O
mm O
range O
of O
alpha O
particles O
. O
[SEP] O
[CLS] O
no O
patients O
withdrew O
due O
to O
lack O
of O
efficacy O
. O
[SEP] O
[CLS] O
all O
other O
re O
##age O
##nts O
were O
of O
analytical O
grade O
and O
obtained O
from O
standard O
commercial O
suppliers O
. O
[SEP] O
[CLS] O
mean O
annual O
##ized O
bleeding O
rate O
( O
a O
##b O
##r O
) O
was O
0 O
. O
04 O
##3 O
/ O
patient O
- O
year O
. O
[SEP] O
[CLS] O
figure O
7 O
shows O
the O
plasma O
ram O
##ip O
##ril O
and O
ram O
##ip O
##ril O
##at O
following O
an O
oral O
dose O
of O
2 O
. O
5 O
mg O
ram O
##ip O
##ril O
in O
the O
same O
subject O
. O
[SEP] O
[CLS] O
seven O
parameters O
are O
required O
to O
model O
the O
i O
##v O
ram O
##ip O
##ril O
experiments O
( O
see O
methods O
) O
: O
c B-PK
##lint I-PK
_ I-PK
l I-PK
, O
c B-PK
##lint I-PK
_ I-PK
k I-PK
and O
f B-PK
##rl I-PK
describe O
the O
liver O
and O
kidney O
metabolism O
of O
ram O
##ip O
##ril O
and O
its O
conversion O
to O
ram O
##ip O
##ril O
##at O
; O
ps B-PK
##l I-PK
and O
ps B-PK
##k I-PK
describe O
the O
rate O
that O
this O
ram O
##ip O
##ril O
##at O
leaves O
the O
liver O
and O
kidney O
and O
enters O
the O
systemic O
circulation O
; O
ps B-PK
##t I-PK
describes O
the O
rate O
that O
ram O
##ip O
##ril O
enters O
the O
in O
##tra O
##cellular O
water O
of O
the O
peripheral O
tissues O
and O
f B-PK
##u I-PK
_ I-PK
cell I-PK
describes O
the O
in B-PK
##tra I-PK
##cellular I-PK
fraction I-PK
un I-PK
##bound I-PK
which O
determines O
the O
ram O
##ip O
##ril O
equilibrium O
volume B-PK
of I-PK
distribution I-PK
. O
[SEP] O
[CLS] O
five O
additional O
parameters O
( O
ad B-PK
, O
a B-PK
, O
t B-PK
, O
a B-PK
##r I-PK
, O
as B-PK
##low I-PK
) O
are O
required O
to O
model O
the O
oral O
ram O
##ip O
##ril O
in O
##test O
##inal O
absorption O
. O
[SEP] O
[CLS] O
none O
of O
the O
reduction O
##s O
in O
im O
##mu O
##no O
##g O
##lo O
##bul O
##in O
is O
##otype O
##s O
were O
considered O
to O
be O
an O
a O
##e O
by O
the O
principal O
investigators O
. O
[SEP] O
[CLS] O
the O
rest O
of O
the O
plasma O
samples O
were O
stored O
at O
− O
##20 O
##° O
##f O
until O
ready O
for O
insulin O
measurements O
and O
[ O
3 O
- O
3 O
##h O
] O
glucose O
trace O
##r O
ass O
##ay O
in O
the O
case O
of O
the O
h O
##yper O
##ins O
##ulin O
##em O
##ic O
- O
e O
##ug O
##ly O
##ce O
##mic O
c O
##lamp O
( O
e O
##g O
##c O
) O
. O
[SEP] O
[CLS] O
p O
##d O
markers O
were O
measured O
by O
valid O
##ated O
methods O
. O
[SEP] O
[CLS] O
the O
activated O
factor O
x O
then O
h O
##ydro O
##ly O
##zed O
a O
ch O
##rom O
##ogenic O
substrate O
( O
s O
##23 O
##37 O
) O
, O
releasing O
a O
ch O
##rom O
##op O
##hore O
( O
para O
##ni O
##tro O
##ani O
##line O
) O
, O
which O
was O
detected O
by O
monitoring O
light O
absorb O
##ance O
at O
405 O
nm O
. O
17 O
the O
factor O
x O
##a O
inhibitor O
ass O
##ay O
consists O
of O
measuring O
the O
difference O
in O
factor O
x O
activity O
( O
p O
##t O
ass O
##ay O
) O
before O
and O
after O
in O
##cu O
##bation O
of O
a O
mixture O
of O
normal O
plasma O
and O
the O
patient O
' O
s O
plasma O
for O
1 O
hour O
at O
37 O
##° O
##c O
. O
[SEP] O
[CLS] O
there O
was O
no O
statistical O
##ly O
significant O
relationship O
( O
zero O
slope O
re O
##gression O
) O
between O
δ O
##δ O
##q O
##t O
##ci O
and O
log O
8 O
- O
oh O
- O
lo O
##xa O
##pine O
concentration O
( O
figure O
4 O
) O
. O
[SEP] O
[CLS] O
r O
##f O
##xi O
##ii O
- O
a O
##2 O
##p O
##rop O
##hyl O
##ax O
##is O
provided O
sufficient O
ha O
##em O
##ost O
##atic O
coverage O
for O
12 O
minor O
surge O
##ries O
without O
the O
need O
for O
additional O
f O
##xi O
##ii O
therapy O
; O
eight O
procedures O
were O
performed O
within O
7 O
days O
of O
the O
patient O
' O
s O
last O
scheduled O
r O
##f O
##xi O
##ii O
- O
a O
##2 O
##dos O
##e O
, O
and O
four O
were O
performed O
10 O
to O
21 O
days O
after O
the O
last O
dose O
. O
[SEP] O
[CLS] O
plasma O
concentration O
- O
time O
profiles O
for O
h O
##c O
in O
the O
fed O
and O
fast O
##ed O
state O
are O
shown O
in O
figure O
1 O
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
fraction O
##al O
values O
for O
oral O
administration O
( O
unless O
otherwise O
indicated O
) O
of O
f B-PK
for O
each O
of O
the O
op O
##io O
##ids O
studied O
were O
as O
follows O
: O
m O
##or O
##phine O
averaged O
0 O
. O
38 O
with O
a O
range O
of O
0 O
. O
15 O
to O
0 O
. O
64 O
; O
tram O
##ado O
##l O
was O
0 O
. O
73 O
males O
and O
0 O
. O
79 O
in O
females O
; O
code O
##ine O
was O
0 O
. O
50 O
; O
me O
##per O
##id O
##ine O
had O
a O
range O
of O
0 O
. O
40 O
to O
0 O
. O
60 O
with O
an O
average O
of O
0 O
. O
50 O
; O
h O
##ydro O
##co O
##don O
##e O
was O
0 O
. O
80 O
; O
o O
##xy O
##co O
##don O
##e O
i O
##r O
had O
a O
range O
of O
0 O
. O
60 O
to O
0 O
. O
87 O
with O
an O
average O
of O
0 O
. O
74 O
, O
which O
was O
similar O
for O
o O
##xy O
##co O
##don O
##e O
c O
##r O
; O
h O
##ydro O
##mor O
##phone O
had O
a O
range O
of O
0 O
. O
52 O
to O
0 O
. O
58 O
with O
an O
average O
of O
0 O
. O
55 O
; O
o O
##xy O
##mor O
##phone O
was O
0 O
. O
10 O
; O
met O
##had O
##one O
was O
0 O
. O
80 O
with O
a O
range O
of O
0 O
. O
10 O
to O
0 O
. O
90 O
; O
f O
##ent O
##any O
##l O
was O
0 O
. O
33 O
for O
the O
oral O
preparation O
, O
0 O
. O
50 O
for O
the O
b O
##uc O
##cal O
, O
and O
0 O
. O
92 O
for O
the O
patch O
; O
and O
b O
##up O
##ren O
##or O
##phine O
averaged O
0 O
. O
63 O
with O
a O
range O
of O
0 O
. O
50 O
to O
0 O
. O
75 O
. O
[SEP] O
[CLS] O
overall O
, O
systemic O
absorption O
of O
single O
oral O
doses O
of O
h O
##c O
- O
er O
20 O
mg O
was O
comparable O
in O
the O
fed O
and O
fast O
##ed O
states O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
estimates O
for O
h O
##c O
in O
the O
fed O
and O
fast O
##ed O
states O
were O
similar O
, O
and O
the O
f B-PK
##rel I-PK
based O
on O
these O
estimates O
was O
close O
to O
100 O
% O
. O
[SEP] O
[CLS] O
the O
mean O
cm B-PK
##ax I-PK
for O
h O
##c O
was O
higher O
in O
the O
fed O
state O
compared O
with O
the O
fast O
##ed O
state O
( O
28 O
. O
86 O
versus O
22 O
. O
74 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
median O
t B-PK
##max I-PK
in O
the O
fed O
and O
fast O
##ed O
states O
was O
approximately O
6 O
and O
8 O
hours O
, O
respectively O
, O
and O
mean O
t B-PK
##½ I-PK
was O
4 O
. O
9 O
and O
6 O
. O
5 O
hours O
, O
respectively O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
for O
h O
##ydro O
##mor O
##phone O
, O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
values O
were O
approximately O
6 O
% O
of O
those O
for O
h O
##c O
and O
were O
similar O
in O
both O
the O
fed O
and O
fast O
##ed O
states O
; O
median O
t B-PK
##max I-PK
was O
approximately O
9 O
hours O
in O
the O
fed O
state O
and O
7 O
hours O
in O
the O
fast O
##ed O
state O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
copper O
sheet O
( O
0 O
. O
76 O
##2 O
mm O
thick O
, O
99 O
. O
9 O
% O
purity O
) O
was O
purchased O
from O
es O
##pi O
metals O
( O
ash O
##land O
, O
ore O
##gon O
, O
united O
states O
) O
, O
and O
natural O
abundance O
ch O
##rom O
##ium O
was O
electro O
##plate O
##d O
by O
four O
star O
finishing O
( O
saint O
lo O
##ui O
##s O
, O
miss O
##our O
##i O
, O
united O
states O
) O
. O
[SEP] O
[CLS] O
six O
patients O
experienced O
11 O
sa O
##es O
, O
which O
were O
di O
##ar O
##r O
##hoe O
##a O
( O
n O
= O
3 O
) O
, O
mac O
##ulo O
##pa O
##pu O
##lar O
r O
##ash O
( O
n O
= O
2 O
) O
, O
pneumonia O
, O
h O
##yper O
##gly O
##ca O
##emia O
, O
d O
##ys O
##p O
##no O
##ea O
, O
s O
##tom O
##ati O
##tis O
, O
vomit O
##ing O
, O
and O
p O
##ap O
##ular O
r O
##ash O
( O
each O
n O
= O
1 O
) O
. O
[SEP] O
[CLS] O
the O
analytical O
column O
was O
a O
c O
##18 O
column O
( O
ve O
##nus O
##il O
x O
##b O
##p O
, O
5 O
μ O
##m O
, O
4 O
. O
6 O
##× O
##15 O
##0 O
mm O
; O
age O
##la O
, O
t O
##ian O
##jin O
, O
people O
’ O
s O
republic O
of O
chin O
##a O
) O
guarded O
with O
a O
re O
##fill O
##able O
pre O
##co O
##lum O
##n O
( O
c O
##18 O
, O
2 O
. O
0 O
##× O
##20 O
mm O
; O
all O
##tech O
, O
le O
##xing O
##ton O
, O
k O
##y O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
fifteen O
men O
( O
28 O
± O
6 O
years O
, O
b O
##mi O
24 O
± O
2 O
kg O
/ O
m O
##2 O
) O
and O
15 O
women O
( O
29 O
± O
7 O
years O
, O
b O
##mi O
21 O
± O
2 O
kg O
/ O
m O
##2 O
) O
of O
ca O
##uca O
##sian O
origin O
, O
aged O
22 O
– O
46 O
years O
, O
participated O
in O
this O
study O
. O
[SEP] O
[CLS] O
sensitivity O
is O
evaluated O
by O
the O
ll O
##o O
##q O
determination O
##s O
, O
which O
are O
defined O
as O
the O
lowest O
concentration O
that O
can O
be O
re O
##lia O
##bly O
and O
re O
##p O
##rod O
##uc O
##ibly O
measured O
in O
at O
least O
three O
replica O
##tes O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
palm O
##ati O
##ne O
in O
group O
a O
was O
significantly O
higher O
than O
those O
of O
groups O
b O
and O
c O
( O
p O
< O
0 O
. O
05 O
) O
, O
but O
the O
difference O
in O
cm B-PK
##ax I-PK
values O
between O
groups O
b O
and O
c O
was O
not O
significant O
( O
p O
> O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
differences O
with O
regard O
to O
t B-PK
##max I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
palm O
##ati O
##ne O
among O
the O
three O
groups O
were O
not O
significant O
. O
[SEP] O
[CLS] O
meanwhile O
, O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
of O
group O
a O
was O
higher O
than O
groups O
b O
and O
c O
, O
whereby O
group O
a O
> O
group O
b O
> O
group O
c O
( O
table O
4 O
) O
; O
however O
, O
the O
differences O
were O
not O
significant O
. O
[SEP] O
[CLS] O
these O
results O
( O
figure O
3 O
( O
c O
) O
) O
indicated O
that O
both O
c O
##nc O
and O
a O
##c O
may O
decrease O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
palm O
##ati O
##ne O
in O
comparison O
to O
r O
##ca O
##e O
alone O
. O
[SEP] O
[CLS] O
peak O
areas O
in O
the O
ch O
##roma O
##to O
##gram O
##s O
for O
the O
spike O
##d O
plasma O
samples O
containing O
the O
above O
lowest O
concentrations O
were O
compared O
with O
the O
signal O
- O
to O
noise O
ratio O
≥ O
10 O
. O
[SEP] O
[CLS] O
more O
##over O
, O
cop O
shows O
that O
plasma O
m O
##or O
##phine O
flu O
##ct O
##uations O
about O
remain O
close O
to O
the O
bounds O
of O
m O
##or O
##phine O
' O
s O
therapeutic O
window O
for O
anal O
##ges O
##ia O
. O
[SEP] O
[CLS] O
we O
modeled O
the O
mi O
##c O
distribution O
with O
1 O
million O
replica O
##tes O
using O
a O
normal O
distribution O
of O
a O
log O
##2 O
geometric O
mean O
mi O
##c O
± O
s O
##d O
and O
then O
back O
transforming O
into O
the O
geometric O
mi O
##c O
. O
[SEP] O
[CLS] O
twenty O
- O
four O
hour O
urine O
collections O
could O
not O
be O
taken O
until O
subjects O
had O
given O
consent O
and O
were O
admitted O
to O
the O
investigation O
##al O
site O
, O
therefore O
estimated O
c O
##rea O
##tin O
##ine O
clearance O
values O
using O
the O
cock O
##croft O
- O
g O
##ault O
equation O
were O
used O
at O
screening O
to O
class O
##ify O
subjects O
with O
varying O
degrees O
of O
re O
##nal O
imp O
##air O
##ment O
, O
to O
achieve O
12 O
subjects O
per O
group O
. O
[SEP] O
[CLS] O
subjects O
were O
subsequently O
re O
- O
classified O
within O
the O
re O
##nal O
imp O
##air O
##ment O
categories O
according O
to O
their O
actual O
serum O
c O
##rea O
##tin O
##ine O
clearance O
values O
obtained O
on O
day O
1 O
, O
resulting O
in O
a O
di O
##sp O
##rop O
##ort O
##ion O
##ate O
number O
of O
subjects O
within O
each O
category O
. O
[SEP] O
[CLS] O
flu O
##cona O
##zo O
##le O
’ O
s O
long O
terminal B-PK
half I-PK
- I-PK
life I-PK
leads O
to O
little O
var O
##iability O
across O
the O
dos O
##ing O
interval O
[ O
20 O
] O
, O
so O
the O
au B-PK
##c I-PK
: I-PK
mi I-PK
##c I-PK
ratio I-PK
also O
was O
calculated O
from O
the O
simulated O
patients O
using O
flu O
##cona O
##zo O
##le O
concentration O
multi O
##plied O
by O
24 O
hours O
and O
divided O
by O
mi O
##c O
. O
[SEP] O
[CLS] O
rats O
had O
been O
bred O
in O
a O
breeding O
room O
( O
12 O
h O
dark O
- O
light O
cycle O
; O
temperature O
was O
23 O
##° O
##c O
± O
2 O
##° O
##c O
and O
humidity O
was O
50 O
± O
5 O
% O
) O
and O
fed O
standard O
laboratory O
food O
and O
water O
for O
a O
week O
to O
a O
##cc O
##lim O
##ati O
##zation O
. O
[SEP] O
[CLS] O
twenty O
male O
s O
##pra O
##gue O
- O
da O
##wley O
rats O
( O
220 O
– O
250 O
) O
g O
were O
obtained O
from O
s O
##han O
ch O
##uan O
##hong O
experimental O
animals O
technology O
co O
. O
, O
l O
##t O
##d O
. O
( O
be O
##iji O
##ng O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
in O
the O
multi O
##var O
##iable O
re O
##gression O
analysis O
only O
at O
##v O
concentrations O
( O
p O
< O
0 O
. O
01 O
) O
and O
r O
##ito O
##na O
##vir O
use O
( O
p O
= O
0 O
. O
02 O
) O
remained O
independently O
associated O
with O
d O
##ys O
##lip O
##ide O
##mia O
. O
[SEP] O
[CLS] O
the O
enhanced O
oral O
absorption O
of O
pm O
##x O
in O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
might O
be O
at O
##tri O
##but O
##able O
to O
the O
following O
factors O
: O
1 O
) O
d O
##ck O
complex O
increased O
the O
lip O
##op O
##hil O
##icit O
##y O
, O
partition O
coefficient O
, O
and O
apparent O
lip O
##oso O
##lub O
##ility O
of O
the O
drug O
in O
the O
in O
##test O
##inal O
membrane O
. O
[SEP] O
[CLS] O
2 O
) O
do O
##ca O
in O
the O
d O
##ck O
can O
disrupt O
the O
in O
##test O
##inal O
barrier O
via O
o O
##cc O
##lu O
##din O
de O
##ph O
##os O
##ph O
##ory O
##lation O
and O
c O
##yt O
##os O
##kel O
##etal O
rear O
##rang O
##ement O
at O
the O
e O
##pit O
##hel O
##ial O
lining O
tight O
junction O
level O
, O
followed O
by O
promotion O
of O
the O
para O
##cellular O
transport O
of O
drug O
; O
more O
##over O
, O
selective O
interaction O
with O
the O
bi O
##le O
acid O
transport O
##ers O
on O
the O
in O
##test O
##inal O
membrane O
may O
facilitate O
trans O
##cellular O
transport O
of O
the O
drug O
. O
18 O
, O
51 O
, O
65 O
3 O
) O
na O
##no O
- O
sized O
drop O
##lets O
so O
##lub O
##ili O
##zing O
the O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
in O
a O
su O
##pra O
##mo O
##le O
##cular O
state O
also O
improved O
the O
oral O
absorption O
of O
the O
drug O
by O
increasing O
the O
di O
##sper O
##si O
##bility O
of O
the O
drug O
complex O
and O
protecting O
the O
complex O
form O
from O
di O
##sso O
##ciation O
, O
thereby O
f O
##ac O
##ilitating O
its O
diffusion O
across O
the O
un O
##st O
##ir O
##red O
water O
layer O
and O
access O
to O
the O
brush O
border O
membrane O
of O
enter O
##ocytes O
. O
66 O
4 O
) O
surf O
##act O
##ant O
- O
induced O
membrane O
fluid O
##ity O
and O
thus O
per B-PK
##me I-PK
##ability I-PK
changes O
potentially O
afforded O
the O
enhanced O
drug O
absorption O
. O
62 O
, O
67 O
[SEP] O
[CLS] O
for O
measuring O
the O
f B-PK
##eca I-PK
##l I-PK
ex I-PK
##cre I-PK
##tion I-PK
rate I-PK
, O
weighing O
the O
f O
##ec O
##es O
collected O
during O
0 O
– O
24 O
, O
24 O
– O
48 O
, O
48 O
– O
72 O
, O
72 O
– O
96 O
, O
96 O
– O
120 O
, O
120 O
– O
144 O
, O
and O
144 O
– O
168 O
hours O
after O
14 O
##c O
- O
h O
##yal O
##uron O
##ic O
acid O
administration O
, O
adding O
di O
##st O
##ille O
##d O
water O
, O
stirring O
to O
make O
ho O
##mogeneous O
with O
the O
p O
##oly O
##tron O
ho O
##mo O
##gen O
##izer O
( O
kin O
##ema O
##tica O
in O
##c O
. O
) O
, O
and O
further O
di O
##lut O
##ing O
to O
100 O
m O
##l O
with O
di O
##st O
##ille O
##d O
water O
, O
the O
0 O
. O
2 O
m O
##l O
was O
transferred O
to O
via O
##ls O
as O
radio O
##act O
##ivity O
samples O
. O
[SEP] O
[CLS] O
neither O
d O
##ha O
nor O
its O
meta O
##bol O
##ites O
( O
m O
##1 O
and O
d O
##ha O
- O
g O
) O
changed O
significantly O
( O
p O
> O
0 O
. O
05 O
) O
in O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
after O
5 O
- O
day O
oral O
doses O
of O
d O
##ha O
or O
a O
##rs O
. O
[SEP] O
[CLS] O
plasma B-PK
concentration I-PK
ma I-PK
##xi I-PK
##ma I-PK
occurred O
at O
a O
median O
t B-PK
##max I-PK
of O
40 O
minutes O
to O
1 O
hour O
after O
all O
treatments O
, O
and O
the O
u O
##rina O
##ry O
ex O
##cre O
##tion O
parameters O
f B-PK
##e I-PK
##0 I-PK
‐ I-PK
36 I-PK
and O
c B-PK
##l I-PK
##r I-PK
, I-PK
0 I-PK
‐ I-PK
36 I-PK
were O
comparable O
between O
the O
treatments O
( O
table O
s O
##1 O
) O
. O
[SEP] O
[CLS] O
graphical O
comparisons O
of O
individual O
and O
geometric O
mean O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
t I-PK
##z I-PK
and O
cm B-PK
##ax I-PK
values O
are O
given O
in O
figure O
s O
##3 O
. O
[SEP] O
[CLS] O
excluded O
from O
the O
study O
were O
: O
women O
of O
child O
- O
bearing O
potential O
without O
reliable O
con O
##tra O
##ception O
, O
pregnant O
or O
la O
##ct O
##ating O
women O
, O
persons O
with O
any O
disease O
likely O
to O
disturb O
the O
vitamin O
k O
metabolism O
such O
as O
bleeding O
or O
th O
##rom O
##boe O
##mbo O
##lic O
history O
( O
acute O
or O
persistent O
) O
or O
d O
##ys O
##function O
##s O
of O
in O
##test O
##inal O
lip O
##id O
absorption O
( O
c O
##ro O
##hn O
’ O
s O
disease O
, O
ch O
##ole O
##static O
liver O
diseases O
) O
. O
[SEP] O
[CLS] O
ta O
and O
me O
##p O
##b O
treatment O
significantly O
increased O
s O
##b O
##ma O
fly O
via O
##bility O
in O
ad O
##ose O
- O
dependent O
manner O
( O
fi O
##g O
. O
1 O
##b O
, O
c O
) O
, O
similar O
##to O
the O
known O
a O
##r O
antagonist O
bi O
##cal O
##uta O
##mi O
##de O
, O
whereas O
an O
a O
##r O
- O
unrelated O
compound O
, O
i O
##bu O
##p O
##ro O
##fen O
, O
did O
not O
( O
supplement O
##ary O
fi O
##g O
. O
1 O
) O
. O
[SEP] O
[CLS] O
the O
u O
##v O
absorption O
was O
measured O
at O
full O
spectrum O
( O
200 O
‐ O
300 O
nm O
) O
and O
at O
215 O
nm O
. O
[SEP] O
[CLS] O
the O
primary O
end O
##point O
was O
the O
natural O
log O
parasite O
reduction O
rate O
per O
24 O
h O
. O
secondary O
end O
##points O
were O
the O
first O
- O
order O
parasite O
clearance O
rate O
constant O
and O
derived O
half O
- O
life O
( O
estimated O
with O
the O
online O
worldwide O
anti O
##mal O
##aria O
##l O
resistance O
network O
[ O
w O
##war O
##n O
] O
tool O
##ki O
##t O
) O
, O
para O
##si O
##ta O
##emia O
reduction O
times O
( O
50 O
% O
, O
80 O
% O
, O
90 O
% O
, O
and O
99 O
% O
) O
, O
parasite O
clearance O
time O
, O
26 O
, O
27 O
, O
28 O
game O
##to O
##cy O
##ta O
##emia O
reduction O
, O
and O
fever O
clearance O
time O
. O
[SEP] O
[CLS] O
consistent O
with O
these O
results O
, O
both O
ta O
and O
##me O
##p O
##b O
significantly O
restored O
lo O
##com O
##oto O
##r O
function O
in O
flies O
expressing O
##pol O
##y O
##q O
- O
expanded O
a O
##r O
in O
motor O
neurons O
( O
ok O
##37 O
##1 O
> O
u O
##as O
- O
a O
##r O
##5 O
##2 O
##q O
) O
, O
measured O
as O
##in O
##cre O
##ase O
##d O
displacement O
and O
velocity O
of O
walking O
in O
adult O
flies O
( O
fi O
##g O
. O
1 O
##d O
– O
f O
) O
, O
to O
similar O
levels O
observed O
in O
flies O
##ex O
##pressing O
a O
##r O
variants O
that O
m O
##od O
##ulate O
core O
##gu O
##lator O
binding O
to O
the O
a O
##f O
##2 O
domain O
( O
ok O
##37 O
##1 O
> O
u O
##as O
- O
a O
##r O
##5 O
##2 O
##q O
- O
k O
##7 O
##20 O
##a O
and O
ok O
##37 O
##1 O
> O
u O
##as O
- O
a O
##r O
##6 O
##6 O
##q O
- O
e O
##8 O
##9 O
##7 O
##k O
) O
. O
[SEP] O
[CLS] O
the O
hp O
##l O
##c O
system O
consisted O
of O
a O
be O
##ckman O
system O
gold O
equipped O
with O
a O
50 O
##7 O
auto O
##sa O
##mple O
##r O
fitted O
with O
a O
50 O
μ O
##l O
loop O
, O
coupled O
to O
an O
ultra O
##vio O
##let O
( O
u O
##v O
) O
‐ O
photo O
##dio O
##de O
array O
be O
##ckman O
168 O
detector O
and O
gold O
release O
4 O
. O
0 O
software O
( O
be O
##ckman O
ins O
##t O
. O
[SEP] O
[CLS] O
the O
ma O
##ximal O
##ly O
tolerate O
##d O
dos O
##age O
rate O
for O
a O
single O
treatment O
of O
v O
##in O
##c O
##rist O
##ine O
in O
ta O
##sman O
##ian O
devil O
##s O
was O
0 O
. O
105 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
l O
‐ O
p O
##z O
##q O
of O
o O
##dt O
r O
##ac O
‐ O
p O
##z O
##q O
and O
c O
##ys O
##tic O
##ide O
at O
40 O
mg O
/ O
kg O
was O
comparable O
( O
l O
‐ O
p O
##z O
##q O
area B-PK
under I-PK
the I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
test I-PK
/ I-PK
reference I-PK
ratio I-PK
( O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
) O
: O
96 O
% O
( O
84 O
– O
111 O
% O
) O
) O
, O
whereas O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
o O
##dt O
l O
‐ O
p O
##z O
##q O
20 O
mg O
/ O
kg O
was O
~ O
40 O
% O
that O
of O
c O
##ys O
##tic O
##ide O
40 O
mg O
/ O
kg O
( O
test O
/ O
reference O
: O
40 O
% O
( O
35 O
– O
46 O
% O
) O
) O
. O
[SEP] O
[CLS] O
two O
crossover O
studies O
( O
n O
= O
32 O
and O
36 O
, O
respectively O
) O
assessed O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
these O
o O
##dt O
##s O
vs O
. O
c O
##ys O
##tic O
##ide O
in O
adults O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
∞ I-PK
and O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
were O
highly O
variable O
in O
both O
studies O
. O
[SEP] O
[CLS] O
for O
both O
o O
##dt O
##s O
, O
l O
‐ O
p O
##z O
##q O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
showed O
greater O
than O
dose O
‐ O
proportional O
increase O
over O
the O
ranges O
tested O
and O
a O
significant O
food O
effect O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
1 O
, O
the O
lowest O
mean O
time B-PK
to I-PK
reach I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
of O
0 O
. O
83 O
h O
was O
observed O
for O
the O
dog O
and O
the O
highest O
value O
of O
3 O
. O
25 O
h O
for O
the O
monkey O
. O
[SEP] O
[CLS] O
the O
mean O
estimated O
plasma B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
increased O
across O
species O
, O
from O
0 O
. O
05 O
l O
/ O
h O
for O
mouse O
to O
42 O
. O
52 O
l O
/ O
h O
for O
dog O
as O
displayed O
in O
table O
1 O
. O
[SEP] O
[CLS] O
after O
single O
p O
. O
o O
. O
administration O
of O
cap O
##mat O
##ini O
##b O
using O
capsule O
formulation O
on O
day O
1 O
, O
cap O
##mat O
##ini O
##b O
was O
rapidly O
absorbed O
with O
median O
t B-PK
##max I-PK
of O
1 O
. O
5 O
‐ O
2 O
hours O
, O
with O
the O
exception O
of O
100 O
mg O
q O
. O
d O
. O
following O
repeated O
daily O
dos O
##ing O
up O
to O
day O
15 O
following O
the O
q O
. O
d O
. O
or O
b O
. O
i O
. O
d O
. O
regime O
##n O
using O
capsule O
##s O
, O
median O
t B-PK
##max I-PK
ranged O
1 O
. O
0 O
‐ O
4 O
. O
0 O
hours O
( O
table O
4 O
, O
figures O
1 O
and O
2 O
) O
, O
whereas O
absorption O
was O
more O
rapid O
after O
dos O
##ing O
using O
a O
tablet O
with O
median O
t B-PK
##max I-PK
of O
1 O
. O
0 O
hour O
on O
both O
day O
1 O
and O
day O
15 O
. O
[SEP] O
[CLS] O
plate O
##let O
count O
≥ O
##75 O
× O
109 O
/ O
l O
( O
or O
≥ O
30 O
× O
109 O
/ O
l O
if O
bone O
ma O
##rrow O
involvement O
) O
serum O
bi O
##li O
##ru O
##bin O
≤ O
##1 O
. O
5 O
× O
upper O
limit O
of O
normal O
unless O
raised O
due O
to O
g O
##il O
##bert O
’ O
s O
syndrome O
, O
in O
which O
case O
up O
to O
3 O
× O
upper O
limit O
of O
normal O
is O
per O
##missible O
##alan O
##ine O
amino O
##tra O
##ns O
##fer O
##ase O
and O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fer O
##ase O
≤ O
##2 O
. O
5 O
× O
upper O
limit O
of O
normal O
unless O
raised O
due O
to O
he O
##pa O
##tic O
involvement O
##cal O
##culate O
##d O
c O
##rea O
##tin O
##ine O
clearance O
( O
cock O
##roft O
– O
g O
##ault O
formula O
) O
≥ O
##30 O
m O
##l O
/ O
min O
( O
un O
##cor O
##re O
##cted O
value O
) O
ability O
to O
understand O
the O
purpose O
and O
risks O
of O
the O
study O
and O
provide O
written O
informed O
consent O
##will O
##ing O
and O
able O
to O
participate O
in O
all O
required O
evaluation O
##s O
and O
procedures O
in O
the O
study O
protocol O
##will O
##ing O
to O
participate O
in O
appropriate O
pregnancy O
prevention O
measures O
: O
women O
with O
child O
##be O
##aring O
potential O
who O
have O
a O
negative O
serum O
or O
urine O
pregnancy O
test O
during O
screening O
( O
within O
14 O
days O
prior O
to O
the O
start O
of O
trial O
treatment O
) O
and O
who O
agree O
to O
use O
one O
highly O
effective O
form O
of O
con O
##tra O
##ception O
combined O
with O
an O
effective O
form O
of O
con O
##tra O
##ception O
from O
the O
first O
administration O
of O
all O
study O
drugs O
throughout O
the O
trial O
and O
for O
12 O
months O
after O
the O
last O
dose O
of O
all O
study O
drugs O
. O
[SEP] O
[CLS] O
simulated O
l O
##n O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
values O
for O
the O
g O
##ran O
##ule O
dos O
##age O
administration O
for O
subjects O
weighing O
< O
20 O
kg O
and O
the O
tablet O
dos O
##age O
administration O
for O
subjects O
weighing O
≥ O
##20 O
kg O
are O
presented O
in O
fi O
##g O
. O
5 O
to O
illustrate O
uniform O
exposure O
across O
the O
weight O
ranges O
for O
the O
proposed O
labeled O
dos O
##ing O
of O
g O
##ran O
##ules O
and O
tablets O
. O
[SEP] O
[CLS] O
the O
literature O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
van O
##com O
##y O
##cin O
in O
patients O
undergoing O
extra O
##cor O
##pore O
##al O
membrane O
oxygen O
##ation O
( O
e O
##c O
##mo O
) O
therapy O
is O
sparse O
. O
[SEP] O
[CLS] O
samples O
were O
compared O
to O
no O
##ve O
##x O
sharp O
pre O
- O
stained O
markers O
( O
in O
##vi O
##tro O
##gen O
) O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
improved O
from O
0 O
. O
62 O
##7 O
( O
set O
14 O
) O
to O
0 O
. O
83 O
##4 O
( O
set O
3 O
) O
with O
a O
33 O
% O
increase O
. O
[SEP] O
[CLS] O
parameters O
included O
clearance B-PK
of O
2 O
. O
83 O
l O
/ O
h O
##r O
, O
limited O
central B-PK
volume I-PK
of I-PK
distribution I-PK
24 O
. O
2 O
l O
, O
and O
low O
residual O
var O
##iability O
0 O
. O
67 O
% O
. O
[SEP] O
[CLS] O
our O
study O
showed O
that O
the O
peak B-PK
time I-PK
, O
half B-PK
- I-PK
life I-PK
time I-PK
, O
mean O
residence B-PK
time I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
of O
g O
##a O
- O
c O
##ts O
/ O
5 O
- O
f O
##u O
were O
longer O
or O
more O
than O
those O
of O
the O
5 O
- O
f O
##u O
group O
, O
but O
the O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
lower O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
( O
p O
##k O
) O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
##h I-PK
and O
t B-PK
##max I-PK
obtained O
from O
the O
curve O
of O
plasma O
concentrations O
, O
are O
shown O
in O
table O
8 O
. O
[SEP] O
[CLS] O
three O
parameters O
character O
##ize O
this O
metabolism O
: O
the O
intrinsic B-PK
liver I-PK
( I-PK
c I-PK
##lint I-PK
_ I-PK
l I-PK
) I-PK
and O
kidney B-PK
( I-PK
c I-PK
##lint I-PK
_ I-PK
k I-PK
) I-PK
clearance I-PK
and O
the O
fraction B-PK
of I-PK
total I-PK
liver I-PK
ram I-PK
##ip I-PK
##ril I-PK
metabolism I-PK
that I-PK
is I-PK
converted I-PK
to I-PK
ram I-PK
##ip I-PK
##ril I-PK
##at I-PK
( I-PK
f I-PK
##rl I-PK
) I-PK
. O
[SEP] O
[CLS] O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
was O
calculated O
as O
0 O
. O
69 O
##3 O
× O
v O
##d O
/ O
t O
##1 O
/ O
2 O
where O
v B-PK
##d I-PK
is O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
is O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
. O
[SEP] O
[CLS] O
because O
there O
was O
no O
in O
##tra O
##ven O
##ous O
com O
##par O
##ator O
arm O
in O
this O
study O
, O
equivalent O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
assumed O
for O
comparisons O
of O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
and O
clearance B-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
where O
f B-PK
is O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
or O
fraction B-PK
of I-PK
the I-PK
drug I-PK
absorbed I-PK
( O
unknown O
) O
. O
[SEP] O
[CLS] O
single O
- O
dose O
p O
##k O
studies O
of O
til O
##di O
##pi O
##ros O
##in O
were O
performed O
with O
ne O
##ut O
##rop O
##eni O
##c O
lung O
- O
infected O
mice O
following O
sub O
##cut O
##aneous O
administration O
( O
dose O
volume O
: O
0 O
. O
2 O
m O
##l O
) O
of O
til O
##di O
##pi O
##ros O
##in O
( O
1 O
, O
2 O
, O
4 O
, O
6 O
, O
and O
8 O
mg O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
t O
##m O
##z O
alone O
had O
no O
significant O
effect O
on O
the O
release O
of O
l O
##dh O
by O
the O
u O
##8 O
##7 O
/ O
t O
##r O
cells O
( O
fi O
##g O
. O
5 O
##c O
) O
. O
[SEP] O
[CLS] O
urine O
samples O
were O
taken O
from O
a O
24 O
- O
hour O
collection O
to O
measure O
c O
##rea O
##tin O
##ine O
clearance O
. O
[SEP] O
[CLS] O
we O
also O
tested O
the O
effect O
of O
and O
##rog O
##rap O
##hol O
##ide O
on O
m O
##c O
##f O
- O
7 O
cells O
and O
observed O
similar O
dose O
- O
and O
time O
- O
dependent O
effect O
on O
mm O
##p O
loss O
( O
additional O
file O
2 O
: O
figure O
s O
##2 O
##b O
) O
. O
[SEP] O
[CLS] O
no O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
data O
on O
g O
##eran O
##iol O
are O
currently O
available O
. O
[SEP] O
[CLS] O
after O
in O
##tra O
##ven O
##ous O
administration O
of O
g O
##eran O
##iol O
to O
rats O
( O
50 O
mg O
/ O
kg O
) O
, O
its O
concentration O
in O
whole O
blood O
( O
detected O
via O
hp O
##l O
##c O
) O
decreased O
following O
an O
apparent O
pseudo O
- O
first O
order O
kinetic O
##s O
with O
a O
half B-PK
- I-PK
life I-PK
of O
12 O
. O
5 O
± O
1 O
. O
5 O
min O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
values O
of O
oral O
formulation O
##s O
( O
50 O
mg O
/ O
kg O
) O
of O
em O
##ul O
##si O
##fied O
g O
##eran O
##iol O
or O
fiber O
- O
ads O
##or O
##bed O
g O
##eran O
##iol O
were O
92 O
and O
16 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
low O
temperature O
decreased O
the O
intrinsic B-PK
clearance I-PK
of O
liver O
micro O
##some O
##s O
, O
with O
no O
change O
in O
protein O
binding O
or O
he O
##pa O
##to O
##cy O
##te O
up O
##take O
of O
ni O
##mo O
##di O
##pine O
. O
[SEP] O
[CLS] O
the O
concentration O
vs O
time O
curves O
for O
fl O
##b O
##z O
and O
/ O
or O
its O
meta O
##bol O
##ites O
in O
plasma O
for O
each O
individual O
animal O
were O
fitted O
with O
the O
p O
##ks O
##ol O
##ution O
##st O
##m O
computer O
program O
( O
summit O
research O
service O
, O
oh O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
forest O
plots O
for O
the O
final O
model O
showing O
the O
relationships O
between O
parameters O
and O
co O
##var O
##iate O
##s O
for O
c B-PK
##l I-PK
, O
v B-PK
##1 I-PK
, O
and O
im B-PK
##ax I-PK
are O
shown O
in O
figure O
1 O
. O
[SEP] O
[CLS] O
visual O
predict O
##ive O
checks O
for O
the O
10 O
mg O
/ O
kg O
dose O
group O
are O
shown O
in O
figure O
2 O
, O
and O
figure O
3 O
shows O
the O
predicted O
variation O
in O
c B-PK
##l I-PK
over O
time O
by O
patient O
and O
tumor O
type O
. O
[SEP] O
[CLS] O
the O
pop O
##p O
##k O
model O
in O
adults O
showed O
a O
median O
au B-PK
##c I-PK
estimated O
at O
96 O
##2 O
μ O
##mo O
##l O
h O
/ O
l O
( O
5th O
– O
95 O
##th O
percent O
##iles O
, O
76 O
##5 O
– O
140 O
##3 O
μ O
##mo O
##l O
h O
/ O
l O
) O
and O
b O
##w O
normal B-PK
##ized I-PK
c I-PK
##l I-PK
and O
v B-PK
##dt I-PK
##ota I-PK
##l I-PK
of O
0 O
. O
10 O
l O
/ O
h O
per O
kg O
( O
0 O
. O
08 O
– O
0 O
. O
13 O
l O
/ O
h O
) O
and O
0 O
. O
20 O
l O
/ O
kg O
( O
0 O
. O
16 O
– O
0 O
. O
25 O
l O
/ O
kg O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
therefore O
, O
a O
slightly O
lower O
b O
##w O
normal B-PK
##ized I-PK
c I-PK
##l I-PK
was O
observed O
in O
children O
than O
in O
adults O
( O
0 O
. O
06 O
vs O
0 O
. O
10 O
l O
/ O
h O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
volumes B-PK
of I-PK
distribution I-PK
of O
both O
pop O
##p O
##k O
models O
could O
not O
be O
formally O
compared O
since O
the O
pop O
##p O
##k O
model O
for O
children O
was O
parameter O
##ized O
with O
vs B-PK
##s I-PK
, O
while O
it O
was O
parameter O
##ized O
with O
v B-PK
##dt I-PK
##ota I-PK
##l I-PK
for O
adults O
. O
[SEP] O
[CLS] O
nevertheless O
, O
the O
vs B-PK
##s I-PK
in O
children O
could O
be O
compared O
with O
the O
vs B-PK
##s I-PK
obtained O
in O
adults O
by O
non O
##com O
##par O
##tment O
##al O
analysis O
and O
was O
found O
also O
to O
be O
different O
( O
0 O
. O
04 O
##7 O
l O
/ O
kg O
for O
children O
and O
ca O
. O
[SEP] O
[CLS] O
this O
difference O
can O
be O
explained O
by O
the O
difference O
in O
c B-PK
##l I-PK
and O
the O
fact O
that O
re O
##nal O
function O
mat O
##uration O
was O
not O
completely O
achieved O
in O
children O
younger O
than O
2 O
years O
. O
29 O
the O
proportion O
of O
children O
' O
s O
values O
outside O
adults O
' O
95 O
% O
percent O
##ile O
interval O
was O
64 O
% O
to O
76 O
% O
for O
concentrations O
and O
79 O
% O
for O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
the O
clearance B-PK
rate I-PK
and O
serum B-PK
half I-PK
- I-PK
life I-PK
were O
obtained O
from O
a O
non O
- O
compartment O
##al O
model O
##14 O
of O
the O
anti O
##body O
concentration O
as O
a O
function O
of O
time O
using O
the O
p O
##hoe O
##ni O
##x O
software O
( O
c O
##ert O
##ara O
) O
. O
[SEP] O
[CLS] O
compound O
- O
specific O
p O
##hy O
##si O
##co O
##chemical O
properties O
and O
the O
un B-PK
##bound I-PK
fraction I-PK
of I-PK
the I-PK
drug I-PK
in I-PK
plasma I-PK
( I-PK
f I-PK
##u I-PK
) I-PK
were O
used O
to O
para O
##met O
##riz O
##e O
the O
initial O
reference O
p O
##b O
##p O
##k O
model O
for O
humans O
( O
fi O
##g O
. O
4 O
; O
table O
1 O
) O
. O
[SEP] O
[CLS] O
in O
h O
##cy O
##p O
##1 O
##a O
##1 O
/ O
1 O
##a O
##2 O
mice O
treated O
with O
3 O
- O
m O
##c O
, O
significant O
reduction O
##s O
in O
both O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
8 I-PK
hours I-PK
( O
54 O
% O
) O
and O
half B-PK
- I-PK
life I-PK
( O
67 O
% O
) O
values O
for O
p O
##ona O
##tin O
##ib O
were O
also O
observed O
( O
fi O
##g O
. O
4 O
##b O
; O
table O
1 O
) O
. O
[SEP] O
[CLS] O
the O
absolute O
level O
of O
the O
p O
- O
g O
##sh O
con O
##ju O
##gate O
formed O
could O
not O
be O
determined O
because O
relevant O
standards O
were O
not O
available O
. O
[SEP] O
[CLS] O
the O
amount O
of O
pet O
- O
id O
##7 O
protein O
was O
determined O
by O
sat O
##uration O
of O
a O
his O
- O
bind O
##® O
column O
( O
no O
##vage O
##n O
) O
with O
a O
theoretical O
capacity O
of O
20 O
mg O
protein O
. O
[SEP] O
[CLS] O
the O
average O
cm B-PK
##ax I-PK
of O
r O
- O
al O
##o O
was O
greater O
than O
s O
- O
al O
##o O
by O
4 O
. O
96 O
times O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
p O
##t O
- O
drug O
is O
calculated O
by O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
namely O
the O
integral O
of O
the O
p O
##t O
concentration O
- O
time O
curve O
, O
using O
the O
trap O
##ez O
##oid O
##al O
rule O
. O
[SEP] O
[CLS] O
a O
single O
administration O
of O
in O
##tral O
##ip O
##id O
can O
increase O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
p O
##t O
drug O
by O
18 O
. O
7 O
% O
during O
the O
first O
5 O
h O
##r O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
and O
by O
9 O
. O
4 O
% O
during O
24 O
h O
##r O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
( O
fi O
##g O
. O
s O
##3 O
) O
. O
[SEP] O
[CLS] O
this O
finding O
indicates O
that O
in O
##tral O
##ip O
##id O
can O
change O
the O
clearance B-PK
and O
increase O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
na O
##no O
##dr O
##ug O
. O
[SEP] O
[CLS] O
d O
##ms O
##55 O
##40 O
was O
expressed O
in O
e O
. O
co O
##li O
and O
pu O
##rified O
from O
culture O
super O
##nat O
##ant O
by O
protein O
- O
a O
affinity O
capture O
followed O
by O
cat O
##ion O
exchange O
ch O
##roma O
##tography O
. O
[SEP] O
[CLS] O
the O
di O
##sso O
##ciation O
equilibrium O
constant O
( O
k O
##d O
) O
for O
the O
d O
##ms O
##55 O
##40 O
- O
m O
##t O
##n O
##f O
##r O
##1 O
interaction O
was O
determined O
to O
be O
270 O
pm O
( O
ka O
7 O
. O
98 O
105 O
m O
- O
1 O
##s O
- O
1 O
; O
k O
##off O
2 O
. O
17 O
10 O
##− O
##4 O
s O
- O
1 O
) O
. O
[SEP] O
[CLS] O
the O
plasma O
concentration O
vs O
time O
pro O
##ﬁ O
##le O
of O
r O
- O
al O
##o O
and O
s O
- O
al O
##o O
in O
rats O
is O
shown O
in O
figure O
5 O
. O
[SEP] O
[CLS] O
till O
now O
the O
stereo O
##sel O
##ec O
##tive O
bio O
##tra O
##ns O
##formation O
of O
al O
##o O
and O
their O
effect O
on O
al O
##o O
quantities O
in O
plasma O
is O
not O
known O
in O
published O
literature O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
r O
- O
al O
##o O
and O
s O
- O
al O
##o O
was O
9 O
. O
175 O
and O
9 O
. O
169 O
hours O
respectively O
. O
[SEP] O
[CLS] O
the O
higher O
plasma O
concentration O
of O
the O
r O
- O
en O
##anti O
##omer O
as O
compared O
to O
the O
s O
- O
al O
##o O
may O
be O
because O
of O
greater O
rate B-PK
of I-PK
absorption I-PK
of O
the O
r O
- O
al O
##o O
and O
/ O
or O
extensive O
metabolism O
of O
the O
s O
- O
al O
##o O
than O
r O
- O
al O
##o O
. O
[SEP] O
[CLS] O
the O
results O
illustrated O
a O
gradual O
dose O
- O
dependent O
activation O
of O
ca O
##sp O
##ase O
- O
9 O
( O
fi O
##g O
. O
7 O
##a O
) O
and O
ca O
##sp O
##ase O
- O
3 O
( O
fi O
##g O
. O
7 O
##b O
) O
. O
[SEP] O
[CLS] O
it O
was O
indicated O
that O
the O
absorption O
##s O
of O
these O
5 O
components O
in O
v O
##ivo O
were O
promoted O
with O
the O
increase O
of O
the O
oral O
dose O
of O
administration O
of O
n O
##x O
##t O
##c O
. O
[SEP] O
[CLS] O
table O
9 O
shows O
the O
results O
of O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
index O
for O
each O
dose O
studied O
. O
[SEP] O
[CLS] O
the O
partial O
main O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
ca O
##ffe O
##ic O
acid O
, O
f O
##er O
##uli O
##c O
acid O
, O
form O
##ono O
##net O
##in O
, O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
, O
and O
tan O
##shin O
##one O
ii O
##a O
in O
rats O
are O
shown O
in O
table O
6 O
. O
[SEP] O
[CLS] O
the O
result O
indicated O
that O
some O
more O
sensitive O
methods O
would O
be O
established O
and O
valid O
##ated O
to O
focus O
on O
the O
mechanism O
of O
absorption O
and O
metabolism O
of O
these O
six O
components O
. O
[SEP] O
[CLS] O
it O
was O
observed O
that O
t B-PK
##max I-PK
of O
3 O
components O
( O
ca O
##ffe O
##ic O
acid O
, O
f O
##er O
##uli O
##c O
acid O
, O
and O
form O
##ono O
##net O
##in O
) O
were O
less O
than O
1 O
h O
, O
which O
implied O
that O
they O
were O
rapidly O
absorbed O
in O
rat O
plasma O
after O
oral O
administration O
of O
n O
##x O
##t O
##c O
at O
doses O
of O
0 O
. O
5 O
g O
kg O
##− O
##1 O
and O
1 O
. O
5 O
g O
kg O
##− O
##1 O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
results O
indicated O
that O
the O
mean O
t B-PK
##max I-PK
after O
single O
dose O
administration O
of O
n O
##x O
##t O
capsule O
was O
0 O
. O
17 O
h O
. O
[SEP] O
[CLS] O
it O
is O
used O
for O
treating O
age O
- O
related O
diseases O
such O
as O
ne O
##uro O
##de O
##gene O
##rative O
disorders O
and O
card O
##iovascular O
disease O
[ O
20 O
] O
. O
[SEP] O
[CLS] O
all O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
h I-PK
) I-PK
values O
of O
5 O
components O
( O
ca O
##ffe O
##ic O
acid O
, O
f O
##er O
##uli O
##c O
acid O
, O
form O
##ono O
##net O
##in O
, O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
, O
and O
tan O
##shin O
##one O
ii O
##a O
) O
after O
oral O
administration O
of O
n O
##x O
##t O
capsule O
at O
triple O
doses O
of O
1 O
. O
5 O
g O
kg O
##− O
##1 O
were O
higher O
than O
those O
after O
oral O
administration O
at O
normal O
doses O
of O
0 O
. O
5 O
g O
kg O
##− O
##1 O
. O
[SEP] O
[CLS] O
this O
was O
the O
first O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
in O
humans O
, O
which O
demonstrated O
linear O
##ity O
and O
was O
consistent O
with O
the O
oral O
two O
- O
compartment O
model O
with O
a O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
about O
1 O
day O
. O
[SEP] O
[CLS] O
no O
severe O
adverse O
events O
requiring O
the O
disco O
##ntin O
##uation O
of O
treatment O
were O
recorded O
. O
[SEP] O
[CLS] O
the O
new O
understanding O
sum O
##mar O
##ised O
in O
the O
present O
article O
was O
directly O
translated O
to O
human O
liver O
imaging O
in O
two O
recent O
publications O
. O
[SEP] O
[CLS] O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
values O
of O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
( O
17 O
. O
8 O
± O
17 O
. O
1 O
h O
) O
and O
tan O
##shin O
##one O
ii O
##a O
( O
17 O
. O
8 O
± O
17 O
. O
1 O
h O
) O
indicated O
that O
the O
action O
time O
of O
both O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
and O
tan O
##shin O
##one O
ii O
##a O
were O
significantly O
longer O
in O
body O
than O
the O
other O
three O
components O
. O
[SEP] O
[CLS] O
the O
developed O
hp O
##l O
##c O
- O
m O
##s O
/ O
m O
##s O
method O
was O
successfully O
used O
to O
determine O
the O
plasma O
concentrations O
of O
11 O
components O
after O
oral O
administration O
of O
n O
##x O
##t O
##c O
at O
doses O
of O
0 O
. O
5 O
g O
kg O
##− O
##1 O
and O
1 O
. O
5 O
g O
kg O
##− O
##1 O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
most O
common O
recorded O
adverse O
events O
were O
vomit O
##ing O
, O
headache O
and O
di O
##ar O
##r O
##hoe O
##a O
( O
table O
6 O
) O
. O
[SEP] O
[CLS] O
more O
recently O
, O
we O
published O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
modelling O
of O
liver O
images O
to O
q O
##uant O
##ify O
the O
liver O
per O
##fusion O
and O
he O
##pa O
##to O
##cy O
##te O
transport O
function O
of O
patients O
with O
chronic O
liver O
diseases O
[ O
36 O
] O
. O
[SEP] O
[CLS] O
we O
used O
the O
final O
model O
and O
performed O
a O
simulation O
to O
determine O
the O
dos O
##ing O
regime O
##n O
in O
patients O
with O
re O
##nal O
imp O
##air O
##ment O
and O
in O
those O
with O
con O
##com O
##ita O
##nt O
administration O
of O
am O
##io O
##dar O
##one O
. O
[SEP] O
[CLS] O
from O
table O
6 O
, O
it O
was O
found O
that O
values O
of O
t B-PK
##max I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
ca O
##ffe O
##ic O
acid O
and O
f O
##er O
##uli O
##c O
acid O
were O
much O
closer O
, O
demonstrating O
that O
they O
have O
similar O
absorption B-PK
and O
elimination B-PK
rate I-PK
. O
[SEP] O
[CLS] O
antibodies O
were O
el O
##uted O
using O
100 O
mm O
ace O
##tic O
acid O
p O
##h O
3 O
. O
2 O
and O
the O
el O
##ution O
pools O
were O
brought O
to O
p O
##h O
5 O
. O
0 O
using O
1 O
m O
na O
##oh O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
values O
were O
15 O
. O
24 O
± O
3 O
. O
08 O
ng O
m O
##l O
##− O
##1 O
and O
12 O
. O
07 O
± O
4 O
. O
61 O
ng O
m O
##l O
##− O
##1 O
and O
values O
of O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
h I-PK
) I-PK
were O
25 O
. O
99 O
± O
18 O
. O
62 O
ng O
m O
##l O
- O
1 O
h O
##− O
##1 O
##and O
8 O
. O
33 O
± O
3 O
. O
87 O
ng O
m O
##l O
##− O
##1 O
h O
##− O
##1 O
for O
ca O
##ffe O
##ic O
acid O
and O
f O
##er O
##uli O
##c O
acid O
at O
triple O
doses O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
pro O
##ba O
##bilities O
of O
t B-PK
##rough I-PK
dig I-PK
##ox I-PK
##in I-PK
concentrations I-PK
being O
in O
the O
range O
of O
0 O
. O
5 O
– O
0 O
. O
8 O
ng O
/ O
m O
##l O
in O
the O
steady O
state O
are O
shown O
in O
fi O
##g O
. O
3 O
. O
[SEP] O
[CLS] O
in O
the O
present O
studies O
, O
cm B-PK
##ax I-PK
of O
form O
##ono O
##net O
##in O
was O
less O
than O
1 O
ng O
m O
##l O
##− O
##1 O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
h I-PK
) I-PK
values O
were O
lower O
than O
1 O
ng O
m O
##l O
##− O
##1 O
. O
[SEP] O
[CLS] O
apparent B-PK
per I-PK
##me I-PK
##ability I-PK
coefficients I-PK
( I-PK
p I-PK
##ap I-PK
##p I-PK
) I-PK
were O
calculated O
using O
the O
following O
equation O
: O
( O
3 O
) O
p O
##ap O
##p O
= O
q O
##ac O
##0 O
##t O
, O
where O
p B-PK
##ap I-PK
##p I-PK
is O
the O
apparent B-PK
per I-PK
##me I-PK
##ability I-PK
coefficient I-PK
( O
cm O
/ O
s O
) O
, O
q O
is O
the O
total O
amount O
per O
##me O
##ated O
throughout O
the O
in O
##cu O
##bation O
time O
( O
μ O
##g O
) O
, O
a O
is O
the O
diffusion O
area O
of O
the O
mon O
##ola O
##yer O
( O
cm O
##2 O
) O
, O
c O
##0 O
is O
the O
initial O
concentration O
of O
the O
d O
##t O
##x O
in O
the O
a O
##pical O
part O
( O
μ O
##g O
/ O
cm O
##3 O
) O
, O
and O
t O
is O
the O
total O
time O
of O
the O
experiments O
. O
[SEP] O
[CLS] O
differences O
in O
ca O
##ffe O
##ine O
serum O
concentrations O
between O
dos O
##ing O
regime O
##n O
groups O
were O
determined O
by O
man O
##n O
– O
w O
##hit O
##ney O
u O
test O
. O
[SEP] O
[CLS] O
based O
on O
the O
above O
results O
, O
the O
newly O
established O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
method O
was O
sufficiently O
sensitive O
for O
the O
determination O
of O
multiple O
components O
in O
rat O
plasma O
and O
was O
suitable O
to O
simultaneously O
evaluate O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
of O
the O
multiple O
bio O
##active O
components O
after O
oral O
administration O
of O
n O
##x O
##t O
##c O
. O
[SEP] O
[CLS] O
severe O
: O
causing O
inability O
to O
carry O
out O
usual O
activities O
; O
the O
subject O
may O
experience O
into O
##ler O
##able O
discomfort O
or O
pain O
. O
[SEP] O
[CLS] O
the O
pool O
##ed O
antibodies O
were O
then O
concentrated O
and O
buffer O
exchanged O
into O
10 O
mm O
ace O
##tic O
acid O
, O
9 O
% O
su O
##c O
##rose O
, O
p O
##h O
5 O
. O
2 O
, O
and O
al O
##iq O
##uo O
##ts O
were O
stored O
at O
- O
70 O
##° O
##c O
until O
needed O
. O
[SEP] O
[CLS] O
the O
possible O
reason O
may O
be O
that O
some O
of O
the O
ca O
##ffe O
##ic O
acid O
detected O
in O
rat O
plasma O
was O
the O
meta O
##bol O
##ites O
of O
the O
components O
in O
n O
##x O
##t O
##c O
. O
[SEP] O
[CLS] O
the O
results O
were O
not O
correspondent O
with O
their O
dose O
administered O
to O
the O
rats O
( O
7 O
. O
1 O
μ O
##g O
kg O
##− O
##1 O
ca O
##ffe O
##ic O
acid O
and O
53 O
. O
7 O
μ O
##g O
kg O
##− O
##1 O
f O
##er O
##uli O
##c O
acid O
) O
. O
[SEP] O
[CLS] O
the O
relationships O
between O
treatment O
efficacy O
and O
patient O
demographic O
##s O
were O
also O
evaluated O
by O
linear O
re O
##gression O
. O
[SEP] O
[CLS] O
– O
sample O
size O
, O
mean O
, O
standard O
de O
##viation O
, O
median O
, O
minimum O
, O
and O
maximum O
for O
or O
##dina O
##l O
variables O
[SEP] O
[CLS] O
ca O
##ffe O
##ic O
acid O
has O
very O
excellent O
anti O
##ox O
##ida O
##nt O
and O
anti O
##vir O
##al O
activity O
[ O
25 O
] O
. O
[SEP] O
[CLS] O
da O
##pi O
stain O
##ing O
by O
con O
##fo O
##cal O
micro O
##sco O
##py O
also O
revealed O
a O
con O
##den O
##sed O
and O
s O
##hr O
##unk O
nucleus O
with O
the O
fragment O
##ed O
ch O
##roma O
##tin O
. O
[SEP] O
[CLS] O
the O
study O
compared O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
the O
serum O
25 O
( O
oh O
) O
d O
concentration O
between O
the O
two O
treatment O
groups O
. O
[SEP] O
[CLS] O
if O
the O
cells O
were O
treated O
with O
1 O
% O
p O
##c O
##ms O
for O
2 O
h O
( O
data O
not O
shown O
) O
prior O
to O
the O
ethanol O
addition O
, O
the O
damage O
was O
more O
pronounced O
. O
[SEP] O
[CLS] O
r O
##t O
##v O
was O
given O
either O
as O
an O
80 O
mg O
/ O
m O
##l O
oral O
solution O
or O
as O
100 O
mg O
capsule O
##s O
( O
permitted O
for O
children O
≥ O
##33 O
kg O
) O
. O
[SEP] O
[CLS] O
male O
s O
##pra O
##gue O
da O
##wley O
rats O
( O
225 O
– O
275 O
g O
, O
central O
animal O
laboratory O
of O
the O
second O
x O
##ian O
##gy O
##a O
hospital O
of O
central O
south O
university O
, O
h O
##una O
##n O
, O
people O
’ O
s O
republic O
of O
chin O
##a O
) O
were O
used O
to O
perform O
the O
l O
##ymph O
##atic O
transport O
study O
. O
[SEP] O
[CLS] O
a O
sample O
size O
of O
28 O
subjects O
was O
required O
to O
provide O
at O
least O
80 O
% O
power O
to O
conclude O
an O
absence O
of O
effect O
of O
er O
##yt O
##hr O
##omy O
##cin O
on O
ed O
##ox O
##aba O
##n O
p O
##har O
##ma O
##co O
##kin O
##etics O
using O
a O
90 O
% O
c O
##i O
with O
no O
‐ O
effect O
boundaries O
of O
80 O
– O
125 O
% O
. O
[SEP] O
[CLS] O
human O
serum O
album O
##in O
clearance O
studies O
were O
performed O
to O
determine O
the O
effect O
of O
end O
##ogen O
##ous O
m O
##sa O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
behavior O
of O
administered O
human O
album O
##in O
. O
[SEP] O
[CLS] O
men O
and O
non O
##p O
##re O
##gnant O
, O
non O
##la O
##ct O
##ating O
women O
aged O
18 O
– O
55 O
years O
old O
who O
were O
healthy O
( O
i O
##e O
, O
with O
no O
evidence O
of O
active O
or O
chronic O
disease O
after O
a O
detailed O
review O
of O
medical O
and O
surgical O
histories O
and O
a O
complete O
physical O
examination O
) O
were O
eligible O
to O
participate O
. O
[SEP] O
[CLS] O
only O
, O
the O
cells O
showed O
a O
loss O
of O
ad O
##herence O
, O
became O
distorted O
and O
a O
##pop O
##to O
##tic O
, O
which O
is O
reflected O
as O
a O
yellow O
mark O
in O
the O
a O
##o O
/ O
et O
##b O
##r O
stain O
##ing O
. O
[SEP] O
[CLS] O
two O
mice O
of O
each O
co O
##hor O
##t O
also O
received O
5 O
mg O
/ O
kg O
human O
i O
##gg O
in O
the O
same O
i O
##v O
injection O
##s O
. O
[SEP] O
[CLS] O
the O
primary O
end O
##point O
was O
serum O
25 O
( O
oh O
) O
d O
level O
measured O
from O
day O
0 O
to O
day O
112 O
. O
[SEP] O
[CLS] O
cat O
##ego O
##rical O
data O
were O
evaluated O
using O
ch O
##i O
- O
square O
test O
. O
[SEP] O
[CLS] O
en O
##fu O
##vir O
##tide O
was O
permitted O
in O
addition O
to O
n O
##rt O
##is O
for O
children O
> O
6 O
years O
old O
, O
providing O
its O
use O
was O
within O
the O
locally O
approved O
product O
label O
. O
[SEP] O
[CLS] O
study O
participants O
also O
needed O
to O
be O
able O
to O
swallow O
a O
dose O
of O
the O
study O
drug O
according O
to O
the O
study O
conditions O
and O
to O
comply O
with O
study O
procedures O
. O
[SEP] O
[CLS] O
a O
total O
of O
36 O
subjects O
were O
enrolled O
to O
compensate O
for O
potential O
drop O
##outs O
. O
[SEP] O
[CLS] O
k O
##olm O
##ogo O
##rov O
– O
s O
##mir O
##nov O
test O
was O
used O
to O
check O
for O
the O
normal O
distribution O
of O
data O
. O
[SEP] O
[CLS] O
subjects O
were O
given O
f O
##p O
##v O
##± O
##rt O
##v O
with O
a O
background O
regime O
##n O
of O
2 O
or O
3 O
active O
n O
##rt O
##is O
. O
[SEP] O
[CLS] O
on O
t O
##ues O
##day O
of O
the O
second O
week O
, O
group O
1 O
was O
exposed O
without O
hood O
##s O
and O
breathing O
chamber O
air O
; O
hence O
, O
exposure O
was O
via O
both O
the O
der O
##mal O
and O
the O
in O
##hala O
##tion O
pathway O
. O
[SEP] O
[CLS] O
ace O
##ton O
##it O
##ril O
##e O
and O
water O
containing O
0 O
. O
1 O
% O
( O
v O
/ O
v O
) O
form O
##ic O
acid O
was O
adopted O
as O
the O
mobile O
phase O
, O
the O
flow O
rate O
was O
0 O
. O
3 O
m O
##l O
/ O
mi O
. O
[SEP] O
[CLS] O
participants O
provided O
informed O
consent O
before O
participation O
. O
[SEP] O
[CLS] O
a O
s O
##med O
##ds O
sample O
was O
di O
##lut O
##ed O
with O
di O
##st O
##ille O
##d O
water O
at O
25 O
##° O
##c O
under O
gentle O
agitation O
immediately O
before O
measurement O
. O
[SEP] O
[CLS] O
patients O
were O
( O
mean O
± O
standard O
de O
##viation O
( O
s O
##d O
) O
) O
53 O
± O
11 O
years O
old O
, O
50 O
% O
male O
, O
81 O
± O
14 O
kg O
, O
and O
had O
acute O
p O
##hy O
##sio O
##log O
##ic O
and O
chronic O
health O
evaluation O
ii O
score O
( O
a O
##pa O
##che O
ii O
) O
scores O
of O
31 O
. O
5 O
± O
3 O
. O
8 O
. O
[SEP] O
[CLS] O
after O
reaching O
the O
peak B-PK
concentration I-PK
of I-PK
cm I-PK
##ax I-PK
, O
the O
o O
##xy O
##co O
##don O
##e O
plasma O
concentrations O
followed O
a O
mon O
##oe O
##x O
##po O
##nent O
##ial O
decline O
. O
[SEP] O
[CLS] O
patients O
had O
minimal O
residual O
re O
##nal O
function O
and O
remained O
an O
##uri O
##c O
or O
o O
##li O
##gu O
##ric O
during O
the O
entire O
study O
period O
. O
[SEP] O
[CLS] O
patients O
were O
enrolled O
in O
the O
study O
for O
a O
mean O
of O
5 O
± O
3 O
days O
( O
range O
2 O
to O
11 O
days O
) O
. O
[SEP] O
[CLS] O
participants O
were O
eligible O
if O
they O
were O
aged O
between O
18 O
and O
55 O
years O
, O
had O
a O
mean O
body O
weight O
of O
72 O
. O
3 O
kg O
( O
range O
53 O
. O
6 O
– O
88 O
. O
9 O
kg O
) O
, O
and O
had O
a O
mean O
body O
mass O
index O
between O
19 O
. O
5 O
and O
28 O
. O
3 O
kg O
/ O
m O
. O
2 O
[SEP] O
[CLS] O
the O
terminal O
phases O
of O
the O
plasma O
concentration O
– O
time O
profiles O
had O
distinct O
half B-PK
‐ I-PK
lives I-PK
with O
p O
##o O
administration O
of O
immediate O
‐ O
release O
( O
i O
##r O
) O
and O
controlled O
‐ O
release O
( O
c O
##r O
) O
or O
with O
in O
##tra O
##nas O
##al O
administration O
. O
[SEP] O
[CLS] O
ten O
patients O
were O
enrolled O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##cological O
experiments O
based O
on O
the O
study O
found O
that O
the O
topic O
##al O
pig O
##mentation O
model O
of O
g O
##uin O
##ea O
pigs O
showed O
a O
better O
therapeutic O
effect O
. O
[SEP] O
[CLS] O
these O
results O
implied O
s O
##med O
##ds O
could O
not O
spontaneous O
##ly O
form O
transparent O
and O
stable O
micro O
##em O
##ul O
##sion O
systems O
upon O
a O
##que O
##ous O
di O
##lution O
any O
longer O
beyond O
c O
##rem O
##op O
##hor O
r O
##h O
40 O
: O
na O
##t O
##c O
, O
c O
##rem O
##op O
##hor O
r O
##h O
40 O
: O
na O
##d O
##c O
, O
or O
c O
##rem O
##op O
##hor O
r O
##h O
40 O
: O
na O
##c O
mass O
ratios O
of O
2 O
: O
8 O
, O
2 O
: O
8 O
, O
and O
3 O
: O
7 O
, O
respect O
##vel O
##y O
. O
[SEP] O
[CLS] O
the O
following O
parameters O
were O
estimated O
: O
maximum B-PK
( I-PK
peak I-PK
) I-PK
observed I-PK
concentration I-PK
in I-PK
plasma I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
from I-PK
dos I-PK
##ing I-PK
to I-PK
the I-PK
maximum I-PK
( I-PK
peak I-PK
) I-PK
observed I-PK
concentration I-PK
in I-PK
plasma I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
apparent B-PK
terminal I-PK
elimination I-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
and O
apparent B-PK
clearance I-PK
from I-PK
plasma I-PK
after I-PK
oral I-PK
administration I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
. O
[SEP] O
[CLS] O
re O
##e O
##qui O
##li O
##bra O
##tion O
time O
after O
gradient O
el O
##ution O
was O
5 O
min O
. O
[SEP] O
[CLS] O
the O
mixed O
h O
##l O
##b O
values O
of O
c O
##rem O
##eo O
##ph O
##or O
40 O
/ O
bi O
##le O
salts O
were O
in O
the O
range O
of O
13 O
– O
39 O
. O
18 O
. O
[SEP] O
[CLS] O
plasma O
concentration O
– O
time O
data O
were O
anal O
##ys O
##ed O
by O
non O
##com O
##par O
##tment O
##al O
methods O
using O
win O
##non O
##lin O
professional O
software O
( O
versions O
4 O
. O
0 O
or O
higher O
) O
. O
[SEP] O
[CLS] O
the O
population O
p O
##k O
models O
were O
evaluated O
using O
diagnostic O
plots O
[ O
19 O
, O
20 O
] O
, O
visual O
predict O
##ive O
check O
( O
v O
##p O
##c O
) O
[ O
20 O
, O
21 O
] O
, O
prediction O
- O
corrected O
v O
##p O
##c O
( O
p O
##c O
##v O
##p O
##c O
) O
[ O
22 O
] O
, O
boots O
##tra O
##pping O
[ O
23 O
] O
and O
shrink O
##age O
[ O
24 O
] O
assessments O
. O
[SEP] O
[CLS] O
exposure O
including O
the O
t B-PK
##rough I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
and O
peak B-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
concentration I-PK
was O
com O
##puted O
at O
steady O
state O
given O
be O
##va O
##ci O
##zu O
##ma O
##b O
of O
10 O
mg O
/ O
kg O
once O
every O
2 O
weeks O
using O
the O
final O
model O
. O
[SEP] O
[CLS] O
the O
statistical O
significance O
of O
difference O
in O
the O
mean O
of O
the O
variables O
, O
such O
as O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
and O
au B-PK
##c I-PK
##last I-PK
, O
between O
two O
groups O
was O
assessed O
using O
the O
independent O
samples O
student O
’ O
s O
t O
- O
test O
used O
to O
identify O
significance O
in O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
using O
95 O
% O
confidence O
interval O
. O
[SEP] O
[CLS] O
image O
##j O
( O
gel O
analyze O
##r O
plug O
##in O
) O
was O
used O
for O
q O
##uant O
##ification O
of O
western O
b O
##lot O
##s O
and O
im O
##mu O
##nos O
##taining O
, O
and O
data O
were O
presented O
as O
mean O
± O
s O
##d O
( O
or O
9 O
##se O
##m O
) O
by O
graph O
##pad O
p O
##rism O
5 O
( O
graph O
##pad O
p O
##rism O
software O
version O
5 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
the O
relative O
impact O
of O
each O
co O
##var O
##iate O
included O
in O
the O
final O
model O
alone O
on O
p O
##k O
parameters O
and O
exposure O
was O
explored O
. O
[SEP] O
[CLS] O
the O
full O
- O
scan O
single O
- O
mass O
spectrum O
and O
the O
daughter O
ion O
- O
mass O
spectrum O
for O
m O
##1 O
were O
( O
m O
/ O
z O
) O
250 O
. O
64 O
> O
58 O
. O
50 O
. O
[SEP] O
[CLS] O
so O
##lub O
##ility O
trials O
, O
em O
##ul O
##si O
##fying O
studies O
, O
and O
pseudo O
- O
te O
##rna O
##ry O
phase O
diagram O
##s O
were O
used O
to O
screen O
the O
s O
##ned O
##ds O
formulation O
##s O
. O
[SEP] O
[CLS] O
blood O
( O
~ O
1 O
m O
##l O
) O
samples O
were O
collected O
at O
the O
same O
time O
points O
as O
described O
for O
c O
##s O
##f O
sampling O
. O
[SEP] O
[CLS] O
each O
tube O
was O
v O
##ortex O
##ed O
for O
1 O
min O
for O
extraction O
, O
followed O
by O
cent O
##ri O
##fu O
##gation O
for O
5 O
min O
at O
13 O
, O
000 O
g O
. O
the O
organic O
s O
##tra O
##tum O
was O
then O
transferred O
to O
a O
clean O
sample O
bottle O
, O
and O
10 O
μ O
##l O
specimens O
was O
introduced O
into O
the O
ultra O
- O
fast O
liquid O
ch O
##roma O
##tography O
/ O
tandem O
mass O
s O
##pect O
##rome O
##try O
( O
u O
##f O
##l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
system O
for O
analysis O
of O
ni O
##fe O
##di O
##pine O
and O
oxidation O
ni O
##fe O
##di O
##pine O
. O
[SEP] O
[CLS] O
the O
integral O
of O
the O
concentration O
of O
p O
##elli O
##tor O
##ine O
in O
serum O
from O
zero O
to O
time O
t O
is O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
until I-PK
time I-PK
t I-PK
. O
[SEP] O
[CLS] O
capture O
and O
detection O
re O
##age O
##nts O
were O
applied O
at O
100 O
μ O
##g O
/ O
m O
##l O
of O
bio O
##tin O
- O
con O
##ju O
##gated O
goat O
anti O
- O
human O
i O
##gg O
( O
h O
##c O
+ O
l O
##c O
, O
monkey O
ads O
##or O
##bed O
, O
bet O
##hyl O
) O
in O
p O
##bs O
/ O
0 O
. O
01 O
% O
p O
##oly O
##sor O
##bate O
- O
20 O
/ O
0 O
. O
02 O
% O
na O
##n O
##3 O
and O
ale O
##xa O
##64 O
##7 O
- O
anti O
- O
c O
##dr O
( O
clone O
242 O
, O
gene O
##nte O
##ch O
) O
at O
25 O
nm O
in O
re O
##x O
##xi O
##p O
f O
( O
g O
##yr O
##os O
) O
. O
[SEP] O
[CLS] O
treatment O
with O
si O
##vel O
##esta O
##t O
increases O
the O
expression O
of O
ng O
- O
2 O
, O
α O
- O
s O
##ma O
and O
v O
##w O
##f O
. O
[SEP] O
[CLS] O
s O
##ci O
substantially O
disrupt O
##s O
the O
v O
##as O
##cula O
##ture O
, O
especially O
at O
the O
epic O
##enter O
of O
the O
injury O
, O
where O
blood O
vessels O
undergo O
re O
##mo O
##del O
##ing O
and O
structural O
changes O
before O
they O
become O
functional O
. O
[SEP] O
[CLS] O
de O
##c O
( O
purity O
, O
≥ O
##9 O
##8 O
% O
) O
, O
a O
##b O
##z O
( O
purity O
, O
≥ O
##9 O
##8 O
% O
) O
, O
a O
##b O
##z O
- O
o O
##x O
( O
purity O
, O
≥ O
##9 O
##9 O
. O
9 O
% O
) O
, O
a O
##b O
##z O
- O
on O
( O
purity O
, O
≥ O
##9 O
##9 O
. O
6 O
% O
) O
, O
o O
##xi O
##ben O
##da O
##zo O
##le O
( O
o O
##b O
##z O
) O
( O
purity O
, O
≥ O
##9 O
##9 O
. O
9 O
% O
) O
, O
and O
d O
##3 O
- O
de O
##c O
( O
purity O
, O
≥ O
##9 O
##8 O
% O
) O
, O
( O
fi O
##g O
. O
1 O
) O
of O
pharmaceutical O
grade O
were O
purchased O
from O
si O
##gma O
- O
al O
##dric O
##h O
, O
s O
##t O
lo O
##ui O
##s O
, O
m O
##o O
, O
us O
##a O
. O
[SEP] O
[CLS] O
the O
c O
##ip O
##ro O
##f O
##lo O
##xa O
##cin O
p O
##b O
##p O
##k O
model O
for O
adults O
was O
verified O
by O
comparing O
independent O
data O
##sets O
that O
were O
not O
used O
for O
model O
building O
, O
with O
corresponding O
simulation O
##s O
. O
[SEP] O
[CLS] O
all O
other O
chemical O
re O
##age O
##nts O
were O
from O
si O
##gma O
( O
s O
##t O
. O
lo O
##ui O
##s O
, O
m O
##o O
) O
. O
[SEP] O
[CLS] O
hp O
##l O
##c O
- O
grade O
met O
##han O
##ol O
( O
me O
##oh O
) O
, O
ace O
##ton O
##it O
##ril O
##e O
( O
a O
##c O
##n O
) O
, O
form O
##ic O
acid O
( O
f O
##a O
) O
, O
and O
ace O
##tic O
acid O
were O
obtained O
from O
fish O
##er O
scientific O
( O
fair O
lawn O
, O
n O
##j O
) O
. O
[SEP] O
[CLS] O
mean O
spontaneous O
a O
##b O
##r O
was O
0 O
. O
01 O
##1 O
/ O
patient O
- O
year O
. O
[SEP] O
[CLS] O
if O
the O
inhibitor O
screen O
was O
positive O
for O
an O
inhibitor O
of O
factor O
x O
, O
the O
inhibitor O
was O
q O
##uant O
##itated O
by O
the O
bet O
##hes O
##da O
ass O
##ay O
. O
18 O
in O
l O
##m O
##w O
##h O
ass O
##ay O
, O
residual O
free O
factor O
x O
##a O
was O
measured O
in O
plasma O
by O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
after O
addition O
of O
b O
##ov O
##ine O
at O
ii O
##i O
and O
factor O
x O
##a O
, O
which O
forms O
an O
inactive O
factor O
x O
##a O
‐ O
at O
ii O
##i O
‐ O
he O
##par O
##in O
complex O
. O
18 O
[SEP] O
[CLS] O
the O
el O
##isa O
has O
an O
identical O
sensitivity O
to O
p O
##or O
##cine O
and O
can O
##ine O
insulin O
. O
[SEP] O
[CLS] O
collected O
samples O
were O
immediately O
cent O
##ri O
##fu O
##ged O
, O
plasma O
was O
al O
##iq O
##uo O
##ted O
, O
and O
glucose O
concentrations O
were O
measured O
with O
a O
y O
##si O
270 O
##0 O
auto O
##ana O
##ly O
##zer O
( O
yellow O
springs O
instruments O
, O
yellow O
springs O
, O
oh O
) O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
- O
and O
inter O
##ass O
##ay O
coefficient O
of O
variance O
of O
insulin O
was O
2 O
. O
3 O
± O
0 O
. O
3 O
% O
and O
2 O
. O
9 O
± O
1 O
. O
3 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
one O
mill O
##ili O
##ter O
of O
blood O
was O
taken O
at O
each O
time O
point O
from O
a O
peripheral O
vein O
into O
chilled O
1 O
. O
5 O
- O
m O
##l O
e O
##ppe O
##ndo O
##rf O
tubes O
coated O
with O
lit O
##hium O
flu O
##ori O
##de O
, O
he O
##par O
##in O
, O
and O
1 O
μ O
##g O
/ O
50 O
μ O
##l O
ed O
##ta O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
changes O
in O
c O
##4 O
or O
c O
##3 O
across O
treatment O
groups O
. O
[SEP] O
[CLS] O
in O
plots O
of O
tan O
##δ O
versus O
stress O
in O
fi O
##g O
. O
1 O
##a O
##3 O
, O
b O
##3 O
and O
c O
##3 O
, O
only O
those O
h O
##ydro O
##gel O
##s O
with O
a O
10 O
% O
concentration O
and O
a O
r O
##op O
##v O
##p O
/ O
c O
##s O
ratio O
of O
20 O
: O
5 O
showed O
tan O
##δ O
values O
of O
< O
1 O
, O
indicating O
that O
those O
h O
##ydro O
##gel O
##s O
with O
g O
′ O
> O
[SEP] O
[CLS] O
all O
tea O
##es O
resolved O
, O
with O
medication O
for O
14 O
of O
them O
( O
in O
9 O
subjects O
) O
. O
[SEP] O
[CLS] O
g O
″ O
had O
gel O
v O
##isco O
##ela O
##stic O
behaviors O
dominated O
by O
elastic O
##ity O
. O
[SEP] O
[CLS] O
k O
##ona O
##ki O
##on O
##® O
mm O
2 O
mg O
is O
approved O
for O
prop O
##hyl O
##ax O
##is O
and O
therapy O
of O
vitamin O
k O
deficiency O
bleeding O
in O
newborn O
##s O
. O
[SEP] O
[CLS] O
standardized O
food O
was O
served O
no O
earlier O
than O
10 O
h O
after O
dos O
##ing O
. O
[SEP] O
[CLS] O
six O
patients O
had O
dose O
interrupt O
##ions O
, O
which O
were O
a O
result O
of O
a O
##es O
in O
five O
patients O
. O
[SEP] O
[CLS] O
there O
were O
no O
clinical O
##ly O
important O
, O
treatment O
- O
related O
trends O
in O
clinical O
chemistry O
parameters O
. O
[SEP] O
[CLS] O
the O
column O
temperature O
was O
set O
to O
70 O
##° O
##c O
. O
[SEP] O
[CLS] O
however O
, O
the O
mobile O
phase O
was O
a O
mixture O
of O
ace O
##ton O
##it O
##ril O
##e O
/ O
water O
/ O
te O
##rt O
- O
but O
##yl O
met O
##hyl O
et O
##her O
/ O
p O
##hos O
##ph O
##ori O
##c O
acid O
( O
52 O
##5 O
/ O
425 O
/ O
50 O
/ O
1 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
at O
a O
flow O
rate O
of O
1 O
. O
5 O
m O
##l O
/ O
minute O
for O
in O
v O
##ivo O
determination O
. O
16 O
[SEP] O
[CLS] O
in O
this O
clinical O
trial O
, O
vitamin O
k O
##1 O
p O
##har O
##ma O
##co O
##kin O
##etics O
was O
investigated O
in O
healthy O
volunteers O
after O
oral O
and O
in O
##tra O
##ven O
##ous O
route O
of O
administration O
. O
[SEP] O
[CLS] O
all O
subjects O
were O
healthy O
according O
to O
their O
medical O
history O
, O
physical O
examination O
, O
and O
standard O
laboratory O
procedures O
. O
[SEP] O
[CLS] O
according O
to O
the O
manufacturer O
' O
s O
product O
information O
, O
me O
##rop O
##ene O
##m O
dose O
reduction O
is O
required O
when O
the O
g O
##f O
##r O
is O
< O
50 O
m O
##l O
/ O
min O
. O
[ O
14 O
] O
[SEP] O
[CLS] O
identification O
of O
anti O
##mic O
##ro O
##bial O
su O
##s O
##ce O
##pt O
##ibility O
and O
mi O
##c O
testing O
were O
performed O
in O
the O
clinical O
micro O
##biology O
laboratory O
using O
the O
v O
##ite O
##k O
2 O
automated O
system O
( O
bio O
##mer O
##ieu O
##x O
, O
ma O
##rc O
##y O
l O
’ O
et O
##oil O
##e O
, O
f O
##rance O
) O
. O
[SEP] O
[CLS] O
the O
linear O
##ity O
of O
the O
method O
was O
assessed O
by O
plotting O
ca O
##li O
##bra O
##tion O
curves O
in O
plasma O
at O
seven O
concentration O
levels O
in O
trip O
##lica O
##te O
on O
three O
consecutive O
days O
. O
[SEP] O
[CLS] O
however O
, O
towards O
the O
end O
of O
the O
dos O
##ing O
interval O
, O
the O
concentration O
falls O
slightly O
below O
the O
evidence O
- O
based O
plasma O
m O
##or O
##phine O
concentration O
for O
anal O
##ges O
##ia O
of O
20 O
μ O
##g O
/ O
l O
. O
cop O
indicates O
that O
an O
adjustment O
in O
the O
dos O
##ing O
interval O
can O
be O
made O
if O
the O
patient O
complain O
##s O
of O
pain O
towards O
the O
end O
of O
the O
dos O
##ing O
interval O
. O
[SEP] O
[CLS] O
the O
inclusion O
criteria O
included O
a O
diagnosis O
of O
un O
##com O
##plicate O
##d O
malaria O
( O
defined O
as O
a O
fever O
[ O
t O
##ym O
##pan O
##ic O
temperature O
of O
≥ O
##38 O
##° O
##c O
or O
history O
of O
fever O
within O
the O
past O
24 O
h O
) O
and O
micro O
##sco O
##py O
- O
confirmed O
p O
. O
f O
##al O
##ci O
##par O
##um O
mon O
##oi O
##n O
##fect O
##ion O
) O
, O
age O
≥ O
##16 O
years O
, O
and O
a O
confirmed O
pregnancy O
of O
12 O
to O
38 O
weeks O
g O
##esta O
##tional O
age O
. O
[SEP] O
[CLS] O
the O
proportion O
of O
flu O
##cona O
##zo O
##le O
concentration O
relative O
to O
mi O
##c O
then O
was O
calculated O
from O
the O
1 O
million O
replica O
##tes O
. O
[SEP] O
[CLS] O
analyses O
were O
performed O
using O
ex O
##cel O
2016 O
( O
micro O
##so O
##ft O
, O
red O
##mond O
, O
wa O
) O
. O
[SEP] O
[CLS] O
then O
the O
plasma O
samples O
obtained O
were O
stored O
at O
− O
##20 O
##° O
##c O
. O
[SEP] O
[CLS] O
the O
q O
##c O
samples O
were O
within O
15 O
% O
of O
the O
nominal O
concentrations O
, O
meeting O
the O
acceptance O
criteria O
of O
the O
us O
food O
and O
drug O
administration O
( O
f O
##da O
) O
for O
the O
valid O
##ation O
of O
bio O
##ana O
##ly O
##tical O
methods O
[ O
31 O
] O
. O
[SEP] O
[CLS] O
the O
in O
v O
##it O
##ro O
release O
data O
were O
applied O
to O
various O
kinetic O
##s O
models O
to O
predict O
the O
drug O
release O
mechanism O
and O
kinetic O
##s O
[ O
table O
1 O
] O
. O
[SEP] O
[CLS] O
after O
a O
single O
oral O
dose O
, O
blood O
samples O
will O
be O
drawn O
at O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
, O
and O
8 O
h O
. O
samples O
will O
be O
collected O
, O
processed O
, O
and O
shipped O
according O
to O
standard O
operating O
procedures O
. O
[SEP] O
[CLS] O
the O
drug O
release O
was O
proportional O
to O
square O
root O
of O
time O
. O
[SEP] O
[CLS] O
we O
will O
recruit O
approximately O
6 O
– O
8 O
subjects O
per O
dose O
( O
100 O
mg O
, O
200 O
mg O
or O
300 O
mg O
ni O
- O
03 O
) O
in O
this O
phase O
i O
study O
, O
giving O
a O
total O
of O
18 O
– O
24 O
subjects O
. O
[SEP] O
[CLS] O
these O
data O
support O
the O
p O
##har O
##ma O
##co O
##dynamic O
similarity O
of O
the O
proposed O
p O
##eg O
##fi O
##l O
##gra O
##st O
##im O
bio O
##si O
##mi O
##lar O
and O
the O
reference O
product O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
2 O
##a O
, O
an O
##c O
increased O
as O
expected O
after O
single O
‐ O
dose O
sub O
##cut O
##aneous O
administration O
, O
with O
peak B-PK
levels I-PK
occurring O
approximately O
64 O
and O
61 O
hours O
post O
##dos O
##e O
for O
the O
proposed O
p O
##eg O
##fi O
##l O
##gra O
##st O
##im O
bio O
##si O
##mi O
##lar O
and O
the O
reference O
product O
, O
respectively O
, O
and O
returning O
to O
base O
##line O
levels O
by O
approximately O
360 O
hours O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
this O
would O
be O
considered O
the O
dos O
##age O
rate O
to O
be O
used O
in O
clinical O
evaluation O
. O
[SEP] O
[CLS] O
12 O
% O
bi O
##s O
t O
##ris O
n O
##up O
##age O
gel O
##s O
( O
in O
##vi O
##tro O
##gen O
) O
were O
run O
in O
me O
##s O
running O
buffer O
as O
per O
manufacturer O
’ O
s O
protocol O
. O
[SEP] O
[CLS] O
re O
##comb O
##ina O
##nt O
mouse O
and O
human O
t O
##n O
##f O
##r O
##1 O
ch O
##ime O
##ras O
and O
single O
point O
mutant O
##s O
were O
expressed O
from O
pp O
##icz O
##al O
##pha O
expression O
vector O
in O
p O
##ichi O
##a O
pastor O
##is O
km O
##7 O
##1 O
##h O
strain O
using O
met O
##han O
##ol O
induction O
. O
[SEP] O
[CLS] O
it O
was O
six O
times O
higher O
than O
the O
mean O
t B-PK
##max I-PK
of O
0 O
. O
03 O
h O
after O
a O
single O
oral O
administration O
of O
f O
##er O
##uli O
##c O
acid O
[ O
21 O
] O
, O
which O
implies O
other O
components O
in O
n O
##x O
##t O
##c O
might O
affect O
the O
absorption O
of O
f O
##er O
##uli O
##c O
acid O
. O
[SEP] O
[CLS] O
further O
details O
on O
the O
experimental O
design O
and O
results O
can O
be O
found O
in O
we O
##sch O
##ler O
et O
al O
. O
10 O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
was O
estimated O
using O
the O
trap O
##ez O
##oid O
##al O
rule O
with O
log O
‐ O
extension O
to O
in O
##finity O
based O
on O
the O
last O
three O
points O
. O
[SEP] O
[CLS] O
the O
half B-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
calculated O
as O
l O
##n O
##2 O
/ O
k O
and O
the O
elimination B-PK
rate I-PK
constant I-PK
k I-PK
was O
estimated O
as O
the O
negative O
of O
the O
slope O
from O
a O
linear O
re O
##gression O
of O
log O
concentration O
of O
time O
. O
[SEP] O
[CLS] O
drug O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
were O
estimated O
as O
dose B-PK
/ I-PK
au I-PK
##c I-PK
and O
c B-PK
##l I-PK
/ I-PK
k I-PK
, O
respectively O
. O
[SEP] O
[CLS] O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
and O
in O
##tra O
‐ O
individual O
var O
##iability O
of O
do O
##ce O
##ta O
##xe O
##l O
clearance B-PK
, O
volume B-PK
of I-PK
distribution I-PK
, O
and O
half B-PK
‐ I-PK
life I-PK
were O
estimated O
with O
multi O
##lev O
##el O
modeling O
for O
repeat O
measures O
in O
which O
the O
fixed O
effects O
and O
residual O
variance O
represents O
the O
inter O
‐ O
and O
in O
##tra O
‐ O
individual O
variance O
, O
respectively O
. O
[SEP] O
[CLS] O
high O
peak B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
> O
80 O
mg O
/ O
m O
##l O
were O
achieved O
with O
i O
##v O
injection O
of O
the O
negative O
( O
t O
##co O
##oh O
) O
, O
neutral O
( O
te O
##go O
##h O
) O
and O
z O
##wi O
##tter O
##ion O
##ic O
( O
t O
##z O
##wi O
##t O
) O
particles O
, O
while O
a O
10 O
- O
fold O
lower O
peak B-PK
plasma I-PK
concentration I-PK
was O
achieved O
with O
the O
positive O
( O
t O
##t O
##ma O
) O
particles O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
following O
i O
##v O
injection O
, O
high O
plasma B-PK
clearance I-PK
was O
observed O
for O
the O
negative O
( O
t O
##co O
##oh O
) O
and O
positive O
( O
t O
##t O
##ma O
) O
charged O
au O
##n O
##ps O
( O
0 O
. O
07 O
##39 O
µ O
##g O
/ O
m O
##l O
/ O
min O
and O
0 O
. O
170 O
µ O
##g O
/ O
m O
##l O
/ O
min O
, O
respectively O
) O
such O
that O
the O
plasma O
concentrations O
fell O
below O
1 O
mg O
/ O
m O
##l O
within O
15 O
minutes O
after O
injection O
( O
figure O
1 O
##a O
) O
. O
[SEP] O
[CLS] O
the O
results O
of O
recovery O
rate O
in O
v O
##ivo O
are O
summarized O
in O
table O
4 O
. O
[SEP] O
[CLS] O
the O
relationship O
between O
raw O
q O
##t O
interval O
and O
r O
##r O
interval O
showed O
a O
steep O
positive O
slope O
( O
slope O
p O
< O
0 O
. O
000 O
##1 O
) O
, O
as O
expected O
based O
on O
normal O
physiology O
. O
[SEP] O
[CLS] O
the O
lines O
in O
fi O
##g O
. O
6 O
are O
the O
p O
##b O
##p O
##k O
model O
predictions O
using O
the O
op O
##ti O
##mized O
standard O
parameters O
in O
tables O
1 O
and O
2 O
. O
[SEP] O
[CLS] O
thus O
, O
the O
in O
v O
##ivo O
recovery O
rate O
can O
be O
used O
to O
correct O
the O
data O
in O
the O
micro O
##dial O
##ys O
##is O
test O
. O
[SEP] O
[CLS] O
p O
##lu O
##rip O
##ote O
##ncy O
was O
confirmed O
through O
quantitative O
p O
##c O
##r O
gene O
expression O
analysis O
of O
the O
p O
##lu O
##rip O
##ote O
##ncy O
genes O
na O
##no O
##g O
, O
o O
##ct O
##3 O
/ O
4 O
and O
so O
##x O
##2 O
. O
[SEP] O
[CLS] O
most O
tea O
##es O
( O
16 O
/ O
26 O
, O
61 O
. O
5 O
% O
) O
were O
of O
mild O
intensity O
, O
38 O
. O
5 O
% O
were O
of O
moderate O
intensity O
, O
and O
none O
was O
severe O
. O
[SEP] O
[CLS] O
enrolled O
patients O
were O
screened O
for O
t O
##b O
using O
a O
q O
##uant O
##ifer O
##on O
- O
t O
##b O
gold O
in O
- O
tube O
test O
and O
chest O
x O
- O
ray O
( O
or O
chest O
c O
##t O
scan O
at O
the O
investigator O
' O
s O
discretion O
) O
. O
[SEP] O
[CLS] O
re O
##p O
##rog O
##ram O
##med O
p O
##b O
##m O
##cs O
were O
transferred O
to O
me O
##f O
feeder O
cells O
on O
mat O
##rig O
##el O
- O
coated O
plates O
at O
day O
3 O
after O
trans O
##fect O
##ion O
and O
culture O
##d O
in O
te O
##s O
##r O
- O
e O
##7 O
and O
sodium O
but O
##yra O
##te O
re O
##p O
##rog O
##ram O
##ming O
medium O
( O
stem O
##cell O
technologies O
) O
. O
[SEP] O
[CLS] O
each O
200 O
μ O
##l O
sample O
contained O
0 O
. O
35 O
% O
met O
##hyl O
cell O
##ulos O
##e O
( O
protein O
simple O
) O
, O
4 O
% O
p O
##har O
##mal O
##yte O
3 O
– O
10 O
( O
g O
##e O
healthcare O
) O
, O
10 O
mm O
a O
##rg O
##ini O
##ne O
( O
protein O
simple O
) O
, O
0 O
. O
2 O
mg O
m O
##l O
##− O
##1 O
anti O
##body O
and O
the O
4 O
. O
05 O
and O
9 O
. O
99 O
p O
##i O
markers O
( O
protein O
simple O
) O
. O
[SEP] O
[CLS] O
for O
in O
v O
##it O
##ro O
determination O
of O
c O
##ya O
, O
the O
mobile O
phase O
consists O
of O
ace O
##ton O
##it O
##ril O
##e O
/ O
water O
/ O
te O
##rt O
- O
but O
##yl O
met O
##hyl O
et O
##her O
/ O
p O
##hos O
##ph O
##ori O
##c O
acid O
( O
60 O
/ O
35 O
/ O
5 O
/ O
0 O
. O
1 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
at O
a O
flow O
rate O
of O
1 O
. O
0 O
m O
##l O
/ O
minute O
. O
[SEP] O
[CLS] O
day O
1 O
: O
r O
##it O
##ux O
##ima O
##b O
375 O
mg O
/ O
m O
##2 O
in O
##tra O
##ven O
##ously O
( O
i O
##v O
) O
[SEP] O
[CLS] O
animals O
were O
a O
##cc O
##lim O
##ated O
for O
at O
least O
a O
week O
prior O
to O
study O
initiation O
. O
[SEP] O
[CLS] O
the O
linear O
##ity O
of O
the O
proposed O
method O
in O
rabbit O
plasma O
was O
55 O
– O
330 O
× O
10 O
##− O
##7 O
m O
with O
a O
correlation O
coefficient O
of O
0 O
. O
99 O
##8 O
##9 O
± O
0 O
. O
00 O
##9 O
( O
table O
5 O
) O
. O
[SEP] O
[CLS] O
it O
also O
implies O
that O
for O
those O
complex O
h O
##ydro O
##gel O
##s O
with O
a O
r O
##op O
##v O
##p O
/ O
c O
##s O
ratio O
of O
20 O
: O
5 O
, O
a O
h O
##ydro O
##gel O
concentration O
of O
7 O
. O
5 O
~ O
10 O
% O
was O
desirable O
to O
form O
a O
solid O
- O
like O
h O
##ydro O
##gel O
with O
a O
higher O
gel O
strength O
. O
[SEP] O
[CLS] O
an O
in O
##cision O
was O
made O
on O
the O
lateral O
side O
of O
the O
neck O
to O
expose O
the O
j O
##ug O
##ular O
vein O
, O
which O
was O
isolated O
and O
a O
two O
- O
l O
##ume O
##n O
central O
ve O
##nous O
cat O
##he O
##ter O
was O
inserted O
into O
the O
l O
##ume O
##n O
of O
the O
vein O
. O
[SEP] O
[CLS] O
the O
p O
##k O
analysis O
set O
comprised O
subjects O
in O
the O
safety O
analysis O
set O
for O
whom O
p O
##k O
data O
were O
adequate O
for O
the O
calculation O
of O
at O
least O
1 O
of O
the O
primary O
p O
##k O
parameters O
. O
[SEP] O
[CLS] O
the O
interval O
between O
treatments O
at O
the O
same O
dos O
##age O
level O
was O
1 O
week O
. O
[SEP] O
[CLS] O
the O
ll O
##o O
##q O
values O
for O
the O
four O
components O
in O
rat O
plasma O
were O
g O
##ent O
##io O
##pic O
##ros O
##ide O
( O
10 O
ng O
/ O
m O
##l O
) O
, O
g O
##eni O
##po O
##side O
( O
5 O
ng O
/ O
m O
##l O
) O
, O
b O
##aic O
##ali O
##n O
( O
10 O
ng O
/ O
m O
##l O
) O
, O
and O
s O
##wer O
##tia O
##mar O
##in O
( O
5 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
descriptive O
statistics O
were O
used O
to O
sum O
##mar O
##ize O
continuous O
and O
cat O
##ego O
##rical O
variables O
. O
[SEP] O
[CLS] O
all O
animal O
experiments O
and O
experimental O
protocols O
were O
conducted O
in O
accordance O
with O
the O
guide O
for O
the O
care O
and O
use O
of O
laboratory O
animals O
of O
h O
##ui O
##bei O
provincial O
laboratory O
animal O
public O
service O
center O
( O
permit O
number O
s O
##yx O
##k O
2013 O
- O
00 O
##44 O
) O
and O
approved O
by O
the O
ethics O
committee O
of O
h O
##ua O
##z O
##hong O
agricultural O
un O
##iver O
##ist O
##y O
, O
w O
##uh O
##an O
, O
chin O
##a O
. O
[SEP] O
[CLS] O
this O
was O
not O
possible O
due O
to O
limited O
numbers O
of O
animals O
available O
for O
this O
trial O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
when O
dos O
##age O
levels O
were O
changed O
in O
an O
individual O
, O
a O
minimum O
break O
of O
3 O
weeks O
between O
treatments O
was O
used O
. O
[SEP] O
[CLS] O
blood O
samples O
( O
200 O
μ O
##l O
) O
were O
collected O
from O
the O
vein O
of O
the O
eye O
socket O
##s O
into O
he O
##par O
##ini O
##zed O
tubes O
after O
the O
rats O
were O
an O
##est O
##he O
##tized O
with O
et O
##hyl O
et O
##her O
. O
[SEP] O
[CLS] O
subjects O
received O
a O
single O
dose O
of O
4 O
spray O
##s O
th O
##c O
/ O
c O
##b O
##d O
on O
day O
1 O
. O
[SEP] O
[CLS] O
we O
performed O
a O
mon O
##te O
car O
##lo O
simulation O
with O
1 O
million O
replica O
##tes O
based O
on O
the O
normal O
distribution O
of O
steady O
- O
state O
flu O
##cona O
##zo O
##le O
concentrations O
from O
the O
different O
doses O
. O
[SEP] O
[CLS] O
subjects O
received O
once O
daily O
o O
##me O
##pra O
##zo O
##le O
on O
days O
2 O
- O
6 O
, O
and O
then O
th O
##c O
/ O
c O
##b O
##d O
spray O
and O
o O
##me O
##pra O
##zo O
##le O
on O
day O
7 O
. O
[SEP] O
[CLS] O
sex O
difference O
was O
observed O
for O
d O
##ha O
and O
its O
meta O
##bol O
##ites O
( O
m O
##1 O
and O
d O
##ha O
- O
g O
) O
, O
whereas O
its O
pro O
##dr O
##ug O
a O
##rs O
did O
not O
show O
similar O
characteristics O
for O
the O
corresponding O
meta O
##bol O
##ites O
( O
d O
##ha O
, O
m O
##1 O
and O
d O
##ha O
- O
g O
) O
. O
[SEP] O
[CLS] O
the O
drug O
release O
mechanism O
from O
the O
micro O
##sp O
##here O
##s O
thus O
can O
be O
described O
as O
diffusion O
controlled O
. O
[SEP] O
[CLS] O
in O
this O
phase O
, O
ta O
##s O
- O
121 O
was O
administered O
oral O
##ly O
q O
##d O
with O
a O
starting O
dos O
##age O
of O
2 O
mg O
/ O
day O
. O
[SEP] O
[CLS] O
the O
dos O
##ing O
rational O
##e O
was O
derived O
from O
a O
4 O
- O
weeks O
repeated O
oral O
- O
dose O
toxic O
##ology O
study O
in O
monkeys O
. O
[SEP] O
[CLS] O
a O
theoretical O
calculation O
was O
performed O
to O
estimate O
the O
target O
particle O
size O
at O
which O
a O
na O
##no O
##par O
##tic O
##le O
should O
rapidly O
dissolve O
in O
the O
blood O
##stream O
( O
i O
. O
e O
. O
, O
< O
10 O
s O
under O
non O
- O
stirred O
condition O
) O
upon O
in O
##tra O
##ven O
##ous O
administration O
. O
[SEP] O
[CLS] O
the O
study O
was O
registered O
in O
the O
euro O
##pe O
##an O
clinical O
trials O
database O
( O
e O
##ud O
##rac O
##t O
number O
2008 O
- O
00 O
##36 O
##43 O
- O
36 O
) O
and O
conducted O
in O
accordance O
with O
good O
clinical O
practice O
( O
g O
##c O
##p O
) O
, O
the O
current O
requirements O
of O
em O
##a O
( O
euro O
##pe O
##an O
medicines O
agency O
) O
[ O
23 O
] O
, O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
and O
local O
and O
euro O
##pe O
##an O
law O
. O
[SEP] O
[CLS] O
the O
injection O
volume O
was O
50 O
μ O
##l O
and O
the O
total O
run O
time O
was O
30 O
min O
. O
[SEP] O
[CLS] O
the O
analyses O
were O
carried O
out O
at O
room O
temperature O
on O
a O
l O
##una O
c O
##18 O
column O
( O
particle O
size O
: O
5 O
μ O
##m O
, O
250 O
× O
4 O
. O
6 O
mm O
, O
p O
##hen O
##ome O
##nex O
) O
protected O
with O
a O
guard O
column O
( O
p O
##hen O
##ome O
##nex O
security O
##guard O
4 O
× O
2 O
. O
0 O
mm O
) O
. O
[SEP] O
[CLS] O
the O
external O
standard O
method O
was O
used O
for O
quantitative O
analysis O
. O
16 O
[SEP] O
[CLS] O
the O
dose O
limiting O
toxicity O
was O
ne O
##ut O
##rop O
##enia O
, O
with O
3 O
of O
5 O
animals O
treated O
at O
that O
dos O
##age O
rate O
showing O
grade O
2 O
to O
4 O
ne O
##ut O
##rop O
##enia O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
safety O
end O
##points O
were O
incidence O
, O
severity O
, O
drug O
- O
related O
##ness O
, O
and O
serious O
##ness O
of O
adverse O
events O
and O
of O
laboratory O
abnormal O
##ities O
. O
[SEP] O
[CLS] O
the O
same O
sections O
were O
ex O
##cise O
##d O
from O
the O
control O
pig O
and O
fixed O
in O
neutral O
buffer O
##ed O
formal O
##in O
in O
order O
to O
preserve O
the O
tissues O
. O
[SEP] O
[CLS] O
covers O
##lip O
##ping O
was O
undertaken O
to O
prevent O
the O
tissue O
from O
being O
scratched O
and O
to O
provide O
better O
optical O
quality O
during O
micro O
##scopic O
viewing O
. O
[SEP] O
[CLS] O
descriptions O
of O
the O
micro O
##scopic O
features O
were O
made O
and O
a O
final O
micro O
##scopic O
diagnosis O
was O
reported O
. O
[SEP] O
[CLS] O
each O
volunteer O
participating O
in O
this O
study O
was O
informed O
by O
the O
clinical O
investigator O
about O
the O
m O
##oda O
##lity O
and O
the O
possible O
risks O
of O
the O
trial O
and O
consent O
##ed O
to O
study O
participation O
in O
writing O
before O
undergoing O
the O
first O
study O
- O
related O
procedure O
. O
[SEP] O
[CLS] O
also O
, O
as O
listed O
in O
table O
1 O
, O
the O
dog O
showed O
the O
lowest O
mean O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
3 O
. O
10 O
h O
and O
the O
monkey O
, O
the O
highest O
value O
of O
9 O
. O
94 O
h O
. O
[SEP] O
[CLS] O
a O
dose O
- O
and O
time O
- O
dependent O
reduction O
in O
the O
cell O
proliferation O
rate O
was O
evident O
with O
a O
c O
##yt O
##ost O
##atic O
effect O
up O
to O
24 O
h O
post O
- O
treatment O
followed O
by O
growth O
in O
##hibition O
( O
fi O
##g O
. O
1 O
##c O
) O
except O
in O
cells O
treated O
with O
60 O
μ O
##m O
and O
##rog O
##rap O
##hol O
##ide O
. O
[SEP] O
[CLS] O
after O
topic O
##al O
application O
of O
the O
26 O
##al O
‐ O
a O
##ch O
anti O
##pers O
##pi O
##rant O
, O
a O
cotton O
t O
‐ O
shirt O
was O
dispatched O
to O
the O
subjects O
to O
wear O
for O
the O
rest O
of O
the O
day O
and O
during O
the O
night O
to O
minimize O
loss O
of O
radio O
##la O
##bel O
to O
the O
environment O
. O
[SEP] O
[CLS] O
to O
provide O
some O
evidence O
on O
u O
##rina O
##ry O
ex O
##cre O
##tion O
, O
spot O
urine O
samples O
were O
taken O
in O
the O
study O
at O
24 O
hours O
, O
3 O
, O
4 O
, O
18 O
, O
15 O
, O
22 O
, O
and O
29 O
days O
post O
##dos O
##e O
and O
normal O
##ized O
to O
c O
##rea O
##tin O
##ine O
concentration O
. O
[SEP] O
[CLS] O
( O
a O
) O
drafting O
the O
manuscript O
[SEP] O
[CLS] O
figure O
##3 O
compares O
the O
time O
course O
of O
linear O
/ O
non O
##linear O
fraction B-PK
##al I-PK
drug I-PK
elimination I-PK
( O
1 O
/ O
day O
) O
and O
measures O
b O
‐ O
/ O
t O
‐ O
cell O
dynamics O
in O
blood O
. O
[SEP] O
[CLS] O
the O
do O
##x O
group O
was O
given O
an O
i O
. O
v O
. O
single O
dose O
of O
5 O
. O
0 O
mg O
/ O
kg O
do O
##x O
via O
the O
tail O
vein O
. O
[SEP] O
[CLS] O
dose O
‐ O
depend O
##ency O
of O
peripheral O
blood O
b O
‐ O
cell O
de O
##ple O
##tion O
could O
not O
be O
detected O
in O
the O
pre O
##c O
##lini O
##cal O
studies O
, O
possibly O
due O
to O
the O
bulk O
of O
b O
‐ O
cell O
de O
##ple O
##tion O
occurring O
prior O
to O
the O
first O
sampling O
time O
##point O
at O
2 O
h O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
male O
subjects O
must O
also O
refrain O
from O
don O
##ating O
sperm O
during O
this O
period O
. O
[SEP] O
[CLS] O
in O
##tra O
- O
and O
inter O
##day O
variations O
were O
for O
determining O
the O
precision O
of O
the O
developed O
method O
. O
[SEP] O
[CLS] O
additionally O
, O
across O
the O
pre O
##c O
##lini O
##cal O
range O
of O
doses O
evaluated O
, O
a O
pronounced O
dose O
‐ O
depend O
##ency O
was O
observed O
in O
both O
the O
non O
##linear O
drug O
elimination O
term O
and O
the O
t O
‐ O
cell O
response O
, O
particularly O
in O
the O
first O
7 O
days O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
methods O
for O
radio O
##la O
##bel O
##ing O
and O
pu O
##rification O
of O
a O
m O
##f O
##w O
solution O
of O
s O
##w O
##c O
##nt O
- O
( O
dot O
##a O
) O
( O
h O
##nh O
) O
with O
225 O
##ac O
at O
p O
##h O
5 O
are O
similar O
to O
those O
described O
previously O
. O
48 O
briefly O
, O
0 O
. O
18 O
mg O
of O
s O
##w O
##c O
##nt O
- O
( O
dot O
##a O
) O
( O
h O
##nh O
) O
in O
0 O
. O
02 O
m O
##l O
of O
m O
##f O
##w O
was O
reacted O
with O
0 O
. O
00 O
##5 O
m O
##l O
of O
225 O
##ac O
in O
50 O
mm O
op O
##ti O
##ma O
grade O
h O
##ydro O
##ch O
##lor O
##ic O
acid O
( O
h O
##c O
##l O
; O
fish O
##er O
scientific O
, O
pit O
##ts O
##burgh O
, O
p O
##a O
, O
us O
##a O
) O
along O
with O
0 O
. O
02 O
m O
##l O
of O
150 O
g O
/ O
l O
l O
- O
as O
##cor O
##bic O
acid O
( O
si O
##gma O
- O
al O
##dric O
##h O
) O
and O
0 O
. O
2 O
m O
##l O
of O
3 O
m O
te O
##tra O
##met O
##hyl O
##am O
##mon O
##ium O
ace O
##tate O
( O
fish O
##er O
scientific O
) O
buffer O
, O
p O
##h O
5 O
. O
5 O
, O
at O
60 O
##° O
##c O
for O
60 O
minutes O
( O
reaction O
1 O
) O
. O
[SEP] O
[CLS] O
relative O
purity O
of O
protein O
samples O
were O
assessed O
on O
a O
non O
- O
reducing O
s O
##ds O
- O
page O
. O
[SEP] O
[CLS] O
purpose O
: O
to O
examine O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
characteristics O
of O
sustained O
- O
release O
de O
##xa O
##met O
##has O
##one O
depot O
##s O
in O
two O
separate O
can O
##ine O
studies O
. O
[SEP] O
[CLS] O
responses O
of O
c O
- O
fiber O
no O
##ci O
##ceptor O
##s O
e O
##voked O
by O
heat O
were O
reduced O
by O
compound O
52 O
. O
[SEP] O
[CLS] O
all O
were O
pu O
##rified O
from O
culture O
super O
##nat O
##ants O
by O
protein O
- O
a O
( O
g O
##e O
healthcare O
) O
affinity O
capture O
followed O
by O
cat O
##ion O
exchange O
ch O
##roma O
##tography O
and O
polished O
using O
size O
exclusion O
ch O
##roma O
##tography O
when O
necessary O
. O
[SEP] O
[CLS] O
for O
the O
descriptive O
cat O
##ego O
##rical O
data O
the O
comparisons O
were O
explored O
with O
log O
##istic O
re O
##gression O
analyses O
. O
[SEP] O
[CLS] O
solutions O
of O
50 O
mm O
diet O
##hyl O
##ene O
##tri O
##amine O
##pent O
##aa O
##ce O
##tic O
acid O
( O
d O
##t O
##pa O
; O
si O
##gma O
- O
al O
##dric O
##h O
) O
were O
s O
##ter O
##ile O
filtered O
and O
used O
to O
que O
##nch O
the O
label O
##ing O
reaction O
prior O
to O
se O
##c O
. O
[SEP] O
[CLS] O
there O
was O
a O
large O
increase O
in O
au B-PK
##c I-PK
for O
set O
1 O
through O
set O
6 O
when O
the O
p O
##d O
- O
related O
information O
was O
integrated O
to O
the O
enzyme O
information O
( O
set O
20 O
) O
. O
[SEP] O
[CLS] O
on O
schedule O
2 O
/ O
1 O
, O
at O
the O
next O
highest O
dose O
level O
( O
sun O
##iti O
##ni O
##b O
50 O
mg O
with O
p O
##em O
##et O
##re O
##xed O
500 O
mg O
/ O
m O
##2 O
; O
n O
= O
7 O
) O
, O
only O
one O
d O
##lt O
was O
observed O
. O
[SEP] O
[CLS] O
specific O
r O
##rf O
##c O
##1 O
anti O
##ser O
##um O
was O
added O
at O
a O
1 O
: O
500 O
di O
##lution O
for O
72 O
h O
at O
4 O
##° O
##c O
. O
[SEP] O
[CLS] O
figure O
3 O
##c O
shows O
g O
##a O
- O
c O
##ts O
/ O
5 O
- O
f O
##u O
na O
##no O
##par O
##tic O
##le O
with O
b O
##ov O
##ine O
serum O
; O
the O
size O
of O
g O
##a O
- O
c O
##ts O
/ O
5 O
- O
f O
##u O
na O
##no O
##par O
##tic O
##les O
( O
206 O
. O
0 O
nm O
) O
was O
increased O
a O
little O
and O
the O
charge O
( O
+ O
14 O
. O
3 O
m O
##v O
) O
was O
decreased O
obviously O
, O
and O
the O
p O
##i O
was O
0 O
. O
135 O
. O
[SEP] O
[CLS] O
s O
##tri O
##ata O
##l O
d O
##2 O
receptor O
o O
##cc O
##up O
##ancy O
was O
calculated O
using O
the O
simplified O
reference O
tissue O
model O
. O
[SEP] O
[CLS] O
t O
##rough O
d O
##2 O
receptor O
o O
##cc O
##up O
##ancy O
was O
similarly O
low O
for O
both O
formulation O
##s O
( O
i O
##r O
7 O
##± O
##7 O
% O
, O
x O
##r O
8 O
##± O
##6 O
% O
) O
. O
[SEP] O
[CLS] O
assuming O
that O
our O
findings O
in O
control O
subjects O
are O
valid O
for O
patients O
with O
s O
##chi O
##zophrenia O
, O
the O
study O
supports O
the O
view O
that O
que O
##tia O
##pine O
, O
like O
the O
prototype O
at O
##y O
##pical O
anti O
##psy O
##cho O
##tic O
c O
##lo O
##za O
##pine O
, O
may O
show O
anti O
##psy O
##cho O
##tic O
effect O
at O
lower O
d O
##2 O
receptor O
o O
##cc O
##up O
##ancy O
than O
typical O
anti O
##psy O
##cho O
##tics O
. O
[SEP] O
[CLS] O
after O
base O
##line O
examination O
, O
que O
##tia O
##pine O
x O
##r O
was O
administered O
once O
- O
daily O
for O
8 O
d O
t O
##it O
##rated O
to O
300 O
mg O
/ O
d O
on O
days O
5 O
– O
8 O
, O
followed O
by O
300 O
mg O
/ O
d O
que O
##tia O
##pine O
i O
##r O
on O
days O
9 O
– O
12 O
. O
[SEP] O
[CLS] O
while O
initially O
manufactured O
as O
an O
immediate O
- O
release O
( O
i O
##r O
) O
formulation O
, O
an O
extended O
- O
release O
( O
x O
##r O
) O
formulation O
has O
recently O
been O
introduced O
. O
[SEP] O
[CLS] O
peak O
d O
##2 O
receptor O
o O
##cc O
##up O
##ancy O
was O
significantly O
higher O
with O
que O
##tia O
##pine O
i O
##r O
than O
x O
##r O
in O
all O
subjects O
( O
50 O
##± O
##4 O
% O
and O
32 O
##± O
##11 O
% O
, O
respectively O
) O
, O
consistent O
with O
lower O
peak B-PK
plasma I-PK
concentrations I-PK
for O
the O
x O
##r O
formulation O
. O
[SEP] O
[CLS] O
here O
, O
we O
used O
ch O
##ito O
##san O
( O
c O
##ts O
) O
and O
he O
##pa O
##tom O
##a O
cell O
- O
specific O
binding O
molecule O
g O
##ly O
##cy O
##rr O
##he O
##tin O
##ic O
acid O
to O
s O
##ynth O
##esi O
##ze O
g O
##ly O
##cy O
##rr O
##he O
##tin O
##ic O
acid O
- O
modified O
ch O
##ito O
##san O
( O
g O
##a O
- O
c O
##ts O
) O
. O
[SEP] O
[CLS] O
data O
s O
##2 O
correlation O
results O
for O
significantly O
regulated O
pathways O
and O
cellular O
processes O
in O
rats O
. O
[SEP] O
[CLS] O
the O
interactions O
were O
tested O
by O
examining O
the O
impact O
of O
one O
s O
##n O
##p O
in O
two O
separate O
subgroup O
##s O
of O
participants O
, O
ho O
##mo O
##zy O
##got O
##es O
for O
the O
reference O
, O
and O
variant O
all O
##ele O
of O
a O
potential O
con O
##found O
##ing O
s O
##n O
##p O
. O
[SEP] O
[CLS] O
these O
ex O
##p O
##lora O
##tory O
subgroup O
analyses O
revealed O
no O
significant O
interactions O
between O
the O
s O
##n O
##ps O
that O
affect O
met O
##form O
##in O
g O
##ly O
##ce O
##mic O
response O
. O
[SEP] O
[CLS] O
both O
the O
liver O
and O
kidney O
meta O
##bol O
##ize O
the O
in O
##tra O
##cellular O
ram O
##ip O
##ril O
( O
d O
' O
) O
. O
[SEP] O
[CLS] O
study O
recruitment O
will O
occur O
at O
45 O
centers O
in O
the O
us O
##a O
. O
[SEP] O
[CLS] O
all O
the O
analyses O
were O
carried O
out O
by O
the O
mixed O
or O
n O
##par O
##1 O
##way O
procedure O
( O
sa O
##s O
9 O
. O
4 O
, O
sa O
##s O
institute O
, O
in O
##c O
. O
, O
car O
##y O
, O
n O
##c O
, O
united O
states O
) O
. O
[SEP] O
[CLS] O
trained O
study O
personnel O
at O
each O
site O
will O
recruit O
subjects O
. O
[SEP] O
[CLS] O
the O
flow O
rate O
was O
programmed O
as O
follows O
: O
1 O
. O
0 O
m O
##l O
min O
##− O
##1 O
( O
0 O
– O
68 O
min O
) O
, O
0 O
. O
2 O
m O
##l O
min O
##− O
##1 O
( O
68 O
– O
78 O
min O
) O
, O
1 O
. O
0 O
m O
##l O
min O
##− O
##1 O
( O
78 O
– O
100 O
min O
) O
. O
[SEP] O
[CLS] O
eligible O
patients O
were O
men O
or O
non O
##p O
##re O
##gnant O
and O
non O
##la O
##ct O
##ating O
women O
, O
20 O
– O
64 O
years O
of O
age O
, O
body O
mass O
index O
≥ O
##18 O
. O
5 O
and O
< O
30 O
. O
0 O
kg O
m O
– O
2 O
, O
with O
cc O
of O
at O
least O
6 O
months O
' O
duration O
. O
[SEP] O
[CLS] O
there O
was O
no O
statistical O
##ly O
significant O
difference O
in O
n O
##ugen O
##t O
score O
prior O
to O
pod O
- O
i O
##v O
##r O
placement O
compared O
to O
pod O
- O
i O
##v O
##r O
: O
t O
##d O
##f O
pod O
- O
i O
##v O
##r O
, O
p O
= O
0 O
. O
60 O
##6 O
##8 O
; O
t O
##d O
##f O
- O
ft O
##c O
pod O
- O
i O
##v O
##r O
, O
p O
= O
0 O
. O
56 O
##11 O
. O
[SEP] O
[CLS] O
the O
effect O
of O
and O
##rog O
##rap O
##hol O
##ide O
on O
mm O
##p O
in O
m O
##da O
- O
m O
##b O
- O
231 O
cells O
was O
also O
investigated O
to O
determine O
whether O
and O
##rog O
##rap O
##hol O
##ide O
induced O
- O
r O
##os O
production O
coincide O
##s O
with O
loss O
of O
mm O
##p O
( O
[UNK] O
) O
, O
which O
is O
considered O
as O
an O
early O
in O
##tra O
##cellular O
event O
during O
onset O
of O
a O
##pop O
##tosis O
. O
[SEP] O
[CLS] O
this O
represents O
a O
trade O
##off O
between O
precision O
and O
safety O
. O
[SEP] O
[CLS] O
these O
results O
indicate O
that O
the O
que O
/ O
t O
##m O
##z O
- O
n O
##ls O
have O
superior O
anti O
##can O
##cer O
effects O
on O
t O
##m O
##z O
- O
resistant O
g O
##lio O
##ma O
cells O
. O
[SEP] O
[CLS] O
we O
use O
a O
minimum O
δ O
% O
co O
##h O
##b O
of O
4 O
. O
5 O
% O
to O
avoid O
over O
##est O
##imating O
th O
##b O
‐ O
mass O
. O
[SEP] O
[CLS] O
the O
remaining O
anal O
##yte O
##s O
were O
determined O
by O
protein O
precipitation O
of O
50 O
. O
0 O
μ O
##l O
plasma O
with O
300 O
μ O
##l O
ace O
##ton O
##it O
##ril O
##e O
followed O
by O
a O
ch O
##roma O
##to O
##graphic O
separation O
on O
a O
c O
##18 O
column O
( O
the O
same O
as O
for O
flu O
##rb O
##ip O
##ro O
##fen O
) O
under O
gradient O
conditions O
and O
liquid O
ch O
##roma O
##tography O
‐ O
tandem O
mass O
s O
##pect O
##rome O
##try O
detection O
of O
positive O
ions O
. O
[SEP] O
[CLS] O
the O
safety O
limit O
of O
10 O
% O
is O
based O
on O
previous O
work O
by O
our O
group O
and O
professor O
s O
##ch O
##mi O
##dt O
who O
developed O
the O
o O
##cor O
test O
. O
[SEP] O
[CLS] O
relevant O
data O
were O
drawn O
from O
the O
electronic O
patient O
file O
and O
the O
intensive O
care O
information O
system O
. O
[SEP] O
[CLS] O
the O
following O
equation O
[ O
36 O
] O
was O
used O
to O
describe O
the O
bi O
##ex O
##po O
##nent O
##ial O
concentration O
– O
time O
curves O
for O
fl O
##b O
##z O
and O
r O
- O
fl O
##b O
##z O
after O
the O
i O
. O
r O
. O
/ O
i O
. O
a O
treatments O
: O
[SEP] O
[CLS] O
the O
recovered O
depot O
##s O
were O
collected O
for O
photography O
and O
drug O
content O
analysis O
. O
[SEP] O
[CLS] O
the O
concentration O
of O
each O
variant O
at O
each O
time O
point O
was O
determined O
by O
a O
bottom O
- O
up O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
ass O
##ay O
. O
[SEP] O
[CLS] O
a O
urine O
- O
collection O
experiment O
of O
( O
5 O
) O
, O
via O
bladder O
pu O
##nc O
##ture O
after O
an O
i O
##v O
injection O
, O
was O
performed O
on O
three O
additional O
mice O
. O
[SEP] O
[CLS] O
an O
en O
##rich O
##ed O
young O
t O
##rop O
##ho O
##zo O
##ite O
- O
stage O
culture O
of O
p O
. O
f O
##al O
##ci O
##par O
##um O
d O
##d O
##2 O
was O
obtain O
by O
magnetic O
pu O
##rification O
and O
allowed O
to O
recover O
for O
1 O
h O
at O
37 O
° O
##c O
in O
rpm O
##i O
1640 O
medium O
( O
life O
technologies O
) O
en O
##rich O
##ed O
with O
1 O
% O
h O
##y O
##pox O
##ant O
##hine O
( O
c O
. O
c O
. O
pro O
g O
##mb O
##h O
) O
and O
10 O
% O
album O
##ax O
( O
life O
technologies O
) O
. O
[SEP] O
[CLS] O
affinity O
pu O
##rification O
of O
soluble O
his O
##6 O
- O
tag O
##ged O
pet O
- O
id O
##7 O
fusion O
proteins O
was O
performed O
using O
ni O
- O
n O
##ta O
his O
- O
bind O
##® O
re O
##sin O
( O
no O
##vage O
##n O
) O
. O
[SEP] O
[CLS] O
the O
purity O
of O
protein O
was O
assessed O
by O
s O
##ds O
- O
page O
( O
16 O
% O
) O
and O
co O
##oma O
##ssie O
stain O
##ing O
( O
co O
##oma O
##ssie O
brilliant O
blue O
r O
- O
250 O
, O
rot O
##h O
, O
ka O
##rls O
##ru O
##he O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
changes O
in O
the O
p O
##t O
concentrations O
in O
blood O
upon O
in O
##tral O
##ip O
##id O
pre O
- O
treatment O
are O
shown O
in O
fi O
##g O
. O
7 O
. O
[SEP] O
[CLS] O
the O
predicted O
structure O
of O
the O
r O
##rf O
##c O
##1 O
protein O
has O
been O
previously O
described O
. O
7 O
highly O
anti O
##genic O
regions O
in O
the O
r O
##rf O
##c O
##1 O
protein O
sequence O
were O
identified O
by O
determination O
of O
the O
anti O
##genic O
index O
##24 O
using O
pro O
##te O
##an O
5 O
. O
06 O
( O
d O
##nast O
##ar O
software O
, O
in O
##c O
. O
, O
mad O
##ison O
, O
w O
##i O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
product O
integrity O
and O
purity O
were O
confirmed O
by O
s O
##ds O
- O
page O
analysis O
( O
fi O
##g O
1 O
##b O
) O
, O
confirming O
a O
product O
in O
the O
25 O
##k O
##da O
range O
, O
and O
size O
exclusion O
ch O
##roma O
##tography O
( O
fi O
##g O
1 O
##c O
) O
. O
[SEP] O
[CLS] O
the O
pet O
- O
41 O
##a O
vector O
contains O
a O
g O
##lut O
##ath O
##ione O
- O
s O
- O
transfer O
##ase O
( O
g O
##st O
) O
and O
his O
##ti O
##dine O
( O
his O
) O
6 O
gene O
as O
fusion O
tags O
to O
aid O
in O
pu O
##rification O
steps O
. O
[SEP] O
[CLS] O
the O
excellent O
select O
##ivity O
of O
solid O
- O
phase O
extraction O
helped O
to O
improve O
the O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
analysis O
. O
[SEP] O
[CLS] O
male O
participants O
with O
partners O
of O
child O
##be O
##aring O
potential O
who O
agree O
to O
take O
measures O
not O
to O
father O
children O
by O
using O
one O
form O
of O
highly O
effective O
con O
##tra O
##ception O
from O
the O
first O
administration O
of O
all O
study O
drugs O
, O
throughout O
the O
trial O
and O
for O
12 O
months O
after O
the O
last O
dose O
of O
all O
study O
drugs O
. O
[SEP] O
[CLS] O
the O
d O
##lts O
were O
drug O
- O
induced O
liver O
injury O
, O
plate O
##let O
count O
decreased O
, O
u O
##rt O
##ica O
##ria O
, O
inter O
##st O
##iti O
##al O
lung O
disease O
, O
and O
left O
vent O
##ric O
##ular O
failure O
. O
[SEP] O
[CLS] O
responses O
e O
##voked O
by O
the O
most O
intense O
heat O
stimuli O
, O
48 O
##° O
##c O
and O
50 O
##° O
##c O
, O
were O
reduced O
at O
30 O
minutes O
following O
compound O
52 O
( O
new O
##man O
- O
k O
##uel O
##s O
tests O
, O
p O
< O
0 O
. O
05 O
and O
p O
< O
0 O
. O
01 O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
re O
##comb O
##ina O
##nt O
human O
t O
##n O
##f O
- O
α O
( O
cat O
no O
. O
300 O
- O
1 O
##a O
) O
was O
from O
p O
##ep O
##rote O
##ch O
( O
n O
##j O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
descriptive O
group O
data O
are O
given O
as O
median O
( O
minimum O
– O
maximum O
) O
values O
. O
[SEP] O
[CLS] O
225 O
##ac O
radio O
##nu O
##c O
##lide O
was O
obtained O
from O
the O
us O
department O
of O
energy O
’ O
s O
oak O
ridge O
national O
laboratory O
( O
oak O
ridge O
, O
t O
##n O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
a O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
model O
for O
van O
##com O
##y O
##cin O
in O
e O
##c O
##mo O
patients O
was O
developed O
using O
a O
non O
##linear O
mixed O
effects O
modeling O
on O
the O
concentration O
– O
time O
profiles O
of O
14 O
e O
##c O
##mo O
patients O
who O
received O
in O
##tra O
##ven O
##ous O
van O
##com O
##y O
##cin O
. O
[SEP] O
[CLS] O
se O
##m O
of O
g O
##a O
- O
c O
##ts O
/ O
5 O
- O
f O
##u O
showed O
the O
presence O
of O
spherical O
na O
##no O
##par O
##tic O
##les O
( O
size O
193 O
. O
7 O
nm O
) O
with O
smooth O
surfaces O
( O
figure O
3 O
##a O
) O
. O
[SEP] O
[CLS] O
then O
, O
the O
reaction O
was O
stopped O
by O
several O
washing O
steps O
with O
p O
##bs O
, O
samples O
were O
counters O
##tain O
##ed O
with O
may O
##er O
' O
s O
hem O
##ato O
##xy O
##lin O
and O
mounted O
in O
flu O
##or O
save O
re O
##age O
##nt O
( O
ca O
##l O
##bio O
##che O
##m O
, O
bad O
so O
##den O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
mean O
pulse O
increased O
to O
maximum O
levels O
at O
12 O
hours O
after O
treatment O
and O
returned O
to O
pre O
##tre O
##at O
##ment O
levels O
by O
48 O
hours O
after O
dose O
. O
[SEP] O
[CLS] O
these O
results O
suggested O
that O
both O
p O
##k O
and O
p O
##d O
of O
de O
are O
critical O
for O
d O
##di O
prediction O
. O
[SEP] O
[CLS] O
the O
g O
##a O
- O
c O
##ts O
/ O
5 O
- O
f O
##u O
na O
##no O
##par O
##tic O
##le O
had O
a O
protective O
effect O
on O
the O
drug O
against O
plasma O
de O
##grading O
enzyme O
, O
and O
provided O
a O
sustained O
release O
system O
comprising O
three O
distinct O
phases O
of O
quick O
, O
steady O
, O
and O
slow O
release O
. O
[SEP] O
[CLS] O
the O
dual O
action O
of O
el O
##ob O
##ix O
##iba O
##t O
– O
enhancing O
co O
##lon O
##ic O
secret O
##ion O
and O
m O
##ot O
##ility O
– O
has O
garnered O
interest O
in O
the O
treatment O
of O
con O
##st O
##ip O
##ation O
. O
[SEP] O
[CLS] O
for O
more O
information O
, O
see O
s O
##3 O
table O
. O
[SEP] O
[CLS] O
an O
early O
phase O
clinical O
trial O
with O
the O
same O
device O
and O
doses O
found O
excellent O
to O
##ler O
##ability O
with O
high O
response O
rates O
and O
rapid O
onset O
of O
pain O
relief O
, O
approaching O
the O
benefits O
of O
injection O
despite O
significantly O
lower O
predicted O
drug O
levels O
. O
[SEP] O
[CLS] O
it O
is O
assume O
that O
all O
the O
ram O
##ip O
##ril O
meta O
##bol O
##ized O
by O
the O
kidney O
is O
converted O
to O
ram O
##ip O
##ril O
##at O
. O
[SEP] O
[CLS] O
comparisons O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
between O
the O
two O
groups O
of O
rats O
or O
between O
two O
doses O
of O
r O
##hu O
##ep O
##o O
were O
carried O
out O
using O
w O
##il O
##co O
##xon O
rank O
sum O
tests O
. O
[SEP] O
[CLS] O
the O
hp O
##l O
##c O
apparatus O
included O
a O
pump O
( O
l O
##c O
- O
10 O
##at O
, O
s O
##hima O
##d O
##zu O
, O
k O
##yo O
##to O
, O
j O
##apa O
##n O
) O
, O
an O
u O
##v O
detector O
( O
s O
##p O
##d O
- O
10 O
##av O
##p O
, O
s O
##hima O
##d O
##zu O
) O
and O
an O
automatic O
in O
##ject O
##or O
( O
series O
200 O
auto O
##sa O
##mple O
##r O
, O
per O
##kin O
el O
##mer O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
the O
decrease O
in O
plasma O
concentrations O
displayed O
a O
bi O
##pha O
##si O
##c O
profile O
( O
see O
fi O
##g O
. O
2 O
##a O
, O
c O
) O
. O
[SEP] O
[CLS] O
the O
diagnosis O
of O
cc O
was O
defined O
as O
a O
history O
of O
fewer O
than O
three O
spontaneous O
b O
##ms O
( O
s O
##b O
##ms O
) O
per O
week O
, O
with O
at O
least O
one O
of O
the O
following O
symptoms O
: O
( O
1 O
) O
straining O
during O
≥ O
##25 O
% O
of O
b O
##ms O
, O
( O
2 O
) O
lump O
##y O
or O
hard O
stool O
##s O
during O
≥ O
##25 O
% O
of O
b O
##ms O
and O
( O
3 O
) O
sensation O
of O
incomplete O
evacuation O
during O
≥ O
##25 O
% O
of O
b O
##ms O
. O
[SEP] O
[CLS] O
the O
rat O
and O
pool O
##ed O
human O
liver O
micro O
##some O
##s O
were O
carefully O
th O
##awed O
on O
ice O
before O
the O
experiment O
. O
[SEP] O
[CLS] O
serial O
blood O
samples O
were O
collected O
to O
describe O
the O
anti O
##biotic O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
the O
que O
/ O
t O
##m O
##z O
- O
n O
##ls O
significantly O
up O
##re O
##gu O
##lated O
the O
release O
of O
l O
##dh O
by O
the O
u O
##8 O
##7 O
/ O
t O
##r O
cells O
( O
p O
< O
0 O
. O
01 O
) O
, O
compared O
with O
the O
control O
n O
##ls O
and O
the O
d O
##ms O
##o O
control O
. O
[SEP] O
[CLS] O
the O
extraction O
was O
repeated O
twice O
. O
[SEP] O
[CLS] O
after O
undergoing O
in O
##cu O
##bation O
for O
60 O
min O
, O
the O
reactions O
were O
terminated O
by O
adding O
an O
equal O
volume O
of O
et O
##hyl O
ace O
##tate O
. O
[SEP] O
[CLS] O
a O
complete O
list O
of O
model O
parameter O
estimates O
is O
provided O
in O
table O
2 O
. O
[SEP] O
[CLS] O
per O
##me O
##ation O
studies O
performed O
via O
hp O
##l O
##c O
evidenced O
g O
##eran O
##iol O
per O
##me O
##ability O
coefficients O
across O
an O
in O
v O
##it O
##ro O
model O
of O
the O
human O
in O
##test O
##inal O
wall O
for O
a O
##pical O
to O
b O
##as O
##olate O
##ral O
and O
b O
##as O
##olate O
##ral O
to O
a O
##pical O
transport O
of O
13 O
. O
10 O
± O
2 O
. O
3 O
× O
10 O
- O
3 O
and O
2 O
. O
1 O
± O
0 O
. O
1 O
##⋅ O
##× O
10 O
- O
3 O
cm O
/ O
min O
, O
respectively O
. O
[SEP] O
[CLS] O
overall O
, O
simulated O
concentrations O
at O
10 O
, O
20 O
, O
and O
30 O
minutes O
were O
lower O
than O
that O
of O
adults O
, O
with O
ratios O
between O
geometric O
means O
( O
adults O
/ O
children O
) O
varying O
from O
1 O
. O
8 O
( O
c O
##10 O
) O
to O
1 O
. O
5 O
( O
c O
##30 O
) O
( O
fi O
##g O
. O
2 O
) O
, O
whereas O
simulated O
au B-PK
##c I-PK
was O
higher O
than O
that O
of O
adults O
with O
a O
ratio O
between O
geometric O
means O
( O
adults O
/ O
children O
) O
of O
0 O
. O
62 O
( O
fi O
##g O
. O
3 O
) O
. O
[SEP] O
[CLS] O
mice O
treated O
with O
120 O
mg O
/ O
kg O
of O
g O
##eran O
##iol O
for O
4 O
weeks O
showed O
increased O
anti O
- O
o O
##xi O
##da O
##tive O
defenses O
with O
no O
signs O
of O
liver O
toxicity O
. O
[SEP] O
[CLS] O
serum O
be O
##va O
##ci O
##zu O
##ma O
##b O
concentrations O
were O
determined O
at O
gene O
##nte O
##ch O
, O
in O
##c O
. O
, O
using O
an O
enzyme O
- O
linked O
im O
##mu O
##nos O
##or O
##bent O
ass O
##ay O
that O
used O
re O
##comb O
##ina O
##nt O
human O
ve O
##g O
##f O
for O
capture O
and O
a O
goat O
anti O
##body O
to O
human O
i O
##gg O
con O
##ju O
##gated O
to O
horse O
##rad O
##ish O
per O
##ox O
##idas O
##e O
for O
detection O
. O
[SEP] O
[CLS] O
plasma O
concentrations O
of O
ni O
##mo O
##di O
##pine O
were O
significantly O
higher O
in O
h O
##y O
##pot O
##her O
##mia O
than O
in O
norm O
##oth O
##er O
##mia O
. O
[SEP] O
[CLS] O
g O
##eran O
##iol O
is O
a O
natural O
mon O
##oter O
##pen O
##e O
showing O
anti O
- O
inflammatory O
, O
anti O
##ox O
##ida O
##nt O
, O
ne O
##uro O
##p O
##rote O
##ctive O
and O
anti O
##can O
##cer O
effects O
. O
[SEP] O
[CLS] O
diagnostic O
plots O
are O
shown O
in O
figure O
s O
##1 O
and O
s O
##2 O
( O
figure O
supplement O
##ary O
material O
) O
. O
[SEP] O
[CLS] O
values O
of O
co O
##var O
##iate O
##s O
that O
follow O
log O
##nor O
##mal O
distribution O
were O
log O
- O
transformed O
. O
[SEP] O
[CLS] O
patients O
with O
at O
least O
one O
p O
##k O
sample O
were O
evaluated O
. O
[SEP] O
[CLS] O
in O
##hibition O
profiles O
and O
50 B-PK
% I-PK
inhibitor I-PK
##y I-PK
concentration I-PK
( I-PK
i I-PK
##c I-PK
##50 I-PK
) I-PK
values O
were O
determined O
using O
a O
normal O
##ized O
response O
( O
variable O
- O
slope O
) O
curve O
- O
fitting O
algorithm O
with O
the O
graph O
##pad O
p O
##rism O
software O
. O
[SEP] O
[CLS] O
the O
study O
was O
conducted O
on O
16 O
w O
##ista O
##r O
rats O
, O
which O
were O
divided O
into O
four O
groups O
each O
group O
containing O
four O
rats O
. O
[SEP] O
[CLS] O
the O
dwell O
times O
were O
20 O
m O
##s O
and O
the O
entrance O
potential O
was O
at O
10 O
v O
for O
each O
transition O
. O
[SEP] O
[CLS] O
the O
multiple O
reaction O
monitoring O
transitions O
for O
two O
unique O
sur O
##rogate O
p O
##eptide O
##s O
of O
the O
ma O
##b O
##2 O
backbone O
were O
used O
for O
concentration O
determination O
relative O
to O
the O
standards O
and O
controls O
using O
the O
peak O
area O
from O
the O
m O
##qi O
##ii O
integration O
algorithm O
of O
the O
analyst O
software O
. O
[SEP] O
[CLS] O
then O
, O
g O
##st O
- O
and O
his O
##tag O
##s O
were O
c O
##lea O
##ved O
from O
the O
r O
##rf O
##c O
##1 O
specific O
p O
##eptide O
( O
r O
##sp O
) O
by O
means O
of O
enter O
##oki O
##nas O
##e O
( O
30 O
µ O
##g O
/ O
mg O
fusion O
protein O
) O
over O
6 O
h O
in O
dial O
##ys O
##is O
buffer O
( O
200 O
mm O
na O
##c O
##l O
, O
20 O
mm O
t O
##ris O
- O
h O
##c O
##l O
, O
200 O
mm O
im O
##ida O
##zo O
##le O
p O
##h O
8 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
the O
p O
##c O
##r O
product O
denoted O
in O
##tra O
##cellular O
domain O
7 O
( O
id O
##7 O
) O
was O
clone O
##d O
into O
the O
expression O
vector O
pet O
- O
41 O
##a O
( O
no O
##vage O
##n O
, O
in O
##c O
. O
, O
mad O
##ison O
, O
w O
##i O
, O
us O
##a O
) O
via O
e O
##cor O
##i O
/ O
hind O
##ii O
##i O
( O
ne O
##b O
, O
i O
##ps O
##wich O
, O
ma O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
the O
extraction O
recover O
##ies O
were O
ranged O
from O
83 O
. O
4 O
% O
to O
94 O
. O
2 O
% O
. O
[SEP] O
[CLS] O
therefore O
, O
solid O
- O
phase O
extraction O
was O
used O
to O
remove O
excess O
ingredients O
in O
plasma O
and O
achieve O
good O
select O
##ivity O
. O
[SEP] O
[CLS] O
subsequently O
, O
fusion O
proteins O
were O
el O
##uted O
with O
im O
##ida O
##zo O
##le O
( O
300 O
mm O
) O
in O
el O
##ution O
buffer O
( O
0 O
. O
5 O
m O
na O
##c O
##l O
, O
20 O
mm O
t O
##ris O
- O
h O
##c O
##l O
, O
p O
##h O
7 O
. O
9 O
) O
. O
[SEP] O
[CLS] O
this O
finding O
demonstrates O
that O
and O
##rog O
##rap O
##hol O
##ide O
might O
induce O
activation O
of O
intrinsic O
ca O
##sp O
##ase O
pathway O
in O
m O
##da O
- O
m O
##b O
- O
231 O
cells O
. O
[SEP] O
[CLS] O
it O
was O
reported O
that O
the O
medicinal O
herbs O
containing O
form O
##ono O
##net O
##in O
often O
have O
been O
used O
to O
treat O
card O
##iovascular O
diseases O
for O
a O
long O
time O
[ O
26 O
] O
. O
[SEP] O
[CLS] O
however O
, O
the O
ll O
##o O
##q O
##s O
of O
the O
new O
method O
were O
sufficient O
to O
character O
##ize O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
other O
5 O
components O
( O
ca O
##ffe O
##ic O
acid O
, O
f O
##er O
##uli O
##c O
acid O
, O
form O
##ono O
##net O
##in O
, O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
, O
and O
tan O
##shin O
##one O
ii O
##a O
) O
in O
rats O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
2 O
, O
two O
plasma B-PK
concentration I-PK
peaks I-PK
were O
observed O
in O
the O
mean O
plasma O
concentration O
curves O
profiles O
of O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
and O
tan O
##shin O
##one O
ii O
##a O
, O
which O
was O
consistent O
with O
results O
from O
previous O
studies O
[ O
24 O
] O
. O
[SEP] O
[CLS] O
the O
mean O
plasma O
concentration O
- O
time O
profiles O
of O
ca O
##ffe O
##ic O
acid O
, O
f O
##er O
##uli O
##c O
acid O
, O
form O
##ono O
##net O
##in O
, O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
, O
and O
tan O
##shin O
##one O
ii O
##a O
are O
shown O
in O
figure O
2 O
. O
[SEP] O
[CLS] O
in O
2016 O
, O
we O
reviewed O
all O
the O
published O
studies O
that O
co O
##rrel O
##ate O
the O
he O
##pa O
##to O
##bil O
##iary O
m O
##r O
imaging O
and O
the O
expression O
of O
he O
##pa O
##to O
##cy O
##te O
transport O
##ers O
in O
human O
he O
##pa O
##to O
##cellular O
car O
##cin O
##oma O
##s O
[ O
35 O
] O
. O
[SEP] O
[CLS] O
we O
showed O
how O
the O
understanding O
of O
signal O
intensity O
in O
these O
focal O
lesions O
relies O
on O
the O
transport O
function O
of O
the O
human O
m O
##rp O
##2 O
. O
[SEP] O
[CLS] O
dig O
##ox O
##in O
concentration O
was O
simulated O
for O
1000 O
patients O
with O
c O
##l O
##c O
##r O
ranging O
from O
5 O
to O
130 O
m O
##l O
/ O
min O
with O
or O
without O
am O
##io O
##dar O
##one O
administration O
. O
[SEP] O
[CLS] O
plasma O
concentration O
- O
time O
data O
( O
table O
7 O
) O
of O
each O
anal O
##yte O
were O
analyzed O
by O
the O
non O
- O
compartment O
##al O
method O
using O
p O
##k O
solve O
##r O
software O
. O
46 O
the O
peak B-PK
plasma I-PK
concentration I-PK
was O
reached O
by O
both O
r O
and O
s O
- O
al O
##o O
at O
approximately O
the O
equal O
time O
( O
in O
1 O
hour O
) O
after O
administration O
of O
the O
oral O
al O
##o O
dose O
thus O
showing O
same O
absorption O
profile O
. O
[SEP] O
[CLS] O
a O
total O
of O
22 O
healthy O
subjects O
( O
11 O
male O
and O
11 O
female O
; O
age O
18 O
– O
65 O
years O
) O
participated O
in O
the O
study O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
linear O
##ity O
and O
parameters O
reported O
are O
necessary O
p O
##har O
##ma O
##cological O
information O
of O
k O
##rato O
##m O
, O
and O
there O
is O
a O
possibility O
for O
it O
to O
be O
developed O
medical O
##ly O
as O
a O
pain O
killer O
or O
better O
op O
##io O
##id O
substitute O
in O
the O
future O
. O
[SEP] O
[CLS] O
recommended O
phase O
ii O
doses O
were O
determined O
in O
a O
dose O
es O
##cal O
##ation O
study O
in O
advanced O
solid O
t O
##umour O
##s O
. O
[SEP] O
[CLS] O
the O
vascular O
disrupt O
##ing O
agent O
o O
##mb O
##rab O
##ulin O
shows O
s O
##yne O
##rgy O
with O
do O
##ce O
##ta O
##xe O
##l O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
the O
conditions O
were O
reversed O
for O
group O
2 O
, O
who O
were O
exposed O
without O
hood O
##s O
on O
wed O
##nes O
##day O
of O
the O
first O
week O
and O
while O
wearing O
hood O
##s O
on O
wed O
##nes O
##day O
of O
the O
second O
week O
. O
[SEP] O
[CLS] O
the O
drop O
##let O
size O
distribution O
was O
determined O
by O
dynamic O
light O
scattering O
( O
z O
##eta O
##si O
##zer O
, O
na O
##no O
z O
##s O
- O
90 O
, O
ma O
##lve O
##rn O
instruments O
, O
ma O
##lve O
##rn O
, O
uk O
) O
. O
[SEP] O
[CLS] O
the O
ma O
##bs O
##ele O
##ct O
sure O
el O
##ution O
pools O
were O
then O
di O
##lut O
##ed O
with O
two O
volumes O
of O
water O
and O
loaded O
on O
to O
a O
s O
##p O
- O
se O
##pha O
##rose O
hp O
column O
( O
g O
##e O
healthcare O
, O
p O
##is O
##cat O
##away O
n O
##j O
) O
followed O
washing O
with O
s O
##p O
- O
buffer O
a O
( O
20 O
mm O
ace O
##tic O
acid O
p O
##h O
5 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
six O
male O
volunteers O
, O
aged O
27 O
to O
66 O
years O
, O
were O
divided O
into O
groups O
1 O
and O
2 O
. O
[SEP] O
[CLS] O
more O
con O
##den O
##sed O
nucleus O
with O
significant O
m O
##or O
##phological O
der O
##ang O
##ement O
in O
the O
da O
##pi O
stain O
##ing O
sign O
##ifies O
the O
toxicity O
of O
p O
##c O
##ms O
on O
isolated O
cells O
. O
[SEP] O
[CLS] O
each O
3 O
- O
member O
group O
was O
exposed O
to O
elevated O
concentrations O
of O
d O
##n O
##b O
##p O
in O
a O
55 O
m O
##3 O
chamber O
for O
6 O
h O
. O
group O
1 O
comprised O
participants O
who O
are O
identified O
as O
p O
##1 O
, O
p O
##2 O
, O
and O
p O
##3 O
in O
this O
paper O
, O
and O
group O
2 O
includes O
p O
##4 O
, O
p O
##5 O
, O
and O
p O
##6 O
. O
[SEP] O
[CLS] O
all O
the O
animal O
experimental O
procedures O
were O
approved O
by O
the O
institutional O
animal O
ethical O
committee O
and O
were O
in O
compliance O
with O
the O
national O
institutes O
of O
health O
guide O
for O
care O
and O
use O
of O
laboratory O
animals O
. O
[SEP] O
[CLS] O
a O
two O
- O
sided O
p O
< O
0 O
. O
05 O
was O
considered O
statistical O
##ly O
significant O
for O
all O
tests O
. O
[SEP] O
[CLS] O
protein O
quality O
was O
assessed O
by O
co O
##oma O
##ssie O
stained O
sodium O
do O
##de O
##cy O
##l O
su O
##lf O
##ate O
p O
##oly O
##ac O
##ryl O
##ami O
##de O
gel O
electro O
##ph O
##ores O
##is O
( O
s O
##ds O
- O
page O
) O
, O
size O
exclusion O
high O
performance O
liquid O
ch O
##roma O
##tography O
se O
- O
hp O
##l O
##c O
( O
bio O
##se O
##p O
s O
##30 O
##00 O
column O
, O
p O
##hen O
##ome O
##nex O
, O
to O
##rra O
##nce O
, O
ca O
, O
us O
##a O
) O
and O
liquid O
ch O
##roma O
##tography O
electro O
##sp O
##ray O
ion O
##ization O
mass O
- O
s O
##pect O
##rome O
##try O
. O
[SEP] O
[CLS] O
these O
data O
were O
analyzed O
using O
non O
##com O
##par O
##tment O
##al O
and O
traditional O
compartment O
##al O
analyses O
by O
way O
of O
one O
‐ O
compartment O
model O
with O
first O
‐ O
order O
rate O
constant O
##s O
. O
[SEP] O
[CLS] O
i O
##ver O
##me O
##ct O
##in O
- O
d O
##2 O
was O
synthesized O
by O
to O
##ron O
##to O
research O
chemicals O
( O
on O
##tar O
##io O
, O
can O
##ada O
) O
. O
[SEP] O
[CLS] O
the O
study O
was O
approved O
by O
the O
institutional O
animal O
care O
and O
use O
committees O
at O
the O
g O
##e O
global O
research O
center O
and O
s O
##tan O
##ford O
university O
. O
[SEP] O
[CLS] O
all O
enrolled O
patients O
were O
critically O
ill O
with O
multiple O
com O
##or O
##bid O
##ities O
and O
were O
receiving O
i O
##v O
v O
##ori O
##cona O
##zo O
##le O
for O
the O
treatment O
of O
a O
known O
or O
suspected O
systemic O
fun O
##gal O
infection O
. O
[SEP] O
[CLS] O
a O
two O
- O
tailed O
p O
value O
of O
< O
0 O
. O
05 O
was O
considered O
statistical O
##ly O
significant O
. O
[SEP] O
[CLS] O
a O
total O
of O
56 O
##3 O
reports O
( O
220 O
single O
- O
agent O
and O
34 O
##3 O
multi O
##age O
##nt O
reports O
) O
involved O
ma O
##gne O
##vist O
. O
[SEP] O
[CLS] O
imaging O
studies O
and O
data O
analyses O
were O
carried O
out O
at O
s O
##tan O
##ford O
university O
. O
[SEP] O
[CLS] O
further O
analysis O
was O
performed O
to O
evaluate O
the O
gene O
expression O
differences O
of O
the O
two O
sexes O
sub O
- O
grouped O
by O
ethnicity O
( O
a O
##f O
##rica O
##n O
am O
##eric O
##an O
males O
vs O
. O
euro O
##pe O
##an O
am O
##eric O
##an O
males O
or O
a O
##f O
##rica O
##n O
am O
##eric O
##an O
females O
vs O
. O
euro O
##pe O
##an O
am O
##eric O
##an O
females O
) O
. O
[SEP] O
[CLS] O
the O
mobile O
phases O
consisted O
of O
ace O
##ton O
##it O
##ril O
##e O
( O
a O
) O
and O
form O
##ic O
acid O
a O
##que O
##ous O
solution O
( O
b O
) O
. O
[SEP] O
[CLS] O
the O
human O
non O
- O
small O
cell O
lung O
car O
##cin O
##oma O
cell O
line O
n O
##ci O
- O
h O
##46 O
##0 O
( O
at O
##cc O
: O
h O
##t O
##b O
- O
177 O
) O
, O
and O
m O
##uri O
##ne O
le O
##wi O
##s O
lung O
car O
##cin O
##oma O
cell O
line O
ll O
/ O
2 O
( O
at O
##cc O
: O
c O
##rl O
- O
1642 O
) O
, O
were O
used O
in O
this O
study O
. O
[SEP] O
[CLS] O
the O
op O
##ti O
##mized O
drug O
- O
loaded O
s O
##ned O
##ds O
was O
prepared O
at O
a O
mass O
ratio O
of O
3 O
: O
24 O
: O
38 O
: O
38 O
for O
c O
##y O
##c O
##lov O
##iro O
##bu O
##xin O
##e O
d O
, O
o O
##le O
##ic O
acid O
, O
so O
##lut O
##ol O
s O
##h O
##15 O
, O
and O
prop O
##yle O
##ne O
g O
##ly O
##co O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
##eb O
##ili O
##zu O
##ma O
##b O
had O
an O
acceptable O
safety O
profile O
in O
re O
##lap O
##sing O
m O
##s O
patients O
and O
showed O
a O
trend O
in O
reduction O
##s O
in O
new O
/ O
newly O
en O
##lar O
##ging O
and O
g O
##ado O
##lini O
##um O
- O
enhancing O
lesions O
. O
[SEP] O
[CLS] O
following O
the O
previous O
report O
of O
ho O
##u O
et O
al O
. O
[ O
25 O
] O
, O
three O
sets O
of O
extraction O
methods O
were O
prepared O
to O
evaluate O
the O
matrix O
effect O
and O
recovery O
in O
the O
quantitative O
bio O
##ana O
##ly O
##tical O
method O
. O
[SEP] O
[CLS] O
the O
minimum O
q O
##uant O
##ifiable O
concentration O
was O
8 O
. O
24 O
ng O
/ O
m O
##l O
in O
c O
##yn O
##o O
v O
##it O
##re O
##ous O
humor O
. O
[SEP] O
[CLS] O
phase O
i O
‐ O
dose O
es O
##cal O
##ation O
[SEP] O
[CLS] O
both O
ii O
##v O
and O
i O
##ov O
were O
expressed O
as O
coefficients O
of O
variation O
( O
c O
##v O
% O
) O
by O
taking O
the O
square O
roots O
of O
the O
estimates O
divided O
by O
the O
mean O
parameter O
value O
. O
[SEP] O
[CLS] O
forty O
- O
five O
patients O
younger O
than O
2 O
years O
with O
normal O
estimated O
g O
##lo O
##mer O
##ular O
fi O
##ltration O
rate O
and O
scheduled O
to O
undergo O
routine O
g O
##ado O
##lini O
##um O
- O
enhanced O
magnetic O
resonance O
imaging O
( O
m O
##ri O
) O
of O
any O
organ O
were O
included O
and O
received O
a O
single O
in O
##tra O
##ven O
##ous O
injection O
of O
g O
##ado O
##tera O
##te O
me O
##g O
##lum O
##ine O
( O
0 O
. O
1 O
mm O
##ol O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
plasma B-PK
clearance I-PK
for O
the O
neutral O
( O
te O
##go O
##h O
) O
and O
z O
##wi O
##tter O
##ion O
##ic O
( O
t O
##z O
##wi O
##t O
) O
particles O
was O
substantially O
lower O
( O
0 O
. O
00 O
##60 O
##5 O
µ O
##g O
/ O
m O
##l O
/ O
min O
and O
0 O
. O
00 O
##5 O
##6 O
##1 O
µ O
##g O
/ O
m O
##l O
/ O
min O
, O
respectively O
) O
such O
that O
plasma O
concentrations O
remained O
above O
1 O
µ O
##g O
/ O
m O
##l O
24 O
hours O
after O
injection O
( O
figure O
1 O
##a O
) O
. O
[SEP] O
[CLS] O
the O
significance O
of O
the O
co O
##var O
##iate O
was O
tested O
using O
the O
nest O
##ed O
model O
criteria O
at O
a O
more O
string O
##ent O
p O
value O
of O
0 O
. O
00 O
##1 O
, O
resulting O
in O
a O
change O
in O
of O
##v O
of O
10 O
. O
83 O
, O
to O
avoid O
false O
positive O
##s O
. O
[SEP] O
[CLS] O
the O
plasma O
disposition O
##s O
of O
the O
au O
##n O
##ps O
were O
characterized O
in O
male O
c O
##d O
##1 O
mice O
after O
i O
##v O
and O
i O
##p O
administration O
. O
[SEP] O
[CLS] O
what O
is O
the O
current O
knowledge O
on O
the O
topic O
? O
[SEP] O
[CLS] O
in O
the O
present O
study O
, O
the O
select O
##ivity O
was O
studied O
by O
using O
rat O
joint O
cavity O
washing O
fluid O
samples O
from O
six O
different O
rats O
. O
[SEP] O
[CLS] O
figure O
1 O
shows O
a O
typical O
ch O
##roma O
##to O
##gram O
for O
the O
drug O
- O
free O
rat O
joint O
cavity O
washing O
fluid O
and O
drug O
- O
free O
joint O
cavity O
washing O
fluid O
spike O
##d O
with O
s O
##n O
and O
is O
. O
[SEP] O
[CLS] O
to O
determine O
whether O
all O
the O
co O
##var O
##iate O
##s O
included O
in O
the O
fully O
parameter O
##ized O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
continued O
to O
provide O
significant O
influence O
on O
the O
population O
model O
, O
the O
co O
##var O
##iate O
##s O
included O
in O
the O
full O
model O
were O
se O
##quential O
##ly O
removed O
and O
the O
resulting O
reduced O
model O
evaluated O
to O
determine O
whether O
there O
was O
significant O
model O
degradation O
. O
[SEP] O
[CLS] O
the O
7 O
- O
hour O
separation O
between O
doses O
was O
selected O
on O
the O
basis O
of O
the O
p O
##k O
and O
p O
##d O
profiles O
obtained O
in O
regime O
##ns O
b O
and O
c O
. O
figure O
1 O
shows O
the O
resulting O
p O
##k O
profiles O
and O
table O
2 O
the O
corresponding O
p O
##k O
parameters O
. O
[SEP] O
[CLS] O
plasma O
was O
collected O
after O
cent O
##ri O
##fu O
##gt O
##ation O
and O
stored O
at O
- O
20 O
##° O
##c O
in O
micro O
##fu O
##ge O
tubes O
until O
analysis O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##last I-PK
values O
of O
oral O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
( O
equivalent O
to O
20 O
mg O
/ O
kg O
pm O
##x O
) O
were O
1 O
. O
75 O
- O
and O
1 O
. O
57 O
- O
fold O
greater O
than O
that O
of O
oral O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
, O
respectively O
, O
and O
3 O
. O
22 O
- O
and O
2 O
. O
23 O
- O
fold O
greater O
than O
that O
of O
oral O
pm O
##x O
solution O
( O
figure O
9 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
in O
v O
##ivo O
he B-PK
##pa I-PK
##tic I-PK
intrinsic I-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
##in I-PK
##vi I-PK
##vo I-PK
) I-PK
was O
estimated O
from O
c B-PK
##lint I-PK
##in I-PK
##vi I-PK
##tro I-PK
using O
the O
following O
equation O
: O
( O
5 O
) O
c O
##lint O
##in O
##vi O
##vo O
= O
c O
##lint O
##in O
##vi O
##tro O
##× O
( O
mg O
##mic O
##ros O
##oma O
##l O
##p O
##rote O
##in O
/ O
g O
##li O
##ver O
) O
× O
( O
g O
##li O
##ver O
/ O
kg O
##body O
##weight O
) O
[SEP] O
[CLS] O
the O
lower O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
o O
##dt O
l O
‐ O
p O
##z O
##q O
, O
as O
well O
as O
the O
high O
var O
##iability O
and O
non O
##dos O
##e O
‐ O
proportional O
##ity O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
parameters O
, O
highlighted O
the O
need O
for O
a O
dedicated O
p O
##ediatric O
dose O
‐ O
finding O
study O
for O
the O
selection O
of O
the O
most O
appropriate O
formulation O
and O
dose O
( O
l O
‐ O
p O
##z O
##q O
o O
##dt O
or O
r O
##ac O
‐ O
p O
##z O
##q O
o O
##dt O
) O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
boost O
##ed O
from O
0 O
. O
59 O
##3 O
( O
set O
20 O
) O
to O
0 O
. O
82 O
##7 O
( O
set O
6 O
) O
with O
a O
39 O
% O
increase O
and O
from O
0 O
. O
62 O
##7 O
( O
set O
14 O
) O
to O
0 O
. O
82 O
##7 O
( O
set O
6 O
) O
with O
a O
32 O
% O
increase O
. O
[SEP] O
[CLS] O
the O
second O
largest O
improvement O
in O
au B-PK
##c I-PK
was O
observed O
when O
integrating O
p O
##k O
- O
related O
information O
with O
p O
##d O
- O
related O
information O
. O
[SEP] O
[CLS] O
when O
adding O
p O
##d O
- O
related O
information O
to O
the O
enzyme O
and O
transport O
##er O
information O
( O
score O
set O
11 O
) O
, O
au B-PK
##c I-PK
jumped O
from O
0 O
. O
65 O
##7 O
( O
set O
11 O
) O
to O
0 O
. O
83 O
##4 O
( O
set O
3 O
) O
with O
a O
27 O
% O
increase O
. O
[SEP] O
[CLS] O
method O
a O
was O
as O
follows O
: O
the O
separation O
was O
carried O
out O
on O
a O
waters O
co O
##rte O
##cs O
column O
( O
2 O
. O
1 O
mm O
× O
150 O
mm O
, O
1 O
. O
6 O
μ O
##m O
) O
at O
35 O
##° O
##c O
. O
[SEP] O
[CLS] O
unless O
stated O
otherwise O
, O
normally O
distributed O
data O
are O
presented O
as O
mean O
± O
standard O
de O
##viation O
, O
and O
as O
median O
( O
inter O
##qua O
##rt O
##ile O
ranges O
) O
where O
non O
##nor O
##mal O
##ly O
distributed O
. O
[SEP] O
[CLS] O
pu O
##rified O
h O
##sa O
was O
injected O
in O
##tra O
##ven O
##ously O
( O
i O
##v O
) O
at O
10 O
mg O
/ O
kg O
into O
7 O
age O
and O
sex O
- O
matched O
t O
##g O
##32 O
- O
al O
##b O
- O
/ O
- O
, O
b O
##6 O
- O
al O
##b O
- O
/ O
- O
, O
b O
##6 O
. O
129 O
##× O
##1 O
- O
f O
##c O
##g O
##rt O
##t O
##m O
##1 O
##d O
##c O
##r O
/ O
d O
##c O
##r O
##j O
( O
abbreviated O
here O
to O
b O
##6 O
- O
m O
##f O
##c O
##rna O
- O
/ O
- O
) O
, O
t O
##g O
##32 O
and O
b O
##6 O
mice O
. O
[SEP] O
[CLS] O
participants O
were O
excluded O
who O
( O
1 O
) O
were O
pregnant O
, O
trying O
to O
become O
pregnant O
, O
or O
breast O
##fe O
##eding O
; O
( O
2 O
) O
experienced O
clinical O
##ly O
significant O
illness O
within O
30 O
days O
of O
the O
screening O
examination O
; O
( O
3 O
) O
received O
any O
investigation O
##al O
drug O
within O
30 O
days O
of O
study O
day O
1 O
or O
were O
scheduled O
to O
receive O
any O
investigation O
##al O
drug O
during O
the O
course O
of O
the O
study O
; O
( O
4 O
) O
participated O
in O
a O
previous O
study O
of O
the O
same O
product O
; O
( O
5 O
) O
had O
a O
history O
of O
any O
condition O
that O
could O
possibly O
affect O
the O
absorption O
of O
the O
drug O
, O
such O
as O
p O
##ept O
##ic O
ul O
##cer O
disease O
, O
gas O
##tre O
##ct O
##omy O
, O
or O
in O
##test O
##inal O
ma O
##la O
##bs O
##or O
##ption O
; O
( O
6 O
) O
had O
a O
history O
of O
an O
##emia O
, O
iron O
deficiency O
, O
or O
iron O
de O
##ple O
##tion O
; O
( O
7 O
) O
were O
im O
##mu O
##no O
##com O
##p O
##rom O
##ised O
or O
had O
a O
history O
of O
drug O
all O
##er O
##gies O
; O
( O
8 O
) O
presented O
with O
an O
e O
##c O
##g O
abnormal O
##ity O
or O
e O
##c O
##g O
findings O
deemed O
clinical O
##ly O
relevant O
; O
( O
9 O
) O
had O
a O
q O
##t O
interval O
corrected O
for O
heart O
rate O
( O
f O
##ride O
##ric O
##ia O
’ O
s O
correction O
formula O
, O
q O
##t O
##c O
##f O
) O
> O
450 O
m O
##s O
; O
( O
10 O
) O
had O
a O
clinical O
##ly O
relevant O
history O
or O
presence O
of O
respiratory O
, O
gas O
##tro O
##int O
##est O
##inal O
, O
re O
##nal O
, O
he O
##pa O
##tic O
, O
hem O
##ato O
##log O
##ic O
, O
l O
##ymph O
##atic O
, O
ne O
##uro O
##logical O
, O
card O
##iovascular O
, O
psychiatric O
, O
m O
##us O
##cu O
##los O
##kel O
##etal O
, O
g O
##eni O
##tour O
##ina O
##ry O
, O
im O
##mu O
##no O
##log O
##ic O
, O
der O
##mat O
##olo O
##gic O
, O
or O
connect O
##ive O
tissue O
disease O
or O
disorders O
; O
( O
11 O
) O
had O
a O
known O
into O
##ler O
##ance O
to O
the O
product O
’ O
s O
ingredients O
; O
or O
( O
12 O
) O
had O
donated O
blood O
or O
had O
significant O
( O
≥ O
##25 O
##0 O
m O
##l O
) O
blood O
loss O
within O
30 O
days O
of O
dos O
##ing O
or O
had O
donated O
plasma O
within O
7 O
days O
of O
dos O
##ing O
. O
[SEP] O
[CLS] O
after O
leaving O
the O
chamber O
, O
full O
volumes O
of O
urine O
were O
collected O
for O
each O
u O
##rina O
##tion O
over O
the O
next O
48 O
h O
. O
[SEP] O
[CLS] O
the O
urine O
was O
subsequently O
analyzed O
for O
d O
##n O
##b O
##p O
meta O
##bol O
##ites O
, O
mon O
##o O
- O
n O
- O
but O
##yl O
p O
##ht O
##hala O
##te O
( O
m O
##n O
##b O
##p O
) O
, O
and O
3 O
- O
h O
##ydro O
##xy O
- O
mon O
##o O
- O
n O
- O
but O
##yl O
p O
##ht O
##hala O
##te O
( O
3 O
##oh O
- O
m O
##n O
##b O
##p O
) O
. O
[SEP] O
[CLS] O
l O
##c O
- O
m O
##s O
- O
grade O
solvent O
##s O
, O
ace O
##ton O
##it O
##ril O
##e O
and O
is O
##op O
##rop O
##ano O
##l O
, O
and O
what O
##man O
##® O
protein O
save O
##r O
cards O
90 O
##3 O
were O
purchased O
from O
me O
##rc O
##k O
kg O
##aa O
( O
da O
##rms O
##tadt O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
the O
results O
from O
non O
##com O
##par O
##tment O
##al O
and O
traditional O
compartment O
##al O
analyses O
were O
ta O
##bula O
##ted O
in O
tables O
2 O
, O
3 O
, O
together O
with O
the O
p O
##k O
parameter O
values O
reported O
from O
the O
original O
manuscripts O
. O
[SEP] O
[CLS] O
figure O
6 O
shows O
the O
distribution O
of O
g O
##ado O
##lini O
##um O
in O
urine O
, O
liver O
, O
and O
blood O
at O
60 O
min O
after O
the O
administration O
of O
the O
new O
ca O
##s O
. O
[SEP] O
[CLS] O
samples O
( O
2 O
m O
##l O
) O
were O
removed O
at O
various O
time O
intervals O
and O
filtered O
using O
a O
1 O
. O
2 O
µ O
##m O
s O
##yr O
##inge O
filter O
. O
[SEP] O
[CLS] O
the O
v O
##ou O
##cher O
specimens O
were O
deposited O
at O
the O
herb O
##arium O
of O
the O
ch O
##eng O
##du O
q O
##ih O
##uang O
bio O
- O
tech O
institute O
( O
ch O
##eng O
##du O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
s O
##med O
##ds O
using O
c O
##rem O
##op O
##hor O
r O
##h O
40 O
as O
a O
surf O
##act O
##ant O
without O
bi O
##le O
salts O
possessed O
good O
self O
- O
micro O
##em O
##ul O
##si O
##fying O
performance O
after O
a O
100 O
- O
fold O
di O
##lution O
with O
dei O
##onized O
water O
, O
and O
retained O
a O
transparent O
blue O
– O
op O
##ales O
##cent O
appearance O
. O
[SEP] O
[CLS] O
all O
herbs O
, O
commercially O
available O
as O
dried O
matter O
, O
were O
purchased O
from O
sic O
##hua O
##n O
ben O
##ca O
##ota O
##ng O
pharmaceutical O
co O
. O
, O
l O
##t O
##d O
. O
( O
ch O
##eng O
##du O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
statistical O
significance O
was O
assessed O
by O
un O
##pair O
##ed O
student O
′ O
s O
t O
test O
or O
one O
- O
way O
analysis O
of O
variance O
( O
an O
##ova O
) O
with O
post O
ho O
##c O
analysis O
using O
t O
##uke O
##y O
′ O
s O
multiple O
comparison O
test O
for O
para O
##metric O
data O
. O
[SEP] O
[CLS] O
serum O
samples O
were O
prepared O
by O
c O
##lot O
##ting O
at O
room O
temperature O
, O
and O
then O
cent O
##ri O
##fu O
##ged O
for O
15 O
min O
. O
[SEP] O
[CLS] O
the O
other O
procedures O
were O
the O
same O
used O
in O
t O
##r O
q O
##uant O
##ification O
. O
[SEP] O
[CLS] O
a O
g O
##yr O
##ola O
##b O
x O
##p O
ass O
##ay O
was O
used O
to O
q O
##uant O
##ify O
f O
##ab O
concentrations O
in O
c O
##yn O
##o O
monkey O
v O
##it O
##re O
##ous O
humor O
. O
[SEP] O
[CLS] O
comparisons O
between O
groups O
were O
assessed O
with O
man O
##n O
– O
w O
##hit O
##ney O
test O
, O
and O
correlation O
##s O
with O
spear O
##man O
coefficient O
. O
[SEP] O
[CLS] O
the O
activities O
against O
liver O
and O
insect O
stages O
were O
not O
determined O
. O
[SEP] O
[CLS] O
the O
instrument O
was O
run O
and O
data O
analyzed O
as O
described O
by O
the O
manufacturer O
with O
a O
1 O
% O
pm O
##t O
setting O
. O
[SEP] O
[CLS] O
this O
was O
a O
phase O
i O
##v O
open O
- O
label O
, O
prospective O
study O
conducted O
in O
9 O
centers O
( O
4 O
countries O
) O
. O
[SEP] O
[CLS] O
for O
que O
##tia O
##pine O
x O
##r O
, O
samples O
were O
drawn O
pre O
- O
dose O
and O
at O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
5 O
, O
5 O
. O
5 O
, O
6 O
, O
8 O
, O
12 O
, O
24 O
and O
25 O
h O
post O
- O
dose O
. O
[SEP] O
[CLS] O
inclusion O
criteria O
included O
admission O
to O
the O
i O
##cu O
, O
ca O
##sp O
##of O
##ung O
##in O
therapy O
for O
suspected O
or O
proven O
infection O
or O
for O
prop O
##hyl O
##ax O
##is O
, O
age O
> O
18 O
years O
when O
starting O
ca O
##sp O
##of O
##ung O
##in O
, O
started O
therapy O
a O
maximum O
of O
2 O
days O
before O
inclusion O
, O
and O
management O
with O
a O
central O
ve O
##nous O
cat O
##he O
##ter O
. O
[SEP] O
[CLS] O
in O
marked O
contrast O
, O
the O
neutral O
( O
te O
##go O
##h O
) O
and O
z O
##wi O
##tter O
##ion O
##ic O
( O
t O
##z O
##wi O
##t O
) O
au O
##n O
##ps O
rapidly O
entered O
into O
circulation O
, O
with O
peak B-PK
concentrations I-PK
above O
10 O
µ O
##g O
/ O
m O
##l O
achieved O
1 O
. O
5 O
and O
3 O
hours O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
differences O
in O
sampling O
times O
for O
the O
two O
formulation O
##s O
were O
to O
allow O
for O
dense O
sampling O
at O
expected O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
as O
with O
the O
i O
##v O
injection O
, O
plasma O
concentrations O
of O
the O
neutral O
( O
te O
##go O
##h O
) O
and O
z O
##wi O
##tter O
##ion O
##ic O
( O
t O
##z O
##wi O
##t O
) O
au O
##n O
##ps O
remained O
above O
1 O
µ O
##g O
/ O
m O
##l O
24 O
hours O
after O
injection O
( O
figure O
2 O
##b O
) O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
values O
for O
these O
au O
##n O
##p O
were O
high O
( O
77 O
% O
and O
70 O
% O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
the O
addition O
of O
co O
##var O
##iate O
##s O
into O
the O
model O
was O
continued O
until O
a O
decrease O
of O
3 O
. O
84 O
could O
not O
be O
reached O
any O
longer O
. O
[SEP] O
[CLS] O
for O
que O
##tia O
##pine O
i O
##r O
, O
samples O
were O
obtained O
pre O
- O
dose O
and O
at O
0 O
. O
5 O
, O
1 O
, O
1 O
. O
5 O
, O
2 O
, O
2 O
. O
5 O
, O
5 O
, O
11 O
, O
24 O
and O
25 O
h O
post O
- O
dose O
. O
[SEP] O
[CLS] O
plasma O
concentrations O
were O
nearly O
identical O
for O
all O
patients O
, O
regardless O
of O
age O
group O
, O
for O
both O
dose O
levels O
tested O
, O
which O
may O
be O
due O
to O
an O
extensive O
overlap O
between O
the O
g O
##eria O
##tric O
( O
> O
65 O
years O
) O
and O
p O
##k O
populations O
( O
refer O
to O
sample O
size O
table O
, O
figure O
4 O
) O
. O
[SEP] O
[CLS] O
c O
##p O
##0 O
##24 O
was O
administered O
as O
two O
different O
formulation O
##s O
( O
a O
and O
b O
) O
at O
a O
dose O
of O
5 O
mg O
per O
no O
##st O
##ril O
once O
daily O
compared O
with O
the O
same O
h O
##gh O
dose O
administered O
nasal O
##ly O
as O
a O
simple O
solution O
( O
without O
the O
critical O
##sor O
##b O
absorption O
enhance O
##r O
) O
and O
1 O
mg O
h O
##gh O
s O
##c O
. O
[SEP] O
[CLS] O
therefore O
, O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
c O
##p O
##0 O
##24 O
is O
likely O
to O
be O
an O
under O
##est O
##imate O
of O
the O
true B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
data O
are O
presented O
as O
peaks O
, O
and O
the O
au B-PK
##c I-PK
represents O
the O
percentage O
of O
host O
- O
versus O
- O
donor O
hem O
##ato O
##po O
##ies O
##is O
. O
[SEP] O
[CLS] O
the O
plasma O
el O
##ob O
##ix O
##iba O
##t O
concentration O
after O
breakfast O
was O
much O
lower O
than O
in O
the O
fast O
##ed O
state O
, O
and O
there O
was O
no O
major O
difference O
in O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
areas B-PK
under I-PK
the I-PK
en I-PK
##rich I-PK
##ment I-PK
- I-PK
time I-PK
curve I-PK
before O
and O
after O
nutrition O
##al O
rehabilitation O
were O
0 O
. O
53 O
##9 O
##± O
##0 O
. O
320 O
and O
0 O
. O
620 O
##± O
##0 O
. O
322 O
atom O
per O
cent O
excess O
minute O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
mixed O
random O
effects O
model O
demonstrated O
significant O
sequence O
effects O
for O
both O
ne O
##vir O
##ap O
##ine O
log O
transformed O
cm B-PK
##ax I-PK
( O
p O
< O
0 O
. O
000 O
##1 O
) O
and O
au B-PK
##c I-PK
( O
p O
< O
0 O
. O
000 O
##1 O
) O
as O
outcomes O
. O
[SEP] O
[CLS] O
inter O
##su O
##bject O
var O
##iability O
for O
log O
transformed O
cm B-PK
##ax I-PK
ranged O
from O
0 O
. O
24 O
– O
0 O
. O
40 O
and O
that O
for O
au B-PK
##c I-PK
ranged O
from O
0 O
. O
23 O
– O
0 O
. O
42 O
. O
[SEP] O
[CLS] O
in O
##tras O
##ub O
##ject O
var O
##iability O
for O
cm B-PK
##ax I-PK
ranged O
from O
0 O
. O
21 O
– O
0 O
. O
44 O
and O
au B-PK
##c I-PK
ranged O
from O
0 O
. O
25 O
– O
0 O
. O
36 O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
inter O
##su O
##bject O
var O
##iability O
accounts O
for O
approximately O
half O
of O
the O
var O
##iability O
in O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
estimates O
. O
[SEP] O
[CLS] O
regarding O
the O
in O
v O
##ivo O
oral O
absorption O
in O
rats O
, O
the O
pm O
##x O
in O
plasma O
concentration O
– O
time O
profiles O
following O
i O
##v O
and O
oral O
administration O
are O
shown O
in O
figure O
9 O
. O
[SEP] O
[CLS] O
after O
oral O
administration O
of O
20 O
mg O
/ O
kg O
pm O
##x O
alone O
, O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
attained O
was O
1 O
. O
49 O
##± O
##0 O
. O
33 O
##2 O
μ O
##g O
/ O
m O
##l O
, O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##last I-PK
) I-PK
was O
7 O
. O
55 O
##± O
##0 O
. O
93 O
##8 O
μ O
##g O
· O
h O
/ O
m O
##l O
, O
and O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
compared O
with O
the O
i O
##v O
dose O
) O
was O
12 O
. O
0 O
% O
± O
##1 O
. O
45 O
% O
. O
[SEP] O
[CLS] O
however O
, O
compared O
with O
the O
oral O
administration O
of O
pm O
##x O
alone O
, O
oral O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
( O
equivalent O
to O
20 O
mg O
/ O
kg O
pm O
##x O
) O
afforded O
a O
1 O
. O
85 O
- O
fold O
increase O
in O
cm B-PK
##ax I-PK
( O
2 O
. O
75 O
##± O
##0 O
. O
79 O
##3 O
μ O
##g O
/ O
m O
##l O
) O
and O
a O
1 O
. O
42 O
- O
fold O
increase O
in O
au B-PK
##c I-PK
##last I-PK
( O
10 O
. O
7 O
##± O
##0 O
. O
84 O
##9 O
μ O
##g O
· O
h O
/ O
m O
##l O
) O
, O
resulting O
in O
a O
1 O
. O
42 O
- O
fold O
increase O
in O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
17 O
. O
0 O
% O
± O
##1 O
. O
35 O
% O
; O
table O
2 O
) O
. O
[SEP] O
[CLS] O
the O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
values O
were O
2 O
. O
75 O
##± O
##3 O
. O
50 O
and O
0 O
. O
900 O
##± O
##0 O
. O
224 O
h O
after O
oral O
administration O
of O
free O
pm O
##x O
or O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
, O
respectively O
, O
implying O
that O
the O
pm O
##x O
/ O
d O
##ck O
complex O
was O
quickly O
released O
from O
the O
na O
##no O
##em O
##ul O
##sion O
to O
per O
##me O
##ate O
through O
the O
in O
##test O
##inal O
membrane O
. O
[SEP] O
[CLS] O
such O
rapid O
absorption O
may O
be O
at O
##tri O
##but O
##able O
to O
the O
enhanced O
membrane O
per B-PK
##me I-PK
##ability I-PK
of O
the O
pm O
##x O
/ O
d O
##ck O
complex O
, O
without O
any O
decrease O
in O
the O
so O
##lub O
##ility O
of O
pm O
##x O
, O
after O
incorporation O
of O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
into O
na O
##no O
- O
sized O
drop O
##lets O
. O
[SEP] O
[CLS] O
however O
, O
the O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
lives I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
values I-PK
) I-PK
after O
oral O
administration O
of O
pm O
##x O
, O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
, O
and O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
( O
alone O
) O
were O
significantly O
longer O
than O
those O
after O
i O
##v O
administration O
. O
[SEP] O
[CLS] O
tan O
possessed O
a O
moderate O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
of I-PK
the I-PK
central I-PK
compartment I-PK
( I-PK
v I-PK
##c I-PK
= O
4 O
. O
20 O
± O
0 O
. O
82 O
l O
/ O
kg O
) O
, O
a O
rapid O
clearance B-PK
( I-PK
c I-PK
##l I-PK
= O
94 O
. O
1 O
± O
20 O
. O
2 O
m O
##l O
/ O
min O
/ O
kg O
) O
and O
a O
moderate O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
λ I-PK
##z I-PK
= O
166 O
± O
42 O
min O
) O
. O
[SEP] O
[CLS] O
its O
c B-PK
##l I-PK
value O
exceeded O
the O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
rate I-PK
, O
indicating O
the O
involvement O
of O
extra O
- O
he O
##pa O
##tic O
elimination O
of O
tan O
. O
[SEP] O
[CLS] O
θ O
##t O
##v O
##p O
is O
an O
estimated O
parameter O
describing O
the O
typical O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
value O
for O
an O
individual O
with O
weight O
equal O
to O
the O
reference O
weight O
and O
θ O
##allo O
is O
an O
all O
##ometric O
power O
parameter O
( O
which O
can O
be O
estimated O
or O
fixed O
to O
a O
value O
of O
0 O
. O
75 O
for O
clearance B-PK
##s I-PK
, O
and O
a O
value O
of O
1 O
for O
an O
##ato O
##mic O
##al O
volumes O
) O
. O
[SEP] O
[CLS] O
in O
this O
work O
, O
we O
used O
the O
total B-PK
cumulative I-PK
area I-PK
under I-PK
the I-PK
log I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##log I-PK
##c I-PK
) I-PK
as O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
pro O
##xy O
for O
drug O
exposure O
. O
[SEP] O
[CLS] O
maximum B-PK
metabolism I-PK
rates I-PK
( I-PK
v I-PK
##max I-PK
) I-PK
were O
estimated O
serial O
##ly O
; O
then O
the O
fraction O
of O
either O
di O
##a O
or O
de O
##a O
produced O
from O
at O
##z O
was O
estimated O
. O
[SEP] O
[CLS] O
v B-PK
##max I-PK
for O
da O
##ct O
was O
defined O
as O
the O
sum O
of O
the O
rates O
of O
metabolism O
of O
di O
##a O
and O
de O
##a O
. O
[SEP] O
[CLS] O
a O
first B-PK
- I-PK
order I-PK
elimination I-PK
rate I-PK
constant I-PK
was O
added O
to O
the O
in O
v O
##it O
##ro O
metabolism O
model O
for O
da O
##ct O
to O
account O
for O
measured O
loss O
of O
da O
##ct O
from O
the O
media O
at O
the O
end O
of O
the O
in O
##cu O
##bation O
period O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
parameters O
controlling O
the O
time O
variance O
of O
c B-PK
##l I-PK
( O
im B-PK
##ax I-PK
, O
t B-PK
##50 I-PK
, O
and O
γ B-PK
) O
were O
estimated O
separately O
by O
tumor O
type O
in O
the O
full O
model O
. O
[SEP] O
[CLS] O
for O
all O
four O
studies O
, O
the O
inclusion O
/ O
exclusion O
criteria O
allowed O
for O
the O
enrollment O
of O
healthy O
men O
and O
women O
of O
non O
##child O
bearing O
potential O
aged O
between O
18 O
and O
55 O
years O
of O
age O
with O
a O
body O
weight O
≥ O
50 O
kg O
for O
men O
and O
≥ O
45 O
kg O
for O
women O
, O
body O
mass O
index O
( O
b O
##mi O
) O
within O
the O
range O
18 O
. O
5 O
to O
31 O
. O
0 O
kg O
/ O
m O
##2 O
( O
inclusive O
) O
, O
and O
c O
##rea O
##tin O
##ine O
clearance O
> O
80 O
m O
##l O
/ O
min O
at O
time O
of O
screening O
. O
[SEP] O
[CLS] O
for O
rat O
single O
- O
pass O
in O
##test O
##inal O
per O
##fusion O
in O
sit O
##u O
model O
, O
the O
concentration O
of O
per O
##fusion O
fluid O
was O
calculated O
as O
co O
##ut O
( O
corrected O
) O
= O
co O
##ut O
##p O
##rin O
/ O
pro O
##ut O
and O
the O
effective B-PK
per I-PK
##me I-PK
##ability I-PK
coefficient I-PK
( I-PK
p I-PK
##ef I-PK
##f I-PK
) I-PK
was O
calculated O
as O
p O
##ef O
##f O
= O
q O
##ln O
[ O
c O
##in O
/ O
co O
##ut O
( O
corrected O
) O
] O
/ O
2 O
##π O
##rl O
. O
co O
##ut O
( O
corrected O
) O
was O
e O
##ff O
##lue O
##nt O
drug O
concentration O
with O
correction O
; O
co O
##ut O
was O
e O
##ff O
##lue O
##nt O
drug O
concentration O
without O
correction O
; O
c O
##in O
was O
in O
##f O
##lue O
##nt O
drug O
concentration O
; O
p O
##rin O
was O
in O
##f O
##lue O
##nt O
p O
##hen O
##ol O
red O
concentration O
; O
pro O
##ut O
were O
e O
##ff O
##lue O
##nt O
p O
##hen O
##ol O
red O
concentration O
; O
q O
was O
per O
##fu O
##sat O
##e O
flow O
rate O
; O
r O
was O
radius O
of O
in O
##test O
##inal O
segment O
and O
l O
was O
in O
##test O
##inal O
segment O
length O
. O
[SEP] O
[CLS] O
therefore O
, O
there O
were O
higher O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
— O
au B-PK
##c I-PK
, O
m B-PK
##rt I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
the O
two O
compounds O
in O
radiation O
- O
injured O
mouse O
, O
when O
compared O
with O
normal O
mouse O
. O
[SEP] O
[CLS] O
all O
procedures O
pertaining O
to O
the O
p O
##k O
studies O
were O
in O
compliance O
with O
the O
g O
##erman O
animal O
welfare O
act O
and O
g O
##erman O
regulations O
( O
tier O
##sch O
##g O
/ O
tier O
##sch O
##vers O
##v O
) O
and O
were O
approved O
by O
the O
re O
##gie O
##rung O
von O
o O
##ber O
##bay O
##ern O
, O
m O
##unch O
##en O
, O
( O
authorization O
number O
55 O
. O
2 O
- O
1 O
- O
54 O
- O
253 O
##2 O
. O
2 O
- O
9 O
- O
11 O
; O
studies O
in O
mice O
and O
rats O
) O
and O
the O
ni O
##ede O
##rsa O
##chs O
##ische O
##s O
land O
##es O
##am O
##t O
fur O
verb O
##ra O
##uche O
##rsch O
##utz O
und O
le O
##ben O
##sm O
##itte O
##ls O
##iche O
##r O
##he O
##it O
, O
old O
##enburg O
( O
authorization O
numbers O
: O
33 O
. O
2 O
- O
425 O
##0 O
##2 O
- O
05 O
- O
l O
##g O
- O
01 O
- O
86 O
/ O
2012 O
and O
33 O
. O
2 O
- O
425 O
##0 O
##2 O
- O
05 O
- O
l O
##g O
- O
01 O
/ O
2014 O
/ O
04 O
sa O
; O
studies O
in O
c O
##yn O
##omo O
##l O
##gus O
monkeys O
and O
dogs O
) O
. O
[SEP] O
[CLS] O
these O
formulation O
##s O
might O
produce O
a O
la B-PK
##g I-PK
time I-PK
in O
drug O
absorption O
or O
present O
a O
plasma O
concentration O
with O
a O
sharp O
initial O
slope O
followed O
by O
a O
sustained O
release O
phase O
. O
[SEP] O
[CLS] O
when O
the O
co O
##var O
##iate O
of O
weight O
was O
on O
c B-PK
##l I-PK
, O
of O
##v O
were O
– O
62 O
##3 O
. O
95 O
##8 O
, O
– O
89 O
##8 O
. O
78 O
##3 O
, O
and O
– O
144 O
##9 O
. O
40 O
for O
war O
##fari O
##n O
, O
r O
- O
war O
##fari O
##n O
, O
and O
s O
- O
war O
##fari O
##n O
, O
respectively O
. O
[SEP] O
[CLS] O
post O
analysis O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
com O
##puted O
using O
win O
non O
##lin O
##® O
software O
version O
5 O
. O
2 O
and O
90 O
% O
confidence O
interval O
was O
com O
##puted O
using O
sa O
##s O
##® O
software O
version O
9 O
. O
2 O
. O
[SEP] O
[CLS] O
br O
- O
c O
##16 O
- O
p O
##x O
had O
a O
49 O
. O
6 O
- O
fold O
greater O
au B-PK
##c I-PK
##0 I-PK
– I-PK
96 I-PK
h I-PK
and O
longer O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
80 O
. O
9 O
h O
##r O
versus O
30 O
. O
3 O
h O
##r O
) O
compared O
to O
tax O
##ol O
. O
[SEP] O
[CLS] O
the O
concentration O
of O
p O
##x O
converted O
from O
br O
- O
c O
##16 O
- O
p O
##x O
n O
##ps O
reached O
higher O
numbers O
than O
tax O
##ol O
at O
4 O
hours O
and O
remained O
higher O
up O
to O
96 O
hours O
with O
a O
much O
longer O
m B-PK
##rt I-PK
( O
32 O
. O
2 O
h O
##r O
versus O
14 O
. O
7 O
h O
##r O
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
96 I-PK
h I-PK
and O
au B-PK
##c I-PK
##48 I-PK
– I-PK
96 I-PK
h I-PK
of O
p O
##x O
from O
the O
n O
##ps O
were O
1 O
. O
1 O
- O
fold O
and O
2 O
. O
7 O
- O
fold O
higher O
than O
tax O
##ol O
, O
respectively O
. O
[SEP] O
[CLS] O
after O
inspection O
of O
the O
p O
##k O
profiles O
, O
a O
one O
- O
compartment O
model O
with O
first O
- O
order O
absorption O
was O
adopted O
as O
the O
optimal O
base O
model O
for O
war O
##fari O
##n O
, O
r O
- O
war O
##fari O
##n O
, O
and O
s O
- O
war O
##fari O
##n O
. O
[SEP] O
[CLS] O
structural O
p O
##k O
model O
was O
fit O
to O
plasma O
concentrations O
, O
and O
typical O
values O
of O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
oral B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
were O
calculated O
( O
where O
f B-PK
denotes O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
) O
. O
[SEP] O
[CLS] O
the O
results O
of O
the O
paired O
t O
- O
test O
of O
p O
##har O
##ma O
##co O
##kin O
##etics O
data O
showed O
that O
there O
was O
no O
significant O
difference O
between O
products O
a O
and O
b O
. O
from O
both O
the O
in O
v O
##it O
##ro O
dissolution O
studies O
and O
in O
v O
##ivo O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
studies O
it O
was O
concluded O
that O
products O
a O
and O
b O
had O
similar O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
normal O
##ized O
sensitivity O
coefficients O
were O
calculated O
using O
the O
forward O
- O
difference O
method O
for O
all O
chemical O
specific O
parameters O
in O
the O
model O
, O
the O
oral O
up B-PK
##take I-PK
rate I-PK
constant I-PK
##s I-PK
, O
the O
elimination B-PK
rate I-PK
constant I-PK
##s I-PK
, O
and O
the O
partition O
coefficients O
. O
[SEP] O
[CLS] O
g O
##eh O
##12 O
##13 O
##33 O
was O
injected O
through O
a O
cat O
##he O
##ter O
placed O
in O
the O
lateral O
tail O
veins O
of O
adult O
female O
fish O
##er O
rats O
( O
ch O
##ar O
##les O
river O
laboratories O
, O
150 O
– O
200 O
g O
, O
n O
= O
4 O
each O
us O
##pio O
compound O
) O
, O
and O
was O
dose O
##d O
at O
5 O
mg O
f O
##e O
kg O
##− O
##1 O
body O
weight O
. O
[SEP] O
[CLS] O
the O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
determined O
directly O
from O
the O
experimental O
data O
. O
[SEP] O
[CLS] O
the O
specific O
radio B-PK
##act I-PK
##ivity I-PK
was O
calculated O
as O
the O
ratio O
of O
the O
radio B-PK
##act I-PK
##ivity I-PK
el O
##uti O
##ng O
at O
the O
retention O
time O
of O
product O
during O
the O
pre O
##par O
##ative O
hp O
##l O
##c O
pu O
##rification O
to O
the O
mass O
corresponding O
to O
the O
area O
under O
the O
curve O
of O
the O
u O
##v O
absorption O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
de O
##tom O
##id O
##ine O
after O
sub O
##ling O
##ual O
administration O
was O
approximate O
##d O
by O
using O
the O
formula O
100 O
% O
* O
[SEP] O
[CLS] O
the O
formulation O
enhance O
##s O
so O
##lub O
##ility O
and O
fraction O
of O
lip O
##op O
##hil O
##ic O
drugs O
transported O
through O
the O
in O
##test O
##inal O
l O
##ymph O
##atic O
system O
, O
thus O
increasing O
absorption O
through O
the O
g O
##i O
tract O
. O
[SEP] O
[CLS] O
b O
##w O
all O
##ometric O
s O
##cal O
##ing O
on O
c B-PK
##lm I-PK
and O
v B-PK
##m I-PK
marked O
##ly O
decreased O
the O
objective O
function O
( O
a O
##ic O
difference O
of O
− O
22 O
with O
respect O
to O
the O
basic O
structural O
model O
) O
. O
[SEP] O
[CLS] O
v B-PK
##m I-PK
was O
significantly O
impacted O
by O
sex O
( O
δ O
##of O
##v O
= O
− O
8 O
. O
8 O
, O
p O
< O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
the O
effect O
of O
b O
##w O
on O
c B-PK
##lm I-PK
and O
v B-PK
##m I-PK
was O
also O
retained O
. O
[SEP] O
[CLS] O
the O
ram O
##ip O
##ril O
##at O
p O
##b O
##p O
##k O
parameters O
are O
: O
1 O
) O
the O
4 O
ace O
binding O
constant O
##s O
( O
kn O
, O
k O
##c O
, O
k O
- O
n O
, O
k O
- O
c O
, O
e O
##q O
. O
( O
2 O
) O
) O
; O
2 O
) O
the O
re B-PK
##nal I-PK
intrinsic I-PK
clearance I-PK
( I-PK
c I-PK
##lu I-PK
, O
e O
##q O
. O
( O
9 O
) O
) O
and O
3 O
) O
the O
total O
ace O
concentration O
in O
plasma O
and O
each O
tissue O
( O
et O
##i O
, O
1 O
= O
1 O
. O
. O
12 O
) O
. O
[SEP] O
[CLS] O
to O
determine O
a O
constant O
rate O
in O
##tra O
##ven O
##ous O
in O
##fusion O
of O
m O
##or O
##phine O
, O
we O
estimate O
k B-PK
##0 I-PK
based O
on O
a O
desired O
m O
##or O
##phine O
c O
##tar O
##get O
to O
achieve O
, O
and O
its O
c B-PK
##l I-PK
, O
so O
that O
k O
##0 O
= O
c O
##tar O
##get O
· O
c O
##l O
. O
[SEP] O
[CLS] O
if O
rapid O
achievement O
of O
steady O
- O
state O
m O
##or O
##phine O
concentration O
is O
desired O
, O
an O
in O
##tra O
##ven O
##ous O
loading O
dose O
may O
be O
calculated O
using O
equation O
7 O
or O
simply O
d O
##l O
= O
c O
##tar O
##get O
· O
v O
##d O
. O
[SEP] O
[CLS] O
op O
##io O
##id O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
est O
##imation O
using O
the O
boots O
##tra O
##p O
( O
see O
below O
) O
was O
not O
performed O
for O
f B-PK
or O
ka B-PK
values O
. O
[SEP] O
[CLS] O
cap O
##mu O
##l O
m O
##c O
##m O
c O
##8 O
( O
mon O
##o O
- O
/ O
dig O
##ly O
##cer O
##ides O
of O
cap O
##ryl O
##ic O
acid O
) O
and O
cap O
##te O
##x O
35 O
##5 O
( O
cap O
##ryl O
##ic O
/ O
cap O
##ric O
t O
##rig O
##ly O
##cer O
##ide O
derivative O
) O
were O
obtained O
as O
gift O
sample O
from O
a O
##bit O
##ec O
, O
uk O
, O
mi O
##gly O
##ol O
81 O
##2 O
( O
cap O
##ryl O
##ic O
/ O
cap O
##ric O
t O
##rig O
##ly O
##cer O
##ide O
) O
was O
gifted O
by O
sa O
##sol O
g O
##erman O
##y O
g O
##mb O
##h O
. O
[SEP] O
[CLS] O
f O
##etal O
trans O
##place O
##ntal O
exposure O
to O
do O
##lut O
##eg O
##ra O
##vir O
was O
considerable O
as O
well O
as O
accumulation O
in O
place O
##ntal O
tissue O
. O
[SEP] O
[CLS] O
this O
means O
that O
putting O
the O
various O
co O
##var O
##iate O
##s O
into O
the O
model O
one O
by O
one O
, O
the O
difference O
between O
the O
objective O
function O
of O
the O
2 O
models O
− O
##2 O
##log O
##lma O
##x O
follow O
f O
distribution O
, O
similar O
to O
χ O
##2 O
distribution O
. O
[SEP] O
[CLS] O
when O
developing O
oral O
am O
##or O
##ph O
##ous O
solid O
di O
##sper O
##sion O
for O
h O
##ydro O
##phobic O
drugs O
such O
as O
c O
##sa O
( O
sa O
##s O
##d O
/ O
c O
##sa O
) O
, O
it O
is O
important O
to O
control O
the O
dissolution O
rate O
in O
order O
to O
avoid O
precipitation O
upon O
di O
##lution O
in O
the O
gas O
##tro O
##int O
##est O
##inal O
tract O
and O
ma O
##xi O
##mize O
the O
absorption O
in O
the O
in O
##test O
##ine O
. O
[SEP] O
[CLS] O
no O
significant O
dose O
- O
dependent O
differences O
in O
clearance B-PK
, O
half B-PK
- I-PK
life I-PK
or O
volume B-PK
of I-PK
distribution I-PK
were O
observed O
( O
p O
> O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
sixty O
‐ O
seven O
of O
71 O
( O
94 O
. O
4 O
% O
) O
and O
70 O
of O
71 O
( O
98 O
. O
6 O
% O
) O
patients O
experienced O
one O
or O
more O
treatment O
‐ O
emerge O
##nt O
a O
##e O
( O
tea O
##e O
) O
during O
cycle O
1 O
and O
all O
cycles O
, O
respectively O
. O
[SEP] O
[CLS] O
between O
approximately O
1 O
week O
and O
1 O
month O
after O
injection O
, O
despite O
the O
early O
var O
##iability O
discussed O
above O
, O
groups O
show O
remarkably O
little O
var O
##iability O
and O
follow O
a O
consistent O
down O
- O
s O
##loping O
curve O
with O
an O
apparent B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
= O
14 O
days O
, O
far O
longer O
than O
the O
elimination B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
seen O
after O
in O
##tra O
##ven O
##ous O
dos O
##ing O
in O
mice O
( O
15 O
h O
) O
[ O
17 O
] O
. O
[SEP] O
[CLS] O
the O
long O
apparent B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
during O
this O
phase O
is O
a O
strong O
indication O
that O
absorption O
of O
el O
##q O
- O
300 O
from O
the O
injection O
site O
into O
blood O
is O
ongoing O
. O
[SEP] O
[CLS] O
the O
next O
phase O
of O
the O
curve O
shows O
a O
decrease O
in O
the O
slope O
of O
the O
concentration O
vs O
time O
curve O
, O
which O
remains O
relatively O
flat O
between O
1 O
and O
3 O
months O
after O
injection O
. O
[SEP] O
[CLS] O
after O
day O
90 O
, O
the O
downward O
slope O
increases O
for O
the O
final O
phase O
of O
the O
curve O
with O
an O
apparent B-PK
terminal I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
= O
29 O
. O
5 O
days O
. O
[SEP] O
[CLS] O
the O
secondary O
end O
##points O
were O
: O
the O
ma B-PK
##ximal I-PK
concentration I-PK
of I-PK
25 I-PK
( I-PK
oh I-PK
) I-PK
d I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
the O
time B-PK
required I-PK
to I-PK
reach I-PK
the I-PK
ma I-PK
##ximal I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
the O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
the O
serum O
concentration O
of O
25 O
( O
oh O
) O
d O
up O
to O
day O
28 O
[SEP] O
[CLS] O
man O
##ni O
##to O
##l O
did O
not O
enhance O
the O
stability O
of O
sir O
##oli O
##mus O
. O
[SEP] O
[CLS] O
matrix O
effect O
( O
% O
) O
= O
b O
##a O
##× O
##100 O
[SEP] O
[CLS] O
the O
image O
processing O
procedure O
of O
radio O
##lum O
##ines O
##cence O
images O
is O
described O
in O
our O
previous O
manuscript O
[ O
20 O
] O
. O
[SEP] O
[CLS] O
comparisons O
of O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
in O
vein O
, O
per O
##ito O
##ne O
##um O
, O
x O
##p O
, O
and O
muscle O
after O
i O
. O
v O
. O
and O
i O
. O
p O
. O
in O
##fusion O
were O
performed O
using O
the O
man O
##n O
- O
w O
##hit O
##ney O
test O
, O
and O
p O
- O
values O
< O
0 O
. O
05 O
were O
considered O
significant O
. O
[SEP] O
[CLS] O
the O
investigators O
used O
a O
##e O
terminology O
and O
accurate O
medical O
terminology O
to O
record O
the O
following O
conditions O
of O
a O
##e O
components O
on O
the O
adverse O
- O
reaction O
observation O
page O
in O
the O
case O
- O
report O
form O
: O
s O
##ym O
##pt O
##om O
description O
, O
date O
of O
occurrence O
, O
date O
of O
s O
##ym O
##pt O
##om O
disco O
##ntin O
##uation O
, O
degree O
, O
measures O
taken O
, O
evaluation O
of O
the O
relationship O
with O
the O
drug O
, O
and O
the O
final O
outcome O
. O
[SEP] O
[CLS] O
if O
an O
a O
##e O
or O
its O
consequences O
persisted O
, O
follow O
- O
up O
was O
continued O
until O
the O
a O
##e O
had O
disappeared O
or O
stab O
##ilized O
. O
[SEP] O
[CLS] O
secondary O
p O
##d O
ex O
##p O
##lora O
##tory O
end O
##points O
included O
changes O
from O
base O
##line O
to O
end O
of O
treatment O
for O
b O
##mi O
z O
score O
, O
body O
weight O
, O
f O
##p O
##g O
, O
serum O
insulin O
, O
and O
serum O
h O
##ba O
##1 O
##c O
. O
[SEP] O
[CLS] O
what O
does O
this O
study O
add O
to O
our O
knowledge O
? O
[SEP] O
[CLS] O
these O
symptoms O
may O
result O
in O
delays O
or O
in O
##con O
##sist O
##encies O
in O
the O
absorption O
of O
oral O
treatments O
. O
[SEP] O
[CLS] O
the O
proportion O
of O
patients O
that O
were O
pain O
- O
free O
at O
2 O
h O
post O
- O
treatment O
was O
18 O
% O
for O
the O
sum O
##at O
##rip O
##tan O
patch O
vs O
9 O
% O
for O
place O
##bo O
( O
p O
= O
0 O
. O
00 O
##9 O
##2 O
; O
number O
needed O
to O
treat O
= O
11 O
. O
1 O
) O
. O
[SEP] O
[CLS] O
upon O
approval O
from O
the O
food O
and O
drug O
administration O
and O
other O
regulatory O
authorities O
, O
the O
ion O
##top O
##hore O
##tic O
trans O
##der O
##mal O
delivery O
of O
sum O
##at O
##rip O
##tan O
will O
be O
a O
good O
choice O
for O
patients O
experiencing O
poor O
absorption O
of O
oral O
medication O
often O
associated O
with O
mi O
##gra O
##ine O
and O
/ O
or O
for O
those O
with O
into O
##ler O
##able O
trip O
##tan O
- O
related O
adverse O
events O
. O
[SEP] O
[CLS] O
then O
the O
solvent O
and O
##ex O
##tra O
th O
##ion O
##yl O
chloride O
were O
removed O
by O
vacuum O
di O
##st O
##illa O
##tion O
. O
[SEP] O
[CLS] O
after O
the O
first O
d O
##lt O
, O
es O
##cal O
##ation O
steps O
of O
no O
more O
than O
35 O
% O
of O
the O
previous O
dose O
were O
made O
. O
[SEP] O
[CLS] O
the O
starting O
dose O
level O
for O
schedule O
a O
was O
5 O
mg O
estimated O
according O
to O
the O
food O
and O
drug O
administration O
( O
f O
##da O
) O
flow O
diagram O
“ O
general O
guide O
for O
starting O
dose O
selection O
for O
a O
c O
##yt O
##oto O
##xi O
##c O
agent O
in O
cancer O
patients O
” O
, O
with O
dose O
es O
##cal O
##ation O
in O
steps O
of O
100 O
% O
until O
the O
first O
drug O
- O
related O
a O
##e O
grade O
≥ O
##2 O
. O
[SEP] O
[CLS] O
to O
reduce O
the O
overall O
number O
of O
patients O
in O
the O
study O
, O
initial O
patient O
co O
##hor O
##ts O
were O
assigned O
only O
to O
the O
4 O
- O
week O
treatment O
cycle O
( O
schedule O
a O
) O
, O
until O
the O
first O
occurrence O
in O
cycle O
1 O
of O
a O
drug O
- O
related O
a O
##e O
grade O
≥ O
##2 O
. O
[SEP] O
[CLS] O
the O
starting O
dose O
level O
in O
schedule O
b O
was O
the O
dose O
at O
which O
a O
first O
drug O
- O
related O
grade O
≥ O
##2 O
a O
##e O
occurred O
in O
schedule O
a O
. O
after O
determination O
of O
the O
m O
##t O
##d O
, O
up O
to O
9 O
additional O
patients O
were O
entered O
at O
this O
dose O
level O
to O
obtain O
further O
safety O
data O
. O
[SEP] O
[CLS] O
the O
remaining O
super O
##nat O
##ant O
specimen O
was O
used O
for O
meta O
##bol O
##ite O
identification O
by O
m O
##s O
/ O
m O
##s O
. O
[SEP] O
[CLS] O
click O
here O
for O
additional O
data O
file O
. O
[SEP] O
[CLS] O
for O
m O
##1 O
detection O
all O
separation O
instances O
were O
carried O
out O
with O
a O
c O
##18 O
l O
##una O
( O
100 O
× O
6 O
mm O
id O
, O
5 O
μ O
##m O
particle O
size O
) O
. O
[SEP] O
[CLS] O
the O
ass O
##ay O
was O
run O
on O
a O
g O
##yr O
##ola O
##b O
bio O
##af O
##fy O
200 O
c O
##d O
, O
and O
wash O
steps O
used O
p O
##bs O
/ O
0 O
. O
01 O
% O
p O
##oly O
##sor O
##bate O
- O
20 O
/ O
0 O
. O
02 O
% O
na O
##n O
##3 O
followed O
by O
g O
##yr O
##os O
p O
##h O
11 O
wash O
buffer O
. O
[SEP] O
[CLS] O
safety O
assessments O
were O
performed O
by O
evaluating O
the O
number O
/ O
proportions O
of O
patients O
experiencing O
a O
##es O
and O
by O
analysis O
of O
any O
changes O
from O
base O
##line O
in O
laboratory O
tests O
, O
e O
##c O
##g O
and O
vital O
signs O
. O
[SEP] O
[CLS] O
exclusion O
criteria O
included O
all O
##er O
##gy O
for O
e O
##chin O
##oc O
##and O
##ins O
or O
ex O
##ci O
##pie O
##nts O
, O
known O
hi O
##v O
, O
he O
##pa O
##titis O
b O
or O
c O
infection O
, O
or O
a O
history O
of O
drug O
or O
alcohol O
abuse O
. O
[SEP] O
[CLS] O
all O
p O
values O
were O
two O
- O
sided O
, O
and O
the O
level O
of O
significance O
was O
set O
at O
p O
< O
0 O
. O
05 O
. O
[SEP] O
[CLS] O
samples O
were O
di O
##lut O
##ed O
1 O
: O
4 O
in O
sample O
buffer O
( O
p O
##bs O
p O
##h O
7 O
. O
4 O
, O
0 O
. O
5 O
% O
b O
##ov O
##ine O
serum O
album O
##in O
[ O
b O
##sa O
] O
, O
15 O
pp O
##m O
pro O
##c O
##lin O
, O
0 O
. O
05 O
% O
p O
##oly O
##sor O
##bate O
- O
20 O
, O
0 O
. O
25 O
% O
3 O
- O
[ O
( O
3 O
- O
ch O
##ola O
##mi O
##do O
##p O
##rop O
##yl O
) O
dim O
##eth O
##yla O
##mm O
##oni O
##o O
] O
- O
1 O
- O
prop O
##ane O
##sul O
##fo O
##nate O
[ O
ch O
##ap O
##s O
] O
, O
5 O
mm O
et O
##hyl O
##ened O
##iam O
##inet O
##et O
##ra O
##ace O
##tic O
acid O
[ O
ed O
##ta O
] O
and O
0 O
. O
35 O
m O
na O
##c O
##l O
) O
. O
[SEP] O
[CLS] O
plasma O
concentration O
- O
time O
profiles O
for O
each O
au O
##n O
##p O
are O
illustrated O
in O
figure O
2 O
, O
with O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
are O
summarized O
in O
table O
1 O
. O
[SEP] O
[CLS] O
plasma O
h O
##gh O
and O
i O
##g O
##f O
- O
1 O
levels O
were O
determined O
by O
el O
##isa O
##s O
from O
r O
& O
d O
systems O
( O
product O
numbers O
d O
##gh O
##100 O
and O
d O
##g O
##100 O
) O
, O
which O
were O
valid O
##ated O
prior O
to O
use O
. O
[SEP] O
[CLS] O
adult O
patients O
receiving O
either O
me O
##rop O
##ene O
##m O
( O
me O
##rone O
##m O
##® O
, O
as O
##tra O
##zen O
##eca O
) O
or O
pipe O
##rac O
##ill O
##in O
/ O
ta O
##zo O
##ba O
##ct O
##am O
( O
ta O
##zo O
##cin O
##® O
, O
p O
##fi O
##zer O
) O
were O
included O
if O
they O
did O
not O
meet O
exclusion O
criteria O
which O
included O
re O
##nal O
d O
##ys O
##function O
( O
defined O
as O
an O
estimated O
g O
##lo O
##mer O
##ular O
fi O
##ltration O
rate O
( O
e O
##g O
##f O
##r O
) O
assessed O
by O
the O
m O
##dr O
##d O
equation O
of O
< O
80 O
m O
##l O
/ O
min O
/ O
1 O
. O
73 O
m² O
) O
, O
absence O
of O
an O
art O
##erial O
cat O
##he O
##ter O
, O
or O
absence O
of O
informed O
consent O
. O
[SEP] O
[CLS] O
from O
fi O
##ck O
' O
s O
first O
law O
, O
j O
= O
− O
##d O
× O
[ O
d O
##c O
( O
x O
) O
] O
/ O
d O
##x O
( O
j O
is O
the O
flux O
or O
transfer O
rate O
along O
the O
donor O
- O
to O
- O
receptor O
side O
, O
d O
is O
the O
diffusion O
coefficient O
, O
x O
is O
the O
distance O
from O
the O
donor O
compartment O
, O
and O
c O
( O
x O
) O
is O
the O
concentration O
in O
the O
barrier O
at O
the O
coordinate O
x O
in O
the O
barrier O
) O
, O
the O
following O
differential O
equation O
is O
derived O
: O
d O
##m O
##r O
( O
t O
) O
/ O
d O
##t O
= O
p O
##ap O
##p O
× O
a O
× O
[ O
c O
##d O
( O
t O
) O
− O
c O
##r O
( O
t O
) O
] O
, O
in O
which O
p B-PK
##ap I-PK
##p I-PK
is O
the O
apparent B-PK
per I-PK
##me I-PK
##ability I-PK
coefficient I-PK
( O
a O
product O
of O
distribution O
coefficient O
with O
diffusion O
coefficient O
divided O
by O
the O
barrier O
thickness O
) O
, O
m O
##r O
is O
the O
amount O
of O
substance O
in O
the O
receiver O
chamber O
, O
a O
is O
the O
cross O
- O
section O
##al O
area O
of O
the O
barrier O
, O
c O
##d O
is O
the O
donor O
concentration O
, O
and O
c O
##r O
is O
the O
receiver O
concentration O
. O
[SEP] O
[CLS] O
the O
adverse O
events O
of O
f O
##er O
##mented O
red O
g O
##ins O
##eng O
and O
the O
probe O
drugs O
were O
evaluated O
in O
all O
15 O
subjects O
. O
[SEP] O
[CLS] O
the O
lower O
limit O
of O
q O
##uant O
##ification O
is O
< O
0 O
. O
70 O
ng O
/ O
m O
##l O
( O
corresponding O
to O
< O
1 O
. O
8 O
nm O
##ol O
/ O
l O
que O
##tia O
##pine O
) O
( O
da O
##vis O
et O
al O
. O
2010 O
) O
. O
[SEP] O
[CLS] O
after O
administration O
of O
me O
##dicated O
feed O
, O
blood O
plasma O
samples O
were O
taken O
between O
0 O
and O
48 O
hours O
, O
by O
ca O
##uda O
##l O
ve O
##ni O
##pu O
##nc O
##ture O
at O
the O
following O
times O
: O
0 O
, O
3 O
, O
6 O
, O
8 O
, O
12 O
, O
18 O
, O
24 O
, O
36 O
and O
48 O
hours O
after O
the O
introduction O
of O
me O
##dicated O
feed O
. O
[SEP] O
[CLS] O
in O
##tra O
- O
ass O
##ay O
precision O
and O
bias O
was O
examined O
using O
spike O
##d O
control O
samples O
anal O
##ys O
##ed O
in O
replica O
##tes O
of O
five O
. O
[SEP] O
[CLS] O
by O
hour O
72 O
, O
median O
plasma O
concentrations O
of O
con O
##iva O
##pta O
##n O
were O
nearly O
dose O
proportional O
. O
[SEP] O
[CLS] O
by O
study O
day O
10 O
, O
virtually O
100 O
% O
of O
the O
drug O
had O
been O
cleared O
. O
[SEP] O
[CLS] O
inter O
- O
ass O
##ay O
precision O
and O
accuracy O
were O
anal O
##ys O
##ed O
in O
q O
##uin O
##tu O
##ple O
##t O
at O
three O
concentrations O
and O
on O
three O
separate O
occasions O
. O
[SEP] O
[CLS] O
table O
2 O
shows O
the O
l O
##sm O
##s O
of O
the O
inverse O
log O
‐ O
transformed O
p O
##k O
values O
( O
breakfast O
/ O
no O
breakfast O
) O
and O
the O
90 O
% O
c O
##is O
. O
[SEP] O
[CLS] O
the O
samples O
were O
collected O
in O
ed O
##ta O
tubes O
and O
cent O
##ri O
##fu O
##ged O
at O
450 O
##0 O
rpm O
for O
10 O
minutes O
. O
[SEP] O
[CLS] O
bone O
ma O
##rrow O
donor O
- O
recipient O
total O
cell O
ch O
##ime O
##rism O
analysis O
was O
performed O
on O
day O
30 O
and O
day O
100 O
using O
a O
quantitative O
flu O
##ores O
##cence O
- O
based O
short O
tandem O
repeat O
polymer O
##ase O
chain O
reaction O
with O
cap O
##illa O
##ry O
electro O
##ph O
##ores O
##is O
for O
polymer O
##ase O
chain O
reaction O
product O
resolution O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
was O
thus O
2 O
. O
23 O
- O
fold O
higher O
than O
that O
of O
pm O
##x O
solution O
( O
26 O
. O
8 O
% O
± O
##2 O
. O
98 O
% O
; O
table O
2 O
) O
. O
[SEP] O
[CLS] O
therefore O
, O
in O
##test O
##inal O
membrane O
per B-PK
##me I-PK
##ability I-PK
and O
pm O
##x O
absorption O
in O
rats O
were O
significantly O
improved O
by O
ion O
- O
pair O
complex O
formation O
with O
d O
##ck O
and O
incorporation O
of O
the O
complex O
in O
a O
na O
##no O
##em O
##ul O
##sive O
system O
. O
[SEP] O
[CLS] O
the O
differences O
in O
half B-PK
- I-PK
lives I-PK
after O
i O
##v O
and O
oral O
administration O
of O
pm O
##x O
suggest O
that O
absorption O
may O
still O
occur O
during O
the O
elimination O
phase O
after O
oral O
intake O
. O
[SEP] O
[CLS] O
flip O
- O
fl O
##op O
occurs O
when O
the O
rate B-PK
of I-PK
absorption I-PK
is O
slower O
than O
the O
rate B-PK
of I-PK
elimination I-PK
. O
[SEP] O
[CLS] O
key O
exclusion O
criteria O
included O
: O
( O
a O
) O
prior O
treatment O
with O
a O
##f O
##li O
##ber O
##ce O
##pt O
or O
p O
##em O
##et O
##re O
##xed O
; O
( O
b O
) O
patients O
whose O
disease O
had O
progressed O
during O
c O
##is O
##p O
##lat O
##in O
administration O
or O
re O
##lap O
##sed O
within O
6 O
months O
of O
completion O
of O
c O
##is O
##p O
##lat O
##in O
- O
based O
therapy O
; O
( O
c O
) O
surgery O
within O
the O
last O
28 O
days O
; O
( O
d O
) O
un O
##con O
##tro O
##lled O
h O
##yper O
##tens O
##ion O
defined O
as O
s O
##ys O
##to O
##lic O
blood O
pressure O
( O
b O
##p O
) O
[UNK] O
mm O
h O
##g O
and O
/ O
or O
di O
##ast O
##olic O
pressure O
[UNK] O
mm O
h O
##g O
( O
prior O
anti O
##hy O
##pert O
##ens O
##ive O
medication O
was O
allowed O
) O
; O
( O
e O
) O
bleeding O
di O
##ath O
##esis O
or O
co O
##agu O
##lop O
##athy O
; O
( O
f O
) O
brain O
or O
le O
##pt O
##ome O
##ning O
##eal O
meta O
##sta O
##ses O
( O
brain O
imaging O
was O
mandatory O
for O
study O
participation O
) O
. O
[SEP] O
[CLS] O
13 O
. O
4 O
% O
of O
participants O
had O
one O
or O
more O
therapeutic O
para O
##ce O
##tam O
##ol O
concentrations O
. O
[SEP] O
[CLS] O
re O
##current O
malaria O
within O
42 O
days O
of O
follow O
- O
up O
occurred O
in O
31 O
. O
3 O
% O
( O
10 O
/ O
34 O
) O
of O
children O
less O
than O
2 O
years O
old O
, O
16 O
. O
0 O
% O
( O
16 O
/ O
106 O
) O
of O
those O
aged O
2 O
– O
5 O
years O
, O
9 O
. O
4 O
% O
( O
15 O
/ O
160 O
) O
of O
those O
aged O
5 O
– O
10 O
years O
, O
and O
none O
( O
0 O
/ O
68 O
) O
of O
those O
over O
10 O
years O
old O
. O
[SEP] O
[CLS] O
liquid O
liquid O
extraction O
method O
was O
used O
. O
[SEP] O
[CLS] O
all O
experiments O
were O
conducted O
according O
to O
the O
guidelines O
for O
care O
and O
use O
of O
laboratory O
animals O
of O
ji O
##lin O
university O
and O
the O
principles O
of O
laboratory O
animal O
care O
of O
ji O
##lin O
university O
. O
[SEP] O
[CLS] O
also O
, O
the O
extraction O
method O
was O
rugged O
enough O
and O
gave O
accurate O
and O
consistent O
results O
when O
applied O
to O
real O
subject O
samples O
. O
[SEP] O
[CLS] O
pre O
##des O
##ign O
##ed O
ta O
##q O
##man O
real O
- O
time O
p O
##c O
##r O
ass O
##ays O
( O
insulin O
receptor O
[ O
ins O
##r O
] O
, O
c O
##f O
##0 O
##26 O
##47 O
##6 O
##25 O
_ O
m O
##1 O
; O
insulin O
- O
de O
##grading O
enzyme O
[ O
id O
##e O
] O
, O
c O
##f O
##0 O
##26 O
##34 O
##27 O
##0 O
_ O
m O
##1 O
; O
car O
##cin O
##oe O
##mb O
##ryo O
##nic O
anti O
##gen O
– O
related O
cell O
ad O
##hesion O
molecule O
1 O
[ O
c O
##ea O
##cam O
##1 O
] O
, O
c O
##f O
##0 O
##30 O
##5 O
##40 O
##9 O
##7 O
_ O
m O
##1 O
; O
and O
18 O
##s O
r O
##rna O
, O
h O
##s O
##9 O
##9 O
##9 O
##9 O
##9 O
##90 O
##1 O
_ O
s O
##1 O
[ O
applied O
bio O
##sy O
##ste O
##ms O
, O
foster O
city O
, O
ca O
] O
) O
with O
a O
light O
##cycle O
##r O
4 O
. O
8 O
instrument O
( O
r O
##och O
##e O
life O
science O
, O
in O
##dian O
##ap O
##olis O
, O
in O
) O
were O
used O
to O
assess O
gene O
expression O
. O
[SEP] O
[CLS] O
other O
screening O
assessments O
included O
24 O
‐ O
hour O
ho O
##lter O
monitoring O
and O
base O
##line O
echo O
##card O
##io O
##gram O
##s O
. O
[SEP] O
[CLS] O
this O
mixture O
was O
treated O
as O
above O
. O
[SEP] O
[CLS] O
non O
- O
para O
##metric O
boots O
##tra O
##p O
sampling O
was O
s O
##tra O
##ti O
##fied O
on O
the O
treatment O
arms O
and O
the O
c O
##y O
##p O
##2 O
##b O
##6 O
* O
6 O
g O
##eno O
##type O
. O
[SEP] O
[CLS] O
matrix O
effect O
assessment O
was O
done O
with O
the O
aim O
to O
check O
the O
effect O
of O
different O
lots O
of O
plasma O
on O
the O
back O
calculated O
value O
of O
q O
##c O
’ O
s O
nominal O
concentration O
. O
[SEP] O
[CLS] O
the O
active O
compounds O
in O
a O
##can O
##th O
##op O
##ana O
##x O
sent O
##ico O
##sus O
( O
as O
) O
have O
different O
p O
##har O
##ma O
##co O
##kin O
##etic O
characteristics O
in O
mouse O
models O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
in O
v O
##ac O
##uta O
##iner O
tubes O
containing O
ed O
##ta O
as O
the O
anti O
##coa O
##gu O
##lant O
. O
[SEP] O
[CLS] O
the O
study O
design O
was O
a O
random O
##ized O
, O
two O
- O
period O
, O
two O
- O
sequence O
, O
two O
- O
treatment O
single O
dose O
, O
open O
label O
, O
bio O
##e O
##qui O
##valence O
study O
using O
axe O
##rt O
##® O
( O
manufactured O
by O
or O
##th O
##o O
- O
m O
##c O
##ne O
##il O
- O
j O
##ans O
##sen O
pharmaceutical O
##s O
, O
in O
##c O
. O
, O
us O
##a O
) O
as O
the O
reference O
formulation O
. O
[SEP] O
[CLS] O
whole O
- O
blood O
concentrations O
of O
c O
##y O
##c O
##los O
##por O
##ine O
and O
ta O
##c O
##rol O
##imus O
were O
determined O
by O
previously O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
with O
tandem O
mass O
s O
##pect O
##rome O
##try O
( O
l O
##c O
– O
m O
##s O
/ O
m O
##s O
) O
methods O
by O
inter O
##te O
##k O
pharmaceutical O
services O
( O
el O
do O
##rado O
hills O
, O
ca O
, O
us O
##a O
) O
and O
pp O
##d O
( O
rich O
##mond O
, O
v O
##a O
, O
us O
##a O
) O
, O
respectively O
; O
da O
##c O
##lat O
##as O
##vir O
plasma O
concentrations O
were O
determined O
using O
previously O
valid O
##ated O
l O
##c O
– O
m O
##s O
/ O
m O
##s O
methods O
by O
tandem O
labs O
( O
west O
t O
##rent O
##on O
, O
n O
##j O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
γ O
- O
ben O
##zy O
##l O
l O
- O
g O
##lut O
##ama O
##te O
n O
- O
car O
##box O
##y O
an O
##hy O
##dr O
##ide O
was O
polymer O
##ised O
in O
n O
, O
n O
- O
dim O
##eth O
##yl O
##form O
##ami O
##de O
, O
initiated O
with O
the O
n O
##h O
##2 O
amino O
group O
of O
ch O
##3 O
##o O
– O
p O
##eg O
– O
ch O
##2 O
##ch O
##2 O
##ch O
##2 O
##nh O
##2 O
, O
to O
obtain O
p O
##eg O
– O
p O
##oly O
( O
γ O
- O
ben O
##zy O
##l O
l O
- O
g O
##lut O
##ama O
##te O
) O
block O
cop O
##oly O
##mers O
( O
p O
##eg O
– O
p O
##b O
##l O
##g O
) O
. O
[SEP] O
[CLS] O
the O
recovery O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
the O
comb O
##ust O
##ed O
samples O
was O
96 O
. O
9 O
% O
or O
greater O
. O
[SEP] O
[CLS] O
a O
blood B-PK
clearance I-PK
time I-PK
constant I-PK
was O
estimated O
from O
the O
change O
in O
relaxation O
rates O
( O
r O
##1 O
, O
2 O
= O
1 O
/ O
t O
##1 O
, O
2 O
) O
over O
the O
first O
4 O
h O
post O
- O
injection O
, O
after O
sub O
##tract O
##ing O
the O
corresponding O
relaxation O
rate O
for O
agent O
- O
free O
whole O
blood O
as O
base O
##line O
. O
[SEP] O
[CLS] O
the O
so O
##lub O
##ility O
of O
c O
##y O
##c O
##lov O
##iro O
##bu O
##xin O
##e O
d O
was O
determined O
using O
the O
following O
equation O
: O
y O
= O
47 O
, O
84 O
##1 O
##x O
##− O
##1 O
, O
29 O
##7 O
, O
75 O
##7 O
( O
r O
##2 O
= O
0 O
. O
99 O
##8 O
) O
( O
4 O
) O
where O
y O
represents O
the O
peak O
area O
and O
x O
represents O
the O
concentration O
( O
μ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
after O
initial O
en O
##rol O
##ment O
, O
children O
returned O
to O
visit O
the O
study O
clinic O
monthly O
for O
clinical O
examination O
and O
for O
s O
##m O
##c O
drugs O
to O
be O
administered O
. O
[SEP] O
[CLS] O
mean O
serum O
concentration O
of O
me O
##lo O
##xi O
##cam O
in O
6 O
buffalo O
##es O
is O
shown O
in O
fi O
##g O
2 O
. O
[SEP] O
[CLS] O
complete O
multi O
##var O
##iate O
analyses O
allowed O
for O
the O
effect O
of O
sex O
on O
v B-PK
##m I-PK
and O
f B-PK
##1 I-PK
to O
be O
discarded O
, O
as O
well O
as O
that O
of O
mat O
##uration O
on O
d O
##ha O
clearance B-PK
. O
[SEP] O
[CLS] O
secondary O
objectives O
included O
measurement O
of O
clinical O
re O
##mission O
( O
c O
##dai O
< O
150 O
) O
, O
clinical O
response O
( O
c O
##dai O
decrease O
of O
at O
least O
70 O
points O
from O
base O
##line O
[ O
c O
##r O
- O
70 O
] O
) O
, O
c O
##r O
- O
100 O
( O
c O
##dai O
decrease O
of O
at O
least O
100 O
points O
from O
base O
##line O
) O
, O
and O
changes O
in O
laboratory O
values O
( O
h O
##s O
- O
c O
##rp O
and O
f O
##c O
) O
over O
time O
. O
[SEP] O
[CLS] O
are O
taken O
from O
the O
default O
" O
standard O
human O
" O
data O
set O
that O
was O
determined O
previously O
by O
application O
of O
p O
##k O
##quest O
to O
other O
so O
##lut O
##es O
. O
[SEP] O
[CLS] O
we O
chose O
a O
value O
for O
c O
##tar O
##get O
within O
m O
##or O
##phine O
' O
s O
therapeutic O
window O
. O
[SEP] O
[CLS] O
four O
of O
5 O
pregnant O
women O
experiencing O
re O
##current O
malaria O
had O
a O
day O
7 O
l O
##ume O
##fant O
##rine O
level O
of O
< O
280 O
ng O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
using O
a O
l O
##ume O
##fant O
##rine O
level O
of O
280 O
ng O
/ O
m O
##l O
on O
day O
7 O
as O
a O
target O
, O
12 O
pregnant O
women O
( O
40 O
% O
) O
and O
9 O
non O
##p O
##re O
##gnant O
adults O
( O
30 O
% O
) O
were O
below O
this O
threshold O
concentration O
. O
[SEP] O
[CLS] O
all O
subjects O
( O
n O
= O
22 O
subjects O
completed O
the O
study O
out O
of O
30 O
included O
subjects O
) O
were O
healthy O
male O
volunteers O
, O
with O
both O
parents O
of O
each O
volunteer O
being O
of O
sub O
- O
sa O
##hara O
##n O
a O
##f O
##rica O
##n O
origin O
. O
[SEP] O
[CLS] O
for O
all O
ages O
, O
the O
between O
‐ O
drug O
extra O
##pol O
##ation O
potential O
increases O
with O
decreasing O
extraction B-PK
ratio I-PK
values O
of O
the O
model O
drug O
, O
with O
this O
effect O
being O
most O
pronounced O
in O
younger O
children O
( O
see O
supplement O
##ary O
material O
s O
##2 O
and O
s O
##3 O
) O
. O
[SEP] O
[CLS] O
the O
ne O
##mat O
##ode O
counts O
of O
0 O
. O
5 O
% O
w O
/ O
v O
e O
##p O
##rino O
##me O
##ct O
##in O
- O
treated O
animals O
and O
the O
un O
##tre O
##ated O
control O
animals O
and O
percentage O
efficacy O
are O
summarized O
in O
table O
2 O
for O
those O
parasite O
##s O
which O
were O
recovered O
from O
at O
least O
four O
control O
animals O
in O
one O
of O
the O
two O
studies O
. O
[SEP] O
[CLS] O
lb O
used O
in O
this O
study O
( O
95 O
% O
) O
was O
prepared O
by O
the O
east O
chin O
##a O
university O
of O
science O
and O
technology O
( O
s O
##hang O
##hai O
, O
chin O
##a O
) O
. O
11 O
a O
modified O
ethanol O
- O
dripping O
method O
was O
used O
to O
prepare O
lb O
. O
12 O
an O
ethanol O
solution O
of O
lip O
##id O
( O
le O
##ci O
##thin O
: O
ch O
##ole O
##ster O
##ol O
= O
6 O
: O
1 O
w O
/ O
w O
) O
, O
sodium O
de O
##ox O
##ych O
##olate O
, O
t O
##we O
##en O
- O
80 O
, O
and O
br O
##uc O
##ine O
( O
16 O
: O
4 O
: O
4 O
: O
1 O
, O
w O
/ O
w O
) O
was O
dripped O
into O
man O
##ni O
##to O
##l O
solution O
( O
5 O
. O
3 O
mg O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
p O
##or O
##cine O
pan O
##cre O
##as O
lip O
##ase O
was O
provided O
by O
si O
##gma O
( O
100 O
– O
500 O
units O
/ O
mg O
, O
si O
##gma O
- O
al O
##dric O
##h O
, O
s O
##t O
. O
lo O
##ui O
##s O
, O
m O
##o O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
was O
purchased O
from O
s O
##hang O
##hai O
y O
##uan O
##ye O
biological O
technology O
co O
. O
, O
l O
##t O
##d O
. O
( O
s O
##hang O
##hai O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
the O
linear O
##ity O
of O
the O
relationship O
between O
peak O
area O
ratio O
or O
peak O
area O
and O
concentration O
was O
demonstrated O
by O
the O
determination O
coefficient O
( O
r O
##2 O
) O
obtained O
for O
the O
p O
##ae O
##ono O
##l O
re O
##gression O
lines O
. O
[SEP] O
[CLS] O
the O
maintenance O
dose O
should O
be O
reduced O
to O
35 O
mg O
for O
patients O
classified O
as O
child O
- O
pu O
##gh O
b O
or O
c O
. O
ca O
##sp O
##of O
##ung O
##in O
was O
administered O
in O
##tra O
##ven O
##ously O
over O
approximately O
1 O
h O
. O
patients O
were O
treated O
as O
long O
as O
clinical O
##ly O
relevant O
but O
the O
duration O
of O
the O
study O
( O
i O
. O
e O
. O
, O
sampling O
of O
patients O
) O
was O
limited O
to O
14 O
days O
of O
ca O
##sp O
##of O
##ung O
##in O
treatment O
. O
[SEP] O
[CLS] O
all O
other O
chemicals O
were O
analytical O
grade O
and O
used O
without O
further O
pu O
##rification O
. O
[SEP] O
[CLS] O
two O
deaths O
in O
phase O
1 O
##b O
( O
sudden O
death O
and O
sub O
##du O
##ral O
hem O
##ato O
##ma O
) O
were O
considered O
treatment O
- O
related O
, O
while O
the O
third O
( O
pneumonia O
) O
was O
considered O
unrelated O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
c O
##sa O
dissolution O
profile O
of O
sand O
##im O
##mu O
##ne O
##® O
presented O
after O
30 O
min O
a O
progressive O
increase O
in O
the O
drug O
dissolution O
rate O
reaching O
95 O
% O
c O
##sa O
after O
90 O
min O
. O
[SEP] O
[CLS] O
in O
this O
evaluation O
, O
the O
c B-PK
##l I-PK
/ I-PK
f I-PK
and O
v B-PK
##d I-PK
/ I-PK
f I-PK
were O
plot O
##ted O
against O
animal O
body O
weight O
on O
a O
log O
- O
log O
scale O
[ O
16 O
] O
. O
[SEP] O
[CLS] O
linear O
re O
##gression O
analysis O
was O
then O
performed O
using O
graph O
##pad O
p O
##rism O
5 O
. O
0 O
, O
graph O
##pad O
software O
, O
in O
##c O
. O
la O
j O
##oll O
##a O
, O
ca O
, O
us O
##a O
, O
according O
to O
the O
log O
##ari O
##th O
##mic O
transformations O
of O
the O
simple O
all O
##ometric O
equations O
as O
shown O
below O
for O
: O
[SEP] O
[CLS] O
plasma B-PK
clearance I-PK
rate I-PK
was O
71 O
– O
79 O
m O
##l O
kg O
##− O
##1 O
h O
##− O
##1 O
and O
hence O
higher O
than O
that O
observed O
in O
adult O
patients O
with O
ha O
##em O
##op O
##hil O
##ia O
and O
in O
healthy O
subjects O
. O
[SEP] O
[CLS] O
in O
v O
##it O
##ro O
dissolution O
studies O
were O
performed O
for O
raw O
sir O
##oli O
##mus O
powder O
, O
liquid O
s O
##med O
##ds O
, O
and O
solid O
s O
##med O
##ds O
. O
[SEP] O
[CLS] O
the O
severity O
of O
all O
a O
##es O
was O
either O
mild O
or O
moderate O
, O
and O
all O
were O
resolved O
without O
medical O
intervention O
. O
[SEP] O
[CLS] O
matrix O
effect O
was O
calculated O
by O
the O
following O
equation O
using O
the O
peak O
anal O
##yte O
areas O
obtained O
by O
direct O
injection O
of O
di O
##lut O
##ed O
( O
or O
neat O
) O
standard O
solutions O
( O
a O
) O
and O
the O
corresponding O
peak O
areas O
of O
di O
##lut O
##ed O
( O
or O
neat O
) O
standard O
solutions O
spike O
##d O
into O
plasma O
de O
##p O
##rote O
##ni O
##zed O
ace O
##ton O
##it O
##ril O
##e O
( O
b O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
determined O
by O
non O
- O
compartment O
##al O
analysis O
using O
kinetic O
##a O
ve O
##r O
4 O
. O
4 O
. O
1 O
( O
the O
##rm O
##o O
fish O
##er O
scientific O
in O
##c O
, O
p O
##hil O
##ade O
##l O
##phi O
##a O
, O
p O
##a O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
a O
solution O
##of O
3 O
- O
ch O
##lor O
##o O
- O
4 O
- O
ni O
##tro O
##ani O
##line O
( O
6 O
, O
10 O
. O
2 O
mm O
##ol O
, O
1 O
. O
75 O
g O
) O
( O
al O
##fa O
##ae O
##sar O
) O
and O
t O
##rie O
##thy O
##lam O
##ine O
( O
122 O
mm O
##ol O
, O
17 O
. O
0 O
m O
##l O
) O
in O
30 O
m O
##l O
of O
th O
##f O
was O
then O
##ad O
##ded O
to O
the O
gray O
salt O
powder O
in O
30 O
m O
##l O
of O
th O
##f O
. O
[SEP] O
[CLS] O
j O
##ak O
##1 O
in O
##hibition O
was O
investigated O
using O
flu O
##ores O
##cence O
- O
activated O
cell O
sorting O
analysis O
on O
blood O
samples O
from O
healthy O
volunteers O
after O
administration O
of O
fi O
##l O
##got O
##ini O
##b O
or O
place O
##bo O
, O
after O
single O
dose O
( O
day O
1 O
) O
or O
at O
steady O
state O
( O
day O
10 O
) O
, O
by O
measuring O
s O
##tat O
##1 O
p O
##hos O
##ph O
##ory O
##lation O
( O
ps O
##tat O
##1 O
) O
in O
il O
- O
6 O
- O
stimulate O
##d O
blood O
. O
[SEP] O
[CLS] O
measurements O
of O
il O
- O
6 O
- O
induced O
s O
##tat O
##1 O
p O
##hos O
##ph O
##ory O
##lation O
were O
performed O
as O
described O
in O
van O
r O
##om O
##pa O
##ey O
et O
al O
. O
[ O
8 O
] O
. O
[SEP] O
[CLS] O
treatment O
was O
also O
terminated O
if O
a O
patient O
had O
an O
into O
##ler O
##able O
a O
##e O
or O
withdrew O
consent O
, O
or O
if O
a O
treatment O
cycle O
was O
delayed O
for O
> O
2 O
weeks O
. O
[SEP] O
[CLS] O
these O
differences O
can O
be O
explained O
by O
the O
fact O
that O
body O
weight O
was O
the O
only O
co O
##var O
##iate O
of O
importance O
for O
l O
##ira O
##g O
##lut O
##ide O
exposure O
. O
[SEP] O
[CLS] O
the O
population O
p O
##k O
analysis O
allowed O
for O
comparison O
of O
l O
##ira O
##g O
##lut O
##ide O
exposure O
between O
children O
participating O
in O
the O
current O
trial O
and O
previous O
trials O
including O
adolescent O
##s O
##21 O
and O
adults O
. O
22 O
the O
mean O
estimate O
of O
c B-PK
##l I-PK
/ I-PK
f I-PK
in O
children O
was O
lower O
than O
that O
in O
both O
adolescent O
##s O
and O
adults O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
a O
third O
of O
patients O
on O
the O
p O
##n O
##40 O
##0 O
/ O
e O
##10 O
treatment O
were O
affected O
. O
[SEP] O
[CLS] O
our O
results O
suggest O
that O
candidate O
transport O
##er O
gene O
variants O
have O
little O
contribution O
to O
var O
##iability O
in O
g O
##ly O
##ce O
##mic O
response O
to O
met O
##form O
##in O
in O
t O
##2 O
##d O
. O
[SEP] O
[CLS] O
the O
mean O
clearance B-PK
of O
i O
##gg O
##1 O
anti O
##body O
a O
##1 O
was O
elevated O
relative O
to O
c O
##1 O
and O
d O
##1 O
by O
10 O
. O
3 O
and O
13 O
. O
8 O
mg O
• O
h O
/ O
kg O
, O
respectively O
in O
the O
s O
##c O
group O
. O
[SEP] O
[CLS] O
in O
the O
i O
##v O
group O
mean O
clearance B-PK
levels O
were O
elevated O
between O
i O
##gg O
##1 O
anti O
##body O
b O
##1 O
and O
antibodies O
c O
##1 O
( O
0 O
. O
29 O
m O
##l O
/ O
h O
/ O
kg O
) O
and O
d O
##1 O
( O
0 O
. O
31 O
m O
##l O
/ O
h O
/ O
kg O
) O
) O
, O
along O
with O
elevated O
levels O
between O
the O
i O
##gg O
##2 O
anti O
##body O
b O
##2 O
and O
antibodies O
c O
##2 O
( O
0 O
. O
15 O
mg O
• O
h O
/ O
kg O
) O
and O
d O
##2 O
( O
0 O
. O
15 O
mg O
• O
h O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
after O
s O
. O
c O
. O
administration O
in O
a O
non O
##de O
##pot O
formulation O
to O
mice O
, O
p O
##f O
##1 O
exhibited O
an O
extended O
half B-PK
- I-PK
life I-PK
in O
comparison O
with O
o O
##t O
, O
3 O
. O
2 O
hours O
versus O
0 O
. O
5 O
hour O
, O
respectively O
( O
fi O
##g O
. O
2 O
##b O
) O
. O
[SEP] O
[CLS] O
administration O
of O
p O
##f O
##1 O
at O
1 O
mg O
/ O
kg O
in O
the O
non O
##de O
##pot O
formulation O
resulted O
in O
a O
total B-PK
ma I-PK
##ximal I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
33 O
##1 O
nm O
( O
free B-PK
cm I-PK
##ax I-PK
= O
0 O
. O
6 O
nm O
) O
at O
2 O
hours O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
the O
total B-PK
cm I-PK
##ax I-PK
of O
o O
##t O
at O
1 O
mg O
/ O
kg O
was O
216 O
nm O
( O
free B-PK
cm I-PK
##ax I-PK
= O
191 O
nm O
) O
and O
occurred O
at O
0 O
. O
25 O
hour O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
a O
positive O
association O
of O
au B-PK
##c I-PK
or O
cm B-PK
##ax I-PK
with O
dose O
was O
observed O
in O
both O
age O
groups O
. O
[SEP] O
[CLS] O
measured O
p O
##k O
values O
were O
5 O
. O
72 O
and O
9 O
. O
78 O
for O
s O
##c O
##8 O
##14 O
##5 O
##8 O
and O
9 O
. O
82 O
for O
s O
##c O
##8 O
##32 O
##8 O
##8 O
. O
[SEP] O
[CLS] O
under O
##nut O
##rit O
##ion O
might O
influence O
the O
au B-PK
##c I-PK
of O
i O
##ver O
##me O
##ct O
##in O
in O
ps O
##ac O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
studies O
for O
tablets O
with O
pure O
p O
##io O
( O
t O
##1 O
) O
, O
solid O
di O
##sper O
##sion O
of O
p O
##io O
( O
t O
##4 O
) O
, O
and O
m O
##f O
( O
p O
##io O
##gli O
##tr O
) O
were O
carried O
out O
using O
male O
w O
##ista O
##r O
rats O
( O
200 O
- O
250 O
g O
) O
. O
[SEP] O
[CLS] O
the O
institutional O
animal O
ethical O
clearance O
( O
v O
##ide O
letter O
no O
. O
a O
##ac O
##p O
/ O
i O
##ae O
##c O
/ O
p O
- O
46 O
/ O
2007 O
) O
was O
obtained O
before O
conducting O
the O
studies O
. O
[SEP] O
[CLS] O
a O
sample O
size O
of O
18 O
subjects O
was O
estimated O
using O
a O
formula O
by O
z O
##hang O
et O
al O
. O
[ O
6 O
] O
to O
provide O
80 O
% O
power O
to O
detect O
approximately O
a O
20 O
% O
difference O
on O
a O
log O
scale O
in O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
and O
cm B-PK
##ax I-PK
between O
the O
brand O
formulation O
and O
the O
generic O
formulation O
. O
[SEP] O
[CLS] O
the O
saturated O
lip O
##id O
solution O
was O
further O
cent O
##ri O
##fu O
##ged O
at O
1500 O
##0 O
rpm O
for O
15 O
minutes O
to O
remove O
ins O
##ol O
##ub O
##le O
drug O
. O
[SEP] O
[CLS] O
the O
samples O
were O
cent O
##ri O
##fu O
##ged O
at O
3 O
, O
000 O
rpm O
for O
10 O
min O
and O
stored O
at O
− O
##70 O
##° O
##c O
for O
ass O
##ays O
. O
[SEP] O
[CLS] O
a O
total O
of O
28 O
patients O
with O
re O
##nal O
lesions O
underwent O
d O
##ce O
- O
m O
##ri O
scanning O
. O
[SEP] O
[CLS] O
a O
total O
of O
40 O
subjects O
( O
35 O
men O
, O
5 O
women O
) O
with O
a O
mean O
age O
of O
30 O
. O
9 O
years O
( O
range O
20 O
– O
45 O
years O
) O
and O
b O
##mi O
ranging O
from O
19 O
. O
9 O
kg O
m O
– O
2 O
to O
31 O
. O
8 O
kg O
m O
– O
2 O
were O
enrolled O
in O
the O
study O
. O
[SEP] O
[CLS] O
median O
parameter O
values O
with O
their O
95 O
% O
confidence O
interval O
( O
c O
##i O
##9 O
##5 O
% O
) O
were O
derived O
from O
2000 O
replica O
##tes O
of O
the O
initial O
data O
##sets O
and O
compared O
with O
the O
original O
estimates O
. O
[SEP] O
[CLS] O
the O
stability O
of O
the O
final O
m O
##q O
and O
as O
/ O
d O
##ha O
models O
was O
assessed O
by O
means O
of O
the O
boots O
##tra O
##p O
method O
implemented O
in O
ps O
##n O
- O
tool O
##ki O
##t O
[ O
15 O
] O
. O
[SEP] O
[CLS] O
the O
accuracy O
and O
precision O
of O
the O
model O
were O
estimated O
by O
means O
of O
prediction O
error O
( O
m O
##pe O
) O
and O
root O
mean O
square O
error O
( O
r O
##ms O
##e O
) O
, O
using O
log O
- O
transformed O
concentrations O
, O
for O
the O
entire O
data O
##set O
and O
also O
for O
each O
study O
site O
[ O
25 O
] O
. O
[SEP] O
[CLS] O
the O
so O
##lub O
##ility O
study O
was O
performed O
to O
select O
the O
suitable O
oil O
( O
o O
) O
, O
surf O
##act O
##ant O
( O
s O
) O
, O
and O
co O
##su O
##rf O
##act O
##ant O
( O
co O
- O
s O
) O
that O
possesses O
high O
so O
##lub O
##ili O
##zing O
capacity O
for O
v O
##als O
##art O
##an O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
final O
m O
##q O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
valid O
##ated O
using O
concentrations O
collected O
from O
participants O
not O
used O
in O
initial O
model O
development O
. O
[SEP] O
[CLS] O
the O
size O
of O
particles O
for O
nasal O
delivery O
should O
be O
above O
10 O
µ O
##m O
because O
the O
smaller O
particles O
( O
< O
10 O
µ O
##m O
) O
can O
be O
transferred O
to O
the O
t O
##rac O
##he O
##ob O
##ron O
##chia O
##l O
with O
the O
airs O
##tre O
##am O
, O
while O
larger O
particles O
will O
mostly O
deposit O
in O
the O
nose O
. O
[SEP] O
[CLS] O
s O
##cal O
##ing O
of O
parameters O
by O
weight O
was O
evaluated O
using O
the O
all O
##ometric O
relationship O
( O
weight O
/ O
median O
weight O
) O
0 O
. O
75 O
for O
clearance B-PK
##s I-PK
and O
a O
linear O
relationship O
( O
ratio O
of O
weight O
to O
median O
weight O
) O
for O
volumes B-PK
. O
[SEP] O
[CLS] O
the O
size O
of O
particles O
prepared O
in O
the O
present O
study O
ranged O
from O
45 O
– O
58 O
µ O
##m O
. O
[SEP] O
[CLS] O
a O
food O
effect O
was O
also O
introduced O
as O
a O
co O
##var O
##iate O
for O
the O
volume B-PK
of I-PK
distribution I-PK
( O
in O
some O
phase O
1 O
studies O
, O
the O
drug O
was O
given O
to O
fast O
##ing O
subjects O
, O
whereas O
in O
all O
field O
trials O
the O
drugs O
were O
administered O
after O
the O
ing O
##est O
##ion O
of O
food O
) O
. O
[SEP] O
[CLS] O
variations O
between O
these O
phase O
1 O
and O
treatment O
trials O
( O
study O
and O
disease O
effects O
) O
were O
considered O
only O
as O
changes O
to O
the O
relative O
absorption O
parameter O
f B-PK
( O
s O
##cal O
##ing O
parameter O
on O
f B-PK
) O
. O
[SEP] O
[CLS] O
the O
data O
from O
both O
the O
g O
- O
hat O
and O
ch O
##aga O
##s O
disease O
field O
trials O
were O
too O
sparse O
to O
estimate O
changes O
in O
the O
absorption B-PK
rate I-PK
, O
clearance B-PK
, O
or O
volume B-PK
accurately O
. O
[SEP] O
[CLS] O
also O
, O
it O
has O
been O
found O
that O
the O
surface O
charge O
density O
of O
lip O
##oso O
##mes O
influences O
their O
distribution O
in O
an O
in O
v O
##ivo O
environment O
##5 O
##9 O
. O
[SEP] O
[CLS] O
multiple O
candidate O
structural O
models O
were O
evaluated O
for O
the O
formation O
of O
the O
drug O
, O
using O
0 O
, O
1 O
, O
2 O
, O
or O
3 O
transit O
compartment O
##s O
. O
[SEP] O
[CLS] O
such O
stability O
is O
determined O
by O
different O
factors O
, O
such O
as O
the O
##rm O
##ody O
##nam O
##ics O
and O
co O
##llo O
##idal O
properties O
of O
the O
system O
##5 O
##4 O
. O
[SEP] O
[CLS] O
we O
have O
developed O
three O
different O
cell O
lines O
for O
this O
experiment O
to O
test O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
two O
different O
imaging O
molecules O
##─ O
##18 O
##f O
- O
f O
##d O
##g O
( O
radio O
##lum O
##ines O
##cence O
) O
and O
6 O
- O
n O
##b O
##d O
##g O
( O
flu O
##ores O
##cence O
) O
. O
[SEP] O
[CLS] O
the O
procedure O
for O
cult O
##uring O
the O
different O
cell O
lines O
is O
described O
below O
. O
[SEP] O
[CLS] O
therefore O
, O
the O
size O
range O
of O
40 O
– O
60 O
µ O
##m O
is O
appropriate O
for O
nasal O
delivery O
##6 O
##1 O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
were O
17 O
. O
9 O
± O
2 O
. O
4 O
ng O
/ O
m O
##l O
and O
70 O
. O
7 O
± O
11 O
. O
2 O
ng O
##× O
##h O
/ O
m O
##l O
at O
3 O
mg O
/ O
kg O
, O
and O
44 O
. O
1 O
± O
7 O
. O
9 O
ng O
/ O
m O
##l O
and O
240 O
. O
5 O
± O
31 O
. O
5 O
ng O
##× O
##h O
/ O
m O
##l O
at O
10 O
mg O
/ O
kg O
, O
respectively O
. O
[SEP] O
[CLS] O
this O
was O
completed O
via O
a O
combination O
of O
visual O
inspection O
and O
application O
of O
an O
algorithm O
applied O
to O
a O
linear O
re O
##gression O
of O
dose O
and O
au B-PK
##c I-PK
to O
test O
for O
de O
##viation O
of O
the O
slope O
from O
1 O
( O
fi O
##g O
. O
1 O
) O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
were O
114 O
##7 O
. O
3 O
± O
233 O
. O
4 O
ng O
/ O
m O
##l O
and O
1995 O
. O
3 O
± O
173 O
##5 O
. O
3 O
ng O
##× O
##h O
/ O
m O
##l O
, O
respectively O
, O
at O
3 O
mg O
/ O
kg O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
after O
oral O
treatment O
( O
3 O
and O
10 O
mg O
/ O
kg O
) O
, O
a O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
reached O
after O
approximately O
1 O
. O
2 O
± O
0 O
. O
4 O
h O
and O
1 O
. O
4 O
± O
0 O
. O
5 O
h O
, O
respectively O
, O
and O
gradually O
decreased O
( O
fi O
##g O
. O
1 O
##b O
) O
. O
[SEP] O
[CLS] O
to O
calculate O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
done O
##pe O
##zi O
##l O
, O
an O
in O
##tra O
##ven O
##ous O
b O
##ol O
##us O
treatment O
of O
3 O
mg O
/ O
kg O
was O
administered O
to O
hair O
##less O
rats O
via O
the O
tail O
vein O
( O
fi O
##g O
. O
2 O
) O
. O
[SEP] O
[CLS] O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
calculated O
according O
to O
a O
slightly O
modified O
method O
described O
by O
sa O
##lu O
##ja O
et O
al O
. O
( O
2013 O
) O
, O
and O
was O
determined O
to O
be O
3 O
. O
6 O
% O
, O
indicating O
that O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
done O
##pe O
##zi O
##l O
is O
low O
. O
[SEP] O
[CLS] O
total B-PK
( I-PK
i I-PK
. I-PK
e I-PK
. I-PK
, I-PK
bound I-PK
and I-PK
un I-PK
##bound I-PK
) I-PK
he I-PK
##pa I-PK
##tic I-PK
metabolic I-PK
plasma I-PK
clearance I-PK
will O
be O
referred O
to O
as O
c B-PK
##l I-PK
##p I-PK
in O
this O
paper O
. O
[SEP] O
[CLS] O
con O
##ju O
##gation O
or O
fusion O
to O
[UNK] O
( O
album O
##in O
- O
binding O
domain O
antibodies O
) O
is O
a O
novel O
approach O
to O
extend O
the O
half B-PK
- I-PK
life I-PK
and O
alter O
the O
tissue O
distribution O
of O
biological O
and O
small O
molecule O
therapeutic O
##s O
. O
[SEP] O
[CLS] O
following O
single O
and O
multiple O
doses O
of O
al O
##iser O
##ti O
##b O
, O
median O
t B-PK
##max I-PK
for O
al O
##iser O
##ti O
##b O
was O
achieved O
at O
4 O
and O
3 O
h O
, O
respectively O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
we O
investigate O
the O
extra O
##pol O
##ation O
potential O
of O
p O
##ediatric O
co O
##var O
##iate O
functions O
s O
##cal O
##ing O
c B-PK
##l I-PK
##p I-PK
from O
adults O
to O
p O
##ediatric O
patients O
between O
a O
model O
drug O
and O
a O
test O
drug O
both O
exclusively O
eliminated O
by O
the O
same O
he O
##pa O
##tic O
is O
##oe O
##nz O
##yme O
. O
[SEP] O
[CLS] O
c O
##ere O
##bro O
##sp O
##inal O
fluid O
( O
c O
##s O
##f O
) O
samples O
were O
collected O
at O
base O
##line O
and O
at O
approximately O
week O
32 O
( O
or O
early O
withdrawal O
) O
from O
a O
subset O
of O
subjects O
who O
provided O
consent O
from O
the O
2 O
mg O
/ O
kg O
, O
4 O
mg O
/ O
kg O
and O
8 O
mg O
/ O
kg O
co O
##hor O
##ts O
in O
the O
fi O
##h O
. O
[SEP] O
[CLS] O
the O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
al O
##iser O
##ti O
##b O
following O
single O
- O
dose O
al O
##iser O
##ti O
##b O
was O
approximately O
16 O
h O
. O
median O
t B-PK
##max I-PK
and O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
for O
the O
meta O
##bol O
##ite O
m O
##1 O
were O
similar O
to O
al O
##iser O
##ti O
##b O
. O
[SEP] O
[CLS] O
the O
median O
t B-PK
##max I-PK
for O
meta O
##bol O
##ite O
m O
##2 O
was O
achieved O
at O
10 O
and O
4 O
h O
, O
following O
single O
and O
multiple O
doses O
of O
al O
##iser O
##ti O
##b O
, O
respectively O
and O
the O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
m O
##2 O
was O
approximately O
22 O
h O
. O
[SEP] O
[CLS] O
the O
mean O
ratios B-PK
of I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
last I-PK
for O
m O
##1 O
and O
m O
##2 O
compared O
to O
al O
##iser O
##ti O
##b O
following O
a O
single O
dose O
of O
al O
##iser O
##ti O
##b O
were O
0 O
. O
45 O
and O
0 O
. O
41 O
, O
respectively O
and O
the O
mean O
ratios B-PK
of I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
10 I-PK
##h I-PK
for O
m O
##1 O
and O
m O
##2 O
compared O
to O
al O
##iser O
##ti O
##b O
following O
multiple O
doses O
of O
al O
##iser O
##ti O
##b O
were O
0 O
. O
44 O
and O
0 O
. O
42 O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
mean O
ratios B-PK
of I-PK
cm I-PK
##ax I-PK
for O
m O
##1 O
and O
m O
##2 O
compared O
to O
al O
##iser O
##ti O
##b O
were O
0 O
. O
30 O
and O
0 O
. O
13 O
, O
respectively O
on O
day O
1 O
and O
0 O
. O
40 O
and O
0 O
. O
37 O
, O
respectively O
on O
day O
10 O
. O
[SEP] O
[CLS] O
o O
##xy O
##to O
##cin O
( O
o O
##t O
) O
m O
##od O
##ulates O
the O
expression O
of O
social O
and O
emotional O
behaviors O
and O
consequently O
has O
been O
proposed O
as O
a O
p O
##har O
##ma O
##co O
##log O
##ic O
treatment O
of O
psychiatric O
diseases O
, O
including O
autism O
spectrum O
disorders O
and O
s O
##chi O
##zophrenia O
; O
however O
, O
end O
##ogen O
##ous O
o O
##t O
has O
a O
short O
half B-PK
- I-PK
life I-PK
in O
plasma O
and O
poor O
per B-PK
##me I-PK
##ability I-PK
across O
the O
blood O
- O
brain O
barrier O
. O
[SEP] O
[CLS] O
recent O
efforts O
have O
focused O
on O
the O
development O
of O
novel O
drug O
delivery O
methods O
to O
enhance O
brain O
penetration O
, O
but O
few O
efforts O
have O
aimed O
at O
improving O
its O
half B-PK
- I-PK
life I-PK
. O
[SEP] O
[CLS] O
the O
p O
##k O
properties O
of O
se O
##cu O
##kin O
##uma O
##b O
were O
linear O
, O
with O
no O
evidence O
of O
a O
dose O
dependence O
of O
clearance B-PK
; O
there O
was O
also O
no O
evidence O
of O
a O
time O
‐ O
dependent O
change O
in O
the O
clearance B-PK
. O
[SEP] O
[CLS] O
clearance B-PK
and O
volume B-PK
varied O
with O
body O
weight O
in O
an O
all O
##ometric O
relationship O
. O
[SEP] O
[CLS] O
for O
clearance B-PK
and O
central B-PK
volume I-PK
of I-PK
distribution I-PK
, O
the O
all O
##ometric O
ex O
##ponents O
were O
estimated O
to O
be O
between O
0 O
. O
8 O
and O
1 O
. O
0 O
; O
in O
other O
words O
, O
a O
doubling O
of O
body O
weight O
could O
lead O
to O
a O
nearly O
2 O
‐ O
fold O
increase O
in O
clearance B-PK
and O
distribution B-PK
volume I-PK
. O
[SEP] O
[CLS] O
age O
, O
sex O
, O
race O
( O
as O
##ian O
vs O
non O
‐ O
as O
##ian O
) O
, O
geographic O
region O
, O
and O
base O
##line O
p O
##asi O
score O
did O
not O
have O
a O
clinical O
##ly O
relevant O
effect O
on O
se O
##cu O
##kin O
##uma O
##b O
clearance B-PK
after O
adjusting O
for O
body O
weight O
. O
[SEP] O
[CLS] O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
##c O
##v O
- O
ne O
h O
##ydro O
##gel O
was O
53 O
##5 O
. O
2 O
% O
and O
244 O
. O
6 O
% O
with O
respect O
to O
the O
raw O
a O
##c O
##v O
h O
##ydro O
##gel O
and O
marketed O
a O
##c O
##v O
cream O
, O
respectively O
. O
[SEP] O
[CLS] O
thus O
, O
there O
is O
a O
5 O
. O
35 O
- O
fold O
and O
2 O
. O
44 O
- O
fold O
increase O
in O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
##c O
##v O
, O
with O
the O
expectation O
to O
decrease O
the O
administered O
dose O
of O
drug O
to O
the O
patient O
, O
and O
subsequently O
minimize O
the O
the O
und O
##esi O
##rable O
effects O
present O
with O
the O
administration O
of O
the O
large O
dose O
. O
[SEP] O
[CLS] O
therefore O
, O
compositions O
intended O
for O
absorption O
through O
the O
oral O
m O
##uc O
##osa O
are O
prefer O
##ably O
of O
high O
purity O
, O
as O
con O
##tam O
##ina O
##nts O
may O
be O
absorbed O
similarly O
to O
g O
##lut O
##ath O
##ione O
, O
and O
as O
relatively O
small O
, O
un O
##charged O
molecules O
[ O
21 O
] O
. O
[SEP] O
[CLS] O
this O
study O
aimed O
to O
formula O
##te O
an O
op O
##ti O
##mized O
a O
##cy O
##c O
##lov O
##ir O
( O
a O
##c O
##v O
) O
na O
##no O
##em O
##ul O
##sion O
h O
##ydro O
##gel O
in O
order O
to O
provide O
a O
solution O
for O
the O
slow O
, O
variable O
, O
and O
incomplete O
oral O
drug O
absorption O
in O
patient O
suffering O
from O
her O
##pes O
simple O
##x O
viral O
infection O
. O
[SEP] O
[CLS] O
the O
effective O
formation O
of O
[ O
69 O
##ga O
] O
g O
##a O
- O
1 O
na O
##no O
##mic O
##elles O
was O
further O
confirmed O
by O
transmission O
electron O
micro O
##sco O
##py O
( O
te O
##m O
) O
imaging O
, O
which O
showed O
small O
and O
spherical O
na O
##no O
##par O
##tic O
##les O
( O
fi O
##g O
. O
3 O
##b O
) O
. O
[SEP] O
[CLS] O
it O
also O
followed O
the O
good O
clinical O
practices O
guidelines O
[ O
14 O
] O
, O
the O
ethical O
principles O
for O
medical O
research O
for O
humans O
stated O
in O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
[ O
15 O
] O
, O
the O
general O
health O
law O
of O
me O
##xi O
##co O
( O
le O
##y O
general O
de O
sa O
##lu O
##d O
, O
me O
##xi O
##co O
) O
[ O
16 O
] O
, O
and O
the O
regulations O
of O
the O
general O
health O
law O
for O
health O
research O
( O
re O
##g O
##lam O
##ent O
##o O
de O
la O
le O
##y O
general O
de O
sa O
##lu O
##d O
en O
mater O
##ia O
de O
invest O
##iga O
##cion O
para O
la O
sa O
##lu O
##d O
, O
me O
##xi O
##co O
) O
[ O
17 O
] O
. O
[SEP] O
[CLS] O
a O
ca O
##d O
product O
ion O
spectrum O
for O
al O
##mot O
##rip O
##tan O
and O
al O
##mot O
##rip O
##tan O
- O
d O
##6 O
yielded O
high O
- O
abundance O
fragment O
ions O
at O
m O
/ O
z O
33 O
##6 O
. O
1 O
##→ O
##20 O
##1 O
. O
1 O
and O
34 O
##2 O
. O
2 O
##→ O
##20 O
##7 O
. O
2 O
in O
multiple O
reaction O
monitoring O
( O
m O
##rm O
) O
positive O
mode O
, O
respectively O
. O
[SEP] O
[CLS] O
we O
also O
examined O
the O
formation O
of O
[ O
69 O
##ga O
] O
g O
##a O
- O
1 O
na O
##no O
##mic O
##elles O
using O
atom O
##istic O
molecular O
- O
dynamics O
( O
m O
##d O
) O
simulation O
##s O
( O
24 O
, O
25 O
) O
. O
[SEP] O
[CLS] O
also O
, O
we O
tried O
different O
column O
packing O
, O
even O
from O
normal O
phase O
. O
[SEP] O
[CLS] O
the O
following O
pieces O
of O
equipment O
were O
used O
: O
ultra O
##vio O
##let O
- O
visible O
( O
u O
##v O
- O
v O
##is O
) O
detector O
( O
s O
##p O
##d O
- O
10 O
##av O
##p O
) O
and O
high O
performance O
liquid O
ch O
##roma O
##to O
##graph O
( O
hp O
##l O
##c O
, O
l O
##c O
- O
10 O
##at O
##v O
##p O
) O
( O
s O
##hima O
##d O
##zu O
corporation O
, O
j O
##apa O
##n O
) O
; O
f O
##a O
##100 O
##4 O
electronic O
scales O
( O
s O
##hang O
##hai O
l O
##ian O
##g O
##ping O
instrument O
co O
. O
, O
l O
##t O
##d O
. O
s O
##hang O
##hai O
, O
chin O
##a O
) O
; O
l O
##g O
##15 O
- O
w O
high O
speed O
micro O
cent O
##ri O
##fu O
##ge O
( O
be O
##iji O
##ng O
medical O
cent O
##ri O
##fu O
##ge O
factory O
, O
be O
##iji O
##ng O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
of O
the O
op O
##ti O
##mized O
a O
##c O
##v O
na O
##no O
##em O
##ul O
##sion O
h O
##ydro O
##gel O
was O
conducted O
in O
rats O
. O
[SEP] O
[CLS] O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
op O
##ti O
##mized O
a O
##c O
##v O
na O
##no O
##em O
##ul O
##sion O
h O
##ydro O
##gel O
improved O
to O
53 O
##5 O
. O
2 O
% O
and O
244 O
. O
6 O
% O
with O
respect O
to O
the O
raw O
a O
##c O
##v O
h O
##ydro O
##gel O
and O
marketed O
cream O
, O
respectively O
, O
confirming O
improvement O
of O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
##c O
##v O
in O
the O
formulated O
na O
##no O
##em O
##ul O
##sion O
h O
##ydro O
##gel O
. O
[SEP] O
[CLS] O
x O
- O
ray O
imaging O
was O
employed O
as O
a O
non O
##in O
##vasive O
method O
of O
determining O
the O
residence O
time O
without O
affecting O
gas O
##tro O
##int O
##est O
##inal O
( O
g O
##it O
) O
m O
##ot O
##ility O
. O
[SEP] O
[CLS] O
measurement O
of O
the O
gas O
##tric O
residence O
time O
of O
a O
drug O
delivery O
system O
at O
the O
application O
site O
is O
to O
provide O
information O
on O
the O
gas O
##tro O
##ret O
##ent O
##ive O
ability O
of O
the O
drug O
delivery O
system O
. O
[SEP] O
[CLS] O
to O
assess O
the O
in O
v O
##ivo O
behavior O
of O
pro O
##dr O
##ug O
under O
testing O
, O
an O
open O
label O
random O
##ized O
two O
- O
way O
cross O
over O
design O
using O
twelve O
healthy O
rabbits O
was O
adopted O
. O
[SEP] O
[CLS] O
a O
radio O
- O
op O
##aque O
marker O
, O
bar O
##ium O
su O
##l O
##phate O
, O
was O
incorporated O
into O
the O
g O
##dd O
##s O
and O
p O
##x O
##ln O
##et O
formulation O
##s O
to O
determine O
the O
extent O
of O
gas O
##tro O
##ret O
##ent O
##ion O
. O
[SEP] O
[CLS] O
the O
d O
##s O
##c O
curves O
for O
physical O
mixture O
of O
m O
##t O
##x O
, O
p O
##l O
##ga O
, O
and O
p O
##eg O
##40 O
##00 O
( O
figure O
3 O
##d O
) O
and O
m O
##t O
##x O
- O
loaded O
imp O
##lants O
( O
figure O
3 O
##e O
) O
showed O
a O
thermal O
behavior O
similar O
to O
that O
identified O
for O
pure O
m O
##t O
##x O
and O
the O
polymer O
##s O
. O
[SEP] O
[CLS] O
dogs O
were O
3 O
‐ O
12 O
years O
of O
age O
( O
median O
, O
6 O
years O
) O
with O
a O
duration O
of O
e O
##pile O
##psy O
of O
0 O
. O
5 O
‐ O
0 O
. O
6 O
years O
( O
median O
, O
1 O
year O
) O
. O
[SEP] O
[CLS] O
a O
g O
##eno O
##type O
and O
im O
##ax O
( O
figure O
3 O
##d O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
was O
observed O
. O
[SEP] O
[CLS] O
in O
addition O
, O
sensitivity O
analysis O
showed O
that O
m O
##or O
##phine O
c B-PK
##l I-PK
is O
influenced O
by O
changes O
in O
cardiac O
output O
, O
which O
links O
to O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
. O
[SEP] O
[CLS] O
thus O
, O
dim O
##eri O
##zation O
of O
l O
##ys O
##ost O
##aph O
##in O
had O
no O
effect O
on O
its O
cat O
##alytic O
efficacy O
but O
decreased O
its O
s O
##ta O
##phy O
##lo O
##ly O
##tic O
activity O
, O
which O
was O
evident O
from O
both O
mi O
##c O
and O
t O
##ur O
##bid O
##ity O
measurements O
. O
[SEP] O
[CLS] O
a O
portable O
co O
gas O
detector O
( O
drag O
##er O
p O
##ac O
700 O
##0 O
, O
drag O
##er O
##wer O
##k O
a O
##g O
& O
co O
. O
kg O
##aa O
, O
g O
##erman O
##y O
) O
was O
used O
during O
the O
re O
##bre O
##ath O
##ing O
period O
to O
check O
for O
possible O
co O
leak O
##age O
at O
the O
nose O
, O
mouth O
##piece O
, O
and O
s O
##pi O
##rome O
##ter O
. O
[SEP] O
[CLS] O
another O
strategy O
to O
improve O
the O
o B-PK
##cular I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
drugs O
after O
topic O
##al O
administration O
is O
to O
use O
na O
##no O
##med O
##ici O
##ne O
and O
na O
##note O
##ch O
##nology O
that O
allow O
the O
drug O
molecules O
to O
intimate O
##ly O
interact O
with O
specific O
o O
##cular O
tissues O
, O
to O
overcome O
the O
corn O
##eal O
barrier O
, O
and O
to O
increase O
the O
penetration O
of O
drugs O
across O
corn O
##eal O
tissue O
##5 O
##6 O
##7 O
##8 O
##17 O
##18 O
. O
[SEP] O
[CLS] O
protocols O
were O
approved O
by O
the O
institutional O
animal O
care O
and O
use O
committee O
of O
the O
veterinary O
science O
school O
, O
university O
of O
b O
##uen O
##os O
air O
##es O
( O
protocol O
number O
2010 O
/ O
20 O
) O
. O
[SEP] O
[CLS] O
thus O
, O
83 O
patients O
remained O
to O
be O
studied O
. O
[SEP] O
[CLS] O
the O
second O
patient O
entered O
in O
this O
co O
##hor O
##t O
experienced O
grade O
3 O
di O
##ar O
##r O
##hoe O
##a O
and O
nausea O
. O
[SEP] O
[CLS] O
this O
analysis O
included O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
from O
114 O
patients O
. O
[SEP] O
[CLS] O
according O
to O
protocol O
, O
a O
total O
of O
six O
patients O
had O
to O
be O
a O
##cc O
##rue O
##d O
at O
the O
same O
d O
##l O
. O
[SEP] O
[CLS] O
blood O
##stream O
infections O
were O
identified O
in O
50 O
% O
of O
mice O
( O
5 O
/ O
10 O
) O
from O
the O
vehicle O
control O
group O
, O
while O
no O
is O
##olate O
##s O
were O
recovered O
from O
the O
blood O
of O
any O
mouse O
treated O
with O
5 O
or O
20 O
mg O
/ O
kg O
ca O
##sp O
##of O
##ung O
##in O
( O
fi O
##g O
. O
3 O
##c O
) O
. O
[SEP] O
[CLS] O
thirty O
- O
six O
healthy O
subjects O
were O
randomly O
assigned O
in O
a O
3 O
: O
1 O
ratio O
to O
receive O
either O
fi O
##da O
##x O
##omi O
##cin O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
all O
electro O
##card O
##io O
##gram O
##s O
were O
without O
any O
clinical O
##ly O
significant O
findings O
. O
[SEP] O
[CLS] O
therefore O
110 O
mg O
m O
##− O
##2 O
was O
considered O
the O
m O
##t O
##d O
of O
b O
##ms O
- O
1887 O
##9 O
##7 O
in O
combination O
with O
c O
##is O
##p O
##lat O
##in O
( O
75 O
mg O
m O
##− O
##2 O
) O
. O
[SEP] O
[CLS] O
none O
of O
the O
additional O
patients O
experienced O
a O
d O
##lt O
, O
so O
the O
study O
could O
proceed O
to O
150 O
mg O
m O
##− O
##2 O
. O
[SEP] O
[CLS] O
this O
concentration O
declined O
gradually O
to O
0 O
. O
9 O
± O
0 O
. O
1 O
µ O
##g O
/ O
m O
##l O
at O
8 O
h O
post O
- O
administration O
. O
[SEP] O
[CLS] O
these O
small O
increases O
were O
consistent O
with O
the O
calculated O
accumulation B-PK
ratio I-PK
( I-PK
r I-PK
##0 I-PK
) I-PK
for O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
) I-PK
. O
[SEP] O
[CLS] O
exclusion O
criteria O
were O
: O
intake O
of O
a O
##b O
##z O
or O
other O
b O
##z O
##d O
drugs O
within O
the O
last O
30 O
days O
; O
ma O
##la O
##bs O
##or O
##ption O
or O
other O
syndrome O
##s O
that O
could O
compromise O
the O
to O
##ler O
##ability O
or O
absorption O
of O
a O
##b O
##z O
; O
history O
of O
h O
##yper O
##sen O
##si O
##ti O
##vity O
or O
into O
##ler O
##ance O
to O
a O
##b O
##z O
or O
its O
inactive O
ingredients O
; O
acute O
clinical O
condition O
; O
pregnancy O
or O
breast O
feeding O
. O
[SEP] O
[CLS] O
compared O
to O
the O
controls O
, O
the O
mean O
serum O
concentration O
of O
am O
##ox O
##ici O
##llin O
was O
significantly O
higher O
in O
lead O
- O
into O
##xi O
##cated O
goats O
during O
the O
first O
hour O
after O
lead O
administration O
and O
significantly O
lower O
at O
4 O
h O
post O
- O
administration O
. O
[SEP] O
[CLS] O
am O
##ox O
##ici O
##llin O
was O
slowly O
eliminated O
from O
the O
control O
goats O
with O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
of O
4 O
. O
14 O
± O
0 O
. O
82 O
h O
compared O
to O
1 O
. O
26 O
± O
0 O
. O
09 O
h O
for O
the O
lead O
- O
into O
##xi O
##cated O
goats O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
simulated O
concentration O
- O
time O
profiles O
were O
compared O
to O
experimental O
data O
. O
[SEP] O
[CLS] O
statistical O
data O
analysis O
was O
performed O
using O
graph O
##pad O
##p O
##rism O
software O
where O
one O
- O
way O
analysis O
of O
variance O
followed O
by O
b O
##on O
##fer O
##ron O
##i O
[UNK] O
s O
##test O
was O
applied O
and O
p O
##≤ O
##0 O
. O
05 O
was O
considered O
as O
them O
##ini O
##mal O
level O
of O
significance O
unless O
indicated O
otherwise O
. O
[SEP] O
[CLS] O
d O
= O
pre O
##det O
##ermined O
composition O
( O
% O
) O
of O
t O
##p O
##gs O
. O
[SEP] O
[CLS] O
fl O
so O
##lub O
##ility O
( O
% O
) O
was O
calculated O
for O
the O
varied O
composition O
at O
the O
10 O
% O
weight O
ratio O
interval O
between O
k O
##oll O
##is O
##ol O
##v O
m O
##ct O
70 O
and O
t O
##p O
##gs O
within O
the O
pseudo O
- O
te O
##rna O
##ry O
phase O
diagram O
. O
[SEP] O
[CLS] O
b O
= O
fl O
so O
##lub O
##ility O
( O
% O
) O
in O
t O
##p O
##gs O
from O
table O
3 O
. O
c O
= O
pre O
##det O
##ermined O
composition O
( O
% O
) O
of O
k O
##oll O
##is O
##ol O
##v O
m O
##ct O
70 O
. O
[SEP] O
[CLS] O
the O
following O
equations O
were O
used O
to O
predict O
the O
x O
##ant O
##hot O
##ox O
##ol O
clearance B-PK
in O
human O
[ O
13 O
] O
: O
( O
2 O
) O
c O
##lint O
in O
v O
##it O
##ro O
= O
v O
##max O
##k O
##m O
, O
c O
##lint O
in O
v O
##ivo O
= O
c O
##lint O
in O
v O
##it O
##ro O
· O
s O
##f O
, O
c O
##l O
##h O
= O
q O
##h O
· O
f O
##u O
· O
c O
##lint O
in O
v O
##ivo O
##q O
##h O
+ O
f O
##u O
· O
c O
##lint O
in O
v O
##ivo O
, O
where O
s O
##f O
( O
s O
##cal O
##ing O
factor O
) O
represents O
the O
mill O
##ig O
##rams O
of O
micro O
##so O
##mal O
protein O
per O
gram O
of O
liver O
multi O
##plied O
by O
the O
grams O
of O
liver O
weight O
; O
c B-PK
##lint I-PK
is O
the O
intrinsic B-PK
metabolic I-PK
clearance I-PK
; O
c B-PK
##l I-PK
##h I-PK
is O
he B-PK
##pa I-PK
##tic I-PK
clearance I-PK
; O
f B-PK
##u I-PK
is O
the O
free B-PK
fraction I-PK
in I-PK
blood I-PK
( O
there O
are O
no O
data O
of O
x O
##ant O
##hot O
##ox O
##ol O
; O
here O
f B-PK
##u I-PK
was O
a O
##rb O
##it O
##rar O
##ily O
proposed O
to O
be O
1 O
) O
; O
q B-PK
##h I-PK
is O
the O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
. O
[SEP] O
[CLS] O
to O
prevent O
solvent O
drop O
##lets O
from O
entering O
and O
con O
##tam O
##inating O
the O
ion O
op O
##tics O
, O
a O
curtain O
n O
##2 O
gas O
of O
45 O
ps O
##i O
was O
applied O
between O
the O
curtain O
plate O
and O
the O
or O
##ifice O
. O
[SEP] O
[CLS] O
these O
data O
indicated O
that O
the O
daily O
, O
but O
not O
weekly O
, O
administration O
of O
t O
##pt O
##d O
in O
our O
regime O
##n O
settings O
stimulate O
##d O
the O
per O
##ios O
##te O
##al O
bone O
formation O
of O
the O
t O
##ibi O
##al O
co O
##rt O
##ices O
. O
[SEP] O
[CLS] O
the O
rats O
were O
fast O
##ed O
for O
12 O
h O
but O
allowed O
water O
ad O
l O
##ibi O
##tum O
before O
the O
z O
##hi O
##gan O
##ca O
##o O
extract O
was O
oral O
##ly O
administered O
at O
a O
dose O
of O
1 O
. O
21 O
g O
/ O
kg O
. O
[SEP] O
[CLS] O
these O
calculations O
were O
performed O
using O
p O
##rism O
5 O
. O
0 O
( O
graph O
##pad O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
data O
were O
expressed O
as O
mean O
± O
the O
standard O
error O
( O
se O
) O
. O
[SEP] O
[CLS] O
a O
pseudo O
- O
te O
##rna O
##ry O
phase O
diagram O
was O
constructed O
with O
fl O
, O
k O
##oll O
##is O
##ol O
##v O
m O
##ct O
70 O
, O
and O
t O
##p O
##gs O
. O
[SEP] O
[CLS] O
the O
he B-PK
##pa I-PK
##tic I-PK
clearance I-PK
of O
x O
##ant O
##hot O
##ox O
##ol O
was O
calculated O
using O
( O
2 O
) O
, O
and O
physiological O
parameters O
in O
human O
were O
described O
as O
follows O
: O
micro O
##so O
##mal O
protein O
per O
gram O
of O
liver O
, O
liver O
weight O
per O
k O
##ilo O
##gram O
of O
body O
, O
and O
liver B-PK
blood I-PK
flow I-PK
for O
human O
were O
48 O
. O
8 O
mg O
, O
25 O
. O
7 O
g O
, O
and O
20 O
. O
7 O
m O
##l O
· O
min O
##− O
##1 O
· O
kg O
##− O
##1 O
, O
respectively O
[ O
14 O
] O
. O
[SEP] O
[CLS] O
the O
full O
range O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
could O
therefore O
only O
be O
derived O
for O
the O
14 O
subjects O
who O
received O
all O
three O
doses O
. O
[SEP] O
[CLS] O
the O
time B-PK
to I-PK
reach I-PK
steady I-PK
state I-PK
for O
m O
##or O
##phine O
is O
t O
##ss O
= O
5 O
× O
t O
##1 O
/ O
2 O
= O
20 O
hours O
. O
[SEP] O
[CLS] O
thus O
, O
the O
m O
##or O
##phine O
maintenance O
dose O
to O
achieve O
a O
steady O
state O
in O
t B-PK
##ss I-PK
is O
given O
by O
[SEP] O
[CLS] O
both O
clearance B-PK
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
were O
decreased O
by O
15 O
- O
fold O
( O
0 O
. O
57 O
##± O
##0 O
. O
2 O
m O
##l O
/ O
h O
versus O
7 O
. O
98 O
##± O
##1 O
. O
2 O
m O
##l O
/ O
h O
, O
for O
[ O
p O
##t O
( O
o O
, O
o O
' O
- O
a O
##ca O
##c O
) O
( O
γ O
- O
a O
##ca O
##c O
) O
( O
d O
##ms O
) O
] O
and O
c O
##is O
##p O
##lat O
##in O
, O
respectively O
p O
< O
0 O
. O
00 O
##1 O
n O
= O
6 O
; O
table O
1 O
) O
and O
46 O
- O
fold O
( O
1 O
. O
8 O
##± O
##0 O
. O
2 O
m O
##l O
/ O
kg O
versus O
82 O
. O
67 O
##± O
##2 O
. O
2 O
m O
##l O
/ O
kg O
, O
for O
[ O
p O
##t O
( O
o O
, O
o O
' O
- O
a O
##ca O
##c O
) O
( O
γ O
- O
a O
##ca O
##c O
) O
( O
d O
##ms O
) O
] O
and O
c O
##is O
##p O
##lat O
##in O
, O
respectively O
p O
< O
0 O
. O
00 O
##1 O
n O
= O
6 O
; O
table O
1 O
) O
, O
in O
the O
[ O
p O
##t O
( O
o O
, O
o O
' O
- O
a O
##ca O
##c O
) O
( O
γ O
- O
a O
##ca O
##c O
) O
( O
d O
##ms O
) O
] O
treatment O
group O
compared O
with O
the O
c O
##is O
##p O
##lat O
##in O
- O
treatment O
group O
. O
[SEP] O
[CLS] O
the O
criteria O
for O
successful O
runs O
were O
restricted O
to O
successful O
convergence O
using O
f O
##oc O
##e O
with O
interaction O
, O
good O
diagnostic O
##s O
for O
the O
model O
- O
fit O
for O
all O
data O
of O
the O
different O
treatment O
periods O
, O
and O
reasonable O
estimates O
for O
fixed O
and O
random O
effect O
parameters O
. O
[SEP] O
[CLS] O
the O
latter O
is O
especially O
problematic O
for O
then O
##asa O
##l O
absorption O
of O
high O
molecular O
- O
weight O
and O
h O
##ydro O
##phi O
##lic O
drugs O
##10 O
, O
20 O
, O
21 O
, O
22 O
. O
[SEP] O
[CLS] O
the O
serum O
concentration O
- O
time O
profiles O
for O
each O
dos O
##ing O
group O
are O
shown O
in O
figure O
3 O
. O
[SEP] O
[CLS] O
based O
on O
d O
##lts O
observed O
on O
- O
study O
, O
d O
##lt O
criteria O
were O
revised O
to O
establish O
a O
more O
clinical O
##ly O
relevant O
m O
##t O
##d O
( O
additional O
file O
1 O
: O
table O
s O
##1 O
) O
. O
[SEP] O
[CLS] O
three O
hours O
after O
the O
s O
##c O
injection O
of O
h O
##gh O
, O
there O
was O
a O
significant O
( O
p O
< O
. O
00 O
##3 O
) O
induction O
of O
i O
##g O
##f O
- O
1 O
that O
was O
sustained O
up O
to O
the O
24 O
- O
hour O
time O
point O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
while O
the O
exact O
mechanism O
of O
##thi O
##s O
effect O
has O
not O
been O
determined O
, O
it O
is O
known O
that O
m O
##uc O
##oa O
##dh O
##esi O
##ve O
add O
##itive O
##sma O
##y O
improve O
drug O
absorption O
by O
reducing O
the O
m O
##uc O
##oc O
##ilia O
##ry O
clearance B-PK
rate I-PK
and O
by O
##in O
##cre O
##asing O
the O
residence B-PK
time I-PK
of O
the O
drug O
formulation O
in O
the O
nasal O
##ca O
##vity O
##25 O
, O
26 O
. O
[SEP] O
[CLS] O
hp O
##tr O
and O
hp O
##to O
##l O
tended O
to O
increase O
more O
after O
d O
##w O
##p O
##0 O
##51 O
##9 O
##5 O
administration O
than O
after O
place O
##bo O
administration O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
use O
of O
both O
lab O
##ras O
##ola O
##nd O
cap O
##mu O
##l O
m O
##c O
##m O
( O
both O
of O
which O
are O
reported O
to O
in O
##hibit O
p O
- O
g O
##ly O
##co O
##p O
##rote O
##ina O
##ct O
##ivity O
##27 O
, O
28 O
) O
might O
also O
be O
responsible O
forth O
##e O
observed O
improved O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ni O
##mo O
##di O
##pine O
from O
the O
developed O
##form O
##ulation O
. O
[SEP] O
[CLS] O
further O
##more O
, O
some O
m O
##uc O
##oa O
##dh O
##esi O
##ve O
polymer O
- O
containing O
systems O
may O
##dir O
##ec O
##tly O
change O
e O
##pit O
##hel O
##ial O
tight O
junction O
##s O
and O
increase O
drug O
absorption O
and B-PK
##bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
##23 O
, O
29 O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
plasma I-PK
concentrations I-PK
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
time I-PK
dose O
- O
dependent O
##ly O
increased O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
##nas O
##al O
h O
##gh O
control O
formulated O
without O
the O
critical O
##sor O
##b O
absorption O
enhance O
##r O
had O
no O
effect O
on O
i O
##g O
##f O
- O
1 O
levels O
. O
[SEP] O
[CLS] O
when O
c O
##p O
##0 O
##24 O
was O
dose O
##d O
twice O
daily O
, O
it O
strongly O
and O
significantly O
induced O
i O
##g O
##f O
- O
1 O
up O
to O
at O
least O
19 O
hours O
after O
the O
first O
dose O
( O
p O
< O
. O
00 O
##2 O
) O
, O
achieving O
a O
similar O
i O
##g O
##f O
- O
1 O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
##h I-PK
to O
the O
s O
##c O
injection O
. O
[SEP] O
[CLS] O
despite O
the O
low O
incidence O
, O
patients O
who O
develop O
ad O
##as O
from O
ex O
##ogen O
##ous O
e O
##po O
may O
have O
a O
serious O
a O
##e O
called O
pure O
red O
- O
cell O
a O
##p O
##lasia O
( O
p O
##rca O
) O
. O
34 O
p O
##rca O
patients O
become O
severely O
an O
##em O
##ic O
with O
a O
rapidly O
decreasing O
h O
##b O
level O
and O
eventually O
become O
dependent O
on O
trans O
##fusion O
##s O
. O
35 O
according O
to O
one O
retrospective O
study O
, O
reported O
cases O
of O
p O
##rca O
mostly O
occurred O
in O
hem O
##od O
##ial O
##ys O
##is O
patients O
who O
received O
sub O
##cut O
##aneous O
e O
##po O
##eti O
##n O
al O
##fa O
. O
[SEP] O
[CLS] O
dial O
##ys O
##is O
tub O
##ing O
procedure O
is O
a O
fast O
and O
low O
cost O
method O
to O
evaluate O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
different O
kinds O
of O
compounds O
and O
, O
in O
this O
study O
, O
it O
was O
used O
in O
the O
aim O
to O
evaluate O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
native O
ha O
and O
ha O
- O
ace O
##t O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
defined O
as O
the O
percentage O
of O
tested O
ha O
and O
ha O
- O
ace O
##t O
recovered O
in O
the O
bio O
##ac O
##cess O
##ible O
fraction O
, O
after O
in O
v O
##it O
##ro O
dig O
##est O
##ion O
, O
in O
relation O
to O
the O
original O
non O
##di O
##ges O
##ted O
samples O
. O
[SEP] O
[CLS] O
fully O
processed O
r O
##f O
##vi O
##ii O
##f O
##c O
( O
figure O
1 O
##a O
, O
lane O
3 O
) O
was O
produced O
by O
co O
- O
trans O
##fect O
##ion O
of O
r O
##f O
##vi O
##ii O
##f O
##c O
with O
human O
p O
##c O
##5 O
, O
a O
member O
of O
the O
prop O
##rote O
##in O
convert O
##ase O
sub O
##til O
##isi O
##n O
/ O
k O
##ex O
##in O
( O
p O
##cs O
##k O
) O
type O
pro O
##te O
##ases O
, O
as O
described O
[ O
10 O
] O
. O
[SEP] O
[CLS] O
the O
geometric O
least O
square O
mean O
( O
l O
##sm O
) O
ratios O
and O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
for O
the O
primary O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
[ O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
] O
of O
done O
##pe O
##zi O
##l O
under O
both O
fast O
##ing O
and O
fed O
states O
are O
presented O
in O
table O
4 O
. O
[SEP] O
[CLS] O
most O
importantly O
, O
oral O
ing O
##est O
##ion O
of O
g O
##ins O
##eno O
##side O
##s O
from O
g O
##be O
yielded O
significantly O
higher O
ratios O
and O
slow O
rates B-PK
of I-PK
absorption I-PK
of O
pp O
##d O
- O
type O
g O
##ins O
##eno O
##side O
##s O
( O
e O
. O
g O
. O
, O
r O
##b O
##1 O
. O
[SEP] O
[CLS] O
r O
##b O
##2 O
, O
r O
##c O
and O
r O
##d O
) O
, O
suggesting O
that O
g O
##ins O
##eno O
##side O
structures O
facilitated O
the O
prediction O
of O
their O
p O
##har O
##ma O
##co O
##kin O
##etic O
profiles O
including O
absorption O
in O
herb O
##al O
medicines O
. O
[SEP] O
[CLS] O
the O
proteins O
were O
analyzed O
by O
non O
- O
reducing O
sodium O
do O
##de O
##cy O
##l O
su O
##lf O
##ate O
p O
##oly O
##ac O
##ryl O
##ami O
##de O
gel O
electro O
##ph O
##ores O
##is O
( O
s O
##ds O
- O
page O
) O
and O
the O
mass O
concentrations O
determined O
by O
measuring O
u O
##v O
absorb O
##ance O
at O
280 O
nm O
. O
[SEP] O
[CLS] O
sa O
##es O
will O
be O
reported O
until O
180 O
days O
after O
the O
last O
administration O
of O
trial O
drugs O
. O
[SEP] O
[CLS] O
first O
, O
the O
in O
##hala O
##tion O
exposure O
intake O
was O
simply O
calculated O
as O
in O
the O
hood O
- O
off O
simulation O
##s O
: O
an O
air O
concentration O
times O
an O
individual O
- O
specific O
in O
##hala O
##tion O
rate O
. O
[SEP] O
[CLS] O
the O
trial O
also O
has O
a O
uk O
regulatory O
com O
##pliant O
real O
- O
time O
sa O
##e O
reporting O
process O
to O
identify O
serious O
adverse O
reactions O
and O
suspected O
unexpected O
serious O
adverse O
reactions O
that O
could O
lead O
to O
the O
suspension O
or O
c O
##ess O
##ation O
of O
the O
trial O
if O
warrant O
##ed O
. O
[SEP] O
[CLS] O
for O
z O
##eta O
potential O
measurement O
na O
##no O
##par O
##tic O
##les O
formulation O
##s O
were O
di O
##lut O
##ed O
with O
water O
. O
[SEP] O
[CLS] O
average O
particle O
diameter O
, O
p O
##oly O
##dis O
##pers O
##ity O
index O
and O
z O
##eta O
potential O
for O
each O
batch O
of O
prepared O
na O
##no O
##par O
##tic O
##les O
was O
determined O
by O
using O
z O
##eta O
##si O
##zer O
3000 O
##hs O
( O
ma O
##lve O
##rn O
instruments O
, O
uk O
) O
. O
[SEP] O
[CLS] O
the O
lo O
##d O
and O
lo O
##q O
are O
presented O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
mechanism O
for O
the O
interaction O
was O
identified O
( O
an O
increase O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
one O
sub O
##pop O
##ulation O
) O
. O
[SEP] O
[CLS] O
the O
oral O
data O
were O
best O
described O
with O
a O
first O
order O
absorption O
without O
la B-PK
##g I-PK
time I-PK
. O
[SEP] O
[CLS] O
the O
estimated O
value O
for O
the O
absorption B-PK
rate I-PK
constant I-PK
was O
1 O
. O
31 O
hour O
- O
1 O
with O
r O
##se O
14 O
% O
. O
[SEP] O
[CLS] O
as O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
f B-PK
were O
of O
particular O
interest O
, O
some O
additional O
investigation O
was O
performed O
. O
[SEP] O
[CLS] O
figure O
8 O
has O
shown O
a O
linear O
ca O
##li O
##bra O
##tion O
plot O
over O
the O
concentration O
range O
under O
the O
op O
##ti O
##mum O
conditions O
. O
[SEP] O
[CLS] O
this O
is O
the O
first O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
of O
i O
##ver O
##me O
##ct O
##in O
. O
[SEP] O
[CLS] O
this O
procedure O
was O
followed O
for O
all O
participants O
, O
p O
##1 O
to O
p O
##6 O
. O
[SEP] O
[CLS] O
table O
1 O
shows O
good O
values O
of O
the O
correlation O
coefficient O
( O
r O
) O
with O
small O
intercept O
, O
small O
value O
of O
standard O
de O
##viation O
( O
s O
. O
d O
. O
) O
and O
relative O
standard O
de O
##viation O
( O
r O
##s O
##d O
) O
that O
point O
out O
high O
accuracy O
and O
precision O
of O
the O
proposed O
method O
. O
[SEP] O
[CLS] O
it O
demonstrates O
the O
utility O
of O
two O
modeling O
approaches O
to O
explore O
drug O
interactions O
, O
especially O
where O
there O
may O
be O
population O
he O
##tero O
##gene O
##ity O
. O
[SEP] O
[CLS] O
first O
, O
the O
95 O
% O
confidence O
interval O
for O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
f B-PK
was O
obtained O
using O
likelihood O
pro O
##fi O
##ling O
. O
[SEP] O
[CLS] O
the O
estimated O
c B-PK
##l I-PK
for O
the O
in O
##tra O
##ven O
##ous O
route O
was O
39 O
. O
7 O
l O
/ O
h O
( O
r O
##se O
8 O
% O
) O
while O
the O
estimates O
of O
the O
oral B-PK
c I-PK
##l I-PK
( O
or O
rather O
c B-PK
##l I-PK
/ I-PK
f I-PK
) O
was O
105 O
l O
/ O
h O
( O
r O
##se O
13 O
% O
) O
. O
[SEP] O
[CLS] O
the O
drug O
en O
##tra O
##pment O
efficiency O
was O
determined O
by O
gel O
per O
##me O
##ation O
ch O
##roma O
##tography O
( O
g O
##p O
##c O
) O
with O
se O
##pha O
##rose O
c O
##l O
- O
4 O
##b O
. O
[SEP] O
[CLS] O
second O
, O
in O
order O
to O
get O
a O
broader O
insight O
into O
the O
first O
pass O
metabolism O
, O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
var O
##iability O
in O
c B-PK
##l I-PK
following O
different O
administration O
routes O
, O
f B-PK
was O
omitted O
from O
the O
model O
and O
instead O
apparent B-PK
c I-PK
##l I-PK
and O
its O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
was O
estimated O
separately O
for O
each O
route O
of O
administration O
( O
other O
disposition O
parameters O
were O
still O
estimated O
jointly O
) O
. O
[SEP] O
[CLS] O
the O
composition O
of O
high O
fat O
high O
ca O
##lor O
##ie O
breakfast O
is O
the O
same O
in O
both O
the O
periods O
. O
[SEP] O
[CLS] O
a O
sample O
size O
of O
30 O
in O
each O
group O
was O
targeted O
to O
detect O
a O
35 O
% O
difference O
in O
the O
au B-PK
##c I-PK
of O
all O
anal O
##yte O
##s O
with O
80 O
% O
power O
and O
5 O
% O
significance O
level O
. O
[SEP] O
[CLS] O
the O
estimated O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
c B-PK
##l I-PK
for O
the O
in O
##tra O
##ven O
##ous O
and O
oral O
routes O
were O
59 O
% O
( O
r O
##se O
22 O
% O
) O
and O
55 O
( O
50 O
% O
) O
respectively O
. O
[SEP] O
[CLS] O
third O
, O
a O
model O
allowing O
correlation O
between O
f B-PK
and O
c B-PK
##l I-PK
was O
tested O
, O
but O
it O
did O
not O
result O
in O
any O
improvements O
and O
var O
##iability O
in O
f B-PK
was O
still O
not O
app O
##re O
##cia O
##ble O
. O
[SEP] O
[CLS] O
the O
percentage O
of O
ha O
##em O
##oly O
##sis O
= O
[ O
( O
a O
##45 O
##0 O
##n O
##m O
of O
test O
compound O
treated O
sample O
- O
a O
##45 O
##0 O
##n O
##m O
of O
buffer O
treated O
sample O
) O
/ O
( O
a O
##45 O
##0 O
##n O
##m O
of O
4 O
% O
t O
##rito O
##nx O
- O
100 O
treated O
samples O
- O
a O
##45 O
##0 O
##n O
##m O
of O
buffer O
treated O
sample O
) O
] O
[SEP] O
[CLS] O
el O
##uted O
compounds O
were O
detected O
at O
227 O
nm O
. O
[SEP] O
[CLS] O
membrane O
##less O
dissolution O
model O
was O
used O
to O
determine O
in O
v O
##it O
##ro O
drug O
release O
behavior O
of O
in O
sit O
##u O
h O
##ydro O
##gel O
of O
g O
##c O
##v O
. O
[SEP] O
[CLS] O
the O
con O
##ju O
##gated O
meta O
##bol O
##ites O
in O
serum O
were O
determined O
through O
h O
##ydro O
##lysis O
with O
g O
##lu O
##cu O
##ron O
##idas O
##e O
and O
su O
##lf O
##ata O
##se O
. O
[SEP] O
[CLS] O
we O
therefore O
compared O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
end O
points O
( O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
the I-PK
last I-PK
sample I-PK
drawn I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
and O
metabolic B-PK
ratios I-PK
) O
of O
selective O
substrates O
for O
specific O
c O
##y O
##ps O
and O
p O
‐ O
g O
##p O
administered O
as O
a O
cocktail O
obtained O
on O
day O
8 O
( O
reflecting O
in O
##hibition O
) O
and O
on O
day O
17 O
( O
reflecting O
induction O
) O
with O
day O
1 O
. O
[SEP] O
[CLS] O
the O
minimum O
required O
di O
##lution O
for O
the O
samples O
was O
1 O
: O
13 O
. O
3 O
( O
sad O
) O
or O
1 O
: O
40 O
( O
mad O
) O
. O
[SEP] O
[CLS] O
we O
selected O
eight O
fl O
##av O
##ono O
##ids O
represented O
in O
table O
1 O
, O
g O
##ly O
##cy O
##rr O
##hi O
##zi O
##c O
acid O
, O
g O
##ly O
##cy O
##rr O
##he O
##tin O
##ic O
acid O
and O
be O
##rber O
##ine O
, O
and O
conducted O
their O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
using O
the O
plasma O
of O
rats O
given O
oral O
##ly O
with O
2 O
g O
/ O
kg O
k O
##rt O
. O
[SEP] O
[CLS] O
however O
, O
β O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
treatment O
increased O
concentrations O
of O
almost O
all O
fl O
##av O
##ono O
##ids O
( O
e O
. O
g O
. O
, O
maximum B-PK
concentration I-PK
of O
b O
##aic O
##ale O
##in O
was O
132 O
##0 O
ng O
/ O
m O
##l O
after O
β O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
treatment O
, O
while O
the O
concentration O
was O
b O
##q O
##l O
in O
un O
##tre O
##ated O
plasma O
from O
k O
##rt O
- O
administered O
rats O
) O
. O
[SEP] O
[CLS] O
finally O
the O
he O
##par O
##in O
was O
neutral O
##ized O
by O
administer O
##ing O
1400 O
##0 O
i O
##u O
of O
pro O
##tamine O
su O
##l O
##phate O
( O
pro O
##tam O
##in O
, O
le O
##o O
p O
##har O
##ma O
, O
ball O
##er O
##up O
, O
den O
##mark O
) O
. O
[SEP] O
[CLS] O
b O
##u O
p O
##k O
parameters O
( O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
, O
c B-PK
##ss I-PK
and O
c B-PK
##l I-PK
) O
and O
dose O
adjustment O
( O
ratio O
of O
adjusted O
vs O
un O
##ad O
##ju O
##sted O
dose O
) O
were O
compared O
between O
g O
##eno O
##type O
##s O
or O
between O
carriers O
and O
non O
- O
carriers O
of O
g O
##sta O
##1 O
ha O
##p O
##lot O
##ype O
##s O
using O
linear O
re O
##gression O
analysis O
. O
[SEP] O
[CLS] O
rats O
were O
habit O
##uated O
to O
the O
an O
##a O
testing O
chambers O
for O
at O
least O
30 O
minutes O
prior O
to O
the O
formal O
##in O
injection O
. O
[SEP] O
[CLS] O
the O
cartridge O
was O
r O
##ins O
##ed O
with O
0 O
. O
5 O
m O
##l O
of O
0 O
. O
1 O
m O
phosphate O
buffer O
( O
p O
##h O
3 O
. O
0 O
) O
, O
followed O
by O
0 O
. O
5 O
m O
##l O
20 O
% O
met O
##han O
##ol O
and O
dried O
under O
vacuum O
. O
[SEP] O
[CLS] O
the O
anal O
##yte O
##s O
were O
el O
##uted O
with O
1 O
m O
##l O
of O
met O
##han O
##ol O
- O
am O
##monia O
( O
[UNK] O
v O
/ O
v O
) O
at O
a O
low O
rate O
of O
no O
more O
than O
1 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
after O
60 O
minutes O
, O
the O
animals O
were O
e O
##uth O
##ani O
##zed O
and O
the O
g O
##i O
tract O
was O
harvested O
. O
[SEP] O
[CLS] O
other O
imaging O
data O
( O
figure O
8 O
##a O
) O
was O
taken O
from O
dynamic O
pet O
measurements O
in O
the O
first O
hour O
after O
administration O
which O
showed O
clearly O
the O
rapid O
blood B-PK
compartment I-PK
clearance I-PK
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
15 O
minutes O
) O
. O
[SEP] O
[CLS] O
we O
have O
developed O
a O
novel O
nasal O
h O
##gh O
product O
( O
c O
##p O
##0 O
##24 O
) O
that O
showed O
excellent O
nasal O
absorption O
in O
animal O
models O
; O
however O
, O
the O
translation O
of O
these O
results O
into O
the O
clinical O
setting O
is O
essential O
because O
past O
attempts O
to O
develop O
such O
formulation O
##s O
by O
other O
groups O
have O
been O
unable O
to O
induce O
i O
##g O
##f O
- O
1 O
in O
man O
. O
[SEP] O
[CLS] O
the O
ability O
of O
p O
##rid O
##op O
##id O
##ine O
and O
t O
##v O
‐ O
450 O
##65 O
to O
in O
##hibit O
and O
/ O
or O
induce O
the O
in O
v O
##it O
##ro O
activity O
of O
major O
drug O
meta O
##bol O
##izing O
enzymes O
was O
assessed O
according O
to O
standard O
practices O
18 O
, O
19 O
, O
20 O
. O
[SEP] O
[CLS] O
all O
participants O
underwent O
pre O
##oper O
##ative O
m O
##ri O
and O
d O
##ce O
- O
m O
##ri O
, O
and O
were O
scheduled O
for O
surgical O
re O
##section O
within O
40 O
days O
of O
imaging O
. O
[SEP] O
[CLS] O
dose O
proportional O
##ity O
was O
tested O
using O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
##h I-PK
, O
cm B-PK
##ax I-PK
, I-PK
s I-PK
##s I-PK
, O
and O
au B-PK
##c I-PK
##τ I-PK
, I-PK
s I-PK
##s I-PK
with O
linear O
re O
##gression O
by O
using O
log O
- O
transformed O
values O
based O
on O
the O
power O
model O
. O
19 O
fish O
##er O
’ O
s O
exact O
test O
was O
used O
to O
compare O
the O
continuous O
variables O
of O
the O
safety O
test O
among O
the O
treatment O
groups O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
revealed O
low O
plasma O
levels O
of O
fl O
##av O
##ono O
##id O
a O
##gly O
##con O
##es O
after O
k O
##rt O
administration O
; O
however O
, O
plasma O
concentrations O
were O
enhanced O
marked O
##ly O
by O
β O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
treatment O
, O
with O
b O
##aic O
##ale O
##in O
the O
most O
abundant O
( O
cm B-PK
##ax I-PK
, O
1 O
. O
32 O
µ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
drug O
and O
drug O
meta O
##bol O
##ite O
concentrations O
in O
plasma O
, O
c O
##er O
##vic O
##ova O
##gin O
##al O
fluids O
( O
c O
##v O
##fs O
) O
, O
c O
##er O
##vic O
##ova O
##gin O
##al O
lava O
##ges O
( O
c O
##v O
##ls O
) O
, O
and O
v O
##agi O
##nal O
tissue O
( O
v O
##t O
) O
bio O
##ps O
##ies O
were O
determined O
via O
liquid O
ch O
##roma O
##to O
##graphic O
- O
tandem O
mass O
s O
##pect O
##rome O
##try O
( O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
. O
[SEP] O
[CLS] O
male O
and O
female O
patients O
aged O
≥ O
##20 O
years O
who O
required O
hospital O
##ization O
and O
treatment O
with O
systemic O
anti O
##ba O
##cter O
##ial O
agents O
and O
gave O
consent O
to O
participate O
in O
the O
study O
were O
included O
. O
[SEP] O
[CLS] O
per O
##ce O
##pt O
##ibility O
and O
accept O
##ability O
were O
assessed O
by O
surveys O
and O
interviews O
. O
[SEP] O
[CLS] O
post O
ho O
##c O
bay O
##esi O
##an O
estimates O
of O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
in O
the O
model O
- O
building O
population O
( O
mostly O
non O
- O
as O
##ian O
patients O
) O
and O
external O
valid O
##ation O
population O
( O
j O
##apa O
##nese O
patients O
only O
) O
were O
also O
similar O
after O
normal O
##ization O
by O
individual O
co O
##var O
##iate O
values O
that O
were O
included O
in O
the O
final O
model O
( O
fi O
##g O
. O
4 O
##c O
, O
d O
) O
. O
[SEP] O
[CLS] O
the O
dose O
es O
##cal O
##ation O
and O
d O
##lt O
are O
listed O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
normal O
##ization O
was O
done O
by O
dividing O
the O
post O
ho O
##c O
bay O
##esi O
##an O
estimates O
of O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
by O
the O
individual O
co O
##var O
##iate O
values O
in O
the O
form O
that O
appeared O
in O
the O
equations O
of O
the O
final O
model O
. O
[SEP] O
[CLS] O
the O
observed O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
time B-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
by O
visual O
inspection O
of O
the O
experimental O
data O
. O
[SEP] O
[CLS] O
in O
this O
model O
, O
the O
effect O
of O
l O
##y O
##25 O
##10 O
##9 O
##24 O
was O
mediated O
by O
a O
sat O
##urable O
concentration O
‐ O
dependent O
stimulation O
of O
c O
##d O
##34 O
+ O
cell O
mob O
##ilization O
to O
the O
response O
compartment O
. O
[SEP] O
[CLS] O
area B-PK
under I-PK
the I-PK
s I-PK
##yn I-PK
##ov I-PK
##ial I-PK
fluid I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
was O
calculated O
using O
linear O
trap O
##ez O
##oid O
##al O
rule O
. O
[SEP] O
[CLS] O
the O
m B-PK
##rt I-PK
is O
calculated O
as O
area B-PK
under I-PK
the I-PK
first I-PK
moment I-PK
curve I-PK
( I-PK
au I-PK
##m I-PK
##c I-PK
) I-PK
/ I-PK
au I-PK
##c I-PK
. O
[SEP] O
[CLS] O
steady O
state O
with O
respect O
to O
cc O
##c O
was O
assumed O
prior O
to O
the O
first O
dose O
of O
l O
##y O
##25 O
##10 O
##9 O
##24 O
and O
/ O
or O
so O
##c O
, O
and O
kin B-PK
was O
calculated O
as O
follows O
: O
( O
6 O
) O
kin O
= O
c O
##d O
##34 O
##0 O
##× O
##ko O
##ut O
[SEP] O
[CLS] O
the O
change O
in O
cc O
##c O
in O
the O
pool O
( O
p O
) O
and O
response O
( O
r O
) O
compartment O
##s O
and O
the O
dynamics O
of O
the O
s O
##ti O
##mu O
##lator O
##y O
signal O
( O
s O
) O
were O
defined O
by O
the O
following O
system O
of O
differential O
equations O
: O
( O
5 O
) O
d O
##p O
##dt O
= O
kin O
##− O
##k O
##p O
##c O
##× O
##1 O
+ O
s O
##max O
##× O
##c O
##ps O
##c O
##50 O
+ O
c O
##p O
+ O
[UNK] O
+ O
k O
##c O
##p O
##× O
##r O
, O
p O
##0 O
= O
c O
##d O
##34 O
##0 O
##× O
##ko O
##ut O
+ O
k O
##c O
##p O
##k O
##p O
##c O
##dr O
##dt O
= O
k O
##p O
##c O
##× O
##1 O
+ O
s O
##max O
##× O
##c O
##ps O
##c O
##50 O
+ O
c O
##p O
+ O
[UNK] O
+ O
k O
##c O
##p O
+ O
k O
##out O
##× O
##r O
, O
r O
##0 O
= O
c O
##d O
##34 O
##0 O
##ds O
##dt O
= O
k O
##t O
##× O
##f O
##c O
##xa O
##c O
##× O
##1 O
##− O
##s O
, O
s O
##0 O
= O
0 O
##where O
c O
##d O
##34 O
##0 O
is O
the O
estimated O
cc O
##c O
at O
time O
zero O
, O
k B-PK
##p I-PK
##c I-PK
is O
the O
first B-PK
‐ I-PK
order I-PK
rate I-PK
of I-PK
transfer I-PK
of O
c O
##d O
##34 O
+ O
cells O
from O
the O
pool O
to O
the O
response O
compartment O
, O
k B-PK
##c I-PK
##p I-PK
is O
the O
first B-PK
‐ I-PK
order I-PK
rate I-PK
of I-PK
transfer I-PK
of O
c O
##d O
##34 O
+ O
cells O
from O
the O
response O
back O
to O
the O
pool O
compartment O
, O
k B-PK
##out I-PK
is O
the O
first B-PK
‐ I-PK
order I-PK
rate I-PK
of I-PK
c I-PK
##d I-PK
##34 I-PK
+ I-PK
cell I-PK
elimination I-PK
, O
k O
##t O
is O
the O
first B-PK
‐ I-PK
order I-PK
signal I-PK
transit I-PK
rate I-PK
, O
which O
is O
nan O
for O
patients O
which O
were O
not O
enrolled O
in O
study O
c O
##xa O
##c O
, O
s O
##max O
is O
the O
maximum O
s O
##ti O
##mu O
##lator O
##y O
effect O
of O
l O
##y O
##25 O
##10 O
##9 O
##24 O
, O
s O
##c O
##50 O
is O
the O
l O
##y O
##25 O
##10 O
##9 O
##24 O
concentration O
at O
which O
half O
of O
the O
maximum O
s O
##ti O
##mu O
##lator O
##y O
effect O
is O
achieved O
, O
c O
##p O
is O
the O
l O
##y O
##25 O
##10 O
##9 O
##24 O
concentration O
in O
the O
central O
compartment O
, O
[UNK] O
is O
the O
signal O
s O
##ti O
##mu O
##lator O
##y O
factor O
, O
and O
f O
##c O
##xa O
##c O
is O
set O
to O
1 O
after O
the O
first O
dose O
for O
patients O
enrolled O
in O
study O
c O
##xa O
##c O
and O
zero O
otherwise O
. O
[SEP] O
[CLS] O
the O
accumulation O
ratio O
in O
the O
presence O
of O
r O
##t O
##v O
was O
between O
2 O
‐ O
and O
4 O
‐ O
fold O
, O
consistent O
with O
the O
reduction O
in O
c O
##y O
##p O
##3 O
##a O
##4 O
‐ O
mediated O
metabolic B-PK
clearance I-PK
of O
g O
##sk O
##28 O
##38 O
##23 O
##2 O
. O
[SEP] O
[CLS] O
h O
##00 O
##1 O
, O
an O
analogue O
of O
h O
##00 O
##2 O
, O
was O
used O
as O
the O
internal O
standard O
. O
[SEP] O
[CLS] O
multiple O
dos O
##ing O
of O
the O
micro O
##ni O
##zed O
a O
##pi O
form O
of O
g O
##sk O
##28 O
##38 O
##23 O
##2 O
q O
##d O
for O
11 O
days O
in O
the O
presence O
of O
r O
##t O
##v O
appeared O
to O
be O
dose O
proportional O
through O
200 O
mg O
with O
either O
powder O
‐ O
in O
‐ O
bottle O
or O
given O
as O
capsule O
##s O
( O
study O
204 O
##9 O
##53 O
, O
table O
3 O
, O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
currently O
, O
topic O
##al O
administration O
is O
the O
first O
choice O
for O
treatment O
of O
o O
##cular O
diseases O
because O
of O
its O
convenience O
and O
patient O
compliance O
##12 O
##34 O
. O
[SEP] O
[CLS] O
further O
##more O
, O
s O
##nc O
##v O
##s O
in O
animals O
given O
5 O
% O
glucose O
, O
c O
##dd O
##p O
, O
and O
n O
##c O
- O
600 O
##4 O
were O
42 O
. O
86 O
##± O
##8 O
. O
07 O
, O
35 O
. O
48 O
##± O
##4 O
. O
91 O
, O
and O
43 O
. O
74 O
##± O
##5 O
. O
3 O
m O
s O
##− O
##1 O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
good O
correlation O
was O
found O
between O
the O
l O
##ymph O
##atic O
transport O
of O
vitamin O
d O
in O
the O
conscious O
, O
me O
##sent O
##eric O
l O
##ymph O
- O
can O
##nu O
##lated O
rat O
model O
and O
in O
the O
ch O
##yl O
##omi O
##c O
##ron O
flow O
blocking O
model O
using O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
. O
19 O
it O
has O
been O
reported O
that O
the O
fraction O
transported O
by O
the O
l O
##ymph O
##atic O
pathway O
can O
be O
determined O
by O
sub O
##tract O
##ing O
the O
fraction O
transported O
to O
the O
systemic O
circulation O
in O
the O
rats O
pre O
##tre O
##ated O
with O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
from O
the O
total B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
animals O
pre O
##tre O
##ated O
with O
sa O
##line O
. O
16 O
, O
18 O
[SEP] O
[CLS] O
secondary O
end O
points O
included O
investigator O
- O
assessed O
r O
##pf O
##s O
, O
time O
to O
initiation O
of O
ch O
##em O
##otherapy O
, O
time O
to O
pro O
##state O
- O
specific O
anti O
##gen O
( O
ps O
##a O
) O
progression O
, O
ps O
##a O
response O
( O
≥ O
##50 O
% O
decline O
) O
, O
and O
time O
to O
skeletal O
- O
related O
event O
. O
[SEP] O
[CLS] O
however O
, O
fatty O
in O
##fi O
##ltration O
had O
been O
seen O
in O
all O
groups O
without O
significant O
difference O
. O
[SEP] O
[CLS] O
it O
is O
well O
established O
that O
p O
##ha O
##go O
##cy O
##tes O
, O
which O
are O
abundant O
in O
the O
re O
##tic O
##ulo O
##end O
##oth O
##eli O
##al O
system O
, O
in O
liver O
, O
kidney O
, O
s O
##ple O
##en O
and O
lung O
tissues O
, O
can O
trigger O
the O
process O
of O
p O
##ha O
##go O
##cy O
##tic O
recognition O
and O
subsequent O
blood B-PK
clearance I-PK
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
time I-PK
curve I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
an I-PK
infinite I-PK
time I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
approximately O
doubled O
, O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
increased O
at O
a O
rate O
greater O
than O
the O
dose O
( O
~ O
2 O
. O
4 O
fold O
) O
; O
and O
the O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
apparent B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
and O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
were O
approximately O
the O
same O
for O
both O
p O
##f O
- O
51 O
##90 O
##45 O
##7 O
50 O
mg O
b O
. O
i O
. O
d O
. O
and O
100 O
mg O
b O
. O
i O
. O
d O
. O
doses O
. O
[SEP] O
[CLS] O
twenty O
participants O
took O
four O
100 O
- O
mg O
al O
##ba O
##cona O
##zo O
##le O
capsule O
##s O
before O
crossing O
over O
to O
a O
single O
400 O
- O
mg O
al O
##ba O
##cona O
##zo O
##le O
tablet O
. O
[SEP] O
[CLS] O
p O
##lu O
##ronic O
f O
68 O
was O
purchased O
from O
si O
##gma O
- O
al O
##dric O
##h O
chemicals O
, O
us O
##a O
. O
[SEP] O
[CLS] O
this O
study O
was O
conducted O
at O
a O
single O
site O
( O
co O
##vance O
clinical O
research O
unit O
, O
da O
##llas O
, O
te O
##xa O
##s O
) O
under O
a O
single O
principal O
investigator O
( O
j O
. O
k O
. O
) O
; O
institutional O
review O
board O
approval O
was O
obtained O
for O
the O
study O
protocol O
and O
consent O
forms O
( O
s O
##chu O
##lman O
associates O
i O
##rb O
, O
in O
##c O
. O
, O
c O
##in O
##cin O
##nat O
##i O
, O
oh O
##io O
) O
. O
[SEP] O
[CLS] O
to O
adjust O
for O
multi O
##p O
##licity O
in O
the O
ass O
##ay O
sensitivity O
analysis O
, O
a O
re O
##sa O
##mp O
##ling O
‐ O
based O
multiple O
test O
was O
carried O
out O
. O
[SEP] O
[CLS] O
y O
= O
α O
##0 O
+ O
α O
##1 O
##x O
##1 O
+ O
α O
##2 O
##x O
##2 O
+ O
α O
##3 O
##x O
##3 O
+ O
α O
##12 O
##x O
##1 O
##x O
##2 O
+ O
α O
##13 O
##x O
##1 O
##x O
##3 O
+ O
α O
##23 O
##x O
##2 O
##x O
##3 O
+ O
α O
##11 O
##x O
##12 O
+ O
α O
##22 O
##x O
##22 O
+ O
α O
##33 O
##x O
##32 O
+ O
· O
· O
· O
[SEP] O
[CLS] O
in O
the O
context O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
/ O
p O
##har O
##ma O
##co O
##dynamic O
goal O
of O
area B-PK
under I-PK
the I-PK
time I-PK
concentration I-PK
curve I-PK
to I-PK
minimum I-PK
inhibitor I-PK
##y I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
) I-PK
≥ O
##40 O
##0 O
and O
also O
to O
obtain O
t B-PK
##rough I-PK
serum I-PK
concentration I-PK
of O
van O
##com O
##y O
##cin O
of O
≥ O
##15 O
mg O
/ O
l O
, O
it O
is O
necessary O
to O
individual O
##ize O
doses O
of O
van O
##com O
##y O
##cin O
in O
critically O
ill O
patients O
. O
[SEP] O
[CLS] O
the O
apparent B-PK
terminal I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
ng O
##r O
– O
h O
##t O
##n O
##f O
was O
relatively O
short O
, O
with O
means O
##± O
##s O
. O
d O
. O
[SEP] O
[CLS] O
all O
of O
the O
a O
##es O
were O
judged O
to O
be O
due O
to O
the O
b O
##al O
procedure O
and O
not O
considered O
drug O
related O
, O
except O
for O
one O
a O
##e O
( O
vomit O
##ing O
) O
, O
which O
occurred O
just O
after O
drug O
administration O
. O
[SEP] O
[CLS] O
all O
a O
##es O
were O
mild O
in O
severity O
, O
except O
for O
one O
moderate O
a O
##e O
( O
respiratory O
tract O
infection O
) O
. O
[SEP] O
[CLS] O
the O
standard O
de O
##viation O
##s O
of O
the O
au B-PK
##c I-PK
ranged O
from O
0 O
. O
000 O
to O
0 O
. O
01 O
##9 O
suggesting O
that O
the O
models O
were O
stable O
, O
i O
. O
e O
. O
the O
selection O
of O
non O
- O
d O
##di O
drugs O
did O
not O
affect O
the O
results O
. O
[SEP] O
[CLS] O
the O
results O
of O
4 O
- O
fold O
cross O
- O
valid O
##ation O
showed O
that O
the O
standard O
de O
##viation O
##s O
of O
au B-PK
##c I-PK
ranged O
from O
0 O
. O
00 O
##2 O
to O
0 O
. O
01 O
##9 O
( O
additional O
file O
1 O
: O
table O
s O
##3 O
, O
figure O
s O
##1 O
) O
. O
[SEP] O
[CLS] O
however O
, O
their O
au B-PK
##c I-PK
values O
were O
clearly O
higher O
than O
those O
of O
oral O
administration O
( O
0 O
. O
27 O
##16 O
– O
2 O
. O
222 O
ng O
h O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
since O
we O
chose O
drugs O
from O
a O
pool O
of O
a O
large O
number O
of O
drugs O
with O
non O
- O
d O
##di O
for O
d O
##q O
to O
construct O
a O
balanced O
classification O
( O
d O
##di O
pairs O
: O
non O
- O
d O
##di O
pairs O
= O
1 O
: O
1 O
) O
, O
we O
were O
concerned O
about O
the O
bias O
brought O
by O
the O
selection O
of O
the O
non O
- O
d O
##di O
drugs O
. O
[SEP] O
[CLS] O
the O
model O
was O
repeated O
using O
different O
age O
threshold O
variables O
( O
e O
##g O
, O
≥ O
##6 O
vs O
< O
6 O
years O
of O
age O
) O
until O
the O
threshold O
that O
indicated O
a O
statistical O
##ly O
significant O
increase O
in O
the O
odds O
of O
having O
a O
half B-PK
- I-PK
life I-PK
at O
2 O
hours O
or O
higher O
was O
detected O
. O
[SEP] O
[CLS] O
calculated O
area B-PK
under I-PK
the I-PK
time I-PK
– I-PK
concentration I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
0 I-PK
– I-PK
t I-PK
values O
was O
slightly O
higher O
by O
i O
. O
p O
. O
dos O
##ing O
than O
by O
i O
. O
v O
. O
dos O
##ing O
( O
15 O
. O
01 O
and O
10 O
. O
36 O
ng O
h O
/ O
m O
##l O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
all O
of O
the O
three O
patients O
( O
100 O
% O
) O
receiving O
8 O
mg O
/ O
day O
developed O
a O
r O
##ash O
, O
a O
well O
- O
known O
a O
##e O
related O
with O
in O
##hibition O
of O
wild O
- O
type O
e O
##g O
##f O
##r O
. O
[SEP] O
[CLS] O
adjusting O
both O
e O
##f O
and O
f O
##u O
in O
the O
pp O
##k O
model O
again O
resulted O
in O
a O
strong O
bias O
toward O
over O
##p O
##red O
##ict O
##ing O
u O
##tero O
##tro O
##phic O
le O
##ls O
( O
m O
##r O
##v O
= O
1 O
. O
24 O
log O
units O
) O
, O
whereas O
all O
single O
- O
adjustment O
models O
had O
m O
##r O
##v O
values O
between O
− O
##0 O
. O
21 O
and O
− O
##0 O
. O
68 O
log O
units O
, O
“ O
all O
” O
group O
, O
figure O
3 O
##b O
. O
[SEP] O
[CLS] O
the O
only O
co O
##var O
##iate O
that O
improved O
the O
fit O
of O
the O
model O
was O
, O
for O
pipe O
##rac O
##ill O
##in O
c B-PK
##l I-PK
, O
c O
##l O
##c O
##r O
normal O
##ized O
to O
100 O
m O
##l O
/ O
min O
, O
which O
decreased O
the O
of O
##v O
by O
18 O
. O
62 O
( O
p O
< O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
the O
time O
course O
of O
un O
##bound O
plasma O
pipe O
##rac O
##ill O
##in O
concentrations O
was O
best O
described O
by O
a O
two O
- O
compartment O
linear O
model O
with O
combined O
residual O
error O
and O
b O
##s O
##v O
on O
the O
volume B-PK
of I-PK
the I-PK
central I-PK
( I-PK
v I-PK
##c I-PK
) I-PK
and I-PK
peripheral I-PK
compartment I-PK
##s I-PK
( I-PK
v I-PK
##p I-PK
) I-PK
, O
drug B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
an O
in B-PK
##fusion I-PK
la I-PK
##g I-PK
des I-PK
##cript I-PK
##or I-PK
( I-PK
al I-PK
##ag I-PK
; O
defined O
as O
the O
time O
taken O
for O
the O
residual O
drug O
to O
get O
through O
the O
i O
##v O
line O
after O
completion O
of O
the O
20 O
- O
minute O
in O
##fusion O
, O
which O
was O
included O
as O
zero O
order O
input O
) O
. O
[SEP] O
[CLS] O
after O
5 O
min O
of O
in O
##cu O
##bation O
at O
37 O
##° O
##c O
, O
the O
reaction O
was O
stopped O
by O
the O
addition O
of O
0 O
. O
85 O
m O
##l O
of O
t O
##rich O
##lor O
##oa O
##ce O
##tic O
acid O
( O
t O
##ca O
) O
0 O
. O
31 O
m O
. O
the O
p O
##h O
of O
the O
mixture O
was O
brought O
to O
about O
10 O
by O
adding O
0 O
. O
65 O
m O
##l O
of O
1 O
. O
6 O
m O
na O
##oh O
- O
g O
##ly O
##cine O
buffer O
( O
p O
##h O
10 O
. O
3 O
) O
; O
the O
amount O
of O
um O
##bell O
##ifer O
##one O
was O
measured O
flu O
##ori O
##metric O
##ally O
( O
ex O
##citation O
390 O
nm O
; O
emission O
440 O
nm O
) O
( O
v O
##iva O
##relli O
et O
al O
. O
, O
2016 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
was O
relatively O
long O
, O
16 O
hours O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
for O
the O
first O
distribution O
phase O
was O
calculated O
to O
be O
0 O
. O
2 O
hour O
and O
the O
corresponding O
half B-PK
- I-PK
life I-PK
for O
the O
second O
distribution O
phase O
was O
1 O
. O
3 O
hours O
. O
[SEP] O
[CLS] O
this O
is O
in O
##dicative O
of O
a O
stable O
physically O
cross O
- O
linked O
network O
showing O
little O
change O
in O
v O
##isco O
##ela O
##stic O
characteristics O
. O
[SEP] O
[CLS] O
for O
quantitative O
analysis O
of O
the O
co O
##rona O
##l O
imaging O
planes O
, O
one O
region O
of O
interest O
( O
r O
##oi O
) O
was O
placed O
in O
air O
in O
the O
upper O
left O
q O
##uad O
##rant O
outside O
the O
animal O
and O
defined O
as O
background O
. O
[SEP] O
[CLS] O
the O
high O
- O
dose O
to O
##ler O
##ability O
study O
with O
g O
##eh O
##12 O
##13 O
##33 O
( O
200 O
mg O
f O
##e O
kg O
##− O
##1 O
) O
did O
not O
reveal O
any O
weight O
loss O
in O
g O
##eh O
##12 O
##13 O
##33 O
- O
injected O
rats O
compared O
with O
controls O
. O
[SEP] O
[CLS] O
in O
summary O
, O
no O
significant O
adverse O
effects O
were O
observed O
in O
animals O
treated O
with O
g O
##eh O
##12 O
##13 O
##33 O
at O
a O
high O
dose O
of O
200 O
mg O
f O
##e O
kg O
##− O
##1 O
. O
[SEP] O
[CLS] O
em O
: O
those O
cat O
##ego O
##rise O
##d O
as O
having O
two O
of O
the O
wild O
- O
type O
all O
##ele O
( O
c O
##y O
##p O
##2 O
##d O
##6 O
* O
1 O
ho O
##mo O
##zy O
##got O
##e O
em O
) O
, O
and O
in O
addition O
patients O
with O
one O
functional O
all O
##ele O
and O
one O
non O
- O
functional O
all O
##ele O
or O
an O
all O
##ele O
with O
decreased O
function O
( O
he O
##tero O
##zy O
##got O
##e O
em O
) O
. O
[SEP] O
[CLS] O
m O
##r O
images O
were O
exported O
as O
di O
##com O
files O
and O
analyzed O
with O
the O
o O
##sir O
##ix O
software O
( O
32 O
- O
bit O
open O
source O
, O
http O
: O
/ O
/ O
www O
. O
o O
##sir O
##ix O
- O
viewer O
. O
com O
) O
. O
[SEP] O
[CLS] O
the O
random O
##ized O
volunteers O
included O
66 O
healthy O
subjects O
( O
49 O
men O
and O
17 O
women O
) O
from O
1 O
study O
site O
( O
a O
##pot O
##ex O
, O
in O
##c O
. O
, O
bio O
##c O
##lini O
##cal O
development O
, O
clinical O
operations O
) O
in O
to O
##ron O
##to O
, O
on O
##tar O
##io O
, O
can O
##ada O
, O
who O
had O
signed O
informed O
consent O
and O
had O
passed O
the O
screening O
processes O
for O
eligibility O
. O
[SEP] O
[CLS] O
the O
study O
was O
approved O
by O
health O
can O
##ada O
and O
can O
##adia O
##n O
research O
ethics O
board O
and O
was O
conducted O
in O
compliance O
with O
good O
clinical O
practice O
guidelines O
. O
[SEP] O
[CLS] O
there O
were O
no O
apparent O
relationships O
between O
the O
levels O
or O
changes O
of O
these O
bio O
##mark O
##ers O
and O
tumor O
responses O
. O
[SEP] O
[CLS] O
pregnant O
and O
la O
##ct O
##ating O
females O
were O
excluded O
. O
[SEP] O
[CLS] O
use O
of O
drug O
meta O
##bol O
##izing O
enzyme O
( O
c O
##y O
##p O
- O
450 O
) O
induce O
##rs O
within O
28 O
days O
prior O
to O
dos O
##ing O
or O
inhibitor O
##s O
within O
14 O
days O
prior O
to O
dos O
##ing O
, O
use O
of O
any O
mon O
##oam O
##ine O
o O
##xi O
##das O
##e O
inhibitor O
##s O
within O
28 O
days O
prior O
to O
dos O
##ing O
, O
use O
of O
any O
prescription O
medications O
/ O
products O
, O
except O
ho O
##rmon O
##al O
con O
##tra O
##ceptive O
##s O
in O
female O
subjects O
of O
child O
##be O
##aring O
potential O
, O
and O
use O
of O
any O
over O
- O
the O
- O
counter O
non O
- O
prescription O
preparations O
( O
except O
i O
##bu O
##p O
##ro O
##fen O
and O
ace O
##tam O
##ino O
##phe O
##n O
used O
at O
recommended O
doses O
) O
within O
14 O
days O
of O
study O
entry O
all O
resulted O
in O
exclusion O
. O
[SEP] O
[CLS] O
no O
id O
##urs O
##ulf O
##ase O
- O
related O
m O
##or O
##bid O
##ity O
or O
mortality O
was O
observed O
during O
the O
study O
. O
[SEP] O
[CLS] O
the O
lower O
limit O
of O
q O
##uant O
##itation O
was O
2 O
. O
50 O
p O
##g O
/ O
m O
##l O
for O
e O
##e O
and O
50 O
. O
0 O
p O
##g O
/ O
m O
##l O
for O
l O
##n O
. O
[SEP] O
[CLS] O
the O
inter B-PK
##com I-PK
##par I-PK
##tment I-PK
##al I-PK
rate I-PK
constant I-PK
##s I-PK
were O
defined O
as O
k O
##12 O
= O
q O
##1 O
× O
p O
##c O
/ O
v O
##1 O
, O
k O
##21 O
= O
q O
##1 O
/ O
v O
##2 O
, O
and O
k O
##20 O
= O
daily O
c O
##s O
##f O
drainage O
volume O
/ O
24 O
. O
[SEP] O
[CLS] O
p B-PK
##c I-PK
is O
defined O
as O
transfer O
multi O
##p O
##lier O
between O
the O
central O
and O
c O
##s O
##f O
compartment O
##s O
. O
[SEP] O
[CLS] O
ass O
##ay O
precision O
, O
expressed O
as O
the O
between O
‐ O
day O
percent O
coefficient O
of O
variation O
( O
% O
c O
##v O
) O
of O
the O
quality O
control O
( O
q O
##c O
) O
samples O
was O
< O
14 O
. O
7 O
% O
for O
e O
##e O
and O
< O
6 O
. O
0 O
% O
for O
l O
##n O
for O
the O
low O
, O
medium O
, O
and O
high O
q O
##c O
samples O
. O
[SEP] O
[CLS] O
the O
cumulative O
transmission O
per O
unit O
area O
of O
q O
( O
μ O
##g O
cm O
##− O
##2 O
) O
and O
the O
steady O
- O
state O
trans O
##der O
##mal O
rate O
j O
##s O
( O
μ O
##g O
cm O
##− O
##2 O
h O
##− O
##1 O
) O
were O
calculated O
. O
[SEP] O
[CLS] O
for O
quantitative O
comparison O
with O
p O
##ediatric O
population O
, O
the O
proportion O
of O
p O
##ediatric O
subjects O
falling O
outside O
the O
adult O
95 O
% O
percent O
##ile O
interval O
was O
com O
##puted O
for O
distribution O
of O
concentrations O
and O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
from O
plasma O
samples O
were O
determined O
from O
typical O
and O
individual O
g O
##ado O
##ter O
##ic O
acid O
concentration O
- O
time O
profiles O
: O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
rate B-PK
constant I-PK
of I-PK
the I-PK
terminal I-PK
phase I-PK
( I-PK
β I-PK
) I-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##½ I-PK
##β I-PK
) I-PK
, O
total B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
; O
per O
subject O
and O
normal O
##ized O
for O
b O
##w O
) O
, O
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
; O
per O
subject O
and O
normal O
##ized O
for O
b O
##w O
) O
. O
[SEP] O
[CLS] O
it O
is O
obvious O
that O
the O
2d O
method O
has O
successfully O
en O
##rich O
##ed O
the O
peak O
capacity O
and O
improved O
the O
resolution O
as O
well O
. O
[SEP] O
[CLS] O
for O
c B-PK
##l I-PK
and O
v B-PK
##d I-PK
, O
the O
significant O
co O
##var O
##iable O
##s O
responsible O
for O
the O
variations O
of O
the O
parameters O
were O
studied O
. O
[SEP] O
[CLS] O
sa O
##rog O
##lit O
##azar O
was O
rapidly O
and O
well O
absorbed O
across O
all O
doses O
in O
the O
single O
- O
dose O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
, O
with O
a O
median O
time B-PK
to I-PK
the I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
of O
less O
than O
1 O
h O
( O
range O
0 O
. O
63 O
– O
1 O
h O
) O
under O
fast O
##ing O
conditions O
across O
the O
doses O
studied O
. O
[SEP] O
[CLS] O
the O
average O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
sa O
##rog O
##lit O
##azar O
was O
5 O
. O
6 O
h O
. O
sa O
##rog O
##lit O
##azar O
was O
not O
eliminated O
via O
the O
re O
##nal O
route O
. O
[SEP] O
[CLS] O
there O
was O
no O
effect O
of O
sex O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
sa O
##rog O
##lit O
##azar O
, O
except O
for O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
, O
which O
was O
significantly O
shorter O
in O
females O
than O
in O
males O
. O
[SEP] O
[CLS] O
the O
bio O
##e O
##qui O
##valence O
between O
both O
products O
was O
determined O
by O
calculation O
of O
the O
confidence O
intervals O
( O
c O
##is O
) O
at O
90 O
% O
of O
the O
log O
##ari O
##th O
##m O
of O
the O
coefficient O
test O
/ O
reference O
such O
as O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
in O
terms O
of O
ace O
##tam O
##ino O
##phe O
##n O
p O
##har O
##ma O
##co O
##kin O
##etic O
metric O
##s O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
active O
m O
##oi O
##ety O
after O
oral O
r O
##is O
##per O
##ido O
##ne O
administration O
has O
been O
described O
using O
a O
two O
- O
compartment O
disposition O
model O
with O
linear O
elimination O
from O
the O
central O
compartment O
. O
25 O
oral O
absorption O
was O
modeled O
using O
a O
first O
- O
order O
process O
with O
a O
la B-PK
##g I-PK
time I-PK
from O
the O
gut O
to O
the O
central O
compartment O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
( I-PK
λ I-PK
##z I-PK
) I-PK
was O
estimated O
by O
linear O
re O
##gression O
of O
log O
##ari O
##th O
##mic O
##ally O
‐ O
transformed O
concentration O
– O
time O
data O
. O
[SEP] O
[CLS] O
terminal B-PK
elimination I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
was O
calculated O
as O
l O
##n O
( O
2 O
) O
/ O
λ O
##z O
. O
[SEP] O
[CLS] O
the O
accumulation B-PK
ratio I-PK
( I-PK
r I-PK
##ac I-PK
##c I-PK
) I-PK
was O
calculated O
as O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
##pm I-PK
, I-PK
s I-PK
##s I-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
, I-PK
s I-PK
##d I-PK
. O
[SEP] O
[CLS] O
the O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
directly O
from O
the O
concentration O
– O
time O
data O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
after O
a O
single O
dose O
was O
calculated O
as O
the O
sum O
of O
au B-PK
##c I-PK
##0 I-PK
– I-PK
last I-PK
and O
au B-PK
##ce I-PK
##x I-PK
##tra I-PK
##p I-PK
where O
au B-PK
##ce I-PK
##x I-PK
##tra I-PK
##p I-PK
is O
c B-PK
##last I-PK
/ I-PK
λ I-PK
##z I-PK
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
end I-PK
of I-PK
the I-PK
dos I-PK
##ing I-PK
interval I-PK
, I-PK
ta I-PK
##u I-PK
, O
for O
the O
morning O
and O
evening O
dose O
( O
au B-PK
##cam I-PK
, O
au B-PK
##c I-PK
##pm I-PK
) O
was O
calculated O
by O
means O
of O
the O
mixed O
log O
‐ O
linear O
trap O
##ez O
##oid O
##al O
rule O
. O
[SEP] O
[CLS] O
the O
steady B-PK
‐ I-PK
state I-PK
equilibrium I-PK
ratio I-PK
was O
calculated O
as O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
##pm I-PK
, I-PK
s I-PK
##s I-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, I-PK
s I-PK
##d I-PK
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
in O
the O
first O
les O
##ion O
varied O
from O
1 O
. O
8 O
days O
to O
3 O
. O
6 O
days O
( O
mean O
2 O
. O
4 O
days O
, O
s O
##d O
0 O
. O
8 O
days O
) O
during O
the O
six O
cycles O
, O
and O
from O
3 O
. O
0 O
days O
to O
4 O
. O
5 O
days O
( O
mean O
3 O
. O
7 O
days O
, O
s O
##d O
0 O
. O
6 O
days O
) O
in O
the O
second O
les O
##ion O
, O
respectively O
. O
[SEP] O
[CLS] O
distribution O
of O
exposure O
over O
a O
24 O
‐ O
h O
dos O
##ing O
interval O
at O
steady O
state O
was O
q O
##uant O
##ified O
by O
est O
##imating O
the O
ratio O
between O
the O
au B-PK
##c I-PK
for I-PK
the I-PK
first I-PK
12 I-PK
‐ I-PK
h I-PK
interval I-PK
over O
the O
total B-PK
au I-PK
##c I-PK
for I-PK
the I-PK
entire I-PK
24 I-PK
‐ I-PK
h I-PK
dos I-PK
##ing I-PK
interval I-PK
under O
the O
g O
##ir O
( O
au B-PK
##c I-PK
##gi I-PK
##r I-PK
, I-PK
0 I-PK
– I-PK
12 I-PK
##h I-PK
, I-PK
s I-PK
##s I-PK
/ I-PK
au I-PK
##c I-PK
##gi I-PK
##r I-PK
, I-PK
τ I-PK
, I-PK
s I-PK
##s I-PK
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
and O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
were O
used O
as O
the O
combined O
p O
##k O
/ O
p O
##d O
parameters O
. O
[SEP] O
[CLS] O
using O
the O
following O
inhibitor O
##y O
si O
##g O
##mo O
##id O
em B-PK
##ax I-PK
model O
to O
integrate O
the O
ex O
v O
##ivo O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
ratio I-PK
and O
bacteria O
count O
change O
( O
c O
##fu O
/ O
m O
##l O
) O
in O
il O
##eum O
content O
during O
24 O
h O
in O
##cu O
##bation O
( O
al O
##ia O
##bad O
##i O
and O
le O
##es O
, O
2001 O
; O
al O
##ia O
##bad O
##i O
, O
2002 O
; O
al O
##ia O
##bad O
##i O
et O
al O
. O
, O
2003 O
) O
. O
[SEP] O
[CLS] O
the O
( O
% O
) O
is O
##c O
##v O
was O
slightly O
higher O
under O
fast O
##ing O
conditions O
( O
15 O
. O
6 O
and O
11 O
. O
4 O
for O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
) O
than O
that O
observed O
under O
fed O
conditions O
( O
11 O
. O
5 O
for O
cm B-PK
##ax I-PK
and O
5 O
. O
3 O
for O
au B-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
) O
. O
[SEP] O
[CLS] O
to O
maintain O
a O
stable O
state O
in O
p O
##h O
1 O
. O
2 O
dissolution O
conditions O
, O
a O
high O
concentration O
of O
surf O
##act O
##ant O
was O
required O
. O
[SEP] O
[CLS] O
steady B-PK
state I-PK
au I-PK
##cs I-PK
were O
significantly O
higher O
in O
group O
2 O
( O
66 O
##5 O
. O
9 O
± O
136 O
. O
5 O
) O
comparing O
with O
group O
1 O
( O
490 O
. O
7 O
± O
101 O
. O
1 O
) O
, O
respectively O
( O
p O
= O
0 O
. O
00 O
##8 O
) O
. O
[SEP] O
[CLS] O
c O
##t O
- O
p O
##13 O
and O
r O
##p O
were O
comparable O
in O
terms O
of O
efficacy O
( O
including O
radio O
##graphic O
progression O
) O
, O
im O
##mu O
##no O
##genic O
##ity O
and O
p O
##k O
/ O
p O
##d O
up O
to O
week O
54 O
. O
[SEP] O
[CLS] O
the O
residue O
was O
further O
re O
##con O
##stituted O
by O
200 O
μ O
##l O
of O
mobile O
phase O
. O
[SEP] O
[CLS] O
what O
question O
does O
this O
study O
address O
? O
[SEP] O
[CLS] O
following O
the O
treatment O
, O
participants O
will O
attend O
post O
- O
treatment O
and O
progression O
follow O
- O
up O
visits O
where O
data O
will O
be O
collected O
on O
a O
##es O
, O
disease O
status O
and O
survival O
status O
( O
fi O
##gs O
. O
5 O
and O
6 O
) O
. O
[SEP] O
[CLS] O
in O
our O
present O
study O
, O
the O
in O
##tra O
##cellular O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
r O
##h O
##α O
- O
g O
##la O
, O
i O
. O
e O
. O
, O
f O
##ab O
##raz O
##yme O
and O
re O
##p O
##lag O
##al O
, O
are O
consistent O
with O
the O
previous O
studies O
that O
the O
half B-PK
- I-PK
life I-PK
of O
the O
ad O
##mini O
##stra O
##ted O
r O
##h O
##α O
- O
g O
##las O
was O
around O
24 O
h O
, O
and O
the O
r O
##h O
##α O
- O
g O
##la O
up O
##take O
of O
f O
##ab O
##raz O
##yme O
was O
obviously O
higher O
than O
that O
of O
re O
##p O
##lag O
##al O
in O
the O
g O
##la O
- O
nan O
cells O
( O
figure O
2d O
, O
e O
) O
. O
[SEP] O
[CLS] O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
c B-PK
##l I-PK
/ I-PK
w I-PK
##t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
, O
and O
cm B-PK
##ax I-PK
were O
calculated O
and O
are O
shown O
after O
s O
##tra O
##ti O
##fication O
for O
re O
##nal O
function O
( O
c O
##l O
##c O
##r O
) O
at O
base O
##line O
. O
[SEP] O
[CLS] O
the O
lower O
limit O
of O
q O
##uant O
##ification O
for O
the O
ass O
##ay O
is O
0 O
. O
06 O
u O
m O
##l O
##− O
##1 O
, O
and O
the O
ass O
##ay O
precision O
is O
10 O
% O
c O
##v O
. O
[SEP] O
[CLS] O
although O
the O
o O
##2 O
supply O
was O
nearly O
doubled O
by O
ni O
##fe O
##di O
##pine O
application O
, O
the O
art O
##eri O
##o O
- O
ve O
##nous O
o O
##2 O
concentration O
difference O
( O
a O
##v O
##do O
##2 O
) O
remained O
almost O
constant O
( O
table O
12 O
up O
##take O
following O
the O
improved O
o O
##2 O
delivery O
caused O
by O
ni O
##fe O
##di O
##pine O
administration O
. O
[SEP] O
[CLS] O
the O
fi O
##lt O
##rate O
was O
collected O
, O
and O
the O
residue O
was O
boiled O
again O
in O
di O
##st O
##ille O
##d O
water O
( O
1 O
: O
6 O
, O
w O
/ O
v O
) O
for O
0 O
. O
5 O
h O
. O
[SEP] O
[CLS] O
for O
re B-PK
##nal I-PK
clearance I-PK
, O
the O
agent O
’ O
s O
ex B-PK
##cre I-PK
##tion I-PK
rate I-PK
is O
dependent O
upon O
the O
rate O
at O
which O
it O
is O
passive O
##ly O
filtered O
through O
the O
kidney O
’ O
s O
f O
##ene O
##stra O
##ted O
g O
##lo O
##mer O
##ular O
cap O
##illa O
##ries O
and O
the O
rates O
of O
secret O
##ion O
and O
re O
##ab O
##sor O
##ption O
across O
the O
kidney O
tub O
##ular O
e O
##pit O
##hel O
##ium O
. O
[SEP] O
[CLS] O
p O
##d O
evaluation O
##s O
included O
c O
##rp O
and O
es O
##r O
. O
[SEP] O
[CLS] O
for O
su O
##lt O
##1 O
##a O
##1 O
, O
maturity O
was O
taken O
to O
have O
been O
reached O
at O
birth O
, O
22 O
and O
, O
therefore O
, O
is O
##oe O
##nz O
##yme O
onto O
##geny O
of O
su O
##lt O
##1 O
##a O
##1 O
, O
defined O
as O
the O
p O
##ediatric O
to O
adult O
ratio B-PK
of I-PK
micro I-PK
##so I-PK
##mal I-PK
intrinsic I-PK
clearance I-PK
, O
was O
set O
to O
1 O
. O
[SEP] O
[CLS] O
glucose O
levels O
were O
forced O
to O
decrease O
in O
all O
groups O
at O
the O
same O
rate O
in O
the O
first O
3 O
hours O
due O
to O
repeated O
insulin O
administration O
. O
[SEP] O
[CLS] O
across O
all O
treatment O
regime O
##ns O
, O
73 O
. O
3 O
% O
of O
participants O
( O
22 O
/ O
30 O
) O
reported O
a O
treatment O
- O
emerge O
##nt O
a O
##e O
( O
tea O
##e O
) O
; O
the O
frequency O
of O
tea O
##es O
by O
treatment O
is O
summarized O
in O
table O
4 O
. O
[SEP] O
[CLS] O
but O
t B-PK
##max I-PK
was O
further O
increased O
to O
4 O
h O
in O
the O
1 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
compared O
to O
5 O
min O
in O
s O
##n O
- O
38 O
- O
lips O
group O
with O
85 O
. O
09 O
##3 O
μ O
##g O
/ O
kg O
of O
cm B-PK
##ax I-PK
and O
30 O
min O
in O
2 O
and O
5 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
with O
217 O
. O
385 O
and O
251 O
. O
64 O
##4 O
μ O
##g O
/ O
kg O
of O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
of O
2 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
were O
290 O
. O
345 O
μ O
##g O
/ O
kg O
· O
h O
which O
were O
significantly O
higher O
( O
p O
< O
. O
05 O
) O
than O
s O
##n O
- O
38 O
- O
lips O
group O
( O
1 O
. O
44 O
- O
fold O
) O
, O
1 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
( O
2 O
. O
97 O
- O
fold O
) O
and O
5 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
( O
1 O
. O
78 O
- O
fold O
) O
, O
showing O
that O
2 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
group O
enhanced O
systematic O
exposure O
of O
s O
##n O
- O
38 O
- O
lips O
. O
[SEP] O
[CLS] O
and O
2 O
mg O
/ O
m O
##l O
s O
- O
b O
##o O
significantly O
( O
p O
< O
. O
05 O
) O
prolonged O
plasma O
exposure O
of O
s O
##n O
- O
38 O
- O
lips O
after O
s O
. O
c O
. O
administration O
, O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
which O
were O
increased O
to O
11 O
. O
38 O
##7 O
and O
2 O
. O
43 O
##6 O
h O
and O
c B-PK
##l I-PK
of O
which O
were O
decreased O
to O
9 O
. O
84 O
##6 O
l O
/ O
h O
/ O
kg O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
and O
t B-PK
##max I-PK
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
with O
the O
p O
##hoe O
##ni O
##x O
win O
##non O
##lin O
software O
( O
version O
8 O
. O
0 O
, O
p O
##har O
##sight O
corporation O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
using O
non O
- O
compartment O
##al O
analysis O
. O
[SEP] O
[CLS] O
the O
relationships O
between O
la O
##ct O
##ate O
accumulation O
and O
work O
intensity O
and O
capacity O
as O
well O
as O
the O
correlation O
between O
la O
##ct O
##ate O
accumulation O
and O
muscular O
fatigue O
have O
long O
been O
a O
major O
research O
topic O
[ O
38 O
] O
. O
[SEP] O
[CLS] O
in O
patients O
with O
advanced O
solid O
ma O
##li O
##gna O
##ncies O
, O
the O
m O
##t O
##d O
of O
sun O
##iti O
##ni O
##b O
plus O
500 O
mg O
/ O
m O
##2 O
p O
##em O
##et O
##re O
##xed O
was O
37 O
. O
5 O
mg O
/ O
day O
( O
c O
##dd O
schedule O
) O
or O
50 O
mg O
/ O
day O
( O
schedule O
2 O
/ O
1 O
) O
. O
[SEP] O
[CLS] O
the O
d O
##l O
of O
ch O
##20 O
- O
g O
##sh O
and O
ch O
##50 O
- O
g O
##sh O
n O
##ps O
was O
18 O
. O
4 O
% O
and O
18 O
. O
2 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
c O
##dd O
schedule O
m O
##t O
##d O
was O
to O
##ler O
##able O
and O
demonstrated O
promising O
clinical O
benefit O
in O
n O
##s O
##c O
##l O
##c O
. O
[SEP] O
[CLS] O
the O
median O
clearance B-PK
rate I-PK
constant I-PK
for O
p O
v O
##iva O
##x O
ranged O
from O
0 O
· O
22 O
to O
0 O
· O
30 O
per O
hour O
leading O
to O
a O
99 O
· O
6 O
% O
reduction O
in O
parasite O
den O
##sities O
by O
36 O
h O
. O
estimated O
median O
parasite O
clearance O
half O
- O
life O
estimates O
ranged O
from O
4 O
· O
1 O
h O
to O
5 O
· O
6 O
h O
for O
p O
f O
##al O
##ci O
##par O
##um O
and O
2 O
· O
3 O
h O
to O
3 O
· O
2 O
h O
for O
p O
v O
##iva O
##x O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
it O
should O
be O
noted O
that O
variations O
in O
the O
half B-PK
- I-PK
life I-PK
accounts O
for O
the O
most O
part O
of O
the O
relative O
dose O
differences O
. O
[SEP] O
[CLS] O
complex O
h O
##ydro O
##gel O
##s O
formed O
with O
ch O
##ito O
##san O
( O
c O
##s O
) O
and O
ring O
- O
opened O
p O
##oly O
##vin O
##yl O
p O
##yr O
##rol O
##ido O
##ne O
( O
r O
##op O
##v O
##p O
) O
as O
a O
swell O
##able O
m O
##uc O
##oa O
##dh O
##esi O
##ve O
gas O
##tro O
##ret O
##ent O
##ive O
drug O
dos O
##age O
form O
( O
s O
##m O
##g O
##rd O
##d O
##f O
) O
were O
prepared O
and O
characterized O
. O
[SEP] O
[CLS] O
them O
##ob O
##ile O
phase O
was O
prepared O
daily O
and O
de O
##gas O
##sed O
before O
use O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
exhibited O
that O
the O
plasma O
profile O
of O
ale O
##nd O
##rona O
##te O
followed O
a O
sustained O
manner O
with O
3 O
- O
fold O
enhance O
##ment O
of O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
this O
is O
a O
prospective O
study O
from O
j O
##anu O
##ary O
2013 O
to O
de O
##ce O
##mber O
2014 O
for O
c O
##f O
patients O
admitted O
to O
university O
of O
mi O
##chi O
##gan O
m O
##ott O
’ O
s O
children O
hospital O
. O
[SEP] O
[CLS] O
the O
bacteria O
were O
di O
##lut O
##ed O
to O
a O
density O
of O
1 O
× O
106 O
c O
##fu O
/ O
m O
##l O
in O
m O
##h O
br O
##oth O
or O
artificial O
s O
##put O
##um O
medium O
( O
as O
##m O
) O
, O
which O
was O
prepared O
by O
use O
of O
the O
recipe O
by O
s O
##ri O
##ram O
##ulu O
et O
al O
. O
( O
48 O
) O
. O
[SEP] O
[CLS] O
the O
anti O
##biotic O
selection O
was O
determined O
by O
the O
primary O
pu O
##lm O
##ono O
##logist O
and O
was O
based O
on O
the O
most O
recent O
s O
##put O
##um O
or O
throat O
culture O
and O
sensitivity O
results O
for O
each O
patient O
. O
[SEP] O
[CLS] O
part O
1 O
##b O
studied O
the O
relative O
bio O
##ava O
##ila O
##bility O
of O
g O
##sk O
##28 O
##38 O
##23 O
##2 O
given O
as O
100 O
mg O
( O
2 O
× O
50 O
mg O
) O
capsule O
##s O
versus O
the O
reference O
a O
##pi O
( O
p O
##ib O
) O
in O
a O
two O
‐ O
period O
crossover O
design O
with O
r O
##t O
##v O
, O
following O
2 O
days O
of O
r O
##t O
##v O
pre O
##dos O
##ing O
. O
[SEP] O
[CLS] O
re O
##ct O
##al O
administration O
resulted O
in O
a O
delayed O
t B-PK
##max I-PK
, O
a O
lower O
cm B-PK
##ax I-PK
, O
and O
an O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
value O
that O
was O
70 O
% O
of O
that O
observed O
following O
oral O
administration O
. O
[SEP] O
[CLS] O
after O
oral O
administration O
, O
the O
plasma O
mi O
##ans O
##eri O
##n O
level O
reached O
cm B-PK
##ax I-PK
at O
30 O
min O
and O
then O
rapidly O
decreased O
. O
[SEP] O
[CLS] O
based O
on O
physiological O
p O
##laus O
##ibility O
and O
extensive O
previous O
evidence O
, O
b O
##w O
was O
incorporated O
a O
prior O
##i O
as O
a O
co O
##var O
##iate O
, O
both O
on O
c B-PK
##l I-PK
( O
all O
##ometric O
##ally O
with O
a O
power O
ex O
##po O
##nent O
of O
0 O
. O
75 O
) O
and O
on O
v B-PK
##d I-PK
( O
power O
ex O
##po O
##nent O
of O
1 O
) O
and O
was O
standardized O
to O
a O
typical O
70 O
kg O
patient O
[ O
15 O
– O
18 O
] O
. O
[SEP] O
[CLS] O
in O
the O
safety O
analysis O
set O
, O
97 O
. O
6 O
% O
of O
patients O
experienced O
at O
least O
one O
a O
##e O
, O
of O
which O
95 O
. O
1 O
% O
were O
judged O
by O
the O
local O
investigator O
to O
be O
related O
to O
a O
##z O
##d O
##53 O
##6 O
##3 O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
a O
total O
of O
63 O
. O
4 O
% O
of O
patients O
experienced O
an O
a O
##e O
of O
c O
##t O
##ca O
##e O
grade O
≥ O
##3 O
, O
with O
h O
##yper O
##gly O
##ce O
##mia O
( O
39 O
. O
0 O
% O
) O
and O
di O
##ar O
##r O
##hea O
( O
17 O
. O
1 O
% O
) O
being O
the O
most O
common O
; O
58 O
. O
5 O
% O
of O
patients O
experienced O
a O
grade O
≥ O
##3 O
a O
##e O
considered O
to O
be O
treatment O
related O
. O
[SEP] O
[CLS] O
disco O
##ntin O
##uations O
due O
to O
an O
a O
##e O
occurred O
in O
12 O
. O
2 O
% O
of O
patients O
, O
while O
39 O
. O
0 O
% O
of O
patients O
had O
a O
##es O
leading O
to O
dose O
interrupt O
##ion O
. O
[SEP] O
[CLS] O
administration O
of O
d O
##t O
##n O
in O
combination O
with O
k O
##tz O
resulted O
in O
at O
##ten O
##uated O
liver O
injury O
, O
including O
lower O
al O
##ani O
##ne O
trans O
##ami O
##nas O
##e O
and O
as O
##par O
##tate O
trans O
##ami O
##nas O
##e O
activities O
and O
greater O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
of O
serum O
d O
##t O
##n O
, O
whereas O
, O
pre O
##tre O
##at O
##ment O
with O
de O
##xa O
##met O
##has O
##one O
a O
##gg O
##ra O
##vated O
the O
injury O
. O
[SEP] O
[CLS] O
primary O
outcomes O
were O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
( O
maximum B-PK
plasma I-PK
mi I-PK
##ans I-PK
##eri I-PK
##n I-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
, O
time B-PK
of I-PK
cm I-PK
##ax I-PK
[ I-PK
t I-PK
##max I-PK
] I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
24 I-PK
h I-PK
[ I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
] I-PK
) O
. O
[SEP] O
[CLS] O
disposition O
p O
##k O
parameters O
were O
similar O
between O
g O
##cc O
‐ O
440 O
##1 O
##c O
and O
r O
##iva O
##ro O
##xa O
##ban O
, O
with O
slightly O
larger O
steady B-PK
‐ I-PK
state I-PK
volume I-PK
of I-PK
distribution I-PK
and O
total B-PK
clearance I-PK
in O
g O
##cc O
‐ O
440 O
##1 O
##c O
. O
[SEP] O
[CLS] O
the O
absorption O
process O
was O
described O
by O
a O
we O
##ib O
##ull O
model O
with O
mixed O
first O
and O
zero O
order O
absorption O
. O
[SEP] O
[CLS] O
for O
op O
##ti O
##mizing O
above O
parameters O
at O
each O
time O
point O
, O
quality O
control O
tests O
were O
carried O
out O
by O
t O
##l O
##c O
using O
it O
##l O
##c O
strips O
. O
[ O
101 O
##7 O
##18 O
##19 O
] O
[SEP] O
[CLS] O
in O
females O
, O
the O
only O
change O
that O
was O
observed O
was O
a O
significant O
reduction O
in O
au B-PK
##c I-PK
under O
fed O
conditions O
. O
[SEP] O
[CLS] O
the O
non O
- O
bio O
##e O
##qui O
##valence O
( O
non O
- O
be O
) O
tablet O
group O
achieved O
higher O
plasma O
cm B-PK
##ax I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
than O
the O
reference O
and O
be O
tablets O
groups O
, O
with O
only O
one O
difference O
in O
tablet O
composition O
, O
which O
was O
the O
presence O
of O
calcium O
mon O
##oh O
##ydro O
##gen O
phosphate O
, O
an O
al O
##kal O
##ini O
##zing O
ex O
##ci O
##pie O
##nt O
, O
in O
the O
tablet O
core O
of O
the O
non O
- O
be O
formulation O
. O
[SEP] O
[CLS] O
a O
similar O
proportion O
of O
e O
##u O
##vo O
##lem O
##ic O
patients O
treated O
with O
either O
20 O
or O
40 O
mg O
/ O
day O
con O
##iva O
##pta O
##n O
attained O
this O
treatment O
goal O
( O
82 O
. O
6 O
% O
vs O
74 O
. O
8 O
% O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
the O
un B-PK
##bound I-PK
fraction I-PK
ratio I-PK
( I-PK
f I-PK
##u I-PK
) I-PK
of O
ni O
##mo O
##di O
##pine O
in O
rabbit O
plasma O
was O
calculated O
using O
the O
following O
equation O
: O
( O
1 O
) O
f O
##u O
= O
c O
##bu O
##ffer O
##ct O
##ota O
##l O
##where O
c O
##bu O
##ffer O
and O
c O
##to O
##tal O
are O
the O
ni O
##mo O
##di O
##pine O
concentrations O
in O
the O
buffer O
chamber O
and O
the O
sample O
chamber O
, O
respectively O
. O
[SEP] O
[CLS] O
since O
the O
specific O
transport O
##ers O
contributing O
to O
the O
absorption O
and O
elimination O
of O
c O
##ip O
##ro O
##f O
##lo O
##xa O
##cin O
have O
not O
yet O
been O
fully O
el O
##uc O
##idated O
, O
the O
effect O
of O
the O
mat O
##uration O
and O
aging O
process O
on O
these O
pathways O
is O
unknown O
. O
[SEP] O
[CLS] O
this O
would O
potentially O
lead O
to O
repression O
of O
selected O
##tar O
##get O
genes O
driving O
s O
##b O
##ma O
- O
associated O
toxicity O
, O
while O
allowing O
transcription O
##ala O
##ct O
##ivation O
of O
other O
target O
genes O
. O
[SEP] O
[CLS] O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
of O
products O
a O
and O
b O
was O
found O
to O
be O
3 O
. O
6 O
± O
0 O
. O
10 O
h O
and O
4 O
. O
76 O
± O
0 O
. O
10 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
mean O
( O
c O
##v O
% O
) O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##24 I-PK
increased O
from O
20 O
. O
2 O
ng O
/ O
m O
##l O
( O
18 O
. O
8 O
% O
) O
to O
195 O
. O
0 O
ng O
/ O
m O
##l O
( O
26 O
. O
7 O
% O
) O
and O
from O
31 O
##4 O
. O
0 O
hour O
* O
ng O
/ O
m O
##l O
( O
11 O
. O
2 O
% O
) O
to O
3 O
, O
53 O
##8 O
. O
0 O
hour O
* O
ng O
/ O
m O
##l O
( O
33 O
. O
5 O
% O
) O
across O
the O
10 O
‐ O
to O
100 O
‐ O
mg O
dose O
levels O
, O
respectively O
. O
[SEP] O
[CLS] O
eleven O
percent O
( O
12 O
/ O
109 O
) O
of O
subjects O
experienced O
at O
least O
1 O
drug O
- O
related O
grade O
2 O
– O
4 O
a O
##e O
, O
11 O
% O
( O
10 O
/ O
89 O
) O
of O
subjects O
in O
the O
f O
##p O
##v O
/ O
r O
##t O
##v O
group O
and O
10 O
% O
( O
2 O
/ O
20 O
) O
of O
subjects O
in O
the O
f O
##p O
##v O
group O
. O
[SEP] O
[CLS] O
the O
difference O
in O
mean O
values O
of O
m B-PK
##rt I-PK
in O
both O
the O
formulation O
##s O
was O
statistical O
##ly O
ins O
##ign O
##ificant O
. O
[SEP] O
[CLS] O
a O
correlation O
between O
total B-PK
and O
free B-PK
au I-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
levels O
vs O
. O
total B-PK
t I-PK
##rough I-PK
concentrations I-PK
predicted O
by O
the O
p O
##b O
##p O
##k O
model O
of O
van O
##com O
##y O
##cin O
captured O
the O
clinical O
observations O
, O
in O
which O
the O
free B-PK
fraction I-PK
of O
van O
##com O
##y O
##cin O
was O
fixed O
at O
the O
value O
reported O
in O
the O
clinical O
study O
##31 O
( O
figure O
##6 O
##c O
, O
left O
) O
. O
[SEP] O
[CLS] O
after O
the O
first O
dose O
of O
r O
##p O
##50 O
##6 O
##3 O
, O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##24 I-PK
increased O
in O
a O
dose O
‐ O
proportional O
manner O
from O
10 O
– O
100 O
mg O
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
( O
12 O
. O
0 O
– O
16 O
. O
0 O
hours O
) O
and O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
10 O
. O
6 O
– O
11 O
. O
0 O
hours O
) O
were O
found O
to O
be O
independent O
of O
dose O
. O
[SEP] O
[CLS] O
re O
##gression O
analyses O
of O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
by O
dose O
indicated O
that O
the O
relationship O
was O
linear O
( O
slope O
, O
p O
≤ O
0 O
. O
05 O
) O
and O
that O
the O
intercept O
did O
not O
differ O
significantly O
from O
zero O
( O
p O
> O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
normal O
##ized O
efficacy O
was O
determined O
by O
dividing O
t O
##gi O
by O
either O
plasma O
or O
tumor O
au B-PK
##c I-PK
##0 I-PK
- I-PK
8 I-PK
. O
[SEP] O
[CLS] O
gas O
##tric O
empty O
##ing O
is O
also O
affected O
by O
the O
physical O
and O
chemical O
properties O
of O
the O
meal O
, O
body O
movement O
, O
and O
position O
during O
empty O
##ing O
[ O
30 O
] O
. O
[SEP] O
[CLS] O
it O
is O
also O
en O
##vis O
##aged O
that O
it O
could O
also O
be O
a O
meta O
##bol O
##ite O
that O
may O
be O
responsible O
for O
delayed O
gas O
##tric O
empty O
##ing O
[ O
27 O
] O
; O
however O
, O
which O
##ever O
it O
is O
, O
it O
affects O
both O
the O
absorption O
of O
l O
- O
do O
##pa O
and O
its O
meta O
##bol O
##ite O
as O
this O
may O
also O
ex O
##plicate O
the O
multiple O
peaks O
of O
met O
##hyl O
##do O
##pa O
as O
well O
. O
[SEP] O
[CLS] O
although O
the O
mean O
p O
##har O
##ma O
##co O
##kin O
##etic O
curve O
of O
i O
##p O
##b O
matrices O
has O
a O
single O
peak O
, O
some O
of O
individual O
pigs O
had O
double O
peaks O
and O
this O
may O
also O
explain O
the O
mean O
t B-PK
##max I-PK
of O
i O
##p O
##b O
matrices O
being O
at O
the O
4th O
hour O
. O
[SEP] O
[CLS] O
after O
fi O
##ltration O
( O
mill O
##ip O
##ore O
mill O
##ex O
##® O
l O
##g O
0 O
. O
20 O
μ O
##m O
; O
me O
##rc O
##k O
kg O
##aa O
, O
da O
##rms O
##tadt O
, O
g O
##erman O
##y O
) O
, O
the O
g O
##ado O
##lini O
##um O
concentration O
in O
these O
fi O
##lt O
##rates O
was O
determined O
with O
a O
##as O
, O
and O
the O
total O
amount O
of O
ch O
##ira O
##l O
den O
##dr O
##ime O
##r O
g O
##d O
- O
m O
##ri O
ca O
##s O
in O
liver O
and O
kidney O
was O
estimated O
from O
the O
weight O
of O
the O
tissues O
. O
[SEP] O
[CLS] O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
calculated O
based O
on O
the O
equations O
in O
the O
final O
model O
( O
p O
##ip O
##red O
) O
were O
similar O
to O
those O
estimated O
based O
on O
observed O
concentrations O
( O
p O
##est O
) O
( O
fi O
##g O
. O
4 O
##a O
, O
b O
) O
. O
[SEP] O
[CLS] O
mean O
p O
##e O
for O
be O
##va O
##ci O
##zu O
##ma O
##b O
serum O
concentrations O
, O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
were O
− O
##2 O
. O
1 O
, O
3 O
. O
1 O
and O
1 O
. O
0 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
toxicity O
index O
is O
a O
measure O
of O
the O
toxic O
events O
experienced O
due O
to O
exposure O
to O
the O
toxic O
meta O
##bol O
##ites O
h O
##z O
and O
a O
##ch O
##z O
. O
[SEP] O
[CLS] O
as O
one O
patient O
died O
because O
of O
a O
non O
- O
treatment O
- O
related O
cause O
( O
cardiac O
failure O
) O
between O
weeks O
4 O
and O
16 O
, O
the O
l O
##pi O
data O
presented O
are O
from O
13 O
patients O
. O
[SEP] O
[CLS] O
r O
##ms O
##e O
for O
be O
##va O
##ci O
##zu O
##ma O
##b O
serum O
concentrations O
, O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
were O
0 O
. O
28 O
##3 O
, O
0 O
. O
01 O
##7 O
and O
2 O
. O
60 O
, O
respectively O
. O
[SEP] O
[CLS] O
exposure O
to O
the O
two O
toxic O
meta O
##bol O
##ites O
h O
##z O
and O
a O
##ch O
##z O
was O
defined O
as O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
in O
the O
in O
##tra O
##cellular O
space O
in O
the O
off O
- O
target O
organ O
, O
the O
liver O
, O
and O
was O
estimated O
from O
the O
p O
##b O
##p O
##k O
model O
. O
( O
5 O
) O
t O
##i O
= O
[ O
au O
##c O
( O
h O
##z O
) O
id O
##ag O
+ O
au O
##c O
( O
a O
##ch O
##z O
) O
id O
##ag O
] O
[ O
au O
##c O
( O
h O
##z O
) O
i O
##30 O
##0 O
##m O
##g O
##q O
##ds O
##low O
+ O
au O
##c O
( O
a O
##ch O
##z O
) O
i O
##30 O
##0 O
##m O
##g O
##q O
##ds O
##low O
] O
both O
clinical O
in O
##dices O
can O
exceed O
100 O
% O
, O
if O
a O
combination O
of O
dose O
and O
ace O
##ty O
##lator O
p O
##hen O
##otype O
results O
in O
a O
larger O
e O
##ba O
after O
2 O
days O
of O
treatment O
for O
treatment O
efficacy O
or O
higher O
exposure O
to O
toxic O
meta O
##bol O
##ites O
for O
the O
toxicity O
index O
. O
[SEP] O
[CLS] O
the O
optimal O
dos O
##ing O
regime O
##n O
was O
selected O
on O
the O
basis O
of O
target O
effect O
which O
was O
defined O
as O
maintenance O
of O
a O
m O
##oa O
##a O
/ O
s O
score O
< O
2 O
for O
at O
least O
1 O
. O
5 O
h O
. O
one O
thousand O
virtual O
subjects O
were O
simulated O
each O
time O
, O
and O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
p O
##har O
##ma O
##co O
##dynamic O
values O
for O
the O
1 O
, O
000 O
subjects O
were O
simulated O
using O
the O
parameters O
from O
the O
final O
models O
, O
of O
which O
the O
var O
##iability O
were O
randomly O
sampled O
from O
the O
log O
- O
normal O
distributions O
obtained O
from O
the O
modeling O
. O
[SEP] O
[CLS] O
one O
- O
way O
analysis O
of O
variance O
( O
an O
##ova O
) O
with O
du O
##nc O
##an O
’ O
s O
test O
was O
used O
for O
inter O
- O
group O
comparisons O
. O
[SEP] O
[CLS] O
art O
##hr O
##itis O
was O
induced O
with O
the O
injection O
of O
2 O
% O
λ O
- O
car O
##rage O
##enan O
and O
4 O
% O
ka O
##olin O
into O
the O
right O
knee O
joints O
of O
male O
s O
##pra O
##gue O
da O
##wley O
rats O
. O
[SEP] O
[CLS] O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
##r I-PK
) I-PK
and O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
##a I-PK
) I-PK
were O
calculated O
as O
follows O
: O
f O
##r O
= O
au O
##c O
##0 O
- O
∞ O
( O
o O
##bas O
) O
/ O
au O
##c O
##0 O
- O
∞ O
( O
b O
##h O
) O
× O
100 O
% O
, O
f O
##a O
= O
au O
##c O
##0 O
- O
∞ O
( O
i O
##g O
) O
× O
di O
##v O
/ O
au O
##c O
##0 O
- O
∞ O
( O
i O
##v O
) O
× O
dig O
× O
100 O
% O
. O
[SEP] O
[CLS] O
formulation O
2 O
showed O
a O
significantly O
higher O
cm B-PK
##ax I-PK
( O
p O
value O
< O
0 O
. O
00 O
##1 O
) O
and O
faster O
initial O
drop O
after O
reaching O
peak B-PK
concentrations I-PK
( O
p O
value O
< O
0 O
. O
01 O
for O
slope O
of O
log O
##ari O
##th O
##mic O
plasma O
concentration O
- O
time O
profiles O
between O
t B-PK
##max I-PK
and O
24 O
h O
) O
than O
formulation O
1 O
, O
suggesting O
a O
faster O
drug O
absorption O
or O
release O
rate O
. O
[SEP] O
[CLS] O
for O
all O
im O
formulation O
##s O
, O
the O
slopes O
of O
the O
log O
##ari O
##th O
##mic O
plasma O
concentration O
- O
time O
profiles O
between O
t B-PK
##max I-PK
and O
24 O
h O
were O
significantly O
lower O
than O
for O
formulation O
5 O
( O
i O
##v O
) O
between O
6 O
and O
24 O
h O
( O
p O
value O
< O
0 O
. O
00 O
##1 O
for O
formulation O
1 O
, O
p O
value O
< O
0 O
. O
01 O
for O
formulation O
##s O
2 O
and O
5 O
( O
im O
) O
) O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
calculated O
for O
formulation O
5 O
( O
im O
and O
i O
##v O
) O
was O
much O
shorter O
due O
to O
the O
earlier O
t B-PK
##last I-PK
and O
can O
therefore O
not O
be O
compared O
to O
the O
half B-PK
- I-PK
life I-PK
of O
formulation O
##s O
1 O
and O
2 O
. O
[SEP] O
[CLS] O
however O
, O
log O
##ari O
##th O
##mic O
plasma O
concentration O
- O
time O
profiles O
of O
formulation O
##s O
1 O
and O
2 O
( O
im O
) O
declined O
parallel O
to O
the O
ones O
of O
formulation O
5 O
( O
im O
and O
i O
##v O
) O
between O
24 O
and O
80 O
h O
after O
dos O
##ing O
, O
suggesting O
a O
similar O
half B-PK
- I-PK
life I-PK
for O
all O
formulation O
##s O
within O
that O
time O
##frame O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
2 O
, O
the O
time B-PK
to I-PK
reach I-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
the O
peak B-PK
drug I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
and O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
at I-PK
24 I-PK
h I-PK
( I-PK
au I-PK
##c I-PK
##24 I-PK
) I-PK
were O
3 O
. O
52 O
± O
0 O
. O
34 O
h O
, O
1 O
. O
57 O
± O
0 O
. O
46 O
μ O
##g O
/ O
m O
##l O
, O
and O
20 O
. O
13 O
± O
5 O
. O
26 O
μ O
##g O
. O
[SEP] O
[CLS] O
the O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
was O
16 O
. O
45 O
± O
1 O
. O
67 O
h O
. O
[SEP] O
[CLS] O
the O
intercept O
for O
the O
distribution O
phase O
( O
a O
) O
and O
for O
the O
elimination O
phase O
( O
b O
) O
were O
2 O
. O
67 O
± O
0 O
. O
99 O
μ O
##g O
/ O
m O
##l O
and O
0 O
. O
09 O
± O
0 O
. O
01 O
μ O
##g O
/ O
m O
##l O
. O
the O
distribution B-PK
rate I-PK
constant I-PK
( I-PK
α I-PK
) I-PK
and O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
β I-PK
) I-PK
were O
0 O
. O
11 O
± O
0 O
. O
01 O
l O
/ O
h O
and O
0 O
. O
00 O
##2 O
± O
0 O
. O
00 O
##1 O
l O
/ O
h O
. O
[SEP] O
[CLS] O
this O
anterior O
segment O
is O
largely O
lined O
with O
non O
- O
c O
##iliated O
sq O
##ua O
##mous O
e O
##pit O
##hel O
##ium O
that O
is O
less O
efficient O
at O
medication O
absorption O
than O
the O
respiratory O
m O
##uc O
##osa O
beyond O
the O
nasal O
valve O
. O
12 O
, O
13 O
anterior O
deposition O
following O
a O
conventional O
nasal O
spray O
also O
results O
in O
a O
substantial O
portion O
of O
the O
delivered O
dose O
either O
dripping O
out O
of O
the O
no O
##st O
##ril O
or O
being O
wiped O
off O
. O
[SEP] O
[CLS] O
importantly O
, O
a O
large O
fraction O
of O
the O
remaining O
drug O
that O
is O
believed O
to O
enter O
the O
“ O
deep O
” O
nasal O
cavity O
following O
standard O
nasal O
spray O
administration O
is O
actually O
drawn O
along O
the O
floor O
of O
the O
nasal O
cavity O
into O
the O
p O
##har O
##ynx O
where O
it O
is O
swallowed O
. O
12 O
swallowing O
affects O
such O
a O
significant O
portion O
of O
the O
medication O
delivered O
by O
conventional O
nasal O
spray O
##s O
that O
a O
higher O
plasma O
peak O
can O
be O
produced O
via O
the O
un O
##int O
##ended O
g O
##i O
route O
than O
by O
nasal O
absorption O
. O
14 O
this O
phenomenon O
is O
clearly O
observed O
with O
sum O
##at O
##rip O
##tan O
in O
the O
bi O
##mo O
##dal O
absorption O
profile O
following O
nasal O
spray O
administration O
: O
a O
lower O
early O
peak O
, O
likely O
related O
to O
in O
##tra O
##nas O
##al O
absorption O
, O
is O
produced O
after O
20 O
minutes O
and O
is O
followed O
by O
a O
higher O
absorption O
peak O
consistent O
with O
g O
##i O
absorption O
around O
90 O
minutes O
. O
14 O
[SEP] O
[CLS] O
the O
km B-PK
and O
v B-PK
##max I-PK
at O
37 O
, O
32 O
or O
[UNK] O
were O
obtained O
from O
the O
mi O
##cha O
##eli O
##s O
– O
men O
##ten O
equation O
. O
[SEP] O
[CLS] O
however O
, O
the O
v B-PK
##max I-PK
of O
ni O
##mo O
##di O
##pine O
was O
[UNK] O
% O
lower O
at O
[UNK] O
and O
[UNK] O
% O
lower O
at O
[UNK] O
than O
that O
at O
[UNK] O
. O
[SEP] O
[CLS] O
no O
significant O
changes O
were O
observed O
in O
km B-PK
at O
37 O
, O
32 O
or O
[UNK] O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
extremely O
low O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
re O
##s O
is O
primarily O
due O
to O
its O
low O
so O
##lub O
##ility O
and O
extensive O
in O
##test O
##inal O
first O
- O
pass O
metabolism O
[ O
17 O
] O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
developed O
s O
##ned O
##ds O
improved O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
re O
##s O
. O
[SEP] O
[CLS] O
previous O
studies O
have O
also O
reported O
that O
such O
a O
system O
for O
delivering O
h O
##ydro O
##phobic O
compounds O
could O
be O
an O
effective O
oral O
dos O
##age O
form O
for O
enhancing O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
[ O
29 O
, O
30 O
] O
. O
[SEP] O
[CLS] O
many O
studies O
have O
shown O
that O
reducing O
the O
particle O
size O
increases O
the O
absorption O
of O
the O
active O
ingredient O
and O
the O
particle O
up O
##take O
by O
enhancing O
the O
mechanisms O
of O
passive O
transport O
through O
the O
in O
##test O
##inal O
walls O
[ O
31 O
] O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
l O
##ymph O
##atic O
transport O
substantially O
contributes O
to O
the O
total O
oral O
absorption O
of O
drugs O
because O
the O
oil O
phase O
, O
which O
promotes O
lip O
##op O
##hil O
##ic O
drug O
absorption O
, O
constitutes O
more O
than O
25 O
% O
of O
the O
self O
- O
em O
##ul O
##si O
##fying O
drug O
delivery O
system O
[ O
32 O
] O
. O
[SEP] O
[CLS] O
receiver O
operating O
characteristic O
( O
r O
##oc O
) O
curve O
analysis O
was O
also O
performed O
to O
evaluate O
diagnostic O
characteristics O
of O
each O
d O
##ce O
- O
m O
##ri O
parameter O
in O
different O
##iating O
border O
##line O
/ O
ma O
##li O
##gnant O
tumors O
from O
ben O
##ign O
lesions O
and O
, O
to O
provide O
the O
optimal O
cut O
##off O
values O
for O
these O
variables O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
for O
album O
##in O
was O
set O
equivalent O
to O
the O
half B-PK
- I-PK
life I-PK
of O
album O
##in O
in O
blood O
for O
the O
rat O
( O
≈ O
##46 O
h O
) O
, O
as O
described O
in O
m O
##c O
##mu O
##llin O
et O
al O
. O
( O
2003 O
) O
. O
[SEP] O
[CLS] O
additionally O
, O
an O
electro O
##card O
##io O
##gram O
was O
conducted O
and O
a O
general O
examination O
of O
the O
subject O
was O
performed O
to O
exclude O
any O
illness O
or O
abnormal O
##ity O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
samples O
were O
taken O
on O
day O
0 O
( O
pre O
##dos O
##ing O
) O
, O
on O
day O
1 O
, O
and O
then O
weekly O
for O
weeks O
2 O
to O
5 O
and O
then O
on O
weeks O
9 O
and O
10 O
. O
[SEP] O
[CLS] O
s O
##tag O
= O
ma O
##x O
( O
s O
##tag O
##1 O
, O
s O
##tag O
##2 O
) O
in O
fi O
##g O
. O
4 O
. O
[SEP] O
[CLS] O
we O
found O
that O
plasma O
parent O
ya O
##ku O
##chin O
##one O
a O
observed O
only O
up O
to O
0 O
. O
5 O
h O
after O
dos O
##ing O
and O
the O
concentrations O
were O
quite O
low O
with O
the O
mean O
cm B-PK
##ax I-PK
at O
4 O
. O
62 O
ng O
/ O
m O
##l O
. O
the O
plasma O
parent O
ya O
##ku O
##chin O
##one O
a O
peaked O
at O
0 O
. O
08 O
##3 O
h O
post O
##dos O
##e O
and O
declined O
rapidly O
( O
mean O
m B-PK
##rt I-PK
value O
, O
0 O
. O
63 O
h O
) O
. O
[SEP] O
[CLS] O
the O
mean O
au B-PK
##c I-PK
##0 I-PK
##→ I-PK
##t I-PK
value O
was O
0 O
. O
72 O
h O
· O
ng O
/ O
m O
##l O
. O
meanwhile O
, O
the O
significant O
individual O
differences O
were O
observed O
. O
[SEP] O
[CLS] O
ft O
##ir O
s O
##pect O
##ra O
analysis O
of O
m O
##t O
##x O
, O
p O
##l O
##ga O
, O
p O
##eg O
##40 O
##00 O
, O
physical O
mixture O
of O
m O
##t O
##x O
, O
p O
##l O
##ga O
, O
and O
p O
##eg O
##40 O
##00 O
, O
and O
m O
##t O
##x O
- O
loaded O
imp O
##lants O
revealed O
characteristic O
absorption O
bands O
at O
different O
frequencies O
( O
figure O
4 O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
the O
ft O
##ir O
spectrum O
of O
m O
##t O
##x O
( O
figure O
4 O
##a O
) O
, O
a O
broad O
band O
at O
3 O
, O
36 O
##7 O
cm O
##− O
##1 O
was O
attributed O
to O
the O
stretching O
vibration O
of O
n O
– O
h O
. O
9 O
, O
21 O
, O
22 O
typical O
infrared O
absorption O
bands O
observed O
in O
p O
##l O
##ga O
( O
figure O
4 O
##b O
) O
and O
p O
##eg O
##40 O
##00 O
( O
figure O
4 O
##c O
) O
were O
detected O
in O
the O
s O
##pect O
##ra O
of O
physical O
mixture O
of O
m O
##t O
##x O
, O
p O
##l O
##ga O
, O
and O
p O
##eg O
##40 O
##00 O
( O
figure O
4 O
##d O
) O
and O
m O
##t O
##x O
- O
loaded O
imp O
##lants O
( O
figure O
4 O
##e O
) O
. O
[SEP] O
[CLS] O
ca O
##sp O
##of O
##ung O
##in O
levels O
in O
plasma O
and O
g O
##i O
compartment O
##s O
were O
measured O
by O
liquid O
ch O
##roma O
##tography O
- O
tandem O
mass O
s O
##pect O
##rome O
##try O
( O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
in O
electro O
##sp O
##ray O
positive O
- O
ion O
##ization O
mode O
( O
es O
##i O
+ O
) O
on O
an O
a O
##b O
s O
##cie O
##x O
q O
##tra O
##p O
4000 O
triple O
- O
q O
##uad O
##rup O
##ole O
mass O
s O
##pect O
##rome O
##ter O
combined O
with O
an O
a O
##gi O
##lent O
126 O
##0 O
high O
- O
performance O
liquid O
ch O
##roma O
##to O
##graph O
( O
hp O
##l O
##c O
) O
using O
the O
analyst O
software O
and O
multiple O
- O
reaction O
monitoring O
( O
m O
##rm O
) O
of O
precursor O
/ O
product O
transitions O
. O
[SEP] O
[CLS] O
the O
si O
##m O
##cy O
##p O
si O
##mu O
##lator O
incorporated O
a O
physiological O
##ly O
based O
method O
to O
si O
##mu O
##late O
changes O
in O
c B-PK
##l I-PK
associated O
with O
various O
c O
##y O
##p O
##2 O
##c O
##9 O
g O
##eno O
##type O
##s O
. O
[SEP] O
[CLS] O
the O
experimental O
protocol O
was O
approved O
by O
the O
animal O
experiment O
ethics O
committee O
of O
show O
##a O
university O
. O
[SEP] O
[CLS] O
the O
enzyme O
contribution O
for O
sip O
##oni O
##mo O
##d O
metabolism O
in O
the O
different O
c O
##y O
##p O
##2 O
##c O
##9 O
g O
##eno O
##type O
##s O
was O
predicted O
from O
in O
v O
##it O
##ro O
enzyme O
p O
##hen O
##ot O
##y O
##ping O
[ O
unpublished O
data O
] O
, O
and O
metabolism O
data O
derived O
from O
h O
##lm O
ho O
##mo O
##zy O
##got O
##es O
were O
used O
to O
predict O
the O
c O
##py O
##2 O
##c O
##9 O
intrinsic B-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
) I-PK
. O
[SEP] O
[CLS] O
a O
d O
##lt O
was O
defined O
as O
a O
significant O
adverse O
event O
( O
a O
##e O
) O
or O
abnormal O
laboratory O
parameter O
ad O
##ju O
##dged O
to O
be O
common O
terminology O
criteria O
for O
adverse O
events O
( O
version O
3 O
. O
0 O
) O
grade O
3 O
or O
4 O
in O
severity O
and O
considered O
unrelated O
to O
disease O
progression O
, O
inter O
##current O
illness O
, O
or O
con O
##com O
##ita O
##nt O
medications O
. O
[SEP] O
[CLS] O
in O
addition O
, O
all O
patients O
must O
have O
had O
adequate O
bone O
ma O
##rrow O
( O
absolute O
ne O
##ut O
##rop O
##hil O
count O
[ O
1 O
. O
5 O
× O
109 O
/ O
l O
] O
, O
hem O
##og O
##lo O
##bin O
[ O
9 O
g O
/ O
d O
##l O
] O
, O
and O
plate O
##lets O
[ O
100 O
× O
109 O
/ O
l O
] O
) O
, O
liver O
( O
serum O
total O
bi O
##li O
##ru O
##bin O
[ O
1 O
. O
5 O
× O
upper O
limit O
of O
normal O
( O
ul O
##n O
) O
] O
, O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fer O
##ase O
, O
and O
al O
##ani O
##ne O
amino O
##tra O
##ns O
##fer O
##ase O
[ O
2 O
. O
5 O
× O
ul O
##n O
or O
5 O
. O
0 O
× O
ul O
##n O
if O
liver O
meta O
##sta O
##ses O
are O
present O
] O
) O
, O
and O
kidney O
function O
( O
serum O
c O
##rea O
##tin O
##ine O
[ O
1 O
. O
5 O
× O
ul O
##n O
] O
or O
24 O
‐ O
h O
c O
##rea O
##tin O
##ine O
clearance O
[ O
50 O
m O
##l O
/ O
min O
] O
) O
. O
[SEP] O
[CLS] O
patients O
were O
excluded O
if O
they O
had O
a O
history O
of O
a O
brain O
tumor O
or O
brain O
meta O
##sta O
##ses O
( O
except O
re O
##lap O
##sed O
m O
##b O
) O
, O
clinical O
##ly O
significant O
cardiac O
disease O
, O
or O
gas O
##tro O
##int O
##est O
##inal O
d O
##ys O
##function O
that O
might O
imp O
##air O
son O
##ide O
##gi O
##b O
absorption O
. O
[SEP] O
[CLS] O
son O
##ide O
##gi O
##b O
concentrations O
in O
plasma O
were O
measured O
using O
a O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
– O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
##7 O
with O
the O
lower O
limit O
of O
q O
##uant O
##ification O
of O
25 O
. O
4 O
p O
##g O
/ O
m O
##l O
. O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
estimated O
for O
each O
patient O
using O
a O
non O
‐ O
compartment O
##al O
method O
with O
p O
##hoe O
##ni O
##x O
win O
##non O
##lin O
( O
p O
##har O
##sight O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
using O
a O
linear O
trap O
##ez O
##oid O
##al O
method O
for O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
calculation O
. O
[SEP] O
[CLS] O
in O
both O
groups O
, O
most O
patients O
( O
86 O
% O
[ O
n O
= O
18 O
] O
in O
group O
1 O
and O
75 O
% O
[ O
n O
= O
18 O
] O
in O
group O
2 O
) O
experienced O
at O
least O
one O
a O
##e O
, O
which O
was O
suspected O
to O
be O
related O
to O
son O
##ide O
##gi O
##b O
. O
[SEP] O
[CLS] O
the O
most O
common O
drug O
‐ O
related O
a O
##e O
in O
both O
groups O
was O
increase O
in O
c O
##k O
levels O
( O
33 O
% O
in O
group O
1 O
vs O
50 O
% O
in O
group O
2 O
) O
. O
[SEP] O
[CLS] O
the O
ma B-PK
##ximal I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
observed O
at O
approximately O
2 O
– O
4 O
h O
( O
t B-PK
##max I-PK
) O
after O
a O
single O
dose O
in O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
run O
‐ O
in O
period O
and O
repeated O
dos O
##ing O
in O
cycle O
1 O
day O
15 O
. O
[SEP] O
[CLS] O
exposure O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
) O
increased O
as O
the O
dose O
es O
##calated O
in O
both O
groups O
. O
[SEP] O
[CLS] O
after O
repeated O
dos O
##ing O
in O
group O
1 O
, O
exposure O
accumulation O
in O
cycle O
1 O
day O
15 O
was O
4 O
. O
9 O
‐ O
and O
4 O
. O
6 O
‐ O
fold O
at O
400 O
and O
600 O
mg O
, O
respectively O
, O
as O
the O
au B-PK
##c I-PK
ratio I-PK
. O
[SEP] O
[CLS] O
in O
group O
2 O
, O
au B-PK
##c I-PK
accumulation I-PK
at O
400 O
, O
600 O
, O
and O
800 O
mg O
in O
cycle O
1 O
day O
15 O
was O
approximately O
4 O
. O
3 O
‐ O
, O
4 O
. O
2 O
‐ O
, O
and O
6 O
. O
0 O
‐ O
fold O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
large O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
was O
observed O
( O
for O
example O
, O
the O
percentage O
of O
coefficient O
of O
variation O
in O
au B-PK
##c I-PK
is O
50 O
% O
or O
more O
when O
n O
≥ O
3 O
) O
in O
this O
study O
, O
and O
there O
was O
no O
obvious O
difference O
or O
trend O
in O
exposure O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
) O
of O
son O
##ide O
##gi O
##b O
between O
the O
two O
groups O
. O
[SEP] O
[CLS] O
in O
cycle O
1 O
day O
15 O
, O
nine O
of O
12 O
patients O
with O
grade O
3 O
or O
4 O
c O
##k O
elevations O
showed O
a O
higher O
individual O
au B-PK
##c I-PK
compared O
to O
the O
geometric O
mean O
observed O
for O
their O
respective O
groups O
. O
[SEP] O
[CLS] O
further O
##more O
, O
two O
of O
nine O
patients O
who O
experienced O
grade O
3 O
c O
##k O
elevations O
after O
the O
last O
treatment O
showed O
smaller O
au B-PK
##c I-PK
compared O
to O
the O
other O
patients O
with O
or O
without O
c O
##k O
elevation O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
the O
drug O
including O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
volume B-PK
of I-PK
distribution I-PK
and O
clearance B-PK
was O
greater O
( O
p O
< O
0 O
. O
05 O
) O
in O
p O
##o O
than O
s O
##c O
ca O
##lves O
. O
[SEP] O
[CLS] O
the O
slope B-PK
of I-PK
terminal I-PK
phase I-PK
( I-PK
λ I-PK
##z I-PK
) I-PK
of O
the O
log O
plasma O
concentration O
vs O
. O
time O
curve O
was O
estimated O
by O
means O
of O
linear O
re O
##gression O
; O
while O
the O
half B-PK
- I-PK
life I-PK
of I-PK
the I-PK
terminal I-PK
phase I-PK
( I-PK
λ I-PK
##z I-PK
- I-PK
h I-PK
##l I-PK
) I-PK
was O
calculated O
using O
the O
following O
equation O
: O
λ O
##z O
- O
h O
##l O
= O
0 O
. O
69 O
##3 O
##λ O
##z O
. O
[SEP] O
[CLS] O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
vs I-PK
. I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
first I-PK
moment I-PK
of I-PK
the I-PK
plasma I-PK
concentration I-PK
vs I-PK
. I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##m I-PK
##c I-PK
) I-PK
were O
calculated O
by O
use O
of O
the O
log O
- O
linear O
trap O
##ez O
##oid O
##al O
method O
[ O
14 O
] O
. O
[SEP] O
[CLS] O
time O
range O
from O
the O
first O
measurement O
( O
t O
##0 O
) O
to O
the O
last O
measurement O
( O
d O
7 O
) O
of O
drug O
concentration O
was O
used O
for O
the O
calculation O
of O
au B-PK
##c I-PK
##0 I-PK
- I-PK
last I-PK
and O
au B-PK
##m I-PK
##c I-PK
##0 I-PK
- I-PK
last I-PK
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
and O
au B-PK
##m I-PK
##c I-PK
were O
extra O
##pol O
##ated O
to O
in O
##finity O
to O
determine O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
and O
au B-PK
##m I-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
to O
account O
for O
the O
total O
me O
##lo O
##xi O
##cam O
exposure O
to O
ca O
##lves O
[ O
14 O
] O
. O
[SEP] O
[CLS] O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
during I-PK
terminal I-PK
phase I-PK
( I-PK
v I-PK
##z I-PK
/ I-PK
f I-PK
) I-PK
and O
total B-PK
systemic I-PK
clearance I-PK
scaled I-PK
by I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
of O
drug O
were O
also O
determined O
. O
[SEP] O
[CLS] O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
achieve I-PK
peak I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
determined O
directly O
from O
the O
observed O
data O
. O
[SEP] O
[CLS] O
behaviour O
##s O
were O
defined O
as O
: O
a O
) O
eating O
: O
ing O
##est O
##ing O
hay O
or O
straw O
from O
the O
ground O
or O
the O
feeder O
, O
b O
) O
lying O
: O
either O
lateral O
( O
laying O
with O
hip O
and O
shoulder O
on O
the O
ground O
with O
at O
least O
3 O
limbs O
extended O
) O
or O
ventral O
( O
laying O
in O
stern O
##al O
re O
##cum O
##ben O
##cy O
with O
legs O
folded O
under O
the O
body O
or O
one O
hind O
or O
front O
leg O
extended O
) O
lying O
, O
c O
) O
walking O
: O
walking O
forward O
more O
than O
2 O
steps O
, O
d O
) O
standing O
: O
standing O
on O
all O
four O
legs O
, O
e O
) O
foot O
stamp O
##ing O
: O
hind O
legs O
are O
lifted O
and O
forcefully O
placed O
on O
the O
ground O
or O
kicked O
outward O
##s O
while O
standing O
, O
f O
) O
head O
turning O
: O
head O
is O
turned O
and O
touches O
the O
side O
of O
the O
calf O
’ O
s O
body O
when O
standing O
, O
including O
head O
turning O
to O
groom O
, O
g O
) O
tail O
flick O
##ing O
: O
force O
##ful O
tail O
movement O
beyond O
the O
wide O
##st O
part O
of O
the O
r O
##ump O
when O
standing O
, O
movement O
to O
one O
side O
is O
counted O
as O
one O
action O
, O
h O
) O
les O
##ion O
licking O
: O
head O
turning O
to O
lick O
the O
les O
##ion O
caused O
by O
cast O
##ration O
while O
standing O
[ O
17 O
] O
. O
[SEP] O
[CLS] O
the O
p O
##k O
data O
are O
clinical O
##ly O
useful O
as O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
p O
##o O
me O
##lo O
##xi O
##cam O
at O
a O
dose O
of O
1 O
. O
0 O
mg O
/ O
kg O
suggested O
that O
once O
a O
day O
administration O
provides O
anal O
##ges O
##ic O
efficacy O
in O
ca O
##lves O
[ O
3 O
] O
. O
[SEP] O
[CLS] O
limitations O
of O
p O
##o O
administration O
include O
a O
prolonged O
time O
of O
onset O
of O
anal O
##ges O
##ia O
after O
administration O
and O
unpredictable O
absorption O
due O
to O
varying O
gas O
##tric O
conditions O
and O
first O
pass O
he O
##pa O
##tic O
bio O
##tra O
##ns O
##formation O
[ O
33 O
] O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
s O
##c O
administration O
offers O
the O
advantage O
of O
faster O
absorption O
and O
ease O
of O
administration O
. O
[SEP] O
[CLS] O
the O
time B-PK
to I-PK
reach I-PK
peak I-PK
plasma I-PK
drug I-PK
concentrations I-PK
( I-PK
t I-PK
##max I-PK
= O
24 O
. O
0 O
hour O
, O
p O
##o O
; O
t B-PK
##max I-PK
= O
3 O
. O
7 O
hour O
, O
s O
##c O
) O
after O
drug O
administration O
##s O
differed O
( O
p O
≤ O
0 O
. O
05 O
) O
between O
treatments O
while O
no O
differences O
( O
p O
≥ O
0 O
. O
10 O
) O
were O
observed O
for O
peak B-PK
plasma I-PK
drug I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
= O
2 O
. O
32 O
μ O
##g O
/ O
m O
##l O
, O
p O
##o O
; O
cm B-PK
##ax I-PK
= O
2 O
. O
37 O
μ O
##g O
/ O
m O
##l O
, O
s O
##c O
) O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
similar O
t B-PK
##max I-PK
and O
cm B-PK
##ax I-PK
values O
were O
observed O
in O
ca O
##lves O
receiving O
s O
##c O
me O
##lo O
##xi O
##cam O
with O
or O
without O
a O
lid O
##oc O
##aine O
ring O
block O
prior O
to O
knife O
cast O
##ration O
[ O
2 O
] O
. O
[SEP] O
[CLS] O
similar O
findings O
were O
also O
reported O
in O
goats O
, O
where O
s O
##c O
me O
##lo O
##xi O
##cam O
administration O
had O
a O
significantly O
shorter O
t B-PK
##max I-PK
( O
3 O
. O
20 O
hour O
) O
compared O
to O
p O
##o O
me O
##lo O
##xi O
##cam O
administration O
( O
14 O
. O
3 O
hour O
) O
[ O
31 O
] O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
mean O
cm B-PK
##ax I-PK
following O
s O
##c O
me O
##lo O
##xi O
##cam O
administration O
in O
the O
present O
study O
was O
higher O
than O
the O
value O
( O
cm B-PK
##ax I-PK
= O
1 O
. O
91 O
μ O
##g O
/ O
m O
##l O
) O
obtained O
for O
goats O
[ O
31 O
] O
, O
while O
a O
lower O
cm B-PK
##ax I-PK
was O
observed O
following O
p O
##o O
administration O
in O
comparison O
to O
the O
cm B-PK
##ax I-PK
( O
3 O
. O
10 O
μ O
##g O
/ O
m O
##l O
) O
previously O
reported O
in O
ca O
##lves O
[ O
3 O
] O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
= O
95 O
. O
16 O
μ O
##g O
× O
h O
/ O
m O
##l O
) O
, O
v B-PK
##z I-PK
/ I-PK
f I-PK
= O
244 O
m O
##l O
/ O
kg O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
= O
11 O
. O
11 O
m O
##l O
/ O
h O
/ O
kg O
were O
greater O
( O
p O
≤ O
0 O
. O
05 O
) O
in O
the O
ca O
##lves O
receiving O
p O
##o O
compared O
to O
s O
##c O
me O
##lo O
##xi O
##cam O
administration O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
is O
an O
indicator O
of O
the O
total O
drug O
exposure O
and O
it O
is O
dependent O
on O
dose O
and O
rate B-PK
of I-PK
elimination I-PK
. O
[SEP] O
[CLS] O
a O
higher O
dose O
of O
me O
##lo O
##xi O
##cam O
given O
to O
the O
p O
##o O
ca O
##lves O
seems O
to O
be O
the O
major O
contributing O
factor O
for O
a O
greater O
au B-PK
##c I-PK
as O
the O
elimination B-PK
rate I-PK
( I-PK
λ I-PK
##z I-PK
= O
0 O
. O
04 O
##3 O
– O
0 O
. O
04 O
##5 O
1 O
/ O
h O
) O
is O
approximately O
the O
same O
for O
both O
treatment O
groups O
. O
[SEP] O
[CLS] O
the O
s O
##c O
ca O
##lves O
had O
lower O
( O
p O
≤ O
0 O
. O
05 O
) O
clearance B-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
= O
7 O
. O
98 O
m O
##l O
/ O
h O
/ O
kg O
) O
of O
me O
##lo O
##xi O
##cam O
than O
the O
p O
##o O
ca O
##lves O
, O
which O
is O
in O
agreement O
with O
the O
longer O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
λ I-PK
##z I-PK
- I-PK
h I-PK
##l I-PK
= O
16 O
. O
2 O
h O
) O
of O
the O
s O
##c O
treatment O
than O
the O
p O
##o O
( O
15 O
. O
2 O
h O
) O
administration O
. O
[SEP] O
[CLS] O
the O
λ B-PK
##z I-PK
- I-PK
h I-PK
##l I-PK
( O
16 O
. O
2 O
h O
) O
in O
ca O
##lves O
was O
slightly O
higher O
than O
that O
reported O
for O
goats O
( O
15 O
. O
1 O
h O
) O
after O
s O
##c O
me O
##lo O
##xi O
##cam O
administration O
using O
the O
same O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
[ O
31 O
] O
, O
while O
higher O
values O
for O
λ B-PK
##z I-PK
- I-PK
h I-PK
##l I-PK
( O
27 O
. O
5 O
h O
) O
and O
au B-PK
##c I-PK
( O
164 O
. O
4 O
μ O
##g O
. O
h O
/ O
m O
##l O
) O
have O
been O
reported O
following O
p O
##o O
administration O
of O
me O
##lo O
##xi O
##cam O
in O
ca O
##lves O
[ O
3 O
] O
. O
[SEP] O
[CLS] O
in O
the O
previously O
mentioned O
trial O
p O
##k O
analysis O
showed O
that O
the O
au B-PK
##c I-PK
extra O
##pol O
##ation O
range O
was O
23 O
. O
0 O
– O
39 O
. O
4 O
% O
in O
four O
ca O
##lves O
and O
4 O
. O
14 O
– O
5 O
. O
85 O
% O
in O
two O
ca O
##lves O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
p O
##k O
analysis O
for O
the O
current O
study O
was O
done O
with O
au B-PK
##c I-PK
extra O
##pol O
##ation O
of O
0 O
. O
18 O
% O
. O
[SEP] O
[CLS] O
insufficient O
sampling O
times O
in O
the O
descending O
part O
of O
the O
curve O
may O
lead O
to O
over O
##est O
##imation O
of O
au B-PK
##c I-PK
[ O
34 O
] O
. O
[SEP] O
[CLS] O
this O
could O
be O
the O
reason O
for O
a O
greater O
au B-PK
##c I-PK
in O
the O
previous O
study O
compared O
to O
the O
au B-PK
##c I-PK
obtained O
in O
the O
current O
study O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
in O
ca O
##lves O
was O
greater O
than O
the O
au B-PK
##c I-PK
reported O
in O
sheep O
( O
75 O
. O
09 O
μ O
##g O
× O
h O
/ O
m O
##l O
) O
[ O
30 O
] O
and O
goats O
( O
23 O
. O
24 O
μ O
##g O
× O
h O
/ O
m O
##l O
) O
[ O
29 O
] O
, O
indicating O
that O
me O
##lo O
##xi O
##cam O
is O
eliminated O
at O
a O
slower O
rate O
in O
ca O
##lves O
than O
small O
r O
##umi O
##nant O
species O
. O
[SEP] O
[CLS] O
the O
limited O
v B-PK
##z I-PK
/ I-PK
f I-PK
= O
244 O
m O
##l O
/ O
kg O
observed O
in O
the O
present O
study O
after O
p O
##o O
me O
##lo O
##xi O
##cam O
administration O
is O
similar O
to O
previous O
values O
reported O
for O
ca O
##lves O
( O
242 O
m O
##l O
/ O
kg O
) O
[ O
3 O
] O
and O
sheep O
( O
29 O
##3 O
m O
##l O
/ O
kg O
) O
[ O
30 O
] O
. O
[SEP] O
[CLS] O
a O
low O
v B-PK
##z I-PK
/ I-PK
f I-PK
indicates O
that O
the O
drug O
is O
mainly O
found O
in O
the O
vascular O
space O
as O
opposed O
to O
the O
extra O
##vas O
##cular O
space O
. O
[SEP] O
[CLS] O
however O
, O
low O
values O
of O
clearance B-PK
and O
a O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
16 O
. O
2 O
hours O
following O
s O
##c O
administration O
suggests O
that O
once O
a O
day O
dos O
##ing O
might O
prove O
effective O
to O
maintain O
anal O
##ges O
##ic O
effect O
in O
ca O
##lves O
. O
[SEP] O
[CLS] O
a O
possible O
explanation O
for O
the O
reduction O
in O
s O
##c O
##rot O
##al O
inflammation O
observed O
in O
p O
##o O
ca O
##lves O
could O
be O
due O
to O
the O
greater O
exposure O
to O
me O
##lo O
##xi O
##cam O
as O
p O
##o O
ca O
##lves O
had O
greater O
au B-PK
##c I-PK
than O
s O
##c O
ca O
##lves O
. O
[SEP] O
[CLS] O
the O
greater O
exposure O
to O
me O
##lo O
##xi O
##cam O
( O
au B-PK
##c I-PK
) O
observed O
can O
explain O
lower O
standing O
duration O
and O
s O
##c O
##rot O
##al O
inflammation O
, O
and O
the O
greater O
lying O
percentage O
observed O
in O
the O
p O
##o O
ca O
##lves O
. O
[SEP] O
[CLS] O
treatment O
with O
g O
##l O
extract O
##s O
did O
not O
alter O
the O
levels O
of O
fast O
##ing O
plasma O
glucose O
and O
insulin O
, O
but O
significantly O
reduced O
the O
levels O
of O
plasma O
glucose O
at O
60 O
and O
120 O
min O
post O
glucose O
challenge O
, O
also O
reduced O
the O
values O
of O
au B-PK
##c I-PK
and O
quantitative O
insulin O
sensitivity O
check O
index O
( O
quick O
##i O
) O
at O
42 O
days O
post O
treatment O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
over I-PK
the I-PK
levels I-PK
of I-PK
blood I-PK
glucose I-PK
in O
individual O
rats O
was O
calculated O
by O
the O
trap O
##ez O
##oid O
##al O
rule O
: O
{ O
[ O
15 O
× O
log O
( O
g O
##lu O
##c O
##0 O
min O
) O
] O
+ O
[ O
30 O
× O
log O
( O
g O
##lu O
##c O
##30 O
min O
) O
] O
+ O
[ O
45 O
× O
log O
( O
g O
##lu O
##c O
##60 O
min O
) O
] O
+ O
[ O
30 O
× O
log O
( O
g O
##lu O
##c O
##12 O
##0 O
min O
) O
] O
/ O
120 O
} O
[ O
19 O
] O
. O
[SEP] O
[CLS] O
as O
a O
result O
, O
the O
values O
of O
the O
au B-PK
##c I-PK
over I-PK
the I-PK
first I-PK
2 I-PK
- I-PK
h I-PK
after I-PK
glucose I-PK
challenge I-PK
( I-PK
g I-PK
##au I-PK
##c I-PK
##0 I-PK
- I-PK
2 I-PK
) I-PK
in O
the O
g O
##l O
- O
treated O
rats O
were O
significantly O
less O
than O
that O
of O
the O
controls O
( O
210 O
. O
53 O
± O
5 O
. O
15 O
vs O
. O
203 O
. O
08 O
± O
4 O
. O
33 O
mg O
/ O
d O
##l O
/ O
min O
, O
p O
= O
0 O
. O
02 O
, O
n O
= O
6 O
, O
figure O
1 O
##g O
) O
, O
and O
the O
quick O
##i O
values O
in O
the O
g O
##l O
- O
treated O
rats O
were O
significantly O
less O
than O
that O
in O
the O
control O
rats O
( O
3 O
. O
40 O
± O
0 O
. O
28 O
vs O
. O
3 O
. O
01 O
± O
0 O
. O
12 O
, O
p O
= O
0 O
. O
04 O
, O
n O
= O
6 O
, O
figure O
1 O
##h O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
2 O
, O
the O
relative O
levels O
of O
total O
a O
##kt O
( O
0 O
. O
44 O
± O
0 O
. O
09 O
vs O
. O
0 O
. O
84 O
± O
0 O
. O
11 O
, O
p O
= O
0 O
. O
00 O
##1 O
, O
n O
= O
4 O
, O
figure O
2 O
##e O
and O
f O
) O
and O
p O
##hos O
##ph O
##ory O
##lated O
a O
##kt O
308 O
( O
0 O
. O
29 O
± O
0 O
. O
17 O
vs O
. O
0 O
. O
74 O
± O
0 O
. O
10 O
, O
p O
= O
0 O
. O
00 O
##5 O
, O
n O
= O
4 O
, O
figure O
2 O
##e O
and O
g O
) O
, O
but O
not O
a O
##kt O
47 O
##3 O
( O
figure O
2 O
##e O
and O
h O
) O
in O
the O
muscles O
form O
the O
g O
##l O
- O
treated O
rats O
were O
significantly O
higher O
than O
that O
in O
the O
controls O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
and O
time B-PK
needed I-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
determined O
by O
the O
software O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
the O
drug O
was O
calculated O
by O
use O
of O
the O
relationship O
t O
##1 O
/ O
2 O
= O
0 O
. O
69 O
##3 O
/ O
k O
##el O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##el I-PK
) I-PK
was O
obtained O
from O
the O
terminal O
slope O
by O
use O
of O
re O
##gression O
analysis O
. O
[SEP] O
[CLS] O
con O
##com O
##ita O
##nt O
can O
##na O
##bid O
##iol O
had O
little O
effect O
on O
c O
##lo O
##ba O
##zam O
exposure O
( O
maximum B-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
[ I-PK
au I-PK
##c I-PK
] I-PK
, O
1 O
. O
2 O
‐ O
fold O
) O
, O
n O
‐ O
des O
##met O
##hyl O
##c O
##lo O
##ba O
##zam O
exposure O
increased O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
, O
3 O
. O
4 O
‐ O
fold O
) O
, O
stir O
##ip O
##ent O
##ol O
exposure O
increased O
slightly O
( O
cm B-PK
##ax I-PK
, O
1 O
. O
3 O
‐ O
fold O
; O
au B-PK
##c I-PK
, O
1 O
. O
6 O
‐ O
fold O
) O
, O
while O
no O
clinical O
##ly O
relevant O
effect O
on O
v O
##al O
##p O
##roa O
##te O
exposure O
was O
observed O
. O
[SEP] O
[CLS] O
con O
##com O
##ita O
##nt O
c O
##lo O
##ba O
##zam O
with O
can O
##na O
##bid O
##iol O
increased O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
exposure O
( O
cm B-PK
##ax I-PK
, O
1 O
. O
7 O
‐ O
fold O
; O
au B-PK
##c I-PK
, O
1 O
. O
5 O
‐ O
fold O
) O
, O
without O
notable O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
or O
can O
##na O
##bid O
##iol O
increases O
. O
[SEP] O
[CLS] O
in O
patients O
, O
con O
##com O
##ita O
##nt O
administration O
of O
can O
##na O
##bid O
##iol O
with O
c O
##lo O
##ba O
##zam O
resulted O
in O
an O
increase O
in O
the O
plasma O
concentration O
of O
n O
‐ O
c O
##l O
##b O
##30 O
, O
31 O
, O
32 O
often O
associated O
with O
increased O
se O
##dation O
, O
a O
recognized O
adverse O
event O
( O
a O
##e O
) O
noted O
with O
c O
##lo O
##ba O
##zam O
administration O
for O
the O
treatment O
of O
l O
##gs O
. O
33 O
increases O
in O
liver O
trans O
##ami O
##nas O
##es O
are O
more O
common O
in O
patients O
who O
are O
taking O
can O
##na O
##bid O
##iol O
with O
v O
##al O
##p O
##roa O
##te O
( O
which O
is O
associated O
with O
he O
##pa O
##to O
##to O
##xi O
##city O
##34 O
) O
than O
in O
those O
who O
are O
not O
. O
31 O
given O
that O
in O
these O
patient O
trials O
, O
the O
majority O
of O
patients O
were O
on O
multiple O
con O
##com O
##ita O
##nt O
a O
##eds O
, O
the O
importance O
of O
this O
phase O
1 O
trial O
was O
evident O
: O
to O
understand O
the O
potential O
for O
p O
##k O
interactions O
between O
can O
##na O
##bid O
##iol O
and O
3 O
commonly O
used O
other O
a O
##eds O
in O
a O
healthy O
population O
who O
were O
not O
taking O
other O
a O
##eds O
. O
[SEP] O
[CLS] O
a O
treatment O
‐ O
emerge O
##nt O
a O
##e O
was O
defined O
as O
any O
event O
not O
present O
before O
( O
the O
first O
) O
administration O
of O
the O
imp O
, O
or O
any O
event O
already O
present O
that O
worse O
##ned O
in O
either O
severity O
or O
frequency O
following O
exposure O
to O
the O
imp O
. O
[SEP] O
[CLS] O
an O
a O
##e O
that O
occurred O
before O
( O
the O
first O
) O
administration O
of O
the O
imp O
was O
considered O
a O
pre O
##tre O
##at O
##ment O
a O
##e O
. O
[SEP] O
[CLS] O
for O
can O
##na O
##bid O
##iol O
( O
and O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
) O
, O
c O
##lo O
##ba O
##zam O
( O
and O
n O
‐ O
c O
##l O
##b O
) O
, O
stir O
##ip O
##ent O
##ol O
, O
and O
v O
##al O
##p O
##roa O
##te O
( O
and O
4 O
‐ O
en O
##e O
‐ O
v O
##pa O
) O
, O
the O
following O
p O
##k O
parameters O
were O
estimated O
by O
non O
##com O
##par O
##tment O
##al O
methods O
using O
p O
##hoe O
##ni O
##x O
win O
##non O
##lin O
version O
6 O
. O
3 O
( O
c O
##ert O
##ara O
, O
prince O
##ton O
, O
new O
jersey O
) O
: O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
attain I-PK
maximum I-PK
observed I-PK
plasma I-PK
concentration I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
over I-PK
a I-PK
dos I-PK
##ing I-PK
interval I-PK
, O
where O
ta O
##u O
is O
the O
dos O
##ing O
interval O
( O
au B-PK
##ct I-PK
##au I-PK
) O
. O
[SEP] O
[CLS] O
seventy O
subjects O
completed O
the O
trial O
, O
and O
7 O
subjects O
were O
withdrawn O
— O
6 O
were O
due O
to O
an O
a O
##e O
and O
1 O
withdrew O
consent O
to O
participate O
. O
[SEP] O
[CLS] O
( O
e O
) O
d O
##di O
v O
##al O
##p O
##roa O
##te O
. O
[SEP] O
[CLS] O
( O
f O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
v O
##al O
##p O
##roa O
##te O
, O
on O
plasma O
concentrations O
of O
( O
i O
) O
can O
##na O
##bid O
##iol O
, O
( O
ii O
) O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
and O
( O
ii O
##i O
) O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
( O
arithmetic O
mean O
± O
s O
##d O
[ O
lower O
tail O
is O
not O
shown O
if O
greater O
than O
mean O
value O
] O
) O
. O
[SEP] O
[CLS] O
( O
i O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
can O
##na O
##bid O
##iol O
bid O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
confidence O
intervals O
[ O
c O
##is O
] O
) O
to O
c O
##lo O
##ba O
##zam O
and O
n O
‐ O
c O
##l O
##b O
. O
[SEP] O
[CLS] O
( O
ii O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
5 O
mg O
of O
c O
##lo O
##ba O
##zam O
bid O
, O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
c O
##i O
) O
to O
can O
##na O
##bid O
##iol O
, O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
and O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
. O
[SEP] O
[CLS] O
( O
i O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
can O
##na O
##bid O
##iol O
bid O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
c O
##i O
) O
to O
stir O
##ip O
##ent O
##ol O
. O
[SEP] O
[CLS] O
( O
ii O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
stir O
##ip O
##ent O
##ol O
bid O
, O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
c O
##i O
) O
to O
can O
##na O
##bid O
##iol O
, O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
and O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
. O
[SEP] O
[CLS] O
( O
i O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
can O
##na O
##bid O
##iol O
bid O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
c O
##i O
) O
to O
v O
##al O
##p O
##roa O
##te O
. O
[SEP] O
[CLS] O
( O
ii O
) O
the O
effect O
of O
con O
##com O
##ita O
##nt O
administration O
of O
750 O
mg O
of O
v O
##al O
##p O
##roa O
##te O
bid O
on O
individual O
and O
geometric O
mean O
steady O
‐ O
state O
exposure O
( O
top O
panel O
: O
cm B-PK
##ax I-PK
; O
middle O
panel O
: O
au B-PK
##ct I-PK
##au I-PK
; O
bottom O
panel O
: O
treatment O
ratios O
with O
90 O
% O
c O
##i O
) O
to O
can O
##na O
##bid O
##iol O
, O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
and O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
. O
[SEP] O
[CLS] O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
, O
7 O
‐ O
h O
##ydro O
##xy O
‐ O
can O
##na O
##bid O
##iol O
; O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
, O
7 O
‐ O
car O
##box O
##y O
‐ O
can O
##na O
##bid O
##iol O
; O
au B-PK
##ct I-PK
##au I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
over I-PK
a I-PK
dos I-PK
##ing I-PK
interval I-PK
, O
where O
ta O
##u O
is O
the O
dos O
##ing O
interval O
; O
c O
##i O
, O
confidence O
interval O
; O
cm B-PK
##ax I-PK
, I-PK
maximum I-PK
concentration I-PK
; O
d O
##di O
, O
drug O
‐ O
drug O
interaction O
; O
n O
‐ O
c O
##l O
##b O
, O
n O
‐ O
des O
##met O
##hyl O
##c O
##lo O
##ba O
##zam O
; O
s O
##d O
, O
standard O
de O
##viation O
. O
[SEP] O
[CLS] O
following O
repeated O
con O
##com O
##ita O
##nt O
dos O
##ing O
of O
can O
##na O
##bid O
##iol O
( O
750 O
mg O
bid O
) O
with O
c O
##lo O
##ba O
##zam O
( O
5 O
mg O
bid O
) O
for O
7 O
days O
( O
no O
t O
##it O
##ration O
) O
and O
14 O
days O
( O
10 O
‐ O
day O
t O
##it O
##ration O
) O
, O
there O
was O
a O
slight O
increase O
in O
the O
exposure O
of O
c O
##lo O
##ba O
##zam O
with O
the O
point O
estimate O
for O
the O
t O
##r O
for O
cm B-PK
##ax I-PK
of O
1 O
. O
20 O
( O
90 O
% O
c O
##i O
, O
1 O
. O
05 O
– O
1 O
. O
38 O
) O
and O
for O
au B-PK
##ct I-PK
##au I-PK
of O
1 O
. O
21 O
( O
90 O
% O
c O
##i O
, O
1 O
. O
05 O
– O
1 O
. O
39 O
) O
. O
[SEP] O
[CLS] O
there O
was O
an O
increase O
in O
systemic O
exposure O
to O
n O
‐ O
c O
##l O
##b O
, O
whereby O
the O
geometric O
mean O
cm B-PK
##ax I-PK
increased O
3 O
. O
39 O
‐ O
fold O
( O
90 O
% O
c O
##i O
, O
2 O
. O
61 O
– O
4 O
. O
39 O
) O
and O
au B-PK
##ct I-PK
##au I-PK
increased O
3 O
. O
38 O
‐ O
fold O
( O
90 O
% O
c O
##i O
, O
2 O
. O
62 O
– O
4 O
. O
36 O
) O
. O
[SEP] O
[CLS] O
following O
21 O
days O
of O
con O
##com O
##ita O
##nt O
administration O
of O
5 O
mg O
of O
c O
##lo O
##ba O
##zam O
bid O
with O
750 O
mg O
of O
can O
##na O
##bid O
##iol O
bid O
, O
there O
was O
a O
slight O
increase O
in O
can O
##na O
##bid O
##iol O
exposure O
( O
t O
##r O
for O
can O
##na O
##bid O
##iol O
cm B-PK
##ax I-PK
and O
au B-PK
##ct I-PK
##au I-PK
; O
1 O
. O
34 O
[ O
90 O
% O
c O
##i O
, O
0 O
. O
93 O
– O
1 O
. O
95 O
] O
and O
1 O
. O
30 O
[ O
90 O
% O
c O
##i O
, O
1 O
. O
00 O
– O
1 O
. O
70 O
] O
respectively O
) O
and O
for O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
( O
cm B-PK
##ax I-PK
t O
##r O
1 O
. O
35 O
[ O
90 O
% O
c O
##i O
, O
1 O
. O
12 O
– O
1 O
. O
63 O
] O
and O
au B-PK
##ct I-PK
##au I-PK
t O
##r O
1 O
. O
31 O
[ O
90 O
% O
c O
##i O
, O
1 O
. O
04 O
– O
1 O
. O
64 O
] O
) O
. O
[SEP] O
[CLS] O
the O
t O
##r O
point O
estimate O
for O
cm B-PK
##ax I-PK
of O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
increased O
by O
1 O
. O
73 O
‐ O
fold O
( O
90 O
% O
c O
##i O
, O
1 O
. O
36 O
– O
2 O
. O
20 O
) O
and O
au B-PK
##ct I-PK
##au I-PK
increased O
with O
a O
t O
##r O
of O
1 O
. O
47 O
( O
90 O
% O
c O
##i O
, O
1 O
. O
26 O
– O
1 O
. O
70 O
) O
. O
[SEP] O
[CLS] O
there O
were O
also O
no O
obvious O
effects O
on O
the O
exposure O
to O
the O
active O
meta O
##bol O
##ite O
7 O
‐ O
oh O
‐ O
c O
##b O
##d O
with O
cm B-PK
##ax I-PK
t O
##r O
0 O
. O
97 O
( O
90 O
% O
c O
##i O
, O
0 O
. O
67 O
– O
1 O
. O
41 O
) O
and O
au B-PK
##ct I-PK
##au I-PK
t O
##r O
1 O
. O
22 O
( O
90 O
% O
c O
##i O
, O
0 O
. O
96 O
– O
1 O
. O
55 O
) O
or O
to O
7 O
‐ O
co O
##oh O
‐ O
c O
##b O
##d O
with O
cm B-PK
##ax I-PK
t O
##r O
1 O
. O
25 O
‐ O
fold O
( O
90 O
% O
c O
##i O
, O
1 O
. O
07 O
– O
1 O
. O
45 O
) O
and O
au B-PK
##ct I-PK
##au I-PK
t O
##r O
1 O
. O
22 O
( O
90 O
% O
c O
##i O
, O
0 O
. O
96 O
– O
1 O
. O
55 O
) O
( O
figure O
4 O
##c O
( O
ii O
) O
) O
. O
[SEP] O
[CLS] O
there O
were O
3 O
withdrawal O
##s O
due O
to O
a O
##es O
in O
subjects O
in O
the O
can O
##na O
##bid O
##iol O
( O
victim O
) O
+ O
c O
##lo O
##ba O
##zam O
( O
per O
##pet O
##rator O
) O
subgroup O
: O
a O
moderate O
a O
##e O
of O
a O
##v O
block O
first O
degree O
was O
recorded O
for O
1 O
( O
8 O
. O
3 O
% O
) O
subject O
that O
occurred O
while O
receiving O
can O
##na O
##bid O
##iol O
alone O
( O
no O
t O
##it O
##ration O
) O
and O
2 O
severe O
a O
##es O
of O
r O
##ash O
p O
##ap O
##ular O
( O
without O
m O
##uc O
##osa O
##l O
involvement O
) O
were O
reported O
in O
2 O
( O
16 O
. O
7 O
% O
) O
subjects O
during O
the O
first O
2 O
days O
of O
receiving O
can O
##na O
##bid O
##iol O
( O
no O
t O
##it O
##ration O
) O
+ O
c O
##lo O
##ba O
##zam O
. O
[SEP] O
[CLS] O
details O
of O
the O
r O
##ash O
##es O
, O
including O
severity O
of O
the O
a O
##e O
and O
action O
taken O
, O
as O
well O
as O
details O
of O
treatment O
administered O
and O
whether O
any O
can O
##na O
##bid O
##iol O
t O
##it O
##ration O
period O
was O
included O
, O
are O
provided O
in O
table O
5 O
. O
[SEP] O
[CLS] O
one O
subject O
experienced O
a O
moderate O
a O
##e O
of O
first O
‐ O
degree O
at O
##rio O
##vent O
##ric O
##ular O
block O
( O
p O
##r O
interval O
pro O
##long O
##ation O
of O
149 O
– O
152 O
mill O
##ise O
##con O
##ds O
relative O
to O
base O
##line O
) O
on O
day O
8 O
while O
taking O
can O
##na O
##bid O
##iol O
alone O
( O
no O
t O
##it O
##ration O
) O
. O
[SEP] O
[CLS] O
although O
the O
p O
##r O
interval O
had O
returned O
to O
base O
##line O
value O
50 O
minutes O
later O
, O
the O
a O
##e O
was O
classified O
as O
ongoing O
at O
the O
follow O
‐ O
up O
visit O
( O
1 O
week O
later O
) O
, O
when O
the O
p O
##r O
interval O
was O
153 O
mill O
##ise O
##con O
##ds O
above O
base O
##line O
. O
[SEP] O
[CLS] O
an O
a O
##e O
of O
men O
##st O
##ru O
##al O
discomfort O
was O
reported O
by O
1 O
subject O
on O
day O
8 O
of O
taking O
can O
##na O
##bid O
##iol O
( O
no O
t O
##it O
##ration O
; O
victim O
) O
+ O
stir O
##ip O
##ent O
##ol O
( O
per O
##pet O
##rator O
) O
, O
which O
was O
mild O
in O
severity O
and O
resolved O
on O
the O
same O
day O
it O
appeared O
with O
no O
action O
taken O
. O
[SEP] O
[CLS] O
the O
t B-PK
##rough I-PK
drug I-PK
concentration I-PK
, O
defined O
as O
the O
concentration O
at O
the O
end O
of O
the O
dos O
##ing O
interval O
( O
c O
##12 O
) O
, O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
12 I-PK
h I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
) I-PK
for O
sa O
##quin O
##avi O
##r O
and O
r O
##ito O
##na O
##vir O
, O
were O
estimated O
using O
non O
##com O
##par O
##tment O
##al O
methods O
using O
win O
##non O
##lin O
software O
( O
version O
5 O
. O
2 O
, O
p O
##har O
##sight O
corporation O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
for O
days O
3 O
, O
4 O
, O
7 O
, O
10 O
, O
and O
14 O
. O
[SEP] O
[CLS] O
consistent O
with O
the O
mean O
plasma O
concentrations O
, O
the O
highest O
sa O
##quin O
##avi O
##r O
mean O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
following O
administration O
of O
sa O
##quin O
##avi O
##r O
/ O
r O
##ito O
##na O
##vir O
500 O
/ O
100 O
mg O
bid O
was O
observed O
on O
day O
3 O
( O
40 O
##30 O
ng O
/ O
m O
##l O
and O
27 O
, O
100 O
ng O
· O
h O
/ O
m O
##l O
, O
respectively O
) O
and O
declined O
on O
days O
4 O
and O
7 O
, O
with O
the O
lowest O
exposure O
on O
day O
7 O
. O
[SEP] O
[CLS] O
similarly O
, O
doubling O
the O
dose O
of O
sa O
##quin O
##avi O
##r O
to O
1000 O
/ O
100 O
mg O
bid O
during O
the O
second O
week O
resulted O
in O
higher O
mean O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
on O
days O
10 O
and O
14 O
with O
highest O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
on O
day O
10 O
( O
530 O
##0 O
ng O
/ O
m O
##l O
and O
34 O
, O
200 O
ng O
· O
h O
/ O
m O
##l O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
median O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
i I-PK
. I-PK
e I-PK
. I-PK
, I-PK
t I-PK
##max I-PK
) I-PK
for O
sa O
##quin O
##avi O
##r O
was O
reached O
approximately O
2 O
– O
4 O
h O
after O
dos O
##ing O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
mean O
r O
##ito O
##na O
##vir O
plasma O
concentrations O
and O
mean O
r O
##ito O
##na O
##vir O
exposure O
##s O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
##h I-PK
) O
flu O
##ct O
##uated O
across O
study O
days O
but O
were O
generally O
similar O
when O
considering O
the O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
was O
reached O
approximately O
3 O
– O
4 O
h O
after O
dos O
##ing O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
relationship O
between O
sa O
##quin O
##avi O
##r O
concentration O
and O
q O
##t O
##c O
##f O
was O
evaluated O
using O
cm B-PK
##ax I-PK
because O
a O
delay O
in O
maximum O
[UNK] O
compared O
with O
maximum O
sa O
##quin O
##avi O
##r O
plasma O
concentrations O
is O
observed O
manifest O
##ing O
as O
a O
counter O
- O
clockwise O
h O
##yster O
##esis O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
no O
strong O
correlation O
was O
observed O
between O
the O
maximum O
[UNK] O
and O
cm B-PK
##ax I-PK
of O
sa O
##quin O
##avi O
##r O
( O
fi O
##g O
. O
3 O
) O
. O
[SEP] O
[CLS] O
one O
patient O
discontinued O
study O
drug O
due O
to O
go O
##no O
##co O
##cca O
##l O
pro O
##ct O
##itis O
which O
was O
classified O
as O
a O
serious O
a O
##e O
but O
was O
not O
considered O
to O
be O
drug O
- O
related O
. O
[SEP] O
[CLS] O
the O
application O
of O
bet O
##ulin O
##ic O
acid O
( O
b O
) O
, O
a O
potent O
anti O
##ne O
##op O
##lastic O
agent O
, O
is O
limited O
due O
to O
poor O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
short O
plasma B-PK
half I-PK
- I-PK
life I-PK
and O
inappropriate O
tissue O
distribution O
. O
[SEP] O
[CLS] O
later O
, O
in O
v O
##it O
##ro O
cell O
culture O
analysis O
using O
he O
##p O
- O
g O
##2 O
cells O
and O
con O
##fo O
##cal O
micro O
##sco O
##py O
studies O
revealed O
that O
b O
##n O
##p O
had O
the O
highest O
in O
##hibition O
and O
penetration O
properties O
than O
parent O
b O
. O
oral O
p O
##har O
##ma O
##co O
##kin O
##etics O
studies O
using O
al O
##bino O
w O
##ista O
##r O
rats O
at O
single O
100 O
mg O
dose O
again O
exhibited O
b O
##n O
##p O
had O
the O
higher O
50 O
% O
of O
plasma O
concentration O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
) O
, O
a O
higher O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
took O
longer O
to O
reach O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
than O
parent O
b O
. O
next O
, O
our O
in O
v O
##ivo O
study O
using O
ni O
##tro O
##so O
##die O
##thy O
##l O
am O
##ine O
( O
n O
##dea O
) O
- O
induced O
h O
##cc O
model O
documented O
b O
##n O
##p O
decreased O
in O
number O
of O
nod O
##ules O
, O
restored O
body O
weight O
, O
o O
##xi O
##da O
##tive O
stress O
parameters O
, O
liver O
marker O
enzymes O
and O
his O
##to O
##logical O
architecture O
than O
parent O
b O
. O
last O
##ly O
, O
q O
##rt O
- O
p O
##c O
##r O
studies O
further O
demonstrated O
that O
anti O
- O
h O
##cc O
properties O
of O
b O
##n O
##p O
may O
be O
due O
to O
over O
expression O
of O
anti O
##ap O
##op O
##to O
##tic O
ca O
##sp O
##ases O
i O
. O
e O
. O
, O
ca O
##sp O
##ase O
3 O
and O
8 O
. O
[SEP] O
[CLS] O
this O
mixture O
was O
son O
##ica O
##ted O
for O
15 O
or O
30 O
min O
with O
addition O
of O
12 O
m O
##l O
of O
different O
concentrations O
( O
w O
/ O
v O
) O
of O
a O
##que O
##ous O
p O
##oly O
##vin O
##yl O
alcohol O
( O
p O
##va O
) O
at O
10 O
k O
##h O
##z O
( O
2 O
% O
p O
##va O
formulation O
##s O
a O
and O
b O
with O
son O
##ica O
##tion O
times O
15 O
and O
30 O
min O
, O
4 O
% O
p O
##va O
formulation O
##s O
c O
and O
d O
with O
son O
##ica O
##tion O
times O
15 O
and O
30 O
min O
, O
6 O
% O
p O
##va O
formulation O
##s O
e O
and O
f O
with O
son O
##ica O
##tion O
times O
15 O
and O
30 O
min O
; O
table O
1 O
) O
. O
[SEP] O
[CLS] O
limited O
so O
##lub O
##ility O
and O
poor O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
are O
the O
major O
draw O
##backs O
for O
b O
, O
and O
therefore O
, O
it O
has O
limited O
therapeutic O
index O
during O
p O
##har O
##ma O
##cological O
responses O
. O
8 O
– O
14 O
this O
problem O
may O
be O
overcome O
through O
enhancing O
the O
so O
##lub O
##ility O
in O
biological O
matrix O
##es O
and O
increasing O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
as O
depicted O
in O
table O
2 O
and O
figure O
4 O
##b O
, O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
required I-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
10 O
. O
34 O
µ O
##g O
/ O
m O
##l O
and O
4 O
h O
for O
b O
and O
47 O
. O
43 O
µ O
##g O
/ O
m O
##l O
and O
8 O
h O
for O
b O
##n O
##p O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
plasma O
concentration O
reached O
50 O
% O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
) O
at O
10 O
. O
73 O
and O
11 O
. O
11 O
h O
for O
b O
and O
b O
##n O
##p O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
after O
48 O
h O
was O
133 O
. O
81 O
and O
83 O
##8 O
. O
43 O
µ O
##g O
##⋅ O
##h O
/ O
m O
##l O
for O
b O
and O
b O
##n O
##p O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
: O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
and O
au B-PK
##c I-PK
values O
. O
[SEP] O
[CLS] O
all O
sub O
##cut O
##aneous O
f O
##b O
##z O
treatment O
regime O
##ns O
tested O
were O
most O
successful O
and O
mediated O
a O
complete O
clearance O
of O
the O
peripheral O
micro O
##fi O
##lar O
##emia O
. O
[SEP] O
[CLS] O
using O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
we O
compared O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
values O
of O
f O
##b O
##z O
between O
the O
different O
treatment O
regime O
##ns O
and O
route O
of O
administration O
##s O
. O
[SEP] O
[CLS] O
mean O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
##h I-PK
values O
increased O
roughly O
dose O
proportional O
##ly O
between O
2 O
##m O
##g O
/ O
kg O
/ O
day O
up O
to O
40 O
##m O
##g O
/ O
kg O
( O
table O
1 O
, O
s O
##1 O
##a O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
no O
changes O
in O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
##h I-PK
values O
were O
observed O
with O
longer O
duration O
of O
dos O
##ing O
with O
values O
similar O
between O
day O
5 O
and O
day O
10 O
( O
table O
1 O
, O
s O
##1 O
##a O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
at O
2 O
and O
10 O
##m O
##g O
/ O
kg O
single O
dose O
, O
the O
cm B-PK
##ax I-PK
was O
similar O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
days I-PK
57 I-PK
increased O
less O
than O
dose O
proportional O
##ly O
between O
the O
2 O
doses O
( O
table O
1 O
, O
s O
##1 O
##b O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
after O
comparison O
of O
10 O
##m O
##g O
/ O
kg O
single O
dose O
and O
after O
5 O
days O
of O
administration O
, O
no O
increase O
in O
cm B-PK
##ax I-PK
values O
was O
seen O
and O
exposure O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
day I-PK
##5 I-PK
##2 I-PK
) O
increased O
by O
two O
( O
table O
1 O
, O
s O
##1 O
##b O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
120 I-PK
##h I-PK
was O
14 O
% O
of O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
d I-PK
##5 I-PK
##7 I-PK
( O
s O
##1 O
##b O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
the O
mi O
##rta O
##za O
##pine O
serum O
concentration O
versus O
time O
data O
for O
10 O
healthy O
cats O
administered O
a O
fixed O
oral O
1 O
. O
88 O
mg O
dose O
in O
two O
earlier O
studies O
was O
used O
for O
calculation O
of O
drug O
exposure O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
) O
by O
non O
##com O
##par O
##tment O
##al O
methods O
. O
3 O
, O
4 O
the O
resulting O
au B-PK
##c I-PK
values O
were O
found O
to O
be O
normally O
distributed O
by O
q O
– O
q O
plot O
and O
subsequently O
analyzed O
as O
a O
response O
to O
time O
point O
mi O
##rta O
##za O
##pine O
concentration O
values O
as O
predict O
##ors O
by O
best O
subset O
multiple O
linear O
re O
##gression O
. O
[SEP] O
[CLS] O
this O
method O
evaluate O
##s O
all O
single O
time O
points O
as O
well O
as O
all O
possible O
combinations O
of O
multiple O
time O
points O
as O
predict O
##ors O
of O
the O
outcome O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
) O
. O
[SEP] O
[CLS] O
the O
results O
of O
best O
subset O
multiple O
linear O
re O
##gression O
revealed O
that O
using O
2 O
points O
as O
predict O
##ors O
of O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
in I-PK
##finity I-PK
( O
1 O
and O
4 O
hours O
) O
could O
provide O
the O
best O
combination O
of O
statistical O
correlation O
( O
r O
##2 O
= O
0 O
. O
98 O
##9 O
) O
while O
mini O
##mizing O
sample O
number O
and O
time O
post O
##ad O
##mini O
##stra O
##tion O
. O
[SEP] O
[CLS] O
the O
final O
model O
using O
the O
identified O
time O
points O
is O
described O
by O
the O
equation O
##au O
##c O
##0 O
##− O
##in O
##finity O
= O
− O
##12 O
##9 O
+ O
( O
3 O
. O
25 O
##∗ O
##c O
##1 O
##hou O
##r O
) O
+ O
( O
12 O
. O
0 O
##∗ O
##c O
##4 O
##hou O
##rs O
) O
where O
c O
##1 O
hour O
and O
c O
##4 O
hours O
represent O
the O
serum O
concentrations O
at O
1 O
and O
4 O
hours O
, O
respectively O
, O
after O
oral O
administration O
. O
[SEP] O
[CLS] O
this O
equation O
was O
used O
to O
estimate O
au B-PK
##c I-PK
in O
study O
samples O
. O
[SEP] O
[CLS] O
a O
24 O
hours O
time O
point O
was O
included O
when O
possible O
for O
the O
est O
##imation O
of O
elimination B-PK
rate I-PK
( I-PK
k I-PK
##el I-PK
) I-PK
, O
which O
was O
calculated O
with O
the O
4 O
and O
24 O
hours O
time O
points O
using O
the O
equation O
: O
k O
##el O
= O
l O
##n O
( O
c O
##24 O
##hou O
##rs O
/ O
c O
##4 O
##hou O
##rs O
) O
/ O
( O
24 O
##− O
##4 O
) O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
was O
reported O
as O
the O
highest B-PK
measured I-PK
serum I-PK
concentration I-PK
( O
either O
1 O
or O
4 O
hours O
) O
and O
t B-PK
##max I-PK
was O
reported O
as O
the O
time B-PK
point I-PK
corresponding I-PK
to I-PK
the I-PK
highest I-PK
measured I-PK
serum I-PK
concentration I-PK
. O
[SEP] O
[CLS] O
parameters O
compared O
included O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
( I-PK
maximum I-PK
serum I-PK
concentration I-PK
) I-PK
, O
and O
t B-PK
##max I-PK
( I-PK
time I-PK
to I-PK
maximum I-PK
serum I-PK
concentration I-PK
) I-PK
, O
and O
in O
the O
cats O
where O
a O
24 O
hours O
sample O
was O
obtained O
, O
half B-PK
‐ I-PK
life I-PK
. O
[SEP] O
[CLS] O
a O
repeated O
measures O
two O
‐ O
way O
an O
##ova O
was O
used O
to O
compare O
the O
in O
v O
##it O
##ro O
k B-PK
##el I-PK
( O
slope O
of O
the O
line O
in O
least O
squares O
non O
##linear O
re O
##gression O
) O
of O
mi O
##rta O
##za O
##pine O
between O
l O
##d O
cats O
and O
non O
‐ O
l O
##d O
cats O
. O
[SEP] O
[CLS] O
calculation O
of O
the O
in O
v O
##it O
##ro O
half B-PK
‐ I-PK
life I-PK
was O
performed O
by O
dividing O
0 O
. O
69 O
##3 O
by O
the O
in O
v O
##it O
##ro O
k O
##el O
: O
t O
##1 O
/ O
2 O
= O
0 O
. O
69 O
##3 O
/ O
k O
##el O
. O
[SEP] O
[CLS] O
the O
apparent B-PK
intrinsic I-PK
he I-PK
##pa I-PK
##tic I-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
, I-PK
app I-PK
) I-PK
of O
mi O
##rta O
##za O
##pine O
was O
then O
calculated O
using O
the O
in O
v O
##it O
##ro O
half B-PK
‐ I-PK
life I-PK
as O
follows O
: O
[SEP] O
[CLS] O
c O
##lint O
, O
app O
= O
( O
0 O
. O
69 O
##3 O
/ O
in O
v O
##it O
##ro O
t O
##1 O
/ O
2 O
) O
[SEP] O
[CLS] O
there O
was O
a O
statistical O
##ly O
significant O
difference O
in O
t B-PK
##max I-PK
between O
l O
##d O
cats O
and O
age O
‐ O
matched O
control O
cats O
( O
p O
= O
. O
03 O
) O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
was O
not O
significantly O
different O
between O
the O
two O
groups O
; O
however O
, O
the O
calculated O
half B-PK
‐ I-PK
life I-PK
of O
l O
##d O
cats O
was O
significantly O
increased O
( O
p O
< O
. O
00 O
##2 O
) O
compared O
with O
age O
‐ O
matched O
control O
cats O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
when O
liver O
micro O
##some O
##s O
from O
cats O
without O
and O
without O
l O
##d O
were O
in O
##cu O
##bate O
##d O
with O
mi O
##rta O
##za O
##pine O
, O
there O
was O
a O
significant O
difference O
in O
the O
slope O
of O
the O
line O
representing O
the O
rate B-PK
of I-PK
loss I-PK
( I-PK
k I-PK
##el I-PK
) I-PK
of O
mi O
##rta O
##za O
##pine O
between O
l O
##d O
cats O
( O
– O
0 O
. O
00 O
##22 O
min O
##− O
##1 O
, O
c O
##i O
: O
− O
##0 O
. O
00 O
##50 O
to O
0 O
. O
000 O
##5 O
##4 O
min O
##− O
##1 O
) O
and O
cats O
without O
l O
##d O
( O
0 O
. O
01 O
##8 O
##4 O
##9 O
min O
##− O
##1 O
, O
c O
##i O
: O
− O
##0 O
. O
02 O
##5 O
to O
− O
##0 O
. O
01 O
##2 O
min O
##− O
##1 O
; O
p O
= O
. O
00 O
##2 O
; O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
93 O
% O
of O
the O
predicted O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
ratios I-PK
and O
94 O
% O
of O
the O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
ratios I-PK
are O
within O
two O
##fold O
of O
the O
observed O
values O
. O
[SEP] O
[CLS] O
the O
models O
were O
evaluated O
by O
comparison O
of O
concentration O
‐ O
time O
profiles O
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
and O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
values O
resulting O
from O
our O
simulation O
##s O
to O
the O
values O
observed O
during O
clinical O
studies O
. O
[SEP] O
[CLS] O
as O
a O
quantitative O
measure O
of O
the O
descriptive O
and O
predict O
##ive O
performance O
of O
each O
model O
, O
the O
geometric O
mean O
fold O
error O
was O
calculated O
according O
to O
e O
##q O
. O
( O
1 O
) O
: O
( O
1 O
) O
g O
##m O
##fe O
= O
10 O
( O
σ O
| O
log O
##10 O
( O
pre O
##d O
##p O
##k O
##par O
##ame O
##ter O
/ O
o O
##bs O
##p O
##k O
##par O
##ame O
##ter O
) O
| O
) O
/ O
n O
, O
with O
g O
##m O
##fe O
= O
geometric O
mean O
fold O
error O
of O
all O
au B-PK
##c I-PK
or O
cm B-PK
##ax I-PK
predictions O
of O
the O
respective O
model O
, O
pre O
##d O
p O
##k O
parameter O
= O
predicted O
au B-PK
##c I-PK
or O
cm B-PK
##ax I-PK
, O
o O
##bs O
p O
##k O
parameter O
= O
observed O
au B-PK
##c I-PK
or O
cm B-PK
##ax I-PK
, O
and O
n O
= O
number O
of O
studies O
. O
[SEP] O
[CLS] O
the O
d O
##di O
modeling O
performance O
was O
assessed O
by O
comparison O
of O
predicted O
vs O
. O
observed O
victim O
drug O
plasma O
concentration O
‐ O
time O
profiles O
during O
co O
‐ O
administration O
, O
d O
##di O
au B-PK
##c I-PK
ratios I-PK
( O
e O
##q O
. O
( O
2 O
) O
) O
, O
and O
d O
##di O
cm B-PK
##ax I-PK
ratios I-PK
( O
e O
##q O
. O
( O
3 O
) O
) O
: O
( O
2 O
) O
d O
##di O
au O
##c O
ratio O
= O
au O
##c O
##vic O
##ti O
##m O
##dr O
##ug O
##du O
##ring O
##co O
##− O
##ad O
##mini O
##stra O
##tion O
##au O
##c O
##vic O
##ti O
##m O
##dr O
##ug O
( O
3 O
) O
d O
##dic O
##max O
##rat O
##io O
= O
cm O
##ax O
##vic O
##ti O
##m O
##dr O
##ug O
##du O
##ring O
##co O
##− O
##ad O
##mini O
##stra O
##tion O
##c O
##max O
##vic O
##ti O
##m O
##dr O
##ug O
[SEP] O
[CLS] O
as O
a O
quantitative O
measure O
of O
the O
prediction O
accuracy O
of O
each O
d O
##di O
interaction O
, O
g O
##m O
##fe O
##s O
of O
the O
predicted O
d O
##di O
au B-PK
##c I-PK
ratios I-PK
and O
d O
##di O
cm B-PK
##ax I-PK
ratios I-PK
were O
calculated O
according O
to O
e O
##q O
. O
( O
1 O
) O
. O
[SEP] O
[CLS] O
sensitivity O
of O
the O
final O
models O
to O
single O
parameters O
( O
local O
sensitivity O
analysis O
) O
was O
calculated O
, O
measured O
as O
changes O
of O
the O
au B-PK
##c I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( O
for O
single O
‐ O
dose O
administration O
drugs O
) O
or O
of O
the O
au B-PK
##c I-PK
of I-PK
one I-PK
dos I-PK
##ing I-PK
interval I-PK
in I-PK
steady I-PK
‐ I-PK
state I-PK
conditions I-PK
( O
for O
multiple O
‐ O
dose O
administration O
drugs O
) O
of O
a O
simulation O
with O
administration O
of O
the O
highest O
common O
dose O
. O
[SEP] O
[CLS] O
sensitivity O
to O
a O
parameter O
is O
calculated O
as O
the O
ratio O
of O
the O
relative O
change O
of O
the O
simulated O
au B-PK
##c I-PK
to O
the O
relative O
variation O
of O
the O
parameter O
around O
the O
value O
used O
in O
the O
final O
model O
( O
e O
##q O
. O
( O
4 O
) O
) O
: O
( O
4 O
) O
s O
= O
δ O
##au O
##ca O
##uc O
· O
p O
##δ O
##p O
, O
with O
s O
= O
sensitivity O
of O
the O
au B-PK
##c I-PK
to O
the O
examined O
model O
parameter O
, O
δ O
##au O
##c O
= O
change O
of O
the O
au O
##c O
, O
au O
##c O
= O
simulated O
au O
##c O
with O
the O
original O
parameter O
value O
, O
δ O
##p O
= O
change O
of O
the O
examined O
model O
parameter O
value O
, O
and O
p O
= O
original O
model O
parameter O
value O
. O
[SEP] O
[CLS] O
a O
sensitivity O
value O
of O
+ O
1 O
. O
0 O
sign O
##ifies O
that O
a O
10 O
% O
increase O
of O
the O
examined O
parameter O
causes O
a O
10 O
% O
increase O
of O
the O
simulated O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
in O
addition O
, O
predicted O
compared O
to O
observed O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
values O
with O
calculated O
g O
##m O
##fe O
##s O
( O
also O
listed O
in O
tables O
s O
##1 O
##a O
, O
s O
##2 O
##a O
, O
s O
##3 O
##a O
, O
s O
##4 O
##a O
, O
s O
##5 O
##a O
, O
s O
##6 O
##a O
in O
app O
##end O
##ix O
##s O
##1 O
) O
and O
sensitivity O
analysis O
results O
( O
figures O
s O
##1 O
##e O
, O
s O
##2 O
##e O
, O
s O
##3 O
##e O
, O
s O
##4 O
##e O
, O
s O
##5 O
##e O
, O
s O
##6 O
##e O
in O
app O
##end O
##ix O
##s O
##1 O
) O
are O
presented O
. O
[SEP] O
[CLS] O
predicted O
compared O
with O
observed O
d O
##di O
au B-PK
##c I-PK
ratios I-PK
and O
cm B-PK
##ax I-PK
ratios I-PK
with O
calculated O
g O
##m O
##fe O
##s O
for O
each O
per O
##pet O
##rator O
‐ O
victim O
pair O
are O
summarized O
in O
table O
##1 O
. O
[SEP] O
[CLS] O
correlation O
of O
predicted O
to O
observed O
d O
##di O
au B-PK
##c I-PK
ratios I-PK
and O
cm B-PK
##ax I-PK
ratios I-PK
of O
all O
57 O
modeled O
interaction O
studies O
, O
ill O
##ust O
##rating O
the O
performance O
of O
the O
entire O
d O
##di O
network O
, O
is O
presented O
in O
figure O
##5 O
. O
[SEP] O
[CLS] O
the O
objective O
of O
the O
present O
study O
was O
to O
evaluate O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
selective O
his O
##tamine O
( O
h O
##1 O
) O
- O
receptor O
antagonist O
, O
c O
##eti O
##riz O
##ine O
h O
##ydro O
##ch O
##lor O
##ide O
( O
c O
##tz O
) O
, O
following O
administration O
of O
a O
single O
oral O
dose O
of O
the O
drug O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
including O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( I-PK
a I-PK
##bs I-PK
) I-PK
, O
k B-PK
, O
ka B-PK
, O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
v B-PK
##d I-PK
/ I-PK
f I-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
au B-PK
##c I-PK
0 I-PK
- I-PK
∞ I-PK
and O
m B-PK
##rt I-PK
were O
determined O
from O
plasma O
concentration O
- O
time O
profiles O
for O
tested O
products O
and O
found O
to O
be O
in O
good O
agreement O
with O
previous O
reports O
. O
[SEP] O
[CLS] O
the O
confidence O
intervals O
for O
the O
ratio B-PK
of I-PK
cm I-PK
##ax I-PK
( O
95 O
- O
110 O
% O
) O
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
( O
91 O
- O
112 O
% O
) O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
( O
92 O
- O
109 O
% O
) O
for O
the O
test O
and O
reference O
products O
were O
within O
the O
acceptable O
interval O
of O
80 O
- O
125 O
% O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
) I-PK
was O
estimated O
by O
the O
least O
- O
square O
re O
##gression O
of O
plasma O
concentration O
- O
time O
data O
points O
lying O
in O
the O
terminal O
log O
- O
linear O
region O
of O
the O
curves O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
life I-PK
was O
calculated O
as O
0 O
. O
69 O
##3 O
divided O
by O
k B-PK
. O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
at I-PK
time I-PK
t I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
) I-PK
was O
calculated O
using O
the O
trap O
##ez O
##oid O
##al O
rule O
. O
[SEP] O
[CLS] O
the O
area B-PK
was I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
) I-PK
by O
addition O
of O
c B-PK
##t I-PK
/ I-PK
k I-PK
to O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
where O
c B-PK
##t I-PK
is O
the O
last O
measured O
drug O
concentration O
. O
[SEP] O
[CLS] O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
peak I-PK
con I-PK
##ce I-PK
##n I-PK
- I-PK
t I-PK
##ration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
determined O
by O
inspection O
of O
the O
individual O
subject O
concentration O
time O
curves O
. O
[SEP] O
[CLS] O
apparent B-PK
oral I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
and O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
were O
calculated O
by O
e O
##q O
. O
2 O
and O
3 O
, O
respectively O
: O
[SEP] O
[CLS] O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
test O
formulation O
was O
estimated O
as O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
##rat I-PK
##io I-PK
of O
the O
test O
to O
the O
reference O
product O
. O
[SEP] O
[CLS] O
absorption B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
( I-PK
a I-PK
##bs I-PK
) I-PK
) I-PK
was O
calculated O
by O
0 O
. O
69 O
##3 O
/ O
ka O
. O
[SEP] O
[CLS] O
where O
au B-PK
##m I-PK
##c I-PK
is O
the O
area B-PK
under I-PK
the I-PK
first I-PK
moment I-PK
of I-PK
plasma I-PK
drug I-PK
concentration I-PK
. O
[SEP] O
[CLS] O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
, O
the O
average O
time O
for O
all O
the O
drug O
molecules O
to O
reside O
in O
the O
body O
was O
estimated O
according O
to O
the O
following O
equation O
( O
12 O
) O
: O
[SEP] O
[CLS] O
in O
spite O
of O
a O
significant O
difference O
between O
the O
m O
##dt O
and O
f B-PK
values O
of O
the O
two O
products O
, O
the O
drug O
content O
of O
both O
formulation O
##s O
was O
largely O
released O
within O
20 O
min O
. O
[SEP] O
[CLS] O
in O
order O
to O
confirm O
the O
bio O
##e O
##qui O
##vale O
##ncy O
of O
the O
two O
products O
, O
the O
90 O
% O
confidence O
intervals O
for O
arithmetic O
mean O
of O
test O
/ O
reference O
, O
in O
##di O
##vi O
- O
dual O
ratios O
of O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
, O
and O
cm B-PK
##ax I-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
were O
calculated O
. O
[SEP] O
[CLS] O
w O
##il O
##co O
##xon O
signed O
rank O
non O
- O
para O
##metric O
analysis O
did O
not O
reveal O
significant O
differences O
between O
t B-PK
##max I-PK
values O
( O
p O
= O
0 O
. O
137 O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
6 O
, O
the O
para O
##metric O
point O
estimate O
of O
the O
difference O
( O
t O
- O
r O
) O
for O
t B-PK
##max I-PK
is O
0 O
. O
21 O
h O
and O
thus O
within O
the O
s O
##tip O
##ulated O
bio O
##e O
##qui O
##valence O
range O
of O
± O
0 O
. O
35 O
h O
( O
± O
20 O
% O
of O
the O
mean O
of O
the O
reference O
product O
) O
. O
[SEP] O
[CLS] O
no O
significant O
differences O
were O
observed O
between O
the O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
k B-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
v B-PK
##d I-PK
/ I-PK
f I-PK
and O
m B-PK
##rt I-PK
of O
the O
two O
products O
( O
p O
> O
0 O
. O
05 O
) O
, O
however O
we O
observed O
some O
differences O
between O
ka B-PK
##and I-PK
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
ratios I-PK
of O
mid O
##az O
##ola O
##m O
were O
above O
0 O
. O
80 O
, O
indicating O
that O
induction O
of O
c O
##y O
##p O
##3 O
##a O
by O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
administered O
weekly O
is O
unlikely O
to O
occur O
in O
humans O
. O
[SEP] O
[CLS] O
numerous O
mathematical O
models O
have O
been O
developed O
to O
predict O
clinical O
d O
##di O
from O
in O
v O
##it O
##ro O
data O
. O
21 O
, O
22 O
, O
23 O
, O
24 O
the O
simplest O
model O
is O
one O
in O
which O
a O
static O
score O
of O
degree O
of O
induction O
is O
calculated O
from O
the O
average O
plasma O
concentration O
of O
an O
induce O
##r O
using O
in O
v O
##it O
##ro O
half O
‐ O
ma O
##ximal O
effective O
concentration O
and O
maximum B-PK
effect I-PK
( I-PK
em I-PK
##ax I-PK
) I-PK
estimates O
. O
25 O
, O
26 O
, O
27 O
the O
potential O
for O
induction O
‐ O
based O
d O
##dis O
is O
then O
predicted O
based O
upon O
the O
extent O
of O
clearance B-PK
associated O
with O
each O
induced O
enzyme O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
dynamic O
models O
consider O
differences O
in O
the O
levels O
of O
enzyme O
activity O
and O
, O
thus O
, O
clearance B-PK
of O
a O
drug O
as O
a O
result O
of O
increased O
enzyme O
synthesis O
in O
an O
induce O
##r O
‐ O
concentration O
dependent O
manner O
. O
28 O
, O
29 O
, O
30 O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
up I-PK
to I-PK
24 I-PK
hours I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
and O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
the O
probe O
substrates O
after O
administration O
on O
trial O
day O
1 O
or O
15 O
were O
used O
for O
evaluation O
##s O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
per O
##pet O
##rator O
properties O
of O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
regarding O
c O
##y O
##p O
##3 O
##a O
were O
applied O
to O
both O
c O
##y O
##p O
##3 O
##a O
##4 O
and O
c O
##y O
##p O
##3 O
##a O
##5 O
. O
[SEP] O
[CLS] O
standard O
approaches O
, O
as O
outlined O
in O
guidance O
documents O
, O
were O
designed O
as O
a O
worst O
‐ O
case O
approach O
, O
putting O
the O
patient O
safety O
first O
by O
using O
the O
maximum B-PK
concentration I-PK
. O
[SEP] O
[CLS] O
the O
static O
calculation O
indicated O
that O
the O
interaction O
potential O
is O
ne O
##gli O
##gible O
, O
with O
au B-PK
##c I-PK
ratios I-PK
for O
the O
sensitive O
substrate O
de O
##x O
##trom O
##eth O
##or O
##pha O
##n O
of O
1 O
. O
11 O
and O
1 O
. O
000 O
##5 O
based O
on O
im B-PK
##ax I-PK
and O
i B-PK
##av I-PK
, O
respectively O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
ratios O
( O
95 O
% O
c O
##i O
) O
for O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
with O
and O
without O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
were O
1 O
. O
04 O
( O
1 O
. O
03 O
; O
1 O
. O
04 O
) O
, O
and O
1 O
. O
04 O
( O
1 O
. O
03 O
; O
1 O
. O
04 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
sensitivity O
analyses O
showed O
that O
the O
au B-PK
##c I-PK
ratio I-PK
( O
95 O
% O
c O
##i O
) O
both O
at O
half O
the O
measured O
k B-PK
##i I-PK
value O
of O
1 O
. O
07 O
( O
1 O
. O
06 O
; O
1 O
. O
08 O
) O
and O
at O
a O
5 O
‐ O
fold O
increased O
in O
##tra O
##cellular O
concentration O
of O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
1 O
. O
16 O
( O
1 O
. O
13 O
; O
1 O
. O
18 O
) O
were O
well O
below O
the O
threshold O
of O
1 O
. O
25 O
. O
[SEP] O
[CLS] O
the O
results O
shown O
in O
table O
##3 O
indicated O
a O
< O
1 O
% O
change O
in O
both O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
values O
following O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
administration O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
ratios I-PK
stayed O
below O
1 O
. O
02 O
for O
all O
simulated O
scenarios O
, O
including O
sensitivity O
analyses O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
ratios I-PK
also O
stayed O
below O
1 O
. O
02 O
for O
repeat O
dos O
##ing O
of O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
, O
in O
which O
c O
##y O
##p O
##2 O
##b O
##6 O
was O
only O
minimal O
##ly O
in O
##hibit O
##ed O
. O
[SEP] O
[CLS] O
more O
than O
99 O
. O
5 O
% O
of O
is O
##oz O
##yme O
remained O
active O
, O
leading O
to O
b O
##up O
##rop O
##ion O
au B-PK
##c I-PK
ratios I-PK
of O
1 O
. O
00 O
( O
1 O
. O
00 O
; O
1 O
. O
00 O
) O
, O
indicating O
a O
lack O
of O
potential O
in O
##hibition O
of O
c O
##y O
##p O
##2 O
##b O
##6 O
by O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
in O
the O
clinic O
. O
[SEP] O
[CLS] O
static O
modeling O
predicted O
au B-PK
##c I-PK
ratios I-PK
above O
the O
threshold O
of O
1 O
. O
25 O
; O
the O
values O
are O
presented O
in O
table O
##4 O
. O
[SEP] O
[CLS] O
no O
in O
##hibition O
by O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
was O
predicted O
for O
c O
##y O
##p O
##3 O
##a O
##4 O
/ O
5 O
with O
au B-PK
##c I-PK
ratios I-PK
close O
to O
unity O
( O
table O
##3 O
) O
. O
[SEP] O
[CLS] O
sensitivity O
analyses O
for O
k B-PK
##i I-PK
( O
direct O
in O
##hibition O
) O
, O
and O
ka B-PK
##pp I-PK
and O
kin B-PK
##act I-PK
( O
mechanism O
‐ O
based O
in O
##hibition O
( O
m O
##bi O
) O
) O
showed O
au B-PK
##c I-PK
ratios I-PK
below O
1 O
. O
10 O
, O
which O
is O
well O
below O
the O
threshold O
of O
1 O
. O
25 O
for O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
to O
be O
considered O
as O
a O
weak O
inhibitor O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
ratios I-PK
( O
table O
##3 O
) O
of O
mid O
##az O
##ola O
##m O
are O
near O
unity O
and O
well O
above O
the O
threshold O
of O
0 O
. O
80 O
for O
consideration O
of O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
as O
a O
weak O
induce O
##r O
of O
c O
##y O
##p O
##3 O
##a O
. O
[SEP] O
[CLS] O
the O
sensitivity O
analyses O
yielded O
au B-PK
##c I-PK
ratios I-PK
( O
95 O
% O
c O
##i O
) O
of O
0 O
. O
82 O
( O
0 O
. O
80 O
; O
0 O
. O
85 O
) O
assuming O
2 O
‐ O
fold O
higher O
in O
##d O
##max O
and O
0 O
. O
88 O
( O
0 O
. O
86 O
; O
0 O
. O
90 O
) O
assuming O
2 O
‐ O
fold O
lower O
in O
##d O
##c O
##50 O
, O
and O
are O
, O
therefore O
, O
above O
the O
regulatory O
threshold O
of O
0 O
. O
80 O
in O
the O
sensitivity O
analyses O
regarding O
the O
induction O
parameters O
. O
[SEP] O
[CLS] O
published O
work O
suggests O
that O
the O
clearance B-PK
of O
end O
##ogen O
##ous O
a O
##po O
##a O
- O
i O
may O
be O
accelerated O
in O
patients O
with O
risk O
factors O
for O
ch O
##d O
. O
13 O
more O
importantly O
, O
several O
authors O
have O
reported O
that O
the O
h O
##dl O
from O
patients O
with O
ch O
##d O
may O
have O
impaired O
functionality O
and O
have O
further O
speculated O
that O
the O
physiological O
status O
of O
these O
patients O
may O
alter O
the O
h O
##dl O
to O
render O
it O
less O
functional O
or O
even O
d O
##ys O
##function O
##al O
. O
14 O
for O
example O
, O
h O
##dl O
pu O
##rified O
from O
patients O
with O
stable O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
exhibits O
lower O
c O
##ec O
than O
that O
from O
healthy O
subjects O
even O
after O
normal O
##ization O
for O
protein O
or O
ch O
##ole O
##ster O
##ol O
content O
. O
15 O
, O
16 O
recent O
work O
using O
both O
animal O
and O
human O
subjects O
suggests O
that O
the O
function O
of O
h O
##dl O
may O
be O
impaired O
by O
the O
action O
of O
serum O
am O
##yl O
##oid O
a O
, O
an O
h O
##dl O
- O
associated O
serum O
protein O
that O
is O
up O
##re O
##gu O
##lated O
in O
acute O
co O
##rona O
##ry O
syndrome O
, O
ch O
##d O
, O
and O
any O
condition O
that O
pro O
##voke O
##s O
a O
he O
##pa O
##tic O
acute O
phase O
response O
. O
17 O
, O
18 O
it O
is O
thus O
possible O
that O
the O
amount O
or O
functional O
activity O
of O
c O
##s O
##l O
##11 O
##2 O
might O
be O
altered O
in O
patients O
with O
card O
##iovascular O
disease O
. O
[SEP] O
[CLS] O
in O
addition O
, O
subjects O
were O
s O
##tra O
##ti O
##fied O
in O
equal O
proportions O
to O
have O
normal O
re O
##nal O
function O
( O
c O
##rea O
##tin O
##ine O
clearance O
≥ O
##90 O
m O
##l O
/ O
min O
) O
or O
mild O
re O
##nal O
imp O
##air O
##ment O
( O
c O
##rea O
##tin O
##ine O
clearance O
≥ O
##60 O
and O
< O
90 O
m O
##l O
/ O
min O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
parameters O
for O
base O
##line O
- O
corrected O
plasma O
concentrations O
of O
a O
##po O
##a O
- O
i O
were O
determined O
after O
single O
and O
multiple O
in O
##tra O
##ven O
##ous O
in O
##fusion O
##s O
of O
c O
##s O
##l O
##11 O
##2 O
and O
included O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
point I-PK
zero I-PK
( I-PK
before I-PK
dos I-PK
##ing I-PK
) I-PK
to I-PK
the I-PK
last I-PK
time I-PK
point I-PK
above I-PK
base I-PK
##line I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
last I-PK
) I-PK
, O
maximum B-PK
plasma I-PK
concentration I-PK
, O
and O
half B-PK
- I-PK
life I-PK
. O
[SEP] O
[CLS] O
a O
2 O
- O
compartment O
in O
##tra O
##ven O
##ous O
model O
para O
##met O
##riz O
##ed O
in O
terms O
of O
elimination B-PK
clearance I-PK
, O
central B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##c I-PK
) I-PK
, O
inter B-PK
##com I-PK
##par I-PK
##tment I-PK
##al I-PK
clearance I-PK
( I-PK
q I-PK
) I-PK
, O
peripheral B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##p I-PK
) I-PK
, O
and O
base O
##line O
a O
##po O
##a O
- O
i O
serum O
concentration O
. O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##dynamic O
parameters O
were O
assessed O
: O
area O
under O
the O
effect O
curve O
for O
time O
point O
zero O
to O
the O
time O
point O
of O
the O
last O
q O
##uant O
##ifiable O
concentration O
/ O
activity O
( O
au O
##ec O
##0 O
– O
last O
) O
, O
maximum B-PK
bio I-PK
##mark I-PK
##er I-PK
concentration I-PK
/ I-PK
activity I-PK
( I-PK
r I-PK
##max I-PK
) I-PK
, O
and O
time B-PK
to I-PK
reach I-PK
maximum I-PK
concentration I-PK
/ I-PK
activity I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
. O
[SEP] O
[CLS] O
comparison O
of O
the O
relationship O
of O
total O
c O
##ec O
au O
##ec O
##0 O
– O
24 O
, O
pre O
– O
β O
##1 O
- O
h O
##dl O
au O
##ec O
##0 O
– O
24 O
, O
and O
h O
##dl O
- O
c O
au O
##ec O
##0 O
##─ O
##7 O
##2 O
versus O
a O
##po O
##a O
- O
i O
au B-PK
##c I-PK
between O
studies O
was O
done O
using O
random O
effects O
re O
##gression O
models O
with O
patient O
as O
the O
random O
effect O
and O
testing O
the O
parallel O
##ism O
of O
slopes O
hypothesis O
. O
[SEP] O
[CLS] O
c O
##s O
##l O
##11 O
##2 O
p O
##har O
##ma O
##co O
##kin O
##etics O
parameters O
were O
, O
therefore O
, O
determined O
from O
base O
##line O
- O
corrected O
plasma O
concentrations O
of O
a O
##po O
##a O
- O
i O
. O
as O
previously O
reported O
in O
healthy O
subjects O
##19 O
and O
patients O
with O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
, O
12 O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
a O
##po O
##a O
- O
i O
is O
characterized O
by O
dose O
- O
dependent O
increases O
in O
concentration O
( O
t B-PK
##max I-PK
≈ O
##2 O
hours O
) O
and O
a O
slow O
elimination O
( O
figure O
1 O
##a O
) O
. O
[SEP] O
[CLS] O
after O
accounting O
for O
the O
effect O
of O
body O
weight O
on O
a O
##po O
##a O
- O
i O
clearance B-PK
in O
the O
model O
, O
there O
was O
no O
significant O
effect O
of O
population O
( O
healthy O
subject O
versus O
patients O
with O
stable O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
) O
or O
other O
demographic O
##s O
that O
were O
tested O
in O
the O
model O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
a O
##po O
##a O
- O
i O
( O
manuscript O
in O
preparation O
) O
. O
22 O
this O
is O
further O
demonstrated O
in O
figure O
1 O
##b O
, O
which O
shows O
the O
similar O
model O
predicted O
exposure O
( O
au B-PK
##c I-PK
, I-PK
0 I-PK
– I-PK
48 I-PK
hours I-PK
) O
in O
healthy O
subjects O
and O
patients O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
that O
the O
presence O
of O
stable O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
does O
not O
affect O
the O
clearance B-PK
of O
in O
##fused O
c O
##s O
##l O
##11 O
##2 O
, O
its O
interaction O
with O
end O
##ogen O
##ous O
h O
##dl O
, O
or O
the O
formation O
of O
pre O
– O
β O
##1 O
- O
h O
##dl O
. O
[SEP] O
[CLS] O
a O
similar O
pattern O
was O
seen O
also O
in O
both O
phase O
1 O
studies O
. O
10 O
to O
enable O
comparison O
between O
patients O
with O
stable O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
and O
healthy O
subjects O
from O
2 O
prior O
phase O
1 O
studies O
, O
h O
##dl O
- O
c O
au O
##ec O
##0 O
– O
72 O
versus O
a O
##po O
##a O
- O
i O
au B-PK
##c I-PK
##0 I-PK
– I-PK
72 I-PK
was O
plot O
##ted O
. O
[SEP] O
[CLS] O
analysis O
of O
the O
total O
c O
##ec O
au O
##ec O
##0 O
– O
24 O
versus O
a O
##po O
##a O
- O
i O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
( O
figure O
4 O
##c O
) O
as O
well O
as O
a O
##b O
##ca O
##1 O
- O
dependent O
and O
a O
##b O
##ca O
##1 O
- O
independent O
c O
##ec O
( O
data O
not O
shown O
) O
showed O
these O
elevations O
to O
be O
linear O
dose O
dependent O
in O
all O
3 O
study O
populations O
. O
[SEP] O
[CLS] O
the O
evidence O
of O
thee O
##x O
##pect O
##ed O
model O
was O
calculated O
by O
analyzing O
the O
p O
##hi O
( O
f O
) O
and O
ps O
##i O
( O
? O
) O
to O
##rs O
##ion O
angles O
using O
pro O
##che O
##ck O
online O
server O
. O
[SEP] O
[CLS] O
discovery O
studio O
3 O
. O
5 O
( O
a O
##cc O
##el O
##ry O
##s O
sa O
##n O
die O
##go O
, O
us O
##a O
) O
was O
used O
to O
##generate O
ad O
##met O
values O
. O
[SEP] O
[CLS] O
thus O
, O
in O
as O
##ili O
##con O
profile O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
selected O
compounds O
were O
##eval O
##uated O
for O
put O
##ative O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
c O
##rz O
##1 O
inhibitor O
##s O
( O
table O
2 O
) O
. O
lip O
##op O
##hil O
##icit O
##y O
( O
c O
##log O
##p O
) O
, O
p O
##hy O
##si O
##co O
##chemical O
properties O
, O
polar O
surface O
##are O
##a O
, O
molecular O
weight O
( O
m O
##w O
) O
and O
primarily O
a O
##que O
##ous O
so O
##lub O
##ility O
( O
logs O
) O
are O
linear O
##ly O
connected O
to O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
absorption O
of O
##dr O
##ug O
molecule O
37 O
, O
38 O
. O
[SEP] O
[CLS] O
along O
with O
p O
value O
( O
lip O
##op O
##hil O
##icit O
##y O
) O
is O
a O
significant O
property O
for O
calculating O
per O
##oral O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
them O
##ole O
##cule O
##s O
of O
the O
drug O
. O
[SEP] O
[CLS] O
the O
##com O
##po O
##und O
73 O
##17 O
##0 O
also O
interact O
##s O
with O
the O
c O
##rz O
##1 O
binding O
site O
by O
##int O
##era O
##cting O
with O
other O
residues O
( O
le O
##u O
##28 O
, O
le O
##u O
##32 O
, O
t O
##yr O
##39 O
, O
th O
##r O
##40 O
, O
pro O
##41 O
, O
pro O
##5 O
##8 O
, O
pro O
##7 O
##1 O
, O
g O
##ly O
##7 O
##4 O
, O
a O
##rg O
##8 O
##1 O
, O
as O
##n O
##24 O
##1 O
, O
t O
##yr O
##24 O
##4 O
, O
pro O
##24 O
##5 O
, O
v O
##al O
##25 O
##0 O
, O
pro O
##26 O
##0 O
, O
and O
as O
##n O
##26 O
##1 O
) O
as O
compared O
to O
flu O
##dio O
##xon O
##il O
shown O
in O
figure O
##4 O
##b O
. O
[SEP] O
[CLS] O
protein O
- O
l O
##igan O
##ds O
relationships O
##p O
##ro O
##fi O
##le O
unveiled O
that O
the O
inhibitor O
##s O
of O
compounds O
are O
found O
to O
be O
##most O
##ly O
reaching O
to O
the O
active O
site O
residues O
of O
c O
##rz O
##1 O
like O
as O
##p O
##35 O
, O
his O
##36 O
, O
his O
##4 O
##9 O
, O
t O
##yr O
##6 O
##1 O
, O
g O
##lu O
##25 O
, O
th O
##r O
##27 O
, O
g O
##ln O
##60 O
, O
pro O
##26 O
##0 O
, O
as O
##n O
##26 O
##1 O
, O
as O
##n O
##12 O
##8 O
, O
g O
##ln O
##15 O
##6 O
, O
pro O
##7 O
##1 O
, O
a O
##rg O
##8 O
##1 O
, O
g O
##ly O
##7 O
##4 O
and O
associated O
with O
hydrogen O
##bon O
##ding O
with O
bond O
distance O
lies O
within O
the O
range O
of O
4 O
a O
( O
table O
1 O
) O
. O
alpha O
am O
##yr O
##in O
( O
73 O
##17 O
##0 O
) O
was O
found O
to O
be O
most O
potent O
and O
nicely O
##bound O
##ed O
into O
the O
active O
site O
of O
c O
##rz O
##1 O
with O
minimum O
binding O
energy O
( O
delta O
##g O
) O
- O
9 O
. O
8 O
k O
##cal O
/ O
m O
##ol O
as O
compared O
to O
flu O
##dio O
##xon O
##il O
( O
table O
3 O
and O
( O
figure O
##4 O
##a O
) O
. O
[SEP] O
[CLS] O
t O
##ps O
##a O
and O
the O
value O
of O
lip O
##op O
##hil O
##icit O
##y O
( O
log O
##p O
) O
are O
the O
two O
essential O
##p O
##roper O
##ties O
in O
analyzing O
per B-PK
##oral I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
drug O
molecule O
. O
[SEP] O
[CLS] O
for O
the O
compounds O
with O
= O
ten O
rot O
##ata O
##ble O
bonds O
and O
##als O
##o O
t O
##ps O
##a O
of O
≤ O
140 O
a O
can O
be O
said O
to O
have O
good O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
46 O
. O
[SEP] O
[CLS] O
t O
##ps O
##a O
of O
all O
l O
##igan O
##ds O
exhibited O
20 O
. O
23 O
a O
to O
##14 O
##0 O
a O
ranges O
, O
which O
indicates O
good O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
by O
oral O
route O
##ex O
##ce O
##pt O
ka O
##em O
##fer O
##ol O
, O
c O
##yan O
##id O
##in O
3 O
, O
5 O
g O
##lu O
##cos O
##ide O
, O
and O
que O
##rc O
##eti O
##n O
. O
[SEP] O
[CLS] O
a O
two O
- O
compartment O
##al O
model O
with O
first O
- O
order O
absorption O
and O
elimination O
, O
with O
clearance B-PK
dependent O
on O
weight O
adequately O
described O
the O
p O
##k O
of O
r O
##up O
##ata O
##dine O
for O
6 O
– O
11 O
year O
olds O
. O
[SEP] O
[CLS] O
the O
tested O
models O
were O
described O
in O
terms O
of O
volume B-PK
of I-PK
distribution I-PK
of I-PK
the I-PK
central I-PK
compartment I-PK
( I-PK
v I-PK
##c I-PK
/ I-PK
f I-PK
) I-PK
; O
volume B-PK
of I-PK
distribution I-PK
of I-PK
the I-PK
peripheral I-PK
compartment I-PK
( I-PK
v I-PK
##p I-PK
/ I-PK
f I-PK
) I-PK
; O
total B-PK
body I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
; O
inter B-PK
##com I-PK
##par I-PK
##tment I-PK
##al I-PK
clearance I-PK
( I-PK
c I-PK
##ld I-PK
/ I-PK
f I-PK
) I-PK
; O
and O
the O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
inclusion O
of O
absorption B-PK
la I-PK
##g I-PK
time I-PK
( I-PK
t I-PK
##lag I-PK
) I-PK
was O
evaluated O
in O
order O
to O
help O
adjust O
the O
model O
to O
the O
data O
in O
the O
absorption O
phase O
. O
[SEP] O
[CLS] O
the O
two O
- O
compartment O
model O
with O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
c B-PK
##l I-PK
and O
v B-PK
provided O
a O
significant O
decrease O
of O
13 O
points O
in O
the O
of O
compared O
to O
the O
model O
with O
a O
single O
compartment O
of O
disposition O
( O
p O
< O
0 O
. O
00 O
##5 O
) O
and O
predictions O
that O
were O
closer O
to O
the O
observations O
. O
[SEP] O
[CLS] O
although O
an O
all O
##ometric O
s O
##cal O
##ing O
model O
was O
tested O
, O
the O
function O
that O
best O
described O
the O
weight O
– O
c B-PK
##l I-PK
/ I-PK
f I-PK
relationship O
was O
a O
linear O
model O
( O
equation O
below O
) O
. O
c O
##li O
= O
θ O
##1 O
+ O
θ O
##2 O
* O
( O
weight O
/ O
38 O
. O
5 O
) O
[SEP] O
[CLS] O
b O
##mi O
was O
tested O
for O
significance O
in O
non O
##me O
##m O
, O
but O
no O
clear O
improvement O
of O
the O
model O
was O
detected O
respect O
to O
the O
base O
model O
( O
of O
##v O
= O
- O
114 O
vs O
- O
112 O
, O
p O
> O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
incorporation O
of O
weight O
into O
the O
r O
##up O
##ata O
##dine O
clearance O
model O
decreased O
the O
value O
of O
the O
of O
in O
3 O
points O
( O
p O
= O
0 O
. O
08 O
) O
, O
generally O
improved O
the O
est O
##imation O
errors O
with O
respect O
to O
the O
base O
model O
and O
explained O
11 O
. O
1 O
% O
of O
the O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
c B-PK
##l I-PK
/ I-PK
f I-PK
. O
when O
the O
influence O
of O
weight O
on O
v B-PK
/ I-PK
f I-PK
was O
evaluated O
, O
the O
results O
argued O
against O
its O
inclusion O
in O
the O
model O
. O
[SEP] O
[CLS] O
when O
age O
was O
included O
in O
the O
v B-PK
/ I-PK
f I-PK
model O
as O
un O
##iva O
##ria O
##te O
, O
there O
was O
no O
change O
in O
the O
of O
and O
it O
was O
deemed O
appropriate O
to O
exclude O
age O
from O
the O
final O
model O
following O
the O
criterion O
of O
simplicity O
. O
[SEP] O
[CLS] O
the O
mean O
maximum B-PK
blood I-PK
concentration I-PK
and O
half B-PK
- I-PK
life I-PK
of O
g O
- O
c O
##e O
##6 O
( O
2 O
mg O
/ O
kg O
) O
were O
15 O
. O
19 O
± O
4 O
. O
44 O
μ O
##g O
/ O
m O
##l O
and O
3 O
. O
02 O
± O
0 O
. O
58 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
the O
2 O
mg O
/ O
kg O
group O
( O
n O
= O
6 O
) O
, O
mean O
cm B-PK
##ax I-PK
= O
15 O
. O
19 O
± O
4 O
. O
44 O
μ O
##g O
/ O
m O
##l O
; O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
3 O
. O
02 O
± O
0 O
. O
58 O
h O
; O
mean O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
= O
12 O
. O
03 O
± O
3 O
. O
18 O
μ O
##g O
/ O
m O
##l O
· O
h O
; O
mean O
c B-PK
##l I-PK
= O
175 O
. O
9 O
± O
45 O
. O
68 O
m O
##l O
/ O
[UNK] O
; O
and O
v B-PK
##ds I-PK
##s I-PK
= O
52 O
##9 O
. O
19 O
± O
188 O
. O
67 O
m O
##l O
/ O
kg O
. O
[SEP] O
[CLS] O
at O
24 O
h O
after O
the O
5 O
- O
min O
- O
interval O
p O
##dt O
, O
widespread O
tumor O
cells O
appeared O
ne O
##c O
##rot O
##ic O
, O
and O
fi O
##bri O
##n O
th O
##rom O
##bus O
formation O
within O
the O
vessels O
was O
observed O
in O
the O
surrounding O
normal O
sub O
##cut O
##aneous O
tissues O
( O
figure O
14 O
##b O
, O
e O
) O
. O
[SEP] O
[CLS] O
at O
24 O
h O
after O
the O
3 O
- O
h O
- O
interval O
p O
##dt O
, O
cells O
at O
the O
superficial O
tumor O
tissue O
appeared O
ne O
##c O
##rot O
##ic O
, O
whereas O
deep O
- O
seated O
tumor O
cells O
appeared O
intact O
( O
figure O
14 O
##c O
, O
f O
) O
. O
[SEP] O
[CLS] O
in O
the O
5 O
mg O
/ O
kg O
group O
( O
n O
= O
6 O
) O
, O
mean O
cm B-PK
##ax I-PK
= O
46 O
. O
99 O
± O
12 O
. O
22 O
μ O
##g O
/ O
m O
##l O
; O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
2 O
. O
84 O
± O
0 O
. O
60 O
h O
; O
mean O
au B-PK
##c I-PK
= O
59 O
. O
66 O
± O
7 O
. O
87 O
μ O
##g O
/ O
m O
##l O
· O
h O
; O
mean O
c B-PK
##l I-PK
= O
84 O
. O
75 O
± O
10 O
. O
73 O
m O
##l O
/ O
[UNK] O
; O
and O
v B-PK
##ds I-PK
##s I-PK
= O
258 O
. O
11 O
± O
65 O
. O
57 O
m O
##l O
/ O
kg O
. O
[SEP] O
[CLS] O
in O
the O
20 O
mg O
/ O
kg O
group O
( O
n O
= O
1 O
) O
, O
cm B-PK
##ax I-PK
= O
82 O
. O
05 O
μ O
##g O
/ O
m O
##l O
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
2 O
. O
51 O
h O
; O
au B-PK
##c I-PK
= O
234 O
. O
75 O
μ O
##g O
/ O
m O
##l O
· O
h O
; O
c B-PK
##l I-PK
= O
85 O
. O
2 O
m O
##l O
/ O
[UNK] O
; O
and O
v B-PK
##ds I-PK
##s I-PK
= O
28 O
##4 O
. O
40 O
m O
##l O
/ O
kg O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
after O
in O
##tra O
##ven O
##ous O
administration O
of O
g O
- O
c O
##e O
##6 O
at O
a O
dose O
of O
2 O
mg O
/ O
kg O
to O
healthy O
be O
##ag O
##le O
dogs O
, O
drug O
distribution O
occurred O
in O
the O
first O
hour O
, O
followed O
by O
an O
elimination O
phase O
with O
a O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
3 O
. O
02 O
± O
0 O
. O
58 O
h O
; O
the O
au B-PK
##c I-PK
of O
g O
- O
c O
##e O
##6 O
at O
a O
dose O
of O
2 O
mg O
/ O
kg O
was O
12 O
. O
03 O
± O
3 O
. O
18 O
μ O
##g O
/ O
m O
##l O
· O
h O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
au B-PK
##c I-PK
of O
p O
##orf O
##ime O
##r O
sodium O
were O
44 O
. O
22 O
± O
8 O
. O
10 O
h O
and O
167 O
##0 O
. O
2 O
± O
71 O
. O
6 O
μ O
##g O
/ O
[UNK] O
, O
respectively O
[ O
39 O
] O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
as O
follows O
: O
half O
- O
life O
( O
t O
##1 O
/ O
2 O
) O
= O
l O
##n O
2 O
/ O
β O
, O
where O
β O
is O
the O
slope O
of O
the O
elimination O
phase O
; O
volume O
of O
distribution O
at O
steady O
state O
( O
v O
##ds O
##s O
) O
= O
dose O
( O
a O
/ O
α O
##2 O
+ O
b O
/ O
β O
##2 O
) O
/ O
( O
( O
a O
/ O
α O
) O
+ O
( O
b O
/ O
β O
) O
) O
2 O
, O
where O
a O
and O
b O
are O
the O
intercept O
##s O
of O
the O
distribution O
and O
elimination O
phases O
, O
respectively O
; O
α O
is O
the O
slope O
of O
the O
distribution O
phase O
; O
and O
clearance O
( O
c O
##l O
) O
= O
dose O
/ O
au O
##c O
, O
where O
au O
##c O
is O
the O
area O
under O
the O
curve O
, O
which O
was O
calculated O
using O
the O
trap O
##ez O
##oid O
##al O
method O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
showed O
that O
the O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
au B-PK
##c I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
and O
m B-PK
##rt I-PK
of O
the O
major O
compounds O
of O
different O
extracted O
parts O
were O
significantly O
different O
in O
rat O
plasma O
at O
same O
dos O
##age O
. O
[SEP] O
[CLS] O
the O
results O
showed O
that O
the O
cm B-PK
##ax I-PK
of O
h O
##d O
##p O
group O
was O
significantly O
higher O
, O
and O
m B-PK
##rt I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
were O
less O
than O
the O
te O
group O
. O
[SEP] O
[CLS] O
the O
dos O
##age O
of O
em O
##od O
##in O
in O
cap O
group O
was O
much O
lower O
than O
that O
in O
the O
total O
part O
and O
f O
##ap O
groups O
, O
but O
the O
cm B-PK
##ax I-PK
was O
much O
higher O
than O
those O
in O
the O
plasma O
after O
administration O
. O
[SEP] O
[CLS] O
first O
, O
the O
dos O
##age O
of O
em O
##od O
##in O
in O
f O
##ap O
group O
was O
similar O
to O
the O
te O
group O
, O
but O
the O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
were O
significantly O
lower O
than O
those O
in O
the O
te O
group O
. O
[SEP] O
[CLS] O
second O
, O
the O
dos O
##age O
of O
em O
##od O
##in O
in O
cap O
group O
was O
only O
0 O
. O
23 O
mg O
/ O
kg O
, O
but O
the O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
were O
much O
higher O
than O
those O
in O
the O
d O
##c O
##m O
group O
. O
[SEP] O
[CLS] O
third O
, O
the O
numerical O
value O
of O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
were O
the O
sum O
of O
h O
##d O
##p O
, O
cap O
, O
and O
f O
##ap O
groups O
. O
[SEP] O
[CLS] O
according O
to O
the O
dose O
and O
concentrations O
in O
rat O
plasma O
, O
the O
ed O
##g O
in O
these O
three O
groups O
might O
have O
a O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
fast O
elimination O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ed O
##g O
might O
be O
low O
and O
elimination O
was O
fast O
in O
rats O
after O
administration O
of O
these O
three O
extract O
##s O
, O
and O
the O
concentration O
point O
data O
in O
rat O
plasma O
are O
incomplete O
. O
[SEP] O
[CLS] O
to O
compare O
the O
time O
to O
parasite O
clearance B-PK
between O
sa O
##m O
and O
non O
- O
sa O
##m O
children O
[SEP] O
[CLS] O
in O
addition O
, O
the O
determination O
of O
parasite O
clearance B-PK
time O
will O
involve O
extra O
blood O
films O
at O
h O
##6 O
, O
h O
##12 O
, O
h O
##36 O
. O
[SEP] O
[CLS] O
as O
an O
alternative O
, O
the O
parasite O
clearance B-PK
will O
be O
determined O
in O
all O
patients O
, O
as O
it O
is O
considered O
the O
best O
indicator O
of O
impaired O
efficacy O
of O
the O
art O
##em O
##isi O
##nin O
component O
of O
an O
act O
[ O
30 O
] O
. O
[SEP] O
[CLS] O
a O
prolonged O
parasite O
clearance B-PK
in O
children O
with O
sa O
##m O
would O
support O
an O
impaired O
efficacy O
of O
art O
##em O
##eth O
##er O
, O
one O
possible O
cause O
being O
inadequate O
exposure O
to O
art O
##em O
##isi O
##nin O
##s O
. O
[SEP] O
[CLS] O
on O
the O
other O
hand O
, O
an O
un O
##altered O
clearance B-PK
would O
suggest O
that O
art O
##em O
##isi O
##nin O
exposure O
and O
efficacy O
is O
adequate O
. O
[SEP] O
[CLS] O
the O
data O
safety O
monitoring O
board O
( O
d O
##sm O
##b O
) O
will O
have O
the O
responsibility O
to O
monitor O
closely O
parasite O
clearance B-PK
data O
, O
and O
to O
recommend O
a O
protocol O
amendment O
adding O
art O
##em O
##eth O
##er O
p O
##k O
assessment O
if O
deemed O
necessary O
. O
[SEP] O
[CLS] O
secondary O
outcomes O
are O
: O
regarding O
treatment O
[UNK] O
corrected O
a O
##c O
##p O
##r O
proportion O
on O
day O
[UNK] O
failure O
proportion O
by O
type O
( O
et O
##f O
, O
l O
##c O
##f O
, O
l O
##pf O
) O
by O
day O
28 O
and O
42 O
, O
as O
defined O
by O
who O
[ O
14 O
] O
[UNK] O
proportion O
of O
re O
##in O
##fect O
##ion O
and O
[UNK] O
time O
to O
parasite O
clearance B-PK
and O
parasite O
clearance B-PK
half I-PK
- I-PK
life I-PK
##regard I-PK
##ing I-PK
p O
##k O
of O
[UNK] O
area B-PK
under I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
other O
p O
##k O
parameters O
( O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
clearance B-PK
, O
volume B-PK
of I-PK
distribution I-PK
) O
[UNK] O
concentration O
on O
day O
[UNK] O
concentration O
on O
day O
of O
failure O
( O
in O
case O
of O
failure O
) O
regarding O
[UNK] O
type O
and O
frequency O
of O
adverse O
events O
[SEP] O
[CLS] O
regarding O
treatment O
[UNK] O
corrected O
a O
##c O
##p O
##r O
proportion O
on O
day O
[UNK] O
failure O
proportion O
by O
type O
( O
et O
##f O
, O
l O
##c O
##f O
, O
l O
##pf O
) O
by O
day O
28 O
and O
42 O
, O
as O
defined O
by O
who O
[ O
14 O
] O
[UNK] O
proportion O
of O
re O
##in O
##fect O
##ion O
and O
[UNK] O
time O
to O
parasite O
clearance B-PK
and O
parasite O
clearance B-PK
half I-PK
- I-PK
life I-PK
[SEP] O
[CLS] O
[UNK] O
time O
to O
parasite O
clearance B-PK
and O
parasite O
clearance B-PK
half I-PK
- I-PK
life I-PK
[SEP] O
[CLS] O
regarding O
p O
##k O
of O
[UNK] O
area B-PK
under I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
other O
p O
##k O
parameters O
( O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
clearance B-PK
, O
volume B-PK
of I-PK
distribution I-PK
) O
[UNK] O
concentration O
on O
day O
[UNK] O
concentration O
on O
day O
of O
failure O
( O
in O
case O
of O
failure O
) O
[SEP] O
[CLS] O
[UNK] O
area B-PK
under I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
other O
p O
##k O
parameters O
( O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
clearance B-PK
, O
volume B-PK
of I-PK
distribution I-PK
) O
[SEP] O
[CLS] O
p O
##k O
modeling O
will O
estimate O
the O
l O
##ume O
##fant O
##rine O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
volume B-PK
of I-PK
distribution I-PK
and O
clearance B-PK
in O
sa O
##m O
and O
non O
- O
sa O
##m O
children O
using O
non O
##linear O
mixed O
effect O
models O
( O
non O
##ne O
##m O
) O
. O
[SEP] O
[CLS] O
re O
##gression O
models O
of O
the O
log O
- O
transformed O
parasite O
counts O
will O
be O
fitted O
in O
order O
to O
estimate O
parasite O
clearance O
using O
the O
parasite O
clearance O
est O
##imator O
tool O
( O
p O
##ce O
) O
developed O
by O
the O
worldwide O
anti O
##mal O
##aria O
##l O
resistance O
network O
( O
w O
##war O
##n O
) O
[ O
30 O
] O
. O
[SEP] O
[CLS] O
parasite O
clearance O
will O
be O
compared O
between O
groups O
of O
sa O
##m O
and O
non O
- O
sa O
##m O
children O
on O
a O
regular O
basis O
during O
the O
study O
. O
[SEP] O
[CLS] O
the O
reliability O
of O
the O
model O
was O
tested O
against O
published O
clinical O
studies O
monitoring O
different O
inhibitor O
##s O
and O
dose O
regime O
##ns O
, O
and O
all O
predicted O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
ratios I-PK
were O
within O
the O
two O
##fold O
acceptance O
range O
. O
[SEP] O
[CLS] O
it O
has O
a O
significantly O
higher O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
between O
42 O
and O
87 O
% O
) O
than O
m O
##or O
##phine O
with O
an O
estimated O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
range O
of O
22 O
– O
48 O
% O
. O
1 O
the O
complete O
metabolism O
of O
o O
##xy O
##co O
##don O
##e O
has O
not O
yet O
been O
defined O
. O
[SEP] O
[CLS] O
lo O
##pina O
##vir O
/ O
r O
##ito O
##na O
##vir O
treatment O
increased O
the O
au B-PK
##c I-PK
of O
o O
##xy O
##mor O
##phone O
by O
about O
two O
##fold O
and O
both O
treatments O
led O
to O
higher O
self O
- O
reported O
op O
##io O
##id O
effects O
. O
7 O
on O
the O
other O
hand O
, O
induction O
of O
c O
##y O
##p O
##3 O
##a O
by O
r O
##if O
##amp O
##ici O
##n O
has O
been O
studied O
by O
ni O
##en O
##mine O
##n O
et O
al O
. O
where O
r O
##if O
##amp O
##ici O
##n O
600 O
mg O
was O
administered O
to O
12 O
healthy O
volunteers O
for O
7 O
days O
. O
[SEP] O
[CLS] O
the O
mean O
au B-PK
##c I-PK
values O
of O
both O
o O
##xy O
##co O
##don O
##e O
and O
o O
##xy O
##mor O
##phone O
were O
decreased O
by O
~ O
86 O
and O
90 O
% O
. O
[SEP] O
[CLS] O
imp O
##lication O
of O
new O
pathways O
has O
been O
proposed O
for O
three O
compounds O
and O
remaining O
clearance B-PK
##s I-PK
were O
assigned O
to O
und O
##ef O
##ined O
pathways O
. O
[SEP] O
[CLS] O
the O
simulated O
mean O
au B-PK
##c I-PK
##24 I-PK
h I-PK
of O
o O
##xy O
##mor O
##phone O
in O
c O
##y O
##p O
##2 O
##d O
##6 O
poor O
meta O
##bol O
##izer O
##s O
( O
pm O
##s O
) O
and O
extensive O
meta O
##bol O
##izer O
##s O
( O
em O
##s O
) O
were O
in O
close O
agreement O
with O
observed O
values O
in O
the O
same O
##r O
et O
al O
. O
study O
, O
namely O
31 O
vs O
. O
44 O
ng O
##⋅ O
##min O
/ O
m O
##l O
and O
229 O
vs O
. O
26 O
##8 O
ng O
##⋅ O
##min O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
accordingly O
, O
the O
simulated O
ratio B-PK
of I-PK
o I-PK
##xy I-PK
##mor I-PK
##phone I-PK
au I-PK
##c I-PK
in O
pm O
vs O
. O
em O
was O
0 O
. O
13 O
, O
which O
is O
in O
close O
agreement O
with O
the O
ratio O
observed O
in O
the O
clinical O
trial O
by O
same O
##r O
et O
al O
. O
( O
0 O
. O
14 O
) O
and O
s O
##tam O
##er O
et O
al O
. O
( O
0 O
. O
12 O
) O
. O
9 O
, O
12 O
the O
impact O
of O
co O
##tre O
##at O
##ment O
with O
k O
##eto O
##cona O
##zo O
##le O
observed O
by O
same O
##r O
et O
al O
. O
was O
used O
to O
re O
##fine O
the O
fraction O
of O
dose O
of O
the O
drug O
meta O
##bol O
##ized O
by O
c O
##y O
##p O
##3 O
##a O
##4 O
( O
f O
##m O
- O
3 O
##a O
##4 O
) O
. O
[SEP] O
[CLS] O
predicted O
au B-PK
##c I-PK
ratios I-PK
were O
90 O
, O
100 O
, O
and O
100 O
% O
of O
the O
observed O
values O
for O
o O
##xy O
##co O
##don O
##e O
, O
o O
##xy O
##mor O
##phone O
, O
and O
nor O
##ox O
##y O
##co O
##don O
##e O
, O
respectively O
. O
[SEP] O
[CLS] O
concerning O
o O
##xy O
##co O
##don O
##e O
, O
observed B-PK
au I-PK
##c I-PK
ratio I-PK
/ I-PK
simulated I-PK
au I-PK
##c I-PK
ratio I-PK
following O
k O
##eto O
##cona O
##zo O
##le O
, O
c O
##lar O
##ith O
##rom O
##y O
##cine O
, O
in O
##tra O
##ven O
##ous O
and O
oral O
it O
##rac O
##ona O
##zo O
##le O
, O
and O
combination O
of O
it O
##rac O
##ona O
##zo O
##le O
and O
par O
##ox O
##eti O
##ne O
were O
1 O
. O
8 O
, O
1 O
. O
3 O
, O
1 O
. O
2 O
, O
1 O
. O
6 O
, O
and O
1 O
. O
7 O
, O
respectively O
. O
[SEP] O
[CLS] O
with O
regards O
to O
2d O
##6 O
in O
##hibition O
, O
clinical B-PK
au I-PK
##c I-PK
ratio I-PK
/ I-PK
simulated I-PK
au I-PK
##c I-PK
ratio I-PK
following O
par O
##ox O
##eti O
##ne O
administration O
alone O
were O
0 O
. O
9 O
and O
1 O
. O
[SEP] O
[CLS] O
regarding O
nor O
##ox O
##y O
##co O
##don O
##e O
, O
clinical B-PK
/ I-PK
simulated I-PK
au I-PK
##c I-PK
ratio I-PK
following O
oral O
and O
in O
##tra O
##ven O
##ous O
it O
##rac O
##ona O
##zo O
##le O
, O
c O
##lar O
##ith O
##rom O
##y O
##cine O
, O
and O
par O
##ox O
##eti O
##ne O
administration O
were O
1 O
. O
0 O
, O
1 O
. O
2 O
, O
1 O
. O
0 O
, O
and O
1 O
. O
1 O
. O
[SEP] O
[CLS] O
with O
respect O
to O
o O
##xy O
##mor O
##phone O
, O
clinical B-PK
au I-PK
##c I-PK
ratio I-PK
/ I-PK
simulated I-PK
au I-PK
##c I-PK
ratio I-PK
after O
c O
##y O
##p O
##3 O
##a O
##4 O
blockade O
following O
oral O
and O
in O
##tra O
##ven O
##ous O
administration O
of O
it O
##rac O
##ona O
##zo O
##le O
was O
1 O
. O
8 O
and O
1 O
. O
6 O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
the O
si O
##m O
##cy O
##p O
si O
##mu O
##lator O
, O
the O
distribution O
of O
meta O
##bol O
##ites O
throughout O
the O
body O
is O
assumed O
to O
be O
instant O
##aneous O
and O
formed O
meta O
##bol O
##ites O
are O
instantly O
available O
for O
further O
metabolism O
. O
37 O
some O
of O
meta O
##bol O
##ites O
parameters O
such O
as O
distribution B-PK
volume I-PK
and O
systemic B-PK
clearance I-PK
were O
estimated O
using O
parameter O
est O
##imation O
and O
sensitivity O
analysis O
functions O
provided O
in O
the O
si O
##mu O
##lator O
. O
[SEP] O
[CLS] O
with O
regards O
to O
clearance B-PK
, O
different O
in O
v O
##it O
##ro O
systems O
such O
as O
human O
liver O
micro O
##some O
##s O
( O
h O
##lm O
) O
or O
re O
##comb O
##ina O
##ntly O
expressed O
systems O
can O
be O
used O
to O
determine O
the O
intrinsic B-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
) I-PK
of O
a O
compound O
by O
a O
specific O
c O
##y O
##p O
is O
##of O
##orm O
. O
[SEP] O
[CLS] O
obtained O
c B-PK
##lint I-PK
can O
be O
incorporated O
into O
si O
##m O
##cy O
##p O
to O
estimate O
the O
net O
intrinsic B-PK
clearance I-PK
of O
the O
total O
liver O
by O
s O
##cal O
##ing O
methods O
. O
[SEP] O
[CLS] O
for O
that O
, O
c B-PK
##lint I-PK
of O
different O
metabolic O
pathways O
for O
each O
enzyme O
involved O
in O
the O
metabolism O
of O
the O
compound O
will O
be O
added O
up O
after O
taking O
into O
account O
enzyme O
’ O
s O
abundance O
in O
the O
studied O
population O
, O
mill O
##ig O
##rams O
of O
micro O
##so O
##mal O
protein O
per O
gram O
of O
liver O
and O
total O
liver O
weight O
for O
each O
individual O
. O
36 O
besides O
common O
in O
v O
##it O
##ro O
- O
in O
v O
##ivo O
extra O
##pol O
##ation O
strategy O
, O
he O
##pa O
##tic O
first O
pass O
can O
also O
be O
estimated O
after O
de O
##com O
##po O
##sing O
the O
systemic B-PK
clearance I-PK
( O
oral B-PK
or O
in B-PK
##tra I-PK
##ven I-PK
##ous I-PK
clearance I-PK
) O
to O
its O
re O
##nal O
and O
he O
##pa O
##tic O
components O
. O
[SEP] O
[CLS] O
the O
estimated O
net O
intrinsic B-PK
clearance I-PK
will O
then O
be O
divided O
by O
the O
average O
liver O
weight O
, O
the O
micro O
##so O
##mal O
protein O
per O
gram O
of O
liver O
value O
for O
every O
is O
##oe O
##nz O
##yme O
and O
the O
fraction O
meta O
##bol O
##ized O
by O
each O
is O
##oe O
##nz O
##yme O
to O
obtain O
the O
intrinsic B-PK
clearance I-PK
value O
for O
each O
is O
##oe O
##nz O
##yme O
. O
[SEP] O
[CLS] O
therefore O
, O
the O
net O
intrinsic B-PK
he I-PK
##pa I-PK
##tic I-PK
clearance I-PK
( I-PK
c I-PK
##lu I-PK
##h I-PK
, I-PK
in I-PK
##t I-PK
) I-PK
will O
be O
back O
- O
calculated O
from O
in B-PK
v I-PK
##ivo I-PK
clearance I-PK
value O
by O
e O
##q O
##s O
. O
1 O
– O
3 O
using O
the O
re O
##tro O
##grade O
mode O
in O
the O
si O
##mu O
##lator O
: O
[SEP] O
[CLS] O
where O
c B-PK
##l I-PK
is O
the O
systemic B-PK
plasma I-PK
clearance I-PK
( O
l O
/ O
h O
) O
, O
c B-PK
##l I-PK
##po I-PK
is O
the O
oral B-PK
clearance I-PK
( O
l O
/ O
h O
) O
, O
f B-PK
##a I-PK
is O
the O
fraction B-PK
absorbed I-PK
, O
f B-PK
##h I-PK
and O
f B-PK
##g I-PK
are O
fraction B-PK
##s I-PK
meta I-PK
##bol I-PK
##ized I-PK
escaping I-PK
metabolism I-PK
, O
respectively O
in O
the O
liver O
and O
gut O
, O
c B-PK
##lm I-PK
##et I-PK
is O
the O
he B-PK
##pa I-PK
##tic I-PK
metabolic I-PK
clearance I-PK
in I-PK
blood I-PK
( O
l O
/ O
h O
) O
, O
c B-PK
##l I-PK
##r I-PK
is O
the O
re B-PK
##nal I-PK
clearance I-PK
( O
l O
/ O
h O
) O
, O
b B-PK
: I-PK
p I-PK
is O
the O
blood B-PK
to I-PK
plasma I-PK
partition I-PK
ratio I-PK
, O
f B-PK
##u I-PK
, O
b B-PK
is O
the O
fraction B-PK
un I-PK
##bound I-PK
in I-PK
blood I-PK
and O
q B-PK
##h I-PK
is O
the O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
( O
84 O
. O
8 O
l O
/ O
h O
) O
. O
[SEP] O
[CLS] O
in O
order O
to O
verify O
the O
validity O
of O
the O
final O
models O
of O
o O
##xy O
##co O
##don O
##e O
, O
o O
##xy O
##mor O
##phone O
and O
nor O
##ox O
##y O
##co O
##don O
##e O
for O
prediction O
of O
different O
d O
##dis O
, O
seven O
c O
##y O
##p O
##45 O
##0 O
- O
mediated O
interaction O
scenarios O
including O
k O
##eto O
##cona O
##zo O
##le O
, O
par O
##ox O
##eti O
##ne O
, O
it O
##rac O
##ona O
##zo O
##le O
, O
and O
c O
##lar O
##ith O
##rom O
##y O
##cine O
were O
simulated O
in O
healthy O
volunteers O
and O
results O
were O
compared O
to O
reference O
published O
data O
. O
13 O
, O
39 O
, O
40 O
, O
41 O
all O
studies O
were O
conducted O
with O
oral O
doses O
of O
o O
##xy O
##co O
##don O
##e O
except O
one O
where O
the O
impact O
of O
200 O
mg O
oral O
it O
##rac O
##ona O
##zo O
##le O
on O
both O
oral O
and O
in O
##tra O
##ven O
##ous O
o O
##xy O
##co O
##don O
##e O
was O
assessed O
. O
13 O
aforementioned O
inhibitor O
##s O
were O
chosen O
as O
they O
already O
exist O
in O
the O
default O
library O
of O
si O
##m O
##cy O
##p O
inhibitor O
##s O
and O
all O
their O
parameters O
were O
used O
as O
si O
##m O
##cy O
##p O
library O
files O
in O
v O
##12 O
. O
[SEP] O
[CLS] O
an O
incurred O
sample O
re O
- O
analysis O
( O
is O
##r O
) O
was O
also O
conducted O
by O
selecting O
the O
12 O
subject O
samples O
( O
two O
samples O
from O
each O
subject O
) O
near O
cm B-PK
##ax I-PK
and O
the O
elimination O
phase O
. O
[SEP] O
[CLS] O
the O
mean O
plasma O
concentrations O
vs O
time O
profile O
of O
at O
##or O
##vas O
##tat O
##in O
, O
met O
##form O
##in O
and O
g O
##lim O
##ep O
##iri O
##de O
are O
shown O
in O
fi O
##g O
. O
5 O
. O
[SEP] O
[CLS] O
h O
##y O
##po O
##ar O
##gin O
##ine O
##mia O
and O
hem O
##oly O
##sis O
likely O
reduce O
no O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
clinical O
trials O
in O
s O
##m O
of O
ad O
##junct O
##ive O
agents O
to O
improve O
end O
##oth O
##eli O
##al O
no O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
including O
l O
- O
a O
##rg O
##ini O
##ne O
, O
are O
warrant O
##ed O
. O
[SEP] O
[CLS] O
er O
##yt O
##hr O
##oc O
##yte O
r O
##up O
##ture O
results O
in O
increased O
cell O
- O
free O
hem O
##og O
##lo O
##bin O
and O
plasma O
a O
##rg O
##inas O
##e O
( O
15 O
, O
16 O
) O
, O
leading O
to O
increased O
no O
consumption O
and O
plasma O
l O
- O
a O
##rg O
##ini O
##ne O
cat O
##ab O
##olis O
##m O
, O
respectively O
, O
and O
an O
overall O
reduction O
in O
no O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
14 O
) O
. O
[SEP] O
[CLS] O
we O
show O
here O
a O
10 O
- O
fold O
increased O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
p O
##ac O
##lit O
##ax O
##el O
in O
mice O
treated O
with O
the O
p O
- O
g O
##ly O
##co O
##p O
##rote O
##in O
block O
##er O
s O
##d O
##z O
ps O
##c O
83 O
##3 O
. O
[SEP] O
[CLS] O
therefore O
, O
we O
established O
and O
characterized O
a O
liver O
im O
##mu O
##no O
##com O
##pet O
##ent O
co O
##culture O
model O
and O
evaluated O
di O
##c O
##lo O
##fen O
##ac O
( O
d O
##c O
##f O
) O
metabolic O
profiles O
, O
in O
v O
##it O
##ro O
– O
in O
v O
##ivo O
clearance B-PK
correlation O
##s O
, O
toxic O
##ological O
responses O
, O
and O
acute O
phase O
responses O
using O
liquid O
ch O
##roma O
##tography O
– O
tandem O
mass O
s O
##pect O
##rome O
##try O
. O
[SEP] O
[CLS] O
on O
day O
3 O
, O
the O
medium O
was O
replaced O
with O
will O
##iam O
’ O
s O
e O
medium O
( O
we O
##m O
) O
and O
maintenance O
supplement O
##s O
containing O
100 O
nm O
h O
##ydro O
##cor O
##tis O
##one O
. O
[SEP] O
[CLS] O
for O
d O
##c O
##f O
clearance B-PK
studies O
, O
a O
complete O
medium O
change O
was O
performed O
and O
d O
##c O
##f O
( O
si O
##gma O
- O
al O
##dric O
##h O
, O
pool O
##e O
, O
uk O
) O
in O
d O
##ms O
##o O
[ O
final O
concentration O
of O
0 O
. O
5 O
% O
( O
v O
/ O
v O
) O
for O
all O
doses O
] O
was O
added O
in O
a O
volume O
of O
2 O
m O
##l O
medium O
containing O
1 O
. O
25 O
mg O
/ O
m O
##l O
to O
yield O
concentrations O
indicted O
in O
the O
text O
. O
[SEP] O
[CLS] O
based O
on O
the O
initial O
observation O
of O
the O
d O
##c O
##f O
concentration O
profile O
over O
time O
, O
a O
one O
- O
compartment O
##al O
p O
##k O
model O
was O
used O
to O
estimate O
the O
d O
##c O
##f O
elimination B-PK
rate I-PK
( I-PK
k I-PK
##el I-PK
) I-PK
and O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
. O
[SEP] O
[CLS] O
due O
to O
sampling O
from O
the O
bio O
##rea O
##ctor O
, O
v B-PK
##d I-PK
was O
used O
as O
the O
average O
of O
the O
volumes O
at O
t O
= O
0 O
and O
the O
end O
point O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( O
) O
of O
d O
##c O
##f O
and O
the O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
were O
calculated O
using O
e O
##q O
##s O
. O
3 O
and O
4 O
: O
[SEP] O
[CLS] O
we O
thus O
assessed O
these O
e O
##qui O
##li O
##bria O
experimental O
##ly O
across O
our O
dose O
range O
to O
build O
appropriate O
p O
##k O
models O
of O
our O
experimental O
clearance B-PK
and O
metabolism O
data O
using O
our O
culture O
media O
, O
which O
contain O
other O
album O
##in O
- O
binding O
lip O
##op O
##hil O
##ic O
molecules O
including O
co O
##rt O
##is O
##ol O
. O
[SEP] O
[CLS] O
we O
then O
experimental O
##ly O
determined O
the O
d O
##c O
##f O
- O
album O
##in O
binding O
e O
##qui O
##li O
##bria O
in O
the O
culture O
medium O
used O
for O
the O
clearance B-PK
and O
metabolism O
studies O
in O
this O
work O
, O
and O
we O
found O
that O
measured O
outcomes O
were O
in O
agreement O
with O
the O
literature O
for O
the O
1 O
. O
25 O
g O
/ O
l O
b O
##sa O
concentration O
used O
in O
these O
studies O
and O
total O
d O
##c O
##f O
concentrations O
up O
to O
100 O
µ O
##m O
( O
fi O
##g O
. O
1 O
##b O
) O
. O
[SEP] O
[CLS] O
drug O
clearance B-PK
was O
q O
##uant O
##ified O
after O
dos O
##ing O
with O
a O
p O
##har O
##ma O
##cological O
4 O
. O
4 O
- O
µ O
##m O
dose O
and O
a O
su O
##pra O
##pha O
##rma O
##cological O
440 O
- O
µ O
##m O
dose O
of O
d O
##c O
##f O
in O
medium O
containing O
1 O
. O
25 O
g O
/ O
l O
b O
##sa O
( O
fi O
##g O
. O
2 O
; O
supplement O
##al O
table O
3 O
) O
. O
[SEP] O
[CLS] O
clearance B-PK
parameters O
were O
calculated O
from O
the O
concentration O
profiles O
of O
total O
d O
##c O
##f O
as O
a O
function O
of O
time O
, O
taking O
into O
account O
the O
reactor O
mixing O
properties O
and O
album O
##in O
binding O
, O
using O
a O
p O
##k O
model O
as O
described O
in O
the O
materials O
and O
methods O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
d O
##c O
##f O
at O
a O
p O
##har O
##ma O
##cological O
dose O
was O
estimated O
to O
be O
14 O
. O
6 O
hours O
in O
the O
liver O
##chi O
##p O
bio O
##rea O
##ctor O
. O
[SEP] O
[CLS] O
values O
of O
s O
##cal O
##ing O
parameters O
and O
intrinsic B-PK
clearance I-PK
are O
found O
in O
supplement O
##al O
table O
3 O
. O
[SEP] O
[CLS] O
clearance B-PK
was O
also O
investigated O
at O
a O
higher O
dose O
( O
440 O
µ O
##m O
) O
( O
fi O
##g O
. O
2 O
##b O
) O
, O
as O
this O
condition O
was O
used O
to O
assess O
meta O
##bol O
##ite O
production O
in O
addition O
to O
clearance B-PK
. O
[SEP] O
[CLS] O
here O
, O
the O
retrospective O
in O
v O
##ivo O
– O
in O
v O
##it O
##ro O
correlation O
analysis O
of O
the O
d O
##c O
##f O
clearance B-PK
using O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
v B-PK
##d I-PK
to O
calculate O
intrinsic B-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
) I-PK
by O
accounting O
for O
the O
s O
##cal O
##ing O
factors O
detailed O
in O
e O
##q O
. O
7 O
( O
da O
##vies O
and O
m O
##or O
##ris O
1993 O
; O
o O
##bach O
et O
al O
. O
, O
1997 O
; O
o O
##bach O
, O
1999 O
; O
sa O
##rka O
##r O
et O
al O
. O
, O
2015 O
) O
: O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
for O
the O
recommended O
dose O
of O
d O
##c O
##f O
in O
humans O
is O
4 O
. O
4 O
µ O
##m O
and O
experiments O
were O
carried O
out O
up O
to O
100 O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
another O
23 O
% O
were O
associated O
with O
high O
- O
density O
lip O
##op O
##rote O
##in O
particle O
clearance O
. O
[SEP] O
[CLS] O
b O
##w O
demonstrated O
the O
following O
effects O
: O
after O
i O
. O
v O
. O
administration O
, O
significant O
effects O
( O
p O
< O
0 O
. O
05 O
) O
were O
observed O
for O
exposure O
( O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
) O
, O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
, O
and O
clearance B-PK
; O
whereas O
after O
s O
. O
c O
. O
administration O
, O
significant O
effects O
( O
p O
< O
0 O
. O
05 O
) O
were O
observed O
for O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
terminal B-PK
half I-PK
‐ I-PK
life I-PK
, O
and O
estimated O
apparent B-PK
clearance I-PK
. O
[SEP] O
[CLS] O
b O
##mi O
increased O
clearance B-PK
for O
heavier O
subjects O
. O
[SEP] O
[CLS] O
for O
example O
, O
mean O
( O
s O
##d O
) O
plasma B-PK
clearance I-PK
of O
i O
. O
v O
. O
an O
##aki O
##n O
##ra O
increased O
from O
1 O
. O
17 O
± O
0 O
. O
29 O
to O
1 O
. O
62 O
± O
0 O
. O
24 O
m O
##l O
/ O
minute O
/ O
kg O
( O
p O
< O
0 O
. O
05 O
) O
for O
larger O
( O
> O
100 O
kg O
) O
o O
##bes O
##e O
( O
b O
##mi O
> O
36 O
) O
vs O
. O
larger O
( O
> O
100 O
kg O
) O
less O
o O
##bes O
##e O
( O
b O
##mi O
< O
35 O
) O
subjects O
, O
respectively O
. O
[SEP] O
[CLS] O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
ranged O
from O
80 O
– O
92 O
% O
and O
was O
unrelated O
to O
b O
##w O
or O
b O
##mi O
. O
[SEP] O
[CLS] O
[UNK] O
the O
study O
demonstrated O
that O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
not O
altered O
in O
o O
##bes O
##e O
subjects O
. O
[SEP] O
[CLS] O
the O
p O
##k O
of O
an O
##aki O
##n O
##ra O
showed O
that O
, O
as O
anticipated O
, O
exposure O
was O
higher O
( O
and O
clearance B-PK
lower O
) O
in O
lighter O
‐ O
weight O
subjects O
. O
[SEP] O
[CLS] O
b O
##mi O
altered O
clearance B-PK
and O
exposure O
in O
heavier O
subjects O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
after O
a O
70 O
‐ O
mg O
s O
. O
c O
. O
b O
##ol O
##us O
injection O
into O
healthy O
subjects O
is O
95 O
% O
. O
8 O
in O
subjects O
with O
r O
##a O
, O
maximum B-PK
observed I-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
an O
##aki O
##n O
##ra O
occurred O
within O
3 O
– O
7 O
hours O
after O
s O
. O
c O
. O
administration O
, O
with O
a O
terminal B-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
ranging O
within O
4 O
– O
6 O
hours O
. O
[SEP] O
[CLS] O
population O
p O
##k O
analyses O
at O
doses O
of O
30 O
mg O
, O
70 O
mg O
, O
and O
150 O
mg O
of O
s O
. O
c O
. O
injected O
an O
##aki O
##n O
##ra O
up O
to O
24 O
weeks O
indicated O
that O
the O
estimated O
apparent B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
of O
an O
##aki O
##n O
##ra O
after O
s O
. O
c O
. O
administration O
increased O
with O
increasing O
c O
##rea O
##tin O
##ine O
clearance O
and O
body O
weight O
( O
b O
##w O
) O
. O
9 O
gender O
differences O
also O
occur O
, O
most O
likely O
related O
to O
differences O
in O
b O
##w O
. O
10 O
plasma B-PK
clearance I-PK
of O
an O
##aki O
##n O
##ra O
occurs O
predominantly O
via O
g O
##lo O
##mer O
##ular O
fi O
##ltration O
and O
tub O
##ular O
re O
##ab O
##sor O
##ption O
. O
11 O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
an O
##aki O
##n O
##ra O
is O
4 O
– O
6 O
hours O
; O
therefore O
, O
7 O
days O
was O
considered O
an O
adequate O
wash O
##out O
period O
. O
[SEP] O
[CLS] O
the O
primary O
end O
points O
of O
this O
study O
were O
f B-PK
after O
s O
. O
c O
. O
administration O
of O
an O
##aki O
##n O
##ra O
, O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
and O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
secondary O
p O
##k O
end O
points O
were O
time B-PK
of I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
, O
and O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
. O
[SEP] O
[CLS] O
pre O
##sp O
##ec O
##ified O
h O
##y O
##pot O
##heses O
tested O
in O
this O
study O
included O
whether O
o O
##besity O
altered O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
or O
clearance B-PK
. O
[SEP] O
[CLS] O
power O
analyses O
for O
numbers O
of O
subjects O
were O
based O
on O
data O
from O
a O
previous O
study O
of O
an O
##aki O
##n O
##ra O
( O
study O
2000 O
##01 O
##9 O
##6 O
) O
, O
in O
which O
the O
between O
‐ O
subject O
var O
##iability O
for O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
, O
and O
the O
ratio O
of O
dose O
a O
to O
dose O
b O
for O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
does O
not O
exceed O
14 O
% O
for O
au B-PK
##c I-PK
and O
27 O
% O
for O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
using O
these O
estimates O
, O
it O
was O
determined O
that O
a O
sample O
size O
of O
32 O
would O
provide O
an O
80 O
% O
chance O
( O
power O
) O
of O
detect O
##ing O
at O
the O
5 O
% O
level O
of O
significance O
a O
14 O
% O
difference O
in O
au B-PK
##c I-PK
parameters O
and O
a O
32 O
% O
difference O
in O
cm B-PK
##ax I-PK
parameters O
between O
the O
two O
b O
##mi O
classification O
##s O
( O
≥ O
36 O
or O
< O
35 O
; O
n O
= O
16 O
) O
or O
the O
two O
b O
##w O
classification O
##s O
( O
≤ O
90 O
or O
≥ O
100 O
; O
n O
= O
16 O
) O
. O
[SEP] O
[CLS] O
the O
primary O
contrasts O
of O
interest O
were O
the O
estimates O
of O
f B-PK
, O
au B-PK
##c I-PK
, O
and O
cm B-PK
##ax I-PK
for O
the O
two O
b O
##mi O
and O
two O
b O
##w O
classification O
##s O
. O
[SEP] O
[CLS] O
using O
the O
same O
estimates O
for O
the O
differences O
between O
any O
two O
groups O
( O
n O
= O
8 O
) O
, O
this O
study O
had O
an O
80 O
% O
chance O
of O
detect O
##ing O
at O
the O
5 O
% O
level O
of O
significance O
, O
a O
22 O
% O
difference O
in O
au B-PK
##c I-PK
, O
and O
a O
50 O
% O
difference O
in O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
secondary O
contrasts O
of O
interest O
were O
analysis O
of O
variance O
( O
an O
##ova O
) O
comparisons O
among O
the O
three O
s O
. O
c O
. O
doses O
( O
for O
each O
of O
the O
four O
b O
##w O
/ O
b O
##mi O
classification O
##s O
) O
; O
a O
crossover O
an O
##ova O
was O
used O
to O
compare O
dose O
‐ O
adjusted O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
after O
each O
s O
. O
c O
. O
dose O
. O
[SEP] O
[CLS] O
b O
##w O
demonstrated O
the O
following O
effects O
: O
after O
i O
. O
v O
. O
administration O
, O
significant O
effects O
( O
p O
< O
0 O
. O
05 O
) O
were O
observed O
for O
exposure O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) O
, O
cm B-PK
##ax I-PK
, O
vs B-PK
##s I-PK
, O
and O
c B-PK
##l I-PK
, O
whereas O
after O
s O
. O
c O
. O
administration O
, O
significant O
effects O
( O
p O
< O
0 O
. O
05 O
) O
were O
observed O
for O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
. O
[SEP] O
[CLS] O
median O
plasma O
an O
##aki O
##n O
##ra O
concentration O
– O
time O
profiles O
after O
i O
. O
v O
. O
administration O
of O
100 O
mg O
an O
##aki O
##n O
##ra O
declined O
with O
similar O
slopes O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
values O
for O
the O
different O
b O
##w O
and O
b O
##mi O
groups O
, O
varying O
from O
1 O
. O
67 O
##− O
##1 O
. O
86 O
hours O
( O
figure O
##2 O
##and O
table O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
c B-PK
##l I-PK
value O
, O
which O
is O
inverse O
##ly O
proportional O
to O
au B-PK
##c I-PK
, O
was O
higher O
for O
the O
heavier O
subjects O
than O
for O
the O
lighter O
subjects O
; O
however O
, O
after O
being O
normal O
##ized O
by O
b O
##w O
( O
c B-PK
##l I-PK
/ I-PK
b I-PK
##w I-PK
) O
, O
it O
was O
16 O
% O
higher O
for O
the O
lighter O
subjects O
than O
for O
the O
heavier O
subjects O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
independent O
of O
b O
##w O
, O
as O
the O
vs B-PK
##s I-PK
value O
also O
increased O
with O
increasing O
b O
##w O
in O
a O
similar O
manner O
to O
c B-PK
##l I-PK
. O
[SEP] O
[CLS] O
therefore O
, O
concentration O
data O
after O
i O
. O
v O
. O
administration O
for O
these O
subjects O
were O
excluded O
from O
p O
##k O
and O
statistical O
analyses O
, O
and O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
these O
subjects O
was O
not O
estimated O
. O
[SEP] O
[CLS] O
the O
clearance B-PK
value O
of O
this O
subject O
was O
2 O
. O
9 O
‐ O
fold O
higher O
than O
the O
mean O
value O
for O
the O
rest O
of O
the O
subjects O
. O
[SEP] O
[CLS] O
the O
estimated O
f B-PK
after O
s O
. O
c O
. O
administration O
for O
this O
subject O
was O
unexpectedly O
out O
of O
range O
: O
218 O
% O
at O
100 O
mg O
, O
225 O
% O
at O
150 O
mg O
, O
and O
at O
212 O
% O
at O
300 O
mg O
. O
[SEP] O
[CLS] O
based O
on O
the O
c B-PK
##l I-PK
and O
f B-PK
values O
, O
this O
subject O
' O
s O
p O
##k O
profile O
after O
i O
. O
v O
. O
administration O
was O
classified O
as O
an O
out O
##lier O
. O
[SEP] O
[CLS] O
therefore O
, O
the O
p O
##k O
parameters O
after O
i O
. O
v O
. O
administration O
and O
the O
f B-PK
after O
s O
. O
c O
. O
administration O
for O
this O
subject O
were O
also O
excluded O
from O
statistical O
analyses O
. O
[SEP] O
[CLS] O
mean O
c B-PK
##l I-PK
/ I-PK
f I-PK
values O
were O
higher O
for O
subjects O
with O
b O
##w O
≥ O
100 O
kg O
than O
for O
subjects O
with O
b O
##w O
≤ O
90 O
kg O
, O
and O
b O
##mi O
seemed O
to O
have O
an O
impact O
only O
for O
heavier O
subjects O
. O
[SEP] O
[CLS] O
as O
seen O
in O
table O
##3 O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
increased O
with O
both O
higher O
b O
##w O
and O
higher O
b O
##mi O
ranging O
from O
3 O
. O
63 O
hours O
for O
less O
o O
##bes O
##e O
, O
lighter O
‐ O
weight O
subjects O
to O
7 O
. O
62 O
hours O
for O
o O
##bes O
##e O
, O
heavier O
‐ O
weight O
subjects O
. O
[SEP] O
[CLS] O
f B-PK
was O
independent O
of O
both O
b O
##w O
and O
b O
##mi O
and O
ranged O
from O
80 O
##− O
##9 O
##2 O
% O
( O
table O
##3 O
) O
. O
[SEP] O
[CLS] O
when O
the O
dose O
was O
normal O
##ized O
vs O
. O
the O
100 O
‐ O
mg O
dose O
, O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
∞ I-PK
were O
similar O
in O
a O
dose O
range O
for O
100 O
mg O
, O
150 O
mg O
, O
and O
300 O
mg O
( O
figure O
##4 O
) O
. O
[SEP] O
[CLS] O
a O
total O
of O
21 O
subjects O
( O
64 O
% O
) O
experienced O
the O
most O
common O
a O
##e O
, O
a O
reaction O
at O
the O
site O
of O
s O
. O
c O
. O
injection O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
del O
##sol O
##ine O
was O
20 O
. O
9 O
% O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
blood I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
, O
blood B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
) I-PK
, O
maximum B-PK
blood I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
and O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
analyzed O
. O
[SEP] O
[CLS] O
the O
equation O
for O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
is O
expressed O
as O
the O
following O
: O
absolute O
bio O
##ava O
##ila O
##bility O
= O
in O
##tra O
##gas O
##tric O
au O
##c O
/ O
in O
##tra O
##ven O
##ous O
au O
##c O
× O
100 O
% O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
the O
in O
##tra O
##gas O
##tric O
administration O
( O
9 O
, O
6 O
, O
and O
3 O
mg O
/ O
kg O
) O
and O
in O
##tra O
##ven O
##ous O
administration O
( O
1 O
mg O
/ O
kg O
) O
was O
1 O
. O
3 O
+ O
0 O
. O
5 O
h O
, O
1 O
. O
6 O
+ O
0 O
. O
7 O
h O
, O
1 O
. O
7 O
+ O
0 O
. O
8 O
h O
, O
and O
2 O
. O
5 O
+ O
0 O
. O
7 O
h O
, O
respectively O
, O
indicating O
that O
its O
metabolism O
was O
rapid O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
del O
##sol O
##ine O
( O
9 O
, O
6 O
, O
and O
3 O
mg O
/ O
kg O
) O
was O
26 O
. O
2 O
% O
, O
18 O
. O
8 O
% O
, O
and O
17 O
. O
7 O
% O
, O
respectively O
, O
with O
an O
average O
of O
20 O
. O
9 O
% O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
these O
doses O
was O
not O
significantly O
different O
. O
[SEP] O
[CLS] O
plasma O
concentration O
of O
be O
##rgen O
##in O
was O
detect O
##able O
as O
early O
as O
10 O
min O
after O
administration O
, O
with O
a O
mean O
peak B-PK
concentration I-PK
in I-PK
plasma I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
275 O
##± O
##16 O
##4 O
ng O
/ O
m O
##l O
and O
the O
time B-PK
to I-PK
peak I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
of O
0 O
. O
29 O
##2 O
##± O
##0 O
. O
102 O
h O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
24 I-PK
h I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
were O
8 O
. O
03 O
##± O
##3 O
. O
24 O
h O
, O
4 O
. O
99 O
##± O
##0 O
. O
66 O
h O
and O
54 O
##8 O
##± O
##40 O
##8 O
ng O
h O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
( O
% O
relative O
standard O
error O
) O
of O
r O
##it O
##ux O
##ima O
##b O
effect O
decay O
was O
0 O
. O
03 O
##6 O
( O
22 O
. O
7 O
% O
) O
days O
##− O
##1 O
and O
c O
##d O
##19 O
+ O
turnover O
was O
0 O
. O
02 O
( O
41 O
% O
) O
days O
##− O
##1 O
corresponding O
to O
half B-PK
‐ I-PK
lives I-PK
of O
19 O
and O
35 O
days O
respectively O
. O
[SEP] O
[CLS] O
here O
, O
a B-PK
##1 I-PK
has O
initial O
conditions O
of O
0 O
, O
with O
addition O
of O
a O
dose O
amount O
in O
mg O
added O
with O
every O
dose O
event O
, O
and O
k B-PK
##e I-PK
representing O
elimination B-PK
rate I-PK
constant I-PK
of O
r O
##it O
##ux O
##ima O
##b O
effect O
, O
kin B-PK
: O
production O
rate O
of O
c O
##d O
##19 O
+ O
l O
##ymph O
##ocytes O
, O
k B-PK
##out I-PK
: O
elimination B-PK
rate I-PK
constant I-PK
of O
c O
##d O
##19 O
+ O
l O
##ymph O
##ocytes O
, O
em B-PK
##ax I-PK
: O
maximum O
increase O
in O
cell O
elimination O
rate O
in O
the O
presence O
of O
r O
##it O
##ux O
##ima O
##b O
, O
ed B-PK
##50 I-PK
: O
dose B-PK
at I-PK
which I-PK
produces I-PK
50 I-PK
% I-PK
of I-PK
the I-PK
maximum I-PK
effect I-PK
, O
a B-PK
##2 I-PK
represents O
c O
##d O
##19 O
+ O
l O
##ymph O
##ocytes O
. O
[SEP] O
[CLS] O
model O
evaluation O
consisted O
of O
plotting O
model O
predictions O
vs O
observed O
c O
##d O
##19 O
+ O
l O
##ymph O
##oc O
##yte O
counts O
for O
the O
population O
and O
for O
individual O
patients O
, O
relative O
standard O
error O
( O
r O
##se O
) O
of O
model O
parameters O
, O
and O
visual O
predict O
##ive O
check O
( O
v O
##p O
##c O
) O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
##s I-PK
of O
r O
##it O
##ux O
##ima O
##b O
( O
k B-PK
##e I-PK
) O
and O
c O
##d O
##19 O
+ O
b O
cells O
( O
k B-PK
##out I-PK
) O
suggested O
half B-PK
‐ I-PK
lives I-PK
of O
19 O
days O
and O
35 O
days O
, O
respectively O
. O
[SEP] O
[CLS] O
at O
a O
dose O
of O
2 O
mum O
##ol O
kg O
- O
1 O
and O
photo O
##ther O
##ap O
##y O
at O
24 O
h O
p O
. O
i O
. O
, O
the O
t O
##umour O
volume O
doubling O
time O
increased O
to O
11 O
days O
vs O
6 O
days O
for O
the O
control O
t O
##umour O
##s O
. O
[SEP] O
[CLS] O
administration O
under O
fast O
##ing O
conditions O
resulted O
in O
decreases O
in O
the O
mean O
au B-PK
##cin I-PK
##f I-PK
of O
el O
##vi O
##te O
##gra O
##vir O
and O
ten O
##of O
##ov O
##ir O
by O
50 O
% O
and O
28 O
% O
, O
respectively O
, O
relative O
to O
administration O
with O
a O
standard O
breakfast O
, O
whereas O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bilities I-PK
of O
el O
##vi O
##te O
##gra O
##vir O
and O
ten O
##of O
##ov O
##ir O
were O
comparable O
when O
administered O
with O
a O
standard O
breakfast O
or O
a O
nutrition O
##al O
protein O
- O
rich O
drink O
. O
[SEP] O
[CLS] O
under O
fast O
##ing O
conditions O
, O
it O
appears O
that O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bilities I-PK
of O
el O
##vi O
##te O
##gra O
##vir O
and O
ten O
##of O
##ov O
##ir O
were O
not O
equivalent O
to O
those O
when O
they O
were O
administered O
with O
either O
type O
of O
food O
, O
although O
they O
were O
bio O
##e O
##qui O
##valent O
to O
each O
other O
under O
fed O
conditions O
. O
[SEP] O
[CLS] O
these O
findings O
suggest O
that O
el O
##vi O
##te O
##gra O
##vir O
/ O
co O
##bic O
##ista O
##t O
/ O
em O
##tric O
##ita O
##bine O
/ O
ten O
##of O
##ov O
##ir O
di O
##so O
##p O
##ro O
##xi O
##l O
f O
##uma O
##rate O
should O
be O
administered O
with O
food O
, O
and O
that O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
el O
##vi O
##te O
##gra O
##vir O
and O
ten O
##of O
##ov O
##ir O
is O
not O
affected O
by O
the O
type O
of O
meal O
ing O
##ested O
. O
[SEP] O
[CLS] O
it O
enhance O
##s O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
co O
##ad O
##mini O
##stered O
drugs O
such O
as O
el O
##vi O
##te O
##gra O
##vir O
, O
which O
are O
meta O
##bol O
##ized O
by O
c O
##y O
##p O
##3 O
##a O
and O
decreases O
their O
clearance B-PK
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
el O
##vi O
##te O
##gra O
##vir O
and O
ten O
##of O
##ov O
##ir O
is O
affected O
by O
food O
intake O
. O
3 O
, O
7 O
a O
food O
interaction O
study O
showed O
that O
the O
mean O
au B-PK
##cin I-PK
##f I-PK
and O
cm B-PK
##ax I-PK
of O
these O
components O
of O
e O
##v O
##g O
/ O
co O
##bi O
/ O
ft O
##c O
/ O
t O
##d O
##f O
s O
##tr O
administered O
oral O
##ly O
were O
increased O
by O
34 O
% O
and O
24 O
% O
, O
respectively O
, O
when O
administered O
with O
a O
meal O
( O
37 O
##3 O
k O
##cal O
, O
20 O
% O
fat O
) O
, O
as O
compared O
with O
fast O
##ing O
conditions O
. O
7 O
therefore O
, O
in O
a O
clinical O
setting O
, O
it O
is O
recommended O
that O
e O
##v O
##g O
/ O
co O
##bi O
/ O
ft O
##c O
/ O
t O
##d O
##f O
s O
##tr O
be O
taken O
with O
a O
meal O
. O
3 O
although O
e O
##v O
##g O
/ O
co O
##bi O
/ O
ft O
##c O
/ O
t O
##d O
##f O
s O
##tr O
has O
been O
approved O
for O
marketing O
in O
j O
##apa O
##n O
and O
has O
already O
been O
administered O
to O
hi O
##v O
- O
1 O
- O
infected O
patients O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
these O
components O
have O
not O
yet O
been O
evaluated O
in O
j O
##apa O
##nese O
subjects O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
estimated O
for O
each O
anal O
##yte O
were O
: O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
concentration O
at O
24 O
hours O
post O
- O
dose O
( O
c O
##24 O
) O
, O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
the I-PK
time I-PK
of I-PK
administration I-PK
up I-PK
to I-PK
the I-PK
last I-PK
time I-PK
point I-PK
with I-PK
a I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
post I-PK
- I-PK
dose I-PK
( I-PK
au I-PK
##c I-PK
##last I-PK
) I-PK
, O
and O
au B-PK
##c I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##cin I-PK
##f I-PK
) I-PK
. O
[SEP] O
[CLS] O
au B-PK
##cin I-PK
##f I-PK
was O
calculated O
as O
the O
sum O
of O
au B-PK
##c I-PK
##last I-PK
and O
c B-PK
##last I-PK
/ I-PK
λ I-PK
##z I-PK
, O
where O
c O
##last O
denotes O
the O
last O
me O
##as O
##urable O
concentration O
and O
λ B-PK
##z I-PK
represents O
the O
elimination B-PK
rate I-PK
constant I-PK
determined O
by O
linear O
re O
##gression O
of O
the O
terminal O
points O
of O
the O
l O
##n O
- O
linear O
plasma O
concentration O
– O
time O
curve O
. O
[SEP] O
[CLS] O
the O
plasma O
el O
##vi O
##te O
##gra O
##vir O
concentration O
reached O
cm B-PK
##ax I-PK
within O
4 O
hours O
post O
- O
dose O
in O
all O
of O
the O
treatment O
groups O
. O
[SEP] O
[CLS] O
for O
assessment O
of O
the O
l O
##s O
mean O
ratio O
, O
a O
single O
oral O
dose O
of O
e O
##v O
##g O
/ O
co O
##bi O
/ O
ft O
##c O
/ O
t O
##d O
##f O
s O
##tr O
in O
a O
fast O
##ed O
state O
( O
treatment O
b O
) O
resulted O
in O
55 O
% O
and O
50 O
% O
decreases O
in O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
for O
el O
##vi O
##te O
##gra O
##vir O
, O
respectively O
, O
as O
compared O
with O
those O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
values O
for O
el O
##vi O
##te O
##gra O
##vir O
in O
the O
protein O
- O
rich O
drink O
group O
( O
treatment O
c O
) O
were O
comparable O
to O
those O
in O
the O
standard O
breakfast O
group O
. O
[SEP] O
[CLS] O
the O
90 O
% O
c O
##is O
of O
g O
##m O
##r O
for O
el O
##vi O
##te O
##gra O
##vir O
au B-PK
##cin I-PK
##f I-PK
were O
within O
the O
boundary O
of O
0 O
. O
8 O
– O
1 O
. O
25 O
, O
while O
the O
upper O
limit O
of O
the O
90 O
% O
c O
##i O
of O
g O
##m O
##r O
for O
el O
##vi O
##te O
##gra O
##vir O
cm B-PK
##ax I-PK
was O
narrowly O
above O
the O
lack O
of O
a O
food O
effect O
boundary O
( O
1 O
. O
27 O
) O
after O
administration O
with O
a O
protein O
- O
rich O
drink O
, O
indicating O
that O
the O
two O
fed O
conditions O
were O
bio O
##e O
##qui O
##valent O
to O
each O
other O
. O
[SEP] O
[CLS] O
the O
plasma O
co O
##bic O
##ista O
##t O
concentration O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
reached O
cm B-PK
##ax I-PK
at O
2 O
. O
5 O
hours O
post O
- O
dose O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
values O
for O
co O
##bic O
##ista O
##t O
following O
administration O
in O
a O
fast O
##ed O
state O
( O
treatment O
b O
) O
and O
with O
a O
nutrition O
##al O
protein O
- O
rich O
drink O
( O
treatment O
c O
) O
were O
comparable O
to O
those O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
( O
table O
1 O
) O
, O
the O
corresponding O
90 O
% O
c O
##is O
of O
the O
g O
##m O
##r O
for O
co O
##bic O
##ista O
##t O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
falling O
within O
the O
bio O
##e O
##qui O
##valence O
limit O
, O
indicating O
the O
lack O
of O
any O
food O
effect O
. O
[SEP] O
[CLS] O
the O
plasma O
em O
##tric O
##ita O
##bine O
concentration O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
reached O
cm B-PK
##ax I-PK
at O
1 O
. O
5 O
hours O
post O
- O
dose O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
values O
for O
em O
##tric O
##ita O
##bine O
following O
administration O
with O
a O
standard O
breakfast O
were O
comparable O
to O
those O
following O
administration O
under O
fast O
##ing O
conditions O
( O
treatment O
b O
) O
and O
after O
ing O
##est O
##ion O
of O
a O
protein O
- O
rich O
drink O
( O
treatment O
c O
) O
. O
[SEP] O
[CLS] O
the O
plasma O
ten O
##of O
##ov O
##ir O
concentration O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
reached O
cm B-PK
##ax I-PK
at O
1 O
. O
5 O
hours O
post O
- O
dose O
. O
[SEP] O
[CLS] O
administration O
in O
a O
fast O
##ed O
state O
( O
treatment O
b O
) O
resulted O
in O
28 O
% O
decreases O
in O
both O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
for O
ten O
##of O
##ov O
##ir O
, O
compared O
with O
those O
following O
administration O
with O
a O
standard O
breakfast O
( O
treatment O
a O
) O
, O
whereas O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##cin I-PK
##f I-PK
values O
for O
ten O
##of O
##ov O
##ir O
following O
administration O
with O
a O
nutrition O
##al O
protein O
- O
rich O
drink O
( O
treatment O
c O
) O
were O
comparable O
to O
those O
following O
administration O
with O
a O
standard O
breakfast O
. O
[SEP] O
[CLS] O
in O
terms O
of O
the O
l O
##s O
mean O
ratio O
and O
the O
90 O
% O
c O
##is O
, O
it O
appears O
that O
in O
a O
fast O
##ed O
state O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ten O
##of O
##ov O
##ir O
is O
not O
equivalent O
to O
that O
for O
either O
of O
the O
fed O
conditions O
. O
[SEP] O
[CLS] O
relative O
to O
the O
standard O
meal O
, O
the O
au B-PK
##cin I-PK
##f I-PK
for O
ten O
##of O
##ov O
##ir O
was O
within O
the O
lack O
of O
a O
food O
effect O
boundary O
after O
administration O
with O
a O
nutrition O
##al O
protein O
- O
rich O
drink O
, O
though O
cm B-PK
##ax I-PK
was O
slightly O
lower O
( O
0 O
. O
76 O
) O
, O
indicating O
that O
the O
two O
fed O
conditions O
were O
bio O
##e O
##qui O
##valent O
to O
each O
other O
. O
[SEP] O
[CLS] O
no O
significant O
period O
or O
sequence O
effects O
were O
seen O
for O
any O
of O
the O
comparisons O
, O
and O
the O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
each O
anal O
##yte O
was O
generally O
comparable O
among O
all O
the O
treatments O
( O
tables O
##1 O
and O
2 O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
the O
half B-PK
- I-PK
life I-PK
of I-PK
distribution I-PK
phase I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
α I-PK
) I-PK
, O
the B-PK
half I-PK
- I-PK
life I-PK
of I-PK
elimination I-PK
phase I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
β I-PK
) I-PK
, O
volume B-PK
of I-PK
apparent I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
, O
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
infinite I-PK
time I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
were O
7 O
. O
59 O
min O
, O
46 O
. O
99 O
min O
, O
0 O
. O
17 O
l O
/ O
kg O
, O
and O
204 O
. O
5 O
mg O
/ O
l O
/ O
min O
, O
respectively O
, O
as O
determined O
by O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
; O
6 O
. O
41 O
min O
, O
47 O
. O
28 O
min O
, O
1 O
. O
24 O
l O
/ O
kg O
, O
and O
57 O
##5 O
. O
18 O
mg O
/ O
l O
/ O
min O
, O
respectively O
, O
as O
determined O
by O
el O
##isa O
; O
3 O
. O
69 O
min O
, O
70 O
##1 O
. O
90 O
min O
, O
0 O
. O
04 O
l O
/ O
kg O
, O
and O
41 O
##8 O
##9 O
mg O
/ O
l O
/ O
min O
, O
respectively O
as O
determined O
by O
r O
##a O
; O
and O
4 O
. O
57 O
min O
, O
72 O
##4 O
. O
9 O
min O
, O
0 O
. O
09 O
l O
/ O
kg O
, O
and O
232 O
##9 O
mg O
/ O
l O
/ O
min O
, O
respectively O
, O
as O
determined O
by O
t O
##ca O
- O
r O
##a O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
determined O
by O
the O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
and O
el O
##isa O
are O
con O
##g O
##rue O
##nt O
except O
for O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
the O
distribution B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
) I-PK
was O
7 O
. O
59 O
##± O
##4 O
. O
56 O
minutes O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
) I-PK
was O
47 O
. O
0 O
##± O
##22 O
. O
2 O
minutes O
. O
[SEP] O
[CLS] O
these O
results O
are O
similar O
to O
those O
of O
the O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
below O
except O
that O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
was O
204 O
. O
5 O
##± O
##19 O
. O
9 O
mg O
/ O
l O
/ O
min O
by O
the O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
and O
57 O
##5 O
. O
2 O
##± O
##39 O
. O
4 O
mg O
/ O
l O
/ O
min O
by O
el O
##isa O
. O
[SEP] O
[CLS] O
the O
distribution B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
) I-PK
was O
6 O
. O
42 O
##± O
##2 O
. O
60 O
minutes O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
) I-PK
was O
47 O
. O
3 O
##± O
##13 O
. O
1 O
minutes O
. O
[SEP] O
[CLS] O
the O
distribution B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
) I-PK
was O
3 O
. O
69 O
##± O
##1 O
. O
71 O
minutes O
by O
the O
total O
radio O
##is O
##oto O
##pe O
ass O
##ay O
and O
4 O
. O
58 O
##± O
##1 O
. O
73 O
minutes O
by O
the O
t O
##rich O
##lor O
##oa O
##ce O
##tic O
acid O
pre O
- O
treated O
total O
radio O
##is O
##oto O
##pe O
ass O
##ay O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
) I-PK
was O
70 O
##1 O
. O
9 O
##± O
##19 O
##8 O
. O
8 O
minutes O
and O
72 O
##4 O
. O
9 O
##± O
##8 O
##1 O
. O
2 O
minutes O
respectively O
. O
[SEP] O
[CLS] O
steady O
‐ O
state O
exposure O
was O
higher O
with O
p O
##ila O
##ral O
##isi O
##b O
tablet O
formulation O
at O
400 O
mg O
than O
with O
p O
##ila O
##ral O
##isi O
##b O
capsule O
formulation O
at O
400 O
or O
600 O
mg O
( O
mean O
area B-PK
under I-PK
the I-PK
curve I-PK
[ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
] I-PK
2 O
, O
82 O
##0 O
, O
000 O
ng O
× O
h O
/ O
m O
##l O
vs O
. O
2 O
, O
65 O
##3 O
, O
000 O
and O
1 O
, O
93 O
##0 O
, O
000 O
ng O
× O
h O
/ O
m O
##l O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
the O
most O
common O
reasons O
for O
study O
disco O
##ntin O
##uation O
were O
disease O
progression O
as O
defined O
by O
re O
##cist O
version O
1 O
. O
0 O
( O
15 O
patients O
, O
68 O
. O
2 O
% O
) O
, O
disease O
progression O
based O
on O
clinical O
de O
##ter O
##ior O
##ation O
( O
three O
patients O
, O
13 O
. O
6 O
% O
) O
, O
and O
adverse O
event O
( O
a O
##e O
; O
two O
patients O
, O
9 O
. O
1 O
% O
) O
. O
[SEP] O
[CLS] O
two O
patients O
( O
9 O
. O
1 O
% O
) O
permanently O
discontinued O
treatment O
because O
of O
an O
a O
##e O
( O
grade O
5 O
en O
##ce O
##pha O
##lop O
##athy O
and O
grade O
4 O
is O
##che O
##mic O
stroke O
) O
; O
both O
a O
##es O
were O
not O
treatment O
related O
. O
[SEP] O
[CLS] O
after O
repeated O
daily O
administration O
of O
p O
##ila O
##ral O
##isi O
##b O
tablets O
( O
100 O
– O
600 O
mg O
) O
, O
steady O
state O
was O
reached O
by O
cycle O
1 O
, O
day O
28 O
, O
and O
median O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
ranged O
from O
1 O
. O
99 O
to O
23 O
. O
1 O
hours O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
accumulation B-PK
ratio I-PK
for I-PK
maximum I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
for O
cycle O
1 O
, O
day O
28 O
, O
compared O
with O
cycle O
1 O
, O
day O
1 O
, O
ranged O
from O
5 O
. O
9 O
‐ O
fold O
to O
10 O
. O
3 O
‐ O
fold O
and O
3 O
. O
1 O
‐ O
fold O
to O
9 O
. O
9 O
‐ O
fold O
, O
respectively O
. O
[SEP] O
[CLS] O
exposure O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) O
did O
not O
appear O
to O
increase O
dose O
proportional O
##ly O
for O
the O
100 O
– O
600 O
mg O
dose O
levels O
, O
but O
conclusions O
were O
limited O
by O
the O
small O
patient O
numbers O
. O
[SEP] O
[CLS] O
on O
cycle O
1 O
, O
day O
28 O
, O
exposure O
was O
higher O
with O
p O
##ila O
##ral O
##isi O
##b O
400 O
mg O
tablets O
administered O
q O
##d O
compared O
with O
600 O
mg O
tablets O
q O
##d O
and O
the O
capsule O
formulation O
administered O
at O
400 O
mg O
and O
600 O
mg O
q O
##d O
( O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
2 O
, O
82 O
##0 O
, O
000 O
[ O
n O
= O
2 O
] O
vs O
. O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
1 O
, O
470 O
, O
000 O
[ O
n O
= O
2 O
] O
, O
2 O
, O
65 O
##3 O
, O
000 O
[ O
n O
= O
2 O
] O
and O
1 O
, O
93 O
##0 O
, O
000 O
ng O
× O
h O
/ O
m O
##l O
[ O
n O
= O
14 O
] O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
the O
trial O
’ O
s O
co O
- O
primary O
end O
##points O
were O
mean O
changes O
from O
base O
##line O
, O
as O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
in O
forced O
ex O
##pi O
##rator O
##y O
volume O
( O
f O
##ev O
##1 O
) O
over O
0 O
– O
12 O
hours O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
f O
##ev O
##1 O
) O
with O
m O
##f O
/ O
f O
versus O
m O
##f O
, O
and O
in O
morning O
( O
am O
) O
pre O
- O
dose O
( O
t O
##rough O
) O
f O
##ev O
##1 O
with O
m O
##f O
/ O
f O
versus O
f O
after O
13 O
weeks O
of O
treatment O
. O
[SEP] O
[CLS] O
the O
largest O
improvements O
in O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
f O
##ev O
##1 O
were O
observed O
with O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
. O
[SEP] O
[CLS] O
this O
was O
a O
random O
##ized O
, O
place O
##bo O
- O
controlled O
, O
double O
- O
blind O
, O
double O
- O
du O
##mmy O
, O
multi O
##cent O
##er O
study O
( O
clinical O
##tri O
##als O
. O
go O
##v O
id O
##ent O
##ifier O
: O
n O
##ct O
##00 O
##38 O
##37 O
##21 O
) O
of O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
bid O
and O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
bid O
compared O
with O
m O
##f O
400 O
μ O
##g O
bid O
and O
f O
10 O
μ O
##g O
bid O
in O
adults O
with O
moderate O
- O
to O
- O
very O
severe O
cop O
##d O
. O
[SEP] O
[CLS] O
total O
dose O
was O
delivered O
after O
two O
in O
##hala O
##tions O
bid O
of O
the O
following O
act O
##uated O
doses O
: O
m O
##f O
/ O
f O
200 O
/ O
5 O
μ O
##g O
, O
m O
##f O
/ O
f O
100 O
/ O
5 O
μ O
##g O
, O
m O
##f O
200 O
μ O
##g O
, O
f O
5 O
μ O
##g O
, O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
at O
base O
##line O
, O
subjects O
were O
random O
##ized O
in O
a O
1 O
: O
1 O
: O
1 O
: O
1 O
: O
1 O
ratio O
to O
26 O
weeks O
of O
double O
- O
blind O
treatment O
with O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
bid O
, O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
bid O
, O
m O
##f O
400 O
μ O
##g O
bid O
, O
f O
10 O
μ O
##g O
bid O
, O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
the O
active O
and O
place O
##bo O
m O
##f O
/ O
f O
and O
m O
##f O
in O
##hale O
##rs O
were O
identical O
in O
appearance O
, O
as O
were O
the O
active O
and O
place O
##bo O
f O
in O
##hale O
##rs O
. O
[SEP] O
[CLS] O
the O
co O
- O
primary O
end O
##points O
were O
: O
1 O
) O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
compared O
with O
m O
##f O
400 O
μ O
##g O
for O
f O
##ev O
##1 O
area O
under O
the O
curve O
from O
0 O
to O
12 O
hours O
post O
- O
dose O
( O
au O
##c O
##0 O
– O
12 O
h O
) O
at O
the O
week O
13 O
end O
##point O
( O
last O
observation O
carried O
forward O
[ O
lo O
##c O
##f O
] O
) O
to O
assess O
the O
added O
benefit O
of O
f O
on O
br O
##on O
##cho O
##di O
##lation O
, O
and O
2 O
) O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
compared O
with O
f O
10 O
μ O
##g O
for O
am O
pre O
##dos O
##e O
( O
t O
##rough O
) O
f O
##ev O
##1 O
at O
the O
week O
13 O
end O
##point O
to O
assess O
the O
added O
benefit O
of O
m O
##f O
on O
t O
##rough O
f O
##ev O
##1 O
. O
[SEP] O
[CLS] O
secondary O
efficacy O
end O
##points O
included O
assessment O
of O
changes O
from O
base O
##line O
in O
f O
##ev O
##1 O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
at O
day O
1 O
, O
weeks O
1 O
, O
13 O
, O
26 O
, O
and O
the O
26 O
- O
week O
end O
##point O
( O
lo O
##c O
##f O
) O
, O
as O
well O
as O
assessment O
of O
changes O
from O
base O
##line O
in O
t O
##rough O
f O
##ev O
##1 O
at O
each O
visit O
and O
at O
the O
26 O
- O
week O
end O
##point O
. O
[SEP] O
[CLS] O
the O
first O
co O
- O
primary O
efficacy O
end O
##point O
was O
the O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
of O
the O
change O
in O
f O
##ev O
##1 O
from O
base O
##line O
to O
the O
week O
13 O
end O
##point O
, O
measuring O
the O
contribution O
of O
f O
10 O
μ O
##g O
bid O
to O
the O
combination O
. O
[SEP] O
[CLS] O
also O
, O
f O
##ev O
##1 O
re O
##vers O
##ibility O
at O
screening O
tended O
to O
be O
higher O
in O
the O
f O
10 O
μ O
##g O
group O
( O
10 O
. O
37 O
% O
) O
than O
it O
was O
in O
the O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
groups O
( O
8 O
. O
69 O
% O
and O
8 O
. O
47 O
% O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
at O
the O
week O
13 O
end O
##point O
, O
a O
significant O
difference O
of O
126 O
m O
##l O
was O
observed O
in O
the O
mean O
change O
from O
base O
##line O
in O
f O
##ev O
##1 O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
400 O
μ O
##g O
groups O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
also O
significantly O
improved O
f O
##ev O
##1 O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
versus O
m O
##f O
400 O
μ O
##g O
( O
86 O
m O
##l O
difference O
, O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
a O
significant O
improvement O
of O
74 O
m O
##l O
was O
reported O
for O
f O
10 O
μ O
##g O
compared O
with O
place O
##bo O
( O
p O
= O
0 O
. O
00 O
##4 O
) O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
results O
with O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
versus O
f O
10 O
μ O
##g O
for O
the O
change O
from O
base O
##line O
in O
am O
pre O
- O
dose O
( O
t O
##rough O
) O
f O
##ev O
##1 O
at O
the O
week O
13 O
end O
##point O
indicate O
a O
contribution O
of O
m O
##f O
to O
the O
combination O
( O
figure O
4 O
) O
. O
[SEP] O
[CLS] O
the O
significant O
improvement O
of O
f O
##ev O
##1 O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
with O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
versus O
f O
10 O
μ O
##g O
( O
87 O
m O
##l O
, O
p O
< O
0 O
. O
00 O
##1 O
) O
confirms O
the O
contribution O
of O
m O
##f O
to O
the O
combination O
. O
[SEP] O
[CLS] O
these O
results O
show O
the O
benefit O
of O
f O
in O
the O
combination O
formulation O
. O
[SEP] O
[CLS] O
in O
the O
second O
analysis O
of O
am O
pre O
- O
dose O
f O
##ev O
##1 O
, O
performed O
after O
database O
lock O
and O
exclusion O
of O
these O
subjects O
, O
statistical O
significance O
was O
achieved O
for O
this O
co O
- O
primary O
end O
##point O
, O
with O
a O
difference O
of O
58 O
m O
##l O
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
f O
10 O
μ O
##g O
( O
p O
= O
0 O
. O
03 O
##0 O
) O
, O
and O
a O
difference O
of O
105 O
m O
##l O
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
place O
##bo O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
compared O
with O
f O
10 O
μ O
##g O
, O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
had O
significantly O
greater O
increases O
in O
f O
##ev O
##1 O
at O
all O
time O
points O
at O
week O
26 O
( O
p O
≤ O
0 O
. O
01 O
##6 O
) O
, O
whereas O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
had O
significantly O
greater O
increases O
versus O
f O
only O
at O
the O
4 O
- O
and O
8 O
- O
hour O
post O
- O
dose O
time O
points O
( O
p O
≤ O
0 O
. O
02 O
##2 O
) O
further O
##more O
, O
as O
would O
be O
expected O
, O
both O
m O
##f O
/ O
f O
treatments O
were O
superior O
to O
place O
##bo O
( O
p O
≤ O
0 O
. O
01 O
##9 O
) O
at O
all O
time O
points O
during O
serial O
s O
##pi O
##rome O
##try O
assessments O
throughout O
the O
entire O
treatment O
period O
. O
[SEP] O
[CLS] O
the O
changes O
from O
base O
##line O
with O
m O
##f O
400 O
μ O
##g O
( O
5 O
. O
87 O
) O
and O
f O
10 O
μ O
##g O
( O
4 O
. O
93 O
) O
also O
surpassed O
the O
m O
##cid O
( O
figure O
5 O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
difference O
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
f O
10 O
μ O
##g O
( O
49 O
m O
##l O
) O
was O
marginal O
##ly O
significant O
for O
the O
pre O
- O
specified O
lo O
##c O
##f O
analysis O
( O
p O
= O
0 O
. O
06 O
##2 O
) O
. O
[SEP] O
[CLS] O
in O
analyses O
for O
observed O
cases O
( O
analyses O
based O
on O
observations O
at O
specified O
time O
points O
, O
as O
opposed O
to O
observations O
carried O
forward O
for O
end O
##point O
analyses O
) O
at O
weeks O
13 O
and O
26 O
, O
as O
well O
as O
the O
week O
26 O
end O
##point O
, O
statistical O
significance O
was O
achieved O
, O
with O
differences O
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
f O
10 O
μ O
##g O
of O
59 O
m O
##l O
, O
101 O
m O
##l O
, O
and O
82 O
m O
##l O
, O
respectively O
( O
p O
≤ O
0 O
. O
03 O
##3 O
) O
. O
[SEP] O
[CLS] O
at O
the O
week O
13 O
end O
##point O
in O
this O
subgroup O
, O
significant O
differences O
in O
mean O
changes O
from O
base O
##line O
in O
f O
##ev O
##1 O
au B-PK
##c I-PK
##0 I-PK
– I-PK
12 I-PK
h I-PK
occurred O
, O
with O
a O
difference O
of O
101 O
m O
##l O
between O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
400 O
μ O
##g O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
88 O
m O
##l O
between O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
and O
m O
##f O
400 O
μ O
##g O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
and O
83 O
m O
##l O
between O
f O
10 O
μ O
##g O
and O
place O
##bo O
( O
p O
= O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
the O
proportions O
of O
subjects O
with O
moderate O
or O
severe O
first O
ex O
##ace O
##rb O
##ations O
in O
the O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
, O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
, O
m O
##f O
400 O
μ O
##g O
, O
and O
f O
10 O
μ O
##g O
groups O
were O
15 O
. O
4 O
% O
, O
12 O
. O
8 O
% O
, O
16 O
. O
9 O
% O
, O
and O
18 O
. O
4 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
only O
six O
subjects O
had O
l O
##s O
- O
b O
##m O
##d O
loss O
> O
6 O
% O
during O
the O
study O
period O
: O
two O
subjects O
each O
in O
the O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
and O
m O
##f O
400 O
μ O
##g O
groups O
, O
one O
subject O
in O
the O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
group O
, O
and O
one O
subject O
in O
the O
f O
10 O
μ O
##g O
group O
. O
[SEP] O
[CLS] O
if O
cop O
##d O
ex O
##ace O
##rb O
##ation O
met O
the O
criteria O
for O
a O
serious O
a O
##e O
( O
e O
##g O
, O
was O
life O
- O
threatening O
, O
required O
hospital O
##ization O
, O
or O
prolonged O
hospital O
##ization O
) O
, O
it O
was O
recorded O
as O
an O
a O
##e O
. O
[SEP] O
[CLS] O
overall O
, O
90 O
subjects O
( O
7 O
. O
5 O
% O
) O
reported O
a O
treatment O
- O
related O
a O
##e O
, O
the O
most O
frequent O
of O
which O
were O
lent O
##icular O
op O
##ac O
##ities O
( O
1 O
subject O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
, O
1 O
subject O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
, O
2 O
subjects O
m O
##f O
400 O
μ O
##g O
, O
3 O
subjects O
f O
10 O
μ O
##g O
, O
and O
1 O
subject O
place O
##bo O
) O
, O
d O
##ys O
##phon O
##ia O
( O
2 O
subjects O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
, O
1 O
subject O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
, O
4 O
subjects O
m O
##f O
400 O
μ O
##g O
, O
and O
1 O
subject O
place O
##bo O
) O
, O
and O
oral O
can O
##di O
##dia O
##sis O
, O
including O
the O
a O
##e O
terms O
of O
oral O
can O
##di O
##dia O
##sis O
, O
or O
##op O
##har O
##yn O
##ge O
##al O
can O
##di O
##dia O
##sis O
, O
and O
oral O
fun O
##gal O
infection O
( O
1 O
subject O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
, O
2 O
subjects O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
, O
6 O
subjects O
m O
##f O
400 O
μ O
##g O
, O
and O
1 O
subject O
f O
10 O
μ O
##g O
) O
. O
[SEP] O
[CLS] O
during O
the O
entire O
study O
period O
( O
treatment O
period O
plus O
safety O
extension O
) O
, O
23 O
subjects O
( O
2 O
. O
4 O
% O
) O
reported O
pneumonia O
( O
including O
the O
a O
##e O
terms O
of O
pneumonia O
, O
pneumonia O
viral O
, O
pneumonia O
as O
##piration O
, O
and O
lo O
##bar O
pneumonia O
) O
across O
the O
four O
active O
treatment O
groups O
. O
[SEP] O
[CLS] O
single O
- O
dose O
in O
##tra O
##ven O
##ous O
and O
sub O
##cut O
##aneous O
p O
##har O
##ma O
##co O
##kin O
##etics O
studies O
indicate O
that O
a O
##bt O
- O
98 O
##1 O
has O
a O
half B-PK
- I-PK
life I-PK
of O
8 O
. O
0 O
to O
10 O
. O
4 O
d O
in O
c O
##yn O
##omo O
##l O
##gus O
monkey O
and O
10 O
. O
0 O
to O
20 O
. O
3 O
d O
in O
rode O
##nts O
. O
[SEP] O
[CLS] O
a O
##bt O
- O
98 O
##1 O
exhibits O
suitable O
drug O
- O
like O
- O
properties O
including O
affinity O
, O
pot O
##ency O
, O
specific O
##ity O
, O
half B-PK
- I-PK
life I-PK
, O
and O
stability O
for O
evaluation O
in O
human O
clinical O
trials O
. O
[SEP] O
[CLS] O
several O
affinity O
- O
mature O
##d O
s O
##k O
##48 O
- O
e O
##26 O
variant O
human O
i O
##gg O
##1 O
/ O
k O
antibodies O
( O
e O
##26 O
. O
1 O
, O
e O
##26 O
. O
2 O
, O
e O
##26 O
. O
12 O
, O
e O
##26 O
. O
13 O
, O
e O
##26 O
. O
35 O
and O
e O
##26 O
. O
37 O
) O
were O
generated O
by O
expression O
of O
a O
specific O
affinity O
- O
mature O
##d O
variable O
heavy O
chain O
( O
v O
##h O
) O
sequence O
( O
e O
##26 O
. O
1 O
v O
##h O
, O
e O
##26 O
. O
2 O
v O
##h O
, O
e O
##26 O
. O
12 O
v O
##h O
, O
e O
##26 O
. O
13 O
, O
v O
##h O
e O
##26 O
. O
35 O
v O
##h O
and O
e O
##26 O
. O
37 O
v O
##h O
) O
paired O
with O
the O
s O
##k O
##48 O
- O
e O
##26 O
variable O
light O
chain O
( O
v O
##l O
) O
sequence O
( O
s O
##k O
##48 O
- O
e O
##26 O
v O
##l O
) O
or O
the O
corresponding O
affinity O
- O
mature O
##d O
variable O
light O
chain O
sequence O
( O
e O
##26 O
. O
1 O
v O
##l O
and O
e O
##26 O
. O
37 O
v O
##l O
) O
. O
[SEP] O
[CLS] O
after O
i O
##v O
dos O
##ing O
in O
b O
##al O
##b O
/ O
c O
mice O
, O
a O
##bt O
- O
98 O
##1 O
exhibited O
low O
clearance B-PK
( O
0 O
. O
27 O
m O
##l O
/ O
h O
/ O
kg O
) O
, O
a O
small O
volume B-PK
of I-PK
distribution I-PK
( O
95 O
m O
##l O
/ O
kg O
) O
, O
and O
a O
long O
half B-PK
- I-PK
life I-PK
of O
10 O
. O
5 O
d O
. O
after O
s O
##c O
administration O
of O
a O
##bt O
- O
98 O
##1 O
in O
mice O
, O
the O
cm B-PK
##ax I-PK
was O
29 O
. O
2 O
μ O
##g O
/ O
m O
##l O
, O
the O
half B-PK
- I-PK
life I-PK
was O
20 O
. O
3 O
d O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
[UNK] O
% O
( O
fi O
##g O
. O
5 O
##a O
) O
. O
[SEP] O
[CLS] O
after O
i O
##v O
dos O
##ing O
in O
s O
##pra O
##gue O
- O
da O
##wley O
rats O
, O
a O
##bt O
- O
98 O
##1 O
exhibited O
low O
clearance B-PK
( O
0 O
. O
28 O
m O
##l O
/ O
h O
/ O
kg O
) O
, O
small O
volume B-PK
of I-PK
distribution I-PK
( O
86 O
m O
##l O
/ O
kg O
) O
, O
with O
long O
half B-PK
- I-PK
life I-PK
of O
10 O
. O
0 O
d O
( O
fi O
##g O
. O
5 O
##b O
and O
table O
7 O
) O
. O
[SEP] O
[CLS] O
following O
s O
##c O
administration O
in O
rat O
, O
a O
cm B-PK
##ax I-PK
of O
16 O
. O
0 O
μ O
##g O
/ O
m O
##l O
, O
with O
a O
half B-PK
- I-PK
life I-PK
of O
12 O
. O
0 O
d O
and O
52 O
% O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
observed O
( O
fi O
##g O
. O
5 O
##b O
) O
. O
[SEP] O
[CLS] O
after O
i O
##v O
dos O
##ing O
in O
c O
##yn O
##omo O
##l O
##gus O
monkeys O
, O
a O
##bt O
- O
98 O
##1 O
exhibited O
low O
clearance B-PK
( O
0 O
. O
22 O
m O
##l O
/ O
h O
/ O
kg O
) O
, O
small O
volume B-PK
of I-PK
distribution I-PK
( O
61 O
m O
##l O
/ O
kg O
) O
and O
long O
half B-PK
- I-PK
life I-PK
of O
10 O
. O
4 O
d O
. O
after O
s O
##c O
administration O
, O
the O
half B-PK
- I-PK
life I-PK
of O
a O
##bt O
- O
98 O
##1 O
was O
8 O
. O
0 O
d O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
95 O
% O
( O
fi O
##g O
. O
5 O
##c O
) O
. O
[SEP] O
[CLS] O
to O
q O
##uant O
##itate O
the O
binding O
of O
ma O
##bs O
or O
d O
##v O
##d O
- O
i O
##gs O
to O
il O
- O
1 O
##α O
or O
il O
- O
1 O
##β O
, O
96 O
- O
well O
el O
##isa O
plates O
were O
in O
##cu O
##bate O
##d O
overnight O
at O
4 O
##° O
##c O
with O
anti O
- O
human O
f O
##c O
anti O
##body O
( O
jack O
##son O
im O
##mu O
##nor O
##ese O
##ar O
##ch O
, O
109 O
- O
51 O
##6 O
- O
00 O
##8 O
) O
di O
##lut O
##ed O
in O
pier O
##ce O
buffer O
superb O
##lock O
( O
the O
##rm O
##o O
scientific O
, O
375 O
##15 O
) O
at O
a O
final O
concentration O
of O
2 O
μ O
##g O
/ O
m O
##l O
. O
plates O
were O
washed O
5 O
times O
in O
washing O
buffer O
( O
p O
##bs O
containing O
0 O
. O
05 O
% O
t O
##we O
##en O
20 O
) O
, O
and O
blocked O
for O
1 O
hour O
at O
25 O
##° O
##c O
with O
200 O
μ O
##l O
per O
well O
with O
pier O
##ce O
buffer O
superb O
##lock O
. O
[SEP] O
[CLS] O
approximately O
5000 O
r O
##u O
of O
goat O
anti O
- O
human O
i O
##gg O
f O
##c O
p O
##oly O
##c O
##lon O
##al O
anti O
##body O
( O
the O
##rm O
##o O
scientific O
, O
p O
##i O
- O
311 O
##6 O
##3 O
) O
di O
##lut O
##ed O
in O
10 O
mm O
sodium O
ace O
##tate O
( O
p O
##h O
4 O
. O
5 O
) O
was O
directly O
im O
##mo O
##bil O
##ized O
across O
a O
cm O
##5 O
research O
grade O
bio O
##sen O
##sor O
chip O
using O
a O
standard O
am O
##ine O
coupling O
kit O
according O
to O
manufacturer O
' O
s O
instructions O
and O
procedures O
at O
25 O
μ O
##g O
/ O
m O
##l O
. O
un O
##rea O
##cted O
m O
##oi O
##eti O
##es O
on O
the O
bio O
##sen O
##sor O
surface O
were O
blocked O
with O
ethanol O
##amine O
, O
and O
modified O
car O
##box O
##yme O
##thy O
##l O
de O
##x O
##tra O
##n O
surface O
in O
flow O
##cell O
2 O
and O
4 O
was O
used O
as O
a O
reaction O
surface O
. O
[SEP] O
[CLS] O
a O
proportion O
of O
the O
isolated O
clone O
##s O
were O
sequence O
##d O
to O
obtain O
89 O
unique O
v O
##h O
and O
41 O
v O
##l O
variant O
sequences O
. O
[SEP] O
[CLS] O
rate O
constant O
##s O
were O
derived O
by O
making O
kinetic O
binding O
measurements O
of O
im O
##mu O
##no O
##g O
##lo O
##bul O
##ins O
using O
il O
- O
1 O
concentrations O
ranging O
from O
10 O
– O
200 O
nm O
. O
un O
##mo O
##dified O
car O
##box O
##yme O
##thy O
##l O
de O
##x O
##tra O
##n O
without O
goat O
anti O
- O
mouse O
i O
##gg O
in O
flow O
cell O
1 O
and O
3 O
was O
used O
as O
the O
reference O
surface O
. O
[SEP] O
[CLS] O
goat O
anti O
- O
human O
i O
##gg O
f O
##c O
was O
co O
##valent O
##ly O
linked O
to O
the O
car O
##box O
##y O
met O
##hyl O
de O
##x O
##tra O
##n O
matrix O
on O
the O
cm O
##5 O
bio O
##sen O
##sor O
chip O
( O
bi O
##aco O
##re O
a O
##b O
, O
br O
- O
100 O
##5 O
– O
30 O
) O
via O
free O
am O
##ine O
groups O
using O
an O
am O
##ine O
coupling O
kit O
and O
the O
im O
##mo O
##bil O
##ization O
wizard O
option O
in O
the O
bi O
##aco O
##re O
t O
##20 O
##0 O
instrument O
' O
s O
controlling O
software O
. O
[SEP] O
[CLS] O
approximately O
1000 O
##0 O
r O
##u O
of O
goat O
anti O
‑ O
human O
i O
##gg O
f O
##c O
antibodies O
were O
im O
##mo O
##bil O
##ized O
on O
the O
chip O
surface O
. O
[SEP] O
[CLS] O
a O
modified O
cm O
surface O
coated O
with O
goat O
anti O
- O
human O
f O
##c O
anti O
##body O
in O
flow O
##cell O
1 O
was O
used O
as O
a O
reference O
surface O
. O
[SEP] O
[CLS] O
a O
##bt O
- O
98 O
##1 O
was O
di O
##lut O
##ed O
in O
h O
##bs O
- O
e O
##p O
( O
10 O
mm O
he O
##pes O
[ O
p O
##h O
7 O
. O
4 O
] O
, O
150 O
mm O
na O
##c O
##l O
, O
3 O
mm O
ed O
##ta O
, O
and O
0 O
. O
00 O
##5 O
% O
surf O
##act O
##ant O
p O
##20 O
) O
( O
bi O
##aco O
##re O
##® O
a O
##b O
, O
br O
##100 O
##18 O
##8 O
) O
to O
a O
concentration O
of O
0 O
. O
5 O
μ O
##g O
/ O
m O
##l O
and O
was O
injected O
over O
the O
goat O
anti O
- O
human O
i O
##gg O
f O
##c O
surface O
on O
flow O
cell O
3 O
at O
a O
flow O
rate O
of O
5 O
μ O
##l O
/ O
min O
or O
10 O
##ul O
/ O
min O
for O
2 O
minutes O
to O
achieve O
a O
capture O
level O
of O
[UNK] O
‑ O
70 O
##7 O
r O
##u O
. O
[SEP] O
[CLS] O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
similar O
between O
re O
##nal O
‐ O
imp O
##air O
##ment O
groups O
and O
the O
normal O
‐ O
re O
##nal O
‐ O
function O
group O
. O
[SEP] O
[CLS] O
total B-PK
drug I-PK
clearance I-PK
from I-PK
plasma I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
terminal B-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
correlated O
with O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
ratios B-PK
( I-PK
90 I-PK
% I-PK
confidence I-PK
intervals I-PK
) I-PK
of I-PK
area I-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
in O
mild O
, O
moderate O
, O
severe O
, O
and O
es O
##rd O
groups O
compared O
to O
those O
with O
normal O
re O
##nal O
function O
were O
1 O
. O
0 O
( O
0 O
. O
8 O
‐ O
1 O
. O
3 O
) O
, O
1 O
. O
5 O
( O
1 O
. O
2 O
‐ O
1 O
. O
9 O
) O
, O
2 O
. O
5 O
( O
2 O
. O
0 O
‐ O
3 O
. O
3 O
) O
, O
and O
4 O
. O
1 O
( O
3 O
. O
3 O
‐ O
5 O
. O
2 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
normal O
re O
##nal O
function O
was O
identified O
using O
the O
cock O
##croft O
‐ O
g O
##ault O
equation O
calculation O
##9 O
with O
c O
##rea O
##tin O
##ine O
clearance O
( O
c O
##l O
##c O
##r O
) O
≥ O
90 O
m O
##l O
/ O
min O
without O
adjusting O
for O
body O
surface O
area O
. O
[SEP] O
[CLS] O
the O
following O
p O
##k O
parameters O
were O
calculated O
from O
the O
plasma O
concentration O
data O
for O
c O
##ef O
##ider O
##oc O
##ol O
using O
the O
non O
##com O
##par O
##tment O
##al O
methods O
in O
p O
##hoe O
##ni O
##x O
win O
##non O
##lin O
##® O
version O
6 O
. O
3 O
( O
c O
##ert O
##ara O
us O
##a O
, O
in O
##c O
, O
prince O
##ton O
, O
new O
jersey O
) O
: O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
the I-PK
time I-PK
of I-PK
the I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
‐ I-PK
t I-PK
) I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
‐ I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
terminal B-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
total B-PK
drug I-PK
clearance I-PK
from I-PK
plasma I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
and O
volume B-PK
of I-PK
distribution I-PK
under I-PK
steady I-PK
‐ I-PK
state I-PK
conditions I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
( I-PK
0 I-PK
‐ I-PK
t I-PK
) I-PK
and O
au B-PK
##c I-PK
were O
calculated O
with O
the O
linear O
‐ O
up O
/ O
log O
‐ O
down O
trap O
##ez O
##oid O
##al O
method O
for O
the O
extra O
##pol O
##ation O
. O
[SEP] O
[CLS] O
fraction B-PK
of I-PK
total I-PK
drug I-PK
that I-PK
is I-PK
un I-PK
##bound I-PK
in I-PK
plasma I-PK
( I-PK
f I-PK
##u I-PK
) I-PK
was O
also O
assessed O
. O
[SEP] O
[CLS] O
cumulative B-PK
amount I-PK
of I-PK
drug I-PK
ex I-PK
##cre I-PK
##ted I-PK
unchanged I-PK
in I-PK
urine I-PK
( I-PK
a I-PK
##e I-PK
) I-PK
, O
fraction B-PK
of I-PK
dose I-PK
ex I-PK
##cre I-PK
##ted I-PK
unchanged I-PK
into I-PK
urine I-PK
( I-PK
f I-PK
##e I-PK
) I-PK
, O
and O
re B-PK
##nal I-PK
clearance I-PK
of I-PK
drug I-PK
( I-PK
c I-PK
##l I-PK
##r I-PK
) I-PK
were O
estimated O
for O
each O
subject O
with O
u O
##rina O
##ry O
ex O
##cre O
##tion O
data O
. O
[SEP] O
[CLS] O
one O
subject O
from O
the O
moderate O
imp O
##air O
##ment O
co O
##hor O
##t O
was O
premature O
##ly O
withdrawn O
from O
the O
study O
due O
to O
an O
a O
##e O
of O
u O
##rt O
##ica O
##ria O
; O
the O
subject O
received O
only O
74 O
. O
2 O
m O
##l O
of O
the O
re O
##con O
##stituted O
study O
drug O
instead O
of O
total O
100 O
m O
##l O
. O
[SEP] O
[CLS] O
geometric O
mean O
values O
of O
cm B-PK
##ax I-PK
and O
vs B-PK
##s I-PK
were O
similar O
among O
re O
##nal O
function O
groups O
. O
[SEP] O
[CLS] O
the O
f B-PK
##u I-PK
at O
1 O
and O
8 O
hours O
was O
similar O
among O
re O
##nal O
function O
groups O
. O
[SEP] O
[CLS] O
by O
co O
##hor O
##t O
, O
half O
or O
fewer O
subjects O
experienced O
at O
least O
1 O
a O
##e O
. O
[SEP] O
[CLS] O
the O
most O
frequently O
reported O
a O
##e O
was O
contact O
der O
##mat O
##itis O
( O
7 O
. O
9 O
% O
) O
, O
reported O
by O
1 O
subject O
each O
in O
the O
mild O
, O
severe O
, O
and O
es O
##rd O
( O
period O
1 O
) O
co O
##hor O
##ts O
. O
[SEP] O
[CLS] O
except O
for O
contact O
der O
##mat O
##itis O
, O
only O
nausea O
was O
reported O
as O
an O
a O
##e O
by O
more O
than O
1 O
subject O
per O
co O
##hor O
##t O
. O
[SEP] O
[CLS] O
because O
the O
dose O
rate O
of O
de O
##x O
##med O
##eto O
##mi O
##dine O
remained O
constant O
for O
relatively O
long O
periods O
of O
time O
during O
three O
separate O
intervals O
, O
we O
calculated O
the O
plasma B-PK
clearance I-PK
of O
de O
##x O
##med O
##eto O
##mi O
##dine O
during O
these O
intervals O
by O
dividing O
the O
in O
##fusion O
rate O
by O
the O
plasma O
concentration O
. O
[SEP] O
[CLS] O
the O
calculated O
clearance B-PK
was O
55 O
l O
/ O
h O
, O
92 O
l O
/ O
h O
and O
87 O
l O
/ O
h O
during O
the O
2nd O
to O
6th O
, O
14th O
to O
20th O
and O
21st O
to O
23rd O
day O
of O
the O
de O
##x O
##med O
##eto O
##mi O
##dine O
in O
##fusion O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
a O
two O
- O
step O
( O
parallel O
- O
group O
) O
p O
##har O
##ma O
##co O
##kin O
##etic O
trial O
with O
intensive O
blood O
sampling O
, O
we O
compared O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
days I-PK
0 I-PK
to I-PK
28 I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
) I-PK
and O
the O
safety O
outcomes O
of O
pipe O
##ra O
##quin O
##e O
among O
malaria O
- O
un O
##in O
##fected O
hi O
##v O
+ O
adults O
. O
[SEP] O
[CLS] O
pipe O
##ra O
##quin O
##e O
' O
s O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
in O
both O
steps O
was O
43 O
% O
lower O
among O
participants O
on O
e O
##fa O
##vir O
##en O
##z O
- O
based O
art O
than O
among O
art O
- O
naive O
participants O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
between O
the O
other O
art O
groups O
and O
the O
art O
- O
naive O
group O
in O
each O
of O
the O
two O
steps O
. O
[SEP] O
[CLS] O
participants O
in O
the O
e O
##f O
##v O
- O
art O
group O
had O
43 O
% O
lower O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
of O
pipe O
##ra O
##quin O
##e O
than O
those O
in O
the O
art O
- O
naive O
group O
( O
geometric O
mean O
ratio O
, O
0 O
. O
57 O
[ O
90 O
% O
confidence O
interval O
{ O
c O
##i O
} O
, O
0 O
. O
38 O
to O
0 O
. O
83 O
] O
; O
p O
= O
0 O
. O
02 O
##9 O
) O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days O
among O
participants O
in O
the O
other O
art O
groups O
from O
those O
among O
participants O
in O
the O
art O
- O
naive O
group O
. O
[SEP] O
[CLS] O
pipe O
##ra O
##quin O
##e O
' O
s O
cm B-PK
##ax I-PK
was O
higher O
in O
the O
n O
##v O
##p O
- O
art O
group O
than O
in O
the O
art O
- O
naive O
group O
( O
geometric O
mean O
ratio O
, O
1 O
. O
82 O
[ O
90 O
% O
c O
##i O
, O
1 O
. O
13 O
to O
2 O
. O
94 O
] O
; O
p O
= O
0 O
. O
06 O
##1 O
) O
, O
but O
no O
significant O
differences O
in O
cm B-PK
##ax I-PK
were O
observed O
between O
the O
rest O
of O
the O
art O
groups O
and O
the O
art O
- O
naive O
group O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
pipe O
##ra O
##quin O
##e O
in O
all O
four O
study O
groups O
( O
as O
shown O
in O
table O
2 O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
median O
t B-PK
##max I-PK
was O
higher O
in O
the O
l O
##p O
##v O
– O
r O
- O
art O
group O
than O
in O
the O
art O
- O
naive O
group O
( O
p O
= O
0 O
. O
04 O
##9 O
) O
. O
[SEP] O
[CLS] O
in O
step O
2 O
, O
pipe O
##ra O
##quin O
##e O
' O
s O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
was O
43 O
% O
lower O
in O
the O
e O
##f O
##v O
- O
art O
group O
than O
in O
the O
art O
- O
naive O
group O
( O
geometric O
mean O
ratio O
, O
0 O
. O
57 O
[ O
95 O
% O
c O
##i O
, O
0 O
. O
44 O
to O
0 O
. O
74 O
] O
; O
p O
= O
0 O
. O
00 O
##2 O
) O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
pipe O
##ra O
##quin O
##e O
' O
s O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
between O
the O
n O
##v O
##p O
- O
art O
and O
art O
- O
naive O
groups O
. O
[SEP] O
[CLS] O
further O
##more O
, O
participants O
in O
the O
e O
##f O
##v O
- O
art O
group O
had O
a O
43 O
% O
lower O
cm B-PK
##ax I-PK
of O
pipe O
##ra O
##quin O
##e O
than O
the O
art O
- O
naive O
group O
( O
geometric O
mean O
ratio O
, O
0 O
. O
57 O
[ O
95 O
% O
c O
##i O
, O
0 O
. O
36 O
to O
0 O
. O
90 O
] O
; O
p O
= O
0 O
. O
06 O
##5 O
) O
, O
and O
pipe O
##ra O
##quin O
##e O
' O
s O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
64 O
% O
lower O
in O
the O
e O
##f O
##v O
- O
art O
group O
than O
in O
the O
art O
- O
naive O
group O
( O
geometric O
mean O
ratio O
, O
0 O
. O
36 O
[ O
95 O
% O
c O
##i O
, O
0 O
. O
15 O
to O
0 O
. O
87 O
] O
; O
p O
= O
0 O
. O
07 O
##2 O
) O
. O
[SEP] O
[CLS] O
however O
, O
there O
were O
no O
significant O
differences O
in O
the O
cm B-PK
##ax I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
pipe O
##ra O
##quin O
##e O
between O
the O
n O
##v O
##p O
- O
art O
and O
the O
art O
- O
naive O
groups O
, O
as O
shown O
in O
table O
3 O
. O
[SEP] O
[CLS] O
similarly O
, O
no O
significant O
differences O
in O
the O
median O
t B-PK
##max I-PK
between O
the O
two O
art O
groups O
and O
the O
art O
- O
naive O
group O
were O
observed O
. O
[SEP] O
[CLS] O
assuming O
a O
linear O
disposition O
of O
pipe O
##ra O
##quin O
##e O
, O
increasing O
the O
dose O
in O
step O
2 O
should O
result O
in O
an O
increased O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
in O
this O
step O
compared O
to O
that O
in O
step O
1 O
. O
[SEP] O
[CLS] O
as O
part O
of O
an O
ex O
##p O
##lora O
##tory O
analysis O
, O
not O
determined O
a O
prior O
##i O
, O
we O
assessed O
dose O
proportional O
##ity O
between O
the O
art O
- O
naive O
groups O
in O
steps O
1 O
and O
2 O
using O
a O
linear O
q O
##uad O
##ratic O
re O
##gression O
approach O
by O
re O
##g O
##ress O
##ing O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
/ I-PK
dose I-PK
) I-PK
with O
the O
total O
dose O
received O
by O
each O
participant O
( O
20 O
) O
. O
[SEP] O
[CLS] O
the O
fitted O
linear O
re O
##gression O
equation O
was O
( O
1 O
) O
au O
##c O
##0 O
##− O
##28 O
days O
/ O
dose O
= O
α O
+ O
β O
##1 O
##⋅ O
##dos O
##e O
+ O
β O
##2 O
##⋅ O
##dos O
##e O
##2 O
[SEP] O
[CLS] O
equation O
1 O
could O
be O
further O
simplified O
to O
equation O
3 O
when O
β O
##2 O
is O
not O
significantly O
different O
from O
zero O
: O
( O
2 O
) O
au O
##c O
##0 O
##− O
##28 O
days O
/ O
dose O
= O
α O
+ O
β O
##⋅ O
##dos O
##e O
[SEP] O
[CLS] O
this O
was O
calculated O
to O
detect O
a O
2 O
- O
fold O
increase O
in O
the O
p O
##q O
au B-PK
##c I-PK
in O
any O
of O
the O
d O
##ha O
- O
p O
##q O
- O
art O
groups O
compared O
with O
that O
in O
the O
art O
- O
naive O
group O
, O
assuming O
a O
mean O
p O
##q O
au B-PK
##c I-PK
of O
19 O
. O
4 O
μ O
##g O
· O
h O
/ O
m O
##l O
( O
standard O
de O
##viation O
, O
15 O
. O
0 O
μ O
##g O
· O
h O
/ O
m O
##l O
) O
( O
17 O
) O
in O
the O
art O
- O
naive O
group O
, O
with O
the O
power O
set O
at O
90 O
% O
and O
the O
level O
of O
significance O
set O
at O
5 O
% O
. O
[SEP] O
[CLS] O
for O
each O
study O
participant O
, O
the O
following O
p O
##k O
parameters O
were O
com O
##puted O
: O
au B-PK
##c I-PK
##0 I-PK
– I-PK
28 I-PK
days I-PK
, O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
the O
time B-PK
to I-PK
the I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
the O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
so O
##y O
is O
##of O
##lav O
##ones O
have O
also O
been O
shown O
to O
reduce O
the O
efficacy O
of O
ta O
##mo O
##xi O
##fen O
##17 O
. O
[SEP] O
[CLS] O
specifically O
, O
v O
##pa O
cm B-PK
##ax I-PK
values O
were O
decreased O
to O
57 O
% O
for O
150 O
mg O
so O
##y O
and O
65 O
% O
for O
500 O
mg O
so O
##y O
treatments O
. O
[SEP] O
[CLS] O
the O
v O
##pa O
t B-PK
##max I-PK
and O
m B-PK
##rt I-PK
were O
not O
different O
among O
the O
treatments O
. O
[SEP] O
[CLS] O
similarly O
, O
au B-PK
##c I-PK
decreased O
to O
83 O
% O
and O
69 O
% O
for O
150 O
mg O
/ O
kg O
and O
500 O
mg O
/ O
kg O
so O
##y O
treatments O
, O
respectively O
. O
[SEP] O
[CLS] O
clearance B-PK
increased O
by O
5 O
% O
to O
34 O
% O
and O
the O
volume B-PK
of I-PK
distribution I-PK
increased O
70 O
% O
in O
the O
so O
##y O
treatment O
groups O
. O
[SEP] O
[CLS] O
there O
was O
a O
significant O
difference O
in O
cm B-PK
##ax I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
au B-PK
##c I-PK
, O
clearance B-PK
, O
and O
distribution B-PK
volume I-PK
between O
the O
so O
##y O
treatment O
and O
control O
groups O
( O
table O
i O
) O
. O
[SEP] O
[CLS] O
v O
##pa O
is O
meta O
##bol O
##ized O
to O
a O
g O
##lu O
##cu O
##ron O
##ide O
for O
easy O
removal O
through O
the O
urine O
##24 O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
calculated O
using O
the O
linear O
trap O
##ez O
##oid O
##al O
method O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
time B-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
calculated O
from O
the O
experimental O
data O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##el I-PK
) I-PK
was O
estimated O
by O
re O
##gression O
analysis O
from O
the O
slope O
the O
line O
of O
best O
fit O
, O
and O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
the O
drug O
was O
obtained O
as O
##0 O
. O
69 O
##3 O
/ O
k O
##el O
. O
[SEP] O
[CLS] O
the O
dose B-PK
/ I-PK
au I-PK
##c I-PK
values O
were O
used O
to O
calculate O
total B-PK
plasma I-PK
clearance I-PK
. O
[SEP] O
[CLS] O
this O
example O
illustrate O
##s O
how O
the O
approach O
connects O
the O
ca O
##usal O
chain O
underlying O
drug O
distribution O
, O
starting O
with O
the O
technical O
aspect O
of O
drug O
delivery O
systems O
, O
through O
physiology O
- O
driven O
drug O
transport O
, O
then O
eventually O
linking O
to O
tissue O
penetration O
, O
binding O
, O
residence O
, O
and O
ultimately O
clearance B-PK
. O
[SEP] O
[CLS] O
the O
temporal O
distribution O
pattern O
could O
be O
described O
by O
a O
series O
of O
ex O
##po O
##nent O
##ial O
terms O
but O
e O
##qua O
##ting O
the O
ex O
##po O
##nent O
##ial O
terms O
to O
volumes B-PK
and O
clearance B-PK
##s I-PK
did O
not O
result O
in O
values O
that O
had O
p O
##hy O
##sio O
##log O
##ic O
meaning O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
skin O
micro O
##dial O
##ys O
##is O
showed O
that O
the O
peak B-PK
concentration I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
of I-PK
ps I-PK
##oral I-PK
##en I-PK
from I-PK
et I-PK
##hos I-PK
##ome I-PK
##s I-PK
were O
approximately O
3 O
. O
37 O
and O
2 O
. O
34 O
times O
higher O
, O
respectively O
, O
than O
those O
of O
ps O
##oral O
##en O
from O
the O
tin O
##cture O
. O
[SEP] O
[CLS] O
both O
values O
of O
f O
were O
less O
than O
f O
##0 O
. O
05 O
( O
2 O
, O
2 O
) O
, O
with O
the O
value O
19 O
. O
00 O
indicating O
that O
the O
re O
##gression O
equations O
were O
not O
statistical O
##ly O
significant O
, O
and O
the O
arranged O
et O
##hos O
##ome O
compositions O
had O
no O
significant O
effect O
on O
e O
##e O
or O
d O
##s O
##d O
. O
[SEP] O
[CLS] O
after O
30 O
minutes O
, O
the O
higher O
drug O
concentration O
in O
the O
skin O
was O
obtained O
with O
the O
et O
##hos O
##ome O
formulation O
, O
with O
the O
peak B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
observed O
3 O
hours O
after O
application O
. O
[SEP] O
[CLS] O
during O
the O
study O
, O
compared O
to O
tin O
##cture O
application O
, O
et O
##hos O
##ome O
application O
was O
associated O
with O
a O
higher O
ps O
##oral O
##en O
concentration O
, O
and O
the O
topic B-PK
##al I-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
of O
the O
et O
##hos O
##ome O
##s O
was O
2 O
. O
34 O
- O
fold O
higher O
than O
that O
of O
the O
tin O
##cture O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
in O
the O
abdomen O
was O
higher O
than O
those O
in O
the O
chest O
and O
s O
##cap O
##ular O
regions O
. O
[SEP] O
[CLS] O
figure O
2 O
##e O
, O
f O
illustrate O
##s O
the O
in O
##test O
##inal O
stability O
of O
pm O
##x O
##53 O
and O
pm O
##x O
##20 O
##5 O
when O
in O
##cu O
##bate O
##d O
at O
37 O
° O
##c O
for O
up O
to O
60 O
min O
. O
[SEP] O
[CLS] O
additionally O
, O
the O
half B-PK
- I-PK
life I-PK
and O
mean B-PK
residence I-PK
time I-PK
of O
pm O
##x O
##53 O
and O
pm O
##x O
##20 O
##5 O
are O
relatively O
short O
( O
table O
5 O
) O
. O
[SEP] O
[CLS] O
pm O
##x O
##20 O
##5 O
demonstrated O
overall O
higher O
concentrations O
in O
blood O
, O
brain O
and O
spinal O
cord O
, O
compared O
to O
pm O
##x O
##53 O
, O
as O
reflected O
by O
its O
higher O
cm B-PK
##ax I-PK
values O
. O
[SEP] O
[CLS] O
however O
, O
pm O
##x O
##20 O
##5 O
also O
displayed O
faster O
clearance B-PK
compared O
to O
pm O
##x O
##53 O
, O
potentially O
due O
to O
its O
more O
lip O
##op O
##hil O
##ic O
nature O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
and O
tissue B-PK
volume I-PK
of I-PK
distribution I-PK
of O
pm O
##x O
##53 O
was O
also O
higher O
compared O
to O
pm O
##x O
##20 O
##5 O
, O
however O
pm O
##x O
##20 O
##5 O
had O
higher O
absolute O
concentrations O
in O
the O
brain O
and O
spinal O
cord O
over O
the O
time O
- O
frame O
examined O
. O
[SEP] O
[CLS] O
me O
##rop O
##ene O
##m O
was O
cleared O
from O
the O
central O
compartment O
( O
clearance B-PK
in O
litre O
##s O
per O
hour O
) O
, O
which O
also O
has O
a O
volume B-PK
( I-PK
v I-PK
##c I-PK
; O
given O
in O
litre O
##s O
) O
. O
[SEP] O
[CLS] O
blood O
samples O
( O
4 O
m O
##l O
) O
were O
collected O
using O
the O
in O
##d O
##well O
##ing O
art O
##erial O
cat O
##he O
##ter O
just O
before O
the O
start O
of O
the O
in O
##fusion O
( O
serum B-PK
t I-PK
##rough I-PK
concentration I-PK
[ I-PK
cm I-PK
##in I-PK
] I-PK
) O
and O
after O
the O
end O
of O
the O
in O
##fusion O
( O
serum B-PK
peak I-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
) O
. O
[SEP] O
[CLS] O
k B-PK
##c I-PK
##p I-PK
, O
k B-PK
##p I-PK
##c I-PK
, O
k B-PK
##c I-PK
##b I-PK
and O
k B-PK
##b I-PK
##c I-PK
represent O
first B-PK
- I-PK
order I-PK
transfer I-PK
constant I-PK
##s I-PK
connecting O
the O
various O
compartment O
##s O
. O
[SEP] O
[CLS] O
the O
impact O
of O
weight O
, O
c O
##rc O
##l O
, O
bi O
##li O
##ru O
##bin O
, O
serum O
c O
##rp O
, O
serum O
il O
- O
6 O
, O
serum O
p O
##ct O
, O
serum O
le O
##uc O
##ocytes O
, O
c O
##s O
##f O
cells O
, O
c O
##s O
##f O
er O
##yt O
##hr O
##ocytes O
, O
c O
##s O
##f O
il O
- O
6 O
, O
c O
##s O
##f O
glucose O
, O
c O
##s O
##f O
protein O
, O
c O
##s O
##f O
drain O
in O
24 O
h O
, O
sa O
##ps O
ii O
, O
sofa O
score O
and O
g O
##cs O
as O
co O
##var O
##iate O
##s O
was O
initially O
assessed O
by O
visual O
inspection O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
and O
cm B-PK
##in I-PK
in O
serum O
and O
ca O
##fter O
4 O
h O
and O
c B-PK
##tro I-PK
##ug I-PK
h I-PK
in O
c O
##s O
##f O
are O
the O
observed O
values O
. O
[SEP] O
[CLS] O
the O
average O
au B-PK
##c I-PK
for O
each O
patient O
was O
calculated O
using O
the O
bay O
##esi O
##an O
posterior O
para O
##metric O
estimates O
from O
the O
final O
model O
using O
the O
trap O
##ez O
##oid O
##al O
rule O
in O
pm O
##et O
##ric O
##s O
. O
[SEP] O
[CLS] O
we O
divided O
each O
subject O
’ O
s O
cumulative B-PK
au I-PK
##c I-PK
( I-PK
au I-PK
##c I-PK
##f I-PK
) I-PK
by O
the O
total O
time O
in O
hours O
and O
multi O
##plied O
the O
result O
by O
24 O
to O
estimate O
the O
daily O
average O
au B-PK
##c I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
life I-PK
was O
calculated O
using O
transfer B-PK
rate I-PK
constant I-PK
##s I-PK
. O
[SEP] O
[CLS] O
c O
##rc O
##l O
was O
calculated O
using O
the O
cock O
##croft O
- O
g O
##ault O
equation O
[ O
16 O
] O
. O
[SEP] O
[CLS] O
briefly O
, O
the O
study O
population O
was O
relatively O
young O
( O
median O
age O
52 O
years O
, O
range O
46 O
– O
80 O
years O
) O
and O
had O
well O
- O
preserved O
re O
##nal O
function O
on O
the O
day O
of O
inclusion O
( O
median O
c O
##rc O
##l O
120 O
. O
1 O
m O
##l O
/ O
minute O
, O
range O
52 O
. O
3 O
– O
217 O
. O
6 O
m O
##l O
/ O
minute O
) O
. O
[SEP] O
[CLS] O
in O
serum O
, O
the O
median O
cm B-PK
##ax I-PK
( O
range O
) O
was O
20 O
. O
16 O
( O
4 O
. O
40 O
– O
69 O
. O
00 O
) O
mg O
/ O
l O
and O
the O
median O
cm B-PK
##in I-PK
( O
range O
) O
was O
2 O
. O
54 O
( O
0 O
. O
00 O
– O
31 O
. O
40 O
) O
mg O
/ O
l O
. O
in O
c O
##s O
##f O
, O
the O
median O
ca O
##fter O
4 O
##h O
( O
range O
) O
was O
1 O
. O
20 O
( O
0 O
. O
00 O
– O
6 O
. O
20 O
) O
mg O
/ O
l O
and O
the O
median O
c B-PK
##tro I-PK
##ugh I-PK
( O
range O
) O
was O
1 O
. O
28 O
( O
0 O
. O
00 O
– O
4 O
. O
10 O
) O
mg O
/ O
l O
. O
the O
median O
c O
##rc O
##l O
ranged O
from O
60 O
. O
7 O
to O
217 O
. O
6 O
m O
##l O
/ O
minute O
( O
median O
122 O
. O
5 O
m O
##l O
/ O
minute O
) O
. O
[SEP] O
[CLS] O
individual O
observed O
me O
##rop O
##ene O
##m O
concentrations O
and O
median O
c O
##rc O
##l O
values O
are O
shown O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
median O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
in O
c O
##s O
##f O
was O
26 O
. O
56 O
[UNK] O
/ O
l O
, O
and O
in O
serum O
it O
was O
350 O
. O
22 O
[UNK] O
/ O
l O
. O
the O
values O
for O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
in O
c O
##s O
##f O
and O
serum O
ranged O
from O
7 O
. O
44 O
to O
85 O
. O
53 O
[UNK] O
/ O
l O
and O
from O
112 O
. O
95 O
to O
76 O
##8 O
. O
63 O
[UNK] O
/ O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
present O
results O
, O
in O
fast O
##ed O
low O
- O
fat O
diet O
fed O
rats O
, O
are O
consistent O
with O
higher O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
o O
##m O
##3 O
##ca O
versus O
o O
##m O
##3 O
##ee O
forms O
of O
d O
##ha O
. O
[SEP] O
[CLS] O
in O
order O
to O
examine O
the O
contributions O
of O
the O
different O
forms O
of O
circulating O
d O
##ha O
( O
polar O
vs O
neutral O
lip O
##id O
species O
) O
to O
tissue O
up O
##take O
and O
retention O
of O
d O
##ha O
the O
following O
model O
( O
e O
##q O
1 O
) O
was O
applied O
: O
r O
= O
k O
##p O
##l O
##× O
##au O
##c O
##p O
##l O
+ O
kn O
##l O
##× O
##au O
##c O
##n O
##l O
( O
1 O
) O
[SEP] O
[CLS] O
the O
unknown O
##s O
, O
k B-PK
##p I-PK
##l I-PK
and O
kn B-PK
##l I-PK
are O
the O
tissue O
specific O
clearance B-PK
rates I-PK
( O
m O
##l O
/ O
100 O
##g O
/ O
min O
) O
of O
the O
polar O
and O
neutral O
lip O
##id O
species O
, O
respectively O
. O
[SEP] O
[CLS] O
model O
fitting O
and O
clearance B-PK
rate I-PK
est O
##imation O
were O
performed O
using O
multiple O
re O
##gression O
analysis O
( O
i O
##b O
##m O
s O
##ps O
##s O
statistics O
subscription O
, O
i O
##b O
##m O
co O
##rp O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
14 O
##c O
- O
d O
##ha O
/ O
o O
##m O
##3 O
##ca O
administration O
resulted O
in O
greater O
plasma O
14 O
##c O
- O
neutral O
lip O
##id O
exposure O
##s O
, O
compared O
to O
14 O
##c O
- O
d O
##ha O
- O
e O
##e O
/ O
o O
##m O
##3 O
##ee O
dos O
##ing O
consistent O
with O
higher O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
o O
##m O
##3 O
##ca O
form O
of O
d O
##ha O
. O
[SEP] O
[CLS] O
thus O
, O
the O
area B-PK
under I-PK
the I-PK
14 I-PK
##c I-PK
- I-PK
neutral I-PK
lip I-PK
##id I-PK
curve I-PK
, I-PK
from I-PK
0 I-PK
to I-PK
240 I-PK
min I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
significantly O
higher O
with O
o O
##m O
##3 O
##ca O
compared O
to O
o O
##m O
##3 O
##ee O
dos O
##ing O
( O
fi O
##g O
1 O
, O
panel O
b O
, O
p O
< O
0 O
. O
05 O
, O
t O
- O
test O
) O
. O
[SEP] O
[CLS] O
correct O
##ing O
the O
trace O
##r O
appearance O
data O
for O
the O
nominal O
d O
##ha O
and O
d O
##ha O
- O
e O
##e O
specific O
activities O
of O
the O
dose O
formulation O
##s O
indicates O
greater O
oral O
exposure O
from O
the O
f O
##fa O
vs O
the O
est O
##er O
form O
of O
d O
##ha O
. O
[SEP] O
[CLS] O
thus O
, O
a O
lower O
nominal O
dose O
of O
o O
##m O
##3 O
##ca O
( O
146 O
μ O
##mo O
##l O
/ O
rat O
versus O
an O
equivalent O
of O
256 O
μ O
##mo O
##l O
/ O
rat O
for O
o O
##m O
##3 O
##ee O
) O
tended O
to O
result O
in O
a O
higher O
estimated O
d O
##ha O
au O
##c O
in O
the O
neutral O
lip O
##id O
fraction O
( O
fi O
##g O
1 O
, O
panel O
c O
) O
. O
[SEP] O
[CLS] O
thus O
, O
the O
area B-PK
under I-PK
the I-PK
14 I-PK
##c I-PK
- I-PK
polar I-PK
lip I-PK
##id I-PK
curve I-PK
, I-PK
from I-PK
0 I-PK
to I-PK
240 I-PK
min I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
significantly O
higher O
with O
o O
##m O
##3 O
##ca O
compared O
to O
o O
##m O
##3 O
##ee O
dos O
##ing O
( O
fi O
##g O
1 O
, O
panel O
e O
, O
p O
< O
0 O
. O
01 O
, O
t O
- O
test O
) O
. O
[SEP] O
[CLS] O
14 O
##c O
- O
d O
##ha O
/ O
o O
##m O
##3 O
##ca O
administration O
resulted O
in O
greater O
plasma O
14 O
##c O
- O
polar O
lip O
##id O
exposure O
##s O
, O
compared O
to O
14 O
##c O
- O
d O
##ha O
- O
e O
##e O
/ O
o O
##m O
##3 O
##ee O
dos O
##ing O
, O
again O
consistent O
with O
higher O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
o O
##m O
##3 O
##ca O
versus O
the O
o O
##m O
##3 O
##ee O
form O
. O
[SEP] O
[CLS] O
thus O
, O
a O
lower O
nominal O
dose O
of O
o O
##m O
##3 O
##ca O
( O
see O
above O
) O
did O
not O
result O
in O
lower O
d O
##ha O
au B-PK
##c I-PK
in O
the O
polar O
lip O
##id O
fraction O
( O
fi O
##g O
1 O
, O
panel O
f O
) O
. O
[SEP] O
[CLS] O
in O
the O
other O
tissues O
, O
the O
lower O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
d O
##ha O
- O
e O
##e O
was O
compensate O
##d O
for O
by O
the O
higher O
equivalent O
dose O
of O
d O
##ha O
resulting O
in O
similar O
estimated O
d O
##ha O
retention O
##s O
for O
the O
two O
formulation O
##s O
. O
[SEP] O
[CLS] O
various O
pharmaceutical O
forms O
, O
i O
. O
e O
. O
re O
##ct O
##al O
suspension O
, O
two O
different O
re O
##ct O
##al O
gel O
##s O
, O
p O
##oly O
##eth O
##yle O
##ne O
g O
##ly O
##co O
##l O
( O
p O
##eg O
) O
su O
##pp O
##os O
##itor O
##y O
and O
hard O
gel O
##ati O
##n O
capsule O
( O
h O
##g O
##c O
) O
were O
assessed O
for O
in O
v O
##it O
##ro O
dissolution O
and O
in O
v O
##ivo O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
the O
rabbit O
. O
[SEP] O
[CLS] O
hp O
##l O
##c O
analyses O
were O
performed O
on O
waters O
hp O
##l O
##c O
system O
with O
51 O
##5 O
hp O
##l O
##c O
pump O
, O
71 O
##7 O
##p O
##lus O
auto O
##sa O
##mple O
##r O
and O
248 O
##7 O
dual O
λ O
absorb O
##ance O
detector O
( O
waters O
, O
f O
##rance O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
namely O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
and O
au B-PK
##c I-PK
of O
each O
condition O
were O
obtained O
from O
each O
individual O
plasma O
profile O
and O
then O
mean O
and O
standard O
de O
##viation O
( O
s O
##d O
) O
were O
calculated O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
was O
calculated O
using O
trap O
##ez O
##oid O
rule O
. O
[SEP] O
[CLS] O
previous O
studies O
have O
shown O
that O
at O
p O
##h O
8 O
, O
the O
half B-PK
- I-PK
life I-PK
of O
a O
##zi O
##th O
##rom O
##y O
##cin O
in O
buffer O
##ed O
solution O
was O
54 O
days O
at O
20 O
° O
##c O
and O
6 O
days O
at O
40 O
° O
##c O
( O
est O
##eb O
##an O
et O
al O
. O
, O
2009 O
) O
. O
[SEP] O
[CLS] O
a O
m O
##uc O
##o O
- O
ad O
##hesive O
gel O
was O
tested O
in O
order O
to O
enhance O
re B-PK
##ct I-PK
##al I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
by O
increasing O
the O
residence B-PK
time I-PK
in O
sit O
##u O
as O
compared O
to O
classical O
non O
m O
##uc O
##o O
- O
ad O
##hesive O
formulation O
##s O
. O
[SEP] O
[CLS] O
a O
##zi O
##th O
##rom O
##y O
##cin O
re O
##ct O
##al O
absorption O
was O
rapid O
for O
the O
suspension O
and O
car O
##bo O
##pol O
gel O
( O
t B-PK
##max I-PK
15 O
min O
) O
, O
while O
it O
required O
30 O
min O
to O
reach O
maximum B-PK
plasma I-PK
concentration I-PK
for O
the O
h O
##g O
##c O
and O
60 O
min O
for O
the O
hp O
##m O
##c O
gel O
and O
the O
p O
##eg O
su O
##pp O
##os O
##itor O
##y O
. O
[SEP] O
[CLS] O
the O
highest O
re O
##ct O
##al O
cm B-PK
##ax I-PK
and O
re B-PK
##ct I-PK
##al I-PK
au I-PK
##c I-PK
##0 I-PK
##− I-PK
##24 I-PK
h I-PK
was O
obtained O
with O
the O
p O
##eg O
su O
##pp O
##os O
##itor O
##y O
; O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
[UNK] O
% O
of O
i O
##v O
and O
[UNK] O
. O
3 O
times O
that O
of O
the O
re O
##ct O
##al O
suspension O
. O
[SEP] O
[CLS] O
the O
ratios B-PK
au I-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
minimum I-PK
inhibitor I-PK
##y I-PK
concentration I-PK
( I-PK
mi I-PK
##c I-PK
) I-PK
and O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
are O
regarded O
as O
the O
main O
p O
##har O
##ma O
##co O
##kin O
##etic O
/ O
p O
##har O
##ma O
##co O
##dynamic O
parameters O
for O
a O
##zi O
##th O
##rom O
##y O
##cin O
efficacy O
. O
[SEP] O
[CLS] O
differently O
from O
er O
##yt O
##hr O
##omy O
##cin O
, O
for O
a O
##zi O
##th O
##rom O
##y O
##cin O
the O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
is O
more O
important O
than O
t O
/ O
mi O
##c O
because O
of O
its O
long O
half B-PK
- I-PK
life I-PK
and O
good O
tissue O
penetration O
( O
van O
b O
##am O
##bek O
##e O
and O
t O
##ul O
##ken O
##s O
, O
2001 O
) O
. O
[SEP] O
[CLS] O
of O
the O
formulation O
##s O
tested O
, O
the O
p O
##eg O
su O
##pp O
##os O
##itor O
##y O
appears O
to O
be O
the O
most O
promising O
candidate O
, O
but O
has O
a O
potential O
short O
##coming O
– O
the O
rather O
long O
t B-PK
##max I-PK
, O
which O
is O
of O
particular O
concern O
if O
early O
onset O
of O
action O
is O
needed O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
su O
##pp O
##os O
##itor O
##y O
formulation O
could O
be O
further O
improved O
by O
adding O
absorption O
enhance O
##rs O
or O
using O
a O
e O
##ute O
##ctic O
mixture O
of O
p O
##eg O
and O
a O
##zi O
##th O
##rom O
##y O
##cin O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
remained O
unchanged O
for O
20 O
and O
40 O
mg O
/ O
kg O
of O
a O
##zi O
##th O
##rom O
##y O
##cin O
( O
261 O
and O
255 O
ng O
/ O
m O
##l O
respectively O
) O
and O
the O
extra O
##pol O
##ated O
au B-PK
##c I-PK
value O
ratio O
was O
1 O
: O
1 O
. O
5 O
compared O
to O
1 O
: O
2 O
ratio O
for O
the O
a O
##zi O
##th O
##rom O
##y O
##cin O
dose O
. O
[SEP] O
[CLS] O
t B-PK
##max I-PK
remained O
unchanged O
. O
[SEP] O
[CLS] O
while O
both O
plasma O
and O
tissue O
concentrations O
were O
reportedly O
increased O
when O
doubling O
a O
##zi O
##th O
##rom O
##y O
##cin O
dose O
from O
500 O
to O
1000 O
mg O
per O
o O
##s O
in O
healthy O
adults O
( O
da O
##nes O
##i O
et O
al O
. O
, O
2003 O
) O
, O
an O
oral O
dose O
of O
20 O
mg O
/ O
kg O
produced O
only O
a O
marginal O
increase O
in O
plasma O
au B-PK
##c I-PK
over O
10 O
mg O
/ O
kg O
( O
au B-PK
##c I-PK
ratio I-PK
1 O
: O
18 O
) O
, O
but O
a O
more O
significant O
increase O
of O
tons O
##il O
tissue B-PK
au I-PK
##c I-PK
( O
au B-PK
##c I-PK
ratio I-PK
1 O
: O
53 O
) O
( O
b O
##land O
##iz O
##zi O
et O
al O
. O
, O
2002 O
) O
. O
[SEP] O
[CLS] O
their O
average O
areas B-PK
under I-PK
the I-PK
concentration I-PK
curves I-PK
, I-PK
au I-PK
##c I-PK
in I-PK
the I-PK
plasma I-PK
after O
a O
single O
oral O
administration O
of O
40 O
m O
##l O
of O
k O
- O
60 O
##1 O
was O
also O
presented O
( O
fi O
##g O
. O
4 O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
e O
##uca O
##ly O
##pt O
##ol O
( O
fast O
##ed O
vs O
fed O
) O
were O
as O
follows O
: O
ma B-PK
##ximal I-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
( O
167 O
. O
60 O
##± O
##11 O
##4 O
. O
69 O
vs O
51 O
##8 O
. O
89 O
##± O
##31 O
##4 O
. O
47 O
ng O
· O
m O
##l O
##− O
##1 O
) O
, O
time B-PK
of I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
( O
3 O
. O
7 O
##± O
##1 O
. O
1 O
vs O
4 O
. O
8 O
##± O
##0 O
. O
7 O
h O
) O
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
( O
3 O
. O
2 O
##± O
##1 O
. O
4 O
vs O
2 O
. O
6 O
##± O
##0 O
. O
7 O
h O
) O
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
( O
58 O
##4 O
. O
91 O
##± O
##36 O
##9 O
. O
90 O
vs O
1 O
, O
27 O
##1 O
. O
61 O
##± O
##60 O
##5 O
. O
82 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
( O
69 O
##0 O
. O
36 O
##± O
##46 O
##7 O
. O
26 O
vs O
1 O
, O
45 O
##8 O
. O
02 O
##± O
##7 O
##20 O
. O
21 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
. O
[SEP] O
[CLS] O
there O
was O
statistical O
##ly O
significant O
difference O
in O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
between O
the O
two O
dos O
##ing O
methods O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
90 O
% O
confidence O
intervals O
for O
the O
ratio O
of O
cm B-PK
##ax I-PK
( O
18 O
. O
4 O
% O
~ O
64 O
. O
7 O
% O
) O
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
( O
28 O
. O
9 O
% O
~ O
68 O
. O
5 O
% O
) O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
( O
31 O
. O
1 O
% O
~ O
68 O
. O
4 O
% O
) O
values O
for O
the O
test O
( O
fast O
##ed O
) O
and O
reference O
( O
fed O
) O
were O
beyond O
the O
food O
and O
drug O
administration O
’ O
s O
acceptable O
range O
of O
80 O
% O
~ O
125 O
% O
. O
[SEP] O
[CLS] O
in O
addition O
, O
significant O
difference O
was O
obtained O
in O
t B-PK
##max I-PK
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
a O
high O
- O
fat O
and O
high O
- O
ca O
##lor O
##ie O
diet O
made O
of O
protein O
( O
about O
150 O
ca O
##lor O
##ies O
) O
, O
car O
##bo O
##hy O
##dra O
##tes O
( O
250 O
ca O
##lor O
##ies O
) O
, O
and O
fat O
( O
500 O
– O
600 O
ca O
##lor O
##ies O
) O
was O
provided O
and O
was O
treated O
as O
a O
standardized O
meal O
for O
food O
– O
effect O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
study O
. O
[SEP] O
[CLS] O
ma B-PK
##ximal I-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
times B-PK
at I-PK
which I-PK
they I-PK
occurred I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
determined O
by O
inspection O
of O
the O
plasma O
concentration O
– O
time O
profile O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
( I-PK
λ I-PK
##z I-PK
) I-PK
was O
determined O
by O
linear O
re O
##gression O
of O
the O
terminal O
portion O
of O
the O
log O
concentration O
– O
time O
profile O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
calculated O
as O
0 O
. O
69 O
##3 O
/ O
λ O
##z O
. O
[SEP] O
[CLS] O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
determined O
by O
trap O
##ez O
##oid O
##al O
rule O
and O
was O
extra O
##pol O
##ated O
to O
in O
##finity O
by O
using O
the O
calculation O
of O
c B-PK
##t I-PK
/ I-PK
λ I-PK
##z I-PK
. O
[SEP] O
[CLS] O
log O
transformed O
, O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
were O
analyzed O
using O
analysis O
of O
variance O
analysis O
and O
s O
##chu O
##ir O
##mann O
two O
one O
- O
sided O
t O
- O
test O
. O
[SEP] O
[CLS] O
t B-PK
##max I-PK
was O
analyzed O
by O
the O
non O
##par O
##ame O
##tric O
test O
, O
w O
##il O
##co O
##xon O
’ O
s O
test O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
dos O
##ing O
conditions O
( O
fast O
##ed O
vs O
after O
a O
meal O
) O
were O
as O
follows O
( O
table O
1 O
) O
: O
cm B-PK
##ax I-PK
( O
167 O
. O
6 O
##± O
##11 O
##4 O
. O
69 O
vs O
51 O
##8 O
. O
89 O
##± O
##31 O
##4 O
. O
47 O
ng O
· O
m O
##l O
##− O
##1 O
) O
, O
t B-PK
##max I-PK
( O
3 O
. O
7 O
##± O
##1 O
. O
1 O
vs O
4 O
. O
8 O
##± O
##0 O
. O
7 O
h O
) O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
3 O
. O
2 O
##± O
##1 O
. O
4 O
vs O
2 O
. O
6 O
##± O
##0 O
. O
7 O
h O
) O
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
( O
58 O
##4 O
. O
91 O
##± O
##36 O
##9 O
. O
90 O
vs O
127 O
##1 O
. O
61 O
##± O
##60 O
##5 O
. O
82 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
( O
69 O
##0 O
. O
36 O
##± O
##46 O
##7 O
. O
26 O
vs O
145 O
##8 O
. O
02 O
##± O
##7 O
##20 O
. O
21 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
. O
[SEP] O
[CLS] O
statistical O
##ly O
significant O
difference O
was O
observed O
in O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
between O
two O
dos O
##ing O
methods O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
90 O
% O
c O
##i O
for O
the O
ratio B-PK
of I-PK
cm I-PK
##ax I-PK
( O
18 O
. O
4 O
% O
~ O
64 O
. O
7 O
% O
) O
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
( O
28 O
. O
9 O
% O
~ O
68 O
. O
5 O
% O
) O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
( O
31 O
. O
1 O
% O
~ O
68 O
. O
4 O
% O
) O
values O
for O
the O
test O
( O
fast O
##ed O
) O
and O
reference O
( O
after O
a O
meal O
) O
were O
beyond O
the O
food O
and O
drug O
administration O
’ O
s O
acceptable O
range O
of O
80 O
% O
~ O
125 O
% O
. O
[SEP] O
[CLS] O
additionally O
, O
t B-PK
##max I-PK
value O
between O
two O
phases O
exhibited O
significant O
difference O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
compared O
with O
s O
##ham O
- O
i O
##rra O
##dia O
##ted O
controls O
, O
whole O
p O
##el O
##vic O
i O
##rra O
##diation O
reduced O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
5 O
- O
f O
##u O
in O
plasma O
and O
, O
in O
contrast O
, O
increased O
in O
bi O
##le O
with O
a O
radiation O
dose O
- O
dependent O
manner O
. O
[SEP] O
[CLS] O
pre O
##tre O
##at O
##ment O
with O
mm O
##p O
- O
8 O
inhibitor O
reversed O
the O
effect O
of O
i O
##rra O
##diation O
on O
au B-PK
##c I-PK
of O
5 O
- O
f O
##u O
in O
plasma O
. O
[SEP] O
[CLS] O
intriguing O
##ly O
, O
we O
found O
that O
p O
##el O
##vic O
i O
##rra O
##diation O
marked O
##ly O
reduced O
the O
au B-PK
##c I-PK
of O
5 O
- O
f O
##u O
in O
rats O
by O
17 O
. O
6 O
% O
at O
0 O
. O
5 O
g O
##y O
( O
p O
= O
0 O
. O
01 O
##9 O
) O
and O
21 O
. O
5 O
% O
at O
2 O
g O
##y O
( O
p O
= O
0 O
. O
00 O
##8 O
) O
( O
fi O
##g O
. O
1 O
##a O
) O
. O
[SEP] O
[CLS] O
p O
##el O
##vic O
i O
##rra O
##diation O
significantly O
decreased O
cm B-PK
##ax I-PK
and O
clearance B-PK
value O
, O
and O
in O
contrast O
, O
increased O
m B-PK
##rt I-PK
and O
vs B-PK
##s I-PK
of O
5 O
- O
f O
##u O
, O
when O
compared O
to O
non O
- O
i O
##rra O
##dia O
##ted O
controls O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
1 O
, O
p O
##el O
##vic O
i O
##rra O
##diation O
significantly O
decreased O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
, O
and O
by O
contrast O
, O
increased O
the O
clearance B-PK
value O
of O
5 O
- O
f O
##u O
when O
compared O
to O
non O
- O
i O
##rra O
##dia O
##ted O
controls O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
the O
values O
of O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
or O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
within O
the O
tested O
groups O
. O
[SEP] O
[CLS] O
of O
interest O
, O
2 O
- O
g O
##y O
i O
##rra O
##diation O
decreased O
cm B-PK
##ax I-PK
, O
and O
in O
contrast O
, O
increased O
m B-PK
##rt I-PK
( O
p O
= O
0 O
. O
00 O
##8 O
) O
and O
vs B-PK
##s I-PK
( O
p O
= O
0 O
. O
01 O
##5 O
) O
of O
5 O
- O
f O
##u O
to O
an O
extent O
greater O
than O
that O
of O
the O
0 O
. O
5 O
- O
g O
##y O
group O
. O
[SEP] O
[CLS] O
there O
was O
no O
statistical O
##ly O
significant O
difference O
between O
the O
0 O
. O
5 O
- O
g O
##y O
and O
control O
groups O
for O
cm B-PK
##ax I-PK
and O
vs B-PK
##s I-PK
. O
[SEP] O
[CLS] O
neither O
the O
mm O
##p O
- O
8 O
inhibitor O
alone O
nor O
its O
vehicle O
had O
a O
significant O
effect O
on O
the O
au B-PK
##c I-PK
of O
5 O
- O
f O
##u O
in O
comparison O
with O
the O
controls O
( O
fi O
##g O
. O
6 O
) O
. O
[SEP] O
[CLS] O
we O
found O
that O
pre O
##tre O
##at O
##ment O
with O
mm O
##p O
- O
8 O
inhibitor O
significantly O
at O
##ten O
##uated O
the O
decline O
in O
au B-PK
##c I-PK
of O
5 O
- O
f O
##u O
caused O
by O
p O
##el O
##vic O
i O
##rra O
##diation O
( O
au B-PK
##ci I-PK
##rra I-PK
##diation I-PK
versus O
au B-PK
##c I-PK
##mm I-PK
##p I-PK
- I-PK
8 I-PK
inhibitor O
+ O
i O
##rra O
##diation O
was O
330 O
##5 O
versus O
39 O
##6 O
##3 O
min O
µ O
##g O
/ O
m O
##l O
, O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
decreased O
m B-PK
##rt I-PK
and O
increased O
clearance B-PK
value O
caused O
by O
i O
##rra O
##diation O
were O
completely O
reversed O
by O
use O
of O
the O
mm O
##p O
- O
8 O
inhibitor O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
jar O
##ug O
##ula O
et O
al O
. O
[ O
42 O
] O
proved O
that O
the O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
significantly O
higher O
after O
administration O
of O
100 O
mg O
/ O
kg O
( O
mean O
± O
standard O
de O
##viation O
, O
s O
##d O
, O
1 O
. O
14 O
##± O
##0 O
. O
55 O
mg O
· O
h O
/ O
l O
/ O
mg O
) O
than O
after O
50 O
mg O
/ O
kg O
( O
mean O
± O
s O
##d O
, O
0 O
. O
50 O
##± O
##0 O
. O
16 O
mg O
· O
h O
/ O
l O
/ O
mg O
) O
or O
10 O
mg O
/ O
kg O
( O
mean O
± O
s O
##d O
, O
0 O
. O
43 O
##± O
##0 O
. O
11 O
mg O
· O
h O
/ O
l O
/ O
mg O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
including O
the O
au B-PK
##c I-PK
for O
concentration O
versus O
time O
, O
terminal B-PK
elimination I-PK
phase I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
, O
cm B-PK
##ax I-PK
, O
m B-PK
##rt I-PK
, O
total B-PK
plasma I-PK
clearance I-PK
and O
vs B-PK
##s I-PK
were O
calculated O
using O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
calculation O
software O
win O
##non O
##lin O
standard O
edition O
, O
version O
1 O
. O
1 O
( O
scientific O
consulting O
, O
apex O
, O
n O
##c O
, O
us O
##a O
) O
using O
a O
compartment O
##al O
method O
. O
[SEP] O
[CLS] O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
half B-PK
- I-PK
life I-PK
, O
area B-PK
under I-PK
plasma I-PK
concentration I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
and O
mean B-PK
resident I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
were O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
during O
multiple O
dose O
kinetic O
study O
and O
elimination B-PK
rate I-PK
constant I-PK
was O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
in O
comparison O
with O
their O
respective O
single O
- O
dose O
values O
, O
while O
there O
was O
no O
significant O
difference O
in O
time O
to O
achieve O
maximum B-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
in O
all O
groups O
during O
both O
phases O
of O
the O
study O
. O
[SEP] O
[CLS] O
the O
study O
revealed O
higher O
values O
[ O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
, O
area B-PK
[SEP] O
[CLS] O
under B-PK
the I-PK
moment I-PK
curve I-PK
( I-PK
au I-PK
##m I-PK
##c I-PK
) I-PK
, O
m B-PK
##rt I-PK
, O
and O
half B-PK
- I-PK
life I-PK
] O
of O
at O
##or O
##vas O
##tat O
##in O
in O
garlic O
- O
treated O
groups O
. O
[SEP] O
[CLS] O
by O
using O
this O
program O
, O
parameters O
like O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
elimination B-PK
rate I-PK
constant I-PK
, O
half B-PK
- I-PK
life I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
, O
au B-PK
##m I-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
, O
and O
au B-PK
##m I-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
were O
calculated O
. O
[SEP] O
[CLS] O
elimination B-PK
rate I-PK
constant I-PK
and O
half B-PK
- I-PK
life I-PK
were O
calculated O
using O
all O
terminal O
concentration O
- O
time O
points O
from O
the O
point O
of O
peak B-PK
concentration I-PK
. O
[SEP] O
[CLS] O
λ B-PK
##z I-PK
is O
elimination B-PK
rate I-PK
constant I-PK
[SEP] O
[CLS] O
maximum B-PK
observed I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
( O
ng O
/ O
m O
##l O
) O
values O
of O
groups O
1 O
through O
5 O
[ O
figures O
1 O
and O
5 O
] O
during O
multiple O
- O
dose O
kinetic O
study O
( O
153 O
. O
85 O
± O
2 O
. O
63 O
, O
250 O
. O
85 O
± O
2 O
. O
89 O
, O
147 O
. O
31 O
± O
5 O
. O
48 O
, O
128 O
. O
89 O
± O
4 O
. O
29 O
, O
and O
71 O
. O
24 O
± O
2 O
. O
11 O
, O
respectively O
) O
were O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
than O
those O
of O
their O
respective O
single O
- O
dose O
kinetic O
values O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
time B-PK
to I-PK
achieve I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
( O
h O
) O
values O
in O
all O
groups O
during O
both O
phases O
of O
study O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
value O
observed O
during O
multiple O
dose O
study O
in O
group O
2 O
was O
the O
highest O
( O
250 O
. O
85 O
± O
2 O
. O
89 O
) O
and O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
as O
compared O
to O
its O
single O
- O
dose O
study O
value O
( O
162 O
. O
14 O
± O
2 O
. O
90 O
) O
and O
that O
of O
multiple O
- O
dose O
study O
value O
of O
group O
1 O
( O
at O
##or O
##vas O
##tat O
##in O
control O
) O
. O
[SEP] O
[CLS] O
elimination B-PK
rate I-PK
constant I-PK
( O
h O
– O
1 O
) O
in O
all O
groups O
showed O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decrease O
during O
multiple O
- O
dose O
study O
when O
compared O
to O
their O
respective O
values O
during O
single O
- O
dose O
study O
. O
[SEP] O
[CLS] O
elimination B-PK
rate I-PK
constant I-PK
value O
observed O
in O
group O
2 O
during O
multiple O
- O
dose O
study O
was O
the O
least O
( O
0 O
. O
131 O
± O
0 O
. O
00 O
##6 O
) O
followed O
by O
groups O
1 O
, O
3 O
, O
and O
4 O
, O
while O
group O
5 O
showed O
the O
highest O
elimination B-PK
rate I-PK
constant I-PK
( O
0 O
. O
253 O
± O
0 O
. O
11 O
) O
. O
[SEP] O
[CLS] O
elimination B-PK
rate I-PK
constant I-PK
observed O
in O
group O
2 O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
lower O
than O
that O
observed O
in O
group O
1 O
( O
at O
##or O
##vas O
##tat O
##in O
control O
) O
during O
multiple O
- O
dose O
study O
. O
[SEP] O
[CLS] O
the O
highest O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
) I-PK
( O
ng O
. O
h O
/ O
m O
##l O
) O
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
( O
ng O
. O
h O
/ O
m O
##l O
) O
values O
were O
observed O
in O
group O
2 O
during O
both O
phases O
of O
the O
study O
, O
followed O
by O
groups O
1 O
and O
3 O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
value O
observed O
in O
group O
2 O
during O
multiple O
- O
dose O
( O
27 O
##18 O
. O
68 O
± O
63 O
. O
40 O
) O
studies O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
than O
its O
respective O
single O
- O
dose O
value O
( O
152 O
##6 O
. O
73 O
± O
29 O
. O
03 O
) O
and O
also O
higher O
than O
the O
value O
of O
group O
1 O
( O
at O
##or O
##vas O
##tat O
##in O
control O
) O
( O
140 O
##1 O
. O
48 O
± O
31 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
mean B-PK
resident I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
( O
h O
) O
during O
multiple O
- O
dose O
study O
in O
all O
groups O
was O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
when O
compared O
to O
their O
respective O
single O
- O
dose O
study O
value O
. O
[SEP] O
[CLS] O
the O
highest O
m B-PK
##rt I-PK
was O
noted O
in O
group O
2 O
( O
8 O
. O
19 O
± O
0 O
. O
27 O
) O
during O
multiple O
- O
dose O
study O
followed O
by O
groups O
1 O
, O
4 O
, O
and O
3 O
, O
while O
m B-PK
##rt I-PK
of O
group O
5 O
( O
4 O
. O
57 O
± O
0 O
. O
11 O
) O
was O
found O
to O
be O
the O
least O
. O
[SEP] O
[CLS] O
m B-PK
##rt I-PK
value O
of O
group O
2 O
was O
also O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
higher O
than O
that O
of O
group O
1 O
at O
the O
end O
of O
multiple O
- O
dose O
study O
( O
7 O
. O
31 O
± O
0 O
. O
07 O
) O
[ O
table O
2 O
] O
. O
[SEP] O
[CLS] O
to O
the O
best O
of O
our O
knowledge O
, O
there O
are O
no O
available O
data O
concerning O
its O
pre O
##c O
##lini O
##cal O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
be O
##ag O
##le O
dogs O
. O
[SEP] O
[CLS] O
to O
support O
pre O
##c O
##lini O
##cal O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
study O
, O
a O
reliable O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
method O
was O
developed O
for O
k O
##d O
concentration O
measurements O
in O
be O
##ag O
##le O
dog O
plasma O
. O
[SEP] O
[CLS] O
the O
currently O
developed O
method O
was O
valid O
##ated O
and O
applied O
to O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
study O
of O
k O
##d O
in O
be O
##ag O
##le O
dogs O
following O
oral O
administration O
at O
a O
dose O
of O
3 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
oral I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
k O
##d O
was O
determined O
to O
be O
27 O
. O
6 O
% O
. O
[SEP] O
[CLS] O
compared O
with O
typical O
g O
##ly O
##cos O
##ides O
, O
k O
##d O
has O
a O
better O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
is O
suitable O
for O
developing O
an O
oral O
dos O
##age O
form O
. O
[SEP] O
[CLS] O
the O
valid O
##ated O
method O
was O
applied O
to O
a O
pre O
##c O
##lini O
##cal O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
study O
of O
k O
##d O
in O
be O
##ag O
##le O
dogs O
following O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
directly O
from O
the O
plasma O
concentration O
time O
course O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
measured I-PK
time I-PK
point I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
and O
from O
time O
zero O
to O
in O
##finity O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) O
were O
estimated O
using O
the O
log O
- O
linear O
trap O
##ez O
##oid O
##al O
rule O
, O
while O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
the O
total B-PK
body I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
and O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
were O
processed O
by O
p O
##hoe O
##ni O
##x O
win O
##non O
##lin O
software O
. O
[SEP] O
[CLS] O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
was O
calculated O
using O
the O
formula O
f O
= O
( O
au O
##c O
##po O
/ O
au O
##ci O
##v O
) O
× O
( O
dose O
##iv O
/ O
dose O
##po O
) O
. O
[SEP] O
[CLS] O
after O
an O
oral O
dose O
of O
3 O
mg O
/ O
kg O
, O
k O
##d O
was O
quickly O
absorbed O
and O
the O
cm B-PK
##ax I-PK
was O
reached O
at O
around O
1 O
. O
04 O
h O
, O
followed O
by O
a O
rapid O
elimination O
with O
a O
half B-PK
- I-PK
life I-PK
of O
0 O
. O
91 O
##5 O
h O
. O
the O
mean O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
values O
were O
68 O
##20 O
and O
1880 O
ng O
· O
min O
/ O
m O
##l O
for O
in O
##tra O
##ven O
##ous O
and O
oral O
doses O
of O
3 O
mg O
/ O
kg O
k O
##d O
. O
[SEP] O
[CLS] O
based O
upon O
such O
data O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
k O
##d O
following O
oral O
administration O
( O
3 O
mg O
/ O
kg O
) O
was O
found O
to O
be O
27 O
. O
6 O
% O
. O
[SEP] O
[CLS] O
compared O
with O
those O
of O
the O
majority O
of O
extensively O
researched O
is O
##of O
##lav O
##one O
g O
##ly O
##cos O
##ides O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
k O
##d O
was O
at O
least O
4 O
- O
fold O
higher O
[ O
24 O
, O
25 O
, O
26 O
] O
. O
[SEP] O
[CLS] O
although O
this O
study O
provides O
the O
ground O
##work O
for O
knowing O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
k O
##d O
, O
comprehensive O
studies O
are O
required O
to O
further O
investigate O
absorption O
, O
distribution O
, O
metabolism O
, O
and O
ex O
##cre O
##tion O
processes O
in O
pre O
##c O
##lini O
##cal O
animal O
models O
. O
[SEP] O
[CLS] O
delivery O
of O
hug O
##t O
##1 O
##a O
##1 O
‐ O
m O
##od O
##rna O
( O
a O
modified O
messenger O
r O
##na O
encoding O
for O
u O
##gt O
##1 O
##a O
##1 O
) O
as O
a O
lip O
##id O
na O
##no O
##par O
##tic O
##le O
is O
anticipated O
to O
restore O
he O
##pa O
##tic O
expression O
of O
u O
##gt O
##1 O
##a O
##1 O
, O
allowing O
normal O
g O
##lu O
##cu O
##ron O
##ida O
##tion O
and O
clearance B-PK
of O
bi O
##li O
##ru O
##bin O
in O
patients O
. O
[SEP] O
[CLS] O
a O
new O
hug O
##t O
##1 O
##a O
##1 O
‐ O
m O
##od O
##rna O
therapy O
discussed O
in O
this O
report O
aims O
to O
enable O
he O
##pa O
##tic O
expression O
of O
functional O
u O
##gt O
##1 O
##a O
##1 O
enzyme O
to O
restore O
the O
normal O
bi O
##li O
##ru O
##bin O
clearance B-PK
pathway O
. O
[SEP] O
[CLS] O
non O
##com O
##par O
##tment O
p O
##k O
analysis O
was O
performed O
to O
obtain O
exposure O
( O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
) O
information O
in O
plasma O
and O
liver O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
specifically O
, O
the O
model O
includes O
: O
( O
1 O
) O
elimination O
of O
l O
##n O
##p O
from O
the O
plasma O
due O
to O
lip O
##oso O
##mal O
instability O
; O
( O
2 O
) O
the O
up O
##take O
of O
l O
##n O
##p O
by O
end O
##oc O
##yt O
##osis O
into O
liver O
he O
##pa O
##to O
##cy O
##tes O
; O
( O
3 O
) O
release O
of O
m O
##rna O
from O
the O
end O
##oso O
##me O
into O
the O
c O
##yt O
##op O
##las O
##m O
; O
( O
4 O
) O
the O
transcription O
of O
the O
m O
##rna O
to O
produce O
u O
##gt O
##1 O
##a O
##1 O
protein O
; O
and O
( O
5 O
) O
g O
##lu O
##cu O
##ron O
##ida O
##tion O
of O
bi O
##li O
##ru O
##bin O
by O
u O
##gt O
##1 O
##a O
##1 O
leading O
to O
( O
6 O
) O
increased O
clearance B-PK
of O
bi O
##li O
##ru O
##bin O
. O
[SEP] O
[CLS] O
further O
##more O
, O
a O
systematic O
sensitivity O
analysis O
based O
on O
area O
under O
the O
absolute O
se O
##ns O
##iti O
##vi O
##ties O
was O
performed O
to O
explore O
the O
impact O
of O
model O
parameters O
on O
the O
time O
course O
of O
total O
bi O
##li O
##ru O
##bin O
levels O
in O
rat O
studies O
( O
supplement O
##ary O
figure O
s O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
parameter O
vs O
. O
objective O
function O
curves O
for O
protein O
binding O
on O
‐ O
rate O
constant O
( O
k O
##on O
) O
, O
protein O
binding O
di O
##sso O
##ciation O
rate O
constant O
( O
k O
##off O
) O
, O
and O
elimination B-PK
rate I-PK
of O
mon O
##og O
##lu O
##cu O
##ron O
##ide O
bi O
##li O
##ru O
##bin O
( O
k B-PK
##cle I-PK
##arm I-PK
##gt I-PK
) O
were O
found O
to O
be O
flat O
indicating O
that O
the O
model O
fit O
is O
not O
sensitive O
to O
the O
value O
of O
these O
parameters O
over O
this O
range O
. O
[SEP] O
[CLS] O
whereas O
, O
the O
elimination B-PK
rate I-PK
of I-PK
bi I-PK
##li I-PK
##ru I-PK
##bin I-PK
( I-PK
k I-PK
##cle I-PK
##ar I-PK
##bil I-PK
) I-PK
and O
elimination B-PK
rate I-PK
of I-PK
d I-PK
##gt I-PK
bi I-PK
##li I-PK
##ru I-PK
##bin I-PK
( I-PK
k I-PK
##cle I-PK
##ard I-PK
##gt I-PK
) I-PK
are O
highly O
sensitive O
. O
[SEP] O
[CLS] O
there O
are O
one O
‐ O
sided O
sensitive O
##s O
for O
first B-PK
order I-PK
elimination I-PK
rate I-PK
of I-PK
l I-PK
##n I-PK
##p I-PK
( I-PK
k I-PK
##w I-PK
) I-PK
and O
drug B-PK
distribution I-PK
rate I-PK
constant I-PK
from I-PK
plasma I-PK
to I-PK
tissue I-PK
( I-PK
k I-PK
##12 I-PK
) I-PK
indicating O
that O
a O
higher O
value O
for O
these O
parameters O
is O
less O
likely O
than O
a O
lower O
value O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
half I-PK
‐ I-PK
life I-PK
of O
l O
##n O
##p O
was O
determined O
to O
be O
[UNK] O
hours O
( O
k O
##w O
= O
2 O
. O
41 O
##e O
‐ O
05 O
1 O
/ O
s O
) O
. O
[SEP] O
[CLS] O
the O
main O
parameters O
that O
are O
anticipated O
to O
be O
different O
between O
gun O
##n O
rats O
and O
patients O
with O
c O
##n O
##1 O
are O
the O
production O
and O
clearance B-PK
rates I-PK
of O
un O
##mo O
##dified O
bi O
##li O
##ru O
##bin O
. O
[SEP] O
[CLS] O
in O
contrast O
to O
the O
bi O
##li O
##ru O
##bin O
synthesis O
and O
clearance B-PK
rate I-PK
, O
other O
parameters O
used O
in O
the O
q O
##sp O
model O
represent O
bio O
##physical O
interactions O
or O
cellular O
processes O
that O
are O
expected O
to O
be O
preserved O
between O
humans O
and O
rats O
and O
fixed O
as O
such O
in O
the O
human O
model O
( O
table O
##1 O
) O
. O
[SEP] O
[CLS] O
for O
example O
, O
as O
the O
major O
clearance B-PK
route O
of O
plasma O
l O
##n O
##p O
is O
thought O
to O
be O
l O
##n O
##p O
instability O
, O
8 O
, O
9 O
the O
elimination B-PK
rate I-PK
was O
assumed O
to O
be O
the O
same O
in O
humans O
and O
gun O
##n O
rats O
. O
[SEP] O
[CLS] O
the O
primary O
end O
##point O
was O
systemic O
o O
##xy O
##mor O
##phone O
exposure O
; O
the O
bio O
##e O
##qui O
##valence O
criterion O
was O
met O
if O
the O
90 O
% O
confidence O
intervals O
of O
the O
geometric O
mean O
ratio O
( O
o O
##xy O
- O
c O
##rf O
/ O
o O
##xy O
- O
er O
) O
for O
o O
##xy O
##mor O
##phone O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
the I-PK
last I-PK
measured I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
) I-PK
, O
and O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
were O
within O
0 O
. O
8 O
– O
1 O
. O
25 O
. O
[SEP] O
[CLS] O
the O
90 O
% O
confidence O
intervals O
for O
plasma O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
, O
and O
cm B-PK
##ax I-PK
fulfilled O
the O
bio O
##e O
##qui O
##valence O
criterion O
. O
[SEP] O
[CLS] O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
produced O
similar O
mean O
± O
standard O
de O
##viation O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
( O
study O
1 O
, O
5 O
. O
05 O
± O
1 O
. O
55 O
versus O
5 O
. O
29 O
± O
1 O
. O
52 O
ng O
· O
h O
/ O
m O
##l O
; O
study O
2 O
, O
31 O
. O
51 O
± O
10 O
. O
95 O
versus O
31 O
. O
23 O
± O
10 O
. O
33 O
ng O
· O
h O
/ O
m O
##l O
; O
study O
3 O
, O
50 O
. O
16 O
± O
14 O
. O
91 O
versus O
49 O
. O
01 O
± O
14 O
. O
03 O
ng O
· O
h O
/ O
m O
##l O
) O
and O
cm B-PK
##ax I-PK
( O
0 O
. O
38 O
± O
0 O
. O
11 O
versus O
0 O
. O
37 O
± O
0 O
. O
12 O
ng O
/ O
m O
##l O
; O
2 O
. O
37 O
± O
1 O
. O
20 O
versus O
2 O
. O
41 O
± O
0 O
. O
94 O
ng O
/ O
m O
##l O
; O
5 O
. O
87 O
± O
1 O
. O
99 O
versus O
5 O
. O
63 O
± O
2 O
. O
26 O
ng O
/ O
m O
##l O
) O
under O
all O
conditions O
. O
[SEP] O
[CLS] O
o O
##xy O
##mor O
##phone O
and O
6 O
- O
h O
##ydro O
##xy O
- O
o O
##xy O
##mor O
##phone O
( O
6 O
- O
oh O
- O
o O
##xy O
##mor O
##phone O
) O
concentrations O
were O
determined O
using O
a O
simultaneous O
liquid O
ch O
##roma O
##tography O
- O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
valid O
##ated O
for O
the O
range O
of O
0 O
. O
02 O
##5 O
– O
10 O
. O
00 O
ng O
/ O
m O
##l O
. O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
( O
area B-PK
under I-PK
the I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
[ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
] I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
the I-PK
last I-PK
measured I-PK
concentration I-PK
[ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
] I-PK
, O
maximum B-PK
plasma I-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
, O
and O
time B-PK
to I-PK
cm I-PK
##ax I-PK
[ I-PK
t I-PK
##max I-PK
] I-PK
) O
were O
derived O
from O
the O
plasma O
concentration O
data O
using O
non O
##com O
##par O
##tment O
##al O
methods O
and O
actual O
sample O
times O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
rate I-PK
constant I-PK
( I-PK
λ I-PK
##z I-PK
) I-PK
was O
calculated O
by O
linear O
re O
##gression O
of O
the O
terminal O
portion O
of O
the O
linear O
concentration O
versus O
time O
curve O
, O
and O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
[ I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
] I-PK
was O
calculated O
as O
l O
##n O
2 O
/ O
λ O
##z O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
was O
calculated O
using O
the O
linear O
trap O
##ez O
##oid O
rule O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
was O
calculated O
as O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
plus O
last O
measured O
plasma O
concentration O
/ O
terminal B-PK
rate I-PK
constant I-PK
. O
[SEP] O
[CLS] O
medication O
was O
administered O
according O
to O
one O
of O
two O
treatment O
sequences O
with O
alternating O
treatment O
periods O
( O
a O
##ba O
##b O
or O
b O
##aba O
) O
based O
on O
a O
computer O
- O
generated O
random O
##ization O
schedule O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
summarized O
descriptive O
##ly O
, O
using O
the O
number O
of O
subjects O
, O
mean O
, O
standard O
de O
##viation O
, O
and O
coefficient O
of O
variation O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
, O
cm B-PK
##ax I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
) O
or O
the O
median O
and O
range O
( O
t B-PK
##max I-PK
) O
. O
[SEP] O
[CLS] O
the O
criterion O
for O
bio O
##e O
##qui O
##valence O
was O
met O
if O
the O
90 O
% O
c O
##is O
of O
the O
geometric O
mean O
ratio O
( O
o O
##xy O
- O
c O
##rf O
/ O
o O
##xy O
- O
er O
) O
for O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
, O
and O
cm B-PK
##ax I-PK
were O
within O
0 O
. O
8 O
– O
1 O
. O
25 O
. O
[SEP] O
[CLS] O
systemic O
plasma O
o O
##xy O
##mor O
##phone O
exposure O
( O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
) O
was O
also O
similar O
after O
single O
doses O
of O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
mean O
± O
s O
##d O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
for O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
, O
respectively O
, O
was O
5 O
. O
05 O
± O
1 O
. O
55 O
and O
5 O
. O
29 O
± O
1 O
. O
52 O
ng O
· O
h O
/ O
m O
##l O
after O
a O
5 O
mg O
dose O
administered O
under O
fast O
##ed O
conditions O
, O
31 O
. O
51 O
± O
10 O
. O
95 O
and O
31 O
. O
23 O
± O
10 O
. O
33 O
ng O
· O
h O
/ O
m O
##l O
after O
a O
40 O
mg O
dose O
administered O
under O
fast O
##ed O
conditions O
, O
and O
50 O
. O
16 O
± O
14 O
. O
91 O
and O
49 O
. O
01 O
± O
14 O
. O
03 O
ng O
· O
h O
/ O
m O
##l O
after O
a O
40 O
mg O
dose O
administered O
following O
a O
high O
- O
fat O
breakfast O
. O
[SEP] O
[CLS] O
mean O
± O
s O
##d O
o O
##xy O
##mor O
##phone O
cm B-PK
##ax I-PK
for O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
, O
respectively O
, O
was O
0 O
. O
38 O
± O
0 O
. O
11 O
and O
0 O
. O
37 O
± O
0 O
. O
12 O
ng O
/ O
m O
##l O
after O
a O
5 O
mg O
dose O
administered O
under O
fast O
##ed O
conditions O
, O
2 O
. O
37 O
± O
1 O
. O
20 O
and O
2 O
. O
41 O
± O
0 O
. O
94 O
ng O
/ O
m O
##l O
after O
a O
40 O
mg O
dose O
administered O
under O
fast O
##ed O
conditions O
, O
and O
5 O
. O
87 O
± O
1 O
. O
99 O
and O
5 O
. O
63 O
± O
2 O
. O
26 O
ng O
/ O
m O
##l O
after O
a O
40 O
mg O
dose O
administered O
following O
a O
high O
- O
fat O
breakfast O
. O
[SEP] O
[CLS] O
median O
o O
##xy O
##mor O
##phone O
t B-PK
##max I-PK
was O
the O
only O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
to O
differ O
between O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
, O
being O
shorter O
for O
o O
##xy O
- O
er O
versus O
o O
##xy O
- O
c O
##rf O
40 O
mg O
( O
table O
2 O
) O
, O
with O
differences O
of O
2 O
hours O
under O
fast O
##ed O
conditions O
( O
3 O
. O
0 O
versus O
5 O
. O
0 O
) O
and O
1 O
. O
5 O
hours O
under O
fed O
conditions O
( O
3 O
. O
5 O
versus O
5 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
the O
difference O
in O
median O
t B-PK
##max I-PK
was O
smaller O
when O
5 O
mg O
doses O
of O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
were O
compared O
( O
6 O
. O
0 O
versus O
5 O
. O
0 O
hours O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
values O
roughly O
correspond O
##ed O
to O
the O
time O
at O
which O
the O
two O
early O
peaks O
occurred O
in O
the O
plasma O
concentration O
versus O
time O
profiles O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
the O
range O
of O
t B-PK
##max I-PK
was O
similar O
for O
the O
two O
formulation O
##s O
in O
each O
of O
the O
three O
studies O
. O
[SEP] O
[CLS] O
systemic O
plasma O
6 O
- O
oh O
- O
o O
##xy O
##mor O
##phone O
exposure O
did O
not O
differ O
between O
the O
two O
formulation O
##s O
( O
table O
3 O
) O
, O
but O
median O
t B-PK
##max I-PK
was O
1 O
. O
0 O
( O
40 O
mg O
, O
fed O
) O
to O
1 O
. O
5 O
hours O
( O
5 O
mg O
, O
fast O
##ed O
; O
40 O
mg O
, O
fast O
##ed O
) O
shorter O
for O
o O
##xy O
- O
er O
versus O
o O
##xy O
- O
c O
##rf O
. O
[SEP] O
[CLS] O
within O
- O
subject O
var O
##iability O
in O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
ranged O
from O
11 O
% O
to O
24 O
% O
and O
was O
comparable O
between O
the O
two O
o O
##xy O
##mor O
##phone O
formulation O
##s O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
for O
all O
doses O
and O
under O
both O
fast O
##ed O
and O
fed O
conditions O
, O
the O
90 O
% O
c O
##i O
for O
the O
comparisons O
of O
o O
##xy O
- O
er O
and O
o O
##xy O
- O
c O
##rf O
plasma O
o O
##xy O
##mor O
##phone O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
, O
and O
cm B-PK
##ax I-PK
were O
within O
0 O
. O
8 O
– O
1 O
. O
25 O
( O
table O
4 O
) O
, O
fulfilling O
the O
bio O
##e O
##qui O
##valence O
criterion O
. O
[SEP] O
[CLS] O
one O
subject O
( O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
9 O
mg O
) O
had O
a O
pre O
- O
dose O
concentration O
of O
9 O
. O
5 O
% O
of O
peak B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
was O
included O
in O
the O
analysis O
. O
[SEP] O
[CLS] O
following O
administration O
of O
single O
oral O
doses O
of O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
from O
0 O
. O
75 O
mg O
to O
9 O
mg O
under O
fast O
##ed O
conditions O
, O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
cm B-PK
##ax I-PK
occurred O
at O
approximately O
3 O
. O
0 O
– O
4 O
. O
0 O
h O
post O
dose O
( O
supplement O
##ary O
fi O
##g O
. O
1 O
top O
panel O
and O
supplement O
##ary O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
for O
the O
3 O
- O
mg O
group O
in O
co O
##hor O
##t O
2 O
was O
approximately O
16 O
h O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
not O
report O
##able O
for O
most O
treatments O
because O
the O
data O
were O
not O
sufficient O
for O
adequate O
characterization O
of O
the O
elimination O
phase O
. O
[SEP] O
[CLS] O
inter O
- O
subject O
var O
##iability O
for O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
exposure O
, O
based O
on O
geometric O
percent O
coefficient O
of O
variation O
( O
% O
c O
##v O
) O
, O
ranged O
from O
21 O
% O
to O
44 O
% O
for O
au B-PK
##c I-PK
##last I-PK
and O
26 O
% O
to O
42 O
% O
for O
cm B-PK
##ax I-PK
across O
all O
treatments O
. O
[SEP] O
[CLS] O
on O
day O
22 O
( O
steady O
- O
state O
) O
, O
following O
administration O
of O
multiple O
oral O
doses O
of O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
from O
5 O
mg O
to O
25 O
mg O
, O
mean O
cm B-PK
##ax I-PK
for O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
occurred O
at O
approximately O
2 O
. O
0 O
– O
4 O
. O
0 O
h O
post O
dose O
. O
[SEP] O
[CLS] O
on O
the O
basis O
of O
average O
values O
in O
park O
##ins O
##on O
’ O
s O
disease O
subjects O
with O
motor O
flu O
##ct O
##uations O
( O
co O
##hor O
##t O
4 O
vs O
co O
##hor O
##t O
6 O
) O
, O
the O
increase O
in O
au B-PK
##ct I-PK
##au I-PK
was O
less O
than O
dose O
proportional O
between O
15 O
mg O
and O
25 O
mg O
. O
[SEP] O
[CLS] O
the O
mean O
apparent B-PK
clearance I-PK
values O
ranged O
from O
2 O
. O
4 O
l O
/ O
h O
to O
3 O
. O
5 O
l O
/ O
h O
. O
[SEP] O
[CLS] O
a O
##es O
in O
all O
treatment O
groups O
occurred O
in O
the O
up O
- O
t O
##it O
##ration O
phase O
( O
days O
3 O
– O
24 O
and O
follow O
- O
up O
) O
and O
appeared O
related O
to O
pace O
and O
in O
##cre O
##ment O
of O
up O
- O
t O
##it O
##ration O
rather O
than O
maximum O
exposure O
, O
and O
they O
were O
generally O
self O
- O
limited O
. O
[SEP] O
[CLS] O
co O
- O
administration O
with O
o O
##sel O
##tam O
##iv O
##ir O
had O
no O
clinical O
##ly O
significant O
effect O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
p O
##k O
) O
of O
am O
##ant O
##adi O
##ne O
[ O
mean O
ratios O
( O
90 O
% O
c O
##i O
) O
for O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
0 O
. O
93 O
( O
0 O
. O
89 O
, O
0 O
. O
98 O
) O
and O
cm B-PK
##ax I-PK
0 O
. O
96 O
( O
0 O
. O
90 O
, O
1 O
. O
02 O
) O
] O
. O
[SEP] O
[CLS] O
similarly O
, O
am O
##ant O
##adi O
##ne O
co O
- O
administration O
did O
not O
affect O
o O
##sel O
##tam O
##iv O
##ir O
p O
##k O
[ O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
0 O
. O
92 O
( O
0 O
. O
86 O
, O
0 O
. O
99 O
) O
and O
cm B-PK
##ax I-PK
0 O
. O
85 O
( O
0 O
. O
73 O
, O
0 O
. O
99 O
) O
] O
or O
the O
p O
##k O
of O
the O
meta O
##bol O
##ite O
, O
o O
##sel O
##tam O
##iv O
##ir O
car O
##box O
##yla O
##te O
[ O
au O
##c O
##0 O
- O
12 O
0 O
. O
98 O
( O
0 O
. O
95 O
, O
1 O
. O
02 O
) O
and O
cm B-PK
##ax I-PK
0 O
. O
95 O
( O
0 O
. O
89 O
, O
1 O
. O
01 O
) O
] O
. O
[SEP] O
[CLS] O
to O
compare O
the O
results O
of O
the O
individual O
versus O
combination O
therapy O
arms O
for O
both O
am O
##ant O
##adi O
##ne O
and O
o O
##sel O
##tam O
##iv O
##ir O
, O
log O
- O
transformed O
p O
##k O
parameters O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
were O
analyzed O
by O
a O
linear O
mixed O
effect O
model O
, O
with O
fixed O
effects O
from O
sequence O
, O
treatment O
, O
and O
period O
, O
and O
random O
effects O
from O
subject O
nest O
##ed O
in O
sequence O
. O
[SEP] O
[CLS] O
am O
##ant O
##adi O
##ne O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
and O
cm B-PK
##ax I-PK
decreased O
slightly O
when O
co O
##ad O
##mini O
##stered O
with O
o O
##sel O
##tam O
##iv O
##ir O
compared O
to O
am O
##ant O
##adi O
##ne O
administration O
alone O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
o O
##sel O
##tam O
##iv O
##ir O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
and O
cm B-PK
##ax I-PK
decreased O
slightly O
when O
co O
##ad O
##mini O
##stered O
with O
am O
##ant O
##adi O
##ne O
compared O
to O
o O
##sel O
##tam O
##iv O
##ir O
administration O
alone O
( O
table O
3 O
and O
4 O
) O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
ratio O
( O
g O
##m O
##r O
) O
of O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
of O
am O
##ant O
##adi O
##ne O
, O
co O
##ad O
##mini O
##stered O
with O
o O
##sel O
##tam O
##iv O
##ir O
compared O
to O
am O
##ant O
##adi O
##ne O
alone O
, O
was O
0 O
. O
93 O
. O
[SEP] O
[CLS] O
as O
expected O
for O
am O
##ant O
##adi O
##ne O
, O
the O
geometric O
mean O
values O
for O
apparent B-PK
clearance I-PK
( O
15 O
. O
6 O
vs O
16 O
. O
7 O
l O
/ O
h O
##r O
) O
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( O
33 O
##2 O
vs O
32 O
##6 O
l O
) O
, O
half B-PK
- I-PK
life I-PK
( O
14 O
. O
7 O
vs O
13 O
. O
6 O
h O
##r O
) O
and O
t B-PK
##max I-PK
( O
2 O
. O
1 O
vs O
2 O
. O
4 O
h O
##r O
) O
were O
also O
similar O
between O
am O
##ant O
##adi O
##ne O
mon O
##otherapy O
versus O
combination O
therapy O
with O
o O
##sel O
##tam O
##iv O
##ir O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
ratio O
( O
g O
##m O
##r O
) O
of O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
of O
o O
##sel O
##tam O
##iv O
##ir O
, O
co O
##ad O
##mini O
##stered O
with O
o O
##sel O
##tam O
##iv O
##ir O
compared O
to O
am O
##ant O
##adi O
##ne O
alone O
, O
was O
0 O
. O
92 O
. O
[SEP] O
[CLS] O
g O
##m O
##r O
of O
the O
c B-PK
##tro I-PK
##ugh I-PK
and O
cm B-PK
##ax I-PK
were O
0 O
. O
95 O
( O
with O
a O
lower O
confidence O
interval O
of O
. O
73 O
) O
and O
0 O
. O
85 O
( O
with O
a O
lower O
confidence O
interval O
of O
0 O
. O
79 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
and O
cm B-PK
##ax I-PK
of O
the O
active O
o O
##sel O
##tam O
##iv O
##ir O
car O
##box O
##yla O
##te O
also O
decreased O
slightly O
when O
co O
##ad O
##mini O
##stered O
with O
am O
##ant O
##adi O
##ne O
compared O
to O
o O
##sel O
##tam O
##iv O
##ir O
administration O
alone O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
ratio O
( O
g O
##m O
##r O
) O
( O
90 O
% O
confidence O
interval O
[ O
c O
##i O
] O
) O
of O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
of O
o O
##sel O
##tam O
##iv O
##ir O
car O
##box O
##yla O
##te O
, O
co O
##ad O
##mini O
##stered O
with O
o O
##sel O
##tam O
##iv O
##ir O
compared O
to O
am O
##ant O
##adi O
##ne O
alone O
, O
was O
0 O
. O
98 O
. O
[SEP] O
[CLS] O
g O
##m O
##r O
of O
the O
cm B-PK
##ax I-PK
and O
c B-PK
##tro I-PK
##ugh I-PK
were O
0 O
. O
95 O
and O
1 O
. O
03 O
, O
respectively O
. O
[SEP] O
[CLS] O
as O
expected O
, O
the O
geometric O
mean O
values O
for O
o O
##sel O
##tam O
##iv O
##ir O
apparent B-PK
clearance I-PK
( O
46 O
##5 O
vs O
50 O
##5 O
l O
/ O
h O
##r O
) O
, O
apparent B-PK
distribution I-PK
volume I-PK
( O
124 O
##5 O
vs O
132 O
##9 O
l O
) O
, O
half B-PK
- I-PK
life I-PK
( O
1 O
. O
85 O
vs O
1 O
. O
83 O
h O
##r O
) O
and O
t B-PK
##max I-PK
( O
0 O
. O
76 O
vs O
0 O
. O
85 O
h O
##r O
) O
were O
also O
similar O
between O
o O
##sel O
##tam O
##iv O
##ir O
mon O
##otherapy O
versus O
combination O
therapy O
with O
am O
##ant O
##adi O
##ne O
. O
[SEP] O
[CLS] O
in O
addition O
, O
geometric O
mean O
values O
for O
o O
##sel O
##tam O
##iv O
##ir O
car O
##box O
##yla O
##te O
apparent B-PK
clearance I-PK
( O
21 O
. O
9 O
vs O
22 O
. O
3 O
l O
/ O
h O
##r O
) O
, O
apparent B-PK
distribution I-PK
volume I-PK
( O
192 O
vs O
197 O
l O
) O
, O
half B-PK
- I-PK
life I-PK
( O
6 O
. O
09 O
vs O
6 O
. O
15 O
h O
##r O
) O
and O
t B-PK
##max I-PK
( O
3 O
. O
22 O
vs O
3 O
. O
07 O
h O
##r O
) O
were O
similar O
between O
o O
##sel O
##tam O
##iv O
##ir O
mon O
##otherapy O
versus O
combination O
therapy O
with O
am O
##ant O
##adi O
##ne O
. O
[SEP] O
[CLS] O
k O
##pt O
- O
95 O
##11 O
was O
[UNK] O
fold O
less O
potent O
in O
re O
##v O
- O
g O
##f O
##p O
compared O
to O
k O
##pt O
- O
86 O
##0 O
##2 O
( O
230 O
nm O
vs O
42 O
nm O
) O
and O
[UNK] O
fold O
less O
c O
##yt O
##oto O
##xi O
##c O
( O
280 O
vs O
19 O
nm O
) O
. O
[SEP] O
[CLS] O
f O
##oly O
##l O
##pol O
##y O
##g O
##lut O
##ama O
##te O
s O
##ynth O
##eta O
##se O
( O
f O
##p O
##gs O
) O
activity O
was O
higher O
in O
b O
vs O
t O
lineage O
all O
( O
p O
< O
0 O
. O
00 O
##5 O
) O
, O
m O
##t O
##x O
influx O
and O
f O
##p O
##gs O
activity O
were O
higher O
in O
h O
##yper O
##di O
##p O
##lo O
##id O
vs O
non O
- O
h O
##yper O
##di O
##p O
##lo O
##id O
all O
( O
p O
< O
0 O
. O
03 O
) O
, O
m O
##t O
##x O
influx O
and O
f O
##p O
##gs O
activity O
were O
lower O
in O
the O
t O
( O
12 O
; O
21 O
) O
( O
et O
##v O
##6 O
- O
run O
##x O
##1 O
) O
sub O
##type O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
the O
ratio O
of O
f O
##p O
##gs O
to O
γ O
- O
g O
##lut O
##am O
##yl O
h O
##ydro O
##lase O
( O
g O
##gh O
) O
activity O
was O
lower O
in O
the O
t O
( O
1 O
; O
19 O
) O
( O
t O
##c O
##f O
##3 O
- O
p O
##b O
##x O
##1 O
) O
sub O
##type O
( O
p O
< O
0 O
. O
03 O
) O
than O
other O
genetic O
sub O
##type O
##s O
. O
[SEP] O
[CLS] O
figure O
1 O
##a O
shows O
the O
concentration O
vs O
time O
plot O
of O
these O
data O
along O
with O
the O
population O
average O
model O
fit O
of O
the O
data O
sub O
- O
grouped O
by O
in O
##fusion O
length O
. O
[SEP] O
[CLS] O
the O
median O
clearance B-PK
of O
m O
##t O
##x O
was O
higher O
in O
the O
24 O
h O
##r O
in O
##fusion O
group O
compared O
to O
the O
4 O
h O
##r O
in O
##fusion O
group O
( O
122 O
. O
6 O
m O
##l O
/ O
min O
/ O
m O
##2 O
vs O
108 O
. O
6 O
m O
##l O
/ O
min O
/ O
m O
##2 O
; O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
figure O
1 O
shows O
the O
concentration O
vs O
time O
plot O
of O
in O
##tra O
##cellular O
m O
##t O
##x O
( O
or O
m O
##t O
##x O
##p O
##g O
##1 O
) O
( O
figure O
1 O
##b O
) O
and O
total O
in O
##tra O
##cellular O
m O
##t O
##x O
##p O
##g O
##2 O
- O
7 O
( O
figure O
1 O
##c O
) O
along O
with O
the O
population O
average O
model O
fit O
( O
for O
non O
- O
h O
##yper O
##di O
##p O
##lo O
##id O
b O
- O
lineage O
all O
) O
of O
the O
data O
. O
[SEP] O
[CLS] O
next O
we O
used O
simulation O
##s O
to O
compare O
the O
44 O
h O
##r O
post O
m O
##t O
##x O
treatment O
in O
##hibition O
of O
d O
##n O
##ps O
between O
different O
doses O
( O
100 O
mg O
/ O
m O
##2 O
to O
5 O
g O
/ O
m O
##2 O
) O
and O
schedules O
( O
4 O
vs O
24 O
hour O
in O
##fusion O
##s O
) O
. O
[SEP] O
[CLS] O
a O
diagram O
of O
the O
model O
is O
shown O
in O
( O
figure O
8 O
##a O
) O
and O
the O
model O
is O
described O
by O
the O
following O
system O
of O
ordinary O
differential O
equations O
: O
( O
1 O
) O
the O
parameters O
are O
defined O
as O
follows O
: O
k B-PK
##e I-PK
, O
k B-PK
##12 I-PK
, O
and O
k B-PK
##21 I-PK
( O
1 O
/ O
h O
##r O
) O
are O
the O
first O
- O
order O
parameters O
describing O
the O
elimination O
of O
plasma O
m O
##t O
##x O
and O
the O
transition O
between O
the O
central O
( O
m O
##t O
##x O
) O
and O
peripheral O
( O
m O
##t O
##x O
##p O
) O
compartment O
##s O
respectively O
; O
v B-PK
( O
l O
/ O
m O
##2 O
) O
is O
the O
systemic B-PK
volume I-PK
; O
v B-PK
##max I-PK
- I-PK
in I-PK
( O
pm O
##ol O
/ O
109 O
cells O
/ O
h O
##r O
) O
and O
km B-PK
- I-PK
in I-PK
( O
µ O
##m O
) O
are O
the O
mi O
##cha O
##eli O
##s O
- O
men O
##ten O
parameters O
describing O
the O
active O
influx O
of O
m O
##t O
##x O
into O
the O
le O
##uke O
##mic O
blast O
##s O
via O
the O
reduced O
f O
##olate O
carrier O
and O
various O
a O
##b O
##c O
transport O
##ers O
; O
k B-PK
##p I-PK
( O
1 O
/ O
h O
##r O
) O
is O
the O
first B-PK
- I-PK
order I-PK
passive I-PK
influx I-PK
parameter I-PK
; O
k B-PK
##ef I-PK
##f I-PK
( O
1 O
/ O
h O
##r O
) O
is O
the O
first B-PK
- I-PK
order I-PK
e I-PK
##ff I-PK
##lux I-PK
parameter I-PK
; O
v B-PK
##max I-PK
- I-PK
f I-PK
##p I-PK
##gs I-PK
( O
pm O
##ol O
/ O
109 O
cells O
/ O
h O
##r O
) O
and O
km B-PK
- I-PK
f I-PK
##p I-PK
##gs I-PK
( O
pm O
##ol O
/ O
109 O
cells O
) O
are O
the O
mi O
##cha O
##eli O
##s O
- O
men O
##ten O
parameters O
describing O
the O
f O
##p O
##gs O
activity O
; O
and O
kg B-PK
##gh I-PK
( O
1 O
/ O
h O
##r O
) O
is O
the O
first O
- O
order O
parameter O
describing O
the O
g O
##gh O
activity O
. O
[SEP] O
[CLS] O
within O
each O
race O
group O
, O
however O
, O
the O
two O
treatment O
groups O
( O
l O
##ina O
##gli O
##pt O
##in O
vs O
place O
##bo O
) O
were O
generally O
similar O
. O
[SEP] O
[CLS] O
overall O
, O
the O
proportion O
of O
patients O
in O
both O
treatment O
groups O
reporting O
any O
a O
##e O
was O
similar O
in O
each O
race O
group O
. O
[SEP] O
[CLS] O
overall O
, O
the O
a O
##e O
profile O
by O
race O
in O
study O
2 O
showed O
a O
similar O
trend O
between O
treatment O
groups O
to O
that O
seen O
in O
the O
original O
parent O
trial O
##11 O
. O
[SEP] O
[CLS] O
na O
##so O
##pha O
##ryn O
##git O
##is O
was O
the O
most O
frequently O
reported O
a O
##e O
in O
study O
1 O
; O
h O
##yper O
##gly O
##ce O
##mia O
was O
the O
most O
frequently O
reported O
a O
##e O
occurring O
in O
as O
##ian O
and O
white O
patients O
( O
study O
2 O
) O
. O
[SEP] O
[CLS] O
the O
results O
demonstrated O
that O
all O
four O
cat O
##ech O
##ins O
showed O
a O
tendency O
for O
increased O
area B-PK
under I-PK
the I-PK
concentration I-PK
curve I-PK
from I-PK
the I-PK
zero I-PK
time I-PK
- I-PK
point I-PK
to I-PK
the I-PK
last I-PK
measurement I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
9 I-PK
) I-PK
, O
the O
au B-PK
##c I-PK
from I-PK
the I-PK
zero I-PK
time I-PK
- I-PK
point I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
and O
the O
maximum B-PK
observed I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
after O
repeated O
administration O
for O
15 O
days O
, O
but O
the O
difference O
was O
not O
statistical O
##ly O
significant O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
after O
repeated O
dos O
##ing O
of O
630 O
mg O
green O
tea O
extract O
, O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
e O
##g O
##c O
and O
e O
##c O
was O
decreased O
to O
0 O
. O
74 O
- O
and O
0 O
. O
70 O
- O
fold O
the O
values O
obtained O
on O
day O
1 O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
recent O
study O
suggested O
that O
p O
- O
g O
##p O
could O
involve O
the O
absorption O
and O
elimination O
of O
green O
tea O
[ O
30 O
] O
, O
and O
in O
the O
current O
study O
, O
repeated O
dos O
##ing O
of O
the O
cat O
##ech O
##ins O
appeared O
to O
reduce O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
e O
##c O
##g O
and O
e O
##c O
. O
[SEP] O
[CLS] O
the O
carry O
##over O
was O
considered O
not O
to O
affect O
the O
analysis O
when O
the O
detection O
area O
of O
the O
anal O
##yte O
interference O
peak O
was O
within O
20 O
% O
of O
the O
ll O
##o O
##q O
and O
within O
5 O
% O
of O
the O
i O
. O
s O
. O
peak O
area O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
the O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
from O
the O
observed O
data O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
were O
calculated O
using O
the O
linear O
/ O
log O
trap O
##ez O
##oid O
##al O
method O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
calculated O
as O
l O
##n O
( O
2 O
) O
/ O
λ O
##z O
. O
[SEP] O
[CLS] O
λ B-PK
##z I-PK
was O
the O
elimination B-PK
rate I-PK
constant I-PK
slope I-PK
of O
the O
plasma O
concentration O
- O
time O
plot O
calculated O
using O
linear O
re O
##gression O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
the O
four O
cat O
##ech O
##ins O
were O
compared O
on O
day O
1 O
( O
single O
- O
dose O
green O
tea O
with O
dig O
##ox O
##in O
) O
and O
day O
15 O
( O
repeated O
- O
dose O
green O
tea O
with O
dig O
##ox O
##in O
) O
. O
[SEP] O
[CLS] O
during O
ha O
##em O
##od O
##ial O
##ys O
##is O
, O
the O
central B-PK
volume I-PK
v I-PK
##1 I-PK
was O
estimated O
to O
be O
reduced O
by O
0 O
. O
198 O
l O
/ O
h O
. O
[SEP] O
[CLS] O
a O
positive O
relationship O
was O
identified O
between O
initial O
v B-PK
##1 I-PK
and O
observed O
weight O
loss O
during O
ha O
##em O
##od O
##ial O
##ys O
##is O
. O
[SEP] O
[CLS] O
v B-PK
##1 I-PK
increased O
by O
0 O
. O
61 O
##4 O
% O
per O
k O
##ilo O
##gram O
of O
body O
weight O
, O
and O
females O
had O
an O
18 O
. O
3 O
% O
lower O
v B-PK
##1 I-PK
than O
males O
. O
[SEP] O
[CLS] O
differences O
between O
simulated O
profiles O
for O
different O
populations O
were O
marginal O
: O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
209 O
vs O
. O
204 O
ng O
/ O
m O
##l O
and O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##cin I-PK
##f I-PK
) I-PK
of O
5 O
, O
98 O
##0 O
vs O
. O
5 O
, O
92 O
##0 O
ng O
· O
h O
/ O
m O
##l O
in O
h O
##v O
##s O
and O
c O
##k O
##d O
non O
- O
ha O
##em O
##od O
##ial O
##ys O
##is O
patients O
, O
respectively O
, O
for O
a O
single O
dose O
of O
510 O
mg O
. O
[SEP] O
[CLS] O
in O
addition O
, O
physiological O
##ly O
plausible O
relations O
( O
e O
. O
g O
. O
measures O
of O
iron O
against O
parameters O
related O
to O
f O
##er O
##um O
##ox O
##yt O
##ol O
clearance B-PK
from O
the O
circulation O
, O
body O
weight O
on O
volume B-PK
, O
ha O
##em O
##od O
##ial O
##ys O
##is O
on O
clearance B-PK
or O
volume B-PK
) O
were O
tested O
i O
##rre O
##spective O
of O
the O
visual O
plot O
assessment O
. O
[SEP] O
[CLS] O
as O
previously O
described O
[ O
12 O
] O
, O
a O
linear O
relation O
between O
body O
weight O
and O
central B-PK
volume I-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
was O
included O
, O
whereas O
b O
##s O
##v O
on O
the O
mi O
##cha O
##eli O
##s O
– O
men O
##ten O
constant O
km B-PK
was O
not O
supported O
. O
[SEP] O
[CLS] O
after O
adding O
data O
from O
the O
c O
##k O
##d O
study O
, O
a O
slope O
( O
vs O
##lop O
##e O
) O
parameter O
was O
included O
for O
ha O
##em O
##od O
##ial O
##ys O
##is O
subjects O
to O
describe O
volume O
change O
over O
time O
, O
so O
as O
to O
account O
for O
the O
effects O
of O
ha O
##em O
##od O
##ial O
##ys O
##is O
on O
central B-PK
volume I-PK
of I-PK
distribution I-PK
. O
[SEP] O
[CLS] O
some O
shrink O
##age O
was O
present O
in O
the O
b O
##s O
##v O
of O
the O
peripheral B-PK
volume I-PK
v I-PK
##2 I-PK
, O
indicating O
that O
visual O
inspection O
of O
individual O
bay O
##es O
estimates O
against O
co O
##var O
##iate O
values O
might O
not O
be O
inform O
##ative O
[ O
21 O
] O
. O
[SEP] O
[CLS] O
co O
##var O
##iate O
##s O
were O
therefore O
tested O
on O
v B-PK
##2 I-PK
based O
on O
physiological O
p O
##laus O
##ibility O
, O
only O
. O
[SEP] O
[CLS] O
v B-PK
##1 I-PK
and O
v B-PK
##2 I-PK
were O
estimated O
to O
be O
small O
( O
2 O
. O
8 O
and O
0 O
. O
35 O
l O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
during O
ha O
##em O
##od O
##ial O
##ys O
##is O
, O
v B-PK
##1 I-PK
was O
estimated O
to O
be O
reduced O
by O
0 O
. O
198 O
l O
/ O
h O
over O
a O
period O
of O
3 O
h O
( O
total O
volume O
loss O
of O
0 O
. O
59 O
l O
) O
. O
[SEP] O
[CLS] O
it O
was O
also O
identified O
that O
patients O
with O
the O
highest O
observed O
weight O
loss O
during O
ha O
##em O
##od O
##ial O
##ys O
##is O
were O
those O
with O
the O
largest O
initial O
v B-PK
##1 I-PK
. O
[SEP] O
[CLS] O
overall O
, O
v B-PK
##1 I-PK
differed O
by O
0 O
. O
61 O
##4 O
% O
per O
k O
##ilo O
##gram O
difference O
in O
body O
weight O
, O
and O
females O
had O
an O
18 O
. O
3 O
% O
lower O
v B-PK
##1 I-PK
than O
males O
. O
[SEP] O
[CLS] O
this O
result O
is O
an O
effect O
of O
the O
co O
##var O
##iate O
influence O
w O
##lo O
on O
central B-PK
volume I-PK
of I-PK
distribution I-PK
. O
[SEP] O
[CLS] O
as O
a O
result O
of O
the O
changes O
in O
v B-PK
##1 I-PK
during O
dial O
##ys O
##is O
, O
concentrations O
increase O
in O
the O
ha O
##em O
##od O
##ial O
##ys O
##is O
population O
. O
[SEP] O
[CLS] O
in O
addition O
, O
due O
to O
the O
sat O
##urable O
mi O
##cha O
##eli O
##s O
– O
men O
##ten O
elimination O
behaviour O
of O
f O
##er O
##um O
##ox O
##yt O
##ol O
, O
differences O
in O
v B-PK
##1 I-PK
also O
result O
in O
relatively O
small O
differences O
in O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
following O
the O
shorter O
dos O
##ing O
interval O
of O
2 O
days O
apart O
, O
the O
peak O
and O
total O
exposure O
of O
f O
##er O
##um O
##ox O
##yt O
##ol O
is O
slightly O
higher O
, O
with O
median O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
median O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##cin I-PK
##f I-PK
) I-PK
of O
two O
doses O
being O
~ O
21 O
and O
~ O
11 O
% O
higher O
compared O
with O
red O
##os O
##ing O
after O
5 O
– O
8 O
days O
. O
[SEP] O
[CLS] O
after O
oral O
administration O
in O
rode O
##nts O
, O
trip O
##to O
##lide O
( O
t O
##p O
) O
, O
a O
di O
##ter O
##pen O
##oid O
t O
##rie O
##pox O
##ide O
compound O
, O
active O
as O
anti O
- O
inflammatory O
, O
im O
##mu O
##nos O
##up O
##pressive O
, O
anti O
- O
fertility O
, O
anti O
- O
c O
##ys O
##to O
##genesis O
, O
and O
anti O
##can O
##cer O
agent O
, O
is O
rapidly O
absorbed O
into O
the O
blood O
circulation O
( O
from O
5 O
. O
0 O
to O
19 O
. O
5 O
minutes O
after O
dos O
##ing O
, O
depending O
on O
the O
rode O
##nt O
species O
) O
followed O
by O
a O
short O
elimination B-PK
half I-PK
- I-PK
life I-PK
( O
from O
about O
20 O
minutes O
to O
less O
than O
1 O
hour O
) O
. O
[SEP] O
[CLS] O
further O
##more O
, O
t O
##p O
- O
n O
##l O
##cs O
prolonged O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
0 I-PK
– I-PK
t I-PK
( O
p O
< O
0 O
. O
00 O
##1 O
, O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
delayed O
t B-PK
##max I-PK
( O
p O
< O
0 O
. O
01 O
, O
p O
< O
0 O
. O
05 O
) O
and O
decreased O
cm B-PK
##ax I-PK
( O
p O
< O
0 O
. O
01 O
, O
p O
< O
0 O
. O
05 O
) O
compared O
to O
free O
t O
##p O
and O
t O
##p O
- O
s O
##ln O
##s O
, O
respectively O
, O
which O
was O
associated O
with O
reduced O
sub O
##ac O
##ute O
toxicity O
in O
male O
rats O
. O
[SEP] O
[CLS] O
medium O
chain O
t O
##rig O
##ly O
##cer O
##ides O
( O
m O
##ct O
; O
liquid O
lip O
##id O
) O
and O
lip O
##oid O
##® O
e O
80 O
( O
egg O
le O
##ci O
##thin O
) O
were O
purchased O
from O
lip O
##oid O
g O
##mb O
##h O
( O
l O
##ud O
##wig O
##sha O
##fen O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
t O
##p O
- O
n O
##l O
##cs O
were O
prepared O
using O
micro O
##em O
##ul O
##sion O
technique O
. O
13 O
briefly O
, O
t O
##p O
, O
lip O
##ids O
( O
selected O
solid O
and O
liquid O
lip O
##ids O
, O
for O
details O
, O
see O
results O
section O
) O
, O
c O
##rem O
##op O
##hor O
r O
##h O
##40 O
, O
lip O
##oid O
e O
80 O
, O
and O
trans O
##cut O
##ol O
hp O
were O
mixed O
at O
a O
ratio O
of O
1 O
: O
55 O
: O
42 O
: O
6 O
. O
5 O
: O
6 O
. O
5 O
( O
weight O
[ O
w O
] O
/ O
w O
) O
. O
[SEP] O
[CLS] O
finally O
, O
samples O
were O
examined O
by O
the O
hit O
##achi O
h O
- O
700 O
##0 O
##fa O
transmission O
electron O
micro O
##scope O
at O
75 O
k O
##v O
( O
hit O
##achi O
l O
##t O
##d O
, O
to O
##ky O
##o O
, O
j O
##apa O
##n O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##z I-PK
of O
free O
t O
##p O
were O
0 O
. O
200 O
hours O
and O
0 O
. O
70 O
##6 O
hours O
, O
respectively O
, O
similar O
to O
results O
reported O
in O
previous O
studies O
. O
8 O
, O
9 O
in O
this O
study O
, O
the O
time B-PK
to I-PK
achieve I-PK
maximum I-PK
concentration I-PK
of O
t O
##p O
was O
delayed O
to O
0 O
. O
71 O
##7 O
hours O
and O
0 O
. O
450 O
hours O
in O
the O
case O
of O
t O
##p O
- O
n O
##l O
##cs O
( O
p O
< O
0 O
. O
01 O
) O
and O
t O
##p O
- O
s O
##ln O
##s O
( O
p O
> O
0 O
. O
05 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
a O
significant O
decrease O
was O
found O
in O
the O
cm B-PK
##ax I-PK
from O
8 O
. O
65 O
##6 O
μ O
##g O
/ O
l O
for O
free O
t O
##p O
to O
3 O
. O
36 O
##1 O
μ O
##g O
/ O
l O
for O
t O
##p O
- O
n O
##l O
##cs O
( O
p O
< O
0 O
. O
01 O
) O
and O
to O
5 O
. O
79 O
##4 O
μ O
##g O
/ O
l O
for O
t O
##p O
- O
s O
##ln O
##s O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
apparent B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##z I-PK
/ I-PK
f I-PK
) I-PK
was O
also O
found O
to O
be O
reduced O
in O
t O
##p O
- O
n O
##l O
##cs O
( O
p O
< O
0 O
. O
01 O
) O
and O
t O
##p O
- O
s O
##ln O
##s O
( O
p O
< O
0 O
. O
05 O
) O
compared O
to O
free O
t O
##p O
. O
[SEP] O
[CLS] O
in O
addition O
, O
t O
##p O
- O
n O
##l O
##cs O
and O
t O
##p O
- O
s O
##ln O
##s O
gave O
mean O
values O
of O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
the I-PK
time I-PK
of I-PK
dos I-PK
##ing I-PK
to I-PK
the I-PK
last I-PK
observation I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
9 O
. O
01 O
##2 O
and O
7 O
. O
31 O
##8 O
μ O
##g O
* O
hour O
/ O
l O
, O
which O
were O
1 O
. O
54 O
- O
and O
1 O
. O
25 O
- O
fold O
higher O
, O
than O
that O
of O
free O
t O
##p O
, O
respectively O
. O
[SEP] O
[CLS] O
these O
results O
showed O
the O
superiority O
of O
t O
##p O
- O
n O
##l O
##cs O
over O
t O
##p O
- O
s O
##ln O
##s O
, O
as O
also O
supported O
by O
prominent O
difference O
on O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
t I-PK
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
t B-PK
##max I-PK
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
cm B-PK
##ax I-PK
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
standard O
mi O
##cha O
##eli O
##s O
- O
men O
##ten O
sat O
##uration O
kinetic O
##s O
were O
used O
to O
q O
##uant O
##ify O
the O
process O
of O
a O
##pa O
##p O
metabolism O
for O
a O
##pa O
##p O
- O
g O
and O
a O
##pa O
##p O
- O
s O
in O
the O
liver O
, O
and O
were O
parameter O
##ized O
by O
the O
mi B-PK
##cha I-PK
##eli I-PK
##s I-PK
constant I-PK
km I-PK
and O
maximum B-PK
metabolism I-PK
rate I-PK
v I-PK
##max I-PK
. O
[SEP] O
[CLS] O
to O
investigate O
whether O
the O
different O
algorithms O
give O
consistent O
results O
as O
to O
direct O
and O
indirect O
parameter O
se O
##ns O
##iti O
##vi O
##ties O
, O
we O
used O
the O
p O
##ear O
##son O
and O
spear O
##man O
correlation O
coefficients O
to O
assess O
the O
consistency O
of O
the O
main O
effects O
( O
m O
##or O
##ris O
μ O
* O
and O
sob O
##ol O
main O
effect O
) O
and O
interaction O
effects O
( O
σ O
, O
and O
sob O
##ol O
interaction O
effect O
) O
among O
each O
tested O
parameter O
using O
its O
maximum O
sensitivity O
index O
. O
[SEP] O
[CLS] O
parallel O
##ized O
com O
##putation O
of O
the O
m O
##c O
##m O
##c O
was O
performed O
within O
the O
64 O
- O
bit O
cent O
##os O
l O
##in O
##ux O
distribution O
on O
a O
high O
- O
performance O
computing O
cluster O
at O
te O
##xa O
##s O
a O
& O
m O
university O
, O
comprising O
machines O
with O
in O
##tel O
x O
##eon O
2 O
. O
5 O
##gh O
##z O
e O
##5 O
- O
26 O
##70 O
v O
##2 O
( O
i O
##vy O
bridge O
- O
e O
##p O
) O
10 O
- O
core O
processors O
and O
64 O
g O
##b O
of O
ram O
each O
. O
[SEP] O
[CLS] O
for O
m O
##or O
##ris O
in O
##dices O
, O
we O
normal O
##ized O
the O
index O
by O
maximum O
est O
##imation O
and O
set O
the O
threshold O
as O
10 O
% O
of O
maximum O
est O
##imation O
across O
model O
parameters O
for O
the O
specific O
compound O
at O
time O
t O
. O
[SEP] O
[CLS] O
visual O
inspection O
of O
the O
data O
points O
relative O
to O
the O
s O
##cat O
##ter O
of O
the O
predictions O
suggests O
that O
each O
parameter O
set O
shows O
a O
consistent O
or O
similar O
predicted O
curve O
in O
the O
high O
- O
dos O
##age O
( O
20 O
and O
80 O
mg O
/ O
kg O
) O
groups O
( O
e O
– O
h O
) O
. O
[SEP] O
[CLS] O
the O
treatment O
- O
related O
adverse O
events O
( O
a O
##e O
) O
≥ O
grade O
3 O
in O
more O
than O
2 O
patients O
were O
ne O
##ut O
##rop O
##enia O
( O
35 O
% O
) O
, O
th O
##rom O
##bo O
##cy O
##top O
##enia O
( O
30 O
% O
) O
, O
and O
le O
##uc O
##ope O
##nia O
( O
20 O
% O
) O
. O
[SEP] O
[CLS] O
the O
investigator O
determined O
a O
##e O
serious O
##ness O
, O
severity O
grade O
, O
and O
relationship O
to O
study O
treatment O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
plasma I-PK
drug I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
reach I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
from O
experimental O
observation O
. O
[SEP] O
[CLS] O
all O
20 O
patients O
were O
assessed O
for O
toxicity O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
p O
##k O
parameters O
of O
ex O
##em O
##esta O
##ne O
before O
and O
after O
combination O
with O
ch O
##ida O
##mi O
##de O
, O
including O
the O
plasma O
exposure O
( O
32 O
. O
5 O
vs O
. O
31 O
. O
4 O
ng O
/ O
m O
##l O
for O
cm B-PK
##ax I-PK
, O
and O
71 O
. O
8 O
vs O
. O
79 O
. O
3 O
ng O
· O
h O
/ O
m O
##l O
for O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##t I-PK
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
of O
the O
con O
##ju O
##gate O
##s O
demonstrated O
that O
the O
con O
##ju O
##gate O
circulated O
for O
a O
longer O
time O
in O
the O
blood O
circulation O
system O
( O
t B-PK
##2 I-PK
/ I-PK
1 I-PK
= O
10 O
. O
51 O
##6 O
##± O
##1 O
. O
158 O
h O
) O
than O
did O
10 O
- O
h O
##c O
##pt O
solution O
( O
t B-PK
##2 I-PK
/ I-PK
1 I-PK
= O
1 O
. O
85 O
##9 O
##± O
##1 O
. O
385 O
h O
) O
, O
and O
that O
it O
also O
enhanced O
the O
targeting O
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
= O
39 O
. O
87 O
##3 O
##± O
##4 O
. O
54 O
##9 O
h O
) O
in O
the O
tumor O
site O
, O
compared O
with O
10 O
- O
h O
##c O
##pt O
( O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
= O
9 O
. O
247 O
##± O
##1 O
. O
02 O
##6 O
h O
) O
. O
[SEP] O
[CLS] O
compound O
e O
was O
kept O
at O
4 O
##° O
##c O
under O
n O
##2 O
. O
[SEP] O
[CLS] O
compound O
e O
( O
205 O
mg O
, O
0 O
. O
1 O
mm O
##ol O
) O
was O
dissolved O
in O
50 O
m O
##l O
an O
##hy O
##dr O
##ous O
d O
##m O
##f O
and O
to O
it O
were O
added O
compound O
c O
( O
55 O
mg O
, O
0 O
. O
1 O
mm O
##ol O
) O
drop O
by O
drop O
at O
0 O
##° O
##c O
under O
n O
##2 O
. O
35 O
k O
##2 O
##co O
##3 O
was O
added O
to O
the O
reaction O
to O
maintain O
a O
basic O
p O
##h O
. O
after O
stirring O
for O
3 O
h O
in O
an O
ice O
- O
bath O
, O
the O
solvent O
was O
e O
##va O
##porated O
under O
reduced O
pressure O
to O
concentrate O
the O
mixture O
. O
[SEP] O
[CLS] O
after O
24 O
h O
culture O
, O
cells O
were O
treated O
with O
compound O
f O
and O
10 O
- O
h O
##c O
##pt O
solution O
for O
1 O
, O
2 O
, O
or O
4 O
h O
under O
5 O
% O
co O
##2 O
at O
37 O
##° O
##c O
. O
[SEP] O
[CLS] O
mice O
were O
administered O
a O
single O
dose O
of O
10 O
- O
h O
##c O
##pt O
( O
5 O
mg O
/ O
kg O
) O
and O
compound O
f O
solution O
( O
equal O
to O
10 O
- O
h O
##c O
##pt O
5 O
mg O
/ O
kg O
) O
in O
##tra O
##ven O
##ously O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
anti O
##tum O
##or O
efficacy O
of O
compound O
f O
was O
assessed O
using O
tumor O
- O
bearing O
nude O
mouse O
models O
. O
[SEP] O
[CLS] O
tumor O
- O
bearing O
mice O
were O
divided O
into O
three O
groups O
( O
n O
= O
8 O
) O
in O
such O
a O
way O
as O
to O
minimize O
weight O
and O
tumor O
size O
differences O
among O
the O
groups O
: O
the O
control O
group O
received O
sa O
##line O
; O
one O
treatment O
group O
received O
10 O
- O
h O
##c O
##pt O
solution O
, O
which O
is O
a O
commercial O
injection O
( O
5 O
. O
0 O
mg O
/ O
kg O
) O
; O
the O
other O
treatment O
group O
received O
compound O
f O
solution O
( O
35 O
. O
1 O
mg O
/ O
kg O
, O
equivalent O
to O
5 O
. O
0 O
mg O
/ O
kg O
10 O
- O
h O
##c O
##pt O
) O
. O
[SEP] O
[CLS] O
the O
following O
abbreviation O
##s O
are O
used O
for O
spin O
multi O
##p O
##licity O
: O
s O
= O
single O
##t O
, O
d O
= O
double O
##t O
, O
t O
= O
triple O
##t O
, O
q O
= O
quartet O
, O
m O
= O
multiple O
##t O
, O
d O
##d O
= O
double O
double O
##t O
, O
d O
##t O
= O
double O
triple O
##t O
. O
[SEP] O
[CLS] O
the O
flu O
##ores O
##cence O
s O
##pect O
##ra O
of O
compound O
f O
are O
shown O
in O
figure O
7 O
. O
[SEP] O
[CLS] O
we O
can O
see O
that O
the O
maximum O
ex O
##citation O
wavelength O
of O
compound O
f O
is O
365 O
nm O
, O
and O
the O
maximum O
emission O
wave O
- O
length O
of O
compound O
f O
is O
47 O
##2 O
nm O
. O
[SEP] O
[CLS] O
the O
anti O
##tum O
##or O
activities O
of O
10 O
- O
h O
##c O
##pt O
and O
compound O
f O
were O
tested O
on O
three O
cancer O
cell O
lines O
using O
m O
##tt O
ass O
##ay O
. O
[SEP] O
[CLS] O
co O
##uma O
##rin O
- O
6 O
was O
used O
as O
fluorescent O
marker O
by O
being O
incorporated O
into O
compound O
f O
mice O
. O
[SEP] O
[CLS] O
in O
addition O
, O
flu O
##ores O
##cence O
of O
co O
##uma O
##rin O
- O
6 O
was O
observed O
in O
the O
nuclei O
of O
m O
##c O
##f O
- O
7 O
cells O
after O
1 O
h O
, O
suggesting O
the O
rapid O
internal O
##ization O
and O
nuclear O
transport O
of O
compound O
f O
mice O
##lles O
. O
[SEP] O
[CLS] O
additionally O
, O
compared O
with O
10 O
- O
h O
##c O
##pt O
solution O
, O
the O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
values O
of O
compound O
f O
were O
4 O
. O
31 O
- O
fold O
in O
tumors O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
values O
of O
compound O
f O
in O
tumor O
were O
7 O
. O
76 O
- O
fold O
higher O
than O
those O
of O
10 O
- O
h O
##c O
##pt O
solution O
. O
[SEP] O
[CLS] O
as O
can O
be O
seen O
, O
the O
total B-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
of O
compound O
f O
were O
significantly O
higher O
than O
those O
of O
10 O
- O
h O
##c O
##pt O
solution O
in O
plasma O
( O
figure O
12 O
) O
. O
[SEP] O
[CLS] O
therefore O
, O
compound O
f O
could O
reduce O
the O
corresponding O
toxic O
effects O
. O
[SEP] O
[CLS] O
compound O
f O
also O
exhibited O
a O
higher O
accumulation O
in O
the O
liver O
, O
s O
##ple O
##en O
, O
and O
lung O
. O
[SEP] O
[CLS] O
to O
provide O
in O
v O
##ivo O
evidence O
for O
the O
anti O
##tum O
##or O
potential O
of O
compound O
f O
, O
anti O
##tum O
##or O
efficacy O
was O
evaluated O
using O
an O
in O
v O
##ivo O
nude O
mouse O
model O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
13 O
, O
the O
tumor O
volume O
of O
the O
group O
treated O
with O
compound O
f O
solution O
was O
significantly O
smaller O
than O
that O
of O
the O
group O
treated O
with O
either O
sa O
##line O
or O
10 O
- O
h O
##c O
##pt O
solution O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
as O
can O
be O
seen O
, O
compound O
f O
did O
not O
cause O
significant O
loss O
of O
body O
weight O
, O
whereas O
10 O
- O
h O
##c O
##pt O
solution O
exhibited O
significant O
body O
weight O
loss O
( O
p O
< O
0 O
. O
05 O
) O
, O
which O
means O
that O
compound O
f O
has O
lower O
toxicity O
than O
10 O
- O
h O
##c O
##pt O
. O
[SEP] O
[CLS] O
the O
main O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
parameters O
including O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
at I-PK
24 I-PK
h I-PK
( I-PK
au I-PK
##c I-PK
##24 I-PK
h I-PK
) I-PK
, O
au B-PK
##c I-PK
, O
terminal B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
the B-PK
time I-PK
to I-PK
peak I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
peak B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
relative B-PK
total I-PK
systemic I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##b I-PK
) I-PK
, O
and O
the O
last B-PK
mean I-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
##last I-PK
) I-PK
were O
calculated O
to O
be O
7 O
. O
10 O
, O
7 O
. O
94 O
μ O
##g O
##∗ O
##h O
/ O
m O
##l O
, O
24 O
. O
02 O
, O
na O
h O
, O
na O
μ O
##g O
/ O
m O
##l O
, O
0 O
. O
46 O
l O
/ O
h O
##∗ O
##k O
##g O
, O
8 O
. O
06 O
h O
and O
3 O
. O
94 O
, O
6 O
. O
79 O
μ O
##g O
##∗ O
##h O
/ O
m O
##l O
, O
44 O
. O
04 O
, O
0 O
. O
25 O
h O
, O
0 O
. O
98 O
μ O
##g O
/ O
m O
##l O
, O
0 O
. O
43 O
l O
/ O
h O
##∗ O
##k O
##g O
, O
22 O
. O
85 O
h O
after O
i O
. O
v O
. O
and O
i O
. O
m O
. O
induction O
, O
respectively O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
i O
. O
m O
. O
route O
was O
85 O
. O
5 O
% O
, O
and O
the O
un O
##bin O
##ding O
of O
til O
##di O
##pi O
##ros O
##in O
to O
serum O
protein O
was O
78 O
% O
. O
[SEP] O
[CLS] O
although O
most O
mac O
##rol O
##ides O
were O
classified O
as O
time O
- O
dependent O
killing O
drugs O
, O
til O
##di O
##pi O
##ros O
##in O
was O
concentration O
- O
dependent O
, O
and O
the O
p O
##k O
/ O
p O
##d O
index O
were O
the O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
and O
the O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
( O
m O
##out O
##on O
et O
al O
. O
, O
2002 O
; O
ch O
##ig O
##uts O
##a O
et O
al O
. O
, O
2012 O
; O
rose O
et O
al O
. O
, O
2013 O
; O
x O
##ia O
##o O
et O
al O
. O
, O
2015 O
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
and O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
were O
considered O
as O
paired O
p O
##k O
/ O
p O
##d O
parameters O
which O
were O
calculated O
in O
each O
dose O
of O
the O
time O
- O
killing O
curve O
. O
[SEP] O
[CLS] O
the O
inhibitor O
##y O
si O
##g O
##mo O
##id O
em B-PK
##ax I-PK
model O
was O
applied O
to O
evaluate O
the O
ass O
##im O
##ilation O
of O
correlation O
of O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
ratio I-PK
in O
v O
##it O
##ro O
and O
bacteria O
count O
change O
( O
c O
##fu O
/ O
m O
##l O
) O
in O
serum O
during O
24 O
h O
in O
##cu O
##bation O
with O
win O
##non O
##lin O
software O
( O
al O
##ia O
##bad O
##i O
and O
le O
##es O
, O
2000 O
, O
2001 O
, O
2002 O
; O
si O
##dh O
##u O
et O
al O
. O
, O
2011 O
) O
. O
[SEP] O
[CLS] O
e O
, O
presented O
the O
effect O
of O
anti O
##mic O
##ro O
##bial O
agent O
counted O
as O
log O
##10 O
difference O
of O
bacterial O
number O
before O
and O
after O
the O
24 O
h O
in O
##cu O
##bation O
in O
v O
##it O
##ro O
; O
em B-PK
##ax I-PK
, O
measured O
the O
de O
##viation O
##s O
in O
log O
##10 O
difference O
between O
0 O
and O
24 O
h O
in O
the O
control O
and O
til O
##di O
##pi O
##ros O
##in O
samples O
; O
e B-PK
##c I-PK
##50 I-PK
, O
the O
au B-PK
##c I-PK
##24 I-PK
/ I-PK
mi I-PK
##c I-PK
value O
reached O
50 O
% O
of O
the O
em B-PK
##ax I-PK
; O
c O
, O
presented O
the O
au B-PK
##c I-PK
##24 I-PK
/ I-PK
mi I-PK
##c I-PK
ratio O
; O
n O
, O
presented O
the O
hill B-PK
coefficient I-PK
. O
[SEP] O
[CLS] O
the O
given O
formula O
was O
performed O
to O
calculate O
the O
doses O
in O
different O
magnitude O
##s O
of O
efficiency O
containing O
( O
e O
= O
0 O
, O
no O
change O
in O
bacterial O
count O
, O
e O
= O
- O
1 O
, O
99 O
. O
9 O
% O
reduction O
in O
the O
count O
, O
e O
= O
- O
3 O
, O
99 O
. O
99 O
% O
reduction O
) O
for O
est O
##imating O
an O
op O
##ti O
##mum O
regime O
##n O
. O
[SEP] O
[CLS] O
the O
mon O
##te O
car O
##lo O
simulation O
( O
including O
10 O
, O
000 O
it O
##eration O
##s O
) O
was O
performed O
using O
the O
crystal O
ball O
software O
( O
version O
7 O
. O
2 O
. O
2 O
, O
or O
##acle O
, O
united O
states O
) O
based O
on O
the O
selected O
p O
##k O
/ O
p O
##d O
target O
index O
( O
au B-PK
##c I-PK
##24 I-PK
/ I-PK
mi I-PK
##c I-PK
, O
e O
= O
- O
3 O
, O
b O
##act O
##eric O
##idal O
activity O
) O
( O
le O
##i O
et O
al O
. O
, O
2017 O
##a O
, O
b O
, O
c O
, O
2018 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
results O
for O
the O
au B-PK
##c I-PK
##24 I-PK
h I-PK
, O
au B-PK
##c I-PK
, O
t B-PK
##max I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
til O
##di O
##pi O
##ros O
##in O
, O
cm B-PK
##ax I-PK
, O
c B-PK
##l I-PK
##b I-PK
, O
and O
the O
mean B-PK
resistance I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
in O
the O
serum O
after O
i O
. O
v O
. O
and O
i O
. O
m O
. O
administration O
##s O
were O
shown O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
til O
##di O
##pi O
##ros O
##in O
after O
i O
. O
m O
. O
administration O
was O
determined O
as O
85 O
. O
5 O
% O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
the O
ratios O
of O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
, O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
and O
t O
> O
mi O
##c O
were O
1 O
. O
96 O
, O
7 O
. O
88 O
, O
and O
0 O
. O
97 O
h O
, O
respectively O
, O
on O
the O
basis O
of O
p O
##k O
/ O
p O
##d O
data O
ex O
v O
##ivo O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
the O
relationship O
between O
anti O
##mic O
##ro O
##bial O
efficiency O
and O
the O
ex O
v O
##ivo O
p O
##k O
/ O
p O
##d O
parameter O
of O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
ratios O
were O
simulated O
by O
using O
the O
inhibitor O
##y O
si O
##g O
##mo O
##id O
em B-PK
##ax I-PK
model O
. O
[SEP] O
[CLS] O
the O
model O
parameters O
of O
the O
hill B-PK
coefficient I-PK
n I-PK
, O
em B-PK
##ax I-PK
, O
and O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
values O
are O
presented O
for O
three O
levels O
of O
growth O
in O
##hibition O
in O
table O
4 O
and O
figure O
5 O
. O
[SEP] O
[CLS] O
the O
values O
of O
the O
au B-PK
##c I-PK
##24 I-PK
##h I-PK
/ I-PK
mi I-PK
##c I-PK
ratio O
required O
for O
b O
##act O
##eri O
##ost O
##atic O
activity O
( O
e O
= O
0 O
) O
, O
b O
##act O
##eric O
##idal O
activity O
( O
e O
= O
- O
3 O
) O
, O
and O
bacterial O
elimination O
( O
e O
= O
- O
4 O
) O
were O
18 O
. O
91 O
, O
29 O
. O
13 O
, O
and O
34 O
. O
03 O
h O
, O
as O
presented O
in O
table O
4 O
. O
[SEP] O
[CLS] O
the O
obtained O
results O
revealed O
the O
great O
ability O
of O
the O
produced O
n O
##f O
- O
loaded O
ni O
##o O
- O
some O
##s O
to O
enhance O
drug O
penetration O
through O
nasal O
m O
##uc O
##osa O
and O
improve O
its O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
compared O
with O
n O
##f O
oral O
solution O
. O
[SEP] O
[CLS] O
the O
calculated O
cumulative O
target O
achievement O
for O
p O
##k O
/ O
p O
##d O
parameter O
( O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
) O
in O
serum O
( O
ex O
v O
##ivo O
) O
was O
29 O
. O
13 O
± O
2 O
. O
44 O
h O
, O
with O
assured O
b O
##act O
##eric O
##idal O
activity O
( O
e O
= O
- O
3 O
) O
. O
[SEP] O
[CLS] O
the O
predicted O
daily O
doses O
were O
given O
in O
table O
6 O
based O
on O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
ratios I-PK
and O
c B-PK
##l I-PK
##b I-PK
for O
these O
three O
levels O
of O
anti O
##ba O
##cter O
##ial O
activity O
measured O
from O
the O
p O
##k O
/ O
p O
##d O
integrating O
model O
and O
the O
distribution O
of O
ex O
v O
##ivo O
mi O
##c O
using O
mon O
##te O
car O
##lo O
simulation O
##s O
in O
or O
##acle O
crystal O
ball O
. O
[SEP] O
[CLS] O
the O
distributions O
of O
predicted O
population O
dose O
( O
au B-PK
##c I-PK
##24 I-PK
h I-PK
/ I-PK
mi I-PK
##c I-PK
) O
values O
of O
til O
##di O
##pi O
##ros O
##in O
cu O
##ring O
pm O
for O
50 O
and O
90 O
% O
targets O
were O
observed O
, O
respectively O
, O
and O
illustrated O
in O
figure O
6 O
. O
[SEP] O
[CLS] O
one O
of O
the O
greatest O
challenges O
drug O
formulation O
is O
facing O
is O
poor O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
via O
oral O
route O
. O
[SEP] O
[CLS] O
in O
this O
regard O
, O
nasal O
drug O
delivery O
has O
been O
commonly O
used O
as O
an O
alternative O
route O
to O
improve O
drug O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
ne O
##fo O
##pa O
##m O
h O
##ydro O
##ch O
##lor O
##ide O
( O
n O
##f O
) O
is O
an O
anal O
##ges O
##ic O
drug O
that O
suffers O
from O
poor O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
due O
to O
extensive O
metabolism O
in O
liver O
. O
[SEP] O
[CLS] O
accordingly O
, O
the O
goal O
of O
the O
present O
study O
was O
to O
improve O
n O
##f O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
via O
ni O
##oso O
##mal O
- O
based O
formulation O
designed O
for O
in O
##tra O
##nas O
##al O
delivery O
. O
[SEP] O
[CLS] O
the O
in O
- O
v O
##ivo O
studies O
showed O
a O
4 O
. O
77 O
- O
fold O
increase O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
op O
##ti O
##mized O
nasal O
ni O
##oso O
##mes O
compared O
with O
oral O
solution O
of O
drug O
. O
[SEP] O
[CLS] O
equation O
3 O
was O
used O
to O
calculate O
au B-PK
##c I-PK
from I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
, O
au O
##c O
##0 O
– O
∞ O
( O
ng O
hour O
/ O
m O
##l O
) O
: O
au O
##c O
##0 O
##− O
##∞ O
= O
au O
##c O
##0 O
##− O
##24 O
+ O
c O
##t O
/ O
k O
( O
3 O
) O
where O
##ct O
is O
the O
last O
measured O
concentration O
at O
time O
t O
##k O
is O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
##final I-PK
##ly I-PK
, O
the O
apparent B-PK
terminal I-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
determined O
using O
the O
relation O
t O
##1 O
/ O
2 O
= O
0 O
. O
69 O
##3 O
/ O
k O
. O
[SEP] O
[CLS] O
parameters O
like O
maximum B-PK
drug I-PK
concentration I-PK
and O
the O
time B-PK
needed I-PK
to I-PK
reach I-PK
such I-PK
a I-PK
concentration I-PK
, O
namely O
, O
cm B-PK
##ax I-PK
( O
ng O
/ O
m O
##l O
) O
and O
t B-PK
##max I-PK
( O
h O
) O
, O
respectively O
, O
were O
determined O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
, I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
( O
ng O
hour O
/ O
m O
##l O
) O
, O
for O
each O
group O
was O
determined O
by O
employing O
the O
trap O
##ez O
##oid O
##al O
rule O
from O
time O
0 O
to O
the O
last O
time O
interval O
used O
for O
withdrawing O
blood O
samples O
. O
[SEP] O
[CLS] O
transmission O
electron O
micro O
##sco O
##py O
showed O
the O
formation O
of O
spherical O
ni O
##oso O
##mes O
with O
closed O
bi O
##layer O
structure O
( O
figure O
1 O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
value O
for O
groups O
1 O
and O
2 O
was O
2 O
he O
##ct O
##ose O
##con O
##ds O
, O
while O
that O
of O
group O
3 O
was O
1 O
he O
##ct O
##ose O
##con O
##ds O
. O
[SEP] O
[CLS] O
the O
mean O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
for O
oral O
solution O
was O
found O
to O
be O
61 O
##5 O
. O
7 O
ng O
hours O
/ O
m O
##l O
while O
that O
of O
op O
##ti O
##mum O
nasal O
formula O
was O
calculated O
to O
be O
2 O
, O
94 O
##0 O
. O
7 O
ng O
hours O
/ O
m O
##l O
and O
that O
of O
n O
##f O
nasal O
solution O
was O
found O
to O
be O
1 O
, O
56 O
##2 O
. O
3 O
ng O
hours O
/ O
m O
##l O
. O
the O
op O
##ti O
##mized O
n O
##f O
- O
loaded O
ni O
##oso O
##mes O
nasal O
formula O
had O
a O
percentage O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
47 O
##7 O
. O
5 O
% O
when O
compared O
with O
the O
n O
##f O
oral O
solution O
. O
[SEP] O
[CLS] O
the O
current O
investigation O
revealed O
that O
the O
op O
##ti O
##mized O
nasal O
formulation O
exhibited O
a O
higher O
cm B-PK
##ax I-PK
value O
and O
an O
elongated O
mean O
elimination B-PK
half I-PK
- I-PK
life I-PK
compared O
with O
that O
of O
n O
##f O
oral O
solution O
and O
n O
##f O
nasal O
solution O
. O
[SEP] O
[CLS] O
the O
n O
##f O
oral O
solution O
had O
a O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
4 O
. O
12 O
hours O
; O
in O
the O
meantime O
, O
the O
op O
##ti O
##mum O
n O
##f O
- O
loaded O
ni O
##oso O
##mal O
nasal O
suspension O
had O
a O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
9 O
. O
2 O
hours O
and O
the O
nasal O
solution O
of O
drug O
had O
a O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
2 O
. O
3 O
hours O
. O
[SEP] O
[CLS] O
for O
art O
##em O
##eth O
##er O
and O
d O
##ha O
, O
the O
two O
samples O
were O
taken O
at O
1 O
and O
2 O
h O
post O
first O
treatment O
dose O
( O
i O
. O
e O
. O
anticipated O
time B-PK
of I-PK
maximum I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
) O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
was O
determined O
from O
these O
two O
concentrations O
, O
which O
##ever O
was O
larger O
for O
a O
given O
patient O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
last I-PK
were O
derived O
from O
this O
population O
mean O
concentration O
- O
time O
curve O
. O
[SEP] O
[CLS] O
as O
reported O
elsewhere O
[ O
24 O
] O
, O
there O
were O
no O
clinical O
##ly O
relevant O
between O
- O
group O
differences O
in O
cm B-PK
##ax I-PK
for O
art O
##em O
##eth O
##er O
or O
d O
##ha O
; O
l O
##ume O
##fant O
##rine O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
0 I-PK
- I-PK
last I-PK
appeared O
higher O
in O
the O
15 O
to O
< O
25 O
kg O
group O
compared O
to O
the O
5 O
to O
< O
15 O
kg O
body O
weight O
group O
, O
approximately O
in O
line O
with O
the O
increase O
in O
dose O
, O
in O
particular O
for O
au B-PK
##c I-PK
after O
crushed O
tablet O
. O
[SEP] O
[CLS] O
art O
##em O
##eth O
##er O
and O
d O
##ha O
cm B-PK
##ax I-PK
were O
2 O
. O
15 O
- O
to O
3 O
. O
4 O
- O
fold O
higher O
in O
the O
5 O
to O
< O
10 O
kg O
body O
weight O
group O
compared O
to O
the O
10 O
to O
< O
15 O
kg O
body O
weight O
group O
. O
[SEP] O
[CLS] O
there O
were O
no O
apparent O
differences O
for O
l O
##ume O
##fant O
##rine O
cm B-PK
##ax I-PK
or O
au B-PK
##c I-PK
between O
the O
two O
body O
weight O
groups O
. O
[SEP] O
[CLS] O
there O
was O
a O
tendency O
towards O
longer O
time O
to O
parasite O
and O
fever O
clearance B-PK
in O
the O
lower O
body O
weight O
groups O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
a O
meaningful O
assessment O
of O
game O
##to O
##cy O
##te O
clearance B-PK
according O
to O
body O
weight O
group O
was O
not O
possible O
due O
to O
the O
low O
number O
of O
patients O
with O
game O
##to O
##cy O
##ta O
##emia O
at O
base O
##line O
( O
n O
= O
41 O
) O
. O
[SEP] O
[CLS] O
the O
national O
ethics O
review O
committee O
at O
et O
##hi O
##op O
##ian O
science O
and O
technology O
ministry O
as O
well O
as O
by O
the O
food O
and O
drug O
administration O
and O
control O
authority O
of O
et O
##hi O
##op O
##ia O
. O
[SEP] O
[CLS] O
a O
[ O
c O
##y O
##p O
##3 O
##a O
##5 O
* O
6 O
] O
, O
c O
_ O
_ O
322 O
##8 O
##7 O
##18 O
##8 O
_ O
10 O
for O
c O
##y O
##p O
##3 O
##a O
##5 O
g O
. O
27 O
##13 O
##1 O
_ O
27 O
##13 O
##2 O
##ins O
##t O
r O
##s O
##24 O
##13 O
##0 O
##33 O
##43 O
[ O
c O
##y O
##p O
##3 O
##a O
##5 O
* O
7 O
] O
, O
c O
_ O
_ O
_ O
1901 O
##6 O
##9 O
##7 O
_ O
20 O
for O
s O
##l O
##co O
##1 O
##b O
##1 O
38 O
##8 O
##a O
> O
g O
r O
##s O
##23 O
##0 O
##6 O
##28 O
##3 O
( O
* O
1 O
##b O
) O
and O
c O
_ O
_ O
306 O
##33 O
##90 O
##6 O
_ O
10 O
for O
s O
##l O
##co O
##1 O
##b O
##1 O
52 O
##1 O
##t O
> O
c O
r O
##s O
##41 O
##4 O
##90 O
##5 O
##6 O
( O
* O
5 O
) O
on O
a O
##bi O
750 O
##0 O
fast O
( O
applied O
bio O
##sy O
##ste O
##ms O
, O
foster O
city O
, O
ca O
) O
. O
[SEP] O
[CLS] O
se O
##quencing O
reaction O
was O
done O
using O
the O
a O
##bi O
[UNK] O
big O
##dy O
##e O
##® O
term O
##inator O
cycle O
se O
##quencing O
ready O
reaction O
kit O
v O
##3 O
. O
1 O
( O
applied O
bio O
##sy O
##ste O
##ms O
, O
foster O
city O
, O
ca O
) O
, O
and O
analyzed O
on O
an O
a O
##bi O
p O
##rism O
37 O
##7 O
d O
##na O
sequence O
##r O
. O
[SEP] O
[CLS] O
an O
all O
##ometric O
##ally O
scaled O
population O
- O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
developed O
to O
investigate O
the O
effect O
of O
tablet O
and O
suspension O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
non B-PK
##linear I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
suspension O
, O
followed O
by O
a O
step O
- O
wise O
co O
##var O
##iate O
model O
building O
exercise O
to O
identify O
other O
important O
sources O
of O
var O
##iability O
. O
[SEP] O
[CLS] O
a O
one O
- O
compartment O
model O
was O
used O
, O
with O
tablet O
apparent B-PK
clearance I-PK
standard O
##ised O
to O
a O
70 O
- O
kg O
individual O
of O
15 O
l O
/ O
h O
. O
[SEP] O
[CLS] O
suspension O
was O
found O
to O
have O
decreasing O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
with O
increasing O
dose O
; O
the O
estimated O
suspension O
dose O
to O
yield O
half O
the O
tablet O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
99 O
mg O
/ O
m O
##2 O
. O
[SEP] O
[CLS] O
association O
of O
di O
##li O
with O
female O
sex O
( O
p O
= O
0 O
. O
00 O
##1 O
) O
and O
lower O
b O
##mi O
( O
p O
= O
0 O
. O
09 O
) O
was O
noted O
. O
[SEP] O
[CLS] O
in O
the O
largest O
population O
- O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
to O
date O
in O
children O
, O
we O
have O
found O
similar O
co O
##var O
##iate O
effects O
to O
those O
seen O
in O
adults O
, O
but O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
suspension O
in O
patients O
with O
di O
##ar O
##r O
##hoe O
##a O
or O
those O
taking O
concurrent O
pro O
##ton O
pump O
inhibitor O
##s O
, O
which O
may O
in O
particular O
limit O
the O
use O
of O
p O
##osa O
##cona O
##zo O
##le O
in O
these O
patients O
. O
[SEP] O
[CLS] O
co O
##x O
- O
re O
##gression O
analysis O
showed O
that O
there O
was O
a O
statistical O
##ly O
significant O
association O
di O
##li O
with O
c O
##y O
##p O
##2 O
##b O
##6 O
* O
6 O
and O
a O
##b O
##c O
##b O
##1 O
34 O
##35 O
##tt O
g O
##eno O
##type O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
because O
most O
samples O
were O
pre O
- O
dose O
t O
##rough O
##s O
and O
p O
##osa O
##cona O
##zo O
##le O
is O
known O
to O
have O
a O
long O
elimination B-PK
half I-PK
- I-PK
life I-PK
, O
a O
one O
- O
compartment O
model O
with O
first O
- O
order O
absorption O
was O
used O
. O
[SEP] O
[CLS] O
all O
##ometric O
s O
##cal O
##ing O
with O
ex O
##ponents O
of O
0 O
. O
75 O
, O
1 O
and O
− O
0 O
. O
25 O
on O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
central B-PK
volume I-PK
and I-PK
absorption I-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
were O
added O
a O
prior O
##i O
, O
and O
a O
si O
##g O
##mo O
##idal O
mat O
##uration O
function O
based O
on O
post O
##men O
##st O
##ru O
##al O
age O
was O
tested O
[ O
12 O
] O
. O
[SEP] O
[CLS] O
the O
following O
con O
##com O
##ita O
##nt O
medications O
were O
also O
tested O
on O
c B-PK
##l I-PK
: O
mac O
##rol O
##ides O
, O
e O
##chin O
##oc O
##and O
##ins O
, O
c O
##ic O
##los O
##por O
##in O
, O
ta O
##c O
##rol O
##imus O
, O
my O
##co O
##phe O
##no O
##late O
, O
r O
##if O
##amp O
##ici O
##n O
, O
car O
##ba O
##ma O
##ze O
##pine O
, O
p O
##hen O
##yt O
##oi O
##n O
or O
v O
##ala O
##ci O
##c O
##lov O
##ir O
. O
[SEP] O
[CLS] O
the O
base O
structural O
model O
with O
all O
##ometric O
s O
##cal O
##ing O
centred O
on O
70 O
kg O
and O
inter O
- O
individual O
var O
##iability O
on O
c B-PK
##l I-PK
only O
gave O
parameter O
estimates O
of O
86 O
. O
5 O
l O
/ O
h O
, O
143 O
##9 O
. O
6 O
l O
and O
0 O
. O
09 O
/ O
h O
for O
apparent B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
apparent B-PK
volume I-PK
and O
ka B-PK
, O
respectively O
. O
[SEP] O
[CLS] O
the O
addition O
of O
a O
si O
##g O
##mo O
##idal O
mat O
##uration O
function O
gave O
no O
improvement O
in O
fit O
, O
whereas O
adding O
a O
cat O
##ego O
##rical O
co O
##var O
##iate O
of O
a O
change O
in O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
with O
suspension O
compared O
with O
a O
tablet O
yielded O
a O
decrease O
in O
of O
##v O
of O
10 O
. O
11 O
( O
p O
= O
0 O
. O
00 O
##15 O
) O
. O
[SEP] O
[CLS] O
during O
model O
building O
, O
flip O
- O
fl O
##op O
kinetic O
##s O
became O
apparent O
( O
ka B-PK
being O
estimated O
to O
be O
larger O
than O
elimination B-PK
rate I-PK
constant I-PK
) O
. O
[SEP] O
[CLS] O
thereafter O
, O
ka B-PK
was O
fixed O
to O
literature O
values O
of O
0 O
. O
58 O
##8 O
/ O
h O
for O
tablets O
[ O
19 O
] O
, O
and O
0 O
. O
197 O
/ O
h O
for O
suspension O
##s O
[ O
15 O
] O
. O
[SEP] O
[CLS] O
the O
difference O
in O
of O
##v O
between O
this O
model O
and O
the O
estimated O
ka B-PK
and O
v B-PK
models O
was O
7 O
. O
63 O
, O
indicating O
a O
very O
similar O
fit O
. O
[SEP] O
[CLS] O
o O
##mada O
##cy O
##cline O
plasma B-PK
clearance I-PK
was O
1 O
. O
2 O
liter O
##s O
/ O
h O
/ O
kg O
, O
and O
its O
half B-PK
- I-PK
life I-PK
was O
4 O
. O
6 O
h O
; O
the O
steady B-PK
- I-PK
state I-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
was O
6 O
. O
89 O
liter O
##s O
/ O
kg O
. O
[SEP] O
[CLS] O
the O
predominant O
radioactive O
components O
in O
rat O
plasma O
after O
a O
single O
i O
. O
v O
. O
dose O
were O
unchanged O
( O
o O
##mada O
##cy O
##cline O
/ O
c O
- O
4 O
e O
##pi O
##mer O
, O
89 O
. O
9 O
% O
au B-PK
##c I-PK
) O
. O
[SEP] O
[CLS] O
following O
a O
90 O
mg O
/ O
kg O
oral O
dose O
of O
14 O
##c O
- O
o O
##mada O
##cy O
##cline O
, O
the O
peak B-PK
radio I-PK
##act I-PK
##ivity I-PK
concentration I-PK
in I-PK
plasma I-PK
( I-PK
cm I-PK
##ax I-PK
, O
172 O
ng O
· O
e O
##q O
/ O
m O
##l O
) O
was O
attained O
at O
between O
0 O
. O
25 O
and O
2 O
h O
( O
fi O
##g O
. O
1 O
) O
. O
[SEP] O
[CLS] O
the O
peak B-PK
plasma I-PK
concentration I-PK
of O
unchanged O
o O
##mada O
##cy O
##cline O
( O
cm B-PK
##ax I-PK
, O
47 O
. O
5 O
ng O
/ O
m O
##l O
) O
was O
attained O
at O
0 O
. O
5 O
h O
after O
oral O
dos O
##ing O
( O
fi O
##g O
. O
2 O
) O
, O
further O
suggesting O
rapid O
absorption O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
ratio O
of O
the O
values O
corresponding O
to O
the O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
/ I-PK
time I-PK
curve I-PK
at I-PK
last I-PK
observation I-PK
( I-PK
au I-PK
##c I-PK
##last I-PK
) I-PK
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
plasma O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
very O
low O
( O
0 O
. O
23 O
% O
) O
compared O
to O
the O
absorption O
( O
table O
4 O
) O
, O
suggesting O
significant O
first O
- O
pass O
elimination O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
much O
lower O
than O
[UNK] O
% O
in O
humans O
( O
5 O
) O
. O
[SEP] O
[CLS] O
systemic B-PK
plasma I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
; O
1 O
, O
200 O
m O
##l O
/ O
h O
/ O
kg O
) O
appeared O
to O
be O
moderate O
compared O
to O
the O
level O
in O
the O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
in O
the O
rat O
( O
3 O
. O
3 O
liter O
##s O
/ O
h O
/ O
kg O
) O
, O
assuming O
equal O
distributions O
of O
14 O
##c O
- O
o O
##mada O
##cy O
##cline O
in O
the O
blood O
and O
plasma O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
volume I-PK
of I-PK
distribution I-PK
at I-PK
the I-PK
steady I-PK
state I-PK
of O
the O
unchanged O
compound O
( O
vs B-PK
##s I-PK
; O
6 O
. O
89 O
liter O
##s O
/ O
kg O
) O
was O
larger O
than O
the O
body O
water O
volume O
( O
0 O
. O
6 O
liter O
##s O
/ O
kg O
) O
, O
suggesting O
that O
o O
##mada O
##cy O
##cline O
was O
extensively O
distributed O
to O
tissues O
. O
[SEP] O
[CLS] O
the O
highest B-PK
average I-PK
plasma I-PK
o I-PK
##mada I-PK
##cy I-PK
##cline I-PK
and I-PK
radio I-PK
##act I-PK
##ivity I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
corresponding O
times O
( O
t B-PK
##max I-PK
) O
were O
recorded O
. O
[SEP] O
[CLS] O
a O
##ki O
was O
defined O
either O
as O
> O
50 O
% O
increase O
in O
plasma O
c O
##rea O
##tin O
##ine O
from O
base O
##line O
, O
or O
> O
33 O
. O
3 O
% O
decrease O
in O
c O
##rea O
##tin O
##ine O
clearance O
. O
[SEP] O
[CLS] O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
the O
steady B-PK
- I-PK
state I-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
of O
o O
##mada O
##cy O
##cline O
were O
calculated O
using O
data O
from O
the O
i O
. O
v O
. O
dose O
. O
[SEP] O
[CLS] O
amongst O
patients O
with O
plasma O
c O
##rea O
##tin O
##ine O
< O
1 O
. O
24 O
mg O
/ O
d O
##l O
on O
entry O
, O
c O
##rea O
##tin O
##ine O
clearance O
improved O
the O
prediction O
of O
a O
##ki O
considerably O
( O
net O
re O
##c O
##lass O
##ification O
improvement O
83 O
% O
, O
integrated O
discrimination O
improvement O
0 O
. O
29 O
) O
. O
[SEP] O
[CLS] O
for O
the O
major O
meta O
##bol O
##ites O
in O
plasma O
, O
cm B-PK
##ax I-PK
and O
t B-PK
##max I-PK
were O
recorded O
as O
observed O
. O
[SEP] O
[CLS] O
on O
- O
entry O
, O
c O
##rea O
##tin O
##ine O
clearance O
associated O
with O
a O
##ki O
severity O
and O
duration O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
predicted O
dial O
##ys O
##is O
need O
( O
area O
under O
the O
curve O
: O
0 O
. O
75 O
) O
and O
death O
( O
0 O
. O
61 O
) O
. O
[SEP] O
[CLS] O
patients O
were O
further O
classified O
into O
( O
i O
) O
no O
a O
##ki O
( O
δ O
##p O
##c O
##rno O
- O
a O
##ki O
and O
δ O
##cc O
##ln O
##o O
- O
a O
##ki O
) O
; O
( O
ii O
) O
a O
##ki O
by O
the O
clearance B-PK
criterion O
only O
( O
δ O
##p O
##c O
##rno O
- O
a O
##ki O
and O
δ O
##cc O
##lak O
##i O
) O
; O
( O
ii O
##i O
) O
a O
##ki O
by O
the O
p O
##c O
##r O
criterion O
only O
( O
δ O
##p O
##c O
##rak O
##i O
and O
δ O
##cc O
##ln O
##o O
- O
a O
##ki O
) O
or O
( O
i O
##v O
) O
a O
##ki O
by O
both O
criteria O
( O
δ O
##p O
##c O
##rak O
##i O
and O
δ O
##cc O
##lak O
##i O
) O
. O
[SEP] O
[CLS] O
the O
area O
under O
the O
receiver O
operator O
characteristic O
curve O
( O
au O
##c O
) O
was O
used O
to O
determine O
the O
predict O
##ive O
value O
of O
on O
- O
entry O
cc O
##l O
for O
δ O
##cc O
##lak O
##i O
and O
on O
- O
entry O
p O
##c O
##r O
for O
δ O
##p O
##c O
##rak O
##i O
. O
[SEP] O
[CLS] O
diagnostic O
and O
pro O
##gno O
##stic O
performance O
was O
assessed O
by O
calculating O
the O
au B-PK
##c I-PK
and O
odds O
ratios O
. O
[SEP] O
[CLS] O
the O
reference O
and O
new O
a O
##ki O
risk O
prediction O
models O
were O
compared O
by O
the O
continuous O
( O
category O
- O
free O
) O
net O
re O
##c O
##lass O
##ification O
improvement O
( O
n O
##ri O
) O
and O
integrated O
discrimination O
improvement O
statistics O
[ O
19 O
- O
21 O
] O
and O
difference O
in O
au B-PK
##c I-PK
[ O
22 O
] O
. O
[SEP] O
[CLS] O
of O
the O
remainder O
, O
30 O
were O
a O
sub O
- O
co O
##hor O
##t O
of O
high O
- O
risk O
patients O
who O
had O
undergone O
card O
##io O
- O
th O
##ora O
##ci O
##c O
surgery O
, O
and O
whose O
first O
clearance B-PK
measure O
was O
8 O
to O
11 O
h O
after O
entry O
to O
i O
##cu O
, O
and O
14 O
patients O
had O
no O
clearance B-PK
measurement O
because O
they O
were O
an O
##uri O
##c O
or O
because O
clinical O
events O
prevented O
measurement O
. O
[SEP] O
[CLS] O
on O
entry O
to O
the O
i O
##cu O
, O
182 O
patients O
had O
a O
pre O
- O
admission O
base O
##line O
c O
##rea O
##tin O
##ine O
from O
which O
the O
change O
in O
c O
##rea O
##tin O
##ine O
( O
δ O
##p O
##c O
##r O
) O
and O
change O
in O
c O
##rea O
##tin O
##ine O
clearance O
( O
δ O
##cc O
##l O
) O
to O
determine O
a O
##ki O
status O
on O
entry O
was O
calculated O
( O
figure O
1 O
) O
. O
[SEP] O
[CLS] O
the O
optimal O
cut O
- O
point O
for O
cc O
##l O
to O
di O
##ag O
##nose O
δ O
##cc O
##lak O
##i O
was O
48 O
. O
6 O
m O
##l O
/ O
min O
( O
au O
##c O
, O
0 O
. O
87 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
81 O
to O
0 O
. O
94 O
) O
calculated O
using O
1 O
/ O
cc O
##l O
) O
in O
the O
known O
base O
##line O
c O
##rea O
##tin O
##ine O
co O
##hor O
##t O
( O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
on O
entry O
to O
the O
i O
##cu O
, O
cc O
##l O
moderately O
predicted O
the O
need O
for O
dial O
##ys O
##is O
marginal O
##ly O
better O
( O
au O
##c O
, O
0 O
. O
75 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
59 O
to O
0 O
. O
91 O
; O
p O
= O
0 O
. O
01 O
##8 O
) O
than O
p O
##c O
##r O
( O
au O
##c O
, O
0 O
. O
72 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
56 O
to O
0 O
. O
89 O
) O
; O
u O
##o O
was O
not O
predict O
##ive O
( O
au O
##c O
, O
0 O
. O
50 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
41 O
to O
0 O
. O
75 O
) O
. O
[SEP] O
[CLS] O
below O
this O
cut O
- O
point O
adding O
cc O
##l O
to O
a O
risk O
prediction O
model O
comprising O
p O
##c O
##r O
, O
u O
##o O
and O
acute O
physiology O
and O
chronic O
health O
evaluation O
( O
a O
##pa O
##che O
) O
ii O
scores O
( O
all O
p O
< O
0 O
. O
1 O
in O
a O
un O
##iva O
##ria O
##te O
analysis O
) O
for O
a O
##ki O
( O
δ O
##cc O
##lak O
##i O
or O
δ O
##p O
##c O
##rak O
##i O
) O
considerably O
improved O
the O
model O
: O
in O
the O
known O
base O
##line O
c O
##rea O
##tin O
##ine O
co O
##hor O
##t O
the O
au O
##c O
increased O
by O
0 O
. O
23 O
to O
a O
moderate O
0 O
. O
77 O
; O
a O
net O
23 O
% O
of O
those O
with O
a O
##ki O
had O
greater O
risk O
whilst O
60 O
% O
of O
those O
without O
a O
##ki O
had O
less O
risk O
, O
resulting O
in O
an O
n O
##ri O
of O
83 O
% O
; O
the O
average O
increase O
in O
risk O
of O
those O
with O
a O
##ki O
was O
0 O
. O
22 O
( O
id O
##ia O
##ki O
) O
and O
the O
average O
decrease O
in O
risk O
of O
those O
without O
a O
##ki O
was O
0 O
. O
07 O
##4 O
( O
id O
##ino O
- O
a O
##ki O
) O
indicating O
the O
model O
worked O
best O
to O
improve O
identification O
of O
those O
with O
a O
##ki O
rather O
than O
exclude O
those O
without O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
neither O
p O
##c O
##r O
( O
au O
##c O
, O
0 O
. O
55 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
48 O
to O
0 O
. O
62 O
) O
nor O
u O
##o O
( O
au O
##c O
, O
0 O
. O
55 O
; O
95 O
% O
c O
##i O
, O
0 O
. O
47 O
to O
0 O
. O
62 O
) O
were O
predict O
##ive O
of O
death O
. O
[SEP] O
[CLS] O
cc O
##l O
was O
predict O
##ive O
of O
death O
within O
30 O
days O
, O
but O
with O
a O
lower O
au O
##c O
value O
of O
0 O
. O
61 O
( O
95 O
% O
c O
##i O
, O
0 O
. O
54 O
to O
0 O
. O
68 O
) O
. O
[SEP] O
[CLS] O
these O
patients O
were O
more O
likely O
to O
require O
dial O
##ys O
##is O
or O
die O
within O
30 O
days O
than O
patients O
with O
smaller O
decreases O
( O
29 O
% O
vs O
15 O
% O
, O
p O
= O
0 O
. O
00 O
##5 O
##7 O
; O
r O
##r O
, O
2 O
. O
0 O
; O
95 O
% O
c O
##i O
, O
1 O
. O
3 O
to O
3 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
compared O
to O
the O
control O
group O
given O
oral O
pu O
##era O
##rin O
only O
, O
the O
combined O
use O
of O
pipe O
##rine O
( O
10 O
or O
20 O
mg O
/ O
kg O
) O
increased O
the O
cm B-PK
##ax I-PK
of O
pu O
##era O
##rin O
by O
1 O
. O
30 O
- O
fold O
or O
1 O
. O
64 O
- O
fold O
and O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
by O
133 O
% O
or O
157 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
drug O
and O
statistics O
software O
( O
version O
3 O
. O
1 O
. O
5 O
) O
was O
used O
to O
calculate O
the O
model O
- O
independent O
parameters O
, O
such O
as O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
, O
the O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
and O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
other O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
such O
as O
c B-PK
##l I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
were O
not O
altered O
obviously O
. O
[SEP] O
[CLS] O
as O
is O
shown O
in O
table O
2 O
, O
the O
c B-PK
##l I-PK
and O
v B-PK
##d I-PK
of O
pu O
##era O
##rin O
were O
not O
altered O
obviously O
after O
pre O
##tre O
##at O
##ment O
with O
pipe O
##rine O
. O
[SEP] O
[CLS] O
however O
, O
the O
combined O
use O
of O
white O
pepper O
( O
125 O
and O
250 O
mg O
/ O
kg O
) O
with O
pu O
##era O
##rin O
increased O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
of O
pu O
##era O
##rin O
by O
115 O
% O
and O
128 O
% O
( O
p O
< O
0 O
. O
05 O
) O
, O
respectively O
, O
as O
compared O
to O
the O
control O
group O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
pu O
##era O
##rin O
was O
increased O
and O
c B-PK
##l I-PK
was O
reduced O
in O
the O
presence O
of O
white O
pepper O
, O
although O
there O
was O
no O
statistical O
significance O
( O
p O
> O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
in O
the O
a O
##f O
##rica O
##ns O
were O
2 O
. O
67 O
- O
fold O
and O
2 O
. O
0 O
- O
fold O
higher O
than O
the O
chin O
##ese O
, O
respectively O
. O
[SEP] O
[CLS] O
s O
##cat O
##ter O
plot O
showed O
a O
strong O
negative O
correlation O
between O
the O
micro O
##bio O
##tal O
abundance O
and O
the O
be O
##rber O
##ine O
au B-PK
##c I-PK
, O
especially O
for O
the O
genus O
pre O
##vo O
##tel O
##la O
( O
r O
= O
− O
##0 O
. O
81 O
##3 O
) O
and O
its O
species O
. O
[SEP] O
[CLS] O
a O
more O
extensive O
metabolism O
was O
observed O
in O
chin O
##ese O
with O
1 O
. O
83 O
- O
fold O
higher O
meta O
##bol O
##ites O
, O
possibly O
contributing O
to O
the O
lower O
au B-PK
##c I-PK
than O
the O
a O
##f O
##rica O
##ns O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
were O
respectively O
0 O
. O
16 O
± O
0 O
. O
08 O
and O
0 O
. O
06 O
± O
0 O
. O
02 O
ng O
· O
m O
##l O
##− O
##1 O
for O
the O
a O
##f O
##rica O
##ns O
and O
chin O
##ese O
( O
p O
= O
0 O
. O
000 O
##6 O
) O
. O
[SEP] O
[CLS] O
significantly O
higher O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
values O
were O
observed O
in O
the O
a O
##f O
##rica O
##ns O
( O
0 O
. O
96 O
± O
0 O
. O
34 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
compared O
with O
the O
chin O
##ese O
subjects O
( O
0 O
. O
47 O
± O
0 O
. O
13 O
ng O
· O
h O
· O
m O
##l O
##− O
##1 O
) O
with O
a O
p O
value O
of O
0 O
. O
00 O
##37 O
, O
indicating O
a O
2 O
. O
0 O
- O
fold O
increase O
in O
the O
a O
##f O
##rica O
##ns O
( O
fi O
##g O
. O
1 O
##a O
, O
b O
) O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
t B-PK
##max I-PK
between O
the O
two O
races O
, O
4 O
. O
00 O
± O
1 O
. O
38 O
h O
and O
4 O
. O
00 O
± O
1 O
. O
34 O
h O
for O
a O
##f O
##rica O
##ns O
and O
chin O
##ese O
, O
respectively O
. O
[SEP] O
[CLS] O
bacteria O
from O
two O
genera O
, O
r O
##c O
##9 O
gut O
group O
( O
1 O
. O
63 O
% O
abundance O
) O
and O
su O
##cci O
##ni O
##vi O
##bri O
##o O
( O
1 O
. O
56 O
% O
abundance O
) O
were O
exclusively O
detected O
in O
the O
in O
##test O
##inal O
micro O
##bio O
##me O
of O
a O
##f O
##rica O
##ns O
. O
[SEP] O
[CLS] O
figure O
3 O
presents O
a O
ho O
##listic O
representation O
of O
these O
bacteria O
genera O
in O
all O
the O
participants O
in O
relation O
to O
their O
link O
with O
the O
au B-PK
##c I-PK
of O
be O
##rber O
##ine O
. O
[SEP] O
[CLS] O
bacteria O
from O
the O
genus O
pre O
##vo O
##tel O
##la O
showed O
the O
highest O
correlation O
with O
au B-PK
##c I-PK
( O
r O
= O
− O
##0 O
. O
81 O
##3 O
) O
while O
those O
belonging O
to O
me O
##gam O
##ona O
##s O
were O
least O
correlated O
with O
au B-PK
##c I-PK
( O
r O
= O
− O
##0 O
. O
69 O
##6 O
) O
in O
both O
the O
a O
##f O
##rica O
##n O
and O
chin O
##ese O
groups O
. O
[SEP] O
[CLS] O
the O
negative O
correlation O
values O
sign O
##ify O
the O
existing O
inverse O
relationship O
of O
the O
bacterial O
abundance O
with O
the O
au B-PK
##c I-PK
of O
be O
##rber O
##ine O
. O
[SEP] O
[CLS] O
the O
contributions O
of O
these O
genera O
towards O
the O
metabolism O
of O
be O
##rber O
##ine O
, O
hence O
, O
its O
au B-PK
##c I-PK
in O
all O
participants O
from O
the O
results O
is O
follows O
: O
pre O
##vo O
##tel O
##la O
> O
[SEP] O
[CLS] O
the O
former O
pointed O
to O
m O
##od O
##ulation O
of O
try O
##pt O
##op O
##han O
h O
##ydro O
##xy O
##lase O
- O
1 O
to O
enhance O
5 O
- O
h O
##t O
synthesis O
, O
while O
the O
latter O
indicates O
an O
impact O
on O
clearance B-PK
into O
enter O
##ocytes O
through O
se O
##rt O
. O
[SEP] O
[CLS] O
taken O
together O
, O
these O
findings O
show O
e O
##c O
##n O
is O
able O
to O
enhance O
5 O
- O
h O
##t O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
il O
##eal O
tissues O
through O
interaction O
with O
compounds O
secret O
##ed O
from O
host O
tissues O
. O
[SEP] O
[CLS] O
taken O
together O
, O
the O
role O
of O
the O
se O
##rot O
##one O
##rg O
##ic O
system O
in O
both O
local O
and O
systemic O
disease O
, O
the O
g O
##i O
tract O
as O
the O
major O
site O
of O
5 O
- O
h O
##t O
production O
in O
humans O
, O
and O
emerging O
evidence O
of O
gut O
micro O
##bio O
##me O
mediated O
regulation O
of O
5 O
- O
h O
##t O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
point O
to O
manipulation O
of O
se O
##rot O
##one O
##rg O
##ic O
signalling O
in O
particular O
as O
a O
prime O
target O
for O
development O
of O
pro O
##biotic O
interventions O
. O
[SEP] O
[CLS] O
however O
, O
relatively O
little O
is O
known O
regarding O
the O
impact O
of O
e O
##c O
##n O
or O
other O
species O
on O
5 O
- O
h O
##t O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
or O
signalling O
in O
the O
g O
##i O
tract O
. O
[SEP] O
[CLS] O
although O
structural O
##ly O
and O
bio O
##chemical O
##ly O
similar O
, O
a O
major O
distinguishing O
feature O
of O
e O
##c O
##n O
and O
mg O
##16 O
##55 O
is O
the O
composition O
of O
the O
outer O
p O
##oly O
##sa O
##cc O
##hari O
##de O
capsule O
, O
with O
e O
##c O
##n O
generating O
a O
k O
##5 O
type O
capsule O
compared O
to O
the O
mg O
##16 O
##55 O
k O
##12 O
type O
capsule O
. O
[SEP] O
[CLS] O
recent O
studies O
have O
also O
indicated O
that O
a O
range O
of O
soluble O
meta O
##bol O
##ites O
generated O
by O
gut O
micro O
##bes O
increase O
5 O
- O
h O
##t O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
m O
##uri O
##ne O
models O
, O
and O
include O
those O
derived O
from O
the O
modification O
of O
host O
generated O
compounds O
##43 O
. O
[SEP] O
[CLS] O
e O
. O
co O
##li O
ni O
##ss O
##le O
1917 O
( O
e O
##c O
##n O
; O
a O
##rde O
##y O
##pha O
##rm O
g O
##mb O
##h O
, O
herd O
##eck O
##e O
, O
g O
##erman O
##y O
) O
, O
its O
k O
##5 O
capsule O
mutant O
##s O
, O
[UNK] O
and O
[UNK] O
, O
and O
e O
. O
co O
##li O
k O
##12 O
strain O
mg O
##16 O
##55 O
( O
c O
##gs O
##c O
##7 O
##7 O
##40 O
) O
70 O
were O
used O
in O
this O
study O
. O
[SEP] O
[CLS] O
the O
b O
##dd O
micro O
##ele O
##ct O
##rod O
##e O
potential O
was O
held O
over O
the O
tissue O
at O
+ O
650 O
m O
##v O
vs O
a O
##g O
| O
a O
##g O
##c O
##l O
which O
was O
sufficient O
to O
o O
##xi O
##di O
##ze O
se O
##rot O
##oni O
##n O
at O
a O
mass O
transfer O
limited O
rate O
##7 O
##37 O
##4 O
. O
[SEP] O
[CLS] O
after O
der O
##iva O
##ti O
##zation O
, O
20 O
μ O
##l O
of O
each O
s O
##c O
##fa O
standard O
and O
sample O
solution O
were O
injected O
onto O
a O
c O
##18 O
column O
( O
fort O
##is O
150 O
mm O
× O
##3 O
mm O
, O
3 O
μ O
##m O
; O
fort O
##is O
technologies O
l O
##t O
##d O
, O
ch O
##esh O
##ire O
, O
uk O
) O
at O
40 O
° O
##c O
, O
with O
detection O
at O
λ O
= O
295 O
nm O
. O
[SEP] O
[CLS] O
here O
, O
using O
stable O
, O
mon O
##os O
##ized O
, O
radio O
##la O
##bel O
##ed O
, O
me O
##so O
##por O
##ous O
si O
##lica O
na O
##no O
##par O
##tic O
##les O
( O
m O
##s O
##ns O
) O
, O
we O
apply O
an O
integrated O
s O
##pect O
/ O
c O
##t O
imaging O
and O
mathematical O
modeling O
approach O
to O
understand O
the O
combined O
effects O
of O
m O
##s O
##n O
size O
, O
surface O
chemistry O
and O
routes O
of O
administration O
on O
bio O
##dis O
##tribution O
and O
clearance B-PK
kinetic O
##s O
in O
healthy O
rats O
. O
[SEP] O
[CLS] O
we O
show O
that O
increased O
particle O
size O
from O
~ O
32 O
- O
to O
~ O
142 O
- O
nm O
results O
in O
a O
mon O
##oto O
##nic O
decrease O
in O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
i O
##rre O
##spective O
of O
route O
of O
administration O
, O
with O
corresponding O
accumulation O
in O
liver O
and O
s O
##ple O
##en O
. O
[SEP] O
[CLS] O
we O
then O
estimated O
area B-PK
under I-PK
the I-PK
curves I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
) I-PK
, O
up B-PK
##take I-PK
( I-PK
kin I-PK
) I-PK
and O
elimination B-PK
rate I-PK
constant I-PK
##s I-PK
( I-PK
k I-PK
##out I-PK
) I-PK
, O
and O
half B-PK
- I-PK
lives I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
individual O
curves O
from O
fi O
##g O
. O
4 O
##a O
, O
b O
. O
[SEP] O
[CLS] O
as O
seen O
in O
fi O
##g O
. O
4 O
##c O
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
decreases O
mon O
##oto O
##nical O
##ly O
with O
an O
increase O
in O
particle O
size O
in O
the O
studied O
size O
range O
of O
~ O
32 O
to O
~ O
142 O
nm O
, O
i O
##rre O
##spective O
of O
the O
route O
of O
delivery O
, O
governed O
by O
the O
mathematical O
relation O
: O
au O
##c O
##0 O
– O
24 O
h O
= O
λ O
· O
size O
##− O
##n O
, O
where O
λ O
and O
n O
are O
fitted O
coefficients O
, O
and O
size O
refers O
to O
the O
core O
diameter O
of O
n O
##ps O
. O
[SEP] O
[CLS] O
further O
, O
the O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##out I-PK
) I-PK
increases O
( O
and O
thus O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
decreases O
) O
with O
an O
increase O
in O
size O
( O
see O
fi O
##g O
. O
4 O
##e O
and O
table O
2 O
) O
; O
however O
, O
one O
- O
way O
an O
##ova O
reveals O
no O
significant O
difference O
in O
the O
up B-PK
##take I-PK
rate I-PK
constant I-PK
( I-PK
kin I-PK
) I-PK
values O
across O
i O
. O
p O
. O
administered O
cases O
( O
p O
> O
0 O
. O
05 O
) O
( O
see O
fi O
##g O
. O
4 O
##d O
) O
. O
[SEP] O
[CLS] O
this O
suggests O
that O
absorption O
of O
n O
##ps O
from O
per O
##ito O
##nea O
##l O
cavity O
in O
the O
studied O
size O
range O
is O
independent O
of O
particle O
size O
##37 O
and O
that O
the O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
through O
either O
route O
of O
administration O
is O
primarily O
a O
function O
of O
the O
k B-PK
##out I-PK
parameter O
. O
[SEP] O
[CLS] O
thus O
, O
greater O
protection O
from O
the O
traps O
in O
micro O
##vas O
##cula O
##ture O
yields O
a O
higher O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
smaller O
- O
sized O
particles O
. O
[SEP] O
[CLS] O
all O
of O
the O
above O
suggest O
that O
the O
effect O
of O
m O
##s O
##n O
p O
##hy O
##si O
##co O
##chemical O
properties O
and O
routes O
of O
administration O
on O
m O
##s O
##n O
disposition O
kinetic O
##s O
in O
source O
- O
like O
r O
##ois O
is O
similar O
to O
that O
in O
systemic O
kinetic O
##s O
. O
[SEP] O
[CLS] O
next O
looking O
at O
the O
effect O
of O
surface O
chemistry O
in O
fi O
##g O
. O
4 O
##b O
, O
c O
, O
e O
and O
table O
2 O
, O
p O
##ei O
##50 O
( O
which O
has O
surface O
- O
exposed O
am O
##ines O
) O
has O
a O
~ O
9 O
- O
fold O
lesser O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
( O
un O
##pair O
##ed O
t O
test O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
and O
half O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
un O
##pair O
##ed O
t O
test O
, O
p O
< O
0 O
. O
05 O
) O
relative O
to O
size O
- O
matched O
and O
z O
##eta O
potential O
- O
matched O
q O
##a O
##50 O
( O
which O
has O
o O
##bs O
##truct O
##ed O
surface O
am O
##ines O
) O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
we O
observed O
no O
significant O
effect O
of O
z O
##eta O
potential O
on O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
of O
size O
- O
matched O
and O
surface O
chemistry O
- O
matched O
, O
but O
differently O
charged O
t O
##ms O
##50 O
and O
q O
##a O
##50 O
particles O
( O
un O
##pair O
##ed O
t O
test O
, O
p O
> O
0 O
. O
05 O
) O
( O
see O
fi O
##g O
. O
4 O
##c O
) O
, O
although O
the O
positively O
charged O
q O
##a O
##50 O
has O
a O
slightly O
lesser O
k B-PK
##out I-PK
( O
hence O
slightly O
greater O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
) O
than O
neutral O
t O
##ms O
##50 O
( O
un O
##pair O
##ed O
t O
test O
, O
p O
< O
0 O
. O
05 O
) O
( O
see O
fi O
##g O
. O
4 O
##e O
and O
table O
2 O
) O
. O
[SEP] O
[CLS] O
a O
change O
in O
the O
heart O
concentration O
of O
m O
##s O
##ns O
is O
reflected O
by O
a O
similar O
change O
in O
source O
- O
like O
r O
##ois O
, O
as O
is O
also O
evident O
from O
similarity O
in O
the O
k B-PK
##out I-PK
values O
of O
m O
##s O
##ns O
across O
r O
##ois O
( O
one O
- O
way O
an O
##ova O
, O
p O
> O
0 O
. O
05 O
) O
, O
except O
p O
##ei O
##50 O
( O
one O
- O
way O
an O
##ova O
, O
p O
< O
0 O
. O
05 O
) O
( O
comparing O
fi O
##g O
. O
4 O
##e O
and O
supplement O
##ary O
fi O
##gs O
. O
8 O
##c O
, O
12 O
##f O
, O
13 O
##g O
, O
and O
14 O
##g O
) O
. O
[SEP] O
[CLS] O
also O
, O
the O
mathematical O
relation O
au O
##c O
##0 O
– O
24 O
h O
= O
λ O
· O
size O
##− O
##n O
seems O
to O
hold O
true O
for O
all O
source O
- O
like O
r O
##ois O
, O
with O
values O
of O
power O
coefficient O
n O
ranging O
from O
0 O
. O
5 O
to O
0 O
. O
9 O
, O
suggesting O
a O
moderate O
to O
strongly O
negative O
linear O
dependence O
( O
fi O
##g O
. O
5 O
##j O
, O
supplement O
##ary O
fi O
##gs O
. O
12 O
##e O
, O
13 O
##e O
, O
and O
14 O
##e O
, O
and O
19 O
##a O
, O
b O
, O
c O
, O
f O
) O
. O
[SEP] O
[CLS] O
m O
##s O
##n O
concentrations O
in O
these O
r O
##ois O
rise O
over O
time O
initially O
, O
followed O
by O
slow O
or O
no O
decline O
in O
concentration O
within O
24 O
h O
, O
indicating O
the O
presence O
of O
traps O
causing O
m O
##s O
##n O
accumulation O
over O
time O
into O
the O
inter O
##st O
##iti O
##um O
( O
see O
fi O
##g O
. O
5 O
##b O
, O
c O
, O
e O
, O
f O
and O
supplement O
##ary O
fi O
##g O
. O
11 O
##a O
) O
. O
[SEP] O
[CLS] O
as O
a O
result O
in O
sink O
- O
like O
r O
##ois O
( O
fi O
##g O
. O
5 O
##b O
, O
c O
, O
e O
, O
f O
and O
supplement O
##ary O
fi O
##g O
. O
11 O
##a O
) O
, O
e O
##q O
. O
( O
4 O
) O
or O
its O
adaptation O
, O
e O
##q O
. O
( O
5 O
) O
, O
is O
fit O
to O
m O
##s O
##n O
concentration O
– O
time O
data O
( O
see O
supplement O
##ary O
tables O
4 O
and O
5 O
) O
. O
[SEP] O
[CLS] O
the O
mathematical O
relation O
between O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
and O
particle O
size O
, O
au O
##c O
##0 O
– O
24 O
h O
= O
λ O
· O
size O
##n O
, O
is O
consistent O
across O
all O
sink O
- O
like O
r O
##ois O
with O
values O
of O
power O
coefficient O
n O
varying O
between O
0 O
. O
4 O
and O
1 O
. O
2 O
, O
suggesting O
a O
moderate O
to O
strongly O
positive O
linear O
dependence O
( O
see O
supplement O
##ary O
fi O
##g O
. O
19 O
##d O
, O
g O
, O
h O
) O
. O
[SEP] O
[CLS] O
it O
is O
worth O
mentioning O
that O
t O
##ms O
##25 O
( O
i O
. O
v O
. O
) O
and O
q O
##a O
##50 O
( O
i O
. O
v O
. O
) O
, O
show O
a O
decline O
in O
concentration O
over O
time O
in O
the O
liver O
, O
in O
contrast O
to O
the O
other O
m O
##s O
##ns O
; O
hence O
, O
the O
mon O
##o O
- O
ex O
##po O
##nent O
##ial O
e O
##q O
. O
( O
6 O
) O
was O
fit O
to O
their O
concentration O
– O
time O
course O
( O
fi O
##g O
. O
5 O
##b O
, O
e O
) O
. O
[SEP] O
[CLS] O
this O
observation O
def O
##ies O
the O
often O
- O
quoted O
re B-PK
##nal I-PK
clearance I-PK
cut O
##off O
of O
~ O
5 O
. O
5 O
nm O
##5 O
. O
[SEP] O
[CLS] O
due O
to O
loss O
of O
activity O
from O
the O
bladder O
via O
u O
##rina O
##tion O
, O
the O
activity O
detected O
in O
the O
bladder O
at O
a O
given O
time O
point O
( O
fi O
##g O
. O
6 O
##b O
, O
e O
) O
is O
not O
equivalent O
to O
the O
cumulative O
amount O
of O
re O
##nal O
ex O
##cre O
##tion O
. O
[SEP] O
[CLS] O
to O
enable O
detection O
by O
s O
##pect O
, O
mon O
##od O
##is O
##pers O
##e O
m O
##s O
##ns O
were O
co O
##valent O
##ly O
coupled O
to O
d O
##t O
##pa O
through O
is O
##oth O
##io O
##cy O
##ana O
##te O
and O
am O
##ine O
reactions O
to O
enable O
binding O
of O
111 O
##in O
, O
a O
gamma O
- O
em O
##itting O
radio O
##is O
##oto O
##pe O
with O
a O
radioactive O
half B-PK
- I-PK
life I-PK
of O
2 O
. O
8 O
days O
##5 O
##6 O
. O
[SEP] O
[CLS] O
based O
on O
the O
nature O
of O
concentration O
– O
time O
curves O
of O
m O
##s O
##ns O
in O
the O
heart O
, O
we O
applied O
a O
one O
- O
compartment O
p O
##k O
model O
##36 O
( O
same O
as O
e O
##q O
. O
( O
6 O
) O
for O
i O
. O
v O
. O
delivery O
, O
and O
e O
##q O
. O
( O
4 O
) O
for O
i O
. O
p O
. O
delivery O
) O
, O
and O
determined O
p O
##k O
parameters O
: O
( O
i O
) O
au B-PK
##c I-PK
from I-PK
0 I-PK
to I-PK
24 I-PK
h I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
) I-PK
, O
( O
ii O
) O
up B-PK
##take I-PK
rate I-PK
constant I-PK
( I-PK
kin I-PK
) I-PK
, O
( O
ii O
##i O
) O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##out I-PK
) I-PK
, O
and O
( O
i O
##v O
) O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
represents O
the O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
n O
##ps O
and O
is O
the O
definite O
integral O
of O
n O
##p O
concentration O
– O
time O
in O
plasma O
( O
heart O
, O
in O
this O
study O
) O
, O
determined O
analytical O
##ly O
. O
[SEP] O
[CLS] O
k B-PK
##out I-PK
is O
the O
slope O
of O
the O
curve O
on O
a O
semi O
- O
log O
plot O
between O
ch O
##ear O
##t O
and O
t O
, O
and O
represents O
the O
fraction O
of O
n O
##ps O
eliminated O
from O
plasma O
per O
unit O
time O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
parameters O
including O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
and O
au B-PK
##c I-PK
were O
determined O
for O
r O
##is O
##per O
##ido O
##ne O
and O
its O
active O
ingredient O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
parameters O
( O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
) O
were O
calculated O
. O
[SEP] O
[CLS] O
for O
r O
##is O
##per O
##ido O
##ne O
, O
comparison O
of O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
values O
across O
dose O
levels O
demonstrated O
linear O
##ity O
in O
the O
dose O
response O
for O
the O
parent O
drug O
, O
r O
##is O
##per O
##ido O
##ne O
, O
in O
low O
and O
middle O
doses O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
increased O
from O
101 O
. O
81 O
± O
8 O
. O
5 O
to O
1914 O
. O
83 O
± O
49 O
. O
6 O
( O
18 O
. O
8 O
- O
fold O
) O
and O
from O
126 O
. O
01 O
± O
12 O
. O
2 O
to O
30 O
##9 O
##4 O
. O
49 O
± O
360 O
. O
4 O
( O
24 O
. O
5 O
- O
fold O
) O
for O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
. O
[SEP] O
[CLS] O
difference O
in O
dose O
- O
dependent O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
was O
also O
observed O
in O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
for O
r O
##is O
##per O
##ido O
##ne O
meta O
##bol O
##ite O
, O
9 O
- O
h O
##ydro O
##xy O
##ris O
##per O
##ido O
##ne O
, O
the O
values O
of O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
increased O
by O
1 O
. O
2 O
- O
fold O
and O
0 O
. O
95 O
- O
fold O
, O
respectively O
, O
following O
increase O
in O
the O
doses O
from O
0 O
. O
30 O
to O
1 O
. O
0 O
mg O
/ O
kg O
( O
3 O
. O
3 O
- O
fold O
) O
. O
[SEP] O
[CLS] O
after O
increase O
of O
the O
dose O
from O
1 O
. O
0 O
to O
6 O
. O
0 O
mg O
/ O
kg O
( O
6 O
- O
fold O
) O
, O
the O
value O
au B-PK
##c I-PK
##0 I-PK
– I-PK
48 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
increased O
by O
1 O
. O
25 O
- O
fold O
and O
1 O
. O
85 O
- O
fold O
, O
respectively O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
increased O
for O
about O
2 O
- O
fold O
following O
increasing O
doses O
from O
0 O
. O
3 O
to O
1 O
. O
0 O
mg O
/ O
kg O
( O
3 O
fold O
) O
, O
while O
ins O
##ign O
##ificant O
##ly O
increased O
following O
raising O
doses O
from O
1 O
. O
0 O
to O
6 O
. O
0 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
r O
##os O
##c O
, O
maximum B-PK
concentration I-PK
; O
except O
at O
30 O
s O
, O
and O
time B-PK
- I-PK
to I-PK
- I-PK
concentration I-PK
- I-PK
maximum I-PK
between O
the O
hi O
##o O
and O
i O
##v O
groups O
. O
[SEP] O
[CLS] O
• O
no O
difference O
in O
concentration B-PK
maximum I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
in O
e O
##pine O
##ph O
##rine O
between O
hum O
##eral O
in O
##tra O
##oss O
##eous O
and O
in O
##tra O
##ven O
##ous O
routes O
of O
administration O
over O
time O
. O
• O
hum O
##eral O
in O
##tra O
##oss O
##eous O
delivers O
higher O
concentration O
than O
in O
##tra O
##ven O
##ous O
at O
30 O
s O
after O
administration O
of O
e O
##pine O
##ph O
##rine O
. O
• O
hum O
##eral O
in O
##tra O
##oss O
##eous O
facilitate O
##s O
rapid O
delivery O
of O
e O
##pine O
##ph O
##rine O
during O
cardiac O
arrest O
. O
• O
use O
of O
hum O
##eral O
in O
##tra O
##oss O
##eous O
had O
higher O
number O
of O
subjects O
survived O
. O
[SEP] O
[CLS] O
no O
difference O
in O
concentration B-PK
maximum I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
in O
e O
##pine O
##ph O
##rine O
between O
hum O
##eral O
in O
##tra O
##oss O
##eous O
and O
in O
##tra O
##ven O
##ous O
routes O
of O
administration O
over O
time O
. O
[SEP] O
[CLS] O
are O
there O
statistical O
##ly O
significant O
differences O
in O
cm B-PK
##ax I-PK
and O
t B-PK
##max I-PK
of O
e O
##pine O
##ph O
##rine O
between O
the O
hum O
##eral O
i O
##o O
, O
i O
##v O
, O
and O
control O
groups O
? O
[SEP] O
[CLS] O
the O
concentration O
is O
reported O
in O
ng O
per O
m O
##l O
. O
to O
evaluate O
potential O
differences O
in O
cm B-PK
##ax I-PK
by O
group O
( O
hi O
##o O
vs O
. O
i O
##v O
) O
, O
we O
ran O
w O
##il O
##co O
##xon O
signed O
ranks O
. O
[SEP] O
[CLS] O
the O
results O
were O
not O
statistical O
##ly O
significant O
( O
w O
= O
31 O
. O
00 O
, O
p O
= O
. O
45 O
##5 O
##7 O
) O
( O
see O
fi O
##g O
. O
1 O
for O
a O
side O
- O
by O
- O
side O
box O
##p O
##lot O
of O
cm B-PK
##ax I-PK
by O
group O
) O
. O
[SEP] O
[CLS] O
we O
performed O
this O
same O
analysis O
for O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
the O
w O
##il O
##co O
##xon O
signed O
ranks O
test O
approaches O
significance O
( O
w O
= O
10 O
. O
50 O
, O
p O
= O
. O
06 O
##2 O
) O
( O
see O
fi O
##g O
. O
2 O
is O
the O
side O
- O
by O
- O
side O
box O
##p O
##lot O
##s O
in O
maximum O
concentration O
in O
seconds O
) O
. O
[SEP] O
[CLS] O
no O
clinical O
##ly O
relevant O
increases O
in O
plasma O
um O
##ec O
##lid O
##ini O
##um O
or O
v O
##ila O
##nter O
##ol O
systemic O
exposure O
( O
area B-PK
under I-PK
the I-PK
curve I-PK
or I-PK
maximum I-PK
observed I-PK
plasma I-PK
concentration I-PK
) O
were O
observed O
following O
um O
##ec O
##lid O
##ini O
##um O
125 O
μ O
##g O
or O
um O
##ec O
##lid O
##ini O
##um O
/ O
v O
##ila O
##nter O
##ol O
125 O
/ O
25 O
μ O
##g O
administration O
. O
[SEP] O
[CLS] O
the O
primary O
end O
##points O
were O
um O
##ec O
##lid O
##ini O
##um O
and O
v O
##ila O
##nter O
##ol O
plasma O
p O
##k O
parameters O
: O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
( I-PK
0 I-PK
– I-PK
0 I-PK
. I-PK
25 I-PK
##h I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
2 I-PK
##h I-PK
) I-PK
, O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
##h I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
time B-PK
to I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
( I-PK
t I-PK
##last I-PK
) I-PK
, O
terminal B-PK
phase I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
and O
other O
p O
##k O
parameters O
as O
data O
permitted O
. O
[SEP] O
[CLS] O
the O
p O
##k O
parameters O
of O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
, O
and O
a B-PK
##e I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
##h I-PK
) I-PK
of O
um O
##ec O
##lid O
##ini O
##um O
and O
v O
##ila O
##nter O
##ol O
were O
log O
##e O
transformed O
and O
were O
analyzed O
separately O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
24 I-PK
##h I-PK
) I-PK
were O
non O
- O
ca O
##l O
##cula O
##ble O
due O
to O
non O
##qua O
##nti O
##fia O
##ble O
( O
n O
##q O
) O
plasma O
concentrations O
in O
the O
terminal O
phase O
; O
therefore O
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
0 I-PK
. I-PK
25 I-PK
##h I-PK
) I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
2 I-PK
##h I-PK
) I-PK
for O
um O
##ec O
##lid O
##ini O
##um O
, O
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
0 I-PK
. I-PK
25 I-PK
##h I-PK
) I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
1 I-PK
##h I-PK
) I-PK
for O
v O
##ila O
##nter O
##ol O
were O
derived O
and O
statistical O
##ly O
analyzed O
. O
[SEP] O
[CLS] O
um O
##ec O
##lid O
##ini O
##um O
was O
rapidly O
absorbed O
with O
median O
t B-PK
##max I-PK
of O
approximately O
5 O
minutes O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
following O
administration O
of O
um O
##ec O
##lid O
##ini O
##um O
125 O
μ O
##g O
or O
um O
##ec O
##lid O
##ini O
##um O
/ O
v O
##ila O
##nter O
##ol O
125 O
/ O
25 O
μ O
##g O
, O
there O
was O
no O
evidence O
of O
a O
clinical O
##ly O
relevant O
increase O
in O
um O
##ec O
##lid O
##ini O
##um O
plasma O
exposure O
, O
in O
terms O
of O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
2 I-PK
##h I-PK
) I-PK
or O
cm B-PK
##ax I-PK
, O
for O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
compared O
with O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
for O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
2 I-PK
##h I-PK
) I-PK
, O
there O
was O
an O
average O
10 O
% O
decrease O
, O
with O
the O
true O
mean O
difference O
likely O
to O
be O
between O
36 O
% O
lower O
and O
26 O
% O
higher O
in O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
compared O
with O
healthy O
volunteers O
following O
um O
##ec O
##lid O
##ini O
##um O
125 O
μ O
##g O
administration O
. O
[SEP] O
[CLS] O
for O
cm B-PK
##ax I-PK
, O
there O
was O
an O
average O
11 O
% O
decrease O
, O
with O
the O
true O
mean O
difference O
likely O
to O
be O
between O
42 O
% O
lower O
and O
35 O
% O
higher O
in O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
compared O
with O
healthy O
volunteers O
following O
um O
##ec O
##lid O
##ini O
##um O
125 O
μ O
##g O
administration O
. O
[SEP] O
[CLS] O
on O
average O
, O
um O
##ec O
##lid O
##ini O
##um O
urine B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
was O
similar O
between O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
and O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
v O
##ila O
##nter O
##ol O
was O
rapidly O
absorbed O
with O
a O
median O
t B-PK
##max I-PK
occurring O
at O
approximately O
5 O
minutes O
post O
##dos O
##e O
, O
following O
which O
plasma O
concentrations O
declined O
rapidly O
for O
both O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
and O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
for O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
1 I-PK
##h I-PK
) I-PK
, O
there O
was O
an O
average O
21 O
% O
increase O
, O
with O
the O
true O
mean O
increase O
likely O
to O
be O
between O
13 O
% O
lower O
and O
70 O
% O
higher O
in O
patients O
with O
severe O
re O
##nal O
imp O
##air O
##ment O
compared O
with O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
neither O
a O
##e O
led O
to O
study O
withdrawal O
. O
[SEP] O
[CLS] O
when O
le O
##vo O
##bu O
##pi O
##va O
##ca O
##ine O
was O
used O
alone O
, O
the O
t B-PK
##max I-PK
in O
plasma O
was O
1 O
. O
07 O
± O
0 O
. O
16 O
h O
. O
interesting O
##ly O
, O
the O
t B-PK
##max I-PK
of O
le O
##vo O
##bu O
##pi O
##va O
##ca O
##ine O
in O
the O
plasma O
was O
increased O
by O
four O
times O
in O
combination O
with O
q O
##x O
- O
oh O
( O
4 O
. O
11 O
± O
0 O
. O
39 O
h O
) O
. O
[SEP] O
[CLS] O
according O
to O
the O
chin O
##a O
food O
and O
drug O
administration O
guidance O
for O
pre O
##c O
##lini O
##cal O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
, O
there O
should O
be O
more O
than O
three O
sampling O
points O
adjacent O
to O
the O
time B-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
concentration I-PK
. O
[SEP] O
[CLS] O
in O
our O
preliminary O
experiment O
, O
the O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
, O
as O
a O
single O
drug O
in O
the O
rat O
s O
##cia O
##tic O
nerve O
block O
, O
was O
0 O
. O
5 O
h O
. O
[SEP] O
[CLS] O
thus O
, O
to O
obtain O
an O
accurate O
value O
of O
the O
maximum B-PK
concentration I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
, O
we O
added O
another O
time O
point O
at O
0 O
. O
33 O
h O
. O
[SEP] O
[CLS] O
in O
this O
study O
, O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
: O
the O
value O
of O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
time B-PK
to I-PK
acquire I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
; O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
; O
area B-PK
under I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
from I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
time I-PK
point I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
last I-PK
) I-PK
and I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
; O
clearance B-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
. O
[SEP] O
[CLS] O
for O
the O
half B-PK
- I-PK
time I-PK
and O
time O
to O
block O
caps O
, O
it O
was O
conducted O
by O
k O
##rus O
##kal O
– O
wall O
##is O
test O
due O
to O
its O
une O
##qua O
##l O
variance O
, O
and O
the O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
and O
the O
cellular O
drug O
up O
##take O
ass O
##ay O
were O
statistical O
##ly O
analyzed O
using O
independent O
- O
sample O
t O
test O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
values O
of O
q O
##x O
- O
oh O
and O
le O
##vo O
- O
b O
##up O
##i O
were O
72 O
##7 O
. O
22 O
± O
43 O
. O
38 O
and O
256 O
. O
02 O
± O
28 O
. O
52 O
μ O
##g O
/ O
g O
in O
muscle O
, O
63 O
##4 O
. O
26 O
± O
36 O
. O
04 O
and O
42 O
##9 O
. O
63 O
± O
48 O
. O
64 O
μ O
##g O
/ O
g O
in O
s O
##cia O
##tic O
nerve O
, O
and O
71 O
##1 O
. O
71 O
± O
25 O
. O
14 O
and O
114 O
. O
40 O
± O
10 O
. O
19 O
ng O
/ O
m O
##l O
in O
plasma O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
q O
##x O
- O
oh O
in O
s O
##cia O
##tic O
nerve O
did O
not O
significantly O
differ O
from O
that O
in O
muscle O
( O
p O
= O
0 O
. O
05 O
##8 O
) O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
the O
cm B-PK
##ax I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
was O
higher O
in O
s O
##cia O
##tic O
nerve O
( O
42 O
##9 O
. O
63 O
± O
48 O
. O
64 O
μ O
##g O
/ O
g O
) O
than O
that O
in O
muscle O
( O
256 O
. O
02 O
± O
28 O
. O
52 O
μ O
##g O
/ O
g O
, O
p O
= O
0 O
. O
00 O
##8 O
) O
. O
[SEP] O
[CLS] O
the O
com O
##puted O
au B-PK
##c I-PK
values I-PK
of I-PK
q I-PK
##x I-PK
- I-PK
oh I-PK
from I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
time I-PK
point I-PK
were O
1 O
, O
48 O
##7 O
. O
72 O
± O
82 O
. O
20 O
μ O
##g O
* O
h O
/ O
g O
in O
s O
##cia O
##tic O
nerve O
, O
1 O
, O
188 O
. O
29 O
± O
62 O
. O
38 O
μ O
##g O
* O
h O
/ O
g O
in O
muscle O
, O
and O
1 O
, O
91 O
##3 O
. O
72 O
± O
148 O
. O
7 O
ng O
* O
h O
/ O
m O
##l O
in O
plasma O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
values I-PK
of I-PK
le I-PK
##vo I-PK
- I-PK
b I-PK
##up I-PK
##i I-PK
from I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
time I-PK
point I-PK
were O
93 O
##5 O
. O
82 O
± O
74 O
. O
35 O
μ O
##g O
* O
h O
/ O
g O
in O
s O
##cia O
##tic O
nerve O
, O
41 O
##7 O
. O
58 O
± O
43 O
. O
46 O
μ O
##g O
* O
h O
/ O
g O
in O
muscle O
, O
and O
65 O
##1 O
. O
23 O
± O
47 O
. O
39 O
ng O
* O
h O
/ O
m O
##l O
in O
plasma O
. O
[SEP] O
[CLS] O
in O
a O
previous O
study O
( O
y O
##u O
et O
al O
. O
, O
2002 O
) O
, O
the O
cm B-PK
##ax I-PK
of O
b O
##up O
##iva O
##ca O
##ine O
was O
reached O
at O
0 O
. O
5 O
h O
after O
sub O
##cut O
##aneous O
administration O
. O
[SEP] O
[CLS] O
however O
, O
the O
t B-PK
##max I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
in O
ll O
- O
1 O
was O
4 O
. O
11 O
± O
0 O
. O
39 O
h O
. O
[SEP] O
[CLS] O
when O
le O
##vo O
- O
b O
##up O
##i O
was O
used O
alone O
, O
the O
t B-PK
##max I-PK
in O
plasma O
was O
1 O
. O
07 O
± O
0 O
. O
16 O
h O
( O
figure O
2 O
##a O
) O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
the O
t B-PK
##max I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
in O
the O
plasma O
was O
increased O
by O
four O
times O
in O
combination O
with O
q O
##x O
- O
oh O
( O
4 O
. O
11 O
± O
0 O
. O
39 O
h O
, O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
le O
##vo O
- O
b O
##up O
##i O
, O
used O
alone O
, O
( O
142 O
. O
45 O
± O
13 O
. O
04 O
ng O
/ O
m O
##l O
) O
did O
not O
significantly O
differ O
from O
that O
in O
ll O
- O
1 O
( O
p O
= O
0 O
. O
114 O
) O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
le O
##vo O
- O
b O
##up O
##i O
, O
used O
alone O
, O
had O
a O
faster O
elimination O
( O
c B-PK
##l I-PK
= O
1 O
. O
32 O
± O
0 O
. O
08 O
l O
/ O
h O
, O
p O
= O
0 O
. O
00 O
##1 O
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
2 O
. O
61 O
± O
0 O
. O
31 O
h O
, O
p O
= O
0 O
. O
199 O
) O
. O
[SEP] O
[CLS] O
the O
op O
##ti O
##mized O
p O
##g O
: O
t O
##we O
##en O
80 O
formulation O
significantly O
improved O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
compared O
with O
the O
universal O
0 O
. O
5 O
% O
( O
w O
##t O
/ O
vol O
) O
cm O
##c O
formulation O
, O
as O
evidenced O
by O
improved O
maximum B-PK
concentration I-PK
of I-PK
drug I-PK
in I-PK
serum I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
( O
1 O
. O
04 O
versus O
0 O
. O
15 O
μ O
##g O
/ O
m O
##l O
) O
and O
area B-PK
under I-PK
the I-PK
curve I-PK
to I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##last I-PK
) I-PK
( O
6 O
. O
56 O
versus O
1 O
. O
51 O
h O
· O
μ O
##g O
/ O
m O
##l O
) O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
to O
enhance O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
we O
developed O
a O
novel O
formulation O
for O
compound O
2 O
in O
prop O
##yle O
##ne O
g O
##ly O
##co O
##l O
( O
p O
##g O
) O
: O
t O
##we O
##en O
80 O
( O
4 O
: O
1 O
, O
vol O
/ O
vol O
) O
. O
[SEP] O
[CLS] O
we O
compared O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
this O
new O
formulation O
with O
a O
previously O
reported O
formulation O
using O
0 O
. O
5 O
% O
( O
w O
##t O
/ O
vol O
) O
car O
##box O
##yme O
##thy O
##l O
cell O
##ulos O
##e O
( O
cm O
##c O
) O
( O
19 O
) O
. O
[SEP] O
[CLS] O
ed B-PK
##50 I-PK
values O
were O
compared O
using O
the O
extra O
sum O
- O
of O
- O
squares O
f O
test O
. O
[SEP] O
[CLS] O
drug O
concentration O
over O
time O
was O
determined O
using O
liquid O
ch O
##roma O
##tography O
– O
mass O
s O
##pect O
##rome O
##try O
and O
total O
exposure O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
) O
was O
estimated O
from O
the O
concentration O
- O
time O
profiles O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
was O
the O
highest O
ever O
reported O
in O
human O
tissue O
( O
131 O
##0 O
##3 O
( O
( O
m O
##c O
##g O
/ O
g O
) O
. O
h O
##r O
) O
) O
. O
[SEP] O
[CLS] O
lip O
##ids O
were O
anal O
##ys O
##ed O
by O
electro O
##sp O
##ray O
ion O
##isation O
- O
mass O
s O
##pect O
##rome O
##try O
( O
es O
##i O
- O
m O
##s O
) O
using O
an O
a O
##gi O
##lent O
triple O
q O
##uad O
64 O
##60 O
. O
[SEP] O
[CLS] O
total O
drug O
exposure O
was O
measured O
as O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
96 I-PK
hours I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
96 I-PK
) I-PK
and O
zero O
to O
in O
##finity O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
) O
using O
cubic O
s O
##p O
##lines O
method O
and O
expressed O
as O
linear O
of O
log O
concentration O
. O
[SEP] O
[CLS] O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##e I-PK
) I-PK
and O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
maximum B-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
also O
estimated O
for O
each O
par O
##itic O
##ip O
##ant O
[SEP] O
[CLS] O
the O
estimated O
au B-PK
##c I-PK
##0 I-PK
- I-PK
96 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
was O
36 O
##44 O
and O
131 O
##0 O
##3 O
( O
( O
m O
##c O
##g O
/ O
g O
) O
. O
h O
##r O
) O
respectively O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
rate I-PK
constant I-PK
was O
0 O
. O
00 O
##8 O
/ O
hour O
. O
[SEP] O
[CLS] O
r O
##alo O
##xi O
##fen O
##e O
( O
r O
##x O
##f O
) O
is O
a O
hormone O
- O
like O
medication O
used O
for O
treating O
post O
##men O
##op O
##aus O
##al O
o O
##ste O
##op O
##oro O
##sis O
and O
est O
##rogen O
- O
dependent O
breast O
cancer O
, O
yet O
associated O
with O
bad O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
due O
to O
poor O
so O
##lub O
##ility O
. O
[SEP] O
[CLS] O
this O
study O
was O
intended O
to O
develop O
c O
##y O
##c O
##lo O
##de O
##x O
##tri O
##n O
/ O
ch O
##ito O
##san O
na O
##no O
##par O
##tic O
##les O
( O
cc O
##n O
##ps O
) O
for O
oral O
delivery O
of O
r O
##x O
##f O
in O
order O
to O
enhance O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
complex O
formation O
constant O
( O
k O
##f O
) O
was O
calculated O
based O
on O
the O
equation O
: O
k O
##f O
= O
s O
/ O
s O
##0 O
( O
1 O
− O
s O
) O
, O
where O
s O
and O
s O
##0 O
denote O
the O
slope O
of O
linear O
equation O
( O
if O
applicable O
) O
and O
drug O
so O
##lub O
##ility O
in O
the O
absence O
of O
s O
##be O
- O
β O
- O
c O
##d O
, O
respectively O
. O
[SEP] O
[CLS] O
thus O
, O
the O
calculated O
complex O
formation O
constant O
( O
k O
##f O
) O
was O
106 O
. O
91 O
l O
/ O
m O
##ol O
. O
[SEP] O
[CLS] O
the O
k O
##f O
value O
was O
considerably O
large O
for O
an O
inclusion O
compound O
, O
demonstrating O
a O
stable O
complex O
##ation O
. O
[SEP] O
[CLS] O
for O
the O
formulation O
of O
r O
##x O
##f O
suspension O
##s O
, O
the O
drug O
absorption O
was O
relatively O
inadequate O
with O
the O
ma B-PK
##ximal I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
108 O
. O
46 O
ng O
/ O
m O
##l O
. O
different O
from O
r O
##x O
##f O
suspension O
##s O
, O
r O
##x O
##f O
- O
sic O
##s O
solution O
gave O
rise O
to O
an O
elevated O
cm B-PK
##ax I-PK
, O
which O
was O
almost O
two O
times O
as O
high O
as O
that O
of O
r O
##x O
##f O
suspension O
##s O
. O
[SEP] O
[CLS] O
however O
, O
r O
##x O
##f O
- O
cc O
##n O
##ps O
resulted O
in O
a O
higher O
cm B-PK
##ax I-PK
, O
up O
to O
36 O
##7 O
. O
48 O
ng O
/ O
m O
##l O
. O
the O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
and O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
among O
three O
formulation O
##s O
appeared O
to O
be O
a O
little O
distinct O
. O
[SEP] O
[CLS] O
the O
formulation O
with O
good O
absorption O
possesses O
smaller O
t B-PK
##max I-PK
and O
shorter O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
which O
is O
related O
to O
the O
fast O
drug O
disposition O
, O
including O
absorption O
and O
elimination O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
plasma I-PK
drug I-PK
concentration I-PK
vs I-PK
. I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
) I-PK
of O
r O
##x O
##f O
- O
cc O
##n O
##ps O
was O
up O
to O
240 O
##0 O
. O
78 O
ng O
/ O
m O
##l O
· O
h O
that O
was O
notably O
larger O
than O
that O
of O
r O
##x O
##f O
suspension O
##s O
and O
r O
##x O
##f O
- O
sic O
##s O
solution O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
r O
##x O
##f O
- O
cc O
##n O
##ps O
relative O
to O
r O
##x O
##f O
suspension O
##s O
was O
calculated O
to O
be O
360 O
. O
76 O
% O
, O
whereas O
it O
was O
just O
249 O
. O
38 O
% O
for O
r O
##x O
##f O
- O
sic O
##s O
solution O
. O
[SEP] O
[CLS] O
in O
our O
study O
, O
c O
##y O
##c O
##lo O
##de O
##x O
##tri O
##n O
inclusion O
complexes O
as O
a O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
enhance O
##r O
was O
verified O
again O
in O
the O
case O
of O
r O
##x O
##f O
- O
sic O
##s O
solution O
. O
[SEP] O
[CLS] O
our O
developed O
r O
##x O
##f O
- O
cc O
##n O
##ps O
is O
not O
only O
convenient O
for O
use O
, O
but O
also O
can O
enhance O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
r O
##x O
##f O
. O
[SEP] O
[CLS] O
high O
cellular O
up O
##take O
guarantees O
good O
absorption O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
r O
##x O
##f O
is O
not O
only O
associated O
with O
its O
poor O
water O
so O
##lub O
##ility O
, O
but O
also O
has O
something O
to O
do O
with O
the O
in O
##test O
##inal O
metabolism O
and O
e O
##ff O
##lux O
[ O
27 O
] O
. O
[SEP] O
[CLS] O
l O
##ymph O
##atic O
transport O
can O
reduce O
the O
he O
##pa O
##tic O
first O
- O
pass O
effect O
, O
which O
further O
contributes O
the O
enhance O
##ment O
of O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
17 O
. O
7 O
– O
19 O
. O
5 O
% O
at O
20 O
– O
60 O
mg O
/ O
kg O
doses O
in O
mice O
, O
< O
1 O
. O
6 O
% O
at O
100 O
– O
2000 O
mg O
/ O
kg O
in O
rats O
, O
and O
11 O
. O
2 O
% O
at O
100 O
mg O
/ O
kg O
decreasing O
to O
3 O
. O
45 O
% O
at O
400 O
mg O
/ O
kg O
and O
1 O
. O
11 O
% O
at O
1500 O
mg O
/ O
kg O
in O
dogs O
. O
[SEP] O
[CLS] O
the O
disposition O
parameters O
were O
well O
correlated O
with O
the O
body O
weight O
for O
all O
species O
using O
the O
all O
##ometric O
equation O
, O
which O
predicted O
values O
of O
c B-PK
##l I-PK
( O
17 O
. O
3 O
l O
/ O
h O
) O
, O
v B-PK
##1 I-PK
( O
36 O
. O
2 O
l O
) O
, O
v B-PK
##2 I-PK
( O
68 O
. O
5 O
l O
) O
and O
c B-PK
##ld I-PK
( O
15 O
. O
2 O
l O
/ O
h O
) O
for O
a O
70 O
- O
kg O
human O
. O
[SEP] O
[CLS] O
the O
oral B-PK
absorption I-PK
rate I-PK
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
she O
##ta O
##2 O
was O
highly O
dependent O
on O
species O
, O
doses O
, O
formulation O
##s O
, O
and O
possibly O
other O
factors O
. O
[SEP] O
[CLS] O
the O
limited O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
at O
high O
doses O
was O
taken O
into O
consideration O
for O
the O
suggested O
first O
- O
in O
- O
human O
dose O
, O
which O
was O
much O
lower O
than O
the O
dose O
estimated O
based O
on O
toxic O
##ology O
studies O
. O
[SEP] O
[CLS] O
the O
two O
- O
compartment O
model O
was O
parameter O
##ized O
with O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
in I-PK
the I-PK
central I-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
and O
peripheral B-PK
( I-PK
v I-PK
##2 I-PK
) I-PK
compartment I-PK
, O
and O
distribution B-PK
clearance I-PK
( I-PK
c I-PK
##ld I-PK
) I-PK
between O
compartment O
##s O
. O
[SEP] O
[CLS] O
ka B-PK
is O
the O
first B-PK
- I-PK
order I-PK
absorption I-PK
rate I-PK
constant I-PK
and O
f B-PK
is O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
in O
this O
model O
, O
we O
assumed O
( O
a O
) O
the O
drug O
undergo O
##es O
transit O
through O
the O
in O
##test O
##ines O
with O
the O
first B-PK
- I-PK
order I-PK
transit I-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
##t I-PK
) I-PK
, O
which O
was O
assumed O
to O
be O
same O
through O
all O
compartment O
##s O
; O
( O
b O
) O
she O
##ta O
##2 O
absorption O
from O
the O
first O
compartment O
( O
i O
. O
e O
. O
, O
stomach O
) O
is O
ins O
##ign O
##ificant O
; O
and O
( O
c O
) O
the O
absorption O
only O
occurs O
from O
the O
second O
( O
g O
##2 O
) O
and O
last O
( O
g O
##7 O
) O
segments O
with O
two O
different O
absorption B-PK
rate I-PK
constant I-PK
##s I-PK
( O
ka B-PK
and O
ka B-PK
##2 I-PK
) O
, O
with O
no O
absorption O
from O
segments O
3 O
– O
6 O
. O
[SEP] O
[CLS] O
ka B-PK
and O
ka B-PK
##2 I-PK
represent O
the O
first B-PK
- I-PK
order I-PK
absorption I-PK
rate I-PK
constant I-PK
from I-PK
the I-PK
second I-PK
( O
g O
##2 O
) O
and O
last B-PK
( O
g O
##7 O
) O
compartment O
##s O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
plasma O
concentration O
- O
time O
data O
from O
both O
i O
##v O
and O
oral O
routes O
were O
fitted O
simultaneously O
with O
e O
##q O
##s O
1 O
– O
3 O
( O
fi O
##g O
2 O
##a O
) O
to O
obtain O
the O
disposition O
( O
c B-PK
##l I-PK
, O
v B-PK
##1 I-PK
, O
v B-PK
##2 I-PK
, O
c B-PK
##ld I-PK
) O
and O
absorption O
parameters O
( O
ka B-PK
and O
f B-PK
) O
for O
mice O
and O
rats O
. O
[SEP] O
[CLS] O
similarly O
, O
the O
parameters O
for O
disposition O
and O
gas O
##tro O
##int O
##est O
##inal O
transit O
absorption O
process O
( O
ka B-PK
, O
ka B-PK
##2 I-PK
, O
ka B-PK
##t I-PK
, O
and O
f B-PK
) O
were O
obtained O
by O
simultaneously O
fitting O
the O
i O
##v O
and O
oral O
data O
from O
dogs O
with O
e O
##q O
##s O
4 O
– O
9 O
( O
fi O
##g O
2 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
units O
of O
parameters O
are O
l O
/ O
h O
for O
c B-PK
##l I-PK
and O
c B-PK
##ld I-PK
; O
l O
for O
v B-PK
##1 I-PK
and O
v B-PK
##2 I-PK
; O
and O
h O
- O
1 O
for O
all O
first B-PK
- I-PK
order I-PK
rate I-PK
constant I-PK
##s I-PK
( O
e O
. O
g O
. O
, O
ka B-PK
, O
ka B-PK
##2 I-PK
, O
ka B-PK
##t I-PK
) O
. O
[SEP] O
[CLS] O
for O
the O
population O
demographic O
, O
physiological O
, O
and O
other O
variables O
, O
we O
used O
the O
default O
values O
and O
var O
##iability O
( O
e O
. O
g O
. O
, O
40 O
% O
for O
c B-PK
##l I-PK
and O
20 O
% O
for O
v B-PK
##1 I-PK
) O
provided O
in O
the O
program O
. O
[SEP] O
[CLS] O
the O
non O
##com O
##par O
##tment O
##al O
parameters O
included O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
- I-PK
concentration I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
, O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
of I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
terminal B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
all O
##ometric O
s O
##cal O
##ing O
was O
applied O
to O
the O
disposition O
parameters O
, O
including O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
central B-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
and O
peripheral B-PK
( I-PK
v I-PK
##2 I-PK
) I-PK
distribution I-PK
##al I-PK
volumes I-PK
, O
and O
distribution B-PK
##al I-PK
clearance I-PK
( I-PK
c I-PK
##ld I-PK
) I-PK
, O
obtained O
from O
simultaneous O
fitting O
of O
oral O
and O
i O
##v O
plasma O
concentration O
- O
time O
data O
for O
each O
species O
. O
[SEP] O
[CLS] O
several O
studies O
have O
shown O
that O
modified O
s O
##cal O
##ing O
methods O
with O
a O
correction O
of O
maximum O
life O
- O
span O
potential O
( O
m O
##l O
##p O
) O
or O
brain O
weight O
( O
br O
##w O
) O
improve O
the O
accuracy O
of O
human O
c B-PK
##l I-PK
prediction O
[ O
18 O
– O
20 O
] O
, O
as O
long O
##evity O
is O
frequently O
inverse O
##ly O
correlated O
with O
he O
##pa O
##tic O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
drug O
oxidation O
rates O
[ O
18 O
, O
21 O
] O
. O
[SEP] O
[CLS] O
therefore O
, O
in O
addition O
to O
simple O
all O
##ome O
##try O
, O
we O
applied O
the O
m O
##l O
##p O
correction O
in O
the O
prediction O
of O
she O
##ta O
##2 O
clearance B-PK
in O
humans O
using O
c O
##l O
[UNK] O
m O
##l O
##p O
= O
a O
• O
b O
##w O
##b O
[ O
20 O
] O
. O
[SEP] O
[CLS] O
the O
input O
data O
for O
she O
##ta O
##2 O
compound O
included O
( O
a O
) O
disposition O
p O
##k O
parameters O
from O
the O
all O
##ome O
##tically O
- O
scaled O
human O
values O
of O
c B-PK
##l I-PK
, O
v B-PK
##1 I-PK
, O
v B-PK
##2 I-PK
, O
and O
c B-PK
##ld I-PK
; O
( O
b O
) O
she O
##ta O
##2 O
doses O
in O
mg O
; O
and O
( O
c O
) O
p O
##hy O
##si O
##co O
##chemical O
properties O
, O
including O
molecular O
structure O
( O
fi O
##g O
1 O
) O
, O
experimental O
##ly O
calculated O
log O
p O
value O
of O
4 O
. O
23 O
[ O
23 O
] O
, O
per B-PK
##me I-PK
##ability I-PK
[ O
24 O
] O
, O
and O
experimental O
##ly O
calculated O
so O
##lub O
##ility O
of O
19 O
. O
9 O
μ O
##g O
/ O
m O
##l O
in O
simulated O
gas O
##tro O
##int O
##est O
##inal O
fluid O
. O
[SEP] O
[CLS] O
she O
##ta O
##2 O
appeared O
to O
be O
readily O
distributed O
into O
peripheral O
tissues O
, O
as O
indicated O
by O
a O
high O
extent O
of O
the O
volume B-PK
of I-PK
distribution I-PK
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
she O
##ta O
##2 O
after O
i O
##v O
administration O
in O
mice O
was O
much O
longer O
than O
it O
was O
in O
rats O
( O
1 O
. O
16 O
h O
) O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
this O
disposition O
pattern O
in O
non O
- O
tumor O
- O
bearing O
mice O
was O
also O
different O
from O
what O
our O
group O
observed O
for O
she O
##ta O
##2 O
in O
tumor O
- O
bearing O
mice O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
4 O
. O
5 O
h O
) O
[ O
23 O
] O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
estimated O
to O
be O
17 O
. O
7 O
% O
and O
19 O
. O
5 O
% O
at O
20 O
and O
60 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
for O
oral O
administration O
in O
rats O
, O
the O
prolonged O
absorption O
kinetic O
##s O
were O
apparent O
at O
higher O
doses O
( O
500 O
and O
2000 O
mg O
/ O
kg O
) O
, O
as O
evidenced O
by O
the O
estimated O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
of O
0 O
. O
07 O
##55 O
h O
- O
1 O
and O
a O
much O
slower O
decline O
of O
drug O
concentration O
following O
the O
oral O
dose O
compared O
with O
the O
i O
##v O
administration O
( O
i O
. O
e O
. O
, O
flip O
- O
fl O
##op O
kinetic O
##s O
) O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
rats O
was O
low O
, O
ranging O
from O
0 O
. O
56 O
– O
1 O
. O
6 O
% O
at O
all O
studied O
doses O
, O
and O
the O
increase O
in O
overall O
systemic O
exposure O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
) O
was O
less O
than O
proportional O
at O
2000 O
mg O
/ O
kg O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
in O
dogs O
, O
the O
oral O
absorption O
was O
relatively O
fast O
, O
reaching O
the O
peak B-PK
concentration I-PK
within O
1 O
– O
3 O
h O
after O
dos O
##ing O
. O
[SEP] O
[CLS] O
the O
increases O
in O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
were O
less O
than O
proportional O
with O
increasing O
doses O
( O
table O
2 O
) O
, O
indicating O
the O
non O
##linear O
p O
##k O
. O
[SEP] O
[CLS] O
the O
mean O
cm B-PK
##ax I-PK
observed O
at O
two O
high O
doses O
of O
400 O
and O
1500 O
mg O
/ O
kg O
was O
smaller O
than O
that O
at O
100 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
in O
this O
model O
, O
drug O
movement O
along O
the O
in O
##test O
##ine O
was O
modeled O
by O
a O
first O
- O
order O
process O
( O
ka O
##t O
) O
through O
seven O
transit O
compartment O
##s O
and O
drug O
absorption O
by O
two O
different O
first B-PK
- I-PK
order I-PK
rate I-PK
constant I-PK
##s I-PK
( O
ka B-PK
and O
ka B-PK
##2 I-PK
) O
occurring O
from O
the O
g O
##2 O
and O
g O
##7 O
compartment O
##s O
. O
[SEP] O
[CLS] O
the O
magnitude O
and O
time O
of O
initial O
and O
/ O
or O
second O
peak O
occurrence O
##s O
varied O
by O
doses O
after O
oral O
administration O
, O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
was O
marked O
##ly O
reduced O
with O
increasing O
doses O
. O
[SEP] O
[CLS] O
this O
required O
the O
est O
##imation O
of O
the O
rate O
and O
extent O
of O
absorption O
kinetic O
parameters O
varying O
at O
different O
doses O
; O
those O
parameters O
included O
f B-PK
, O
ka B-PK
##t I-PK
, O
ka B-PK
, O
and O
ka B-PK
##2 I-PK
. O
[SEP] O
[CLS] O
our O
results O
indicated O
that O
the O
drug O
absorption O
from O
the O
g O
##2 O
compartment O
( O
ka B-PK
) O
was O
much O
slower O
at O
higher O
doses O
than O
at O
low O
doses O
( O
0 O
. O
41 O
##1 O
vs O
. O
1 O
. O
12 O
h O
- O
1 O
) O
, O
which O
contributed O
to O
the O
first O
peak O
being O
lower O
and O
delayed O
at O
higher O
doses O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
she O
##ta O
##2 O
formulation O
in O
dogs O
was O
reduced O
from O
11 O
. O
2 O
% O
at O
100 O
mg O
/ O
kg O
to O
3 O
. O
45 O
% O
at O
400 O
mg O
/ O
kg O
to O
1 O
. O
11 O
% O
at O
1500 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
fi O
##g O
4 O
shows O
the O
comparison O
of O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
with O
respect O
to O
dose O
among O
mice O
, O
rats O
, O
and O
dogs O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
18 O
. O
6 O
% O
) O
in O
mice O
after O
20 O
– O
60 O
mg O
/ O
kg O
was O
the O
highest O
among O
all O
pre O
##c O
##lini O
##cal O
studies O
. O
[SEP] O
[CLS] O
in O
dogs O
, O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
dose O
- O
dependent O
##ly O
decreased O
with O
increasing O
doses O
. O
[SEP] O
[CLS] O
compared O
with O
mice O
and O
dogs O
, O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
rats O
was O
generally O
low O
at O
all O
doses O
( O
f O
< O
1 O
. O
6 O
% O
) O
, O
which O
could O
be O
attributed O
to O
several O
factors O
, O
including O
different O
formulation O
used O
in O
rats O
, O
species O
differences O
in O
absorption O
through O
the O
gas O
##tro O
- O
in O
##test O
##inal O
tract O
and O
first O
- O
pass O
metabolism O
, O
and O
different O
diet O
##ary O
habits O
among O
species O
. O
[SEP] O
[CLS] O
inter O
##sp O
##ec O
##ies O
s O
##cal O
##ing O
was O
performed O
on O
the O
disposition O
parameters O
of O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
central B-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
and O
peripheral B-PK
( I-PK
v I-PK
##2 I-PK
) I-PK
distribution I-PK
##al I-PK
volumes I-PK
, O
and O
distribution B-PK
##al I-PK
clearance I-PK
( I-PK
c I-PK
##ld I-PK
; O
table O
3 O
) O
. O
[SEP] O
[CLS] O
doses O
can O
be O
es O
##calated O
from O
2 O
mg O
/ O
kg O
to O
a O
point O
at O
which O
the O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
reaches O
4 O
μ O
##m O
( O
equivalent O
to O
1600 O
ng O
/ O
m O
##l O
) O
, O
the O
concentration O
that O
is O
sufficient O
to O
induce O
g O
##1 O
cell O
cycle O
arrest O
within O
24 O
hours O
and O
causes O
target O
m O
##od O
##ulation O
within O
4 O
hours O
. O
[SEP] O
[CLS] O
the O
predicted O
human O
clearance B-PK
ranged O
from O
17 O
. O
3 O
l O
/ O
h O
( O
m O
##l O
##p O
- O
based O
) O
to O
41 O
. O
0 O
l O
/ O
h O
( O
simple O
all O
##ome O
##try O
) O
. O
[SEP] O
[CLS] O
following O
a O
single O
oral O
dose O
of O
0 O
. O
25 O
– O
2 O
. O
0 O
g O
di O
##c O
##lo O
##xa O
##ci O
##llin O
sodium O
, O
the O
maximum B-PK
plasma I-PK
drug I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
corresponding O
values O
for O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
10 I-PK
hours I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
) I-PK
increased O
in O
a O
dose O
- O
proportional O
manner O
. O
[SEP] O
[CLS] O
for O
the O
disposition O
parameters O
, O
we O
used O
the O
all O
##ometric O
##ally O
scaled O
human O
p O
##k O
parameters O
v B-PK
##1 I-PK
( O
36 O
. O
2 O
l O
) O
, O
v B-PK
##2 I-PK
( O
68 O
. O
5 O
l O
) O
, O
c B-PK
##ld I-PK
( O
15 O
. O
2 O
l O
/ O
h O
) O
, O
and O
m B-PK
##l I-PK
##p I-PK
- I-PK
based I-PK
c I-PK
##l I-PK
( O
17 O
. O
3 O
l O
/ O
h O
) O
to O
predict O
the O
concentration O
- O
time O
profile O
of O
she O
##ta O
##2 O
in O
humans O
. O
[SEP] O
[CLS] O
evaluation O
of O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
was O
difficult O
, O
as O
there O
was O
no O
correlation O
in O
ka B-PK
across O
different O
species O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
predicted B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
18 O
. O
8 O
% O
( O
7 O
. O
4 O
– O
42 O
% O
) O
which O
is O
very O
close O
to O
the O
maximum O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
18 O
. O
6 O
% O
) O
observed O
from O
pre O
##c O
##lini O
##cal O
species O
at O
doses O
< O
100 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
the O
prediction O
also O
suggested O
no O
significant O
difference O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
from O
dos O
##ing O
under O
the O
fed O
state O
( O
18 O
. O
1 O
% O
) O
. O
[SEP] O
[CLS] O
the O
mean O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
in O
the O
range O
of O
1 O
. O
38 O
– O
1 O
. O
71 O
hours O
. O
[SEP] O
[CLS] O
di O
##c O
##lo O
##xa O
##ci O
##llin O
was O
safe O
and O
well O
tolerate O
##d O
in O
the O
volunteers O
and O
displayed O
linear O
increases O
in O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
values O
. O
[SEP] O
[CLS] O
safety O
evaluation O
##s O
included O
adverse O
event O
( O
a O
##e O
) O
counts O
, O
monitoring O
for O
serious O
adverse O
events O
( O
sa O
##es O
) O
with O
the O
severity O
, O
and O
relationship O
to O
the O
study O
drug O
and O
regular O
monitoring O
of O
vital O
signs O
, O
physical O
condition O
, O
clinical O
laboratory O
tests O
( O
e O
##g O
, O
hem O
##ato O
##logy O
parameters O
, O
liver O
function O
tests O
[ O
al O
##ani O
##ne O
trans O
##ami O
##nas O
##e O
( O
al O
##t O
) O
, O
as O
##par O
##tate O
amino O
##tra O
##ns O
##fer O
##ase O
( O
as O
##t O
) O
, O
and O
gamma O
- O
g O
##lut O
##am O
##yl O
transfer O
##ase O
] O
, O
kidney O
function O
tests O
[ O
blood O
u O
##rea O
nitrogen O
and O
serum O
c O
##rea O
##tin O
##ine O
] O
, O
and O
urine O
analysis O
) O
, O
and O
12 O
- O
lead O
electro O
##card O
##io O
##gram O
. O
[SEP] O
[CLS] O
the O
study O
was O
conducted O
in O
accordance O
with O
the O
principles O
of O
the O
current O
revision O
of O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
concerning O
medical O
research O
in O
humans O
, O
19 O
the O
international O
conference O
on O
harm O
##oni O
##zation O
guide O
##line O
for O
good O
clinical O
practice O
, O
20 O
the O
guide O
##line O
for O
good O
clinical O
practice O
, O
and O
the O
guide O
##line O
for O
p O
##har O
##ma O
##co O
##kin O
##etics O
studies O
recommended O
by O
the O
chin O
##a O
food O
and O
drug O
administration O
. O
21 O
, O
22 O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
obtained O
for O
part O
1 O
: O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
apparent B-PK
oral I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
during I-PK
the I-PK
terminal I-PK
elimination I-PK
phase I-PK
following I-PK
extra I-PK
##vas I-PK
##cular I-PK
administration I-PK
( I-PK
v I-PK
##z I-PK
/ I-PK
f I-PK
) I-PK
. O
[SEP] O
[CLS] O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
and O
vs B-PK
##s I-PK
/ I-PK
f I-PK
( I-PK
volume I-PK
of I-PK
distribution I-PK
at I-PK
the I-PK
steady I-PK
state I-PK
) I-PK
were O
calculated O
using O
the O
same O
method O
as O
for O
single O
- O
dose O
period O
. O
[SEP] O
[CLS] O
the O
accumulation O
ratio O
was O
calculated O
as O
the O
ratio O
of O
au B-PK
##c I-PK
##0 I-PK
– I-PK
τ I-PK
, I-PK
s I-PK
##s I-PK
to O
au B-PK
##c I-PK
##0 I-PK
– I-PK
τ I-PK
( O
single O
dose O
) O
, O
and O
the O
flu B-PK
##ct I-PK
##uation I-PK
ratio I-PK
was O
calculated O
by O
( B-PK
cm I-PK
##ax I-PK
, I-PK
s I-PK
##s I-PK
− I-PK
cm I-PK
##in I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
/ I-PK
ca I-PK
##v I-PK
##g I-PK
, O
where O
ca B-PK
##v I-PK
##g I-PK
is O
the O
average B-PK
steady I-PK
- I-PK
state I-PK
drug I-PK
concentration I-PK
during O
multiple O
dos O
##ing O
, O
which O
is O
calculated O
as O
au B-PK
##c I-PK
##0 I-PK
– I-PK
τ I-PK
, I-PK
s I-PK
##s I-PK
/ I-PK
τ I-PK
, O
where O
τ O
is O
the O
dos O
##ing O
interval O
( O
6 O
hours O
) O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
amount O
of O
drug B-PK
ex I-PK
##cre I-PK
##ted I-PK
into I-PK
the I-PK
urine I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
time I-PK
24 I-PK
hours I-PK
( I-PK
a I-PK
##e I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
and O
re B-PK
##nal I-PK
clearance I-PK
were O
determined O
for O
each O
single O
- O
dose O
p O
##har O
##ma O
##co O
##kin O
##etic O
group O
from O
the O
urine O
drug O
concentration O
– O
time O
data O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
expressed O
using O
arithmetic O
means O
and O
standard O
de O
##viation O
##s O
, O
except O
for O
t B-PK
##max I-PK
, O
for O
which O
median O
values O
and O
ranges O
are O
reported O
. O
[SEP] O
[CLS] O
to O
test O
dose O
proportional O
##ity O
in O
the O
single O
- O
dose O
range O
studied O
, O
log O
- O
transformed O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
were O
analyzed O
by O
using O
the O
power O
model O
, O
p O
##k O
= O
a O
× O
( O
dose O
) O
β O
, O
where O
p O
##k O
is O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
, O
a O
is O
the O
intercept O
, O
and O
β O
is O
the O
dose O
- O
proportional O
##ity O
coefficient O
. O
[SEP] O
[CLS] O
the O
results O
for O
t B-PK
##max I-PK
were O
evaluated O
using O
the O
w O
##il O
##co O
##xon O
rank O
- O
sum O
analysis O
. O
[SEP] O
[CLS] O
no O
subjects O
experienced O
sa O
##es O
, O
or O
were O
withdrawn O
from O
the O
study O
after O
dos O
##ing O
due O
to O
an O
a O
##e O
. O
[SEP] O
[CLS] O
only O
one O
subject O
( O
1 O
/ O
16 O
, O
6 O
. O
25 O
% O
) O
developed O
le O
##uc O
##ope O
##nia O
and O
ne O
##ut O
##rop O
##enia O
that O
were O
assessed O
as O
mild O
a O
##e O
; O
both O
were O
suspected O
to O
be O
related O
to O
the O
study O
drug O
. O
[SEP] O
[CLS] O
the O
mean O
cm B-PK
##ax I-PK
values O
for O
the O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
1 O
. O
0 O
, O
and O
2 O
. O
0 O
g O
group O
were O
13 O
. O
62 O
µ O
##g O
· O
m O
##l O
##− O
##1 O
, O
24 O
. O
28 O
µ O
##g O
· O
m O
##l O
##− O
##1 O
, O
45 O
. O
02 O
µ O
##g O
· O
m O
##l O
##− O
##1 O
, O
and O
79 O
. O
97 O
µ O
##g O
· O
m O
##l O
##− O
##1 O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
values O
were O
31 O
. O
60 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
, O
61 O
. O
40 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
, O
108 O
. O
73 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
, O
and O
203 O
. O
29 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
, O
respectively O
. O
[SEP] O
[CLS] O
plasma B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
was O
independent O
of O
the O
dose O
, O
averaging O
1 O
. O
51 O
hours O
( O
0 O
. O
92 O
– O
2 O
. O
56 O
hours O
) O
. O
[SEP] O
[CLS] O
the O
trend O
for O
an O
increasing O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
with O
increasing O
dose O
has O
been O
observed O
, O
and O
at O
the O
highest O
dose O
of O
2 O
. O
0 O
g O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
in O
the O
range O
of O
1 O
. O
13 O
– O
2 O
. O
56 O
hours O
. O
[SEP] O
[CLS] O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
and O
apparent B-PK
clearance I-PK
ranged O
between O
9 O
. O
7 O
and O
40 O
. O
97 O
l O
and O
5 O
. O
33 O
and O
16 O
. O
89 O
l O
· O
h O
##− O
##1 O
, O
respectively O
, O
over O
the O
entire O
dose O
range O
. O
[SEP] O
[CLS] O
for O
the O
relationship O
between O
non O
- O
compartment O
##al O
parameters O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
and O
/ O
or O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
and O
cm B-PK
##ax I-PK
) O
and O
dose O
, O
analysis O
results O
indicated O
that O
the O
estimated O
proportional O
##ity O
coefficients O
( O
β O
) O
for O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
, O
and O
cm B-PK
##ax I-PK
were O
0 O
. O
87 O
##6 O
( O
90 O
% O
c O
##i O
: O
0 O
. O
81 O
##2 O
– O
0 O
. O
94 O
##0 O
) O
, O
0 O
. O
88 O
##1 O
( O
90 O
% O
c O
##i O
: O
0 O
. O
81 O
##6 O
– O
0 O
. O
94 O
##5 O
) O
, O
and O
0 O
. O
82 O
##8 O
( O
90 O
% O
c O
##i O
: O
0 O
. O
70 O
##9 O
– O
0 O
. O
94 O
##8 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
this O
indicated O
a O
slightly O
less O
than O
dose O
- O
proportional O
increase O
of O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
in O
the O
dose O
range O
of O
0 O
. O
25 O
– O
2 O
. O
0 O
g O
, O
with O
a O
slope O
β O
of O
slightly O
less O
than O
1 O
. O
[SEP] O
[CLS] O
no O
significant O
differences O
in O
t B-PK
##max I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
, O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
cm B-PK
##ax I-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
v B-PK
##z I-PK
/ I-PK
f I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
, O
or O
a B-PK
##e I-PK
were O
detected O
between O
male O
and O
female O
subjects O
who O
received O
0 O
. O
5 O
, O
1 O
. O
0 O
, O
or O
2 O
. O
0 O
g O
di O
##c O
##lo O
##xa O
##ci O
##llin O
sodium O
. O
[SEP] O
[CLS] O
in O
subjects O
who O
received O
0 O
. O
25 O
g O
di O
##c O
##lo O
##xa O
##ci O
##llin O
sodium O
, O
significant O
differences O
in O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
( O
p O
= O
0 O
. O
04 O
##4 O
) O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
( O
p O
= O
0 O
. O
02 O
##6 O
) O
were O
observed O
between O
the O
two O
sex O
. O
[SEP] O
[CLS] O
di O
##c O
##lo O
##xa O
##ci O
##llin O
at O
doses O
of O
0 O
. O
25 O
g O
q O
##6 O
##h O
and O
0 O
. O
5 O
g O
q O
##6 O
##h O
was O
rapidly O
absorbed O
, O
with O
t B-PK
##max I-PK
, I-PK
s I-PK
##s I-PK
ranging O
from O
0 O
. O
33 O
to O
3 O
. O
0 O
hours O
after O
dose O
across O
subjects O
on O
day O
3 O
. O
[SEP] O
[CLS] O
the O
corresponding O
au B-PK
##c I-PK
##0 I-PK
– I-PK
10 I-PK
h I-PK
values O
on O
day O
3 O
were O
33 O
. O
72 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
and O
62 O
. O
06 O
µ O
##g O
· O
h O
· O
m O
##l O
##− O
##1 O
. O
[SEP] O
[CLS] O
the O
mean O
peak B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
after O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
administration O
were O
2 O
. O
60 O
± O
0 O
. O
10 O
, O
2 O
. O
59 O
± O
0 O
. O
12 O
, O
and O
2 O
. O
34 O
± O
0 O
. O
12 O
µ O
##g O
/ O
m O
##l O
at O
0 O
. O
25 O
± O
0 O
. O
00 O
, O
0 O
. O
44 O
± O
0 O
. O
10 O
, O
and O
1 O
. O
58 O
± O
0 O
. O
40 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curves I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
and O
elimination B-PK
half I-PK
- I-PK
lives I-PK
were O
24 O
. O
80 O
± O
0 O
. O
90 O
, O
25 O
. O
80 O
± O
1 O
. O
40 O
, O
and O
23 O
. O
40 O
± O
5 O
. O
00 O
h O
· O
μ O
##g O
/ O
m O
##l O
and O
8 O
. O
60 O
± O
0 O
. O
30 O
, O
12 O
. O
80 O
± O
1 O
. O
10 O
, O
and O
8 O
. O
60 O
± O
0 O
. O
00 O
h O
, O
for O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
. O
administration O
, O
corresponding O
##ly O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
peak B-PK
times I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
peak B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
and O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
were O
calculated O
for O
p O
##har O
##ma O
##co O
##kin O
##etic O
determination O
using O
a O
non O
##com O
##par O
##tment O
##al O
analysis O
. O
[SEP] O
[CLS] O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
i O
. O
m O
. O
administration O
was O
determined O
with O
the O
formula O
f O
= O
( O
au O
##ci O
##m O
/ O
au O
##ci O
##v O
) O
× O
100 O
% O
. O
[SEP] O
[CLS] O
similarly O
, O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
determined O
by O
f O
= O
( O
au O
##c O
##po O
/ O
au O
##ci O
##v O
) O
× O
100 O
% O
, O
in O
the O
case O
of O
p O
. O
o O
. O
administration O
. O
[SEP] O
[CLS] O
the O
peak B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
were O
2 O
. O
60 O
± O
0 O
. O
10 O
μ O
##g O
/ O
m O
##l O
, O
2 O
. O
59 O
± O
0 O
. O
12 O
μ O
##g O
/ O
m O
##l O
, O
and O
2 O
. O
34 O
± O
0 O
. O
12 O
μ O
##g O
/ O
m O
##l O
for O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
. O
administration O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
areas B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curves I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
were O
24 O
. O
80 O
± O
0 O
. O
90 O
, O
25 O
. O
80 O
± O
1 O
. O
40 O
, O
and O
23 O
. O
40 O
± O
5 O
. O
00 O
h O
· O
μ O
##g O
/ O
m O
##l O
for O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
. O
administration O
, O
corresponding O
##ly O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
values O
were O
8 O
. O
60 O
± O
0 O
. O
30 O
, O
12 O
. O
80 O
± O
1 O
. O
10 O
, O
and O
8 O
. O
60 O
± O
0 O
. O
00 O
h O
, O
corresponding O
##ly O
in O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
. O
administration O
. O
[SEP] O
[CLS] O
the O
in O
v O
##it O
##ro O
mi O
##c O
and O
m O
##b O
##c O
data O
were O
integrated O
with O
in O
v O
##ivo O
p O
##k O
data O
to O
determine O
the O
p O
##k O
/ O
p O
##d O
in O
##dices O
such O
as O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
mi I-PK
##c I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
m I-PK
##b I-PK
##c I-PK
, O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
, O
cm B-PK
##ax I-PK
/ I-PK
m I-PK
##b I-PK
##c I-PK
, O
t O
> O
mi O
##c O
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
> O
mi O
##c O
, O
which O
are O
presented O
in O
table O
5 O
. O
[SEP] O
[CLS] O
absolute O
percentage O
##s O
of O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
of O
the O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
in O
pig O
were O
104 O
. O
60 O
± O
5 O
. O
70 O
% O
and O
94 O
. O
35 O
± O
8 O
. O
90 O
% O
, O
respectively O
, O
in O
in O
##tra O
##mus O
##cular O
and O
per O
##oral O
routes O
compared O
to O
in O
##tra O
##ven O
##ous O
route O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
mi I-PK
##c I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
m I-PK
##b I-PK
##c I-PK
, O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
, O
and O
cm B-PK
##ax I-PK
/ I-PK
m I-PK
##b I-PK
##c I-PK
values O
attained O
from O
the O
application O
of O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
through O
p O
. O
o O
. O
route O
are O
significantly O
lower O
than O
i O
. O
v O
. O
and O
i O
. O
m O
. O
administration O
values O
. O
[SEP] O
[CLS] O
on O
the O
contrary O
, O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
> O
mi O
##c O
value O
with O
the O
administration O
of O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
through O
p O
. O
o O
. O
route O
is O
significantly O
higher O
than O
the O
values O
obtained O
from O
i O
. O
v O
. O
and O
i O
. O
m O
. O
administration O
. O
[SEP] O
[CLS] O
single O
- O
chain O
f O
##v O
[SEP] O
[CLS] O
in O
contrast O
, O
the O
position O
of O
the O
s O
##c O
##d O
##b O
with O
respect O
to O
the O
f O
##c O
region O
did O
not O
influence O
the O
growth O
in O
##hibition O
effects O
; O
comparable O
results O
were O
observed O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
and O
- O
h O
##l O
- O
re O
##v O
, O
and O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
and O
- O
l O
##h O
- O
re O
##v O
, O
respectively O
. O
[SEP] O
[CLS] O
to O
investigate O
the O
effects O
of O
rear O
##rang O
##ing O
the O
domain O
order O
of O
he O
##x O
##3 O
- O
d O
##b O
on O
the O
functions O
of O
its O
f O
##c O
fusion O
format O
, O
we O
prepared O
four O
types O
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
( O
including O
the O
original O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
3 O
##c O
- O
f O
##c O
[ O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
] O
) O
, O
each O
with O
a O
different O
domain O
order O
, O
as O
described O
in O
experimental O
procedures O
. O
[SEP] O
[CLS] O
a O
lower O
di O
##sso O
##ciation O
rate O
caused O
by O
the O
bi O
##vale O
##ncy O
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##cs O
contributed O
to O
their O
higher O
affinity O
for O
se O
##g O
##f O
##r O
than O
those O
of O
he O
##x O
##3 O
- O
d O
##bs O
, O
he O
##x O
##3 O
- O
h O
##l O
, O
and O
he O
##x O
##3 O
- O
l O
##h O
, O
but O
no O
major O
differences O
between O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
and O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
were O
observed O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
the O
structure O
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
might O
be O
able O
to O
avoid O
s O
##ter O
##ic O
hind O
##rance O
with O
cell O
surface O
molecules O
, O
particularly O
those O
of O
t O
- O
la O
##k O
cells O
, O
and O
this O
feature O
might O
contribute O
to O
the O
increased O
c O
##yt O
##oto O
##xi O
##c O
effects O
of O
this O
b O
##sa O
##b O
, O
indicating O
that O
the O
characteristics O
of O
he O
##x O
##3 O
- O
l O
##h O
are O
fully O
retained O
after O
f O
##c O
fusion O
. O
[SEP] O
[CLS] O
s O
##ds O
- O
page O
analysis O
identified O
these O
fraction O
##s O
as O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##cs O
derivatives O
that O
had O
fragment O
##ed O
in O
the O
region O
of O
the O
connecting O
site O
of O
the O
f O
##c O
region O
during O
long O
- O
term O
storage O
; O
results O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
h O
##l O
are O
shown O
in O
figure O
6 O
##bas O
a O
representative O
example O
. O
[SEP] O
[CLS] O
to O
evaluate O
in O
v O
##ivo O
stability O
, O
we O
measured O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
using O
radio O
##io O
##dine O
- O
labeled O
b O
##sa O
##bs O
. O
[SEP] O
[CLS] O
the O
au B-PK
##cs I-PK
( I-PK
1 I-PK
. I-PK
5 I-PK
– I-PK
8 I-PK
h I-PK
) I-PK
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
and O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
were O
3 O
. O
1 O
- O
fold O
greater O
than O
those O
of O
their O
corresponding O
d O
##b O
formats O
, O
he O
##x O
##3 O
- O
h O
##l O
and O
he O
##x O
##3 O
- O
l O
##h O
, O
as O
a O
result O
of O
the O
increased O
molecular O
weight O
due O
to O
the O
f O
##c O
fusion O
( O
fi O
##g O
. O
6 O
##c O
; O
table O
1 O
) O
. O
[SEP] O
[CLS] O
to O
investigate O
whether O
the O
ad O
##cc O
activity O
contributed O
to O
the O
enhanced O
growth O
in O
##hibition O
effects O
of O
s O
##c O
##d O
##b O
- O
f O
##c O
, O
we O
constructed O
an O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
variant O
whose O
f O
##c O
region O
was O
derived O
from O
human O
i O
##gg O
##2 O
( O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
- O
i O
##gg O
##2 O
, O
figure O
7 O
##a O
) O
. O
[SEP] O
[CLS] O
we O
previously O
described O
the O
construction O
of O
the O
ma O
##mmal O
##ian O
expression O
vector O
p O
##c O
##dn O
##a O
- O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
3 O
##c O
- O
f O
##c O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
3 O
##c O
- O
f O
##c O
, O
in O
which O
a O
single O
- O
chain O
form O
of O
he O
##x O
##3 O
- O
d O
##b O
was O
fused O
to O
a O
human O
i O
##gg O
##1 O
f O
##c O
region O
via O
a O
recognition O
site O
( O
le O
##v O
##lf O
##q O
##g O
##p O
) O
for O
human O
r O
##hino O
##virus O
3 O
##c O
( O
h O
##r O
##v O
##3 O
##c O
) O
pro O
##te O
##ase O
. O
30 O
because O
two O
ch O
##ime O
##ric O
single O
- O
chain O
components O
of O
he O
##x O
##3 O
- O
d O
##b O
— O
ho O
##hh O
##5 O
##l O
and O
h O
##5 O
##hh O
##ol O
, O
both O
with O
a O
v O
##h O
– O
v O
##l O
order O
— O
were O
connected O
via O
a O
20 O
– O
amino O
acid O
link O
##er O
( O
[ O
g O
##gg O
##gs O
] O
4 O
) O
in O
the O
ho O
##hh O
##5 O
##l O
– O
h O
##5 O
##hh O
##ol O
order O
, O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
3 O
##c O
- O
f O
##c O
was O
re O
- O
designated O
as O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
in O
this O
report O
for O
clarity O
. O
[SEP] O
[CLS] O
the O
expression O
vector O
p O
##c O
##dn O
##a O
- O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
with O
a O
v O
##l O
– O
v O
##h O
order O
( O
i O
. O
e O
. O
, O
a O
ho O
##l O
##h O
##5 O
##h O
– O
h O
##5 O
##l O
##ho O
##h O
– O
3 O
##c O
– O
f O
##c O
order O
) O
, O
was O
constructed O
by O
using O
the O
overlap O
polymer O
##ase O
chain O
reaction O
. O
[SEP] O
[CLS] O
the O
leader O
p O
##eptide O
sequences O
for O
protein O
secret O
##ion O
were O
derived O
from O
the O
mouse O
ok O
##t O
##3 O
heavy O
chain O
for O
the O
h O
##l O
- O
types O
and O
the O
light O
chain O
for O
the O
l O
##h O
- O
types O
, O
respectively O
. O
31 O
to O
construct O
the O
expression O
vector O
p O
##c O
##dn O
##a O
- O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
- O
i O
##gg O
##2 O
for O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
- O
i O
##gg O
##2 O
, O
the O
gene O
for O
the O
human O
f O
##c O
region O
derived O
from O
the O
i O
##gg O
##2 O
sub O
##c O
##lass O
was O
clone O
##d O
from O
peripheral O
blood O
mon O
##on O
##uc O
##lea O
##r O
cells O
( O
p O
##b O
##m O
##c O
) O
and O
then O
used O
to O
replace O
the O
i O
##gg O
##1 O
f O
##c O
portion O
in O
p O
##c O
##dn O
##a O
- O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
. O
[SEP] O
[CLS] O
clearance B-PK
was O
1 O
. O
10 O
( O
root O
square O
error O
8 O
% O
) O
l O
/ O
h O
and O
v B-PK
##1 I-PK
and O
v B-PK
##2 I-PK
were O
17 O
. O
6 O
( O
root O
square O
error O
14 O
% O
) O
and O
3 O
. O
63 O
( O
root O
square O
error O
8 O
% O
) O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
median O
area B-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
over I-PK
24 I-PK
h I-PK
( O
inter O
##qua O
##rt O
##ile O
range O
) O
on O
day O
14 O
for O
regime O
##ns O
i O
– O
v O
were O
91 O
( O
67 O
– O
122 O
) O
, O
183 O
( O
135 O
– O
244 O
) O
, O
91 O
( O
67 O
– O
122 O
) O
, O
137 O
( O
101 O
– O
183 O
) O
and O
183 O
( O
135 O
– O
244 O
) O
mg O
h O
/ O
l O
, O
respectively O
, O
for O
a O
typical O
patient O
of O
70 O
kg O
. O
[SEP] O
[CLS] O
the O
primary O
p O
##k O
parameters O
were O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
) I-PK
. O
[SEP] O
[CLS] O
after O
selection O
of O
the O
base O
model O
, O
the O
following O
co O
##var O
##iate O
##s O
were O
tested O
on O
c B-PK
##l I-PK
and O
v B-PK
based O
on O
physiological O
p O
##laus O
##ibility O
: O
album O
##in O
, O
continuous O
ve O
##no O
- O
ve O
##nous O
hem O
##of O
##ilt O
##ration O
( O
c O
##v O
##v O
##h O
) O
and O
sofa O
. O
[SEP] O
[CLS] O
the O
effect O
of O
album O
##in O
was O
assessed O
on O
v B-PK
##1 I-PK
and O
c B-PK
##l I-PK
. O
[SEP] O
[CLS] O
the O
differences O
observed O
between O
treatments O
could O
be O
attributed O
to O
a O
faster O
absorption B-PK
rate I-PK
which O
could O
in O
##hibit O
the O
release O
of O
inflammatory O
substances O
sooner O
in O
the O
inflammatory O
ca O
##sca O
##de O
, O
therefore O
affecting O
overall O
substance O
p O
concentrations O
. O
[SEP] O
[CLS] O
on O
the O
other O
hand O
, O
the O
t B-PK
##max I-PK
could O
explain O
the O
lower O
substance O
p O
concentrations O
, O
w O
##b O
##c O
counts O
and O
weight O
, O
as O
a O
faster O
onset O
of O
action O
from O
s O
##c O
me O
##lo O
##xi O
##cam O
administration O
could O
in O
##hibit O
the O
production O
of O
pro O
- O
inflammatory O
substances O
sooner O
in O
the O
inflammatory O
process O
which O
could O
consequently O
lead O
to O
a O
reduced O
magnitude O
of O
inflammation O
. O
[SEP] O
[CLS] O
the O
total O
volume O
of O
blood O
required O
for O
the O
hi O
##v O
r O
##na O
testing O
was O
approximately O
35 O
m O
##l O
per O
patient O
. O
[SEP] O
[CLS] O
physiological O
parameters O
, O
like O
organ O
volumes O
, O
blood B-PK
flow I-PK
rates I-PK
, O
and O
surface O
per O
##me O
##abi O
##lities O
, O
are O
provided O
within O
the O
software O
. O
7 O
absorption O
, O
distribution O
, O
metabolism O
, O
and O
ex O
##cre O
##tion O
‐ O
relevant O
proteins O
reported O
to O
govern O
the O
p O
##k O
of O
a O
drug O
, O
such O
as O
meta O
##bol O
##izing O
enzymes O
, O
transport O
##ers O
, O
or O
binding O
partners O
, O
were O
implemented O
into O
the O
models O
and O
tested O
. O
[SEP] O
[CLS] O
fraction O
##al O
absorbed O
data O
for O
each O
subject O
and O
treatment O
was O
used O
for O
est O
##imation O
of O
the O
apparent B-PK
absorption I-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
. O
[SEP] O
[CLS] O
vascular O
- O
targeting O
p O
##dt O
has O
been O
reported O
to O
induce O
blood B-PK
flow I-PK
imp O
##air O
##ment O
and O
blood O
vessel O
destruction O
, O
resulting O
in O
tissue O
h O
##y O
##pox O
##ia O
, O
nut O
##rient O
de O
##p O
##ri O
##vation O
, O
and O
tumor O
destruction O
[ O
34 O
, O
36 O
, O
37 O
] O
. O
[SEP] O
[CLS] O
o O
##xy O
##co O
##don O
##e O
distribution O
was O
considered O
to O
be O
per O
##fusion O
- O
rate O
limited O
assuming O
that O
the O
diffusion O
through O
cap O
##illa O
##ry O
membrane O
occurs O
very O
quickly O
and O
the O
rate O
- O
limiting O
factor O
for O
distribution O
into O
tissues O
is O
the O
blood B-PK
flow I-PK
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
of O
each O
of O
these O
compounds O
in O
the O
silk O
##worm O
hem O
##oly O
##mp O
##h O
was O
18 O
, O
26 O
and O
34 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
per O
protocol O
, O
subjects O
were O
categorized O
by O
b O
##w O
and O
b O
##mi O
( O
figure O
##1 O
) O
. O
[SEP] O
[CLS] O
the O
re O
##comb O
##ina O
##nt O
hi O
##rud O
##ins O
in O
the O
plasma O
was O
analyzed O
by O
ch O
##rom O
##ogenic O
substrate O
ass O
##ay O
, O
enzyme O
- O
linked O
im O
##mu O
##nos O
##or O
##bent O
ass O
##ay O
( O
el O
##isa O
) O
, O
total O
radio O
##is O
##oto O
##pe O
ass O
##ay O
( O
r O
##a O
) O
and O
t O
##rich O
##lor O
##oa O
##ce O
##tic O
acid O
pre O
- O
treated O
total O
radio O
##is O
##oto O
##pe O
ass O
##ay O
( O
t O
##ca O
- O
r O
##a O
) O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
re O
##nal O
imp O
##air O
##ment O
impacted O
au B-PK
##c I-PK
, O
c B-PK
##l I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
without O
affecting O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
the O
blood B-PK
flow I-PK
rate I-PK
and O
the O
dial O
##ys O
##ate O
flow O
rate O
were O
400 O
to O
500 O
m O
##l O
/ O
min O
and O
600 O
to O
700 O
m O
##l O
/ O
min O
, O
respectively O
. O
[SEP] O
[CLS] O
for O
subjects O
on O
hem O
##od O
##ial O
##ys O
##is O
, O
cumulative B-PK
amount I-PK
of I-PK
drug I-PK
recovered I-PK
unchanged I-PK
in I-PK
dial I-PK
##ys I-PK
##ate I-PK
( I-PK
a I-PK
##r I-PK
) I-PK
, O
hem B-PK
##od I-PK
##ial I-PK
##ys I-PK
##is I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##h I-PK
##d I-PK
) I-PK
, O
and O
fraction B-PK
of I-PK
the I-PK
total I-PK
body I-PK
pool I-PK
of I-PK
drug I-PK
removed I-PK
by I-PK
hem I-PK
##od I-PK
##ial I-PK
##ys I-PK
##is I-PK
( I-PK
f I-PK
##r I-PK
) I-PK
were O
determined O
. O
10 O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
values O
in O
normal O
, O
mild O
, O
moderate O
, O
severe O
, O
and O
hem O
##od O
##ial O
##ys O
##is O
( O
dos O
##ing O
post O
##hem O
##od O
##ial O
##ys O
##is O
, O
without O
h O
##d O
) O
groups O
were O
2 O
. O
8 O
, O
3 O
. O
0 O
, O
4 O
. O
1 O
, O
6 O
. O
9 O
, O
and O
9 O
. O
6 O
hours O
, O
respectively O
. O
[SEP] O
[CLS] O
geometric O
mean O
( O
c O
##v O
% O
geometric O
mean O
) O
of O
a O
##r O
relative O
to O
c O
##ef O
##ider O
##oc O
##ol O
dose O
was O
56 O
. O
1 O
% O
( O
12 O
. O
2 O
% O
) O
, O
and O
f B-PK
##r I-PK
was O
62 O
. O
3 O
% O
( O
8 O
. O
4 O
% O
) O
, O
suggesting O
that O
intermittent O
h O
##d O
removed O
approximately O
60 O
% O
of O
the O
c O
##ef O
##ider O
##oc O
##ol O
dose O
. O
[SEP] O
[CLS] O
v O
##al O
##p O
##roi O
##c O
acid O
β O
- O
d O
g O
##lu O
##cu O
##ron O
##ide O
( O
v O
##pa O
##g O
) O
was O
purchased O
from O
sa O
##nta O
c O
##ru O
##z O
bio O
##tech O
##nology O
, O
in O
##c O
. O
( O
sa O
##nta O
c O
##ru O
##z O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
it O
was O
in O
the O
order O
of O
0 O
. O
1 O
mm O
/ O
s O
, O
yet O
faster O
than O
molecular O
diffusion O
of O
large O
molecules O
such O
as O
mon O
##oc O
##lon O
##al O
antibodies O
( O
m O
##w O
~ O
150 O
k O
##da O
) O
. O
[SEP] O
[CLS] O
equation O
( O
3 O
) O
describes O
the O
rate O
of O
change O
of O
the O
amount O
of O
me O
##rop O
##ene O
##m O
( O
in O
mill O
##ig O
##rams O
) O
in O
the O
c O
##s O
##f O
compartment O
( O
x O
##3 O
) O
. O
[SEP] O
[CLS] O
an O
important O
assumption O
of O
this O
multiple O
re O
##gression O
analysis O
is O
that O
the O
independent O
variables O
( O
au B-PK
##cs I-PK
) O
are O
not O
correlated O
. O
[SEP] O
[CLS] O
compared O
with O
dos O
##ing O
at O
fast O
##ed O
state O
, O
taking O
my O
##rt O
##ol O
standardized O
capsule O
##s O
after O
a O
meal O
achieve O
##s O
a O
delayed O
absorption B-PK
rate I-PK
and O
an O
increased O
absorption O
extent O
. O
[SEP] O
[CLS] O
spear O
##man O
rank O
test O
was O
used O
to O
assess O
correlation O
between O
al O
##t O
, O
al O
##p O
, O
total O
bi O
##li O
##ru O
##bin O
, O
album O
##in O
, O
and O
half B-PK
‐ I-PK
life I-PK
. O
[SEP] O
[CLS] O
log O
##ari O
##th O
##mic O
transformation O
of O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
, O
and O
cm B-PK
##ax I-PK
were O
compared O
by O
the O
analysis O
of O
variance O
( O
an O
##ova O
) O
for O
a O
crossover O
design O
followed O
by O
90 O
% O
confidence O
interval O
test O
for O
the O
arithmetic O
mean O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
c O
##tz O
formulation O
##s O
. O
[SEP] O
[CLS] O
similarly O
, O
the O
equation O
for O
i O
##rre O
##versible O
in O
##hibition O
is O
: O
( O
2 O
) O
au O
##c O
′ O
au O
##c O
= O
f O
##gi O
##f O
##g O
##× O
##1 O
##f O
##m O
##cy O
##pi O
##1 O
+ O
kin O
##act O
##× O
##i O
/ O
k O
##de O
##g O
##× O
##ka O
##pp O
+ O
i O
+ O
1 O
##− O
##f O
##m O
##cy O
##pi O
##with O
kin O
##act O
as O
the O
ma O
##ximal O
in O
##act O
##ivation O
rate O
constant O
, O
ka B-PK
##pp I-PK
the O
inhibitor O
concentration O
at O
50 O
% O
of O
kin B-PK
##act I-PK
, O
and O
k B-PK
##de I-PK
##g I-PK
the O
end O
##ogen O
##ous O
degradation B-PK
rate I-PK
constant I-PK
of O
the O
c O
##y O
##p O
enzyme O
. O
[SEP] O
[CLS] O
assuming O
a O
5 O
‐ O
fold O
accumulation O
of O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
in O
he O
##pa O
##to O
##cy O
##tes O
, O
the O
au B-PK
##c I-PK
ratio I-PK
was O
1 O
. O
14 O
( O
1 O
. O
12 O
; O
1 O
. O
17 O
) O
, O
again O
below O
the O
threshold O
of O
1 O
. O
25 O
. O
[SEP] O
[CLS] O
during O
follow O
- O
up O
, O
the O
child O
will O
have O
several O
cap O
##illa O
##ry O
blood O
collections O
that O
are O
not O
performed O
routinely O
, O
although O
the O
total O
blood O
volume O
sampled O
will O
be O
limited O
to O
under O
10 O
m O
##l O
so O
is O
not O
associated O
with O
a O
particular O
risk O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
lives I-PK
of O
compound O
a O
, O
b O
, O
and O
c O
at O
the O
second O
stage O
were O
estimated O
to O
be O
18 O
, O
26 O
, O
and O
34 O
h O
##rs O
, O
respectively O
( O
figure O
4 O
) O
. O
[SEP] O
[CLS] O
q O
##uad O
##rup O
##ole O
##s O
q O
##1 O
and O
q O
##3 O
were O
set O
on O
unit O
resolution O
. O
[SEP] O
[CLS] O
recover O
##ies O
of O
at O
##or O
##vas O
##tat O
##in O
, O
met O
##form O
##in O
, O
g O
##lim O
##ep O
##iri O
##de O
and O
is O
were O
determined O
by O
comparing O
the O
peak O
area O
of O
extracted O
anal O
##yte O
standard O
with O
the O
peak O
area O
of O
non O
- O
extracted O
standard O
. O
[SEP] O
[CLS] O
after O
s O
. O
c O
. O
administration O
of O
100 O
mg O
an O
##aki O
##n O
##ra O
, O
the O
mean O
cm B-PK
##ax I-PK
value O
was O
46 O
% O
lower O
and O
the O
mean O
au B-PK
##c I-PK
value O
was O
33 O
% O
lower O
for O
subjects O
with O
b O
##w O
≥ O
100 O
kg O
than O
for O
subjects O
with O
b O
##w O
≤ O
90 O
kg O
. O
[SEP] O
[CLS] O
internal O
standard O
( O
13 O
##c O
##6 O
- O
d O
##c O
##f O
) O
was O
added O
to O
25 O
µ O
##l O
co O
##culture O
medium O
to O
give O
a O
final O
concentration O
of O
20 O
μ O
##m O
d O
##c O
##f O
when O
at O
50 O
– O
100 O
##× O
cm B-PK
##ax I-PK
( O
4 O
. O
4 O
µ O
##m O
was O
cm B-PK
##ax I-PK
for O
our O
study O
) O
, O
and O
2 O
μ O
##m O
with O
d O
##c O
##f O
at O
1 O
##× O
cm B-PK
##ax I-PK
of O
d O
##5 O
- O
g O
##ca O
( O
0 O
. O
5 O
– O
1 O
μ O
##m O
) O
was O
added O
as O
an O
internal O
standard O
prior O
to O
sample O
extraction O
for O
bi O
##le O
acid O
measurements O
. O
[SEP] O
[CLS] O
standard O
series O
of O
various O
concentrations O
were O
prepared O
with O
standard O
working O
solution O
, O
and O
the O
standard O
concentrations O
ranged O
from O
0 O
. O
1 O
to O
1000 O
ng O
/ O
m O
##l O
. O
the O
peak O
area O
was O
measured O
under O
the O
same O
condition O
as O
the O
tested O
blood O
sample O
. O
[SEP] O
[CLS] O
simulation O
##s O
of O
the O
time O
course O
of O
c O
##d O
##19 O
+ O
l O
##ymph O
##ocytes O
for O
the O
4 O
dose O
regime O
##ns O
are O
shown O
in O
figure O
4 O
, O
where O
a O
single O
in O
##fusion O
of O
375 O
mg O
/ O
m O
##2 O
produced O
mostly O
identical O
effect O
on O
c O
##d O
##19 O
+ O
l O
##ymph O
##oc O
##yte O
suppression O
within O
10 O
weeks O
and O
the O
effect O
remained O
similar O
after O
6 O
months O
, O
in O
comparison O
to O
the O
highest O
suppression O
achieved O
by O
4 O
weekly O
375 O
mg O
/ O
m O
##2 O
in O
##fusion O
##s O
( O
6 O
. O
2 O
% O
vs O
3 O
. O
3 O
% O
of O
base O
##line O
c O
##d O
##19 O
+ O
l O
##ymph O
##oc O
##yte O
counts O
after O
6 O
months O
) O
. O
[SEP] O
[CLS] O
d O
##na O
was O
analyzed O
by O
drop O
##let O
digital O
polymer O
##ase O
chain O
reaction O
( O
d O
##d O
##p O
##c O
##r O
; O
bio O
##rad O
, O
mountain O
view O
, O
ca O
) O
for O
copy O
number O
am O
##p O
##lification O
##s O
at O
the O
following O
12 O
g O
##eni O
##c O
lo O
##ci O
: O
b O
##c O
##l O
##2 O
, O
cc O
##nd O
##1 O
, O
c O
##d O
##k O
##4 O
, O
e O
##g O
##f O
##r O
, O
er O
##bb O
##2 O
, O
f O
##g O
##f O
##r O
##1 O
, O
f O
##g O
##f O
##r O
##2 O
, O
f O
##g O
##f O
##r O
##3 O
, O
f O
##g O
##f O
##r O
##4 O
, O
met O
, O
p O
##d O
##g O
##fra O
, O
and O
p O
##ik O
##3 O
##ca O
. O
[SEP] O
[CLS] O
subjects O
( O
n O
= O
119 O
##6 O
) O
, O
at O
least O
40 O
years O
old O
, O
were O
current O
or O
ex O
- O
smoke O
##rs O
random O
##ized O
to O
twice O
- O
daily O
inhaled O
m O
##f O
/ O
f O
400 O
/ O
10 O
μ O
##g O
, O
m O
##f O
/ O
f O
200 O
/ O
10 O
μ O
##g O
, O
m O
##f O
400 O
μ O
##g O
, O
f O
10 O
μ O
##g O
, O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
the O
effect O
of O
hem O
##od O
##ial O
##ys O
##is O
on O
the O
clearance B-PK
of O
c O
##ef O
##ider O
##oc O
##ol O
was O
also O
assessed O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
elimination I-PK
half I-PK
‐ I-PK
life I-PK
of O
c O
##ef O
##ider O
##oc O
##ol O
was O
1 O
. O
98 O
to O
2 O
. O
74 O
hours O
in O
these O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
the O
composite O
samples O
were O
prepared O
by O
treating O
each O
matrix O
( O
plasma O
, O
urine O
, O
and O
dial O
##ys O
##ate O
) O
with O
a O
buffer O
( O
0 O
. O
2 O
m O
##ol O
/ O
l O
am O
##mon O
##ium O
ace O
##tate O
, O
p O
##h O
5 O
) O
in O
1 O
: O
1 O
volume O
ratio O
and O
used O
for O
measurement O
of O
c O
##ef O
##ider O
##oc O
##ol O
concentrations O
. O
[SEP] O
[CLS] O
the O
total O
volume O
of O
the O
c O
##s O
##f O
in O
humans O
is O
170 O
m O
##l O
on O
average O
, O
of O
which O
approximately O
33 O
% O
is O
found O
in O
##tra O
##c O
##rani O
##ally O
within O
the O
brain O
vent O
##ric O
##les O
[ O
14 O
] O
. O
[SEP] O
[CLS] O
since O
the O
c O
##rani O
##um O
is O
nearly O
rigid O
, O
the O
pu O
##ls O
##ation O
in O
blood B-PK
flow I-PK
must O
be O
accounted O
for O
. O
[SEP] O
[CLS] O
this O
q O
##sp O
model O
adequately O
captured O
the O
observed O
plasma O
and O
liver O
bio O
##mark O
##er O
behavior O
across O
a O
range O
of O
doses O
and O
dose O
regime O
##ns O
in O
gun O
##n O
rats O
. O
[SEP] O
[CLS] O
in O
a O
subsequent O
study O
( O
data O
not O
shown O
) O
similar O
behavior O
was O
observed O
in O
a O
larger O
set O
of O
animals O
that O
was O
seen O
to O
be O
an O
age O
effect O
, O
and O
part O
of O
the O
natural O
history O
of O
gun O
##n O
rats O
. O
[SEP] O
[CLS] O
on O
day O
22 O
, O
inter O
- O
subject O
var O
##iability O
for O
p O
##f O
- O
06 O
##64 O
##9 O
##75 O
##1 O
exposure O
, O
based O
on O
geometric O
% O
c O
##v O
, O
ranged O
from O
35 O
% O
to O
61 O
% O
for O
au B-PK
##ct I-PK
##au I-PK
and O
26 O
% O
to O
46 O
% O
for O
cm B-PK
##ax I-PK
across O
all O
co O
##hor O
##ts O
. O
[SEP] O
[CLS] O
supplement O
##ary O
material O
1 O
( O
p O
##d O
##f O
90 O
##7 O
k O
##b O
) O
[SEP] O
[CLS] O
a O
micro O
##scopic O
examination O
including O
r O
##b O
##c O
, O
w O
##b O
##c O
, O
proteins O
, O
and O
casts O
was O
performed O
only O
when O
dip O
##stick O
evaluation O
was O
positive O
for O
w O
##b O
##c O
, O
or O
proteins O
, O
or O
blood O
. O
[SEP] O
[CLS] O
the O
following O
cell O
lines O
( O
at O
##cc O
, O
except O
where O
noted O
) O
were O
grown O
in O
culture O
medium O
supplemented O
with O
10 O
% O
heat O
- O
inactivated O
f O
##etal O
b O
##ov O
##ine O
serum O
( O
f O
##bs O
, O
g O
##ib O
##co O
) O
, O
100 O
units O
/ O
m O
##l O
pen O
##ici O
##llin O
, O
100 O
μ O
##g O
/ O
m O
##l O
s O
##tre O
##pt O
##omy O
##cin O
( O
g O
##ib O
##co O
) O
, O
and O
1 O
##x O
g O
##lut O
##ama O
##x O
( O
g O
##ib O
##co O
) O
( O
except O
where O
noted O
) O
, O
and O
maintained O
in O
a O
humid O
##ified O
in O
##cu O
##bat O
##or O
at O
37 O
##° O
##c O
in O
5 O
% O
co O
##2 O
; O
re O
##v O
- O
g O
##f O
##p O
u O
##2 O
##os O
[ O
m O
##cco O
##y O
' O
s O
5 O
##a O
, O
200 O
u O
##g O
/ O
m O
##l O
g O
##41 O
##8 O
( O
si O
##gma O
) O
] O
, O
mm O
. O
1 O
##s O
( O
rpm O
##i O
) O
, O
m O
##v O
- O
4 O
– O
11 O
( O
im O
##d O
##m O
) O
, O
th O
##p O
- O
1 O
( O
rpm O
##i O
) O
, O
h O
##ct O
- O
116 O
( O
m O
##cco O
##y O
' O
s O
5 O
##a O
) O
, O
am O
##l O
##2 O
( O
d O
##sm O
##z O
, O
rpm O
##i O
) O
, O
am O
##l O
##3 O
( O
d O
##sm O
##z O
, O
rpm O
##i O
) O
, O
h O
##t O
##10 O
##80 O
( O
em O
##em O
) O
, O
he O
##l O
( O
d O
##sm O
##z O
, O
rpm O
##i O
) O
, O
ka O
##su O
##mi O
- O
6 O
( O
rpm O
##i O
, O
2 O
mm O
l O
- O
g O
##lut O
##amine O
, O
1 O
. O
5 O
##g O
/ O
l O
sodium O
bio O
##car O
##bon O
##ate O
, O
4 O
. O
5 O
g O
/ O
l O
glucose O
, O
10 O
mm O
he O
##pes O
, O
1 O
. O
0 O
mm O
sodium O
p O
##yr O
##u O
##vate O
, O
2 O
ng O
/ O
m O
##l O
g O
##m O
- O
c O
##s O
##f O
, O
20 O
% O
f O
##bs O
) O
, O
sin O
##e O
compound O
resistant O
h O
##t O
##10 O
##80 O
( O
em O
##em O
, O
600 O
nm O
k O
##pt O
- O
185 O
) O
, O
a O
##5 O
##4 O
##9 O
( O
rpm O
##i O
) O
, O
u O
##ch O
##1 O
( O
4 O
: O
1 O
im O
##d O
##m O
: O
rpm O
##i O
) O
, O
u O
##ch O
##2 O
( O
4 O
: O
1 O
im O
##d O
##m O
: O
rpm O
##i O
) O
, O
l O
##s O
##17 O
##4 O
##t O
( O
em O
##em O
) O
, O
and O
as O
##ps O
- O
k O
##y O
( O
gifted O
from O
a O
. O
og O
##ose O
, O
rpm O
##i O
) O
. O
[SEP] O
[CLS] O
el O
##uate O
##s O
and O
inputs O
were O
analyzed O
using O
a O
cap O
##illa O
##ry O
western O
method O
( O
p O
##eg O
##gy O
sue O
; O
protein O
simple O
) O
with O
the O
following O
primary O
antibodies O
: O
x O
##po O
##1 O
( O
sa O
##nta O
c O
##ru O
##z O
) O
and O
β O
- O
act O
##in O
( O
sa O
##nta O
c O
##ru O
##z O
) O
. O
[SEP] O
[CLS] O
we O
set O
slope O
= O
0 O
for O
subjects O
without O
ha O
##em O
##od O
##ial O
##ys O
##is O
or O
after O
volume O
recovery O
following O
ha O
##em O
##od O
##ial O
##ys O
##is O
; O
slope O
= O
vs O
##lop O
##e O
in O
subjects O
during O
ha O
##em O
##od O
##ial O
##ys O
##is O
and O
slope O
= O
− O
##v O
##s O
##lop O
##eu O
##p O
in O
subjects O
3 O
h O
after O
ha O
##em O
##od O
##ial O
##ys O
##is O
, O
respectively O
. O
[SEP] O
[CLS] O
we O
illustrated O
this O
approach O
using O
a O
published O
human O
p O
##b O
##p O
##k O
model O
for O
ace O
##tam O
##ino O
##phe O
##n O
( O
a O
##pa O
##p O
) O
and O
its O
two O
primary O
meta O
##bol O
##ites O
a O
##pa O
##p O
- O
g O
##lu O
##cu O
##ron O
##ide O
and O
a O
##pa O
##p O
- O
su O
##lf O
##ate O
. O
[SEP] O
[CLS] O
the O
pure O
fraction O
##s O
of O
compound O
f O
were O
pool O
##ed O
and O
the O
solvent O
was O
e O
##va O
##porated O
under O
reduced O
pressure O
. O
[SEP] O
[CLS] O
compound O
f O
was O
dissolved O
in O
met O
##han O
##ol O
at O
a O
concentration O
of O
5 O
µ O
##g O
/ O
m O
##l O
and O
scanned O
for O
its O
flu O
##ores O
##cence O
spectrum O
from O
300 O
to O
900 O
nm O
in O
a O
flu O
##ores O
##cence O
s O
##pect O
##rop O
##hot O
##ometer O
( O
f O
- O
460 O
##0 O
, O
hit O
##achi O
high O
- O
technologies O
corporation O
, O
j O
##apa O
##n O
) O
to O
get O
its O
maximum O
flu O
##ores O
##cence O
ex O
##citation O
and O
absorption O
wavelength O
. O
[SEP] O
[CLS] O
twenty O
mill O
##ig O
##ram O
of O
compound O
f O
was O
dissolved O
in O
4 O
m O
##l O
water O
. O
[SEP] O
[CLS] O
solutions O
of O
compound O
f O
( O
5 O
. O
0 O
mg O
/ O
m O
##l O
) O
and O
camp O
##to O
##the O
##cin O
with O
a O
final O
concentration O
of O
1 O
. O
0 O
µ O
##g O
/ O
m O
##l O
as O
an O
internal O
standard O
were O
added O
to O
5 O
m O
##l O
human O
serum O
to O
give O
a O
final O
concentration O
of O
0 O
. O
5 O
mg O
/ O
m O
##l O
and O
in O
##cu O
##bate O
##d O
at O
37 O
##° O
##c O
. O
[SEP] O
[CLS] O
after O
entering O
tumor O
cells O
, O
the O
h O
##yd O
##raz O
##one O
bond O
in O
compound O
f O
is O
to O
r O
##up O
##ture O
to O
generate O
compound O
b O
and O
play O
efficacy O
so O
the O
release O
of O
compound O
b O
is O
important O
. O
[SEP] O
[CLS] O
the O
results O
showed O
that O
compound O
f O
had O
the O
strongest O
c O
##yt O
##oto O
##xi O
##city O
for O
the O
three O
cell O
lines O
. O
[SEP] O
[CLS] O
the O
concentrations O
of O
compound O
f O
in O
the O
plasma O
and O
tissues O
of O
heart O
, O
liver O
, O
s O
##ple O
##en O
, O
lung O
, O
kidney O
, O
brain O
, O
and O
tumor O
were O
measured O
after O
in O
##tra O
##ven O
##ous O
injection O
of O
compound O
f O
solution O
. O
[SEP] O
[CLS] O
it O
is O
suggested O
that O
compound O
f O
could O
c O
##ir O
##culate O
for O
a O
much O
longer O
time O
in O
the O
blood O
circulation O
system O
than O
10 O
- O
h O
##c O
##pt O
solution O
, O
which O
would O
result O
in O
their O
higher O
affinity O
to O
the O
tumor O
cells O
or O
extra O
##cellular O
spaces O
. O
[SEP] O
[CLS] O
k B-PK
is O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
[SEP] O
[CLS] O
significant O
differences O
were O
observed O
for O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( O
p O
= O
0 O
. O
01 O
##25 O
) O
, O
and O
total B-PK
body I-PK
clearance I-PK
( O
p O
= O
0 O
. O
02 O
##01 O
) O
in O
a O
##f O
##rica O
##ns O
and O
chin O
##ese O
. O
[SEP] O
[CLS] O
the O
relationship O
of O
gut O
micro O
##bio O
##ta O
with O
the O
p O
##k O
was O
plot O
##ted O
in O
a O
network O
by O
co O
##rrel O
##ating O
the O
bacterial O
o O
##tus O
with O
the O
au B-PK
##cs I-PK
of O
be O
##rber O
##ine O
in O
participants O
. O
[SEP] O
[CLS] O
non O
##com O
##par O
##tment O
##al O
analysis O
was O
applied O
to O
obtain O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
using O
the O
win O
##non O
##lin O
##® O
software O
, O
version O
2 O
. O
0 O
( O
p O
##har O
##sight O
co O
##rp O
. O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
the O
study O
was O
prospective O
##ly O
registered O
with O
the O
au O
##stra O
##lian O
drug O
regulatory O
authority O
, O
the O
therapeutic O
goods O
administration O
( O
t O
##ga O
) O
, O
clinical O
trial O
not O
##ification O
( O
c O
##t O
- O
2015 O
- O
c O
##t O
##n O
- O
03 O
##23 O
##7 O
- O
1 O
v O
##2 O
) O
in O
compliance O
with O
the O
requirements O
of O
the O
human O
ethics O
committee O
and O
retrospective O
##ly O
with O
the O
au O
##stra O
##lian O
new O
z O
##eal O
##and O
clinical O
trials O
registry O
( O
trial O
id O
: O
act O
##rn O
##12 O
##6 O
##16 O
##00 O
##16 O
##6 O
##64 O
##15 O
) O
. O
[SEP] O
[CLS] O
this O
physiological O
absorption O
model O
accounts O
for O
p O
##h O
, O
transit O
time O
, O
lengths O
and O
r O
##adi O
##i O
of O
each O
gas O
##tro O
##int O
##est O
##inal O
compartment O
, O
plasma O
protein O
binding O
, O
stomach O
volume O
, O
he B-PK
##pa I-PK
##tic I-PK
blood I-PK
flow I-PK
rate I-PK
, O
and O
gut O
enzyme O
and O
transport O
##er O
distribution O
. O
[SEP] O
[CLS] O
the O
second O
peak O
, O
which O
occurred O
at O
around O
9 O
h O
, O
was O
depicted O
by O
a O
combination O
of O
varying O
transit B-PK
constant I-PK
( I-PK
ka I-PK
##t I-PK
; O
0 O
. O
53 O
##2 O
– O
1 O
. O
25 O
h O
- O
1 O
) O
and O
absorption B-PK
rate I-PK
constant I-PK
from I-PK
the I-PK
g I-PK
##7 I-PK
compartment I-PK
( I-PK
ka I-PK
##2 I-PK
; O
0 O
. O
92 O
##9 O
– O
0 O
. O
08 O
##9 O
##8 O
h O
- O
1 O
) O
at O
different O
doses O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
in O
mice O
, O
plasma O
concentrations O
reached O
the O
peak O
at O
2 O
h O
after O
oral O
administration O
and O
declined O
in O
parallel O
with O
the O
terminal B-PK
slope I-PK
of O
the O
i O
##v O
profile O
, O
with O
elimination B-PK
half I-PK
- I-PK
lives I-PK
of O
7 O
– O
11 O
h O
. O
[SEP] O
[CLS] O
for O
both O
parts O
of O
this O
study O
, O
di O
##c O
##lo O
##xa O
##ci O
##llin O
sodium O
capsule O
##s O
( O
0 O
. O
25 O
g O
per O
capsule O
; O
lot O
91 O
##30 O
##5 O
##7 O
##4 O
) O
were O
supplied O
by O
bright O
future O
pharmaceutical O
##s O
factory O
( O
y O
##uen O
long O
, O
n O
. O
t O
. O
, O
ho O
##ng O
k O
##ong O
) O
. O
[SEP] O
[CLS] O
for O
multiple O
- O
dose O
study O
, O
the O
time B-PK
to I-PK
reach I-PK
peak I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
and O
maximum B-PK
and O
minimum B-PK
plasma I-PK
concentration I-PK
at I-PK
the I-PK
steady I-PK
state I-PK
( O
cm B-PK
##ax I-PK
, I-PK
s I-PK
##s I-PK
and O
cm B-PK
##in I-PK
, I-PK
s I-PK
##s I-PK
) O
were O
determined O
directly O
from O
experimental O
observations O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
values O
were O
26 O
. O
58 O
± O
18 O
. O
84 O
, O
26 O
. O
48 O
± O
18 O
. O
77 O
, O
and O
23 O
. O
94 O
± O
16 O
. O
97 O
, O
and O
t O
> O
mi O
##cs O
were O
42 O
. O
80 O
± O
1 O
. O
01 O
, O
36 O
. O
40 O
± O
1 O
. O
24 O
, O
and O
38 O
. O
60 O
± O
1 O
. O
18 O
h O
, O
after O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
p O
. O
o O
. O
administration O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
were O
analyzed O
by O
win O
##non O
##lin O
6 O
. O
1 O
software O
( O
p O
##har O
##sight O
corporation O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
cultures O
( O
20 O
μ O
##l O
) O
from O
all O
micro O
##well O
##s O
in O
96 O
- O
well O
plates O
that O
showed O
no O
visible O
growth O
were O
spotted O
on O
try O
##ptic O
so O
##y O
a O
##gar O
( O
t O
##sa O
) O
plates O
and O
in O
##cu O
##bate O
##d O
for O
24 O
h O
at O
35 O
##° O
##c O
. O
[SEP] O
[CLS] O
each O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
predominantly O
formed O
mon O
##omer O
##s O
, O
which O
correspond O
##ed O
to O
the O
functional O
s O
##c O
##d O
##b O
- O
f O
##c O
fraction O
( O
[UNK] O
k O
##da O
) O
; O
however O
, O
small O
amounts O
of O
multi O
##mer O
##ic O
forms O
also O
appeared O
on O
the O
ch O
##roma O
##to O
##graphs O
( O
fi O
##g O
. O
1 O
##c O
) O
. O
[SEP] O
[CLS] O
l O
##ymph O
##oki O
##ne O
- O
activated O
killer O
cells O
with O
the O
t O
- O
cell O
p O
##hen O
##otype O
( O
t O
- O
la O
##k O
) O
were O
induced O
as O
previously O
described O
. O
34 O
in O
brief O
, O
p O
##b O
##m O
##c O
were O
culture O
##d O
for O
48 O
h O
at O
a O
density O
of O
1 O
× O
106 O
cells O
/ O
m O
##l O
in O
medium O
supplemented O
with O
100 O
i O
##u O
/ O
m O
##l O
of O
re O
##comb O
##ina O
##nt O
human O
il O
- O
2 O
( O
s O
##hi O
##ono O
##gi O
pharmaceutical O
co O
. O
, O
o O
##sa O
##ka O
, O
j O
##apa O
##n O
) O
in O
a O
culture O
fl O
##ask O
( O
a O
/ O
s O
nun O
##c O
, O
r O
##os O
##ki O
##lde O
, O
den O
##mark O
) O
that O
was O
pre O
##coat O
##ed O
with O
anti O
- O
c O
##d O
##3 O
mon O
##oc O
##lon O
##al O
anti O
##body O
( O
10 O
μ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
effect O
of O
c O
##v O
##v O
##h O
was O
assessed O
on O
v B-PK
##1 I-PK
( O
di O
##cho O
##tom O
##ous O
co O
##var O
##iate O
) O
. O
[SEP] O
[CLS] O
the O
sofa O
score O
was O
divided O
into O
a O
low O
score O
( O
< O
10 O
) O
and O
a O
high O
score O
( O
> O
10 O
) O
based O
on O
associated O
mortality O
risks O
[ O
20 O
, O
21 O
] O
and O
was O
assessed O
as O
a O
cat O
##ego O
##rical O
co O
##var O
##iate O
on O
c B-PK
##l I-PK
and O
v B-PK
. O
[SEP] O
[CLS] O
ii O
##v O
on O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
further O
improved O
the O
model O
while O
data O
did O
not O
support O
the O
addition O
of O
ii O
##v O
on O
q B-PK
or O
v B-PK
##2 I-PK
. O
[SEP] O
[CLS] O
allowing O
a O
correlation O
between O
ii O
##v O
of O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
further O
improved O
the O
model O
( O
difference O
of O
##v O
= O
13 O
. O
98 O
) O
. O
[SEP] O
[CLS] O
c B-PK
##l I-PK
, O
v B-PK
##1 I-PK
, O
q B-PK
and O
v B-PK
##2 I-PK
were O
estimated O
to O
be O
1 O
. O
10 O
l O
/ O
h O
, O
17 O
. O
6 O
l O
, O
0 O
. O
36 O
##3 O
l O
/ O
h O
and O
3 O
. O
63 O
l O
. O
the O
ii O
##v O
on O
c B-PK
##l I-PK
and O
v B-PK
##1 I-PK
were O
estimated O
to O
be O
40 O
and O
73 O
% O
c O
##v O
with O
et O
##a O
shrink O
##age O
of O
1 O
. O
2 O
and O
41 O
% O
, O
respectively O
, O
while O
i O
##ov O
on O
v B-PK
##1 I-PK
was O
estimated O
to O
be O
37 O
% O
c O
##v O
. O
[SEP] O
[CLS] O
no O
co O
##var O
##iate O
##s O
were O
identified O
to O
significantly O
affect O
c B-PK
##l I-PK
or O
v B-PK
##1 I-PK
. O
[SEP] O
[CLS] O
from O
the O
plasma O
profile O
, O
it O
was O
shown O
that O
the O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
values O
for O
b O
##ud O
suspension O
##s O
and O
b O
##ud O
micro O
##sp O
##here O
##s O
were O
8 O
. O
41 O
and O
4 O
. O
57 O
μ O
##g O
/ O
m O
##l O
, O
respectively O
, O
and O
the O
time B-PK
to I-PK
reach I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
values O
were O
1 O
and O
6 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
was O
6 O
h O
for O
b O
##ud O
micro O
##sp O
##here O
##s O
, O
while O
it O
was O
1 O
h O
for O
b O
##ud O
suspension O
##s O
. O
[SEP] O
[CLS] O
extra B-PK
##pol I-PK
##ation I-PK
to I-PK
infinite I-PK
time I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
was O
calculated O
as O
follows O
: O
au O
##c O
##0 O
– O
∞ O
= O
au O
##c O
##0 O
– O
t O
+ O
c O
##t O
/ O
k O
##e O
, O
where O
c O
##t O
is O
the O
last O
me O
##as O
##urable O
plasma O
concentration O
and O
k B-PK
##e I-PK
is O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
determined O
by O
linear O
re O
##gression O
of O
the O
terminal O
portion O
of O
the O
plasma O
concentration O
- O
time O
data O
. O
[SEP] O
[CLS] O
radio B-PK
##act I-PK
##ivity I-PK
was O
detected O
and O
q O
##uant O
##itated O
using O
a O
pack O
##ard O
fl O
##o O
- O
one O
/ O
beta O
radio O
##matic O
detector O
a O
##500 O
or O
a O
##25 O
##0 O
with O
a O
0 O
. O
5 O
m O
##l O
flow O
cell O
, O
a O
y O
##ts O
##i O
solid O
cell O
, O
or O
by O
collecting O
1 O
minute O
fraction O
##s O
. O
[SEP] O
[CLS] O
extract O
##s O
from O
individual O
and O
pool O
##ed O
samples O
were O
applied O
to O
thin O
layer O
ch O
##roma O
##tography O
( O
t O
##l O
##c O
) O
plates O
and O
el O
##uted O
with O
a O
solvent O
consisting O
of O
di O
##ch O
##lor O
##ome O
##than O
##e O
, O
met O
##han O
##ol O
, O
and O
concentrated O
am O
##monia O
solution O
in O
a O
volume O
ratio O
of O
74 O
: O
25 O
: O
1 O
. O
[SEP] O
[CLS] O
radio O
##la O
##bel O
##ed O
components O
were O
visual O
##ized O
by O
placing O
the O
t O
##l O
##c O
plates O
in O
contact O
with O
a O
b O
##as O
##20 O
##00 O
p O
##hos O
##ph O
##oi O
##maging O
plate O
( O
f O
##u O
##ji O
photo O
film O
co O
l O
##t O
##d O
, O
j O
##apa O
##n O
) O
, O
and O
the O
exposed O
plates O
were O
read O
with O
a O
f O
##u O
##ji O
##x O
b O
##as O
##20 O
##00 O
bio O
- O
imaging O
analyze O
##r O
( O
f O
##u O
##ji O
photo O
film O
co O
l O
##t O
##d O
, O
j O
##apa O
##n O
) O
. O
[SEP] O
[CLS] O
after O
cent O
##ri O
##fu O
##gation O
to O
remove O
part O
##iculate O
matter O
, O
25 O
to O
50 O
μ O
##l O
al O
##iq O
##uo O
##ts O
of O
urine O
were O
applied O
to O
commercially O
prepared O
0 O
. O
25 O
mm O
thick O
si O
##lica O
gel O
t O
##l O
##c O
plates O
with O
a O
60 O
f O
##25 O
##4 O
coating O
( O
e O
. O
me O
##rc O
##k O
a O
##g O
, O
da O
##rms O
##tadt O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
all O
h O
##ydro O
##ly O
##zed O
samples O
were O
subsequently O
profile O
##d O
by O
t O
##l O
##c O
. O
[SEP] O
[CLS] O
samples O
were O
prepared O
by O
scraping O
the O
relevant O
regions O
of O
the O
t O
##l O
##c O
plates O
followed O
by O
extraction O
with O
met O
##han O
##ol O
and O
e O
##va O
##por O
##ation O
to O
dry O
##ness O
prior O
to O
trim O
##eth O
##yl O
##si O
##ly O
##l O
der O
##iva O
##ti O
##zation O
. O
[SEP] O
[CLS] O
the O
proportions O
of O
radioactive O
components O
recovered O
in O
urine O
, O
expressed O
as O
the O
percentage O
of O
administered O
dose O
, O
were O
generally O
in O
good O
agreement O
between O
t O
##l O
##c O
and O
hp O
##l O
##c O
( O
figure O
5 O
) O
, O
and O
indicated O
the O
presence O
of O
three O
major O
radioactive O
components O
( O
m O
##1 O
, O
m O
##2 O
, O
and O
m O
##3 O
) O
. O
[SEP] O
[CLS] O
on O
t O
##l O
##c O
, O
components O
m O
##1 O
, O
m O
##2 O
, O
and O
m O
##3 O
el O
##uted O
with O
respective O
r O
##f O
values O
of O
0 O
. O
41 O
, O
0 O
. O
57 O
, O
and O
0 O
. O
63 O
to O
0 O
. O
81 O
. O
[SEP] O
[CLS] O
for O
each O
study O
, O
p O
##k O
parameters O
were O
calculated O
from O
the O
plasma O
concentration O
- O
time O
data O
using O
non O
##com O
##par O
##tment O
##al O
methods O
. O
22 O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
included O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
time I-PK
of I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
##− I-PK
##t I-PK
) I-PK
calculated O
using O
the O
linear O
trap O
##ez O
##oid O
##al O
rule O
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
##− I-PK
##∞ I-PK
) I-PK
calculated O
using O
the O
linear O
trap O
##ez O
##oid O
##al O
rule O
of O
sum O
##mation O
and O
extra O
##pol O
##ated O
to O
in O
##finity O
, O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
top O
##ira O
##mate O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
increased O
with O
ascending O
doses O
of O
us O
##l O
##25 O
##5 O
. O
[SEP] O
[CLS] O
the O
median O
t B-PK
##max I-PK
for O
us O
##l O
##25 O
##5 O
dos O
##ing O
groups O
ranged O
from O
16 O
to O
23 O
h O
. O
[SEP] O
[CLS] O
for O
participants O
who O
received O
at O
least O
three O
doses O
of O
us O
##l O
##25 O
##5 O
in O
study O
1 O
, O
in O
##tras O
##ub O
##ject O
% O
c O
##v O
of O
dose O
- O
normal O
##ized O
mean O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##∞ I-PK
, O
and O
cm B-PK
##ax I-PK
values O
were O
less O
than O
14 O
% O
( O
% O
c O
##v O
: O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##t I-PK
, O
10 O
. O
8 O
% O
; O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##∞ I-PK
, O
8 O
. O
2 O
% O
; O
cm B-PK
##ax I-PK
, O
13 O
. O
2 O
% O
) O
. O
[SEP] O
[CLS] O
both O
visual O
( O
parameter O
vs O
co O
##var O
##iate O
s O
##cat O
##ter O
plots O
) O
and O
numerical O
( O
generalized O
add O
##itive O
model O
in O
x O
##pose O
, O
version O
4 O
. O
0 O
. O
4 O
) O
co O
##var O
##iate O
screening O
procedures O
were O
performed O
before O
adding O
each O
co O
##var O
##iate O
to O
the O
basic O
model O
. O
[SEP] O
[CLS] O
the O
distribution O
pattern O
of O
c O
##w O
##res O
at O
individual O
t B-PK
##max I-PK
also O
showed O
the O
out O
##per O
##form O
##ance O
of O
the O
transit O
compartment O
model O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
changes O
caused O
by O
meals O
were O
not O
considered O
in O
the O
model O
because O
the O
changes O
were O
not O
acknowledged O
in O
the O
statistical O
tests O
of O
linear O
- O
trap O
##ez O
##oid O
##al O
area B-PK
under I-PK
the I-PK
curves I-PK
( I-PK
au I-PK
##cs I-PK
; O
not O
shown O
in O
this O
report O
) O
. O
[SEP] O
[CLS] O
e O
is O
the O
m O
##olar O
a O
##bs O
##or O
##pt O
##ivity O
value O
of O
o O
##xy O
##hem O
##og O
##lo O
##bin O
at O
415 O
nm O
, O
and O
1 O
. O
65 O
##5 O
is O
the O
correction O
factor O
accounting O
for O
plasma O
t O
##ur O
##bid O
##ity O
. O
% O
hem O
##oly O
##sis O
= O
plasma O
h O
##b O
value O
of O
sample O
##to O
##tal O
h O
##b O
value O
of O
blood O
##× O
##100 O
( O
7 O
) O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
and O
c B-PK
##l I-PK
values O
changed O
minimal O
##ly O
throughout O
the O
two O
modes O
of O
in O
##tra O
##ven O
##ous O
administration O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
of O
pulmonary O
administration O
were O
significantly O
higher O
than O
those O
of O
combined O
or O
single O
in O
##tra O
##ven O
##ous O
administration O
( O
p O
< O
0 O
. O
05 O
) O
, O
whereas O
the O
c B-PK
##l I-PK
and O
cm B-PK
##ax I-PK
were O
lower O
than O
those O
of O
other O
groups O
. O
[SEP] O
[CLS] O
after O
pulmonary O
administration O
with O
pm O
##s O
, O
the O
postponed O
t B-PK
##max I-PK
demonstrated O
that O
the O
absorption O
of O
p O
##t O
##x O
slowed O
down O
. O
[SEP] O
[CLS] O
results O
showed O
that O
combined O
in O
##tra O
##ven O
##ous O
administration O
and O
pulmonary O
administration O
could O
improve O
the O
p O
##t O
##x O
absorption B-PK
rate I-PK
, O
amount O
, O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
p O
##t O
##x O
was O
significantly O
enhanced O
by O
the O
pulmonary O
administration O
of O
pm O
##s O
. O
[SEP] O
[CLS] O
the O
amount O
and O
time O
are O
used O
to O
calculate O
the O
rate O
( O
rate O
= O
am O
##t O
/ O
time O
##h O
) O
. O
[SEP] O
[CLS] O
n O
##s O
##c O
##23 O
##9 O
##25 O
##b O
concentrations O
declined O
bi O
##ex O
##po O
##nent O
##ially O
after O
the O
t B-PK
##max I-PK
with O
a O
mean O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
of O
8 O
. O
69 O
± O
4 O
. O
18 O
hours O
for O
mice O
and O
9 O
. O
24 O
± O
3 O
. O
77 O
hours O
for O
rats O
. O
[SEP] O
[CLS] O
however O
, O
some O
of O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
ch O
##em O
##oth O
##era O
##pe O
##uti O
##c O
drug O
p O
##ac O
##lit O
##ax O
##el O
, O
such O
as O
v B-PK
##ds I-PK
##s I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
k B-PK
##el I-PK
, O
m B-PK
##rt I-PK
##iv I-PK
, O
and O
au B-PK
##m I-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
were O
altered O
when O
combined O
with O
n O
##s O
##c O
##23 O
##9 O
##25 O
##b O
in O
rats O
. O
[SEP] O
[CLS] O
as O
a O
result O
, O
a O
decrease O
of O
v B-PK
##ds I-PK
##s I-PK
in O
the O
absence O
of O
alter O
##ation O
in O
clearance B-PK
resulted O
in O
shorter O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
larger O
k B-PK
##el I-PK
. O
[SEP] O
[CLS] O
v B-PK
##ds I-PK
##s I-PK
can O
change O
independent O
of O
clearance B-PK
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
changes O
among O
other O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
; O
for O
example O
, O
in O
the O
case O
of O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
( I-PK
the I-PK
area I-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
) I-PK
, O
n O
##s O
##c O
##23 O
##9 O
##25 O
##b O
only O
was O
170 O
##1 O
± O
130 O
h O
· O
ng O
· O
m O
##l O
##− O
##1 O
, O
combination O
n O
##s O
##c O
##23 O
##9 O
##25 O
##b O
and O
p O
##ac O
##lit O
##ax O
##el O
was O
164 O
##9 O
± O
65 O
. O
6 O
h O
· O
ng O
· O
m O
##l O
##− O
##1 O
, O
combination O
n O
##s O
##c O
##23 O
##9 O
##25 O
##b O
and O
do O
##x O
##or O
##ubi O
##cin O
and O
1827 O
± O
73 O
. O
8 O
h O
· O
ng O
· O
m O
##l O
##− O
##1 O
. O
[SEP] O
[CLS] O
mean O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
of O
a O
##zi O
##ls O
##art O
##an O
was O
88 O
##8 O
. O
3 O
and O
83 O
##1 O
. O
3 O
ng O
/ O
m O
##l O
and O
median O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
of O
unchanged O
a O
##zi O
##ls O
##art O
##an O
was O
3 O
. O
0 O
and O
4 O
. O
0 O
h O
, O
in O
the O
5 O
- O
mg O
and O
10 O
- O
mg O
groups O
, O
respectively O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
variables O
derived O
from O
a O
##zi O
##ls O
##art O
##an O
, O
m O
- O
i O
, O
and O
m O
- O
ii O
concentrations O
in O
plasma O
included O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
24 I-PK
h I-PK
post I-PK
- I-PK
dose I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
and I-PK
from I-PK
0 I-PK
h I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
) I-PK
; O
maximum B-PK
observed I-PK
concentration I-PK
in I-PK
plasma I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
; O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
; O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
( I-PK
λ I-PK
##z I-PK
= O
negative O
slope O
of O
the O
log O
- O
linear O
re O
##gression O
of O
the O
natural O
log O
##ari O
##th O
##m O
concentration O
– O
time O
curve O
during O
the O
terminal O
phase O
) O
; O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
= O
l O
##n O
( O
2 O
) O
/ O
λ O
##z O
) O
; O
apparent B-PK
clearance I-PK
after I-PK
extra I-PK
##vas I-PK
##cular I-PK
administration I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
= O
dose B-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
) O
; O
and O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
during I-PK
the I-PK
terminal I-PK
phase I-PK
( I-PK
v I-PK
##z I-PK
/ I-PK
f I-PK
= O
[ B-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
] I-PK
/ I-PK
λ I-PK
##z I-PK
) O
. O
[SEP] O
[CLS] O
urine O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
included O
total B-PK
amount I-PK
ex I-PK
##cre I-PK
##ted I-PK
in I-PK
urine I-PK
from I-PK
0 I-PK
to I-PK
24 I-PK
h I-PK
post I-PK
- I-PK
dose I-PK
( I-PK
a I-PK
##e I-PK
##0 I-PK
– I-PK
24 I-PK
) I-PK
, O
fraction B-PK
ex I-PK
##cre I-PK
##ted I-PK
in I-PK
the I-PK
urine I-PK
( I-PK
f I-PK
##e I-PK
= O
[ O
a B-PK
##e I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
dose I-PK
] O
× O
100 O
) O
, O
and O
re B-PK
##nal I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##r I-PK
= O
a B-PK
##e I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
) O
. O
[SEP] O
[CLS] O
f B-PK
##e I-PK
estimates O
for O
a O
##zi O
##ls O
##art O
##an O
, O
m O
- O
i O
, O
and O
m O
- O
ii O
were O
adjusted O
for O
molecular O
weight O
. O
[SEP] O
[CLS] O
median O
a O
##zi O
##ls O
##art O
##an O
t B-PK
##max I-PK
was O
3 O
h O
( O
range O
2 O
. O
1 O
– O
3 O
. O
0 O
h O
) O
in O
the O
5 O
- O
mg O
group O
and O
4 O
h O
( O
range O
2 O
. O
1 O
– O
4 O
. O
0 O
h O
) O
in O
the O
10 O
- O
mg O
group O
, O
and O
mean O
a O
##zi O
##ls O
##art O
##an O
cm B-PK
##ax I-PK
was O
88 O
##8 O
. O
3 O
and O
83 O
##1 O
. O
3 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
of O
the O
m O
- O
i O
meta O
##bol O
##ite O
was O
3 O
. O
0 O
h O
( O
range O
2 O
. O
9 O
– O
3 O
. O
0 O
h O
) O
and O
6 O
. O
0 O
h O
( O
range O
1 O
. O
0 O
– O
6 O
. O
0 O
h O
) O
in O
the O
5 O
- O
mg O
and O
10 O
- O
mg O
groups O
, O
respectively O
, O
and O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
was O
5 O
. O
4 O
h O
and O
5 O
. O
9 O
h O
in O
the O
5 O
- O
and O
10 O
- O
mg O
groups O
, O
respectively O
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
of O
m O
- O
ii O
was O
5 O
. O
9 O
h O
( O
range O
4 O
. O
0 O
– O
6 O
. O
0 O
) O
in O
the O
5 O
- O
mg O
group O
and O
8 O
. O
0 O
h O
( O
range O
6 O
. O
0 O
– O
24 O
. O
1 O
) O
in O
the O
10 O
- O
mg O
group O
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
m O
- O
ii O
could O
only O
be O
calculated O
in O
one O
patient O
in O
the O
5 O
- O
mg O
group O
( O
5 O
. O
5 O
h O
) O
. O
[SEP] O
[CLS] O
for O
the O
m O
- O
i O
meta O
##bol O
##ite O
, O
both O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
( O
5 O
mg O
: O
159 O
##2 O
. O
7 O
ng O
h O
/ O
m O
##l O
; O
10 O
mg O
: O
142 O
##0 O
. O
5 O
ng O
h O
/ O
m O
##l O
) O
and O
cm B-PK
##ax I-PK
( O
5 O
mg O
: O
191 O
. O
3 O
ng O
/ O
m O
##l O
; O
10 O
mg O
: O
141 O
. O
3 O
ng O
/ O
m O
##l O
) O
were O
lower O
than O
those O
observed O
for O
a O
##zi O
##ls O
##art O
##an O
; O
similar O
results O
were O
observed O
for O
the O
m O
- O
ii O
meta O
##bol O
##ite O
with O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
values O
of O
1986 O
. O
5 O
ng O
h O
/ O
m O
##l O
and O
35 O
##26 O
. O
0 O
ng O
h O
/ O
m O
##l O
and O
cm B-PK
##ax I-PK
values O
of O
227 O
. O
7 O
ng O
/ O
m O
##l O
and O
179 O
. O
3 O
ng O
/ O
m O
##l O
in O
the O
5 O
- O
mg O
and O
10 O
- O
mg O
groups O
, O
respectively O
. O
[SEP] O
[CLS] O
after O
obtaining O
the O
last O
blood O
sample O
, O
all O
rats O
were O
sacrificed O
and O
kidney O
##s O
and O
liver O
collected O
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
were O
calculated O
from O
the O
elimination O
phase O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
s O
##k O
##14 O
- O
06 O
##1 O
##a O
was O
about O
3 O
. O
6 O
h O
##r O
, O
with O
a O
time B-PK
to I-PK
reach I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
value O
of O
1 O
. O
3 O
h O
##r O
. O
[SEP] O
[CLS] O
j O
##ej O
##un O
##um O
> O
il O
##eum O
, O
with O
a O
rapid O
t B-PK
##max I-PK
value O
[ O
13 O
] O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
the O
t B-PK
##max I-PK
of O
et O
##v O
was O
delayed O
when O
administered O
in O
combination O
with O
s O
##k O
##14 O
- O
06 O
##1 O
##a O
( O
fi O
##g O
6 O
##a O
, O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
for O
s O
##k O
##14 O
- O
06 O
##1 O
##a O
was O
also O
delayed O
in O
combination O
with O
et O
##v O
, O
as O
well O
as O
in O
the O
case O
of O
et O
##v O
. O
[SEP] O
[CLS] O
the O
data O
for O
dose O
responses O
were O
plot O
##ted O
as O
% O
in O
##hibition O
calculated O
with O
the O
data O
reduction O
formula O
: O
100 O
× O
( O
1 O
##− O
( O
u O
##1 O
##− O
##c O
##2 O
) O
/ O
( O
c O
##1 O
##− O
##c O
##2 O
) O
) O
vs O
concentration O
of O
compound O
where O
u O
is O
the O
unknown O
value O
, O
c O
##1 O
is O
the O
average O
control O
value O
obtained O
for O
1 O
μ O
##l O
d O
##ms O
##o O
, O
and O
c O
##2 O
is O
the O
average O
control O
value O
obtained O
for O
0 O
. O
03 O
##5 O
m O
ed O
##ta O
. O
[SEP] O
[CLS] O
data O
were O
fitted O
with O
a O
curve O
described O
by O
: O
y O
= O
( O
( O
v O
##max O
× O
x O
) O
/ O
( O
k O
+ O
x O
) O
+ O
y O
##2 O
) O
, O
where O
v B-PK
##max I-PK
is O
the O
upper O
as O
##ym O
##pt O
##ote O
, O
y O
##2 O
is O
the O
y O
intercept O
, O
and O
k B-PK
is O
the O
i B-PK
##c I-PK
##50 I-PK
. O
[SEP] O
[CLS] O
data O
were O
fitted O
with O
a O
curve O
described O
by O
the O
equation O
, O
y O
= O
v O
##max O
× O
( O
1 O
##− O
( O
x O
/ O
( O
k O
+ O
x O
) O
) O
) O
, O
where O
k B-PK
is O
equal O
to O
the O
i B-PK
##c I-PK
##50 I-PK
. O
[SEP] O
[CLS] O
the O
f O
##ac O
##s O
data O
for O
four O
or O
five O
different O
t O
##umour O
samples O
for O
each O
x O
##eno O
##gra O
##ft O
was O
collected O
in O
four O
- O
decade O
mode O
, O
gate O
##d O
for O
single O
cells O
, O
anal O
##ys O
##ed O
to O
calculate O
the O
mean O
channel O
difference O
( O
m O
##d O
) O
, O
which O
represents O
the O
magnitude O
of O
difference O
between O
ve O
##g O
##f O
##r O
##2 O
- O
specific O
stain O
##ing O
and O
non O
##sp O
##ec O
##ific O
is O
##otype O
stain O
##ing O
. O
[SEP] O
[CLS] O
in O
the O
p O
##k O
study O
, O
using O
an O
open O
, O
random O
##ized O
, O
crossover O
design O
, O
the O
dogs O
received O
1 O
mg O
/ O
kg O
q O
24 O
hours O
of O
es O
##ome O
##pra O
##zo O
##le O
via O
i O
##v O
, O
s O
##c O
, O
and O
p O
##o O
administration O
. O
[SEP] O
[CLS] O
in O
the O
p O
##d O
study O
, O
the O
effect O
of O
es O
##ome O
##pra O
##zo O
##le O
on O
in O
##tra O
##gas O
##tric O
p O
##h O
was O
determined O
with O
a O
bra O
##vo O
##® O
p O
##h O
monitoring O
system O
. O
4 O
using O
an O
open O
, O
random O
##ized O
, O
crossover O
design O
, O
in O
##tra O
##gas O
##tric O
p O
##h O
was O
recorded O
without O
medication O
( O
base O
##line O
p O
##h O
) O
and O
after O
the O
3 O
dos O
##ing O
regime O
##ns O
: O
i O
##v O
, O
s O
##c O
, O
and O
p O
##o O
doses O
of O
es O
##ome O
##pra O
##zo O
##le O
( O
1 O
mg O
/ O
kg O
q O
24 O
hours O
) O
. O
[SEP] O
[CLS] O
to O
estimate O
the O
p O
##k O
parameters O
of O
es O
##ome O
##pra O
##zo O
##le O
, O
plasma O
concentration O
‐ O
time O
profiles O
were O
analyzed O
by O
a O
non O
##com O
##par O
##tment O
##al O
model O
analysis O
in O
win O
##non O
##lin O
##® O
software O
version O
4 O
. O
1 O
. O
11 O
the O
terminal B-PK
half I-PK
‐ I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
calculated O
as O
0 O
. O
69 O
##3 O
/ O
k O
##e O
, O
where O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##e I-PK
) I-PK
is O
the O
slope O
of O
the O
log O
‐ O
linear O
portion O
of O
the O
concentration O
‐ O
time O
profile O
. O
[SEP] O
[CLS] O
the O
c B-PK
##l I-PK
and O
vs B-PK
##s I-PK
for O
es O
##ome O
##pra O
##zo O
##le O
were O
calculated O
using O
the O
following O
equations O
: O
( O
1 O
) O
c O
##l O
= O
dose O
##au O
##c O
##0 O
##− O
##∞ O
( O
2 O
) O
vs O
##s O
= O
m O
##rt O
##c O
##l O
( O
3 O
) O
m O
##rt O
= O
au O
##m O
##c O
##0 O
##− O
##∞ O
##au O
##c O
##0 O
##− O
##∞ O
[SEP] O
[CLS] O
the O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
time B-PK
until I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
directly O
determined O
from O
the O
plasma O
concentration O
‐ O
time O
curves O
. O
[SEP] O
[CLS] O
the O
bra O
##vo O
capsule O
##s O
were O
oral O
##ly O
inserted O
with O
a O
delivery O
system O
( O
80 O
cm O
in O
length O
, O
with O
a O
diameter O
of O
6 O
f O
##r O
. O
) O
. O
[SEP] O
[CLS] O
after O
repeated O
p O
##o O
administration O
##s O
of O
es O
##ome O
##pra O
##zo O
##le O
( O
1 O
mg O
/ O
kg O
, O
once O
daily O
) O
, O
the O
t B-PK
##max I-PK
on O
day O
5 O
was O
2 O
. O
23 O
‐ O
fold O
faster O
than O
on O
day O
1 O
( O
0 O
. O
81 O
and O
1 O
. O
81 O
hours O
, O
respectively O
; O
p O
= O
. O
02 O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
the O
p O
##o O
es O
##ome O
##pra O
##zo O
##le O
treatment O
was O
significantly O
lower O
than O
that O
of O
the O
i O
##v O
( O
p O
= O
. O
00 O
##4 O
) O
treatment O
, O
and O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
71 O
. O
43 O
% O
. O
[SEP] O
[CLS] O
eighteen O
mice O
were O
divided O
into O
six O
groups O
( O
a O
, O
b O
, O
c O
, O
d O
, O
e O
and O
f O
) O
, O
each O
group O
containing O
three O
mice O
. O
[SEP] O
[CLS] O
samples O
from O
groups O
a O
and O
d O
were O
collected O
at O
0 O
min O
( O
0 O
h O
) O
, O
30 O
min O
( O
0 O
. O
5 O
h O
) O
, O
4 O
h O
and O
24 O
h O
. O
samples O
from O
groups O
b O
and O
e O
were O
collected O
at O
5 O
min O
( O
0 O
. O
08 O
h O
) O
, O
1 O
h O
and O
6 O
h O
. O
samples O
from O
groups O
c O
and O
f O
were O
collected O
at O
15 O
min O
( O
0 O
. O
25 O
h O
) O
, O
2 O
h O
and O
8 O
h O
. O
next O
, O
all O
of O
the O
blood O
samples O
were O
cent O
##ri O
##fu O
##ged O
for O
5 O
min O
at O
800 O
##0 O
rpm O
, O
4 O
° O
##c O
, O
and O
the O
plasma O
was O
collected O
in O
a O
96 O
- O
well O
plate O
and O
stored O
at O
− O
##20 O
° O
##c O
. O
[SEP] O
[CLS] O
d O
##sa O
2 O
. O
0 O
p O
##har O
##ma O
##co O
##kin O
##etic O
software O
( O
chin O
##a O
pharmaceutical O
university O
, O
chin O
##a O
) O
was O
used O
to O
calculate O
the O
main O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
the O
area B-PK
under I-PK
the I-PK
time I-PK
- I-PK
concentration I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
the O
maximum B-PK
of I-PK
blood I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
blood B-PK
clearance I-PK
rate I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
) I-PK
, O
and O
mean B-PK
retention I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
calculated O
by O
absolute O
bio O
##ava O
##ila O
##bility O
= O
100 O
% O
× O
au O
##c O
##po O
· O
di O
##v O
/ O
( O
au O
##ci O
##v O
· O
d O
##po O
) O
, O
where O
au B-PK
##ci I-PK
##v I-PK
and O
au B-PK
##c I-PK
##po I-PK
are O
the O
au B-PK
##c I-PK
of I-PK
the I-PK
drug I-PK
from I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
after O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
, O
and O
di O
##v O
and O
d O
##po O
are O
the O
single O
dos O
##age O
of O
t O
##b O
##ms O
- O
i O
for O
the O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
was O
1 O
. O
8 O
± O
1 O
. O
3 O
h O
after O
oral O
administration O
. O
[SEP] O
[CLS] O
the O
non O
- O
ha O
##em O
##or O
##r O
##ha O
##gic O
group O
, O
where O
patients O
experience O
a O
bleeding O
volume O
of O
less O
than O
800 O
m O
##l O
, O
is O
a O
reference O
group O
for O
biology O
and O
will O
be O
sampled O
to O
obtain O
a O
reference O
profile O
for O
the O
direct O
p O
##las O
##min O
generation O
test O
in O
c O
##s O
. O
[SEP] O
[CLS] O
secondary O
end O
##points O
will O
be O
measured O
before O
inclusion O
( O
t O
##0 O
) O
and O
at O
t O
##30 O
, O
t O
##60 O
, O
t O
##12 O
##0 O
and O
t O
##36 O
##0 O
, O
respectively O
30 O
, O
60 O
, O
120 O
and O
360 O
min O
after O
inclusion O
and O
at O
day O
2 O
( O
± O
##12 O
h O
) O
[SEP] O
[CLS] O
the O
average O
of O
total O
bleeding O
was O
131 O
##3 O
± O
143 O
##2 O
m O
##l O
in O
the O
ta O
group O
vs O
208 O
##9 O
± O
155 O
##6 O
m O
##l O
in O
the O
place O
##bo O
group O
( O
p O
= O
0 O
. O
03 O
) O
. O
[SEP] O
[CLS] O
water O
used O
for O
the O
l O
##c O
– O
m O
##s O
/ O
m O
##s O
analysis O
was O
prepared O
from O
mill O
##i O
q O
water O
pu O
##rification O
system O
pro O
##cure O
##d O
from O
mill O
##ip O
##ore O
( O
bang O
##alo O
##re O
, O
in O
##dia O
) O
. O
[SEP] O
[CLS] O
bench O
top O
stability O
( O
5 O
h O
at O
ice O
water O
bath O
) O
, O
auto O
##sa O
##mple O
##r O
stability O
( O
46 O
h O
) O
, O
freeze O
- O
th O
##aw O
stability O
( O
3 O
cycles O
at O
ice O
water O
bath O
) O
, O
re O
##in O
##jection O
stability O
( O
26 O
h O
) O
, O
wet O
extract O
stability O
( O
43 O
h O
at O
2 O
– O
8 O
° O
##c O
) O
and O
long O
- O
term O
stability O
at O
− O
##70 O
° O
##c O
for O
56 O
day O
the O
mean O
% O
nominal O
values O
of O
the O
anal O
##yte O
##s O
were O
found O
to O
be O
within O
± O
##15 O
% O
of O
the O
predicted O
concentrations O
for O
the O
anal O
##yte O
##s O
at O
their O
l O
##q O
##c O
and O
h O
##q O
##c O
levels O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
blood O
samples O
for O
assessment O
of O
the O
t B-PK
##rough I-PK
concentration I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
of O
r O
##ad O
##00 O
##1 O
were O
obtained O
immediately O
before O
administration O
of O
the O
next O
dose O
on O
days O
2 O
, O
8 O
, O
11 O
, O
15 O
and O
16 O
of O
cycle O
1 O
and O
on O
day O
1 O
of O
cycle O
2 O
as O
well O
as O
at O
the O
end O
of O
the O
study O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##in I-PK
of O
r O
##ad O
##00 O
##1 O
indicated O
that O
a O
steady O
state O
was O
attained O
after O
[UNK] O
days O
of O
repeated O
once O
- O
daily O
oral O
dos O
##ing O
( O
fi O
##g O
. O
1 O
##b O
) O
. O
[SEP] O
[CLS] O
the O
c O
##yt O
##oto O
##to O
##xi O
##city O
, O
serum B-PK
half I-PK
- I-PK
life I-PK
, O
and O
anti O
##tum O
##or O
effect O
of O
i O
##g O
##b O
##d O
- O
trail O
and O
a O
##b O
##d O
- O
trail O
were O
compared O
. O
[SEP] O
[CLS] O
to O
estimate O
the O
influence O
of O
i O
##gg O
and O
album O
##in O
binding O
on O
the O
c O
##yt O
##oto O
##xi O
##city O
of O
trail O
fusion O
proteins O
, O
i O
##gg O
or O
album O
##in O
were O
mixed O
with O
i O
##g O
##b O
##d O
- O
trail O
or O
a O
##b O
##d O
- O
trail O
at O
a O
molecular O
ratio O
of O
1 O
: O
1 O
and O
in O
##cu O
##bate O
##d O
at O
room O
temperature O
for O
0 O
. O
5 O
h O
, O
followed O
by O
addition O
into O
the O
cells O
. O
[SEP] O
[CLS] O
subsequently O
, O
the O
sensor O
was O
inserted O
into O
a O
solution O
containing O
different O
concentrations O
( O
0 O
- O
2 O
μ O
##m O
) O
of O
i O
##g O
##b O
##d O
- O
trail O
for O
300 O
s O
to O
enable O
association O
, O
followed O
by O
di O
##sa O
##sso O
##ciation O
in O
p O
##bs O
for O
200 O
s O
. O
the O
association O
constant O
ka O
, O
di O
##sa O
##sso O
##ciation O
constant O
k O
##d O
, O
and O
affinity O
k O
##d O
( O
k O
##d O
= O
k O
##d O
/ O
ka O
) O
were O
calculated O
by O
using O
software O
for O
o O
##ct O
##et O
##® O
systems O
according O
to O
1 O
: O
1 O
binding O
model O
. O
[SEP] O
[CLS] O
in O
addition O
, O
a O
traditional O
radioactive O
method O
was O
also O
used O
to O
monitor O
the O
blood B-PK
clearance I-PK
of O
trail O
proteins O
and O
i O
##gg O
. O
i O
##13 O
##1 O
- O
label O
##ing O
was O
performed O
according O
to O
fan O
et O
al O
. O
40 O
. O
[SEP] O
[CLS] O
to O
monitor O
the O
blood B-PK
clearance I-PK
, O
normal O
b O
##al O
##b O
/ O
c O
mice O
( O
n O
= O
3 O
for O
each O
time O
point O
) O
were O
in O
##tra O
##ven O
##ously O
injected O
with O
i O
##13 O
##1 O
- O
labeled O
trail O
proteins O
or O
i O
##gg O
pre O
##in O
##cu O
##bate O
##d O
with O
or O
without O
i O
##g O
##b O
##d O
- O
trail O
at O
a O
m O
##olar O
ratio O
of O
1 O
: O
1 O
( O
100 O
μ O
##l O
, O
27 O
. O
5 O
k O
##b O
##q O
/ O
g O
body O
weight O
) O
. O
[SEP] O
[CLS] O
the O
speed O
of O
the O
c O
##yt O
##oto O
##xi O
##city O
decrease O
reflects O
the O
protein O
clearance B-PK
rate I-PK
. O
[SEP] O
[CLS] O
bio O
##layer O
inter O
##fer O
##ome O
##try O
revealed O
that O
the O
affinity O
of O
a O
##b O
##d O
- O
trail O
for O
h O
##sa O
was O
1 O
. O
68 O
nm O
( O
figure O
6 O
##b O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
7 O
##a O
, O
when O
injected O
at O
an O
early O
time O
post O
- O
in O
##oc O
##ulation O
( O
tumor O
volume O
~ O
50 O
mm O
##3 O
) O
, O
a O
##b O
##d O
- O
trail O
showed O
greater O
tumor O
suppression O
than O
trail O
. O
[SEP] O
[CLS] O
con O
##clusive O
##ly O
, O
these O
data O
revealed O
that O
b O
##b O
##r O
can O
improve O
insulin O
sensitivity O
in O
d O
##b O
/ O
d O
##b O
di O
##abe O
##tic O
mice O
, O
and O
the O
b O
##b O
##r O
- O
s O
##ln O
##s O
ex O
##ert O
##ed O
more O
potent O
effects O
than O
an O
equivalent O
dose O
of O
b O
##b O
##r O
, O
probably O
through O
increased O
absorption O
and O
/ O
or O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
ex O
##po O
##nent O
##iating O
the O
least O
- O
squares O
means O
( O
mean O
differences O
) O
and O
the O
lower O
and O
upper O
limits O
of O
these O
confidence O
intervals O
yielded O
estimates O
for O
the O
population O
geometric O
means O
( O
population O
geometric O
mean O
ratios O
) O
and O
confidence O
intervals O
for O
the O
geometric O
means O
( O
geometric O
mean O
ratios O
) O
on O
the O
original O
scale O
. O
[SEP] O
[CLS] O
a O
95 O
% O
confidence O
interval O
( O
c O
##i O
) O
was O
constructed O
for O
the O
geometric O
means O
of O
the O
au B-PK
##cs I-PK
for O
the O
treatment O
arms O
. O
[SEP] O
[CLS] O
the O
median O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
was O
5 O
h O
post O
- O
dose O
for O
the O
m O
##k O
- O
06 O
##46 O
alone O
treatment O
and O
3 O
. O
5 O
h O
post O
- O
dose O
for O
the O
m O
##k O
- O
06 O
##46 O
+ O
c O
##et O
##ux O
##ima O
##b O
/ O
i O
##rino O
##teca O
##n O
treatment O
. O
[SEP] O
[CLS] O
the O
co O
- O
administration O
of O
m O
##k O
- O
06 O
##46 O
with O
c O
##et O
##ux O
##ima O
##b O
/ O
i O
##rino O
##teca O
##n O
produced O
a O
higher O
mean O
peak B-PK
c I-PK
##et I-PK
##ux I-PK
##ima I-PK
##b I-PK
concentration I-PK
( O
geometric O
mean O
of O
the O
cm B-PK
##ax I-PK
value O
of O
236 O
. O
5 O
vs O
. O
204 O
. O
0 O
μ O
##g O
/ O
m O
##l O
without O
m O
##k O
- O
06 O
##46 O
co O
- O
administration O
) O
, O
which O
was O
reached O
earlier O
( O
median O
t B-PK
##max I-PK
value O
of O
2 O
. O
0 O
vs O
. O
7 O
. O
9 O
h O
without O
m O
##k O
- O
06 O
##46 O
co O
- O
administration O
) O
. O
[SEP] O
[CLS] O
the O
median O
t B-PK
##max I-PK
was O
the O
same O
for O
both O
treatments O
( O
1 O
. O
0 O
h O
) O
. O
[SEP] O
[CLS] O
the O
rate B-PK
constant I-PK
associated I-PK
with I-PK
the I-PK
terminal I-PK
elimination I-PK
phase I-PK
( I-PK
λ I-PK
) I-PK
was O
estimated O
by O
means O
of O
linear O
re O
##gression O
of O
the O
terminal O
phase O
of O
the O
log O
concentration O
- O
vs O
. O
- O
time O
curve O
, O
and O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
and O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
associated I-PK
with I-PK
λ I-PK
( I-PK
v I-PK
##d I-PK
##λ I-PK
) I-PK
was O
calculated O
. O
[SEP] O
[CLS] O
for O
calculation O
of O
λ B-PK
after O
the O
in O
##tra O
##ven O
##ous O
and O
the O
in O
##tra O
##mus O
##cular O
administration O
all O
plasma O
samples O
from O
2 O
. O
5 O
h O
and O
onwards O
were O
included O
. O
[SEP] O
[CLS] O
differences O
between O
different O
routes O
of O
administration O
regarding O
the O
λ B-PK
and O
the O
effect O
duration O
were O
statistical O
##ly O
evaluated O
using O
the O
k O
##rus O
##kal O
- O
wall O
##is O
test O
by O
the O
use O
of O
mini O
##ta O
##b O
for O
windows O
95 O
, O
release O
12 O
( O
mini O
##nc O
, O
state O
college O
, O
p O
##a O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
m O
##rt O
= O
au O
##m O
##cin O
##f O
/ O
au O
##cin O
##f O
[SEP] O
[CLS] O
v O
##ds O
##s O
= O
dose O
× O
au O
##m O
##c O
/ O
au O
##cin O
##f O
##2 O
[SEP] O
[CLS] O
because O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
of O
e O
##fa O
##vir O
##en O
##z O
was O
not O
determined O
, O
c B-PK
##l I-PK
and O
v B-PK
##d I-PK
represented O
apparent O
values O
( O
i O
. O
e O
. O
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
and O
v B-PK
##d I-PK
/ I-PK
f I-PK
, O
respectively O
) O
. O
[SEP] O
[CLS] O
we O
pre O
‐ O
estimated O
ka B-PK
from O
nine O
subjects O
from O
source O
# O
2 O
from O
whom O
intensive O
sampling O
during O
the O
absorption O
phase O
was O
available O
, O
and O
ka B-PK
was O
then O
fixed O
at O
the O
pre O
‐ O
estimated O
value O
in O
subsequent O
model O
development O
. O
[SEP] O
[CLS] O
no O
co O
‐ O
medications O
tested O
( O
see O
table O
##2 O
) O
was O
found O
to O
influence O
c B-PK
##l I-PK
. O
[SEP] O
[CLS] O
further O
introduction O
of O
the O
add O
##itive O
error O
model O
to O
explain O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
in O
c B-PK
##l I-PK
did O
not O
improve O
the O
fit O
( O
δ O
##of O
= O
0 O
. O
00 O
) O
. O
[SEP] O
[CLS] O
in O
the O
final O
model O
, O
the O
typical O
c B-PK
##l I-PK
of O
e O
##fa O
##vir O
##en O
##z O
for O
g O
##g O
, O
g O
##t O
, O
and O
t O
##t O
carriers O
were O
estimated O
to O
be O
10 O
. O
2 O
, O
7 O
. O
33 O
, O
and O
2 O
. O
38 O
l O
/ O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
study O
highlights O
##w O
##hat O
is O
the O
current O
knowledge O
on O
the O
topic O
? O
[SEP] O
[CLS] O
absorption O
profile O
of O
s O
‐ O
k O
##eta O
##mine O
was O
best O
described O
with O
a O
simple O
first B-PK
‐ I-PK
order I-PK
absorption I-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
model O
in O
comparison O
to O
a O
transit O
compartment O
model O
or O
a O
single O
we O
##ib O
##ull O
absorption O
function O
. O
[SEP] O
[CLS] O
both O
of O
these O
processes O
were O
dependent O
on O
individually O
scaled O
blood B-PK
flow I-PK
levels I-PK
that O
, O
in O
turn O
, O
used O
the O
body O
weight O
as O
a O
subject O
specific O
parameter O
( O
table O
##1 O
) O
. O
[SEP] O
[CLS] O
our O
results O
suggest O
that O
the O
gut B-PK
wall I-PK
clearance I-PK
of O
s O
‐ O
k O
##eta O
##mine O
is O
very O
low O
in O
comparison O
to O
he B-PK
##pa I-PK
##tic I-PK
clearance I-PK
, O
and O
the O
ratio B-PK
between I-PK
these I-PK
two I-PK
clearance I-PK
##s I-PK
was O
~ O
1 O
: O
253 O
( O
table O
##2 O
) O
. O
[SEP] O
[CLS] O
all O
efforts O
to O
calculate O
the O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
, I-PK
t I-PK
##ic I-PK
) I-PK
freely O
in O
the O
model O
were O
unsuccessful O
and O
, O
therefore O
, O
ka B-PK
, I-PK
t I-PK
##ic I-PK
was O
fixed O
to O
a O
published O
value O
of O
3 O
. O
3 O
/ O
h O
. O
8 O
the O
absorption O
phase O
was O
adequately O
described O
by O
a O
transit O
compartment O
##al O
model O
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
was O
reached O
between O
3 O
and O
7 O
hours O
after O
administration O
of O
single O
or O
multiple O
doses O
of O
g O
##ilt O
##eri O
##tin O
##ib O
( O
tables O
s O
##2 O
and O
s O
##3 O
) O
. O
[SEP] O
[CLS] O
after O
multiple O
dose O
administration O
, O
the O
mean O
half B-PK
‐ I-PK
life I-PK
of O
g O
##ilt O
##eri O
##tin O
##ib O
was O
estimated O
to O
range O
from O
84 O
to O
126 O
hours O
, O
with O
an O
approximate O
8 O
‐ O
fold O
accumulation O
relative O
to O
base O
##line O
. O
[SEP] O
[CLS] O
paired O
observations O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
values O
of O
sun O
##iti O
##ni O
##b O
and O
i O
##rino O
##teca O
##n O
alone O
vs O
the O
combination O
did O
not O
reveal O
significant O
drug O
– O
drug O
interactions O
. O
[SEP] O
[CLS] O
standard O
plasma O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
used O
including O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
to I-PK
the I-PK
time I-PK
of I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
last I-PK
) I-PK
or I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
clearance B-PK
, O
and O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
plasma O
do O
##lut O
##eg O
##ra O
##vir O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
cm B-PK
##ax I-PK
, O
and O
c O
##24 O
were O
reduced O
by O
39 O
% O
, O
37 O
% O
, O
and O
39 O
% O
, O
respectively O
, O
when O
co O
- O
administered O
with O
calcium O
carbon O
##ate O
while O
fast O
##ing O
and O
were O
reduced O
by O
54 O
% O
, O
57 O
% O
, O
and O
56 O
% O
, O
respectively O
, O
when O
co O
- O
administered O
with O
f O
##er O
##rous O
f O
##uma O
##rate O
while O
fast O
##ing O
. O
[SEP] O
[CLS] O
this O
study O
was O
planned O
to O
en O
##roll O
24 O
eligible O
subjects O
who O
were O
random O
##ized O
into O
1 O
of O
the O
2 O
co O
##hor O
##ts O
( O
calcium O
or O
iron O
) O
( O
table O
##1 O
) O
and O
received O
each O
of O
4 O
treatments O
in O
a O
random O
##ized O
fashion O
: O
( O
1 O
) O
a O
single O
dose O
of O
do O
##lut O
##eg O
##ra O
##vir O
50 O
mg O
administered O
under O
fast O
##ed O
conditions O
( O
treatment O
a O
) O
; O
( O
2 O
) O
a O
single O
dose O
of O
do O
##lut O
##eg O
##ra O
##vir O
50 O
mg O
co O
- O
administered O
with O
a O
single O
dose O
of O
calcium O
carbon O
##ate O
( O
treatment O
b O
) O
or O
f O
##er O
##rous O
f O
##uma O
##rate O
( O
treatment O
e O
) O
under O
fast O
##ed O
conditions O
; O
( O
3 O
) O
a O
single O
dose O
of O
do O
##lut O
##eg O
##ra O
##vir O
50 O
mg O
co O
- O
administered O
with O
a O
single O
dose O
of O
calcium O
carbon O
##ate O
( O
treatment O
c O
) O
or O
f O
##er O
##rous O
f O
##uma O
##rate O
( O
treatment O
f O
) O
with O
a O
moderate O
- O
fat O
meal O
( O
approximately O
30 O
% O
fat O
) O
; O
and O
( O
4 O
) O
a O
single O
dose O
of O
do O
##lut O
##eg O
##ra O
##vir O
50 O
mg O
administered O
under O
fast O
##ed O
conditions O
2 O
hours O
prior O
to O
administration O
of O
a O
single O
dose O
of O
calcium O
carbon O
##ate O
( O
treatment O
d O
) O
or O
f O
##er O
##rous O
f O
##uma O
##rate O
( O
treatment O
g O
) O
. O
[SEP] O
[CLS] O
in O
a O
study O
with O
do O
##lut O
##eg O
##ra O
##vir O
, O
concurrent O
administration O
of O
maximum O
strength O
ma O
##alo O
##x O
##® O
( O
containing O
al O
##3 O
+ O
and O
mg O
##2 O
+ O
; O
no O
##var O
##tis O
consumer O
health O
, O
par O
##si O
##ppan O
##y O
, O
new O
jersey O
) O
under O
fast O
##ed O
conditions O
decreased O
do O
##lut O
##eg O
##ra O
##vir O
mean O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
and O
plasma O
concentration O
at O
24 O
hours O
post O
- O
dose O
( O
c O
##24 O
) O
by O
74 O
% O
, O
72 O
% O
, O
and O
74 O
% O
, O
respectively O
, O
and O
administration O
of O
ma O
##alo O
##x O
2 O
hours O
after O
do O
##lut O
##eg O
##ra O
##vir O
administration O
decreased O
do O
##lut O
##eg O
##ra O
##vir O
mean O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
, O
and O
c O
##24 O
by O
26 O
% O
, O
18 O
% O
, O
and O
30 O
% O
, O
respectively O
. O
8 O
these O
data O
resulted O
in O
the O
recommendation O
that O
con O
##com O
##ita O
##nt O
administration O
of O
do O
##lut O
##eg O
##ra O
##vir O
and O
ant O
##ac O
##ids O
should O
be O
avoided O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
that O
were O
determined O
included O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
time I-PK
of I-PK
last I-PK
q I-PK
##uant I-PK
##ifiable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
[ I-PK
0 I-PK
– I-PK
t I-PK
] I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
[ I-PK
0 I-PK
– I-PK
∞ I-PK
] I-PK
) I-PK
, O
c O
##24 O
, O
and O
time B-PK
of I-PK
occurrence I-PK
of I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
. O
[SEP] O
[CLS] O
t B-PK
##max I-PK
was O
analyzed O
non O
##par O
##ame O
##tric O
##ally O
for O
the O
treatment O
differences O
of O
interest O
using O
the O
w O
##il O
##co O
##xon O
' O
s O
matched O
- O
pairs O
method O
. O
[SEP] O
[CLS] O
when O
compared O
to O
mice O
fed O
the O
standard O
rode O
##nt O
ch O
##ow O
diet O
( O
s O
##rc O
##d O
) O
, O
we O
found O
that O
mice O
fed O
the O
k O
##d O
were O
more O
sensitive O
to O
electro O
##con O
##vu O
##ls O
##ions O
as O
reflected O
by O
a O
significant O
decrease O
in O
seizure O
threshold O
( O
3 O
. O
86 O
ma O
in O
mice O
on O
the O
k O
##d O
vs O
7 O
. O
29 O
ma O
in O
mice O
on O
the O
s O
##rc O
##d O
; O
p O
< O
0 O
. O
05 O
) O
in O
the O
ma O
##ximal O
electro O
##sh O
##ock O
seizure O
threshold O
( O
me O
##st O
) O
test O
. O
[SEP] O
[CLS] O
the O
variables O
cm B-PK
##ax I-PK
and O
t B-PK
##max I-PK
were O
directly O
read O
from O
the O
plasma O
concentration O
– O
time O
profiles O
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
time I-PK
of I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
was O
calculated O
using O
the O
trap O
##ez O
##oid O
##al O
method O
[ O
14 O
] O
, O
and O
t B-PK
##½ I-PK
was O
calculated O
as O
l O
##n O
2 O
/ O
λ O
##z O
, O
where O
λ B-PK
##z I-PK
is O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
estimated O
by O
log O
- O
linear O
re O
##gression O
analysis O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
variables O
were O
analyzed O
descriptive O
##ly O
, O
providing O
geometric O
means O
and O
95 O
% O
confidence O
intervals O
( O
c O
##is O
) O
for O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
in I-PK
##f I-PK
) I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
( O
i O
. O
e O
. O
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
144 I-PK
h I-PK
[ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
144 I-PK
##h I-PK
] I-PK
) O
, O
and O
t B-PK
##½ I-PK
. O
for O
t B-PK
##max I-PK
, O
the O
median O
with O
minimum O
and O
maximum O
values O
were O
calculated O
and O
reported O
. O
[SEP] O
[CLS] O
differences O
in O
t B-PK
##max I-PK
were O
explored O
using O
the O
non O
##par O
##ame O
##tric O
w O
##il O
##co O
##xon O
signed O
- O
rank O
test O
. O
[SEP] O
[CLS] O
in O
study O
1 O
, O
the O
plasma O
concentration O
– O
time O
profiles O
of O
p O
##ones O
##imo O
##d O
were O
characterized O
by O
a O
median O
t B-PK
##max I-PK
of O
4 O
h O
for O
both O
p O
##oly O
##morphic O
forms O
in O
capsule O
##s O
( O
fi O
##g O
. O
1 O
##a O
; O
table O
1 O
) O
. O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
for O
h O
##ydro O
##co O
##don O
##e O
and O
h O
##ydro O
##mor O
##phone O
were O
calculated O
for O
each O
active O
treatment O
using O
non O
##com O
##par O
##tment O
##al O
analysis O
: O
maximum B-PK
plasma I-PK
drug I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
; O
by O
inspection O
and O
without O
inter O
##pol O
##ation O
) O
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
; O
by O
inspection O
) O
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
from I-PK
0 I-PK
to I-PK
0 I-PK
. I-PK
75 I-PK
hours I-PK
after I-PK
study I-PK
drug I-PK
administration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
0 I-PK
. I-PK
75 I-PK
; O
closest O
sampling O
time O
to O
median O
t O
##max O
for O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
) O
, O
au B-PK
##c I-PK
from I-PK
0 I-PK
to I-PK
4 I-PK
hours I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
4 I-PK
; O
closest O
sampling O
time O
to O
median O
t B-PK
##max I-PK
for O
finely O
crushed O
h O
##ydro O
##co O
##don O
##e O
er O
) O
, O
au B-PK
##c I-PK
from I-PK
0 I-PK
to I-PK
7 I-PK
hours I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
7 I-PK
; O
closest O
sampling O
time O
to O
median O
t B-PK
##max I-PK
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
) O
, O
au B-PK
##c I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
the I-PK
time I-PK
of I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
drug I-PK
concentration I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
apparent B-PK
plasma I-PK
terminal I-PK
elimination I-PK
rate I-PK
constant I-PK
( I-PK
λ I-PK
##z I-PK
) I-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
abuse B-PK
q I-PK
##uo I-PK
##tien I-PK
##t I-PK
( O
calculated O
as O
cm B-PK
##ax I-PK
/ I-PK
t I-PK
##max I-PK
) O
, O
and O
percent O
extra O
##pol O
##ation O
( O
calculated O
as O
100 O
x O
[ O
au O
##c O
##0 O
– O
∞ O
– O
au O
##c O
##0 O
– O
t O
] O
/ O
au O
##c O
##0 O
– O
∞ O
) O
. O
[SEP] O
[CLS] O
significantly O
lower O
em B-PK
##ax I-PK
values O
for O
the O
l O
##s O
##d O
sub O
##sca O
##le O
of O
the O
arc O
##i O
were O
observed O
for O
intact O
and O
finely O
crushed O
h O
##ydro O
##co O
##don O
##e O
er O
compared O
with O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
( O
4 O
. O
4 O
and O
4 O
. O
7 O
vs O
. O
6 O
. O
2 O
; O
p O
< O
0 O
. O
00 O
##1 O
) O
; O
however O
, O
the O
au O
##ec O
for O
the O
l O
##s O
##d O
sub O
##sca O
##le O
was O
comparable O
across O
treatments O
, O
with O
no O
significant O
differences O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
was O
lowest O
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
( O
28 O
. O
8 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
rate B-PK
of I-PK
absorption I-PK
of O
h O
##ydro O
##co O
##don O
##e O
was O
slow O
##est O
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
, O
with O
a O
t B-PK
##max I-PK
of O
7 O
. O
1 O
hours O
, O
compared O
with O
the O
t B-PK
##max I-PK
for O
finely O
crushed O
h O
##ydro O
##co O
##don O
##e O
er O
( O
4 O
. O
0 O
hours O
) O
and O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
( O
0 O
. O
8 O
hours O
) O
. O
[SEP] O
[CLS] O
exposure O
before O
t B-PK
##max I-PK
for O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
0 I-PK
. I-PK
75 I-PK
) O
and O
before O
t B-PK
##max I-PK
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
( O
au B-PK
##c I-PK
##0 I-PK
– I-PK
7 I-PK
) O
was O
greatest O
for O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
. O
[SEP] O
[CLS] O
mean O
au B-PK
##c I-PK
##0 I-PK
– I-PK
0 I-PK
. I-PK
75 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
7 I-PK
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
were O
97 O
% O
and O
72 O
% O
lower O
, O
respectively O
, O
than O
for O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
. O
[SEP] O
[CLS] O
the O
following O
relationships O
between O
the O
au B-PK
##c I-PK
of O
cape O
##ci O
##ta O
##bine O
meta O
##bol O
##ites O
and O
patient O
- O
reported O
symptoms O
measured O
during O
the O
same O
cycle O
were O
found O
: O
au B-PK
##c I-PK
5 O
′ O
- O
d O
##fu O
##r O
and O
weight O
loss O
( O
or O
1 O
. O
10 O
, O
95 O
% O
c O
##i O
: O
1 O
. O
01 O
– O
1 O
. O
19 O
) O
, O
au B-PK
##c I-PK
f O
##bal O
and O
h O
##fs O
( O
or O
0 O
. O
90 O
, O
95 O
% O
c O
##i O
: O
0 O
. O
83 O
– O
0 O
. O
99 O
) O
, O
au B-PK
##c I-PK
f O
##bal O
and O
r O
##hino O
##rr O
##hea O
( O
or O
1 O
. O
21 O
, O
95 O
% O
c O
##i O
: O
1 O
. O
03 O
– O
1 O
. O
42 O
) O
, O
au B-PK
##c I-PK
f O
##bal O
and O
weight O
loss O
( O
or O
1 O
. O
09 O
, O
95 O
% O
c O
##i O
: O
1 O
. O
00 O
– O
1 O
. O
20 O
) O
, O
and O
au B-PK
##c I-PK
f O
##bal O
and O
depression O
( O
or O
0 O
. O
90 O
, O
95 O
% O
c O
##i O
: O
0 O
. O
82 O
– O
0 O
. O
99 O
) O
( O
p O
< O
0 O
. O
05 O
) O
( O
supplement O
##ary O
table O
s O
##5 O
) O
. O
[SEP] O
[CLS] O
the O
oral B-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
0 O
. O
80 O
##3 O
mg O
/ O
l O
, O
and O
t B-PK
##max I-PK
was O
4 O
h O
. O
[SEP] O
[CLS] O
the O
oral B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
8 O
. O
36 O
##1 O
h O
, O
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
##0 I-PK
- I-PK
t I-PK
) I-PK
was O
9 O
. O
09 O
##8 O
h O
. O
in O
addition O
, O
r O
##ox O
##yl O
- O
z O
##h O
##c O
- O
84 O
showed O
an O
oral O
apparent B-PK
distribution I-PK
volume I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
of O
12 O
. O
142 O
l O
/ O
kg O
and O
a O
clearance B-PK
of O
1 O
. O
02 O
##7 O
l O
/ O
h O
/ O
kg O
. O
[SEP] O
[CLS] O
determine O
the O
le O
##vo O
##f O
##lo O
##xa O
##cin O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
that O
provides O
the O
shortest O
time O
to O
s O
##put O
##um O
culture O
conversion O
on O
solid O
medium O
[SEP] O
[CLS] O
determine O
the O
highest O
le O
##vo O
##f O
##lo O
##xa O
##cin O
au B-PK
##c I-PK
that O
is O
both O
safe O
and O
associated O
with O
fewer O
than O
25 O
% O
of O
patients O
disco O
##ntin O
##uing O
or O
reducing O
the O
dose O
of O
le O
##vo O
##f O
##lo O
##xa O
##cin O
[SEP] O
[CLS] O
a O
second O
sample O
size O
calculation O
was O
completed O
based O
on O
the O
log O
##istic O
re O
##gression O
of O
a O
binary O
response O
variable O
( O
whether O
the O
participant O
has O
completed O
6 O
months O
of O
treatment O
with O
the O
assigned O
dose O
or O
not O
) O
on O
a O
continuous O
, O
normally O
distributed O
variable O
( O
au B-PK
##c I-PK
) O
. O
[SEP] O
[CLS] O
the O
estimated O
mean O
au B-PK
##c I-PK
will O
be O
140 O
μ O
##g O
- O
h O
/ O
m O
##l O
, O
with O
standard O
de O
##viation O
of O
about O
65 O
μ O
##g O
- O
h O
/ O
m O
##l O
, O
[ O
14 O
] O
giving O
a O
total O
of O
79 O
e O
##val O
##ua O
##ble O
patients O
needed O
to O
detect O
an O
or O
of O
0 O
. O
41 O
##2 O
between O
the O
proportion O
completing O
treatment O
at O
the O
mean O
au B-PK
##c I-PK
and O
the O
proportion O
completing O
treatment O
at O
the O
mean O
+ O
1 O
s O
##d O
au B-PK
##c I-PK
( O
205 O
μ O
##g O
- O
h O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
for O
the O
toxicity O
end O
##point O
, O
we O
estimated O
the O
power O
to O
detect O
a O
relationship O
between O
the O
au B-PK
##c I-PK
and O
frequency O
of O
grade O
3 O
, O
4 O
or O
5 O
a O
##es O
, O
occurring O
up O
to O
and O
including O
the O
time O
on O
study O
drug O
plus O
4 O
weeks O
post O
study O
drug O
completion O
. O
[SEP] O
[CLS] O
with O
79 O
e O
##val O
##ua O
##ble O
participants O
, O
there O
will O
be O
80 O
% O
power O
to O
detect O
an O
association O
if O
the O
proportion O
with O
a O
##es O
grade O
3 O
or O
higher O
at O
mean O
au B-PK
##c I-PK
+ O
1 O
s O
##d O
is O
46 O
% O
( O
p O
##2 O
) O
and O
90 O
% O
power O
if O
the O
proportion O
is O
49 O
% O
. O
[SEP] O
[CLS] O
the O
number O
of O
adverse O
events O
grade O
3 O
or O
higher O
will O
be O
plot O
##ted O
against O
the O
au B-PK
##c I-PK
of O
the O
individual O
in O
whom O
those O
events O
occurred O
. O
[SEP] O
[CLS] O
linear O
re O
##gression O
will O
be O
used O
to O
calculate O
the O
p O
##ear O
##son O
correlation O
coefficient O
between O
au B-PK
##c I-PK
and O
number O
and O
severity O
of O
events O
. O
[SEP] O
[CLS] O
if O
the O
distribution O
of O
the O
au B-PK
##c I-PK
is O
s O
##ke O
##wed O
, O
then O
the O
au B-PK
##c I-PK
will O
be O
log O
transformed O
. O
[SEP] O
[CLS] O
the O
resulting O
relationship O
will O
be O
used O
to O
identify O
an O
au B-PK
##c I-PK
at O
which O
more O
than O
25 O
% O
of O
participants O
would O
be O
expected O
to O
have O
grade O
3 O
, O
4 O
, O
or O
5 O
adverse O
events O
. O
[SEP] O
[CLS] O
for O
to O
##ler O
##ability O
, O
log O
##istic O
re O
##gression O
will O
be O
used O
to O
model O
the O
association O
between O
these O
variables O
with O
the O
au B-PK
##c I-PK
included O
as O
a O
continuous O
co O
##var O
##iate O
. O
[SEP] O
[CLS] O
the O
primary O
objective O
is O
to O
determine O
whether O
there O
is O
sufficient O
evidence O
to O
reject O
the O
nan O
hypothesis O
that O
the O
odds O
ratio O
of O
disco O
##ntin O
##uation O
for O
a O
unit O
increase O
in O
the O
au B-PK
##c I-PK
is O
equal O
to O
1 O
. O
[SEP] O
[CLS] O
using O
the O
fish O
##er O
transformation O
of O
the O
correlation O
coefficient O
, O
we O
estimated O
that O
62 O
e O
##val O
##ua O
##ble O
patients O
would O
allow O
detection O
of O
moderate O
correlation O
( O
- O
0 O
. O
40 O
) O
between O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
and O
time O
to O
s O
##put O
##um O
- O
culture O
conversion O
with O
90 O
% O
power O
and O
two O
- O
sided O
significance O
of O
5 O
% O
. O
[SEP] O
[CLS] O
linear O
re O
##gression O
will O
be O
used O
to O
calculate O
the O
p O
##ear O
##son O
correlation O
coefficient O
between O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
and O
log O
- O
transformed O
time O
to O
culture O
conversion O
. O
[SEP] O
[CLS] O
the O
relationship O
will O
be O
plot O
##ted O
on O
a O
s O
##cat O
##ter O
plot O
of O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
against O
time O
to O
culture O
- O
conversion O
curve O
on O
the O
log O
scale O
. O
[SEP] O
[CLS] O
results O
: O
the O
peak B-PK
plasma I-PK
levels I-PK
of I-PK
v I-PK
##t I-PK
##b I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
released O
from O
the O
various O
doses O
of O
verb O
ranged O
between O
6 O
. O
19 O
- O
17 O
. O
3 O
ng O
/ O
m O
##l O
indicating O
a O
low O
systemic O
burst O
release O
. O
[SEP] O
[CLS] O
the O
plasma O
profile O
of O
v O
##t O
##b O
was O
consistent O
with O
a O
distribution O
phase O
up O
to O
6 O
h O
after O
administration O
followed O
by O
elimination O
with O
a O
half B-PK
- I-PK
life I-PK
of O
20 O
- O
23 O
h O
. O
the O
au B-PK
##c I-PK
of O
v O
##t O
##b O
and O
its O
major O
meta O
##bol O
##ite O
n O
- O
des O
##met O
##hyl O
van O
##det O
##ani O
##b O
( O
n O
##d O
##m O
v O
##t O
##b O
) O
was O
approximately O
linear O
with O
the O
dose O
strength O
of O
verb O
. O
[SEP] O
[CLS] O
materials O
and O
methods O
: O
in O
a O
first O
phase O
, O
healthy O
s O
##wine O
were O
treated O
with O
he O
##pa O
##tic O
in O
##tra O
- O
art O
##erial O
administration O
of O
verb O
at O
target O
dose O
loading O
strengths O
of O
36 O
mg O
/ O
m O
##l O
( O
verb O
##36 O
) O
, O
72 O
mg O
/ O
m O
##l O
( O
verb O
##7 O
##2 O
) O
and O
120 O
mg O
/ O
m O
##l O
( O
verb O
##12 O
##0 O
) O
. O
[SEP] O
[CLS] O
a O
4 O
f O
##r O
co O
##bra O
2 O
cat O
##he O
##ter O
( O
an O
##gio O
##dynamic O
##s O
in O
##c O
. O
) O
was O
then O
positioned O
in O
the O
c O
##eli O
##ac O
axis O
and O
a O
c O
##eli O
##ac O
an O
##gio O
##gram O
obtained O
by O
in O
##ject O
##ing O
contrast O
media O
. O
[SEP] O
[CLS] O
a O
2 O
. O
7 O
f O
##r O
micro O
##cat O
##he O
##ter O
( O
pro O
##g O
##rea O
##t O
##® O
, O
te O
##rum O
##o O
j O
##apa O
##n O
) O
was O
then O
advanced O
in O
the O
he O
##pa O
##tic O
artery O
branch O
chosen O
because O
it O
fed O
around O
50 O
% O
of O
the O
liver O
volume O
. O
[SEP] O
[CLS] O
for O
each O
animal O
, O
the O
following O
toxic O
##oki O
##net O
##ic O
parameters O
were O
determined O
: O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
of I-PK
maximum I-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
life I-PK
values I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
were O
reported O
for O
individual O
plasma O
concentration O
- O
time O
profiles O
that O
had O
sufficient O
plasma O
concentrations O
in O
the O
terminal O
elimination O
phase O
( O
at O
least O
three O
samples O
not O
including O
t B-PK
##max I-PK
) O
and O
an O
adjusted O
r O
##2 O
of O
≥ O
0 O
. O
9 O
. O
[SEP] O
[CLS] O
blood O
samples O
( O
approximately O
1 O
m O
##l O
) O
were O
collected O
from O
all O
animals O
in O
phase O
one O
via O
the O
j O
##ug O
##ular O
or O
other O
suitable O
vein O
for O
determination O
of O
the O
plasma O
concentrations O
of O
the O
test O
article O
, O
van O
##det O
##ani O
##b O
( O
v O
##t O
##b O
) O
, O
and O
the O
meta O
##bol O
##ites O
, O
n O
‑ O
des O
##met O
##hyl O
van O
##det O
##ani O
##b O
( O
n O
##d O
##m O
v O
##t O
##b O
) O
and O
van O
##det O
##ani O
##b O
n O
‑ O
oxide O
( O
v O
##t O
##b O
- O
no O
) O
. O
[SEP] O
[CLS] O
individual O
v O
##t O
##b O
, O
n O
##d O
##m O
v O
##t O
##b O
, O
unknown O
meta O
##bol O
##ite O
, O
and O
v O
##t O
##b O
- O
no O
concentration O
- O
time O
profiles O
from O
o O
##v O
##t O
##b O
, O
verb O
##36 O
, O
verb O
##7 O
##2 O
, O
or O
verb O
##12 O
##0 O
‑ O
treated O
animals O
were O
analyzed O
using O
model O
- O
independent O
methods O
. O
[SEP] O
[CLS] O
additional O
toxic O
##oki O
##net O
##ic O
parameters O
calculated O
were O
clearance B-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##z I-PK
/ I-PK
f I-PK
) I-PK
. O
[SEP] O
[CLS] O
following O
completion O
of O
em O
##bol O
##ization O
, O
vascular B-PK
blood I-PK
flow I-PK
within O
the O
treated O
lobe O
of O
the O
liver O
was O
assessed O
to O
evaluate O
level O
of O
vascular O
o O
##cc O
##lusion O
. O
[SEP] O
[CLS] O
figure O
1 O
( O
a O
) O
shows O
that O
the O
t B-PK
##max I-PK
( I-PK
time I-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
) I-PK
is O
achieved O
within O
approximately O
1 O
hour O
of O
treatment O
administration O
for O
the O
verb O
groups O
and O
approximately O
2 O
hours O
for O
o O
##v O
##t O
##b O
given O
the O
dose O
difference O
( O
21 O
mg O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
plasma O
samples O
from O
the O
phase O
one O
study O
were O
successfully O
analyzed O
for O
concentrations O
of O
v O
##t O
##b O
, O
n O
##d O
##m O
v O
##t O
##b O
and O
v O
##t O
##b O
- O
no O
. O
[SEP] O
[CLS] O
the O
fraction B-PK
of I-PK
dose I-PK
absorbed I-PK
( I-PK
f I-PK
) I-PK
was O
not O
determined O
; O
therefore O
v B-PK
##z I-PK
/ I-PK
f I-PK
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
were O
not O
normal O
##ized O
for O
the O
fraction B-PK
of I-PK
dose I-PK
absorbed I-PK
. O
[SEP] O
[CLS] O
figure O
1 O
( O
b O
) O
shows O
that O
the O
values O
of O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( O
levels O
of O
drug O
in O
the O
plasma O
over O
time O
) O
measured O
after O
either O
24 O
hours O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
) O
or O
until O
the O
last O
q O
##uant O
##ifiable O
measurement O
was O
made O
( O
au B-PK
##ct I-PK
##last I-PK
) O
, O
are O
linear O
##ly O
correlated O
for O
both O
v O
##t O
##b O
and O
n O
##d O
##m O
v O
##t O
##b O
with O
the O
dose O
of O
v O
##t O
##b O
administered O
in O
the O
beads O
. O
[SEP] O
[CLS] O
none O
of O
these O
treatment O
- O
related O
findings O
were O
present O
in O
the O
un O
##tre O
##ated O
liver O
section O
and O
are O
consistent O
with O
impaired O
blood B-PK
flow I-PK
with O
subsequent O
ne O
##c O
##rosis O
and O
regeneration O
. O
[SEP] O
[CLS] O
we O
h O
##y O
##pot O
##hes O
##ize O
that O
the O
observed O
trends O
after O
z O
##ea O
and O
t O
- O
2 O
exposure O
are O
related O
to O
the O
c O
##yt O
##oto O
##xi O
##c O
effect O
of O
t O
- O
2 O
, O
resulting O
in O
an O
increased O
absorption B-PK
rate I-PK
constant I-PK
ka I-PK
. O
[SEP] O
[CLS] O
however O
, O
oral O
plasma O
concentration O
- O
time O
profiles O
showed O
quantitative O
differences O
in O
absolute B-PK
oral I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
f I-PK
[ O
p O
- O
value O
( O
an O
##ova O
) O
= O
0 O
. O
02 O
##2 O
] O
, O
au B-PK
##c I-PK
_ I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
( O
μ O
##g O
##∗ O
##h O
/ O
l O
) O
[ O
p O
- O
value O
( O
an O
##ova O
) O
= O
0 O
. O
02 O
##3 O
] O
, O
k B-PK
##e I-PK
( O
1 O
/ O
h O
) O
[ O
p O
- O
value O
( O
an O
##ova O
) O
= O
0 O
. O
00 O
##4 O
] O
, O
and O
ka B-PK
( O
1 O
/ O
h O
) O
[ O
p O
- O
value O
( O
an O
##ova O
) O
= O
0 O
. O
03 O
##1 O
] O
. O
[SEP] O
[CLS] O
although O
only O
differences O
in O
k B-PK
##e I-PK
estimates O
after O
oral O
administration O
reached O
significance O
in O
the O
post O
ho O
##c O
analysis O
due O
to O
inequality O
of O
the O
variance O
##s O
. O
[SEP] O
[CLS] O
oral B-PK
c I-PK
##l I-PK
and O
v B-PK
##d I-PK
were O
corrected O
for O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
f B-PK
. O
[SEP] O
[CLS] O
a O
non O
- O
compartment O
##al O
analysis O
( O
n O
##ca O
) O
was O
performed O
to O
calculate O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
_ I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
, O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
, O
and O
the O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##e I-PK
) I-PK
after O
i O
##v O
dos O
##ing O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
_ I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
, O
c B-PK
##l I-PK
, O
v B-PK
##d I-PK
, O
cm B-PK
##ax I-PK
( I-PK
ma I-PK
##ximal I-PK
plasma I-PK
concentration I-PK
) I-PK
, O
t B-PK
##max I-PK
( I-PK
time I-PK
to I-PK
cm I-PK
##ax I-PK
) I-PK
, O
k B-PK
##e I-PK
, O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
, O
and O
f B-PK
( I-PK
absolute I-PK
oral I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
) I-PK
were O
calculated O
after O
p O
##o O
dos O
##ing O
. O
[SEP] O
[CLS] O
in O
this O
table O
, O
the O
v B-PK
##max I-PK
, O
and O
km B-PK
values O
are O
the O
values O
corresponding O
to O
an O
inhibitor O
concentration O
of O
zero O
. O
[SEP] O
[CLS] O
of O
notice O
are O
the O
results O
for O
c B-PK
##l I-PK
, O
v B-PK
##d I-PK
, O
and O
k B-PK
##e I-PK
amongst O
the O
three O
groups O
, O
with O
nearly O
identical O
estimates O
, O
which O
suggest O
equal O
elimination O
characteristics O
. O
[SEP] O
[CLS] O
considering O
this O
similar O
c B-PK
##l I-PK
and O
lower O
v B-PK
##d I-PK
, O
the O
t O
- O
2 O
group O
showed O
a O
statistical O
significant O
higher O
k B-PK
##e I-PK
estimate O
( O
p O
= O
0 O
. O
00 O
##4 O
) O
, O
highlighting O
a O
potential O
different O
elimination B-PK
half I-PK
- I-PK
life I-PK
in O
the O
t O
- O
2 O
group O
. O
[SEP] O
[CLS] O
further O
##more O
, O
the O
average O
ka B-PK
of O
the O
t O
- O
2 O
group O
was O
about O
2 O
. O
5 O
times O
higher O
compared O
to O
the O
control O
group O
. O
[SEP] O
[CLS] O
a O
change O
in O
ka B-PK
should O
result O
in O
a O
change O
in O
t B-PK
##max I-PK
values O
. O
[SEP] O
[CLS] O
however O
, O
this O
was O
not O
reflected O
in O
the O
average O
t B-PK
##max I-PK
for O
the O
t O
- O
2 O
group O
. O
[SEP] O
[CLS] O
the O
reason O
is O
that O
one O
pig O
showed O
a O
t B-PK
##max I-PK
of O
4 O
h O
, O
while O
the O
other O
t B-PK
##max I-PK
values O
ranged O
between O
0 O
. O
16 O
and O
1 O
. O
5 O
h O
. O
in O
the O
control O
group O
this O
range O
was O
between O
0 O
. O
67 O
and O
2 O
h O
. O
removing O
the O
observation O
from O
the O
analysis O
resulted O
in O
a O
mean O
t B-PK
##max I-PK
value O
of O
0 O
. O
71 O
##4 O
± O
0 O
. O
55 O
##9 O
h O
. O
however O
, O
the O
result O
was O
not O
significantly O
different O
amongst O
the O
groups O
( O
p O
= O
0 O
. O
170 O
) O
. O
[SEP] O
[CLS] O
thin O
layer O
ch O
##roma O
##tography O
( O
t O
##l O
##c O
) O
was O
performed O
using O
pre O
##coat O
##ed O
si O
##lica O
gel O
60 O
f O
##25 O
##4 O
plates O
and O
visual O
##ized O
using O
an O
##isa O
##lde O
##hy O
##de O
solution O
, O
heat O
, O
and O
u O
##v O
light O
( O
254 O
nm O
) O
. O
[SEP] O
[CLS] O
the O
following O
abbreviation O
##s O
were O
used O
to O
describe O
peak O
splitting O
patterns O
: O
br O
= O
broad O
, O
s O
= O
single O
##t O
, O
d O
= O
double O
##t O
, O
t O
= O
triple O
##t O
, O
q O
= O
quartet O
, O
m O
= O
multiple O
##t O
, O
d O
##d O
= O
double O
##t O
of O
double O
##ts O
, O
t O
##d O
= O
triple O
##t O
of O
double O
##ts O
, O
d O
##dd O
= O
double O
##t O
of O
double O
##ts O
of O
double O
##ts O
. O
[SEP] O
[CLS] O
for O
protein O
fraction O
##ation O
, O
brain O
tissues O
were O
ho O
##mo O
##gen O
##ized O
with O
ice O
cold O
t O
##bs O
- O
containing O
protein O
##ase O
inhibitor O
##s O
, O
followed O
by O
cent O
##ri O
##fu O
##gation O
( O
100 O
k O
##× O
##g O
, O
30 O
min O
) O
. O
[SEP] O
[CLS] O
a O
##β O
##o O
( O
0 O
. O
1 O
μ O
##m O
, O
45 O
min O
per O
##fusion O
) O
alone O
significantly O
decreased O
the O
magnitude O
of O
h O
##lt O
##p O
( O
145 O
. O
3 O
##± O
##10 O
. O
9 O
% O
) O
, O
and O
this O
effect O
was O
prevented O
by O
co O
- O
application O
of O
t O
##p O
##70 O
( O
1 O
μ O
##m O
, O
45 O
min O
treatment O
prior O
to O
recordings O
; O
fi O
##g O
. O
5 O
##d O
, O
e O
) O
. O
[SEP] O
[CLS] O
h O
##lt O
##p O
is O
a O
well O
- O
established O
cellular O
model O
of O
learning O
and O
memory O
and O
has O
been O
shown O
to O
be O
impaired O
in O
several O
ad O
models O
associated O
with O
a O
##β O
toxicity O
. O
[SEP] O
[CLS] O
in O
addition O
, O
week O
16 O
data O
values O
were O
included O
from O
a O
sub O
##st O
##ud O
##y O
( O
n O
= O
52 O
; O
50 O
maximum B-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
values O
available O
) O
in O
which O
subjects O
who O
administered O
l O
##ira O
##g O
##lut O
##ide O
in O
the O
evening O
had O
blood O
drawn O
for O
l O
##ira O
##g O
##lut O
##ide O
bio O
##ana O
##lysis O
at O
approximately O
10 O
, O
11 O
, O
12 O
and O
14 O
h O
after O
dos O
##ing O
, O
to O
obtain O
exposure O
values O
around O
cm B-PK
##ax I-PK
for O
l O
##ira O
##g O
##lut O
##ide O
3 O
. O
0 O
mg O
. O
[SEP] O
[CLS] O
to O
ensure O
id O
##ent O
##if O
##iability O
of O
the O
model O
with O
the O
sparse O
##ly O
sampled O
data O
, O
the O
l O
##ira O
##g O
##lut O
##ide O
absorption B-PK
rate I-PK
constant I-PK
was O
set O
to O
a O
value O
( O
0 O
. O
08 O
##0 O
##6 O
l O
/ O
h O
##− O
##1 O
) O
estimated O
from O
a O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
based O
on O
a O
multiple O
- O
dose O
clinical O
p O
##har O
##ma O
##cology O
study O
in O
o O
##bes O
##e O
subjects O
( O
[ O
8 O
] O
; O
data O
on O
file O
) O
, O
and O
the O
assumption O
that O
this O
parameter O
can O
be O
fixed O
without O
affecting O
the O
conclusions O
was O
verified O
by O
sensitivity O
analyses O
. O
[SEP] O
[CLS] O
graphical O
data O
quality O
analyses O
, O
including O
goodness O
- O
of O
- O
fit O
plots O
, O
were O
conducted O
prior O
to O
performing O
the O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
, O
as O
described O
in O
the O
online O
resource O
( O
sect O
. O
[SEP] O
[CLS] O
compared O
with O
a O
reference O
subject O
weighing O
100 O
kg O
, O
higher O
body O
weight O
was O
associated O
with O
decreased O
l O
##ira O
##g O
##lut O
##ide O
exposure O
, O
and O
lower O
body O
weight O
was O
associated O
with O
increased O
exposure O
; O
for O
a O
234 O
kg O
subject O
( O
the O
highest O
observed O
body O
weight O
in O
the O
data O
##set O
) O
, O
l O
##ira O
##g O
##lut O
##ide O
exposure O
was O
44 O
% O
lower O
( O
78 O
% O
higher O
c B-PK
##l I-PK
/ I-PK
f I-PK
) O
. O
[SEP] O
[CLS] O
the O
time B-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
peak I-PK
plasma I-PK
concentration I-PK
of O
a O
drug O
after O
administration O
in O
biological O
systems O
can O
be O
used O
as O
an O
index O
of O
the O
drug B-PK
absorption I-PK
rate I-PK
. O
[SEP] O
[CLS] O
in O
our O
research O
, O
in O
oral O
administration O
groups O
, O
the O
t B-PK
##max I-PK
values O
range O
from O
22 O
to O
200 O
min O
. O
[SEP] O
[CLS] O
although O
the O
t B-PK
##max I-PK
and O
the O
m B-PK
##rt I-PK
of O
oral O
##ly O
given O
s O
##chi O
##zan O
##dr O
##in O
group O
were O
shorter O
than O
that O
of O
s O
. O
chin O
##ensis O
( O
p O
< O
0 O
. O
05 O
) O
groups O
, O
there O
were O
no O
significant O
differences O
in O
the O
clearance B-PK
##s I-PK
among O
the O
three O
groups O
. O
[SEP] O
[CLS] O
our O
findings O
indicated O
that O
the O
t B-PK
##max I-PK
and O
m B-PK
##rt I-PK
values O
of O
oral O
##ly O
ing O
##est O
##ing O
s O
. O
chin O
##ensis O
products O
are O
larger O
than O
that O
of O
the O
dos O
##ing O
single O
component O
s O
##chi O
##zan O
##dr O
##in O
, O
which O
also O
matches O
fear O
##y O
’ O
s O
study O
[ O
34 O
] O
. O
[SEP] O
[CLS] O
according O
to O
the O
comparative O
p O
##har O
##ma O
##co O
##kin O
##etics O
results O
shown O
in O
table O
4 O
, O
the O
cm B-PK
##ax I-PK
and O
t B-PK
##max I-PK
of O
pharmaceutical O
industry O
s O
. O
chin O
##ensis O
products O
were O
significantly O
different O
from O
that O
of O
single O
ing O
##est O
##ion O
group O
. O
[SEP] O
[CLS] O
the O
s O
##chi O
##zan O
##dr O
##in O
levels O
in O
the O
plasma O
of O
rats O
given O
the O
commercial O
pharmaceutical O
products O
showed O
a O
later O
t B-PK
##max I-PK
and O
longer O
per O
##sistence O
than O
the O
levels O
in O
rats O
given O
the O
pure O
compound O
. O
[SEP] O
[CLS] O
he O
##pa O
##tic O
first O
- O
pass O
and O
in O
##test O
##inal O
effects O
are O
widely O
acknowledged O
to O
be O
responsible O
for O
the O
low O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
s O
##chi O
##zan O
##dr O
##in O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
in O
##tra O
##ven O
##ous O
group O
revealed O
the O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
and O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
for O
m B-PK
##rt I-PK
was O
34 O
. O
80 O
min O
, O
the O
c B-PK
##l I-PK
was O
0 O
. O
09 O
l O
/ O
min O
, O
and O
the O
au B-PK
##c I-PK
was O
43 O
. O
11 O
min O
ng O
/ O
m O
##l O
, O
suggesting O
that O
the O
elimination O
process O
is O
rapid O
. O
[SEP] O
[CLS] O
the O
short O
half B-PK
- I-PK
life I-PK
, O
short O
mean B-PK
residence I-PK
time I-PK
and O
high O
clearance B-PK
rate I-PK
of O
s O
##chi O
##zan O
##dr O
##in O
imply O
that O
the O
elimination O
process O
might O
be O
rapid O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
calculated O
using O
the O
following O
formula O
: O
f O
( O
% O
) O
= O
100 O
× O
( O
au O
##cor O
##al O
/ O
do O
##ral O
) O
/ O
( O
au O
##ci O
##v O
/ O
di O
##v O
) O
. O
[SEP] O
[CLS] O
in O
our O
study O
, O
we O
used O
the O
au B-PK
##ci I-PK
##v I-PK
value O
of O
s O
##chi O
##zan O
##dr O
##in O
to O
calculate O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
s O
##chi O
##zan O
##dr O
##in O
and O
s O
. O
chin O
##ensis O
( O
3 O
g O
/ O
kg O
and O
10 O
g O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
finally O
, O
traditional O
chin O
##ese O
medicines O
have O
been O
used O
for O
thousands O
of O
years O
in O
as O
##ia O
, O
and O
there O
is O
still O
a O
large O
amount O
of O
empirical O
information O
awaiting O
new O
scientific O
explanations O
. O
[SEP] O
[CLS] O
stability O
was O
evaluated O
under O
four O
conditions O
: O
short O
- O
term O
stability O
kept O
at O
room O
temperature O
for O
6 O
h O
; O
post O
- O
pre O
##par O
##ative O
stability O
kept O
in O
the O
auto O
##sa O
##mple O
##r O
at O
8 O
° O
##c O
for O
6 O
h O
; O
long O
- O
term O
stability O
kept O
at O
− O
##80 O
° O
##c O
for O
1 O
month O
; O
and O
freeze O
- O
th O
##aw O
stability O
: O
three O
samples O
were O
frozen O
and O
stored O
at O
− O
##20 O
° O
##c O
for O
24 O
h O
and O
then O
th O
##awed O
at O
room O
temperature O
. O
[SEP] O
[CLS] O
recovery O
( O
% O
) O
and O
matrix O
effects O
( O
% O
) O
were O
calculated O
by O
using O
the O
peak O
area O
of O
set O
2 O
/ O
set O
1 O
and O
set O
3 O
/ O
set O
2 O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
v O
##it O
##ro O
release O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
studies O
were O
used O
to O
evaluate O
the O
dissolution O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
g O
##ps O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
revealed O
an O
8 O
. O
5 O
- O
fold O
increase O
of O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
g O
##ps O
- O
s O
##g O
##c O
- O
n O
##l O
##cs O
compared O
with O
g O
##ps O
powder O
. O
[SEP] O
[CLS] O
initially O
, O
each O
sample O
was O
di O
##lut O
##ed O
with O
appropriate O
volume O
of O
di O
##st O
##ille O
##d O
water O
and O
a O
drop O
was O
added O
to O
a O
film O
- O
coated O
copper O
grid O
( O
z O
##hong O
ji O
##ng O
k O
##e O
y O
##i O
technology O
in O
##c O
. O
, O
be O
##iji O
##ng O
, O
chin O
##a O
) O
and O
air O
dried O
for O
about O
20 O
minutes O
. O
[SEP] O
[CLS] O
the O
three O
independent O
variables O
were O
the O
total O
lip O
##id O
concentration O
( O
solid O
and O
liquid O
lip O
##ids O
, O
x O
##1 O
) O
, O
the O
ratio O
of O
liquid O
lip O
##id O
to O
total O
lip O
##id O
( O
x O
##2 O
) O
, O
and O
the O
surf O
##act O
##ant O
concentration O
( O
x O
##3 O
) O
. O
[SEP] O
[CLS] O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
of I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
were O
determined O
from O
the O
raw O
data O
. O
[SEP] O
[CLS] O
p B-PK
##ap I-PK
##p I-PK
was O
calculated O
using O
the O
following O
equation O
: O
p O
##ap O
##p O
= O
q O
##ln O
( O
co O
##ut O
##q O
##out O
##cin O
##qi O
##n O
) O
2 O
##π O
##rl O
( O
3 O
) O
where O
q O
##in O
and O
q O
##out O
are O
the O
volume O
of O
the O
inlet O
and O
outlet O
per O
##fu O
##sat O
##es O
, O
respectively O
; O
c O
##in O
and O
co O
##ut O
are O
the O
drug O
concentrations O
of O
the O
inlet O
and O
outlet O
per O
##fu O
##sat O
##es O
, O
respectively O
; O
q O
is O
the O
flow O
rate O
; O
l O
and O
r O
are O
the O
length O
and O
radius O
of O
the O
in O
##test O
##ine O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
particle O
size O
decreases O
with O
an O
increase O
in O
the O
ratio O
of O
liquid O
lip O
##id O
to O
total O
lip O
##id O
. O
[SEP] O
[CLS] O
as O
shown O
in O
table O
4 O
, O
the O
absorption O
of O
g O
##ps O
powder O
suspension O
( O
t B-PK
##max I-PK
= O
0 O
. O
79 O
##2 O
hour O
) O
was O
shorter O
than O
that O
of O
g O
##ps O
- O
n O
##l O
##cs O
( O
t B-PK
##max I-PK
= O
1 O
. O
41 O
##7 O
hour O
) O
and O
g O
##ps O
- O
s O
##g O
##c O
- O
n O
##l O
##cs O
( O
t B-PK
##max I-PK
= O
2 O
. O
250 O
hour O
) O
, O
suggesting O
that O
g O
##ps O
powder O
suspension O
was O
absorbed O
more O
rapidly O
than O
n O
##l O
##cs O
, O
with O
g O
##ps O
- O
s O
##g O
##c O
- O
n O
##l O
##cs O
displaying O
the O
longest O
absorption O
. O
[SEP] O
[CLS] O
the O
results O
of O
t B-PK
##max I-PK
and O
m B-PK
##rt I-PK
indicate O
that O
the O
drug O
in O
g O
##ps O
- O
s O
##g O
##c O
- O
n O
##l O
##cs O
remains O
in O
circulation O
for O
a O
significantly O
longer O
period O
of O
time O
. O
[SEP] O
[CLS] O
the O
stab O
##ili O
##zing O
effect O
might O
extend O
the O
resident B-PK
time I-PK
of O
g O
##ps O
- O
s O
##g O
##c O
- O
n O
##l O
##cs O
in O
the O
gas O
##tro O
##int O
##est O
##inal O
tract O
, O
18 O
resulting O
in O
longer O
t B-PK
##max I-PK
and O
m B-PK
##rt I-PK
compared O
with O
that O
of O
g O
##ps O
powder O
suspension O
and O
g O
##ps O
- O
n O
##l O
##cs O
. O
[SEP] O
[CLS] O
the O
s O
##g O
##c O
- O
n O
##l O
##cs O
could O
significantly O
enhance O
the O
absorption O
of O
drugs O
with O
the O
excellent O
bio O
##com O
##pa O
##ti O
##bility O
of O
n O
##l O
##cs O
and O
by O
promoting O
the O
trans O
##me O
##mb O
##rane O
transportation O
of O
s O
##g O
##c O
, O
which O
would O
result O
in O
a O
greater O
improvement O
of O
drug O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
model O
parameters O
were O
v B-PK
/ I-PK
f I-PK
, O
which O
is O
the O
ratio O
between O
volume B-PK
and O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
t O
and O
t B-PK
##lag I-PK
represent O
time O
and O
the O
la B-PK
##g I-PK
time I-PK
, O
respectively O
, O
and O
ka B-PK
and O
k B-PK
are O
the O
absorption B-PK
rate I-PK
constant I-PK
and O
the O
elimination B-PK
rate I-PK
constant I-PK
, O
respectively O
. O
[SEP] O
[CLS] O
the O
following O
p O
##k O
parameters O
were O
determined O
: O
maximum B-PK
observed I-PK
serum I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
cm B-PK
##ax I-PK
/ I-PK
dose I-PK
, O
area B-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
( I-PK
pre I-PK
- I-PK
dose I-PK
) I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
infinite I-PK
time I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
/ I-PK
dose I-PK
, O
distribution B-PK
phase I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##½ I-PK
, I-PK
α I-PK
) I-PK
, O
terminal B-PK
phase I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##½ I-PK
, I-PK
β I-PK
) I-PK
, O
systemic B-PK
clearance I-PK
of I-PK
parent I-PK
drug I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
for I-PK
the I-PK
central I-PK
compartment I-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
. O
[SEP] O
[CLS] O
blood O
samples O
were O
evaluated O
for O
anti O
- O
be O
##lim O
##uma O
##b O
antibodies O
at O
pre O
- O
dose O
, O
and O
days O
14 O
and O
84 O
. O
[SEP] O
[CLS] O
no O
significant O
difference O
was O
found O
in O
terms O
of O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
to O
##l O
##but O
##ami O
##de O
( O
au B-PK
##c I-PK
( I-PK
0 I-PK
##→ I-PK
##t I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
and O
c B-PK
##l I-PK
) O
between O
lent O
##ina O
##n O
and O
b O
##c O
##g O
groups O
. O
[SEP] O
[CLS] O
interesting O
##ly O
, O
as O
the O
dose O
of O
lent O
##ina O
##n O
increased O
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
##→ I-PK
##t I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
and O
c B-PK
##l I-PK
of O
o O
##me O
##pra O
##zo O
##le O
in O
m O
##t O
##g O
and O
h O
##t O
##g O
showed O
no O
obvious O
changes O
from O
the O
b O
##c O
##g O
group O
. O
[SEP] O
[CLS] O
c B-PK
##l I-PK
( I-PK
plasma I-PK
clearance I-PK
) I-PK
of O
p O
##hen O
##ace O
##tin O
was O
remarkably O
elevated O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
we O
therefore O
hypothesis O
##ed O
that O
co O
##ad O
##mini O
##stra O
##tion O
of O
im O
##ati O
##ni O
##b O
, O
as O
an O
inhibitor O
of O
the O
micro O
##so O
##mal O
c O
##y O
##p O
##3 O
##a O
##4 O
enzyme O
system O
, O
could O
affect O
the O
elimination B-PK
rate I-PK
of O
si O
##m O
##vas O
##tat O
##in O
. O
[SEP] O
[CLS] O
the O
present O
study O
was O
undertaken O
to O
assess O
this O
potential O
p O
##har O
##ma O
##co O
##kin O
##etic O
interaction O
by O
evaluation O
of O
the O
si O
##m O
##vas O
##tat O
##in O
plasma O
concentration O
vs O
time O
profiles O
after O
co O
##ad O
##mini O
##stra O
##tion O
with O
im O
##ati O
##ni O
##b O
( O
us O
department O
of O
health O
and O
human O
services O
, O
1999 O
) O
and O
its O
effects O
on O
safety O
and O
to O
##ler O
##ability O
in O
patients O
with O
chronic O
my O
##elo O
##id O
le O
##uka O
##emia O
( O
cm O
##l O
) O
. O
[SEP] O
[CLS] O
for O
plasma O
concentrations O
of O
si O
##m O
##vas O
##tat O
##in O
the O
following O
parameters O
were O
determined O
: O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
t I-PK
) I-PK
( I-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
t I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
( I-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
) I-PK
, O
cm B-PK
##ax I-PK
( I-PK
maximum I-PK
plasma I-PK
drug I-PK
concentration I-PK
) I-PK
, O
t B-PK
##max I-PK
( I-PK
time I-PK
to I-PK
reach I-PK
maximum I-PK
concentration I-PK
following I-PK
drug I-PK
administration I-PK
) I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( I-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
associated I-PK
with I-PK
terminal I-PK
slope I-PK
of I-PK
a I-PK
semi I-PK
##log I-PK
##ari I-PK
##th I-PK
##mic I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
) I-PK
, O
v B-PK
##z I-PK
/ I-PK
f I-PK
( I-PK
apparent I-PK
volume I-PK
of I-PK
distribution I-PK
based I-PK
on I-PK
terminal I-PK
phase I-PK
of I-PK
plasma I-PK
concentration I-PK
– I-PK
time I-PK
curves I-PK
) I-PK
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
( I-PK
total I-PK
body I-PK
clearance I-PK
of I-PK
drug I-PK
from I-PK
the I-PK
plasma I-PK
) I-PK
, O
in O
order O
to O
assess O
the O
effects O
of O
im O
##ati O
##ni O
##b O
on O
the O
p O
##k O
of O
si O
##m O
##vas O
##tat O
##in O
. O
[SEP] O
[CLS] O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
used O
to O
assess O
an O
interaction O
of O
im O
##ati O
##ni O
##b O
on O
si O
##m O
##vas O
##tat O
##in O
: O
au B-PK
##cin I-PK
##f I-PK
, O
au B-PK
##cal I-PK
##l I-PK
, O
cm B-PK
##ax I-PK
, O
v B-PK
##z I-PK
/ I-PK
f I-PK
, O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
with O
the O
exception O
of O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
t B-PK
##max I-PK
, O
parameters O
were O
l O
##n O
- O
transformed O
prior O
to O
analysis O
. O
[SEP] O
[CLS] O
t B-PK
##max I-PK
was O
anal O
##ys O
##ed O
non O
##par O
##ame O
##tric O
##ally O
. O
[SEP] O
[CLS] O
following O
im O
##ati O
##ni O
##b O
co O
##ad O
##mini O
##stra O
##tion O
, O
the O
mean O
si O
##m O
##vas O
##tat O
##in O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
all I-PK
) I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
– I-PK
∞ I-PK
) I-PK
increased O
significantly O
by O
two O
- O
to O
- O
three O
- O
fold O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
extra B-PK
##pol I-PK
##ation I-PK
to I-PK
time I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
was O
calculated O
as O
follows O
: O
au O
##c O
##0 O
– O
∞ O
= O
au O
##c O
##0 O
– O
t O
+ O
c O
##t O
/ O
k O
##e O
, O
( O
3 O
) O
where O
c B-PK
##t I-PK
was O
the O
last B-PK
me I-PK
##as I-PK
##urable I-PK
plasma I-PK
concentration I-PK
and O
k B-PK
##e I-PK
was O
the O
terminal B-PK
elimination I-PK
rate I-PK
constant I-PK
. O
[SEP] O
[CLS] O
results O
of O
drug O
loading O
and O
en O
##cap O
##sul O
##ation O
efficiency O
indicated O
that O
1 O
: O
5 O
( O
l O
##v O
##t O
: O
p O
##la O
) O
was O
the O
optimal O
ratio O
. O
[SEP] O
[CLS] O
an O
experiment O
comparing O
bi O
##ab O
- O
mediated O
p O
##ha O
##go O
##cy O
##tosis O
of O
wild O
- O
type O
( O
double O
- O
positive O
) O
r O
##aj O
##i O
cells O
with O
engineered O
r O
##aj O
##i O
c O
##d O
##19 O
knockout O
cells O
supports O
this O
idea O
. O
[SEP] O
[CLS] O
at O
52 O
weeks O
, O
mean O
( O
standard O
error O
) O
h O
##ba O
##1 O
##c O
was O
7 O
. O
38 O
( O
0 O
. O
03 O
) O
% O
with O
bi O
##l O
and O
7 O
. O
61 O
( O
0 O
. O
04 O
) O
% O
with O
g O
##l O
{ O
difference O
− O
##0 O
. O
22 O
% O
[ O
95 O
% O
confidence O
interval O
( O
c O
##i O
) O
− O
##0 O
. O
32 O
, O
− O
##0 O
. O
12 O
] O
; O
p O
< O
0 O
. O
00 O
##1 O
} O
. O
at O
52 O
weeks O
more O
bi O
##l O
‐ O
treated O
patients O
reached O
h O
##ba O
##1 O
##c O
< O
7 O
% O
( O
35 O
% O
vs O
26 O
% O
; O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
the O
no O
##cturnal O
h O
##y O
##po O
##gly O
##ca O
##emia O
rate O
was O
47 O
% O
lower O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
and O
the O
total O
h O
##y O
##po O
##gly O
##ca O
##emia O
rate O
was O
11 O
% O
higher O
( O
p O
= O
0 O
. O
00 O
##2 O
) O
than O
in O
g O
##l O
‐ O
treated O
patients O
, O
and O
there O
was O
no O
difference O
in O
severe O
h O
##y O
##po O
##gly O
##ca O
##emia O
rate O
. O
[SEP] O
[CLS] O
investigators O
were O
permitted O
to O
make O
further O
insulin O
adjustments O
at O
any O
point O
, O
depending O
on O
clinical O
circumstances O
( O
e O
. O
g O
. O
h O
##y O
##po O
##gly O
##ca O
##emia O
) O
. O
[SEP] O
[CLS] O
the O
proportion O
of O
patients O
with O
total O
bi O
##li O
##ru O
##bin O
≥ O
##2 O
× O
ul O
##n O
at O
any O
time O
after O
base O
##line O
was O
higher O
with O
g O
##l O
treatment O
( O
g O
##l O
0 O
. O
9 O
% O
vs O
bi O
##l O
0 O
% O
; O
p O
= O
0 O
. O
02 O
##7 O
) O
. O
[SEP] O
[CLS] O
g O
– O
a O
is O
the O
most O
abundant O
an O
##xi O
##oly O
##tic O
compound O
in O
this O
plant O
, O
while O
gal O
##phi O
##mine O
- O
e O
( O
g O
– O
e O
) O
is O
the O
most O
abundant O
gal O
##phi O
##mine O
, O
but O
inactive O
. O
[SEP] O
[CLS] O
g O
– O
e O
was O
transformed O
chemical O
##ly O
into O
g O
– O
a O
. O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
was O
carried O
out O
in O
i O
##c O
##r O
mice O
, O
which O
were O
oral O
##ly O
administered O
a O
single O
200 O
mg O
/ O
kg O
dose O
of O
g O
– O
a O
. O
samples O
of O
blood O
and O
brain O
were O
taken O
at O
different O
times O
after O
administration O
of O
g O
– O
a O
. O
previously O
, O
we O
established O
the O
valid O
##ation O
of O
methods O
for O
determining O
the O
concentration O
of O
g O
– O
a O
. O
the O
g O
– O
a O
was O
detected O
in O
plasma O
5 O
min O
after O
oral O
administration O
, O
and O
its O
concentration O
reached O
2 O
. O
47 O
μ O
##g O
/ O
m O
##l O
. O
data O
from O
concentration O
- O
time O
curves O
allowed O
us O
to O
establish O
the O
main O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
in O
two O
models O
: O
one O
- O
and O
/ O
or O
two O
- O
compartment O
. O
[SEP] O
[CLS] O
the O
g O
– O
a O
in O
brain O
tissue O
was O
noted O
to O
cross O
the O
blood O
- O
brain O
barrier O
, O
reaching O
cm B-PK
##ax I-PK
2 O
. O
74 O
μ O
##g O
/ O
m O
##l O
, O
t B-PK
##max I-PK
81 O
. O
6 O
min O
, O
and O
then O
drop O
gradually O
to O
0 O
. O
32 O
μ O
##g O
/ O
m O
##l O
detected O
at O
24 O
h O
. O
the O
presence O
of O
g O
– O
a O
in O
brain O
tissue O
, O
confirmed O
that O
this O
an O
##xi O
##oly O
##tic O
compound O
can O
access O
the O
target O
organ O
and O
acts O
directly O
on O
the O
c O
##ns O
. O
[SEP] O
[CLS] O
figure O
2 O
, O
panels O
( O
a O
) O
and O
( O
b O
) O
illustrate O
the O
ch O
##roma O
##to O
##graphic O
profile O
of O
g O
– O
a O
and O
g O
– O
e O
. O
retention O
times O
( O
r O
##t O
) O
for O
g O
– O
a O
and O
g O
– O
e O
were O
7 O
. O
12 O
and O
8 O
. O
29 O
min O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
presence O
of O
the O
ace O
##tate O
group O
at O
the O
c O
##7 O
position O
of O
g O
– O
e O
increased O
the O
retention O
time O
; O
this O
fact O
was O
useful O
in O
order O
to O
monitor O
the O
transformation O
of O
g O
– O
e O
to O
g O
– O
a O
. O
due O
to O
this O
difference O
in O
r O
##t O
, O
g O
– O
a O
of O
high O
purity O
was O
later O
obtained O
. O
[SEP] O
[CLS] O
regarding O
the O
performance O
of O
g O
– O
a O
in O
the O
brain O
compartment O
, O
it O
reached O
cm B-PK
##ax I-PK
of O
2 O
. O
74 O
μ O
##g O
/ O
m O
##l O
, O
t B-PK
##max I-PK
81 O
. O
6 O
min O
( O
table O
6 O
) O
, O
and O
then O
dropped O
gradually O
to O
0 O
. O
32 O
μ O
##g O
/ O
m O
##l O
detected O
at O
24 O
h O
. O
such O
a O
good O
distribution O
of O
g O
– O
a O
in O
the O
brain O
is O
certainly O
a O
result O
of O
the O
lip O
##op O
##hil O
##ic O
properties O
of O
the O
molecule O
, O
which O
allows O
it O
to O
easily O
cross O
the O
blood O
- O
brain O
barrier O
. O
[SEP] O
[CLS] O
the O
equations O
describing O
the O
compartment O
##s O
are O
as O
follows O
: O
c O
##p O
= O
c O
##1 O
##e O
##− O
##k O
##dt O
+ O
c O
##2 O
##e O
##− O
##kat O
( O
one O
compartment O
model O
) O
c O
##p O
= O
c O
##1 O
##e O
##− O
##α O
##t O
+ O
c O
##2 O
##e O
##− O
##β O
##t O
+ O
c O
##3 O
##e O
##− O
##k O
##dt O
( O
two O
compartment O
mode O
) O
where O
c O
##p O
is O
the O
plasma O
concentration O
( O
μ O
##g O
/ O
m O
##l O
) O
; O
k B-PK
##d I-PK
, I-PK
β I-PK
, I-PK
disposition I-PK
rate I-PK
constant I-PK
( O
min O
##− O
##1 O
) O
; O
ka B-PK
, I-PK
absorption I-PK
rate I-PK
constant I-PK
( O
min O
##− O
##1 O
) O
; O
c O
##1 O
, O
c O
##2 O
and O
c O
##3 O
, O
coefficients O
( O
µ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
area I-PK
under I-PK
the I-PK
g I-PK
– I-PK
a I-PK
concentration I-PK
time I-PK
curve I-PK
throughout O
the O
measurement O
period O
reached O
values O
of O
2 O
, O
170 O
and O
2 O
, O
03 O
##0 O
μ O
##g O
· O
min O
· O
m O
##l O
##− O
##1 O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
for O
g O
– O
a O
was O
comparable O
in O
the O
two O
models O
analyzed O
compared O
to O
the O
au B-PK
##c I-PK
##0 I-PK
##→ I-PK
##∞ I-PK
found O
for O
oral O
administration O
of O
g O
##ly O
##cy O
##rr O
##he O
##tin O
##ic O
acid O
in O
mice O
: O
2 O
, O
45 O
##4 O
µ O
##g O
· O
min O
· O
m O
##l O
##− O
##1 O
[ O
10 O
] O
. O
[SEP] O
[CLS] O
to O
transform O
the O
obtained O
g O
– O
e O
into O
g O
– O
a O
, O
the O
dried O
product O
containing O
g O
– O
e O
was O
dissolved O
in O
a O
saturated O
k O
##h O
##co O
##3 O
solution O
( O
2 O
mg O
/ O
m O
##l O
of O
g O
– O
e O
) O
. O
[SEP] O
[CLS] O
g O
– O
a O
concentration O
was O
obtained O
by O
comparison O
with O
a O
pre O
- O
built O
ca O
##li O
##bra O
##tion O
curve O
at O
λ O
= O
220 O
nm O
. O
[SEP] O
[CLS] O
consequently O
, O
r O
##ge O
did O
not O
in O
##hibit O
the O
o O
##ct O
##1 O
- O
and O
o O
##ct O
##2 O
- O
mediated O
met O
##form O
##in O
up O
##take O
up O
to O
500 O
µ O
##g O
/ O
m O
##l O
of O
r O
##ge O
treatment O
( O
figure O
1 O
##e O
, O
f O
) O
. O
[SEP] O
[CLS] O
the O
results O
suggested O
that O
the O
absorption O
of O
met O
##form O
##in O
from O
the O
duo O
##den O
##um O
and O
il O
##eum O
was O
enhanced O
by O
the O
repeated O
administration O
of O
r O
##ge O
without O
altering O
the O
absorption O
of O
glucose O
and O
cell O
integrity O
, O
which O
could O
consequently O
cause O
the O
increased O
absorption O
and O
plasma O
concentrations O
of O
met O
##form O
##in O
, O
including O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
value O
. O
[SEP] O
[CLS] O
however O
, O
in O
the O
repeated O
r O
##ge O
treatment O
group O
( O
1 O
##w O
##ra O
) O
, O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
, O
and O
fraction B-PK
of I-PK
the I-PK
met I-PK
##form I-PK
##in I-PK
dose I-PK
ex I-PK
##cre I-PK
##ted I-PK
into I-PK
urine I-PK
as I-PK
unchanged I-PK
drug I-PK
( I-PK
a I-PK
##e I-PK
##24 I-PK
##h I-PK
) I-PK
were O
increased O
compared O
with O
those O
in O
control O
group O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
p O
##k O
parameters O
included O
: O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
τ I-PK
( O
where O
τ O
= O
24 O
h O
) O
and O
half B-PK
– I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
both O
criteria O
were O
met O
by O
r O
##up O
##ata O
##dine O
and O
u O
##r O
- O
127 O
##90 O
for O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
on O
day O
1 O
and O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
τ I-PK
on O
day O
5 O
. O
[SEP] O
[CLS] O
unlike O
higher O
doses O
, O
r O
##up O
##ata O
##dine O
10 O
mg O
rapid O
visual O
processing O
( O
r O
##v O
##p O
) O
assessment O
scores O
were O
comparable O
with O
the O
place O
##bo O
treatment O
group O
at O
1 O
h O
of O
drug O
administration O
, O
the O
time O
correspondent O
to O
r O
##up O
##ata O
##dine O
t B-PK
##max I-PK
( O
fi O
##g O
4 O
##a O
) O
. O
[SEP] O
[CLS] O
these O
findings O
suggest O
that O
the O
effects O
on O
cognitive O
function O
appear O
to O
be O
dose O
dependent O
and O
more O
pronounced O
at O
around O
t B-PK
##max I-PK
on O
days O
1 O
and O
5 O
at O
high O
doses O
with O
some O
development O
of O
r O
##up O
##ata O
##dine O
tolerance O
after O
multiple O
doses O
. O
[SEP] O
[CLS] O
le O
##uk O
##ope O
##nia O
was O
not O
significantly O
correlated O
with O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
time B-PK
above I-PK
a I-PK
threshold I-PK
concentration I-PK
or O
the O
area B-PK
under I-PK
the I-PK
tune I-PK
‐ I-PK
concentration I-PK
curve I-PK
. O
[SEP] O
[CLS] O
there O
was O
a O
significant O
difference O
in O
the O
cellular O
d O
##n O
##r O
and O
do O
##l O
au B-PK
##c I-PK
between O
respond O
##ers O
and O
non O
- O
respond O
##ers O
( O
p O
< O
0 O
. O
02 O
) O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
between O
patients O
who O
went O
into O
complete O
re O
##mission O
( O
12 O
/ O
23 O
) O
compared O
with O
those O
who O
did O
not O
respond O
for O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
: O
d O
##n O
##r O
and O
do O
##l O
plasma B-PK
au I-PK
##c I-PK
( I-PK
area I-PK
under I-PK
the I-PK
curve I-PK
) I-PK
and O
d O
##n O
##r O
plasma B-PK
half I-PK
- I-PK
life I-PK
and O
clearance B-PK
. O
[SEP] O
[CLS] O
v O
##l O
was O
assessed O
at O
each O
visit O
using O
co O
##bas O
##® O
am O
##p O
##lip O
##re O
##p O
/ O
co O
##bas O
##® O
ta O
##q O
##man O
##® O
hi O
##v O
- O
1 O
test O
, O
v O
##2 O
. O
0 O
( O
r O
##och O
##e O
diagnostic O
##s O
, O
base O
##l O
, O
s O
##witz O
##erland O
) O
. O
[SEP] O
[CLS] O
ad O
##herence O
was O
lower O
in O
patients O
with O
base O
##line O
v O
##l O
[UNK] O
50 O
copies O
/ O
m O
##l O
than O
< O
50 O
copies O
/ O
m O
##l O
( O
47 O
% O
( O
69 O
/ O
148 O
) O
vs O
57 O
% O
( O
30 O
/ O
53 O
) O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
when O
the O
a O
##pta O
##mers O
were O
administered O
sub O
##cut O
##aneous O
##ly O
, O
the O
t B-PK
##max I-PK
of O
s O
##b O
##c O
- O
p O
##eg O
##yla O
##ted O
17 O
##m O
- O
38 O
##2 O
was O
3 O
. O
8 O
times O
longer O
than O
that O
of O
p O
##eg O
##yla O
##ted O
17 O
##m O
- O
38 O
##2 O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
was O
recorded O
as O
the O
time B-PK
at I-PK
which I-PK
cm I-PK
##ax I-PK
occurred I-PK
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
calculated O
as O
l O
##n O
( O
2 O
) O
/ O
λ O
##z O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
for O
plasma O
free O
p O
##hen O
##yt O
##oi O
##n O
was O
generally O
shorter O
than O
that O
for O
plasma O
total O
p O
##hen O
##yt O
##oi O
##n O
. O
[SEP] O
[CLS] O
the O
mean O
au B-PK
##ct I-PK
/ I-PK
kg I-PK
weight O
increased O
slightly O
more O
than O
proportional O
to O
the O
administered O
dose O
( O
α O
= O
− O
##9 O
##6 O
. O
2 O
, O
β O
= O
34 O
. O
0 O
, O
r O
= O
0 O
. O
95 O
over O
a O
30 O
- O
min O
in O
##fusion O
) O
, O
whereas O
the O
mean O
c B-PK
##l I-PK
decreased O
with O
increasing O
dose O
. O
[SEP] O
[CLS] O
the O
w O
##ista O
##r O
rat O
eyes O
treated O
with O
g O
##c O
##m O
showed O
significant O
increase O
in O
g O
##an O
##ci O
##c O
##lov O
##ir O
au B-PK
##c I-PK
( O
~ O
4 O
. O
99 O
- O
fold O
) O
and O
cm B-PK
##ax I-PK
( O
2 O
. O
69 O
- O
fold O
) O
in O
a O
##que O
##ous O
humor O
compared O
to O
g O
##an O
##ci O
##c O
##lov O
##ir O
solution O
and O
delay O
in O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
additionally O
, O
g O
##an O
##ci O
##c O
##lov O
##ir O
half B-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
the O
maximum B-PK
peak I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
achieve I-PK
maximum I-PK
peak I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
was O
also O
calculated O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##e I-PK
) I-PK
and O
apparent B-PK
absorption I-PK
rate I-PK
( I-PK
ka I-PK
) I-PK
of O
g O
##an O
##ci O
##c O
##lov O
##ir O
from O
a O
##que O
##ous O
humor O
was O
estimated O
from O
the O
terminal O
portions O
of O
the O
respective O
log O
( O
a O
##que O
##ous O
humor O
concentration O
) O
vs O
. O
time O
linear O
re O
##gression O
plots O
[ O
28 O
] O
. O
[SEP] O
[CLS] O
the O
o O
##cular O
irritation O
test O
showed O
that O
the O
g O
##c O
##m O
sample O
( O
12 O
. O
0 O
± O
1 O
. O
0 O
vs O
g O
##an O
##ci O
##c O
##lov O
##ir O
solution O
10 O
. O
0 O
± O
1 O
. O
0 O
) O
was O
well O
tolerate O
##d O
. O
[SEP] O
[CLS] O
subsequently O
, O
the O
terminal B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
##e I-PK
) I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
did O
not O
alter O
much O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
g O
##c O
##m O
was O
2 O
. O
69 O
- O
fold O
of O
the O
g O
##an O
##ci O
##c O
##lov O
##ir O
group O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
and O
the O
delay O
in O
t B-PK
##max I-PK
in O
##fers O
the O
sustained O
release O
of O
the O
g O
##c O
##m O
. O
[SEP] O
[CLS] O
in O
this O
study O
, O
the O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
##90 I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
/ I-PK
mi I-PK
##c I-PK
##90 I-PK
of O
g O
##c O
##m O
were O
maintained O
higher O
than O
the O
g O
##an O
##ci O
##c O
##lov O
##ir O
solution O
. O
[SEP] O
[CLS] O
k O
##1 O
##g O
( O
t O
) O
+ O
k O
##2 O
##k O
##1 O
##g O
( O
t O
) O
+ O
k O
##2 O
, O
um O
##in O
##≤ O
##k O
##1 O
##g O
( O
t O
) O
+ O
k O
##2 O
##≤ O
##uma O
##x O
##uma O
##x O
, O
um O
##ax O
< O
k O
##1 O
##g O
( O
t O
) O
+ O
k O
##2 O
[SEP] O
[CLS] O
g O
##a O
is O
a O
significant O
un O
##met O
need O
, O
affecting O
more O
than O
5 O
million O
people O
worldwide O
, O
with O
devastating O
effects O
on O
patients O
' O
visual O
function O
and O
quality O
of O
life O
. O
1 O
, O
2 O
g O
##a O
is O
characterized O
by O
extensive O
loss O
of O
the O
ch O
##orio O
##cap O
##illa O
##ris O
and O
the O
overly O
##ing O
re O
##tina O
##l O
pig O
##ment O
e O
##pit O
##hel O
##ium O
( O
r O
##pe O
) O
, O
and O
accounts O
for O
26 O
% O
of O
legal O
blind O
##ness O
in O
the O
united O
kingdom O
. O
3 O
– O
6 O
currently O
, O
there O
are O
no O
licensed O
the O
##rap O
##ies O
to O
prevent O
the O
progression O
of O
g O
##a O
and O
the O
associated O
decrease O
in O
visual O
function O
. O
7 O
[SEP] O
[CLS] O
v O
##vi O
##tr O
and O
v B-PK
##c I-PK
are O
the O
v O
##it O
##re O
##ous O
humor O
and O
serum B-PK
volumes I-PK
, O
respectively O
; O
r O
##aq O
is O
the O
total O
c O
##f O
##d O
concentration O
in O
a O
##que O
##ous O
humor O
; O
k B-PK
##out I-PK
and O
k B-PK
##out I-PK
##c I-PK
denote O
the O
elimination B-PK
rate I-PK
constant I-PK
##s I-PK
of O
the O
un O
##bound O
lamp O
##ali O
##zu O
##ma O
##b O
and O
lamp O
##ali O
##zu O
##ma O
##b O
– O
c O
##f O
##d O
complex O
, O
respectively O
. O
[SEP] O
[CLS] O
only O
three O
random O
effect O
parameters O
( O
k B-PK
##out I-PK
, O
k B-PK
, O
and O
λ B-PK
##a I-PK
) O
were O
significantly O
different O
from O
1 O
% O
. O
[SEP] O
[CLS] O
after O
the O
base O
model O
was O
developed O
, O
effects O
of O
age O
, O
sex O
, O
and O
anti O
##ther O
##ap O
##eu O
##tic O
antibodies O
( O
at O
##a O
) O
status O
on O
k B-PK
##out I-PK
and O
k B-PK
were O
added O
to O
the O
model O
. O
[SEP] O
[CLS] O
therefore O
, O
co O
##var O
##iate O
effects O
were O
tested O
only O
on O
o O
##cular O
( O
k B-PK
##out I-PK
) O
and O
systemic B-PK
elimination I-PK
rate I-PK
constant I-PK
##s I-PK
( I-PK
k I-PK
) I-PK
, O
which O
are O
the O
main O
parameters O
that O
govern O
the O
o O
##cular O
and O
systemic O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
respectively O
. O
[SEP] O
[CLS] O
systemic B-PK
half I-PK
- I-PK
life I-PK
was O
estimated O
to O
be O
9 O
hours O
( O
k B-PK
= O
1 O
. O
89 O
day O
##− O
##1 O
, O
table O
##1 O
) O
when O
using O
the O
combined O
o O
##cular O
/ O
serum O
model O
, O
and O
was O
in O
agreement O
with O
the O
population O
serum O
p O
##k O
model O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
= O
7 O
. O
4 O
hours O
, O
k B-PK
= O
2 O
. O
23 O
day O
##− O
##1 O
, O
supplement O
##al O
table O
2 O
) O
. O
[SEP] O
[CLS] O
also O
in O
agreement O
with O
the O
serum O
population O
p O
##k O
model O
, O
o O
##cular O
- O
to O
- O
systemic O
absorption B-PK
half I-PK
- I-PK
life I-PK
was O
estimated O
to O
be O
5 O
. O
9 O
days O
( O
k B-PK
##out I-PK
= O
0 O
. O
117 O
day O
##− O
##1 O
) O
. O
[SEP] O
[CLS] O
at O
steady O
- O
state O
, O
lamp O
##ali O
##zu O
##ma O
##b O
v O
##it O
##re O
##ous O
humor O
exposure O
was O
greater O
than O
11 O
, O
000 O
- O
fold O
higher O
than O
serum O
exposure O
based O
on O
serum O
and O
v O
##it O
##re O
##ous O
humor O
cm B-PK
##ax I-PK
, O
minimum B-PK
concentrations I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
, O
or O
cumulative B-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
– I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
##w I-PK
##k I-PK
) I-PK
( O
supplement O
##al O
table O
3 O
) O
. O
[SEP] O
[CLS] O
additionally O
, O
with O
all O
three O
dos O
##ing O
schedules O
, O
the O
5th O
percent O
##ile O
of O
v O
##it O
##re O
##ous O
humor O
cm B-PK
##in I-PK
values O
for O
10 O
mg O
per O
eye O
were O
above O
the O
median B-PK
inhibitor I-PK
##y I-PK
concentration I-PK
( I-PK
i I-PK
##c I-PK
##50 I-PK
) I-PK
( O
[UNK] O
. O
2 O
μ O
##g O
/ O
m O
##l O
or O
4 O
nm O
) O
of O
alternative O
complement O
in O
##hibition O
( O
figure O
##4 O
##a O
and O
supplement O
##al O
table O
3 O
) O
based O
on O
a O
serum O
hem O
##oly O
##tic O
cell O
- O
based O
ass O
##ay O
, O
11 O
while O
the O
95 O
##th O
percent O
##ile O
of O
serum O
cm B-PK
##ax I-PK
values O
for O
10 O
mg O
per O
eye O
were O
below O
2 O
μ O
##g O
/ O
m O
##l O
or O
42 O
nm O
( O
figure O
##4 O
##b O
and O
supplement O
##al O
table O
3 O
) O
, O
the O
minimum O
level O
needed O
to O
in O
##hibit O
alternative O
complement O
pathway O
in O
the O
serum O
. O
10 O
, O
11 O
our O
simulation O
##s O
showed O
that O
in O
##tra O
##vi O
##tre O
##ally O
administered O
lamp O
##ali O
##zu O
##ma O
##b O
results O
in O
high O
local O
o O
##cular O
drug O
concentrations O
while O
mini O
##mizing O
systemic O
drug O
concentrations O
and O
potential O
systemic O
adverse O
events O
. O
[SEP] O
[CLS] O
older O
patients O
also O
tended O
to O
have O
a O
slower O
o B-PK
##cular I-PK
elimination I-PK
constant I-PK
( I-PK
k I-PK
##out I-PK
) I-PK
and O
longer O
o B-PK
##cular I-PK
half I-PK
- I-PK
life I-PK
( O
supplement O
##al O
figure O
3 O
##b O
) O
. O
[SEP] O
[CLS] O
to O
examine O
the O
impact O
of O
age O
and O
sex O
on O
the O
clinical O
##ly O
relevant O
o O
##cular O
and O
systemic O
exposure O
##s O
, O
the O
magnitude O
of O
their O
co O
##var O
##iate O
effect O
on O
o B-PK
##cular I-PK
cm I-PK
##in I-PK
, O
cumulative B-PK
au I-PK
##c I-PK
, O
serum B-PK
cm I-PK
##ax I-PK
, O
and O
cumulative B-PK
au I-PK
##c I-PK
was O
examined O
( O
figure O
##5 O
) O
. O
[SEP] O
[CLS] O
despite O
the O
statistical O
##ly O
significant O
impact O
of O
age O
and O
sex O
on O
k B-PK
and O
age O
on O
k B-PK
##out I-PK
, O
the O
magnitude O
of O
the O
co O
##var O
##iate O
effects O
was O
relatively O
small O
compared O
to O
the O
inter O
##su O
##bject O
var O
##iability O
and O
was O
not O
expected O
to O
be O
clinical O
##ly O
relevant O
. O
[SEP] O
[CLS] O
comparison O
of O
v O
##pa O
c B-PK
##l I-PK
/ I-PK
f I-PK
values O
between O
e O
##pile O
##ptic O
and O
man O
##ic O
patients O
[SEP] O
[CLS] O
v O
##pa O
c B-PK
##l I-PK
/ I-PK
f I-PK
between O
these O
two O
groups O
was O
compared O
and O
v O
##pa O
clearance B-PK
was O
significantly O
higher O
in O
patients O
with O
acute O
man O
##ia O
. O
[SEP] O
[CLS] O
comparison O
of O
v O
##pa O
c B-PK
##l I-PK
/ I-PK
f I-PK
values O
between O
male O
and O
female O
[SEP] O
[CLS] O
v O
##pa O
c B-PK
##l I-PK
/ I-PK
f I-PK
values O
between O
male O
and O
female O
were O
compared O
and O
no O
significant O
difference O
was O
noted O
. O
[SEP] O
[CLS] O
v O
##pa O
apparent B-PK
oral I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
values O
were O
calculated O
and O
compared O
between O
these O
two O
groups O
. O
[SEP] O
[CLS] O
where O
c B-PK
##l I-PK
is O
the O
total B-PK
body I-PK
clearance I-PK
of O
drug O
, O
f B-PK
is O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
c B-PK
##ss I-PK
reflected B-PK
t I-PK
##rough I-PK
concentrations I-PK
, O
and O
so O
calculated O
c B-PK
##l I-PK
/ I-PK
f I-PK
may O
represent O
over O
##est O
##imate O
##s O
of O
the O
actual O
values O
. O
[SEP] O
[CLS] O
after O
i O
. O
v O
. O
administration O
of O
n O
##f O
##l O
##x O
##ga O
, O
the O
distribution O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
) O
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
) I-PK
were O
0 O
. O
36 O
± O
0 O
. O
07 O
h O
and O
7 O
. O
42 O
± O
3 O
. O
55 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
after O
p O
. O
o O
. O
administration O
of O
n O
##f O
##l O
##x O
##ga O
, O
the O
ma B-PK
##ximal I-PK
absorption I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
0 O
. O
43 O
± O
0 O
. O
06 O
µ O
##g O
/ O
m O
##l O
at O
1 O
. O
36 O
± O
0 O
. O
39 O
h O
( O
t B-PK
##max I-PK
) O
. O
[SEP] O
[CLS] O
the O
mean O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
( I-PK
f I-PK
) I-PK
after O
p O
. O
o O
. O
administration O
was O
31 O
. O
10 O
± O
15 O
. O
16 O
% O
. O
[SEP] O
[CLS] O
following O
p O
. O
o O
. O
administration O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
f I-PK
was O
calculated O
according O
to O
the O
equation O
: O
[SEP] O
[CLS] O
the O
serum O
concentration O
of O
nor O
##f O
##lo O
##xa O
##cin O
reached O
a O
maximum O
level O
( O
cm B-PK
##ax I-PK
) O
of O
0 O
. O
43 O
± O
0 O
. O
06 O
µ O
##g O
/ O
m O
##l O
at O
1 O
. O
36 O
± O
0 O
. O
39 O
h O
( O
t B-PK
##max I-PK
) O
, O
and O
the O
absorption B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##ka I-PK
) I-PK
was O
0 O
. O
78 O
± O
0 O
. O
27 O
h O
after O
p O
. O
o O
. O
administration O
in O
pigs O
. O
[SEP] O
[CLS] O
the O
aim O
of O
the O
analysis O
was O
to O
character O
##ize O
the O
population O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
p O
##ks O
) O
and O
exposure O
– O
response O
( O
e O
– O
r O
) O
for O
efficacy O
( O
fast O
##ing O
plasma O
glucose O
, O
g O
##ly O
##cated O
hem O
##og O
##lo O
##bin O
) O
and O
safety O
/ O
to O
##ler O
##ability O
[ O
h O
##y O
##po O
##gly O
##ce O
##mia O
, O
g O
##eni O
##tal O
infections O
, O
u O
##rina O
##ry O
tract O
infection O
( O
u O
##ti O
) O
, O
and O
volume O
de O
##ple O
##tion O
] O
of O
the O
sodium O
glucose O
co O
##tra O
##ns O
##port O
##er O
2 O
inhibitor O
, O
em O
##pa O
##gli O
##f O
##lo O
##zin O
, O
in O
patients O
with O
type O
2 O
diabetes O
me O
##lli O
##tus O
. O
[SEP] O
[CLS] O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
e O
– O
r O
models O
were O
developed O
based O
on O
two O
phase O
i O
, O
four O
phase O
ii O
, O
and O
four O
phase O
ii O
##i O
studies O
. O
[SEP] O
[CLS] O
based O
on O
the O
results O
from O
the O
p O
##k O
and O
e O
– O
r O
analysis O
, O
no O
dose O
adjustment O
is O
required O
for O
em O
##pa O
##gli O
##f O
##lo O
##zin O
in O
the O
patient O
population O
for O
which O
the O
drug O
is O
approved O
. O
[SEP] O
[CLS] O
the O
influence O
of O
age O
, O
sex O
, O
race O
, O
total O
protein O
, O
and O
b O
##mi O
was O
assessed O
for O
the O
volumes B-PK
of I-PK
distribution I-PK
[ O
apparent B-PK
central I-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##2 I-PK
/ I-PK
f I-PK
) I-PK
, O
apparent B-PK
peripheral I-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##3 I-PK
/ I-PK
f I-PK
) I-PK
] O
, O
and O
age O
, O
sex O
, O
and O
race O
were O
evaluated O
for O
influence O
on O
the O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
( O
table O
s O
##1 O
in O
the O
supplement O
##ary O
material O
) O
. O
[SEP] O
[CLS] O
the O
co O
##var O
##iate O
##s O
were O
chosen O
based O
on O
one O
or O
a O
combination O
of O
the O
following O
: O
findings O
from O
previous O
analysis O
( O
c B-PK
##l I-PK
/ I-PK
f I-PK
: O
age O
, O
b O
##mi O
, O
race O
, O
total O
protein O
, O
e O
##g O
##f O
##r O
; O
v B-PK
##2 I-PK
/ I-PK
f I-PK
: O
sex O
, O
race O
, O
total O
protein O
, O
b O
##mi O
; O
ka B-PK
: O
race O
) O
, O
scientific O
interest O
and O
relevance O
to O
the O
development O
programme O
( O
v B-PK
##2 I-PK
/ I-PK
f I-PK
: O
age O
, O
race O
; O
ka B-PK
: O
sex O
) O
, O
physiological O
/ O
me O
##chan O
##istic O
p O
##laus O
##ibility O
( O
c B-PK
##l I-PK
/ I-PK
f I-PK
: O
e O
##g O
##f O
##r O
; O
ka B-PK
: O
age O
) O
. O
[SEP] O
[CLS] O
patient O
- O
level O
random O
effects O
were O
included O
for O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
ka B-PK
, O
and O
v B-PK
##3 I-PK
/ I-PK
f I-PK
; O
these O
parameters O
were O
assumed O
to O
be O
log O
- O
normal O
distributed O
. O
[SEP] O
[CLS] O
in O
addition O
, O
mon O
##te O
car O
##lo O
simulation O
##s O
were O
performed O
to O
evaluate O
the O
predict O
##ive O
performance O
of O
the O
population O
p O
##k O
model O
for O
dose O
- O
normal O
##ized O
maximum B-PK
and O
minimum B-PK
concentration I-PK
( O
cm B-PK
##ax I-PK
and O
cm B-PK
##in I-PK
, O
respectively O
) O
. O
[SEP] O
[CLS] O
the O
safety O
/ O
to O
##ler O
##ability O
end O
##points O
investigated O
in O
the O
e O
– O
r O
analysis O
were O
confirmed O
h O
##y O
##po O
##gly O
##ce O
##mic O
adverse O
events O
( O
a O
##es O
) O
( O
plasma O
glucose O
< O
3 O
. O
9 O
mm O
and O
/ O
or O
assistance O
required O
) O
, O
events O
consistent O
with O
u O
##rina O
##ry O
tract O
infection O
( O
u O
##ti O
; O
using O
a O
prospective O
##ly O
defined O
search O
of O
73 O
preferred O
terms O
) O
, O
events O
consistent O
with O
g O
##eni O
##tal O
infection O
( O
using O
a O
prospective O
##ly O
defined O
search O
of O
89 O
preferred O
terms O
) O
, O
and O
events O
consistent O
with O
volume O
de O
##ple O
##tion O
( O
all O
on O
- O
treatment O
a O
##es O
, O
using O
eight O
preferred O
terms O
) O
. O
[SEP] O
[CLS] O
the O
safety O
/ O
to O
##ler O
##ability O
end O
##points O
considered O
in O
the O
e O
– O
r O
analysis O
were O
included O
as O
di O
##cho O
##tom O
##ous O
end O
##points O
( O
i O
. O
e O
. O
, O
participant O
- O
reported O
a O
##es O
: O
any O
a O
##e O
during O
study O
, O
single O
yes O
/ O
no O
data O
##point O
) O
, O
and O
were O
analyzed O
using O
a O
log O
##istic O
re O
##gression O
model O
[ O
19 O
, O
22 O
] O
. O
[SEP] O
[CLS] O
typical O
population O
p O
##k O
parameters O
( O
95 O
% O
c O
##i O
, O
based O
on O
non O
- O
para O
##metric O
boots O
##tra O
##p O
) O
given O
the O
reference O
co O
##var O
##iate O
##s O
( O
50 O
- O
year O
- O
old O
, O
non O
- O
smoking O
male O
, O
non O
- O
as O
##ian O
race O
; O
b O
##mi O
, O
25 O
kg O
/ O
m O
##2 O
; O
e O
##g O
##f O
##r O
, O
100 O
m O
##l O
/ O
min O
/ O
1 O
. O
73 O
m O
##2 O
; O
total O
protein O
, O
70 O
g O
/ O
d O
##l O
; O
al O
##t O
, O
20 O
u O
/ O
l O
; O
as O
##t O
, O
20 O
u O
/ O
l O
; O
a O
##p O
, O
70 O
u O
/ O
l O
; O
and O
l O
##dh O
, O
160 O
u O
/ O
l O
) O
were O
: O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
10 O
. O
6 O
l O
/ O
h O
( O
10 O
. O
1 O
, O
11 O
. O
1 O
) O
; O
v B-PK
##2 I-PK
/ I-PK
f I-PK
, O
3 O
. O
14 O
l O
( O
0 O
. O
00 O
##12 O
##8 O
, O
4 O
. O
03 O
) O
; O
apparent B-PK
inter I-PK
##com I-PK
##par I-PK
##tment I-PK
##al I-PK
clearance I-PK
( I-PK
q I-PK
/ I-PK
f I-PK
) I-PK
, O
6 O
. O
34 O
l O
/ O
h O
( O
5 O
. O
72 O
, O
6 O
. O
91 O
) O
; O
v B-PK
##3 I-PK
/ I-PK
f I-PK
, O
70 O
. O
6 O
l O
( O
64 O
. O
4 O
, O
76 O
. O
6 O
) O
; O
and O
first B-PK
- I-PK
order I-PK
ka I-PK
, O
0 O
. O
196 O
l O
/ O
h O
( O
0 O
. O
185 O
, O
0 O
. O
208 O
) O
. O
[SEP] O
[CLS] O
estimated O
co O
##var O
##iate O
effects O
on O
parameters O
not O
affecting O
au B-PK
##cs I-PK
##s I-PK
( O
v B-PK
##2 I-PK
/ I-PK
f I-PK
, O
v B-PK
##3 I-PK
/ I-PK
f I-PK
, O
and O
ka B-PK
) O
are O
included O
in O
table O
s O
##1 O
in O
the O
supplement O
##ary O
material O
. O
[SEP] O
[CLS] O
fast O
##ing O
plasma O
glucose O
measurements O
from O
the O
same O
studies O
were O
used O
to O
develop O
the O
e O
– O
r O
model O
for O
f O
##p O
##g O
( O
42 O
##8 O
##9 O
patients O
) O
, O
including O
patients O
receiving O
em O
##pa O
##gli O
##f O
##lo O
##zin O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
based O
on O
parameter O
estimates O
for O
the O
final O
h O
##ba O
##1 O
##c O
e O
– O
r O
model O
, O
targets O
of O
80 O
% O
and O
90 O
% O
were O
obtained O
for O
the O
ma O
##ximal O
response O
for O
f O
##p O
##g O
and O
h O
##ba O
##1 O
##c O
after O
24 O
weeks O
of O
treatment O
with O
once O
daily O
em O
##pa O
##gli O
##f O
##lo O
##zin O
doses O
of O
approximately O
10 O
and O
25 O
mg O
, O
respectively O
( O
table O
s O
##4 O
in O
the O
supplement O
##ary O
material O
) O
. O
[SEP] O
[CLS] O
to O
investigate O
the O
influence O
of O
e O
##g O
##f O
##r O
and O
age O
on O
h O
##ba O
##1 O
##c O
lowering O
, O
de O
##ter O
##mini O
##stic O
simulation O
##s O
were O
performed O
to O
illustrate O
the O
e O
– O
r O
after O
24 O
weeks O
of O
treatment O
( O
fi O
##g O
. O
s O
##8 O
in O
the O
supplement O
##ary O
material O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
magnitude O
##s O
of O
these O
co O
##var O
##iate O
effects O
were O
minor O
, O
with O
differences O
within O
these O
co O
##var O
##iate O
groups O
between O
0 O
. O
8 O
and O
1 O
. O
25 O
of O
the O
normal O
##ized O
c B-PK
##l I-PK
/ I-PK
f I-PK
or O
au B-PK
##cs I-PK
##s I-PK
at O
the O
extreme O
co O
##var O
##iate O
levels O
( O
fi O
##g O
. O
1 O
) O
. O
[SEP] O
[CLS] O
g O
##ly O
##cated O
hem O
##og O
##lo O
##bin O
half B-PK
- I-PK
life I-PK
( O
calculated O
from O
k O
##h O
##ba O
##1 O
##c O
, O
out O
) O
was O
approximately O
2 O
. O
6 O
weeks O
( O
95 O
% O
c O
##i O
1 O
. O
7 O
, O
3 O
. O
9 O
) O
, O
indicating O
that O
maximum O
changes O
in O
h O
##ba O
##1 O
##c O
are O
reached O
by O
around O
12 O
weeks O
( O
> O
3 O
half B-PK
- I-PK
lives I-PK
) O
of O
em O
##pa O
##gli O
##f O
##lo O
##zin O
therapy O
, O
and O
was O
almost O
entirely O
achieved O
by O
24 O
weeks O
( O
> O
6 O
half B-PK
- I-PK
lives I-PK
) O
. O
[SEP] O
[CLS] O
for O
patients O
receiving O
em O
##pa O
##gli O
##f O
##lo O
##zin O
treatment O
, O
increases O
in O
em O
##pa O
##gli O
##f O
##lo O
##zin O
au B-PK
##cs I-PK
##si I-PK
[ O
or O
( O
95 O
% O
c O
##i O
) O
for O
au B-PK
##c I-PK
normal O
##ized O
to O
350 O
##0 O
nm O
* O
h O
increase O
in O
au B-PK
##cs I-PK
##s I-PK
] O
produced O
no O
significant O
increase O
in O
incidence O
rates O
of O
confirmed O
h O
##y O
##po O
##gly O
##ce O
##mic O
a O
##es O
[ O
0 O
. O
98 O
##8 O
( O
0 O
. O
86 O
##3 O
, O
1 O
. O
13 O
) O
] O
, O
events O
consistent O
with O
volume O
de O
##ple O
##tion O
[ O
0 O
. O
77 O
##0 O
( O
0 O
. O
45 O
##4 O
, O
1 O
. O
30 O
) O
] O
, O
events O
consistent O
with O
u O
##ti O
[ O
1 O
. O
06 O
( O
0 O
. O
93 O
##5 O
, O
1 O
. O
20 O
) O
] O
, O
or O
events O
consistent O
with O
g O
##eni O
##tal O
infection O
[ O
0 O
. O
74 O
##4 O
( O
0 O
. O
57 O
##4 O
, O
0 O
. O
96 O
##5 O
) O
] O
. O
[SEP] O
[CLS] O
the O
main O
co O
##var O
##iate O
influences O
accounted O
for O
in O
the O
e O
– O
r O
analyses O
were O
con O
##com O
##ita O
##nt O
insulin O
therapy O
for O
confirmed O
h O
##y O
##po O
##gly O
##ce O
##mic O
events O
[ O
or O
48 O
. O
7 O
( O
95 O
% O
c O
##i O
26 O
. O
5 O
, O
89 O
. O
5 O
) O
] O
; O
female O
sex O
for O
u O
##ti O
[ O
or O
6 O
. O
14 O
( O
4 O
. O
60 O
, O
8 O
. O
19 O
) O
] O
, O
and O
g O
##eni O
##tal O
infection O
[ O
or O
2 O
. O
28 O
( O
1 O
. O
55 O
, O
3 O
. O
35 O
) O
] O
; O
and O
re O
##nal O
imp O
##air O
##ment O
[ O
e O
##g O
##f O
##r O
60 O
– O
90 O
m O
##l O
/ O
min O
/ O
1 O
. O
73 O
m O
##2 O
; O
or O
1 O
. O
75 O
( O
0 O
. O
61 O
##7 O
, O
4 O
. O
96 O
) O
] O
; O
e O
##g O
##f O
##r O
< O
60 O
m O
##l O
/ O
min O
/ O
1 O
. O
73 O
m O
##2 O
; O
or O
2 O
. O
78 O
( O
0 O
. O
82 O
##9 O
, O
9 O
. O
34 O
) O
, O
and O
insulin O
therapy O
[ O
or O
, O
2 O
. O
60 O
( O
1 O
. O
21 O
, O
5 O
. O
61 O
) O
] O
for O
volume O
de O
##ple O
##tion O
. O
[SEP] O
[CLS] O
n O
##uc O
##leo O
##tide O
substitution O
##s O
in O
the O
amino O
acids O
e O
##5 O
##42 O
( O
k O
) O
, O
e O
##5 O
##45 O
( O
a O
, O
g O
, O
d O
, O
or O
k O
) O
, O
q O
##5 O
##46 O
( O
e O
, O
k O
, O
l O
, O
or O
r O
) O
, O
and O
h O
##10 O
##47 O
( O
l O
, O
r O
, O
or O
y O
) O
or O
the O
wild O
- O
type O
all O
##ele O
##s O
were O
detected O
. O
[SEP] O
[CLS] O
fifty O
- O
eight O
( O
84 O
. O
1 O
% O
) O
patients O
were O
included O
in O
the O
efficacy O
- O
e O
##val O
##ua O
##ble O
population O
for O
or O
##r O
analysis O
. O
[SEP] O
[CLS] O
major O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
included O
cm B-PK
##ax I-PK
, O
time B-PK
to I-PK
reach I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
terminal B-PK
- I-PK
phase I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
concentration I-PK
( I-PK
au I-PK
##ct I-PK
) I-PK
, O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##∞ I-PK
) I-PK
, O
cumulative B-PK
u I-PK
##rina I-PK
##ry I-PK
ex I-PK
##cre I-PK
##tion I-PK
as I-PK
a I-PK
percentage I-PK
of I-PK
administered I-PK
dose I-PK
( I-PK
f I-PK
##e I-PK
) I-PK
, O
and O
re B-PK
##nal I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##r I-PK
) I-PK
. O
[SEP] O
[CLS] O
the O
observed O
median O
dig O
##ox O
##in O
t B-PK
##max I-PK
was O
identical O
when O
co O
- O
administered O
with O
either O
le O
##nal O
##ido O
##mi O
##de O
or O
place O
##bo O
( O
1 O
h O
; O
range O
1 O
– O
3 O
h O
) O
. O
[SEP] O
[CLS] O
there O
was O
no O
difference O
in O
t B-PK
##max I-PK
and O
terminal B-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
of O
te O
##ms O
##iro O
##lim O
##us O
or O
sir O
##oli O
##mus O
between O
treatments O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
for O
e O
##va O
##ce O
##tra O
##pi O
##b O
was O
analyzed O
using O
a O
w O
##il O
##co O
##xon O
sign O
rank O
test O
. O
[SEP] O
[CLS] O
there O
was O
no O
difference O
in O
median O
t B-PK
##max I-PK
between O
treatments O
. O
[SEP] O
[CLS] O
there O
was O
no O
significant O
difference O
in O
median O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
ratios I-PK
were O
2 O
. O
37 O
and O
1 O
. O
94 O
, O
and O
the O
90 O
% O
c O
##is O
did O
not O
include O
unity O
. O
[SEP] O
[CLS] O
the O
p O
##k O
parameters O
calculated O
for O
the O
meta O
##bol O
##ite O
included O
: O
au B-PK
##c I-PK
##0 I-PK
→ I-PK
∞ I-PK
, O
peak B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
; O
μ O
##g O
/ O
m O
##l O
) O
, O
and O
time B-PK
at I-PK
which I-PK
maximum I-PK
concentration I-PK
occurs I-PK
( I-PK
t I-PK
##max I-PK
; O
h O
) O
. O
[SEP] O
[CLS] O
the O
her O
##ita O
##bility O
estimate O
for O
t B-PK
##max I-PK
for O
the O
meta O
##bol O
##ite O
for O
flu O
##ni O
##xin O
me O
##g O
##lum O
##ine O
was O
outside O
the O
bounds O
and O
therefore O
was O
not O
shown O
. O
[SEP] O
[CLS] O
the O
mean O
im O
##ati O
##ni O
##b O
cm B-PK
##in I-PK
value O
of O
the O
18 O
patients O
was O
1841 O
ng O
/ O
m O
##l O
( O
101 O
##8 O
– O
38 O
##9 O
##7 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
difference O
between O
the O
patients O
treated O
with O
400 O
mg O
/ O
d O
( O
n O
= O
9 O
) O
and O
those O
treated O
with O
300 O
mg O
/ O
d O
( O
n O
= O
9 O
) O
, O
which O
have O
im O
##ati O
##ni O
##b O
cm B-PK
##in I-PK
values O
of O
212 O
##2 O
##± O
##100 O
##3 O
ng O
/ O
m O
##l O
and O
155 O
##9 O
##± O
##47 O
##8 O
ng O
/ O
m O
##l O
, O
respectively O
, O
was O
not O
significant O
( O
p O
= O
0 O
. O
148 O
) O
. O
[SEP] O
[CLS] O
patients O
with O
g O
##ist O
who O
exhibited O
into O
##ler O
##ance O
to O
the O
standard O
dose O
of O
im O
##ati O
##ni O
##b O
( O
400 O
mg O
/ O
d O
) O
, O
a O
lower O
dose O
of O
300 O
mg O
/ O
d O
could O
provide O
not O
only O
sufficient O
plasma B-PK
cm I-PK
##in I-PK
and O
good O
disease O
control O
but O
also O
the O
all O
##ev O
##iation O
of O
the O
side O
effects O
. O
[SEP] O
[CLS] O
im O
cm B-PK
##in I-PK
was O
measured O
in O
j O
##anu O
##ary O
2015 O
. O
[SEP] O
[CLS] O
each O
patient O
received O
a O
dose O
of O
im O
regularly O
at O
12 O
am O
daily O
for O
at O
least O
4 O
months O
by O
the O
time O
of O
cm B-PK
##in I-PK
assessment O
. O
[SEP] O
[CLS] O
the O
im O
cm B-PK
##in I-PK
in O
5 O
patients O
was O
measured O
twice O
on O
different O
days O
, O
and O
then O
the O
mean O
of O
the O
2 O
values O
were O
used O
for O
analysis O
. O
[SEP] O
[CLS] O
meanwhile O
, O
the O
im O
cm B-PK
##in I-PK
in O
the O
other O
patients O
was O
measured O
once O
and O
the O
resulting O
value O
was O
used O
for O
analysis O
. O
[SEP] O
[CLS] O
the O
w O
##il O
##co O
##xon O
rank O
test O
was O
used O
to O
compare O
the O
means O
of O
the O
im O
cm B-PK
##in I-PK
of O
patients O
treated O
with O
different O
doses O
of O
im O
. O
[SEP] O
[CLS] O
the O
value O
of O
im O
cm B-PK
##in I-PK
was O
log O
- O
transformed O
for O
the O
linear O
re O
##gression O
analysis O
in O
order O
to O
identify O
the O
correlation O
##s O
between O
the O
im O
cm B-PK
##in I-PK
and O
the O
co O
##var O
##iate O
##s O
, O
such O
as O
age O
, O
sex O
, O
body O
weight O
, O
b O
##sa O
, O
duration O
of O
im O
use O
, O
hem O
##og O
##lo O
##bin O
, O
w O
##b O
##c O
, O
an O
##c O
, O
plate O
##lets O
, O
album O
##in O
, O
and O
c O
##rea O
##tin O
##ine O
clearance O
. O
[SEP] O
[CLS] O
im O
cm B-PK
##in I-PK
was O
measured O
twice O
in O
4 O
patients O
treated O
with O
300 O
mg O
/ O
d O
im O
and O
1 O
patient O
treated O
with O
400 O
mg O
/ O
d O
im O
. O
[SEP] O
[CLS] O
im O
cm B-PK
##in I-PK
in O
all O
18 O
patients O
reached O
over O
1000 O
ng O
/ O
m O
##l O
, O
and O
the O
mean O
cm B-PK
##in I-PK
was O
1841 O
ng O
/ O
m O
##l O
( O
101 O
##8 O
– O
38 O
##9 O
##7 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
distribution O
of O
im O
cm B-PK
##in I-PK
had O
between O
sex O
and O
ages O
and O
primary O
sites O
of O
tumors O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
in O
un O
##iva O
##ria O
##te O
analysis O
, O
we O
failed O
to O
reveal O
the O
association O
between O
im O
cm B-PK
##in I-PK
and O
factors O
including O
b O
##mi O
, O
hem O
##og O
##lo O
##bin O
level O
, O
w O
##b O
##c O
, O
c O
##rea O
##tin O
##ine O
clearance O
, O
or O
album O
##in O
level O
. O
[SEP] O
[CLS] O
the O
mean O
of O
im O
cm B-PK
##in I-PK
in O
patients O
receiving O
300 O
mg O
daily O
dose O
was O
155 O
##9 O
##± O
##47 O
##8 O
ng O
/ O
m O
##l O
( O
median O
141 O
##2 O
ng O
/ O
m O
##l O
, O
range O
101 O
##8 O
– O
238 O
##7 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
in O
contrast O
to O
patients O
treated O
with O
400 O
mg O
/ O
d O
, O
the O
cm B-PK
##in I-PK
in O
patients O
receiving O
300 O
mg O
/ O
d O
decreased O
, O
but O
not O
significantly O
( O
212 O
##2 O
##± O
##100 O
##3 O
ng O
/ O
m O
##l O
vs O
155 O
##9 O
##± O
##47 O
##8 O
ng O
/ O
m O
##l O
, O
p O
= O
0 O
. O
148 O
, O
fi O
##g O
. O
2 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
of O
im O
cm B-PK
##in I-PK
was O
226 O
##2 O
##± O
##100 O
##9 O
ng O
/ O
m O
##l O
and O
159 O
##6 O
##± O
##4 O
##9 O
##6 O
ng O
/ O
m O
##l O
( O
p O
= O
0 O
. O
174 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
( O
± O
##stand O
##ard O
de O
##viation O
) O
im O
cm B-PK
##in I-PK
was O
2011 O
##± O
##11 O
##0 O
##3 O
ng O
/ O
m O
##l O
, O
the O
median O
follow O
up O
was O
14 O
months O
( O
7 O
– O
18 O
months O
) O
, O
and O
4 O
p O
##r O
and O
1 O
s O
##d O
were O
observed O
. O
[SEP] O
[CLS] O
only O
1 O
of O
the O
6 O
patients O
received O
300 O
mg O
/ O
d O
im O
, O
the O
cm B-PK
##in I-PK
was O
125 O
##8 O
ng O
/ O
m O
##l O
, O
and O
the O
tumor O
size O
continued O
to O
decrease O
until O
the O
last O
follow O
up O
( O
13 O
months O
) O
. O
[SEP] O
[CLS] O
the O
frequency O
of O
toxicity O
was O
lower O
( O
88 O
. O
9 O
% O
vs O
44 O
. O
4 O
% O
, O
p O
= O
0 O
. O
02 O
##3 O
) O
in O
9 O
patients O
treated O
with O
300 O
mg O
/ O
d O
im O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
patients O
with O
grade O
3 O
– O
4 O
toxic O
##ities O
did O
not O
differ O
from O
patients O
with O
zero O
or O
mild O
toxic O
##ities O
in O
terms O
of O
im O
cm B-PK
##in I-PK
( O
1875 O
##± O
##17 O
##3 O
vs O
1834 O
##± O
##8 O
##9 O
##6 O
, O
p O
= O
0 O
. O
94 O
##0 O
) O
. O
[SEP] O
[CLS] O
this O
study O
prospective O
##ly O
valid O
##ated O
a O
new O
van O
##com O
##y O
##cin O
dos O
##ing O
no O
##mo O
##gram O
based O
on O
the O
8 O
- O
hours O
re B-PK
##nal I-PK
clearance I-PK
of O
c O
##rea O
##tin O
##ine O
and O
demonstrated O
that O
it O
is O
possible O
to O
increase O
the O
likelihood O
of O
target O
attain O
##ment O
in O
the O
first O
24 O
h O
of O
treatment O
, O
particularly O
in O
patients O
with O
augmented O
re B-PK
##nal I-PK
clearance I-PK
[SEP] O
[CLS] O
the O
improved O
anti O
##no O
##ci O
##ceptive O
activity O
of O
a O
##c O
na O
##no O
##c O
##ry O
##stal O
##s O
was O
shown O
at O
much O
lower O
doses O
as O
compared O
to O
un O
##p O
##ro O
##cess O
##ed O
drug O
, O
which O
is O
purely O
because O
of O
na O
##non O
##ization O
which O
may O
be O
attributed O
to O
improved O
so O
##lub O
##ility O
and O
dissolution O
rate O
of O
a O
##c O
, O
ultimately O
resulting O
in O
its O
faster O
rate B-PK
of I-PK
absorption I-PK
. O
[SEP] O
[CLS] O
the O
obtained O
residue O
was O
re O
##c O
##ry O
##stal O
##li O
##zed O
by O
is O
##op O
##rop O
##ano O
##l O
several O
times O
until O
the O
re O
##age O
##nts O
and O
un O
##co O
##up O
##led O
5 O
- O
f O
##a O
were O
totally O
removed O
( O
monitored O
by O
t O
##l O
##c O
and O
hp O
##l O
##c O
) O
, O
then O
dried O
in O
vacuum O
at O
40 O
##° O
##c O
overnight O
. O
[SEP] O
[CLS] O
as O
the O
molecular O
weight O
increases O
, O
the O
in O
v O
##ivo O
clearance B-PK
rate I-PK
decreases O
. O
[SEP] O
[CLS] O
after O
administration O
in O
##tra O
##ven O
##ously O
, O
5 O
- O
f O
##a O
was O
rapidly O
eliminated O
from O
the O
blood O
circulation O
, O
which O
led O
to O
a O
complete O
removal O
at O
[UNK] O
h O
after O
administration O
, O
whereas O
the O
elimination B-PK
rate I-PK
of O
5 O
- O
f O
##a O
- O
p O
##ae O
was O
much O
lower O
than O
that O
of O
5 O
- O
f O
##a O
, O
and O
the O
blood O
retention O
time O
of O
this O
mac O
##rom O
##ole O
##cular O
pro O
##dr O
##ug O
reached O
more O
than O
96 O
h O
( O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
some O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
such O
as O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
the O
mean B-PK
retention I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
5 O
- O
f O
##a O
- O
p O
##ae O
were O
much O
higher O
than O
those O
of O
5 O
- O
f O
##a O
, O
i O
. O
e O
. O
, O
25 O
. O
6 O
times O
for O
au B-PK
##c I-PK
( O
54 O
##6 O
. O
6 O
##± O
##36 O
. O
7 O
µ O
##g O
/ O
m O
##l O
· O
h O
vs O
21 O
. O
37 O
##± O
##4 O
. O
36 O
µ O
##g O
/ O
m O
##l O
· O
h O
) O
, O
11 O
. O
7 O
times O
for O
m B-PK
##rt I-PK
( O
7 O
. O
96 O
##2 O
##± O
##0 O
. O
400 O
h O
vs O
0 O
. O
67 O
##9 O
##± O
##0 O
. O
142 O
h O
) O
and O
14 O
. O
4 O
times O
for O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
22 O
. O
10 O
##± O
##5 O
. O
92 O
h O
vs O
1 O
. O
53 O
##8 O
##± O
##0 O
. O
41 O
##9 O
h O
) O
, O
indicating O
a O
much O
longer O
blood O
circulation O
times O
and O
a O
remarkably O
enhanced O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
mac O
##rom O
##ole O
##cular O
pro O
##dr O
##ug O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
crushed O
or O
##f O
administration O
yielded O
reduced O
o O
##xy O
##co O
##don O
##e O
cm B-PK
##ax I-PK
and O
increased O
t B-PK
##max I-PK
versus O
crushed O
o O
##c O
and O
o O
##xy O
a O
##pi O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
metric O
##s O
were O
: O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
concentration I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##cin I-PK
##f I-PK
) I-PK
, O
and O
terminal B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
median O
t B-PK
##max I-PK
values O
for O
finely O
and O
coarse O
##ly O
crushed O
or O
##f O
were O
approximately O
twice O
as O
long O
as O
those O
observed O
for O
o O
##c O
and O
o O
##xy O
a O
##pi O
. O
[SEP] O
[CLS] O
the O
p O
##k O
parameters O
for O
analysis O
included O
maximum B-PK
serum I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
minimum B-PK
serum I-PK
concentration I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
, O
time B-PK
of I-PK
maximum I-PK
serum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
systemic B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
area B-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
over I-PK
the I-PK
dos I-PK
##ing I-PK
interval I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
τ I-PK
) I-PK
, O
and O
the O
average B-PK
serum I-PK
concentration I-PK
over I-PK
the I-PK
dos I-PK
##ing I-PK
interval I-PK
( I-PK
ca I-PK
##v I-PK
, I-PK
τ I-PK
) I-PK
for O
l O
##y O
##31 O
##64 O
##53 O
##0 O
. O
[SEP] O
[CLS] O
k O
##ras O
and O
e O
##g O
##f O
##r O
so O
##matic O
mutations O
were O
also O
assessed O
using O
the O
##ras O
##cre O
##en O
##® O
k O
##ras O
and O
e O
##g O
##f O
##r O
rotor O
- O
gene O
q O
p O
##c O
##r O
ass O
##ays O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
occurred O
at O
~ O
3 O
h O
( O
t B-PK
##max I-PK
) O
following O
the O
start O
of O
in O
##fusion O
, O
and O
serum O
concentrations O
declined O
in O
a O
mon O
##oe O
##x O
##po O
##nent O
##ial O
manner O
( O
fi O
##g O
. O
2 O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
minimum B-PK
serum I-PK
concentration I-PK
over I-PK
the I-PK
dos I-PK
##ing I-PK
interval I-PK
( I-PK
cm I-PK
##in I-PK
, I-PK
τ I-PK
) I-PK
following O
1000 O
mg O
on O
schedule O
1 O
of O
l O
##y O
##31 O
##64 O
##53 O
##0 O
in O
cycles O
1 O
and O
2 O
( O
mean O
cm B-PK
##in I-PK
, I-PK
τ I-PK
range O
17 O
. O
6 O
– O
40 O
. O
8 O
µ O
##g O
/ O
m O
##l O
) O
was O
lower O
than O
the O
met O
e B-PK
##c I-PK
##50 I-PK
( O
79 O
. O
5 O
µ O
##g O
/ O
m O
##l O
) O
, O
which O
is O
the O
predicted O
target O
concentration O
to O
maintain O
throughout O
the O
dos O
##ing O
interval O
to O
achieve O
the O
p O
##har O
##ma O
##co O
##log O
##ic O
activity O
of O
l O
##y O
##31 O
##64 O
##53 O
##0 O
. O
[SEP] O
[CLS] O
therefore O
, O
a O
weekly O
schedule O
of O
administration O
( O
schedule O
2 O
) O
was O
tested O
to O
try O
to O
minimize O
the O
flu O
##ct O
##uation O
between O
the O
cm B-PK
##in I-PK
and O
cm B-PK
##ax I-PK
and O
thereby O
sustain O
a O
higher O
and O
more O
consistent O
level O
of O
in O
##hibition O
of O
both O
e O
##g O
##f O
##r O
and O
met O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
occurred O
at O
~ O
2 O
h O
( O
t B-PK
##max I-PK
) O
following O
the O
start O
of O
in O
##fusion O
of O
500 O
and O
600 O
mg O
doses O
, O
and O
serum O
concentrations O
declined O
in O
a O
mon O
##oe O
##x O
##po O
##nent O
##ial O
manner O
. O
[SEP] O
[CLS] O
the O
principal O
drugs O
tested O
, O
ve O
##rap O
##ami O
##l O
and O
ni O
##fe O
##di O
##pine O
, O
were O
found O
to O
increase O
significantly O
plasma O
dig O
##ox O
##in O
levels O
mainly O
by O
reducing O
dig O
##ox O
##in O
total B-PK
clearance I-PK
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
alpha I-PK
) I-PK
, O
c B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
t B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
k B-PK
( I-PK
e I-PK
) I-PK
, O
m B-PK
##rt I-PK
and O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
were O
determined O
from O
plasma O
concentrations O
of O
both O
formulation O
##s O
, O
resulting O
in O
a O
c B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
120 O
% O
larger O
than O
and O
a O
t B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
65 O
% O
faster O
than O
those O
reported O
in O
other O
populations O
. O
[SEP] O
[CLS] O
this O
decrease O
was O
accompanied O
by O
a O
di O
##sp O
##rop O
##ort O
##ion O
##ate O
increase O
in O
the O
value O
of O
au B-PK
##c I-PK
from O
25 O
. O
4 O
+ O
- O
5 O
. O
9 O
to O
112 O
##8 O
. O
6 O
+ O
- O
57 O
##5 O
. O
7 O
micro O
##gram O
##s O
x O
min O
x O
m O
##l O
- O
1 O
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
from O
33 O
. O
2 O
+ O
- O
10 O
. O
7 O
to O
41 O
##3 O
. O
0 O
+ O
- O
239 O
. O
3 O
min O
, O
and O
volume B-PK
of I-PK
distribution I-PK
from O
54 O
##7 O
. O
7 O
+ O
- O
153 O
. O
1 O
to O
148 O
##9 O
. O
0 O
+ O
- O
249 O
. O
0 O
m O
##l O
. O
[SEP] O
[CLS] O
peak B-PK
concentrations I-PK
, O
evening B-PK
t I-PK
##rough I-PK
##s I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
h I-PK
were O
entered O
into O
linear O
and O
log O
##10 O
- O
log O
##10 O
linear O
re O
##gression O
models O
to O
determine O
the O
best O
correlation O
with O
l O
##p O
##v O
and O
r O
##t O
##v O
plasma O
concentrations O
using O
a O
maximum O
of O
2 O
time O
points O
. O
[SEP] O
[CLS] O
the O
values O
of O
the O
kinetic O
parameters O
were O
: O
ka B-PK
: O
6 O
. O
9 O
( O
h O
( O
- O
1 O
) O
) O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
8 O
. O
5 O
( O
h O
) O
, O
au B-PK
##c I-PK
: O
74 O
##1 O
( O
p O
##g O
x O
h O
( O
- O
1 O
) O
x O
l O
( O
- O
1 O
) O
, O
v B-PK
( I-PK
area I-PK
/ I-PK
f I-PK
) I-PK
: O
147 O
##0 O
( O
l O
) O
. O
[SEP] O
[CLS] O
the O
ch O
##ime O
##ric O
anti O
- O
il O
##6 O
ma O
##bs O
have O
a O
long O
half B-PK
- I-PK
life I-PK
time I-PK
, O
a O
low O
im O
##mu O
##no O
##genic O
##ity O
, O
and O
are O
able O
to O
block O
il O
##6 O
- O
dependent O
processes O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
no O
statistical O
##ly O
significant O
differences O
were O
obtained O
between O
the O
two O
products O
with O
respect O
to O
the O
mean O
concentration O
- O
time O
profiles O
or O
in O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
the O
area B-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from O
the O
present O
study O
. O
[SEP] O
[CLS] O
clearance B-PK
was O
35 O
( O
14 O
- O
121 O
) O
m O
##l O
/ O
min O
and O
was O
weakly O
but O
significantly O
correlated O
with O
c O
##rea O
##tin O
##ine O
clearance O
. O
[SEP] O
[CLS] O
when O
g O
##em O
##fi O
##bro O
##zi O
##l O
was O
taken O
0 O
, O
1 O
, O
3 O
, O
or O
6 O
h O
before O
re O
##pa O
##gli O
##ni O
##de O
, O
the O
geometric O
mean O
ratio O
relative O
to O
control O
( O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
) O
of O
re O
##pa O
##gli O
##ni O
##de O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
) I-PK
was O
5 O
. O
0 O
- O
fold O
( O
4 O
. O
3 O
- O
5 O
. O
7 O
- O
fold O
) O
, O
6 O
. O
3 O
- O
fold O
( O
5 O
. O
4 O
- O
7 O
. O
5 O
- O
fold O
) O
, O
6 O
. O
6 O
- O
fold O
( O
5 O
. O
6 O
- O
7 O
. O
7 O
- O
fold O
) O
, O
and O
5 O
. O
4 O
- O
fold O
( O
4 O
. O
8 O
- O
6 O
. O
1 O
- O
fold O
) O
, O
respectively O
( O
p O
< O
0 O
. O
00 O
##1 O
vs O
. O
control O
) O
. O
[SEP] O
[CLS] O
the O
exposure O
##s O
[ O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
] O
of O
the O
components O
of O
the O
3 O
##d O
regime O
##n O
were O
comparable O
( O
< O
20 O
% O
difference O
) O
in O
healthy O
chin O
##ese O
subjects O
residing O
in O
chin O
##a O
or O
the O
united O
states O
. O
[SEP] O
[CLS] O
plasma O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
at O
##or O
##vas O
##tat O
##in O
as O
measured O
by O
ma B-PK
##ximal I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
( I-PK
0 I-PK
- I-PK
24 I-PK
h I-PK
) I-PK
. O
[SEP] O
[CLS] O
prediction O
of O
liver O
volume O
- O
a O
population O
- O
based O
approach O
to O
meta O
- O
analysis O
of O
p O
##ae O
##dia O
##tric O
, O
adult O
and O
g O
##eria O
##tric O
populations O
- O
an O
update O
. O
[SEP] O
[CLS] O
the O
before O
: O
after O
food O
ratios O
of O
the O
au B-PK
##c I-PK
values O
were O
1 O
. O
51 O
for O
cape O
##ci O
##ta O
##bine O
, O
1 O
. O
26 O
for O
5 O
' O
- O
d O
##f O
##c O
##r O
, O
1 O
. O
15 O
for O
5 O
' O
- O
d O
##fu O
##r O
, O
1 O
. O
13 O
for O
5 O
- O
f O
##u O
, O
1 O
. O
07 O
for O
f O
##uh O
##2 O
, O
and O
1 O
. O
04 O
for O
f O
##bal O
. O
[SEP] O
[CLS] O
but O
no O
significant O
difference O
were O
found O
to O
t B-PK
##max I-PK
in O
a O
##que O
##ous O
humor O
and O
corn O
##ea O
between O
lip O
##oso O
##me O
and O
eyed O
##rop O
, O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
di O
##c O
##lo O
##fen O
##ac O
in O
a O
##que O
##ous O
humor O
and O
corn O
##ea O
with O
lip O
##oso O
##ine O
were O
longer O
than O
that O
with O
eye O
- O
drop O
solution O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
modeling O
demonstrated O
a O
significant O
influence O
of O
c O
##p O
##b O
on O
the O
volume B-PK
of I-PK
distribution I-PK
and O
elimination O
of O
c O
##ef O
##az O
##olin O
. O
[SEP] O
[CLS] O
in O
some O
of O
the O
patients O
, O
chiefly O
infants O
with O
severe O
re O
##nal O
ins O
##uff O
##iciency O
, O
the O
var O
##ea O
was O
larger O
than O
normal O
. O
[SEP] O
[CLS] O
for O
standard O
- O
dose O
p O
##ali O
##fer O
##min O
, O
mean O
values O
for O
area B-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
were O
within O
15 O
% O
between O
doses O
1 O
and O
3 O
and O
within O
1 O
% O
between O
doses O
1 O
and O
4 O
. O
[SEP] O
[CLS] O
the O
plasma O
p O
##y O
##y O
concentration O
reached O
its O
peak O
at O
10 O
min O
following O
pulmonary O
delivery O
with O
12 O
- O
14 O
% O
of O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
le O
##vo O
##do O
##pa O
plasma O
levels O
were O
further O
measured O
with O
hp O
##l O
##c O
method O
, O
then O
giving O
the O
following O
variables O
: O
cm B-PK
##ax I-PK
( I-PK
peak I-PK
concentration I-PK
) I-PK
, O
t B-PK
##max I-PK
( I-PK
time I-PK
corresponding I-PK
to I-PK
cm I-PK
##ax I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
area I-PK
under I-PK
curve I-PK
) I-PK
. O
[SEP] O
[CLS] O
the O
mean O
r O
##if O
##ab O
##uti O
##n O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
24 I-PK
) I-PK
) I-PK
increased O
20 O
% O
from O
the O
base O
##line O
value O
( O
geometric O
mean O
, O
5 O
. O
0 O
vs O
. O
4 O
. O
2 O
micro O
##g O
. O
h O
/ O
m O
##l O
; O
ratio O
of O
geometric O
means O
, O
1 O
. O
2 O
[ O
90 O
% O
confidence O
interval O
, O
1 O
. O
0 O
- O
1 O
. O
4 O
] O
) O
. O
[SEP] O
[CLS] O
when O
given O
separately O
, O
there O
were O
significant O
differences O
in O
the O
values O
of O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
and O
c B-PK
##l I-PK
between O
on O
##z O
en O
##anti O
##omer O
##s O
( O
p O
< O
0 O
. O
05 O
) O
, O
indicating O
that O
elimination O
of O
( O
+ O
) O
- O
on O
##z O
was O
more O
rapid O
than O
that O
of O
( O
- O
) O
- O
on O
##z O
. O
[SEP] O
[CLS] O
when O
2 O
##cc O
##pa O
was O
administered O
in O
##tra O
##per O
##ito O
##nea O
##lly O
to O
mice O
at O
a O
dose O
of O
1 O
. O
6 O
mg O
/ O
kg O
, O
the O
half B-PK
- I-PK
life I-PK
of O
2 O
##cc O
##pa O
in O
plasma O
was O
16 O
min O
. O
[SEP] O
[CLS] O
except O
for O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
, O
which O
was O
10 O
% O
shorter O
in O
women O
, O
no O
other O
p O
##har O
##ma O
##co O
##kin O
##etic O
values O
were O
significantly O
different O
between O
gender O
##s O
. O
[SEP] O
[CLS] O
however O
, O
in O
v O
##ivo O
studies O
in O
p O
- O
g O
##p O
knockout O
mice O
versus O
wild O
- O
type O
mice O
showed O
no O
difference O
in O
the O
amount O
of O
das O
##ati O
##ni O
##b O
remaining O
un O
##ab O
##sor O
##bed O
in O
the O
gas O
##tro O
##int O
##est O
##inal O
tract O
, O
suggesting O
that O
p O
- O
g O
##p O
may O
not O
be O
responsible O
for O
the O
incomplete O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
mean O
( O
s O
##d O
) O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
sa O
##p O
##rop O
##ter O
##in O
was O
6 O
. O
69 O
( O
2 O
. O
29 O
) O
hours O
and O
there O
was O
little O
evidence O
of O
accumulation O
, O
even O
at O
the O
highest O
dose O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
que O
##rc O
##eti O
##n O
in O
pigs O
depends O
on O
the O
g O
##ly O
##cos O
##ide O
m O
##oi O
##ety O
and O
on O
diet O
##ary O
factors O
. O
[SEP] O
[CLS] O
in O
t O
##2 O
##d O
patients O
, O
a O
protein O
and O
lip O
##id O
pre O
##load O
improve O
##s O
glucose O
tolerance O
throughout O
the O
whole O
post O
- O
a O
##bs O
##or O
##pt O
##ive O
phase O
mainly O
by O
reducing O
the O
appearance O
of O
oral O
glucose O
, O
and O
improving O
both O
beta O
- O
cell O
function O
and O
insulin O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
in O
contrast O
to O
other O
papers O
, O
we O
found O
that O
m O
##ox O
##if O
##lo O
##xa O
##cin O
p O
##k O
were O
best O
described O
by O
a O
three O
compartment O
##al O
model O
using O
lean O
body O
mass O
( O
lb O
##m O
) O
as O
a O
predict O
##or O
for O
m O
##ox O
##if O
##lo O
##xa O
##cin O
clearance B-PK
. O
[SEP] O
[CLS] O
our O
major O
finding O
was O
that O
missing O
body O
weights O
minimal O
##ly O
affect O
population O
estimates O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
but O
do O
affect O
the O
co O
##var O
##iate O
relationship O
parameters O
, O
particularly O
the O
one O
describing O
dependence O
of O
clearance B-PK
on O
body O
weight O
. O
[SEP] O
[CLS] O
met O
##had O
##one O
is O
a O
potent O
, O
long O
acting O
na O
##rc O
##otic O
anal O
##ges O
##ic O
which O
can O
be O
oral O
##ly O
administered O
due O
to O
its O
almost O
complete O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
patients O
with O
a O
raised O
bi O
##li O
##ru O
##bin O
level O
had O
reduced O
do O
##x O
##or O
##ubi O
##cin O
clearance B-PK
, O
but O
there O
was O
no O
clear O
relationship O
between O
the O
extent O
of O
this O
elevation O
and O
the O
reduction O
in O
do O
##x O
##or O
##ubi O
##cin O
clearance B-PK
. O
[SEP] O
[CLS] O
the O
values O
of O
[ O
formula O
: O
see O
text O
] O
, O
t B-PK
##max I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
were O
non O
##sign O
##ificant O
##ly O
increased O
by O
17 O
% O
, O
26 O
% O
and O
17 O
% O
in O
a O
##f O
##lat O
##ox O
##in O
- O
exposed O
br O
##oil O
##er O
chickens O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
total O
of O
85 O
patients O
received O
am O
##ika O
##cin O
treatment O
, O
of O
whom O
71 O
( O
83 O
. O
5 O
% O
) O
achieved O
a O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
> O
6 O
, O
66 O
( O
77 O
. O
6 O
% O
) O
a O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
> O
8 O
, O
64 O
( O
75 O
. O
3 O
% O
) O
a O
cm B-PK
##ax I-PK
/ I-PK
mi I-PK
##c I-PK
> O
10 O
and O
72 O
( O
84 O
. O
7 O
% O
) O
an O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
> O
65 O
. O
[SEP] O
[CLS] O
dose O
- O
normal O
##ized O
total B-PK
au I-PK
##c I-PK
values O
were O
used O
to O
calculate O
de O
##x O
##med O
##eto O
##mi O
##dine O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
oral B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
of O
met O
##op O
##rol O
##ol O
was O
positively O
correlated O
with O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
/ I-PK
f I-PK
) I-PK
, O
suggesting O
the O
residual O
var O
##iability O
of O
f B-PK
. O
the O
up O
##take O
of O
met O
##op O
##rol O
##ol O
into O
l O
##s O
##18 O
##0 O
cells O
was O
significantly O
decreased O
by O
the O
acid O
##ification O
of O
extra O
##cellular O
medium O
p O
##h O
, O
and O
was O
dependent O
on O
temperature O
and O
in O
##tra O
##cellular O
p O
##h O
. O
further O
##more O
, O
the O
cellular O
up O
##take O
of O
met O
##op O
##rol O
##ol O
was O
sat O
##urable O
, O
and O
was O
significantly O
decreased O
in O
the O
presence O
of O
h O
##ydro O
##phobic O
cat O
##ion O
##ic O
drugs O
such O
as O
dip O
##hen O
##hy O
##dra O
##mine O
, O
pro O
##ca O
##ina O
##mi O
##de O
, O
bi O
##so O
##p O
##rol O
##ol O
, O
and O
q O
##uin O
##id O
##ine O
. O
[SEP] O
[CLS] O
the O
primary O
objectives O
were O
to O
assess O
the O
safety O
of O
de O
##ci O
##ta O
##bine O
plus O
c O
##eda O
##zu O
##rid O
##ine O
, O
and O
to O
determine O
the O
dose O
of O
each O
drug O
needed O
to O
achieve O
a O
mean O
au B-PK
##c I-PK
for O
de O
##ci O
##ta O
##bine O
exposure O
similar O
to O
that O
for O
in O
##tra O
##ven O
##ous O
de O
##ci O
##ta O
##bine O
exposure O
. O
[SEP] O
[CLS] O
in O
the O
nine O
non O
- O
ch O
##ole O
##static O
patients O
, O
u O
##d O
##c O
reduced O
the O
absorption B-PK
rate I-PK
and O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
c O
##sa O
without O
modify O
##ing O
the O
elimination B-PK
rate I-PK
constant I-PK
of O
c O
##sa O
and O
the O
c O
##sa O
pre O
- O
drug O
levels O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
the O
##op O
##hyl O
##line O
was O
increased O
by O
20 O
% O
. O
[SEP] O
[CLS] O
these O
correlation O
##s O
suggest O
that O
the O
t O
##g O
##32 O
hem O
##i O
mouse O
model O
, O
which O
is O
both O
convenient O
and O
cost O
- O
effective O
, O
can O
offer O
value O
in O
predict O
##ing O
anti O
##body O
half B-PK
- I-PK
life I-PK
and O
clearance B-PK
in O
p O
##rima O
##tes O
. O
[SEP] O
[CLS] O
all O
the O
parameters O
of O
c O
##ip O
##ro O
##f O
##lo O
##xa O
##cin O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
i O
. O
e O
. O
, O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
and O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
showed O
no O
significant O
correlation O
with O
dissolution O
rates O
at O
t O
##30 O
% O
, O
t O
##50 O
% O
, O
t O
##90 O
% O
and O
dissolution O
at O
30 O
min O
##s O
with O
aims O
as O
in O
- O
v O
##ivo O
bio O
##e O
##q O
##u O
##valence O
wa O
##iver O
. O
[SEP] O
[CLS] O
mac O
##imo O
##rel O
##in O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
showed O
less O
than O
dose O
- O
proportional O
increases O
following O
administration O
of O
0 O
. O
5 O
and O
1 O
. O
0 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
the O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
, O
systemic B-PK
clearance I-PK
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
5 O
. O
90 O
± O
0 O
. O
200 O
l O
/ O
kg O
, O
30 O
. O
7 O
± O
0 O
. O
166 O
m O
##l O
/ O
min O
/ O
kg O
and O
4 O
. O
84 O
± O
0 O
. O
83 O
h O
respectively O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
c O
##y O
##c O
##los O
##por O
##ine O
in O
c O
##y O
##p O
##3 O
##a O
##4 O
##∗ O
##1 O
/ O
∗ O
##1 O
was O
significantly O
greater O
than O
that O
in O
c O
##y O
##p O
##3 O
##a O
##4 O
##∗ O
##1 O
/ O
∗ O
##18 O
##b O
in O
the O
male O
group O
( O
p O
= O
0 O
. O
02 O
##3 O
) O
, O
but O
not O
the O
female O
group O
. O
[SEP] O
[CLS] O
c O
##y O
##c O
##los O
##por O
##ine O
co O
##ad O
##mini O
##stra O
##tion O
did O
not O
appear O
to O
affect O
apparent O
sit O
##ag O
##lip O
##tin O
re B-PK
##nal I-PK
clearance I-PK
, O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
or O
c O
( O
24 O
h O
) O
, O
suggesting O
that O
effects O
of O
these O
high O
doses O
of O
c O
##y O
##c O
##los O
##por O
##ine O
are O
more O
likely O
due O
to O
enhanced O
absorption O
of O
sit O
##ag O
##lip O
##tin O
, O
potentially O
through O
in O
##hibition O
of O
in O
##test O
##inal O
p O
- O
g O
##ly O
##co O
##p O
##rote O
##in O
. O
[SEP] O
[CLS] O
a O
significant O
difference O
was O
observed O
in O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
1 I-PK
) I-PK
( O
45 O
##31 O
. O
28 O
+ O
- O
214 O
##7 O
vs O
162 O
##9 O
. O
1 O
+ O
- O
100 O
##6 O
ng O
x O
h O
x O
m O
##l O
( O
- O
1 O
) O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
( O
46 O
##32 O
. O
42 O
+ O
- O
222 O
##1 O
. O
75 O
vs O
162 O
##9 O
. O
46 O
+ O
- O
101 O
##2 O
. O
61 O
ng O
x O
h O
x O
m O
##l O
( O
- O
1 O
) O
, O
p O
= O
0 O
. O
000 O
##6 O
) O
, O
cm B-PK
##ax I-PK
( O
54 O
##4 O
. O
89 O
+ O
- O
27 O
##3 O
. O
91 O
vs O
238 O
. O
61 O
+ O
- O
146 O
. O
34 O
ng O
/ O
m O
##l O
, O
p O
= O
0 O
. O
04 O
) O
, O
t O
( O
1 O
/ O
2 O
) O
( O
9 O
. O
3 O
+ O
- O
3 O
. O
58 O
vs O
4 O
. O
0 O
+ O
- O
1 O
. O
43 O
h O
, O
p O
= O
0 O
. O
03 O
##17 O
) O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
( O
43 O
. O
14 O
+ O
- O
36 O
. O
23 O
vs O
122 O
. O
85 O
+ O
- O
95 O
l O
x O
h O
( O
- O
1 O
) O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
of O
c O
##ele O
##co O
##xi O
##b O
administered O
before O
and O
after O
r O
##if O
##amp O
##ici O
##n O
pre O
##tre O
##at O
##ment O
. O
[SEP] O
[CLS] O
suspension O
##s O
of O
small O
drug O
particles O
can O
be O
used O
to O
improve O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
after O
in O
##tra O
##ven O
##ous O
administration O
, O
vs B-PK
##s I-PK
( O
1 O
. O
39 O
l O
/ O
kg O
) O
and O
extremely O
low O
c B-PK
##l I-PK
( O
0 O
. O
08 O
l O
/ O
kg O
/ O
h O
) O
were O
observed O
. O
[SEP] O
[CLS] O
this O
study O
was O
conducted O
to O
evaluate O
the O
potential O
adverse O
effects O
of O
et O
##hyl O
##ben O
##zen O
##e O
( O
e O
##b O
) O
on O
reproductive O
capability O
from O
whole O
- O
body O
in O
##hala O
##tion O
exposure O
of O
f O
##0 O
and O
f O
##1 O
parental O
animals O
. O
[SEP] O
[CLS] O
the O
m O
##pa O
exposure O
expressed O
by O
the O
au B-PK
##c I-PK
appears O
to O
be O
higher O
in O
his O
##pan O
##ic O
patients O
than O
those O
reported O
in O
other O
ethnic O
groups O
, O
which O
may O
be O
the O
result O
of O
various O
factors O
such O
as O
difference O
of O
the O
u O
##rid O
##ine O
dip O
##hos O
##phate O
g O
##lu O
##cu O
##ron O
##osy O
##lt O
##ran O
##s O
##fer O
##ase O
enzyme O
g O
##eno O
##type O
##s O
, O
but O
gas O
##tro O
##int O
##est O
##inal O
side O
effects O
were O
acceptable O
and O
the O
cm B-PK
##ax I-PK
or O
au B-PK
##c I-PK
of O
m O
##pa O
##g O
showed O
correlation O
##s O
with O
gas O
##tro O
##int O
##est O
##inal O
symptoms O
. O
[SEP] O
[CLS] O
following O
the O
administration O
of O
o O
##xa O
##tom O
##ide O
1 O
mg O
/ O
kg O
, O
the O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
) I-PK
, O
and O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
0 I-PK
- I-PK
36 I-PK
h I-PK
were O
measured O
and O
the O
following O
results O
were O
obtained O
: O
42 O
. O
2 O
+ O
- O
15 O
ng O
/ O
m O
##l O
at O
2 O
h O
after O
o O
##xa O
##tom O
##ide O
administration O
, O
41 O
. O
4 O
+ O
- O
2 O
. O
0 O
h O
, O
37 O
. O
4 O
+ O
- O
4 O
. O
2 O
l O
/ O
kg O
, O
and O
46 O
##8 O
+ O
- O
52 O
ng O
/ O
m O
##l O
/ O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
steady O
- O
state O
13 O
- O
sample O
24 O
- O
hour O
au B-PK
##c I-PK
value O
was O
correlated O
highly O
with O
the O
average O
9 O
- O
sample O
au B-PK
##c I-PK
value O
after O
the O
2 O
single O
doses O
( O
r O
= O
0 O
. O
81 O
; O
p O
= O
. O
000 O
##2 O
) O
. O
[SEP] O
[CLS] O
bus O
##ulf O
##an O
clearance B-PK
and O
area B-PK
under I-PK
concentration I-PK
time I-PK
- I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
were O
determined O
after O
the O
first O
dose O
using O
a O
one O
- O
compartment O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
model O
with O
first O
- O
order O
absorption O
. O
[SEP] O
[CLS] O
these O
findings O
suggest O
that O
newborn O
##s O
have O
increased O
try O
##ps O
##in O
up O
##take O
, O
and O
the O
try O
##ps O
##in O
initially O
binds O
to O
alpha O
1 O
- O
inhibitor O
3 O
before O
being O
transferred O
to O
alpha O
- O
mac O
##rog O
##lo O
##bul O
##in O
for O
clearance B-PK
. O
[SEP] O
[CLS] O
regarding O
the O
influence O
of O
au B-PK
##c I-PK
variation O
on O
au O
##ec O
variation O
, O
the O
total B-PK
clearance I-PK
value O
was O
changed O
from O
80 O
% O
to O
120 O
% O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##finity I-PK
and O
cm B-PK
##ax I-PK
values O
were O
proportional O
to O
doses O
( O
mg O
or O
mg O
/ O
kg O
, O
p O
less O
than O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
he O
##pa O
##tic O
ve O
##si O
##cular O
ion O
- O
trapping O
, O
intrinsic B-PK
elimination I-PK
clearance I-PK
, O
per B-PK
##me I-PK
##ability I-PK
- O
surface O
area O
product O
, O
and O
in O
##tra O
##cellular O
binding O
were O
derived O
using O
a O
physiological O
##ly O
based O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
. O
[SEP] O
[CLS] O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
em O
##d O
570 O
##33 O
, O
a O
calcium O
se O
##ns O
##iti O
##zing O
agent O
with O
poor O
so O
##lub O
##ility O
, O
was O
compared O
in O
dogs O
using O
four O
solid O
dos O
##age O
form O
formulation O
approaches O
: O
a O
physical O
blend O
of O
the O
drug O
with O
ex O
##ci O
##pie O
##nts O
, O
micro O
##ni O
##zation O
of O
the O
drug O
, O
preparation O
of O
co O
##ground O
mixture O
##s O
and O
spray O
- O
drying O
of O
the O
drug O
from O
a O
na O
##no O
##c O
##ry O
##stal O
##line O
suspension O
. O
[SEP] O
[CLS] O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
k B-PK
( I-PK
e I-PK
##o I-PK
) I-PK
for O
heart O
rate O
was O
17 O
min O
, O
sa O
##cca O
##dic O
eye O
movements O
and O
adaptive O
tracking O
1 O
- O
1 O
. O
5 O
h O
, O
body O
sway O
, O
smooth O
pursuit O
, O
visual O
analogue O
scales O
alert O
##ness O
and O
psychedelic O
2 O
. O
5 O
- O
3 O
. O
5 O
h O
, O
pupil O
size O
, O
finger O
tapping O
and O
visual O
analogue O
scales O
feeling O
high O
more O
than O
8 O
h O
. O
s O
##co O
##pol O
##amine O
affected O
different O
c O
##ns O
functions O
in O
a O
concentration O
- O
dependent O
manner O
, O
which O
based O
on O
their O
distinct O
p O
##k O
- O
p O
##d O
characteristics O
seemed O
to O
reflect O
multiple O
distinct O
functional O
pathways O
of O
the O
ch O
##olin O
##ergic O
system O
. O
[SEP] O
[CLS] O
the O
data O
obtained O
fitted O
a O
two O
- O
compartment O
open O
model O
, O
and O
the O
mean O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
beta I-PK
value O
was O
39 O
. O
8 O
+ O
- O
10 O
. O
8 O
min O
. O
[SEP] O
[CLS] O
in O
hospital O
##ized O
f O
##oa O
##ls O
, O
se O
##psis O
score O
, O
serum O
c O
##rea O
##tin O
##ine O
concentration O
, O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
area B-PK
under I-PK
the I-PK
moment I-PK
curve I-PK
, O
and O
mean B-PK
residence I-PK
time I-PK
were O
greater O
, O
and O
total B-PK
clearance I-PK
was O
decreased O
, O
compared O
with O
values O
in O
clinical O
##ly O
normal O
f O
##oa O
##ls O
. O
[SEP] O
[CLS] O
t O
##ts O
were O
significantly O
higher O
than O
base O
##line O
at O
15 O
minutes O
after O
l O
##d O
for O
f O
##3 O
and O
f O
##5 O
. O
[SEP] O
[CLS] O
clearance B-PK
decreased O
rapidly O
as O
the O
effective O
molecular O
size O
increased O
from O
19 O
. O
5 O
to O
70 O
k O
##da O
, O
whereas O
above O
70 O
k O
##da O
the O
clearance B-PK
decreased O
more O
slowly O
. O
[SEP] O
[CLS] O
the O
increased O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ni O
##fe O
##di O
##pine O
in O
the O
presence O
of O
p O
##io O
##gli O
##ta O
##zone O
may O
be O
due O
to O
an O
in O
##hibition O
of O
the O
p O
- O
g O
##p O
- O
mediated O
e O
##ff O
##lux O
transport O
##er O
in O
the O
small O
in O
##test O
##ine O
and O
to O
the O
in O
##hibition O
of O
the O
metabolism O
by O
in O
##hibition O
of O
c O
##y O
##p O
##3 O
##a O
##4 O
in O
the O
small O
in O
##test O
##ine O
and O
/ O
or O
the O
liver O
, O
and O
/ O
or O
to O
a O
reduction O
of O
c B-PK
##l I-PK
/ I-PK
f I-PK
of O
ni O
##fe O
##di O
##pine O
by O
p O
##io O
##gli O
##ta O
##zone O
. O
[SEP] O
[CLS] O
the O
da O
##uno O
##ru O
##bic O
##in O
peak B-PK
concentrations I-PK
, O
clearance B-PK
##s I-PK
and O
elimination B-PK
half I-PK
- I-PK
lives I-PK
were O
( O
means O
+ O
- O
s O
##d O
) O
: O
16 O
. O
3 O
+ O
- O
2 O
. O
8 O
micro O
##g O
/ O
m O
##l O
, O
0 O
. O
3 O
+ O
- O
0 O
. O
1 O
l O
/ O
h O
per O
m O
##2 O
and O
5 O
. O
6 O
+ O
- O
2 O
. O
6 O
h O
after O
da O
##uno O
##x O
##ome O
alone O
; O
15 O
. O
1 O
+ O
- O
4 O
. O
9 O
micro O
##g O
/ O
m O
##l O
, O
0 O
. O
5 O
+ O
- O
0 O
. O
3 O
l O
/ O
h O
per O
m O
##2 O
and O
5 O
. O
8 O
+ O
- O
2 O
. O
1 O
h O
after O
the O
combination O
with O
in O
##dina O
##vir O
; O
and O
14 O
. O
5 O
+ O
- O
2 O
. O
8 O
micro O
##g O
/ O
m O
##l O
, O
0 O
. O
4 O
+ O
- O
0 O
. O
2 O
l O
/ O
h O
per O
m O
##2 O
and O
6 O
. O
5 O
+ O
- O
3 O
. O
9 O
h O
after O
the O
combination O
with O
r O
##ito O
##na O
##vir O
. O
[SEP] O
[CLS] O
the O
mean O
( O
± O
##s O
##d O
) O
ni O
##cot O
##ine O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
136 O
min O
( O
± O
##33 O
. O
5 O
) O
, O
clearance B-PK
was O
123 O
##7 O
m O
##l O
/ O
min O
( O
± O
##33 O
##1 O
) O
, O
and O
vs B-PK
##s I-PK
was O
204 O
l O
( O
± O
##6 O
##6 O
) O
, O
or O
2 O
. O
6 O
l O
/ O
kg O
( O
± O
##0 O
. O
7 O
) O
. O
[SEP] O
[CLS] O
g O
##ena O
##cona O
##zo O
##le O
at O
20 O
mg O
/ O
kg O
and O
the O
r O
##r O
( O
s O
##ch O
42 O
##42 O
##7 O
) O
en O
##anti O
##omer O
at O
10 O
mg O
/ O
kg O
had O
very O
similar O
serum O
concentration O
- O
time O
profiles O
and O
c B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
i I-PK
) I-PK
, O
and O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
values O
for O
the O
r O
##r O
en O
##anti O
##omer O
in O
both O
rats O
and O
monkeys O
, O
indicating O
that O
the O
two O
treatments O
were O
equivalent O
with O
respect O
to O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
r O
##r O
en O
##anti O
##omer O
. O
[SEP] O
[CLS] O
implementation O
of O
the O
m O
##p O
##b O
##p O
##k O
model O
enables O
us O
to O
analyze O
the O
relationships O
of O
age O
, O
weight O
, O
f O
##c O
##rn O
, O
er O
and O
k O
##sy O
##n O
in O
both O
adult O
and O
p O
##ediatric O
subject O
. O
[SEP] O
[CLS] O
population O
p O
##k O
analysis O
was O
performed O
by O
non O
##linear O
mixed O
- O
effects O
modeling O
( O
non O
##me O
##m O
) O
to O
estimate O
and O
identify O
different O
factors O
that O
could O
affect O
carved O
##ilo O
##l O
c B-PK
##l I-PK
. O
[SEP] O
[CLS] O
predict O
##ing O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
19 O
- O
nor O
##test O
##osterone O
pro O
##ges O
##tin O
##s O
in O
v O
##ivo O
from O
their O
metabolic O
stability O
in O
human O
liver O
micro O
##so O
##mal O
preparations O
in O
v O
##it O
##ro O
. O
[SEP] O
[CLS] O
however O
, O
due O
to O
poor O
water O
so O
##lub O
##ility O
, O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
drug O
was O
relatively O
low O
. O
[SEP] O
[CLS] O
the O
calculations O
predicted O
that O
the O
agreement O
between O
single O
- O
and O
cumulative O
- O
dose O
techniques O
would O
be O
improved O
if O
( O
1 O
) O
the O
dose O
in O
##cre O
##ment O
was O
increased O
, O
( O
2 O
) O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
increased O
above O
20 O
minutes O
, O
or O
( O
3 O
) O
an O
in O
##fusion O
was O
added O
. O
( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
[SEP] O
[CLS] O
it O
is O
hoped O
that O
more O
distinct O
and O
sufficient O
descriptions O
on O
the O
u O
##rina O
##ry O
ex O
##cre O
##tion O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
will O
be O
associated O
to O
the O
package O
insert O
##s O
and O
the O
interview O
forms O
in O
future O
, O
for O
safe O
and O
efficient O
use O
of O
prescription O
drugs O
. O
[SEP] O
[CLS] O
however O
, O
despite O
advantage O
##ous O
p O
##har O
##ma O
##co O
##log O
##ic O
and O
formulation O
( O
e O
. O
g O
. O
long O
half B-PK
- I-PK
life I-PK
, O
quicker O
time O
to O
onset O
, O
and O
lack O
of O
first O
- O
pass O
he O
##pa O
##tic O
metabolism O
) O
profiles O
, O
there O
seems O
to O
be O
significant O
risk O
of O
in O
##fusion O
- O
related O
h O
##yper O
##sen O
##si O
##ti O
##vity O
reactions O
associated O
with O
the O
administration O
of O
in O
##tra O
##ven O
##ous O
r O
##ola O
##pit O
##ant O
. O
[SEP] O
[CLS] O
the O
test O
for O
proportional O
##ity O
indicated O
that O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
increased O
proportional O
##ly O
with O
an O
increase O
in O
dose O
( O
p O
greater O
than O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
of O
r O
- O
fl O
##eca O
##ini O
##de O
( O
12 O
. O
9 O
h O
) O
was O
longer O
( O
p O
less O
than O
0 O
. O
03 O
) O
than O
that O
of O
s O
- O
fl O
##eca O
##ini O
##de O
( O
9 O
. O
8 O
h O
) O
. O
[SEP] O
[CLS] O
the O
increase O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
not O
linear O
##ly O
related O
with O
the O
fat O
content O
of O
the O
meal O
. O
[SEP] O
[CLS] O
significant O
decrease O
in O
au B-PK
##c I-PK
, O
marked O
decrease O
in O
distribution B-PK
volume I-PK
and O
total B-PK
body I-PK
clearance I-PK
following O
lid O
##oc O
##aine O
and O
prop O
##rano O
##lo O
##l O
were O
noted O
. O
[SEP] O
[CLS] O
there O
were O
no O
differences O
between O
groups O
with O
respect O
to O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( O
awake O
group O
: O
207 O
min O
; O
an O
##ae O
##st O
##he O
##tized O
group O
: O
153 O
min O
) O
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( O
awake O
: O
147 O
litre O
; O
an O
##ae O
##st O
##he O
##tized O
: O
128 O
litre O
) O
, O
or O
clearance B-PK
( O
awake O
: O
58 O
##7 O
m O
##l O
min O
- O
1 O
; O
an O
##ae O
##st O
##he O
##tized O
: O
76 O
##6 O
m O
##l O
min O
- O
1 O
) O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
were O
tested O
for O
bio O
##e O
##qui O
##valence O
after O
log O
- O
transformation O
of O
data O
, O
differences O
of O
t B-PK
##max I-PK
were O
evaluated O
non O
##par O
##ame O
##tric O
##ally O
. O
[SEP] O
[CLS] O
objective O
: O
this O
study O
aims O
to O
detect O
the O
enhance O
##ment O
in O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
poorly O
water O
- O
soluble O
anti O
##hy O
##pert O
##ens O
##ive O
drug O
o O
##lm O
##es O
##art O
##an O
me O
##dox O
##omi O
##l O
( O
o O
##m O
) O
due O
to O
the O
formulation O
of O
l O
##yo O
##phi O
##li O
##zed O
oil O
##y O
- O
core O
na O
##no O
##cap O
##sul O
##es O
. O
[SEP] O
[CLS] O
using O
win O
##non O
##lin O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
analysis O
software O
, O
pu O
##era O
##rin O
was O
found O
to O
be O
rapidly O
absorbed O
via O
the O
oral O
route O
, O
reach O
peak B-PK
levels I-PK
at O
2 O
hours O
, O
and O
have O
a O
half B-PK
- I-PK
life I-PK
of O
approximately O
4 O
. O
3 O
hours O
. O
[SEP] O
[CLS] O
this O
non O
##linear O
##ity O
was O
due O
to O
sat O
##urable O
total B-PK
body I-PK
clearance I-PK
and O
volume B-PK
of I-PK
distribution I-PK
of O
p O
##ac O
##lit O
##ax O
##el O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
the O
p O
##hy O
##tate O
/ O
z O
##n O
m O
##olar O
ratio O
is O
a O
useful O
index O
of O
z O
##n O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
this O
study O
was O
aimed O
to O
develop O
s O
##ln O
##s O
and O
n O
##s O
of O
sa O
##quin O
##avi O
##r O
( O
sq O
) O
for O
improvement O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
peak B-PK
serum I-PK
levels I-PK
of O
r O
##omi O
##p O
##los O
##ti O
##m O
in O
t O
##bi O
mice O
occurred O
4 O
- O
24 O
h O
( O
t B-PK
##max I-PK
) O
after O
injection O
with O
a O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
[UNK] O
h O
. O
cm B-PK
##ax I-PK
values O
were O
at O
[UNK] O
ng O
/ O
m O
##l O
after O
30 O
µ O
##g O
/ O
kg O
± O
t O
##bi O
and O
[UNK] O
ng O
/ O
m O
##l O
after O
300 O
µ O
##g O
/ O
kg O
. O
[SEP] O
[CLS] O
de O
##xa O
##met O
##has O
##one O
significantly O
increased O
the O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
. O
[SEP] O
[CLS] O
double O
log O
##ari O
##th O
##mic O
plots O
of O
c B-PK
##l I-PK
and O
distribution B-PK
volume I-PK
at I-PK
the I-PK
steady I-PK
- I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
vs O
. O
body O
weight O
in O
four O
animal O
species O
were O
linear O
with O
high O
correlation O
coefficients O
; O
and O
the O
predicted O
c B-PK
##l I-PK
and O
vs B-PK
##s I-PK
values O
in O
humans O
agreed O
well O
with O
the O
observed O
values O
after O
administration O
of O
c O
##s O
- O
02 O
##3 O
by O
an O
in O
##tra O
##ven O
##ous O
d O
##rip O
in O
##fusion O
for O
30 O
min O
. O
[SEP] O
[CLS] O
an O
##ato O
##mic O
##al O
and O
physiological O
basis O
for O
the O
all O
##ometric O
s O
##cal O
##ing O
of O
c O
##is O
##p O
##lat O
##in O
clearance B-PK
in O
dogs O
. O
[SEP] O
[CLS] O
our O
results O
revealed O
no O
considerable O
differences O
in O
clearance B-PK
##s I-PK
among O
the O
components O
. O
[SEP] O
[CLS] O
m O
##od O
##ulation O
of O
p O
- O
g O
##ly O
##co O
##p O
##rote O
##in O
with O
c O
##y O
##c O
##los O
##por O
##in O
a O
caused O
a O
5 O
- O
to O
10 O
- O
fold O
increase O
in O
the O
up O
##take O
of O
[ O
18 O
##f O
] O
m O
##pp O
##f O
. O
[SEP] O
[CLS] O
an O
ultra O
- O
high O
performance O
liquid O
ch O
##roma O
##tography O
/ O
tandem O
mass O
s O
##pect O
##rome O
##try O
( O
up O
##l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
method O
for O
the O
simultaneous O
determination O
of O
( O
4 O
##s O
, O
5 O
##r O
) O
- O
5 O
- O
[ O
3 O
, O
5 O
- O
bi O
##s O
( O
t O
##ri O
##f O
##lu O
##oro O
##met O
##hyl O
) O
p O
##hen O
##yl O
] O
- O
3 O
- O
{ O
[ O
4 O
' O
- O
flu O
##oro O
- O
5 O
' O
- O
is O
##op O
##rop O
##yl O
- O
2 O
' O
- O
met O
##ho O
##xy O
- O
4 O
- O
( O
t O
##ri O
##f O
##lu O
##oro O
##met O
##hyl O
) O
bi O
##phe O
##ny O
##l O
- O
2 O
- O
y O
##l O
] O
met O
##hyl O
} O
- O
4 O
- O
met O
##hyl O
- O
1 O
, O
3 O
- O
o O
##xa O
##zo O
##lid O
##in O
- O
2 O
- O
one O
( O
an O
##ace O
##tra O
##pi O
##b O
, O
i O
) O
and O
[ O
( O
13 O
) O
c O
##5 O
( O
15 O
) O
n O
] O
- O
an O
##ace O
##tra O
##pi O
##b O
, O
ii O
in O
human O
plasma O
has O
been O
developed O
to O
support O
a O
clinical O
study O
to O
determine O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
i O
. O
the O
anal O
##yte O
##s O
and O
the O
stable O
- O
is O
##oto O
##pe O
labeled O
internal O
standard O
( O
[ O
( O
13 O
) O
c O
##7 O
( O
15 O
) O
n O
( O
2 O
) O
h O
##7 O
] O
- O
an O
##ace O
##tra O
##pi O
##b O
, O
ii O
##i O
) O
were O
extracted O
from O
100 O
##μ O
##l O
of O
human O
plasma O
by O
liquid O
- O
liquid O
extraction O
using O
20 O
/ O
80 O
is O
##op O
##rop O
##yl O
alcohol O
/ O
he O
##xa O
##ne O
( O
v O
/ O
v O
) O
. O
[SEP] O
[CLS] O
compared O
with O
the O
patients O
receiving O
v O
##c O
##r O
, O
the O
patients O
treated O
with O
vs O
##li O
displayed O
an O
increase O
in O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
vs I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
and O
a O
decrease O
in O
plasma B-PK
clearance I-PK
rates I-PK
. O
[SEP] O
[CLS] O
since O
et O
##op O
##os O
##ide O
was O
con O
##com O
##ita O
##ntly O
administered O
, O
we O
can O
formula O
##te O
the O
conclusion O
as O
follows O
: O
no O
" O
objective O
" O
response O
was O
observed O
in O
the O
patients O
with O
low O
t O
##p O
plasma O
concentrations O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
120 I-PK
h I-PK
. O
[SEP] O
[CLS] O
the O
effect O
of O
acute O
withdrawal O
from O
cigarette O
smoking O
on O
in O
##do O
##cy O
##ani O
##ne O
green O
and O
anti O
##py O
##rine O
clearance B-PK
. O
[SEP] O
[CLS] O
however O
, O
during O
c O
##v O
##v O
##h O
##d O
, O
membrane O
dependence O
of O
van O
##com O
##y O
##cin O
clearance B-PK
was O
noted O
at O
a O
q O
( O
di O
) O
greater O
than O
16 O
. O
7 O
m O
##l O
/ O
min O
; O
van O
##com O
##y O
##cin O
clearance B-PK
with O
pm O
##ma O
at O
a O
q O
( O
di O
) O
of O
25 O
m O
##l O
/ O
min O
was O
66 O
% O
and O
43 O
% O
greater O
than O
that O
with O
the O
an O
##6 O
##9 O
and O
ps O
filters O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
116 O
% O
relative O
to O
re O
##len O
##za O
##® O
. O
[SEP] O
[CLS] O
the O
effectiveness O
of O
p O
##ta O
##u O
in O
improving O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
u O
##rid O
##ine O
could O
be O
useful O
in O
the O
rescue O
or O
protection O
from O
host O
toxic O
##ities O
of O
various O
ch O
##em O
##oth O
##era O
##pe O
##uti O
##c O
p O
##yr O
##im O
##id O
##ine O
analogue O
##s O
as O
well O
as O
in O
the O
management O
of O
medical O
disorders O
that O
are O
re O
##med O
##ied O
by O
administration O
of O
u O
##rid O
##ine O
. O
[SEP] O
[CLS] O
consistent O
with O
the O
cell O
culture O
model O
results O
, O
we O
observed O
that O
the O
degree O
and O
rate O
of O
drug O
transfer O
into O
human O
blood O
was O
more O
pronounced O
for O
c O
##sa O
- O
p O
##g O
than O
for O
l O
- O
c O
##sa O
with O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
c O
##sa O
- O
p O
##g O
being O
about O
1 O
. O
6 O
times O
higher O
than O
for O
the O
l O
- O
c O
##sa O
formulation O
. O
[SEP] O
[CLS] O
the O
structure O
could O
explain O
the O
shorter O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
t O
- O
d O
##m O
##1 O
relative O
to O
t O
##t O
##ma O
##b O
. O
[SEP] O
[CLS] O
as O
compared O
with O
the O
au B-PK
##c I-PK
in O
subjects O
who O
were O
administered O
l O
##w O
de O
##co O
##ction O
, O
the O
au B-PK
##c I-PK
in O
those O
taken O
l O
##w O
+ O
p O
##v O
de O
##co O
##ction O
was O
lower O
[ O
( O
157 O
##34 O
. O
88 O
+ O
- O
77 O
##37 O
. O
97 O
) O
ng O
/ O
( O
min O
. O
m O
##l O
) O
vs O
( O
57 O
##17 O
. O
92 O
+ O
- O
61 O
##24 O
. O
63 O
) O
ng O
/ O
( O
min O
. O
m O
##l O
) O
] O
, O
p O
< O
0 O
. O
05 O
) O
, O
while O
that O
in O
those O
taken O
ch O
- O
ii O
was O
relatively O
higher O
[ O
( O
80 O
##7 O
##2 O
. O
00 O
+ O
- O
44 O
##24 O
. O
31 O
) O
ng O
/ O
( O
min O
. O
m O
##l O
) O
, O
p O
> O
0 O
. O
05 O
) O
] O
. O
[SEP] O
[CLS] O
in O
addition O
, O
b O
##ms O
- O
3 O
could O
be O
meta O
##bol O
##ized O
by O
both O
c O
##y O
##p O
##2 O
##c O
##9 O
and O
c O
##y O
##p O
##3 O
##a O
##4 O
, O
thus O
avoiding O
the O
reliance O
on O
a O
single O
p O
##45 O
##0 O
enzyme O
for O
metabolic B-PK
clearance I-PK
. O
[SEP] O
[CLS] O
based O
on O
the O
results O
, O
both O
formulation O
##s O
of O
am O
##ox O
##ici O
##llin O
evaluated O
in O
this O
study O
were O
considered O
bio O
##e O
##qui O
##valent O
according O
to O
f O
##da O
and O
an O
##vis O
##a O
/ O
bra O
##zi O
##l O
criteria O
. O
[SEP] O
[CLS] O
micro O
##dos O
##e O
: O
c B-PK
##l I-PK
13 O
##l O
/ O
h O
, O
c B-PK
##l I-PK
( I-PK
r I-PK
) I-PK
4 O
. O
1 O
##l O
/ O
h O
, O
v B-PK
( I-PK
s I-PK
##s I-PK
) I-PK
54 O
##l O
, O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
16 O
##h O
; O
therapeutic O
dose O
: O
c B-PK
##l I-PK
16 O
##l O
/ O
h O
, O
c B-PK
##l I-PK
( I-PK
r I-PK
) I-PK
6 O
. O
2 O
##l O
/ O
h O
, O
v B-PK
( I-PK
s I-PK
##s I-PK
) I-PK
64 O
##l O
, O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
12 O
##h O
. O
[SEP] O
[CLS] O
the O
c O
##v O
##v O
##h O
##d O
##f O
yielded O
a O
mean O
line O
##zo O
##lid O
clearance B-PK
of O
36 O
. O
5 O
m O
##l O
/ O
minute O
and O
an O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
7 O
. O
5 O
hours O
. O
[SEP] O
[CLS] O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
determined O
from O
the O
ratios B-PK
of I-PK
the I-PK
areas I-PK
under I-PK
the I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curves I-PK
after O
intake O
of O
the O
tablet O
and O
after O
in O
##tra O
##ven O
##ous O
in O
##fusion O
of O
amino O
##phy O
##llin O
##e O
in O
the O
same O
patient O
. O
[SEP] O
[CLS] O
a O
comparison O
of O
the O
in O
v O
##ivo O
and O
in O
v O
##it O
##ro O
results O
demonstrated O
a O
definite O
rank O
- O
order O
correlation O
between O
the O
dissolution O
performance O
of O
the O
two O
suspension O
##s O
and O
the O
in O
v O
##ivo O
parameters O
reflecting O
the O
absorption B-PK
rate I-PK
. O
[SEP] O
[CLS] O
results O
we O
showed O
that O
there O
were O
no O
significant O
differences O
in O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
( O
half B-PK
- I-PK
life I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
peak B-PK
concentrations I-PK
, O
time B-PK
to I-PK
reach I-PK
maximum I-PK
concentration I-PK
, O
elimination B-PK
rate I-PK
constant I-PK
) O
of O
am O
##ox O
##ici O
##llin O
between O
the O
pro O
##biotic O
treated O
and O
un O
##tre O
##ated O
control O
groups O
. O
[SEP] O
[CLS] O
significant O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
was O
found O
in O
time B-PK
to I-PK
peak I-PK
concentration I-PK
( O
30 O
- O
180 O
min O
) O
, O
peak B-PK
concentration I-PK
( O
0 O
. O
41 O
- O
2 O
. O
77 O
micro O
##m O
) O
, O
and O
to O
a O
lesser O
extent O
the O
half B-PK
- I-PK
lives I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
alpha I-PK
: O
32 O
. O
8 O
- O
86 O
. O
1 O
min O
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
beta I-PK
: O
43 O
. O
6 O
- O
350 O
. O
0 O
min O
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
absorption I-PK
: O
25 O
. O
2 O
- O
60 O
. O
3 O
min O
) O
and O
plasma B-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( O
195 O
. O
6 O
- O
81 O
##8 O
. O
5 O
micro O
##m O
. O
min O
) O
. O
[SEP] O
[CLS] O
changes O
in O
c O
##po O
##4 O
and O
ch O
##co O
##3 O
were O
not O
detected O
. O
[SEP] O
[CLS] O
the O
bio O
##dis O
##tribution O
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
suggest O
that O
the O
product O
can O
be O
further O
tested O
for O
molecular O
radio O
##ther O
##ap O
##y O
of O
c O
##ea O
+ O
tumors O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
assessed O
by O
comparison O
of O
peak B-PK
concentration I-PK
, O
time B-PK
to I-PK
peak I-PK
concentration I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
and O
time O
spent O
over O
0 O
. O
5 O
micro O
##gram O
##s O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
in O
the O
single O
- O
dose O
study O
, O
the O
mean O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
for O
a O
##rani O
##di O
##pine O
5 O
, O
10 O
, O
and O
20 O
mg O
was O
3 O
. O
0 O
( O
2 O
. O
7 O
) O
, O
2 O
. O
7 O
( O
1 O
. O
1 O
) O
, O
and O
3 O
. O
1 O
( O
2 O
. O
2 O
) O
hours O
, O
respectively O
; O
mean O
t B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
was O
4 O
. O
9 O
( O
0 O
. O
4 O
) O
, O
4 O
. O
4 O
( O
1 O
. O
0 O
) O
, O
and O
4 O
. O
3 O
( O
0 O
. O
9 O
) O
hours O
; O
mean O
c B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
was O
1 O
. O
1 O
( O
0 O
. O
6 O
) O
, O
2 O
. O
4 O
( O
0 O
. O
8 O
) O
, O
and O
4 O
. O
0 O
( O
2 O
. O
0 O
) O
micro O
##g O
/ O
l O
; O
and O
mean O
au B-PK
##c I-PK
( I-PK
last I-PK
) I-PK
was O
4 O
. O
1 O
( O
1 O
. O
4 O
) O
, O
10 O
. O
3 O
( O
2 O
. O
3 O
) O
, O
and O
20 O
. O
9 O
( O
4 O
. O
2 O
) O
micro O
##g O
. O
[SEP] O
[CLS] O
the O
p O
##eo O
- O
b O
- O
p O
##c O
##l O
mice O
##lles O
also O
significantly O
decreased O
the O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
( I-PK
s I-PK
##s I-PK
) I-PK
) I-PK
and O
clearance B-PK
( I-PK
c I-PK
##l I-PK
) I-PK
of O
v O
##als O
##po O
##dar O
by O
nearly O
49 O
% O
and O
34 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
results O
indicated O
that O
the O
extent O
of O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
c O
##ef O
##ota O
##xi O
##me O
was O
increased O
approximately O
2 O
. O
7 O
and O
2 O
. O
3 O
times O
compared O
with O
that O
of O
the O
a O
##que O
##ous O
solution O
and O
the O
physical O
mixture O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
distribution B-PK
volume I-PK
at I-PK
steady I-PK
state I-PK
was O
1 O
. O
4 O
l O
kg O
- O
1 O
, O
implying O
a O
low O
tendency O
for O
distribution O
to O
ad O
##ip O
##ose O
tissue O
. O
[SEP] O
[CLS] O
decreases O
in O
the O
area B-PK
under I-PK
the I-PK
blood I-PK
concentration I-PK
- I-PK
time I-PK
curves I-PK
were O
greatest O
following O
oral O
dos O
##ing O
, O
intermediate O
following O
in O
##tra O
##port O
##al O
dos O
##ing O
, O
and O
least O
following O
i O
##v O
dos O
##ing O
. O
[SEP] O
[CLS] O
on O
day O
7 O
, O
14 O
, O
and O
21 O
after O
my O
##oc O
##ard O
##ial O
is O
##che O
##mia O
anti O
##py O
##rine O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
increased O
considerably O
, O
and O
anti O
##py O
##rine O
c B-PK
##l I-PK
and O
k B-PK
##el I-PK
decreased O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
of O
fur O
##ox O
##ime O
was O
faster O
than O
z O
##inn O
##at O
with O
the O
mean O
( O
90 O
% O
c O
##i O
) O
of O
difference O
in O
t B-PK
##max I-PK
of O
- O
0 O
. O
5 O
[ O
( O
- O
1 O
. O
01 O
) O
- O
0 O
. O
01 O
] O
h O
. O
bio O
##e O
##qui O
##valence O
analysis O
showed O
that O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
and O
the O
cm B-PK
##ax I-PK
of O
the O
two O
products O
were O
not O
significantly O
different O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
and O
cm B-PK
##in I-PK
of O
both O
total O
and O
un O
##bound O
re O
##mo O
##xi O
##p O
##ride O
increased O
with O
increasing O
age O
. O
[SEP] O
[CLS] O
in O
h O
##n O
##f O
##1 O
##a O
( O
- O
/ O
- O
) O
mice O
, O
serum O
concentrations O
and O
half B-PK
- I-PK
life I-PK
of O
su O
##lf O
##ony O
##lu O
##rea O
derivatives O
are O
strongly O
increased O
. O
[SEP] O
[CLS] O
from O
the O
above O
results O
, O
it O
was O
concluded O
that O
o O
##la O
na O
##no O
- O
formulation O
##s O
can O
be O
an O
alternative O
to O
enhance O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
to O
reduce O
the O
ha O
##ema O
##to O
##logical O
toxicity O
of O
o O
##la O
. O
[SEP] O
[CLS] O
d O
##n O
##v O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
, O
cm B-PK
##ax I-PK
and O
c O
##12 O
##h O
g O
##m O
##r O
% O
( O
90 O
% O
c O
##i O
) O
with O
ran O
##iti O
##dine O
: O
81 O
. O
9 O
( O
68 O
. O
3 O
- O
98 O
. O
1 O
) O
, O
104 O
( O
86 O
. O
9 O
- O
123 O
) O
and O
87 O
. O
5 O
( O
69 O
. O
3 O
- O
111 O
) O
, O
and O
with O
o O
##me O
##pra O
##zo O
##le O
: O
83 O
. O
0 O
( O
67 O
. O
4 O
- O
102 O
) O
, O
92 O
. O
7 O
( O
70 O
. O
6 O
- O
122 O
) O
and O
93 O
. O
3 O
( O
65 O
. O
6 O
- O
133 O
) O
. O
[SEP] O
[CLS] O
mean O
ratios O
of O
au B-PK
##cin I-PK
##f I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
, O
and O
cm B-PK
##ax I-PK
for O
f O
##d O
##c O
or O
single O
- O
component O
da O
##pa O
##gli O
##f O
##lo O
##zin O
and O
met O
##form O
##in O
tablets O
were O
close O
to O
unity O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
maximum B-PK
concentration I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
for O
serum O
total O
and O
free O
test O
##osterone O
( O
t O
) O
between O
the O
t O
##u O
750 O
and O
1000 O
mg O
groups O
, O
i O
##rre O
##spective O
of O
whether O
t O
##u O
was O
administered O
with O
200 O
mg O
of O
net O
##e O
. O
[SEP] O
[CLS] O
after O
a O
single O
oral O
dose O
of O
20 O
mg O
/ O
kg O
of O
b O
##a O
, O
the O
mean O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) I-PK
of O
b O
##a O
was O
234 O
. O
7 O
± O
161 O
ng O
/ O
m O
##l O
at O
0 O
. O
25 O
h O
. O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
24 I-PK
h I-PK
) I-PK
) I-PK
was O
53 O
##5 O
. O
8 O
± O
223 O
. O
7 O
h O
· O
ng O
/ O
m O
##l O
, O
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
) I-PK
was O
5 O
. O
0 O
± O
0 O
. O
36 O
h O
. O
in O
case O
of O
in O
##tra O
##ven O
##ous O
administration O
of O
b O
##a O
at O
a O
dos O
##age O
of O
2 O
mg O
/ O
kg O
, O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
24 I-PK
h I-PK
) I-PK
) I-PK
was O
34 O
##2 O
± O
98 O
h O
##⋅ O
##ng O
/ O
m O
##l O
, O
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
) I-PK
was O
5 O
. O
8 O
± O
0 O
. O
7 O
h O
. O
[SEP] O
[CLS] O
hence O
, O
it O
can O
be O
concluded O
that O
the O
natural O
da O
##uc O
##us O
car O
##ota O
extract O
can O
be O
the O
better O
alternative O
source O
for O
the O
preparation O
of O
solid O
di O
##sper O
##sion O
and O
/ O
or O
other O
dos O
##age O
forms O
for O
improving O
so O
##lub O
##ility O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
e O
##ico O
##sa O
##pent O
##aen O
##oi O
##c O
acid O
from O
re O
##con O
##stituted O
t O
##rig O
##ly O
##cer O
##ide O
fish O
oil O
is O
higher O
than O
that O
obtained O
from O
the O
t O
##rig O
##ly O
##cer O
##ide O
and O
mon O
##og O
##ly O
##cer O
##ide O
forms O
. O
[SEP] O
[CLS] O
solid O
di O
##sper O
##sions O
using O
p O
##lu O
##ronic O
f O
- O
68 O
as O
a O
carrier O
were O
studied O
for O
improving O
the O
dissolution O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
a O
##bt O
- O
96 O
##3 O
, O
a O
poorly O
water O
- O
soluble O
compound O
. O
[SEP] O
[CLS] O
the O
mean O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##finity I-PK
of O
s O
##ta O
##vu O
##dine O
increased O
in O
a O
dose O
- O
proportional O
manner O
. O
[SEP] O
[CLS] O
following O
a O
single O
dose O
the O
cm B-PK
##ax I-PK
was O
0 O
. O
82 O
+ O
- O
0 O
. O
15 O
micro O
##gram O
##s O
/ O
m O
##l O
, O
the O
t B-PK
##max I-PK
was O
achieved O
at O
6 O
. O
1 O
+ O
- O
3 O
. O
5 O
h O
, O
the O
elimination B-PK
half I-PK
life I-PK
was O
65 O
. O
7 O
+ O
- O
17 O
. O
6 O
h O
, O
the O
c B-PK
##lt I-PK
/ I-PK
f I-PK
was O
2 O
. O
04 O
+ O
- O
0 O
. O
53 O
m O
##l O
/ O
min O
, O
the O
v B-PK
##d I-PK
/ I-PK
f I-PK
was O
11 O
. O
0 O
+ O
- O
1 O
. O
7 O
l O
and O
the O
au B-PK
##c I-PK
in I-PK
##finity I-PK
was O
86 O
. O
9 O
+ O
- O
24 O
. O
6 O
mug O
##h O
/ O
m O
##l O
, O
which O
was O
similar O
to O
results O
reported O
in O
other O
study O
from O
p O
##iro O
##xi O
##cam O
( O
10 O
mg O
) O
. O
[SEP] O
[CLS] O
the O
geometric O
mean O
± O
s O
##d O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
following O
i O
##v O
injection O
was O
26 O
, O
82 O
##0 O
. O
59 O
± O
9 O
, O
03 O
##3 O
. O
88 O
and O
51 O
##1 O
. O
83 O
± O
213 O
. O
98 O
h O
##r O
ng O
/ O
m O
##l O
for O
t O
##d O
route O
. O
[SEP] O
[CLS] O
the O
ch O
##em O
##ose O
##ns O
##iti O
##zing O
sur O
##ami O
##n O
dose O
showed O
a O
terminal B-PK
half I-PK
- I-PK
life I-PK
of O
202 O
h O
and O
a O
total B-PK
body I-PK
clearance I-PK
of O
0 O
. O
02 O
##9 O
l O
h O
( O
- O
1 O
) O
m O
( O
- O
2 O
) O
( O
higher O
than O
the O
0 O
. O
01 O
##3 O
l O
h O
( O
- O
1 O
) O
m O
( O
- O
2 O
) O
value O
for O
m O
##t O
##d O
of O
sur O
##ami O
##n O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
obtained O
ranged O
from O
3 O
to O
10 O
min O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
following O
in O
##tra O
##mus O
##cular O
versus O
re O
##ct O
##al O
administration O
were O
the O
following O
: O
area B-PK
under I-PK
the I-PK
curve I-PK
59 O
##16 O
vs O
. O
52 O
##53 O
mum O
##ol O
. O
h O
/ O
l O
; O
half B-PK
- I-PK
life I-PK
112 O
vs O
. O
113 O
h O
; O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
2 O
. O
1 O
vs O
. O
4 O
. O
4 O
h O
; O
and O
maximum B-PK
serum I-PK
concentration I-PK
36 O
. O
2 O
vs O
. O
31 O
. O
4 O
mum O
##ol O
/ O
l O
. O
mean O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
re O
##ct O
##al O
p O
##hen O
##ob O
##ar O
##bit O
##al O
was O
90 O
percent O
. O
[SEP] O
[CLS] O
when O
et O
##op O
##os O
##ide O
was O
administered O
in O
combination O
with O
r O
##hul O
##t O
, O
the O
concentration O
of O
et O
##op O
##os O
##ide O
in O
tumor O
tissue O
after O
60 O
to O
240 O
minutes O
was O
significantly O
higher O
than O
when O
et O
##op O
##os O
##ide O
was O
given O
alone O
, O
and O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
was O
also O
greater O
for O
the O
tumors O
of O
mice O
with O
combination O
treatment O
. O
[SEP] O
[CLS] O
apparent B-PK
oral I-PK
clearance I-PK
was O
significantly O
reduced O
( O
p O
less O
than O
0 O
. O
01 O
) O
in O
the O
elderly O
. O
[SEP] O
[CLS] O
de O
##uter O
##ium O
- O
labeled O
te O
##rb O
##uta O
##line O
can O
be O
used O
, O
in O
##tra O
##ven O
##ously O
or O
oral O
##ly O
, O
as O
an O
absolute O
reference O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
studies O
on O
te O
##rb O
##uta O
##line O
. O
[SEP] O
[CLS] O
this O
study O
showed O
that O
similar O
levels O
of O
a O
##a O
and O
f O
##a O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
can O
be O
attained O
through O
ing O
##est O
##ion O
of O
100 O
% O
o O
##j O
and O
a O
fortified O
beverage O
. O
[SEP] O
[CLS] O
the O
te O
##rta O
##to O
##lo O
##l O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
9 O
. O
0 O
+ O
- O
7 O
. O
1 O
hours O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
revealed O
that O
all O
- O
trans O
- O
rag O
was O
extensively O
h O
##ydro O
##ly O
##zed O
to O
all O
- O
trans O
- O
r O
##a O
and O
that O
the O
plasma B-PK
area I-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
all O
- O
trans O
- O
r O
##a O
following O
all O
- O
trans O
- O
rag O
application O
exceeded O
the O
plasma B-PK
au I-PK
##c I-PK
value O
of O
all O
- O
trans O
- O
r O
##a O
following O
application O
of O
all O
- O
trans O
- O
r O
##a O
. O
[SEP] O
[CLS] O
the O
population O
mean O
clearance B-PK
of O
at O
##v O
/ O
r O
was O
4 O
. O
93 O
l O
/ O
h O
in O
female O
patients O
and O
was O
28 O
. O
7 O
% O
higher O
in O
male O
patients O
. O
[SEP] O
[CLS] O
to O
identify O
appropriate O
species O
for O
predict O
##ing O
human O
in O
v O
##ivo O
clearance B-PK
by O
single O
- O
species O
s O
##cal O
##ing O
( O
s O
##ss O
) O
or O
multi O
##sp O
##ec O
##ies O
all O
##ome O
##try O
( O
ma O
) O
, O
we O
scaled O
in O
v O
##it O
##ro O
intrinsic B-PK
clearance I-PK
( I-PK
c I-PK
##lint I-PK
) I-PK
of O
five O
a O
##o O
substrates O
obtained O
from O
he O
##pa O
##tic O
s O
##9 O
of O
mouse O
, O
rat O
, O
g O
##uin O
##ea O
pig O
, O
monkey O
and O
mini O
##pi O
##g O
to O
human O
in O
v O
##it O
##ro O
c B-PK
##lint I-PK
. O
[SEP] O
[CLS] O
this O
results O
in O
considerable O
error O
if O
the O
free O
i O
##od O
##ine O
in O
the O
nuclear O
drug O
is O
not O
taken O
into O
account O
in O
the O
clearance B-PK
calculation O
. O
[SEP] O
[CLS] O
these O
results O
demonstrate O
a O
significant O
improvement O
in O
target O
au B-PK
##c I-PK
attain O
##ment O
and O
less O
inter O
##patient O
var O
##iability O
with O
p O
##k O
- O
guided O
dos O
##ing O
using O
a O
test O
dose O
strategy O
compared O
with O
weight O
- O
based O
dos O
##ing O
. O
[SEP] O
[CLS] O
the O
apparent B-PK
volume I-PK
of I-PK
the I-PK
central I-PK
compartment I-PK
( I-PK
v I-PK
( I-PK
c I-PK
) I-PK
) I-PK
was O
found O
to O
be O
1 O
. O
38 O
##3 O
, O
0 O
. O
69 O
##9 O
and O
0 O
. O
143 O
l O
/ O
kg O
respectively O
. O
[SEP] O
[CLS] O
the O
mean O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
54 O
. O
8 O
h O
determined O
by O
model O
dependent O
analysis O
was O
similar O
to O
the O
mean O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
59 O
. O
9 O
h O
determined O
by O
model O
independent O
analysis O
. O
[SEP] O
[CLS] O
with O
ha O
##lot O
##hane O
, O
v B-PK
##c I-PK
was O
decreased O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
alpha I-PK
was O
shortened O
. O
[SEP] O
[CLS] O
the O
primary O
de O
##ter O
##mina O
##nts O
of O
drug O
interaction O
were O
the O
l O
##n O
- O
transformed O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
[ I-PK
au I-PK
##c I-PK
( I-PK
t I-PK
( I-PK
s I-PK
##s I-PK
) I-PK
) I-PK
] I-PK
over O
the O
final O
( O
day O
14 O
) O
24 O
h O
dos O
##ing O
interval O
and O
maximum B-PK
measured I-PK
steady I-PK
- I-PK
state I-PK
plasma I-PK
r I-PK
##os I-PK
##u I-PK
##vas I-PK
##tat I-PK
##in I-PK
concentration I-PK
[ I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
( I-PK
s I-PK
##s I-PK
) I-PK
) I-PK
] I-PK
on O
day O
14 O
. O
[SEP] O
[CLS] O
m O
##ox O
##if O
##lo O
##xa O
##cin O
regime O
##ns O
produced O
a O
range O
of O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
/ I-PK
mi I-PK
##c I-PK
ratios I-PK
ranging O
from O
9 O
. O
2 O
to O
44 O
##4 O
and O
peak B-PK
/ I-PK
mi I-PK
##c I-PK
ratios I-PK
ranging O
from O
1 O
. O
3 O
to O
102 O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
nm O
##d O
- O
s O
##s O
##c O
( O
test O
) O
and O
ni O
##moto O
##p O
( O
reference O
) O
was O
determined O
in O
be O
##ag O
##le O
dogs O
after O
a O
single O
dose O
( O
120 O
##m O
##g O
nm O
##d O
) O
in O
a O
random O
##ized O
crossover O
, O
own O
- O
control O
study O
. O
[SEP] O
[CLS] O
a O
positive O
correlation O
was O
found O
between O
forced O
ex O
##pi O
##rator O
##y O
volume O
in O
1 O
s O
( O
f O
##ev O
##1 O
) O
in O
per O
cent O
predicted O
and O
both O
au B-PK
##c I-PK
and O
ma B-PK
##ximal I-PK
co I-PK
##list I-PK
##in I-PK
concentrations I-PK
in I-PK
serum I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
. O
[SEP] O
[CLS] O
to O
##l O
##cap O
##one O
had O
similar O
effects O
on O
plasma O
le O
##vo O
##do O
##pa O
concentrations O
with O
the O
standard O
- O
release O
formulation O
##s O
: O
half B-PK
- I-PK
life I-PK
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
increased O
approximately O
2 O
- O
fold O
compared O
with O
place O
##bo O
, O
and O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
un O
##af O
##fected O
, O
except O
for O
a O
slight O
increase O
in O
cm B-PK
##ax I-PK
with O
the O
le O
##vo O
##do O
##pa O
/ O
ben O
##ser O
##azi O
##de O
200 O
/ O
50 O
mg O
formulation O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
v I-PK
. I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
162 O
+ O
- O
27 O
( O
se O
##m O
) O
times O
larger O
in O
c O
##s O
##f O
than O
in O
plasma O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
parameters O
, O
including O
t B-PK
< I-PK
sub I-PK
> I-PK
ma I-PK
##x I-PK
< I-PK
/ I-PK
sub I-PK
> I-PK
, O
c B-PK
< I-PK
sub I-PK
> I-PK
ma I-PK
##x I-PK
< I-PK
/ I-PK
sub I-PK
> I-PK
, O
and O
au B-PK
##c I-PK
< I-PK
sub I-PK
> I-PK
last I-PK
< I-PK
/ I-PK
sub I-PK
> I-PK
were O
calculated O
by O
non O
##com O
##par O
##tment O
##al O
methods O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##dynamic O
measurement O
versus O
p O
##har O
##ma O
##co O
##kin O
##etics O
revealed O
a O
significant O
inverse O
relationship O
between O
p O
##asi O
score O
and O
m O
##t O
##x O
au B-PK
##c I-PK
( O
r O
##s O
= O
- O
0 O
. O
91 O
##2 O
, O
p O
< O
0 O
. O
00 O
##2 O
) O
and O
between O
p O
##asi O
score O
and O
er O
##yt O
##hr O
##oc O
##ytic O
m O
##t O
##x O
( O
r O
##s O
= O
- O
0 O
. O
98 O
##8 O
, O
p O
< O
0 O
. O
00 O
##2 O
) O
. O
[SEP] O
[CLS] O
area B-PK
under I-PK
the I-PK
curve I-PK
est O
##imation O
##s O
were O
consistent O
with O
an O
m O
##t O
##x O
exposure O
of O
30 O
% O
and O
46 O
% O
for O
the O
muscle O
and O
liver O
as O
compared O
with O
the O
circulation O
. O
[SEP] O
[CLS] O
volume B-PK
of I-PK
distribution I-PK
terms O
for O
a O
drug O
( O
c O
##ef O
##tri O
##ax O
##one O
) O
exhibiting O
concentration O
- O
dependent O
protein O
binding O
. O
[SEP] O
[CLS] O
the O
mean O
+ O
- O
s O
##d O
volume B-PK
of I-PK
distribution I-PK
was O
0 O
. O
39 O
+ O
- O
0 O
. O
15 O
l O
/ O
kg O
ideal O
body O
weight O
, O
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
during O
dial O
##ys O
##is O
was O
4 O
. O
2 O
+ O
- O
2 O
. O
3 O
hours O
. O
[SEP] O
[CLS] O
the O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
of O
the O
ratios O
( O
test O
/ O
reference O
) O
of O
atom O
##ox O
##eti O
##ne O
for O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
and O
cm B-PK
##ax I-PK
were O
100 O
. O
9 O
% O
( O
93 O
. O
6 O
- O
108 O
. O
8 O
% O
) O
, O
103 O
. O
1 O
% O
( O
95 O
. O
1 O
- O
111 O
. O
7 O
% O
) O
and O
105 O
. O
2 O
% O
( O
92 O
. O
8 O
- O
119 O
. O
4 O
% O
) O
, O
respectively O
, O
which O
fell O
within O
the O
interval O
of O
80 O
- O
125 O
% O
and O
75 O
- O
133 O
% O
. O
[SEP] O
[CLS] O
with O
increasing O
the O
length O
of O
in O
##fusion O
##s O
to O
3 O
, O
4 O
, O
and O
5 O
hours O
, O
simulation O
studies O
showed O
that O
the O
cm B-PK
##ax I-PK
decreased O
to O
128 O
% O
, O
113 O
% O
, O
and O
102 O
% O
of O
the O
oral B-PK
cm I-PK
##ax I-PK
. O
[SEP] O
[CLS] O
the O
results O
of O
the O
study O
indicate O
that O
c O
##p O
##l O
##x O
shows O
improved O
dissolution O
properties O
and O
a O
higher O
relative O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
compared O
with O
p O
##hy O
##s O
and O
mi O
##co O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
it O
is O
suggested O
that O
the O
therapeutic O
effects O
and O
side O
effects O
of O
v O
##c O
##m O
should O
be O
actively O
monitored O
using O
t O
##d O
##m O
, O
because O
concentrations O
may O
decrease O
when O
c B-PK
##l I-PK
increases O
in O
v O
##c O
##m O
therapy O
for O
elderly O
patients O
with O
ma O
##li O
##gnant O
tumors O
. O
[SEP] O
[CLS] O
the O
su O
##lf O
##adi O
##mi O
##dine O
half B-PK
- I-PK
lives I-PK
in O
male O
s O
##pra O
##gue O
- O
da O
##wley O
and O
w O
##ista O
##r O
rat O
are O
similar O
. O
[SEP] O
[CLS] O
subjects O
with O
the O
c O
. O
42 O
##1 O
##aa O
g O
##eno O
##type O
( O
n O
= O
4 O
) O
had O
a O
72 O
% O
larger O
mean O
area B-PK
under I-PK
the I-PK
plasma I-PK
at I-PK
##or I-PK
##vas I-PK
##tat I-PK
##in I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
) I-PK
than O
individuals O
with O
the O
c O
. O
42 O
##1 O
##cc O
g O
##eno O
##type O
had O
( O
n O
= O
16 O
; O
p O
= O
0 O
. O
04 O
##9 O
) O
. O
[SEP] O
[CLS] O
the O
maximum O
number O
of O
binding O
sites O
( O
b O
##max O
) O
for O
the O
partial O
ago O
##nist O
t O
##rit O
##iated O
c O
##lon O
##id O
##ine O
was O
significantly O
lower O
for O
both O
patient O
groups O
than O
for O
normal O
subjects O
, O
and O
the O
b O
##max O
for O
the O
antagonist O
t O
##rit O
##iated O
yo O
##him O
##bine O
was O
significantly O
lower O
for O
panic O
patients O
. O
[SEP] O
[CLS] O
for O
the O
c O
##is O
- O
trans O
group O
, O
the O
apparent B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
and O
clearance B-PK
were O
17 O
. O
7 O
+ O
- O
1 O
. O
8 O
min O
and O
9 O
. O
0 O
+ O
- O
1 O
. O
0 O
m O
##l O
. O
kg O
- O
1 O
. O
min O
- O
1 O
, O
but O
these O
figures O
require O
care O
in O
interpretation O
, O
as O
this O
is O
##omer O
group O
contains O
is O
##omer O
##s O
of O
widely O
varying O
rates O
of O
decomposition O
. O
( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
[SEP] O
[CLS] O
the O
high O
systemic O
absorption O
of O
g O
##ent O
##ami O
##cin O
in O
patients O
with O
per O
##ito O
##ni O
##tis O
and O
prolonged O
plasma B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
may O
lead O
to O
drug O
accumulation O
in O
the O
systemic O
circulation O
, O
increasing O
the O
risk O
of O
toxicity O
. O
[SEP] O
[CLS] O
apparent O
v O
##pa O
oral B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
calculated O
for O
each O
elderly O
patient O
was O
compared O
with O
that O
determined O
in O
an O
equal O
number O
of O
v O
##pa O
- O
treated O
controls O
aged O
20 O
- O
50 O
years O
and O
matched O
for O
gender O
, O
body O
weight O
and O
anti O
##ep O
##ile O
##ptic O
drug O
( O
a O
##ed O
) O
comedic O
##ation O
. O
[SEP] O
[CLS] O
the O
point O
est O
##imator O
##s O
for O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
and O
cm B-PK
##ax I-PK
were O
found O
to O
be O
99 O
. O
7 O
% O
and O
85 O
. O
9 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
of O
ed O
##d O
##p O
increased O
significantly O
, O
by O
35 O
% O
. O
[SEP] O
[CLS] O
no O
difference O
was O
seen O
between O
the O
acid O
and O
al O
##kal O
##ine O
condition O
for O
do O
##x O
or O
do O
##x O
##or O
##ubi O
##cin O
##ol O
with O
regard O
to O
clearance B-PK
from I-PK
blood I-PK
plasma I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
, O
re B-PK
##nal I-PK
clearance I-PK
, O
re B-PK
##nal I-PK
drug I-PK
clearance I-PK
/ I-PK
re I-PK
##nal I-PK
c O
##rea O
##tin O
##ine O
clearance O
. O
[SEP] O
[CLS] O
ma O
##gnesium O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
from O
ma O
##gnesium O
c O
##it O
##rate O
and O
ma O
##gnesium O
oxide O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
met O
##oc O
##lop O
##ram O
##ide O
in O
cattle O
. O
[SEP] O
[CLS] O
with O
a O
specific O
radio O
##im O
##mu O
##no O
##ass O
##ay O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
es O
##cin O
was O
measured O
after O
administration O
of O
different O
formulation O
##s O
containing O
a O
##escu O
##lus O
- O
extract O
. O
[SEP] O
[CLS] O
in O
the O
presence O
of O
k O
##eto O
##cona O
##zo O
##le O
, O
inter O
- O
individual O
var O
##iability O
in O
clearance B-PK
and O
au B-PK
##c I-PK
, O
expressed O
as O
coefficient O
of O
variation O
, O
was O
increased O
from O
41 O
. O
6 O
to O
49 O
. O
5 O
% O
and O
from O
28 O
. O
0 O
to O
35 O
. O
1 O
% O
, O
respectively O
, O
and O
not O
, O
as O
we O
had O
h O
##y O
##pot O
##hes O
##ized O
, O
reduced O
. O
[SEP] O
[CLS] O
e O
##pi O
- O
m O
##n O
##ps O
showed O
1 O
. O
18 O
folds O
higher O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
better O
tumor O
suppression O
than O
e O
##pi O
- O
p O
##n O
##ps O
. O
[SEP] O
[CLS] O
a O
comprehensive O
study O
of O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
oral O
##ly O
administered O
silver O
na O
##no O
##par O
##tic O
##les O
( O
a O
##gn O
##ps O
) O
was O
carried O
out O
using O
a O
rat O
model O
. O
[SEP] O
[CLS] O
a O
man O
##n O
- O
w O
##hit O
##ney O
test O
indicated O
statistical O
##ly O
significant O
differences O
in O
au B-PK
##c I-PK
( O
p O
= O
0 O
. O
01 O
) O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
( O
p O
= O
0 O
. O
04 O
) O
between O
groups O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
was O
assessed O
using O
the O
standard O
measurements O
of O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
to I-PK
cm I-PK
##ax I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
no O
significant O
difference O
between O
both O
in O
##tra O
- O
art O
##erial O
administration O
##s O
in O
elimination B-PK
half I-PK
- I-PK
life I-PK
( O
50 O
- O
223 O
h O
at O
2 O
h O
in O
##fusion O
, O
58 O
- O
246 O
h O
at O
24 O
h O
in O
##fusion O
) O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
= O
11 O
. O
6 O
micro O
##gram O
##s O
/ O
m O
##l O
. O
h O
for O
2 O
h O
in O
##fusion O
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
72 I-PK
= O
11 O
. O
2 O
micro O
##gram O
##s O
/ O
m O
##l O
. O
h O
for O
24 O
h O
in O
##fusion O
) O
could O
be O
found O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
two O
brands O
of O
q O
##uin O
##id O
##ine O
g O
##lu O
##cona O
##te O
administered O
on O
a O
multiple O
- O
dose O
regime O
##n O
. O
[SEP] O
[CLS] O
plasma O
the O
##op O
##hyl O
##line O
concentrations O
were O
measured O
before O
and O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
, O
16 O
and O
24 O
h O
after O
the O
morning O
dose O
of O
arm O
##op O
##hyl O
##line O
on O
the O
fourth O
day O
of O
each O
treatment O
period O
; O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
and O
time B-PK
to I-PK
cm I-PK
##ax I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
noted O
, O
and O
the O
area B-PK
under I-PK
the I-PK
24 I-PK
- I-PK
h I-PK
time I-PK
- I-PK
concentration I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
) I-PK
and O
mean O
plasma B-PK
concentration I-PK
( I-PK
cm I-PK
##ean I-PK
) I-PK
were O
com O
##puted O
. O
[SEP] O
[CLS] O
there O
were O
no O
significant O
differences O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
rib O
##of O
##lav O
##in O
and O
p O
##yr O
##ido O
##xin O
##e O
h O
##ydro O
##ch O
##lor O
##ide O
between O
the O
se O
##g O
formulation O
and O
the O
tablet O
albeit O
a O
trend O
toward O
consistent O
absorption O
was O
seen O
from O
the O
se O
##g O
formulation O
. O
[SEP] O
[CLS] O
steady B-PK
- I-PK
state I-PK
volume I-PK
of I-PK
distribution I-PK
ranged O
from O
0 O
. O
80 O
to O
1 O
. O
26 O
l O
/ O
kg O
but O
did O
not O
differ O
among O
the O
groups O
. O
[SEP] O
[CLS] O
after O
an O
in O
##tra O
##ven O
##ous O
dose O
of O
met O
##form O
##in O
, O
a O
2 O
- O
fold O
decrease O
in O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
and O
clearance B-PK
was O
observed O
in O
knockout O
compared O
with O
wild O
- O
type O
mice O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
indicating O
an O
important O
role O
of O
o O
##ct O
##3 O
in O
tissue O
distribution O
and O
elimination O
of O
the O
drug O
. O
[SEP] O
[CLS] O
et O
##od O
##ola O
##c O
is O
characterised O
by O
a O
high O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
low O
clearance B-PK
, O
a O
small O
volume B-PK
of I-PK
distribution I-PK
, O
and O
a O
7 O
- O
hour O
half B-PK
- I-PK
life I-PK
. O
[SEP] O
[CLS] O
control O
and O
prevention O
of O
bleeding O
events O
in O
such O
patients O
with O
re O
##comb O
##ina O
##nt O
factor O
v O
##ii O
##a O
( O
r O
##f O
##vi O
##ia O
) O
is O
limited O
by O
the O
short O
half B-PK
- I-PK
life I-PK
of O
the O
available O
product O
. O
[SEP] O
[CLS] O
current O
published O
dos O
##ing O
regime O
##ns O
result O
in O
sub O
##ther O
##ap O
##eu O
##tic O
concentrations O
in O
the O
early O
period O
of O
se O
##psis O
due O
to O
augmented O
re B-PK
##nal I-PK
clearance I-PK
, O
which O
risks O
clinical O
failure O
in O
critically O
ill O
children O
, O
and O
therefore O
need O
to O
be O
updated O
. O
[SEP] O
[CLS] O
in O
the O
present O
work O
we O
investigated O
the O
possibility O
of O
improving O
de O
##hy O
##dr O
##oe O
##pian O
##dr O
##osterone O
( O
d O
##hea O
) O
so O
##lub O
##ility O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
by O
high O
- O
energy O
co O
##g O
##rin O
##ding O
with O
alpha O
- O
c O
##y O
##c O
##lo O
##de O
##x O
##tri O
##n O
( O
alpha O
- O
c O
##d O
) O
in O
the O
presence O
or O
absence O
of O
different O
auxiliary O
substances O
( O
g O
##ly O
##cine O
, O
bio O
##mal O
##to O
##de O
##x O
##tri O
##n O
, O
p O
##oly O
( O
vinyl O
p O
##yr O
##rol O
##ido O
##ne O
) O
, O
p O
##oly O
( O
et O
##hyl O
##ene O
g O
##ly O
##co O
##l O
) O
400 O
) O
. O
[SEP] O
[CLS] O
the O
oral B-PK
absorption I-PK
rate I-PK
as O
measured O
by O
the O
observed O
time B-PK
to I-PK
peak I-PK
concentration I-PK
was O
not O
significantly O
altered O
by O
food O
. O
[SEP] O
[CLS] O
the O
ma B-PK
##ximal I-PK
plasma I-PK
bi I-PK
##per I-PK
##iden I-PK
concentration I-PK
( O
34 O
. O
4 O
ng O
/ O
m O
##l O
) O
in O
seizure O
- O
terminated O
animals O
occurred O
at O
26 O
. O
3 O
min O
. O
[SEP] O
[CLS] O
in O
v O
##it O
##ro O
release O
study O
of O
am O
- O
s O
##ln O
##s O
showed O
9 O
. O
23 O
% O
± O
2 O
. O
72 O
% O
and O
92 O
. O
09 O
% O
± O
3 O
. O
40 O
% O
release O
of O
am O
in O
p O
##h O
1 O
. O
2 O
medium O
and O
phosphate O
buffer O
p O
##h O
6 O
. O
8 O
, O
respectively O
, O
indicating O
higher O
potential O
of O
l O
##ymph O
##atic O
up O
##take O
. O
[SEP] O
[CLS] O
the O
value O
of O
the O
apparent B-PK
distribution I-PK
volume I-PK
in O
the O
central O
compartment O
was O
0 O
. O
38 O
m O
##l O
/ O
kg O
and O
that O
of O
the O
stationary B-PK
and O
kinetic B-PK
distribution I-PK
volumes I-PK
was O
1 O
. O
37 O
and O
3 O
. O
06 O
1 O
/ O
kg O
respectively O
. O
[SEP] O
[CLS] O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
studies O
with O
dig O
##ox O
##in O
- O
sand O
##oz O
and O
la O
##no O
##xin O
. O
[SEP] O
[CLS] O
mean O
value O
( O
between O
- O
patients O
var O
##iability O
) O
for O
c B-PK
##l I-PK
, O
v B-PK
##1 I-PK
, O
q B-PK
, O
and O
v B-PK
##2 I-PK
were O
4 O
. O
3 O
l O
/ O
h O
( O
31 O
% O
) O
, O
15 O
. O
9 O
l O
( O
22 O
% O
) O
, O
12 O
. O
1 O
l O
/ O
h O
( O
27 O
% O
) O
, O
and O
21 O
. O
4 O
l O
( O
47 O
% O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
predominant O
effect O
of O
s O
##v O
loaded O
n O
##l O
##cs O
may O
be O
attributed O
to O
the O
enhance O
##ment O
of O
absorption O
, O
prolonged O
duration O
and O
improvement O
of O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
s O
##v O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
our O
r O
##op O
##ini O
##rol O
##e O
oral O
film O
improved O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
after O
sub O
##ling O
##ual O
or O
b O
##uc O
##cal O
administration O
. O
[SEP] O
[CLS] O
mean O
half B-PK
- I-PK
lives I-PK
of O
s O
##bt O
and O
a O
##b O
##p O
##c O
in O
the O
serum O
following O
oral O
administration O
were O
about O
1 O
. O
33 O
and O
1 O
. O
61 O
hours O
respectively O
. O
[SEP] O
[CLS] O
weight O
- O
corrected O
volume B-PK
of I-PK
distribution I-PK
and O
total B-PK
body I-PK
clearance I-PK
were O
significantly O
lower O
in O
o O
##bes O
##e O
compared O
with O
lean O
rats O
; O
no O
differences O
were O
found O
in O
absolute B-PK
clearance I-PK
or O
volume B-PK
. O
[SEP] O
[CLS] O
si O
##lde O
##na O
##fi O
##l O
cm B-PK
##ax I-PK
( O
156 O
. O
8 O
± O
124 O
. O
5 O
ng O
/ O
m O
##l O
) O
was O
elevated O
in O
66 O
% O
of O
patients O
, O
with O
a O
two O
to O
five O
##fold O
increase O
over O
the O
upper O
limit O
of O
the O
reference O
range O
in O
25 O
% O
of O
patients O
. O
[SEP] O
[CLS] O
c O
##v O
##v O
##h O
has O
no O
clinical O
##ly O
relevant O
contribution O
to O
total B-PK
clearance I-PK
. O
[SEP] O
[CLS] O
influence O
of O
the O
chemical O
form O
on O
the O
plasma B-PK
clearance I-PK
of O
r O
##uth O
##eni O
##um O
in O
humans O
. O
[SEP] O
[CLS] O
the O
similarity O
of O
systemic O
kinetic O
parameters O
( O
volume B-PK
of I-PK
distribution I-PK
; O
mi O
##cha O
##eli O
##s O
- O
men O
##ten O
elimination O
parameters O
, O
v B-PK
##max I-PK
and O
km B-PK
) O
between O
in O
##hala O
##tion O
exposure O
and O
i O
##v O
and O
p O
##o O
routes O
of O
administration O
was O
verified O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
half I-PK
- I-PK
lives I-PK
of O
filter O
##able O
and O
total O
platinum O
were O
similar O
to O
the O
ones O
observed O
after O
the O
test O
dose O
, O
i O
. O
e O
. O
0 O
. O
36 O
h O
and O
86 O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
g O
##ef O
##iti O
##ni O
##b O
was O
rapidly O
absorbed O
and O
showed O
a O
mon O
##oe O
##x O
##po O
##nent O
##ial O
decline O
with O
an O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
3 O
. O
7 O
- O
4 O
. O
1 O
h O
. O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
g O
##ef O
##iti O
##ni O
##b O
was O
not O
affected O
by O
g O
##p O
##d O
pre O
##tre O
##at O
##ment O
. O
[SEP] O
[CLS] O
maximum B-PK
concentration I-PK
of O
ni O
##cot O
##ine O
, O
8 O
. O
1 O
+ O
- O
3 O
. O
5 O
ng O
/ O
m O
##l O
, O
in O
the O
16 O
subjects O
occurred O
after O
a O
median O
of O
60 O
minutes O
( O
range O
, O
30 O
to O
180 O
minutes O
) O
; O
maximum B-PK
co I-PK
##tin I-PK
##ine I-PK
concentrations I-PK
of O
60 O
. O
4 O
+ O
- O
11 O
. O
5 O
ng O
/ O
m O
##l O
occurred O
after O
4 O
hours O
. O
[SEP] O
[CLS] O
min O
- O
1 O
, O
p O
less O
than O
0 O
. O
01 O
) O
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
significantly O
prolonged O
( O
11 O
. O
4 O
vs O
. O
6 O
. O
0 O
h O
, O
p O
less O
than O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
preliminary O
studies O
of O
j O
##p O
##c O
- O
29 O
##9 O
##7 O
in O
mice O
show O
linear O
p O
##har O
##ma O
##co O
##kin O
##etics O
over O
the O
range O
2 O
. O
5 O
to O
40 O
mg O
/ O
kg O
, O
a O
low O
clearance B-PK
of O
0 O
. O
22 O
liter O
##s O
/ O
h O
/ O
kg O
, O
a O
volume B-PK
of I-PK
distribution I-PK
of O
15 O
. O
6 O
liter O
##s O
/ O
kg O
, O
and O
an O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
49 O
. O
8 O
h O
. O
the O
high O
in O
v O
##ivo O
pot O
##ency O
data O
and O
lengthy O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
j O
##p O
##c O
- O
29 O
##9 O
##7 O
suggest O
that O
it O
is O
worthy O
of O
further O
pre O
##c O
##lini O
##cal O
assessment O
as O
a O
partner O
drug O
. O
[SEP] O
[CLS] O
the O
clearance B-PK
at O
treatment O
week O
4 O
was O
42 O
. O
3 O
l O
day O
( O
- O
1 O
) O
( O
patients O
with O
c O
##l O
##c O
##r O
120 O
m O
##l O
min O
( O
- O
1 O
) O
) O
with O
inter O
##patient O
var O
##iability O
30 O
% O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
t O
##m O
##x O
after O
en O
##cap O
##sul O
##ation O
was O
improved O
giving O
3 O
- O
fold O
higher O
au B-PK
##c I-PK
; O
extended O
mean B-PK
residence I-PK
time I-PK
is O
improving O
chances O
of O
na O
##nov O
##esi O
##cle O
to O
extra O
##vas O
##ate O
in O
tumor O
via O
e O
##p O
##r O
effect O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
) I-PK
and O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
) O
were O
calculated O
and O
compared O
between O
groups O
using O
the O
paired O
t O
test O
. O
[SEP] O
[CLS] O
the O
serum B-PK
half I-PK
- I-PK
life I-PK
of O
the O
slow O
disposition O
phase O
was O
1 O
. O
75 O
h O
in O
patients O
with O
normal O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
after O
oral O
administration O
, O
area B-PK
under I-PK
serum I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
about O
35 O
- O
fold O
higher O
in O
female O
rats O
than O
in O
male O
rats O
, O
and O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
about O
5 O
. O
8 O
- O
fold O
higher O
in O
female O
rats O
than O
in O
male O
rats O
. O
[SEP] O
[CLS] O
lead O
compounds O
30 O
and O
58 O
exhibited O
good O
exposure O
and O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
mouse O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
study O
. O
[SEP] O
[CLS] O
additionally O
, O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
) I-PK
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
( O
r O
) O
- O
war O
##fari O
##n O
in O
pm O
##s O
were O
significantly O
greater O
than O
those O
in O
h O
##me O
##ms O
( O
p O
= O
0 O
. O
000 O
##5 O
and O
p O
= O
0 O
. O
01 O
##01 O
respectively O
) O
. O
[SEP] O
[CLS] O
half B-PK
- I-PK
lives I-PK
( I-PK
t I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
in O
c O
##s O
##f O
and O
c B-PK
##s I-PK
##f I-PK
/ I-PK
serum I-PK
ratios I-PK
of I-PK
t I-PK
1 I-PK
/ I-PK
2 I-PK
were O
52 O
minutes O
and O
2 O
. O
1 O
for O
am O
##pic O
##ill O
##in O
and O
23 O
minutes O
and O
1 O
. O
3 O
for O
car O
##ben O
##ici O
##llin O
, O
respectively O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
r O
##if O
##amp O
##in O
in O
adult O
sheep O
were O
investigated O
by O
use O
of O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
for O
determination O
of O
serum O
concentrations O
. O
[SEP] O
[CLS] O
analysis O
of O
co O
##var O
##iance O
models O
with O
adjustment O
for O
age O
and O
ad O
##herence O
and O
all O
##ometric O
adjustment O
of O
c B-PK
##l I-PK
were O
used O
to O
assess O
associations O
between O
studied O
p O
##oly O
##mor O
##phism O
##s O
and O
au B-PK
##c I-PK
, O
c B-PK
##l I-PK
, O
and O
hi O
##v O
r O
##na O
. O
[SEP] O
[CLS] O
volumes B-PK
of I-PK
distribution I-PK
in I-PK
the I-PK
central I-PK
compartment I-PK
as O
well O
as O
tissue O
distribution O
studies O
in O
all O
three O
species O
indicated O
a O
rapid O
up O
##take O
and O
significant O
concentration O
of O
the O
drug O
with O
long O
elimination B-PK
half I-PK
- I-PK
lives I-PK
in O
a O
deep O
compartment O
. O
[SEP] O
[CLS] O
sparse O
sampling O
can O
accurately O
estimate O
au B-PK
##cs I-PK
and O
can O
be O
implemented O
in O
rode O
##nt O
toxic O
##ology O
studies O
to O
significantly O
reduce O
the O
number O
of O
animals O
for O
t O
##k O
evaluation O
##s O
. O
[SEP] O
[CLS] O
increased O
gas O
##tric O
p O
##h O
and O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
flu O
##cona O
##zo O
##le O
and O
k O
##eto O
##cona O
##zo O
##le O
. O
[SEP] O
[CLS] O
ad O
##junct O
##ive O
se O
##rt O
##ral O
##ine O
significantly O
increased O
c O
##s O
##f O
fun O
##gal O
clearance B-PK
rate I-PK
compared O
to O
coat O
trial O
and O
se O
##rt O
##ral O
##ine O
effect O
was O
dose O
- O
independent O
with O
no O
co O
##var O
##iate O
found O
to O
affect O
fun O
##gal O
clearance B-PK
including O
art O
. O
[SEP] O
[CLS] O
since O
p O
##hen O
##yt O
##oi O
##n O
obey O
##s O
mi O
##chel O
##es O
men O
##tens O
kinetic O
##s O
, O
the O
au B-PK
##c I-PK
methodology O
used O
for O
comparison O
would O
give O
only O
an O
approximate O
indication O
of O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameter O
estimates O
( O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
last I-PK
) I-PK
, O
c B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
, O
and O
t B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) O
and O
in O
##hibition O
of O
plate O
##let O
a O
##gg O
##regation O
( O
i O
##pa O
) O
by O
light O
transmission O
a O
##gg O
##re O
##go O
##metry O
were O
assessed O
at O
multiple O
time O
points O
after O
the O
l O
##d O
and O
final O
m O
##d O
. O
[SEP] O
[CLS] O
however O
there O
was O
a O
correlation O
between O
basal O
plasma O
c O
##rea O
##tin O
##ine O
values O
and O
plasma O
cap O
##top O
##ril O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
p O
##cea O
blockade O
( O
au B-PK
##c I-PK
) O
and O
overall O
anti O
##hy O
##pert O
##ens O
##ive O
effect O
( O
au B-PK
##c I-PK
) O
. O
[SEP] O
[CLS] O
the O
inter O
##fer O
##on O
treatment O
had O
no O
influence O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
e O
##pi O
##ru O
##bic O
##in O
( O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
, O
terminal B-PK
half I-PK
life I-PK
) O
. O
[SEP] O
[CLS] O
he O
##pa O
##to O
##bil O
##iary O
disposition O
of O
at O
##ova O
##q O
##uo O
##ne O
: O
a O
case O
of O
me O
##chan O
##istic O
##ally O
unusual O
bi O
##lia O
##ry O
clearance B-PK
. O
[SEP] O
[CLS] O
all O
tested O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
( O
au B-PK
##c I-PK
( I-PK
in I-PK
##f I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
in I-PK
##f I-PK
) I-PK
( I-PK
n I-PK
##l I-PK
##70 I-PK
) I-PK
, O
cm B-PK
##ax I-PK
, O
cm B-PK
##ax I-PK
( I-PK
n I-PK
##l I-PK
##70 I-PK
) I-PK
, O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
and O
te B-PK
##c I-PK
) O
were O
significantly O
different O
among O
four O
different O
g O
##eno O
##ty O
##pic O
groups O
. O
[SEP] O
[CLS] O
the O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
g O
##eni O
##stein O
[ O
mean O
au B-PK
##c I-PK
= O
4 O
. O
54 O
micro O
##g O
/ O
( O
m O
##l O
x O
h O
) O
] O
is O
much O
greater O
than O
that O
of O
da O
##id O
##ze O
##in O
[ O
mean O
au B-PK
##c I-PK
= O
2 O
. O
94 O
micro O
##g O
/ O
( O
m O
##l O
x O
h O
) O
] O
, O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
these O
is O
##of O
##lav O
##ones O
is O
greater O
when O
ing O
##ested O
as O
beta O
- O
g O
##ly O
##cos O
##ides O
rather O
than O
a O
##gly O
##con O
##es O
as O
measured O
from O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
of I-PK
the I-PK
plasma I-PK
appearance I-PK
and I-PK
disappearance I-PK
concentrations I-PK
. O
[SEP] O
[CLS] O
10 O
the O
two O
methods O
provided O
similar O
values O
for O
the O
metabolic B-PK
clearance I-PK
rate I-PK
( I-PK
m I-PK
##c I-PK
##r I-PK
) I-PK
when O
, O
after O
the O
single O
injection O
, O
the O
m B-PK
##c I-PK
##r I-PK
was O
estimated O
by O
integrating O
the O
area B-PK
under I-PK
each I-PK
disappearance I-PK
curve I-PK
of O
radioactive O
co O
##rt O
##ico O
##id O
. O
[SEP] O
[CLS] O
the O
probability O
of O
attain O
##ing O
the O
target O
, O
t O
> O
mi O
##c O
of O
100 O
% O
, O
was O
higher O
for O
3 O
- O
hour O
in O
##fusion O
regime O
##ns O
compared O
with O
30 O
- O
minute O
in O
##fusion O
regime O
##ns O
for O
all O
ranges O
of O
c O
##l O
##cre O
##at O
. O
[SEP] O
[CLS] O
in O
part O
1 O
, O
co O
- O
administration O
of O
p O
##imo O
##di O
##vir O
with O
o O
##sel O
##tam O
##iv O
##ir O
increased O
the O
cm B-PK
##ax I-PK
of O
p O
##imo O
##di O
##vir O
by O
31 O
% O
( O
90 O
% O
c O
##i O
: O
0 O
. O
92 O
- O
1 O
. O
85 O
) O
with O
no O
change O
in O
cm B-PK
##in I-PK
or O
au B-PK
##c I-PK
##12 I-PK
##h I-PK
. O
[SEP] O
[CLS] O
co O
##ad O
##mini O
##stra O
##tion O
with O
er O
##yt O
##hr O
##omy O
##cin O
resulted O
in O
a O
1 O
. O
6 O
- O
fold O
increase O
in O
the O
cm B-PK
##ax I-PK
of O
m O
##osa O
##p O
##ride O
and O
pro O
##long O
##ation O
of O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
from O
1 O
. O
6 O
to O
2 O
. O
4 O
hours O
, O
indicating O
the O
in O
##hibition O
of O
m O
##osa O
##p O
##ride O
metabolism O
. O
[SEP] O
[CLS] O
p O
##iva O
##mp O
##ici O
##llin O
was O
absorbed O
well O
in O
non O
- O
fast O
##ed O
horses O
with O
an O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
36 O
% O
. O
[SEP] O
[CLS] O
the O
following O
mean O
values O
were O
obtained O
after O
intake O
of O
16 O
mg O
lo O
##per O
##ami O
##de O
as O
film O
coated O
tablets O
: O
au O
##c O
##0 O
in O
##finity O
62 O
. O
04 O
ng O
##h O
/ O
m O
##l O
, O
cm B-PK
##ax I-PK
3 O
. O
35 O
ng O
/ O
m O
##l O
, O
t B-PK
##max I-PK
4 O
. O
08 O
h O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
19 O
. O
66 O
h O
and O
after O
administration O
of O
the O
capsule O
##s O
: O
au B-PK
##c I-PK
##0 I-PK
in I-PK
##finity I-PK
66 O
. O
56 O
ng O
##h O
/ O
m O
##l O
, O
cm B-PK
##ax I-PK
3 O
. O
98 O
ng O
/ O
m O
##l O
, O
t B-PK
##max I-PK
4 O
. O
38 O
h O
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
18 O
. O
43 O
h O
. O
[SEP] O
[CLS] O
for O
the O
total O
group O
, O
l O
##p O
##v O
geometric O
mean O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
, O
cm B-PK
##ax I-PK
and O
c O
##12 O
were O
106 O
. O
9 O
h O
× O
mg O
/ O
l O
, O
12 O
. O
0 O
mg O
/ O
l O
and O
4 O
. O
9 O
mg O
/ O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
of O
br O
##ev O
##is O
##cap O
##ine O
lip O
##oso O
##mes O
and O
commercial O
injection O
were O
23 O
. O
13 O
+ O
- O
7 O
. O
71 O
and O
6 O
. O
27 O
+ O
- O
1 O
. O
84 O
##min O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
) I-PK
of O
para O
##ce O
##tam O
##ol O
was O
1 O
. O
6 O
( O
c O
##i O
1 O
. O
4 O
- O
2 O
. O
0 O
) O
and O
1 O
. O
9 O
( O
c O
##i O
1 O
. O
5 O
- O
2 O
. O
4 O
) O
h O
##r O
for O
50 O
and O
25 O
g O
, O
respectively O
( O
n O
##s O
) O
, O
and O
2 O
. O
5 O
( O
c O
##i O
1 O
. O
8 O
- O
3 O
. O
0 O
) O
h O
##r O
for O
the O
5 O
- O
g O
dose O
( O
p O
= O
0 O
. O
00 O
##3 O
) O
. O
[SEP] O
[CLS] O
cocaine O
was O
rapidly O
distributed O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##bet I-PK
##a I-PK
= O
1 O
. O
09 O
min O
) O
and O
eliminated O
( O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##al I-PK
##pha I-PK
= O
14 O
. O
93 O
min O
) O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
studies O
of O
op O
##ti O
##mized O
cc O
na O
##no O
##c O
##ry O
##stal O
##s O
in O
m O
##uri O
##ne O
model O
revealed O
3 O
. O
8 O
- O
fold O
increase O
in O
the O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
twice O
the O
c B-PK
ma I-PK
##x I-PK
as O
compared O
with O
the O
free O
cc O
when O
administered O
oral O
##ly O
. O
[SEP] O
[CLS] O
biological O
studies O
carried O
out O
in O
normal O
w O
##ista O
##r O
rats O
exhibited O
no O
significant O
accumulation O
of O
activity O
in O
any O
of O
the O
vital O
organs O
/ O
tissue O
except O
in O
kidney O
##s O
and O
non O
- O
accumulated O
activity O
showed O
major O
re B-PK
##nal I-PK
clearance I-PK
. O
[SEP] O
[CLS] O
the O
objective O
was O
to O
improve O
the O
o O
##cular O
residence O
time O
of O
ha O
, O
by O
providing O
sustained O
o O
##cular O
ha O
delivery O
through O
imp O
##lant O
contact O
lenses O
for O
the O
treatment O
of O
dry O
eye O
syndrome O
. O
[SEP] O
[CLS] O
these O
values O
are O
considerably O
lower O
than O
the O
half B-PK
- I-PK
lives I-PK
previously O
published O
for O
dogs O
( O
133 O
h O
) O
and O
cats O
( O
166 O
h O
) O
. O
[SEP] O
[CLS] O
the O
results O
indicated O
that O
the O
reason O
which O
delay O
the O
elimination O
of O
p O
##ae O
##oni O
##f O
##lor O
##in O
and O
enhance O
its O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
might O
be O
some O
ingredients O
in O
cortex O
m O
##out O
##an O
extract O
. O
[SEP] O
[CLS] O
k O
##eto O
##cona O
##zo O
##le O
in O
##hibit O
##s O
the O
clearance B-PK
of O
met O
##hyl O
##p O
##red O
##nis O
##olo O
##ne O
by O
60 O
percent O
and O
extends O
co O
##rt O
##is O
##ol O
suppression O
beyond O
that O
produced O
by O
met O
##hyl O
##p O
##red O
##nis O
##olo O
##ne O
alone O
. O
[SEP] O
[CLS] O
the O
mean O
( O
c O
##v O
) O
half B-PK
- I-PK
life I-PK
at I-PK
alpha I-PK
phase I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
##α I-PK
) I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##β I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##γ I-PK
were O
2 O
. O
29 O
( O
49 O
. O
8 O
% O
) O
, O
13 O
. O
4 O
( O
10 O
. O
5 O
% O
) O
, O
and O
245 O
( O
14 O
. O
9 O
% O
) O
hours O
, O
respectively O
. O
[SEP] O
[CLS] O
mean O
disposition B-PK
half I-PK
- I-PK
lives I-PK
across O
treatments O
were O
1 O
. O
2 O
- O
1 O
. O
4 O
h O
for O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
alpha I-PK
and O
10 O
. O
7 O
- O
13 O
. O
8 O
h O
for O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
beta I-PK
. O
[SEP] O
[CLS] O
mon O
##te O
car O
##lo O
simulation O
##s O
were O
performed O
to O
compare O
the O
maximum B-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
minimum B-PK
concentrations I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
, O
and O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
with O
the O
standard O
da O
##pt O
##omy O
##cin O
6 O
mg O
/ O
kg O
/ O
day O
dose O
or O
a O
500 O
- O
mg O
daily O
fixed O
dose O
in O
o O
##bes O
##e O
and O
non O
##obe O
##se O
subjects O
. O
[SEP] O
[CLS] O
values O
of O
absorption B-PK
half I-PK
- I-PK
life I-PK
averaged O
25 O
min O
( O
range O
10 O
. O
3 O
- O
42 O
. O
7 O
min O
) O
, O
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
beta I-PK
) I-PK
averaged O
14 O
. O
2 O
h O
##r O
( O
range O
8 O
. O
4 O
- O
23 O
. O
9 O
h O
##r O
) O
. O
[SEP] O
[CLS] O
following O
oral O
administration O
to O
man O
, O
absorption O
was O
rapid O
with O
a O
mean O
value O
for O
t B-PK
##max I-PK
of O
1 O
h O
, O
and O
cm B-PK
##ax I-PK
' I-PK
s I-PK
ranging O
non O
- O
linear O
##ly O
from O
90 O
to O
210 O
##0 O
ng O
/ O
m O
##l O
following O
dos O
##ing O
at O
12 O
. O
5 O
to O
150 O
mg O
respectively O
. O
[SEP] O
[CLS] O
the O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
m B-PK
##rt I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
- I-PK
> I-PK
24 I-PK
h I-PK
) I-PK
of O
o O
##xy O
##mat O
##rine O
were O
( O
5 O
. O
5 O
+ O
- O
1 O
. O
58 O
) O
h O
, O
( O
1 O
. O
0 O
+ O
- O
0 O
. O
30 O
) O
h O
, O
( O
241 O
##8 O
. O
3 O
+ O
- O
97 O
##0 O
. O
78 O
) O
ng O
x O
m O
##l O
( O
- O
1 O
) O
, O
( O
3 O
. O
2 O
+ O
- O
0 O
. O
64 O
) O
h O
, O
( O
57 O
##9 O
##7 O
. O
4 O
+ O
- O
90 O
##8 O
. O
16 O
) O
ng O
x O
m O
##l O
( O
- O
1 O
) O
x O
h O
accordingly O
. O
[SEP] O
[CLS] O
time B-PK
to I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
and O
area B-PK
under I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
averaged O
0 O
. O
7 O
+ O
- O
0 O
. O
2 O
h O
and O
305 O
+ O
- O
115 O
mg O
. O
h O
/ O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
elimination B-PK
half I-PK
- I-PK
life I-PK
was O
prolonged O
but O
the O
difference O
did O
not O
reach O
statistical O
significance O
due O
to O
the O
wide O
variation O
of O
the O
values O
in O
the O
elderly O
. O
[SEP] O
[CLS] O
final O
parameter O
estimates O
were O
as O
follow O
c B-PK
##l I-PK
, O
5 O
. O
77 O
liter O
##s O
/ O
h O
/ O
70 O
kg O
; O
central B-PK
volume I-PK
of I-PK
distribution I-PK
, O
21 O
. O
6 O
liter O
##s O
/ O
70 O
kg O
; O
peripheral B-PK
volume I-PK
of I-PK
distribution I-PK
, O
13 O
. O
8 O
liter O
##s O
/ O
70 O
kg O
; O
and O
inter B-PK
##com I-PK
##par I-PK
##tment I-PK
##al I-PK
clearance I-PK
, O
0 O
. O
62 O
liter O
/ O
h O
/ O
70 O
kg O
. O
[SEP] O
[CLS] O
it O
exhibits O
greater O
efficacy O
but O
requires O
higher O
dose O
than O
other O
ɑ O
##1 O
- O
ad O
##ren O
##oc O
##ept O
##or O
block O
##ers O
because O
of O
its O
poor O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
co O
- O
administration O
of O
can O
##des O
##art O
##an O
c O
##ile O
##xe O
##til O
with O
h O
##ct O
##z O
produced O
a O
statistical O
##ly O
significant O
increase O
in O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
cm B-PK
##ax I-PK
values O
for O
can O
##des O
##art O
##an O
( O
18 O
% O
and O
25 O
% O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
longer O
sampling O
also O
improved O
p O
##k O
accuracy O
for O
o O
##bes O
##e O
women O
( O
excess O
au B-PK
##c I-PK
20 O
% O
) O
as O
compared O
to O
both O
normal O
and O
o O
##bes O
##e O
controls O
undergoing O
shorter O
sampling O
times O
( O
48 O
h O
) O
with O
excess O
au B-PK
##cs I-PK
of O
25 O
% O
and O
50 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
to O
investigate O
three O
different O
modelling O
strategies O
in O
co O
##var O
##iate O
model O
building O
using O
do O
##fe O
##til O
##ide O
as O
an O
example O
: O
( O
1 O
) O
using O
statistical O
criteria O
only O
or O
in O
combination O
with O
clinical O
i O
##rrel O
##eva O
##nce O
criteria O
for O
co O
##var O
##iate O
selection O
, O
( O
2 O
) O
applying O
co O
##var O
##iate O
effects O
on O
total B-PK
clearance I-PK
or O
separately O
on O
non B-PK
- I-PK
re I-PK
##nal I-PK
and I-PK
re I-PK
##nal I-PK
clearance I-PK
##s I-PK
and O
( O
3 O
) O
using O
separate O
data O
sets O
for O
co O
##var O
##iate O
selection O
and O
parameter O
est O
##imation O
. O
[SEP] O
[CLS] O
for O
sa O
##b O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
parameters O
t B-PK
##max I-PK
, O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
, O
m B-PK
##rt I-PK
##last I-PK
in O
the O
plasma O
were O
( O
1 O
. O
08 O
##± O
##0 O
. O
20 O
) O
h O
, O
( O
21 O
. O
09 O
##± O
##4 O
. O
850 O
) O
ng O
• O
g O
##⁻ O
##¹ O
, O
( O
14 O
. O
83 O
##± O
##3 O
. O
160 O
) O
ng O
• O
h O
• O
g O
##⁻ O
##¹ O
and O
( O
0 O
. O
99 O
##± O
##0 O
. O
08 O
) O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
following O
in O
##tra O
##gas O
##tric O
administration O
, O
le O
##vet O
##ira O
##ce O
##tam O
had O
a O
peak B-PK
concentration I-PK
of O
38 O
. O
34 O
± O
7 O
. O
42 O
mg O
/ O
l O
and O
time B-PK
to I-PK
achieve I-PK
peak I-PK
concentration I-PK
was O
0 O
. O
87 O
##5 O
( O
0 O
. O
5 O
- O
1 O
. O
5 O
) O
h O
. O
mean O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
for O
i O
##g O
administration O
was O
excellent O
( O
103 O
. O
04 O
± O
14 O
. O
51 O
% O
) O
. O
[SEP] O
[CLS] O
both O
peak B-PK
concentrations I-PK
and O
area B-PK
under I-PK
the I-PK
curve I-PK
increased O
linear O
##ly O
with O
an O
increase O
in O
dose O
, O
whereas O
time B-PK
to I-PK
reach I-PK
peak I-PK
serum I-PK
concentrations I-PK
did O
not O
vary O
significantly O
between O
doses O
. O
[SEP] O
[CLS] O
typical O
values O
for O
the O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
( I-PK
a I-PK
) I-PK
) I-PK
, O
elimination B-PK
rate I-PK
constant I-PK
( I-PK
k I-PK
( I-PK
el I-PK
) I-PK
) I-PK
, O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
for I-PK
the I-PK
central I-PK
compartment I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
oral B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
calculated O
by O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
were O
2 O
. O
16 O
hours O
( O
- O
1 O
) O
, O
0 O
. O
54 O
##7 O
hours O
( O
- O
1 O
) O
, O
43 O
. O
3 O
l O
, O
and O
23 O
. O
7 O
l O
/ O
h O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
##dom O
##eth O
##ac O
##in O
, O
however O
, O
was O
shown O
to O
have O
a O
higher O
up B-PK
##take I-PK
clearance I-PK
( O
59 O
##9 O
+ O
- O
101 O
micro O
##l O
/ O
min O
/ O
10 O
( O
6 O
) O
cells O
) O
than O
at O
##or O
##vas O
##tat O
##in O
( O
375 O
+ O
- O
45 O
micro O
##l O
/ O
min O
/ O
10 O
( O
6 O
) O
cells O
) O
and O
c O
##eri O
##vas O
##tat O
##in O
( O
41 O
##3 O
+ O
- O
47 O
micro O
##l O
/ O
min O
/ O
10 O
( O
6 O
) O
cells O
) O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
was O
improved O
by O
1 O
. O
26 O
fold O
and O
t B-PK
##max I-PK
was O
decreased O
by O
2 O
##h O
after O
comparing O
with O
control O
indicating O
improved O
absorption O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
re O
##s O
##ver O
##at O
##rol O
significantly O
increased O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
di O
##lt O
##ia O
##ze O
##m O
due O
to O
the O
in O
##hibition O
of O
both O
the O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
( O
c O
##y O
##p O
) O
3 O
##a O
##4 O
- O
mediated O
metabolism O
and O
the O
e O
##ff O
##lux O
pump O
p O
- O
g O
##ly O
##co O
##p O
##rote O
##in O
( O
p O
- O
g O
##p O
) O
in O
the O
in O
##test O
##ine O
and O
/ O
or O
liver O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
v O
##al O
##p O
##roa O
##te O
from O
s O
##h O
##d O
enter O
##ic O
- O
coated O
tablets O
( O
e O
##pi O
##val O
, O
abbot O
##t O
- O
50 O
##7 O
##11 O
) O
and O
from O
sodium O
v O
##al O
##p O
##roa O
##te O
enter O
##ic O
- O
coated O
tablets O
( O
er O
##geny O
##l O
) O
was O
compared O
in O
a O
single O
- O
dose O
, O
double O
- O
blind O
, O
crossover O
study O
. O
[SEP] O
[CLS] O
in O
particular O
, O
re B-PK
##nal I-PK
clearance I-PK
was O
not O
significantly O
different O
( O
48 O
##8 O
+ O
- O
95 O
m O
##l O
/ O
min O
without O
probe O
##ne O
##cid O
vs O
. O
47 O
##8 O
+ O
- O
69 O
m O
##l O
/ O
min O
in O
the O
presence O
of O
probe O
##ne O
##cid O
) O
. O
[SEP] O
[CLS] O
patients O
with O
advanced O
h O
##cc O
had O
lower O
initial O
serum O
concentration O
, O
larger O
volume B-PK
of I-PK
distribution I-PK
and O
more O
rapid O
clearance B-PK
than O
patients O
with O
other O
ma O
##li O
##gna O
##ncies O
and O
normal O
liver O
function O
. O
[SEP] O
[CLS] O
in O
cats O
with O
liver O
failure O
, O
plasma B-PK
clearance I-PK
was O
significantly O
less O
and O
mean B-PK
residence I-PK
time I-PK
greater O
than O
in O
control O
cats O
( O
2 O
. O
8 O
+ O
- O
0 O
. O
6 O
vs O
. O
14 O
. O
1 O
+ O
- O
6 O
. O
5 O
m O
##l O
. O
kg O
- O
1 O
. O
min O
- O
1 O
and O
33 O
##4 O
+ O
- O
225 O
vs O
. O
49 O
+ O
- O
29 O
min O
, O
mean O
+ O
- O
s O
##d O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
dig O
##ox O
##in O
solution O
was O
s O
##p O
##rinkled O
directly O
over O
the O
surface O
of O
the O
duo O
##den O
##um O
using O
an O
end O
##os O
##cope O
, O
and O
its O
absorption B-PK
rate I-PK
was O
evaluated O
by O
serial O
monitoring O
of O
the O
serum O
concentration O
and O
by O
analysis O
of O
its O
initial O
15 O
- O
min O
increasing O
phase O
. O
[SEP] O
[CLS] O
au B-PK
##cs I-PK
( I-PK
area I-PK
under I-PK
the I-PK
drug I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
) I-PK
were O
34 O
##6 O
to O
89 O
##6 O
micro O
##gram O
##s O
. O
min O
/ O
m O
##l O
and O
they O
were O
the O
equivalent O
of O
in O
v O
##it O
##ro O
cell O
kills O
in O
excess O
of O
3 O
logs O
for O
rat O
9 O
##l O
g O
##lio O
##sar O
##com O
##a O
and O
human O
g O
##lio O
##ma O
126 O
cells O
. O
[SEP] O
[CLS] O
ben O
##az O
##ep O
##ril O
##at O
concentrations O
accumulated O
moderately O
with O
repeated O
administration O
, O
with O
a O
peak B-PK
concentration I-PK
that O
was O
23 O
% O
higher O
and O
an O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
that O
was O
34 O
% O
higher O
after O
the O
15th O
dose O
of O
ben O
##az O
##ep O
##ril O
, O
compared O
with O
values O
after O
a O
single O
dose O
. O
[SEP] O
[CLS] O
the O
initial O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##1 I-PK
) I-PK
correspond O
##ed O
to O
the O
vascular O
compartment O
whereas O
the O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
( I-PK
vs I-PK
##s I-PK
) I-PK
was O
somewhat O
larger O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
were O
half O
of O
these O
values O
after O
administration O
of O
250 O
mg O
. O
[SEP] O
[CLS] O
the O
primary O
objective O
of O
the O
study O
was O
to O
estimate O
the O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
for O
it O
##rac O
##ona O
##zo O
##le O
and O
h O
##ydro O
##xy O
- O
it O
##rac O
##ona O
##zo O
##le O
, O
in O
particular O
, O
the O
relative B-PK
oral I-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
capsule O
compared O
with O
solution O
in O
adult O
c O
##ys O
##tic O
fi O
##bro O
##sis O
patients O
, O
in O
order O
to O
develop O
new O
dos O
##ing O
guidelines O
. O
[SEP] O
[CLS] O
comparative O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
two O
z O
##ol O
##pid O
##em O
hem O
##ita O
##rt O
##rate O
formulation O
##s O
in O
healthy O
human O
bra O
##zi O
##lian O
volunteers O
using O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
coupled O
to O
tandem O
mass O
s O
##pect O
##rome O
##try O
. O
[SEP] O
[CLS] O
no O
significant O
difference O
in O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
of O
anti O
##py O
##rine O
was O
observed O
. O
[SEP] O
[CLS] O
in O
##hibition O
of O
pu O
##rom O
##y O
##cin O
- O
induced O
re O
##nal O
injury O
by O
a O
super O
##oxide O
di O
##sm O
##uta O
##se O
derivative O
with O
prolonged O
in O
v O
##ivo O
half B-PK
- I-PK
life I-PK
. O
[SEP] O
[CLS] O
net O
##ih O
##er O
di O
##lt O
##ia O
##ze O
##m O
or O
is O
##oso O
##rb O
##ide O
din O
##it O
##rate O
significantly O
altered O
the O
time B-PK
to I-PK
reach I-PK
maximum I-PK
serum I-PK
dig I-PK
##ox I-PK
##in I-PK
concentration I-PK
. O
[SEP] O
[CLS] O
production O
of O
f O
##b O
##z O
was O
enhanced O
as O
reflected O
by O
increased O
( O
> O
60 O
% O
) O
au B-PK
##c I-PK
, O
delayed O
t B-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
and O
a O
significantly O
delayed O
( O
> O
45 O
% O
) O
elimination O
( O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
( I-PK
el I-PK
) I-PK
) O
. O
[SEP] O
[CLS] O
co O
##list O
##in O
elimination O
is O
not O
limited O
by O
the O
formation O
rate O
because O
its O
half B-PK
- I-PK
life I-PK
( O
3 O
h O
) O
is O
longer O
than O
that O
of O
cm O
##s O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
for O
36 O
##c O
##l O
- O
absorption O
from O
plasma O
was O
19 O
. O
2 O
h O
corresponding O
to O
a O
rate B-PK
constant I-PK
of O
0 O
. O
03 O
##6 O
##1 O
h O
- O
1 O
, O
while O
the O
half B-PK
- I-PK
life I-PK
for O
36 O
##c O
##l O
- O
elimination O
from O
plasma O
was O
51 O
. O
9 O
h O
, O
corresponding O
to O
a O
rate B-PK
constant I-PK
of O
0 O
. O
01 O
##34 O
h O
- O
1 O
. O
[SEP] O
[CLS] O
the O
drug O
was O
immediately O
converted O
to O
di O
##hy O
##dr O
##oar O
##tem O
##isi O
##nin O
( O
d O
##ha O
) O
, O
with O
elimination B-PK
half I-PK
- I-PK
lives I-PK
ranging O
0 O
. O
12 O
- O
0 O
. O
24 O
and O
1 O
. O
15 O
- O
2 O
. O
37 O
hours O
for O
as O
and O
d O
##ha O
, O
respectively O
. O
[SEP] O
[CLS] O
self O
- O
na O
##no O
##em O
##ul O
##si O
##fying O
drug O
delivery O
system O
for O
enhanced O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
improved O
he O
##pa O
##top O
##rote O
##ctive O
activity O
of O
bi O
##phe O
##ny O
##l O
dim O
##eth O
##yl O
di O
##car O
##box O
##yla O
##te O
. O
[SEP] O
[CLS] O
it O
was O
concluded O
that O
delta O
##met O
##hr O
##in O
was O
rapidly O
but O
incomplete O
##ly O
absorbed O
after O
in O
##tra O
##c O
##rop O
administration O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
at O
a O
low O
level O
. O
[SEP] O
[CLS] O
another O
random O
##ized O
, O
open O
, O
three O
- O
way O
crossover O
study O
was O
conducted O
in O
12 O
healthy O
male O
volunteers O
to O
investigate O
the O
effect O
of O
food O
in O
the O
gas O
##tro O
##int O
##est O
##inal O
tract O
on O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
t O
##rov O
##af O
##lo O
##xa O
##cin O
. O
[SEP] O
[CLS] O
the O
valid O
##ated O
method O
has O
been O
successfully O
applied O
to O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
study O
of O
g O
##w O
##9 O
##50 O
##8 O
in O
rat O
plasma O
, O
and O
our O
results O
demonstrated O
that O
g O
##w O
##9 O
##50 O
##8 O
showed O
low O
clearance B-PK
, O
moderate O
half B-PK
- I-PK
life I-PK
and O
ideal O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
( O
54 O
. O
88 O
% O
) O
. O
[SEP] O
[CLS] O
after O
in O
##tra O
##ven O
##ous O
d O
##rip O
in O
##fusion O
for O
60 O
minutes O
, O
tissue O
level O
reached O
to O
the O
maximum O
during O
1 O
. O
01 O
- O
1 O
. O
82 O
hours O
with O
half B-PK
- I-PK
life I-PK
of O
0 O
. O
65 O
- O
1 O
. O
4 O
hours O
and O
au B-PK
##c I-PK
of O
tissue O
concentration O
achieved O
about O
20 O
- O
57 O
% O
of O
that O
of O
u O
##ter O
##ine O
artery O
. O
[SEP] O
[CLS] O
me O
##l O
##pha O
##lan O
au B-PK
##c I-PK
ranged O
from O
4 O
. O
9 O
to O
24 O
. O
6 O
mg O
l O
( O
- O
1 O
) O
h O
, O
median O
12 O
. O
84 O
mg O
l O
( O
- O
1 O
) O
h O
. O
me O
##l O
##pha O
##lan O
au B-PK
##c I-PK
above O
the O
median O
was O
a O
risk O
factor O
for O
severe O
m O
##uc O
##os O
##itis O
( O
h O
##r O
1 O
. O
21 O
, O
95 O
% O
c O
##i O
1 O
. O
06 O
, O
1 O
. O
38 O
, O
p O
= O
0 O
. O
00 O
##4 O
) O
but O
was O
also O
associated O
with O
significantly O
improved O
overall O
survival O
( O
o O
##s O
) O
( O
h O
##r O
0 O
. O
40 O
, O
95 O
% O
c O
##i O
0 O
. O
20 O
, O
0 O
. O
81 O
, O
p O
= O
0 O
. O
00 O
##1 O
) O
, O
with O
an O
estimated O
median O
survival O
of O
8 O
. O
50 O
years O
vs O
. O
5 O
. O
38 O
years O
for O
high O
vs O
. O
low O
au B-PK
##c I-PK
groups O
. O
[SEP] O
[CLS] O
multiple O
re O
##gression O
analysis O
showed O
that O
the O
variables O
with O
the O
greatest O
predict O
##ive O
value O
for O
clearance B-PK
in O
into O
##xi O
##cated O
patients O
were O
age O
and O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
from O
the O
results O
of O
re B-PK
##nal I-PK
clearance I-PK
experiments O
, O
tub O
##ular O
secret O
##ion O
appeared O
to O
be O
the O
predominant O
mechanism O
of O
re O
##nal O
elimination O
for O
these O
three O
drugs O
. O
[SEP] O
[CLS] O
for O
plasma O
total O
cap O
##top O
##ril O
( O
the O
sum O
of O
free O
unchanged O
cap O
##top O
##ril O
and O
its O
di O
##sul O
##fi O
##de O
compounds O
) O
the O
values O
were O
time B-PK
to I-PK
ma I-PK
##ximal I-PK
concentration I-PK
3 O
. O
5 O
+ O
- O
0 O
. O
6 O
h O
and O
ma B-PK
##ximal I-PK
plasma I-PK
concentration I-PK
2 O
, O
77 O
##7 O
+ O
- O
42 O
##9 O
ng O
x O
m O
##l O
- O
1 O
. O
[SEP] O
[CLS] O
the O
p O
##k O
parameters O
were O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
time B-PK
at I-PK
which I-PK
the I-PK
cm I-PK
##ax I-PK
occurred I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
data I-PK
from I-PK
time I-PK
0 I-PK
to I-PK
selected I-PK
time I-PK
point I-PK
( I-PK
t I-PK
) I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
) I-PK
. O
[SEP] O
[CLS] O
because O
of O
an O
influence O
of O
body O
weight O
on O
the O
clearance B-PK
of O
a O
##po O
##a O
- O
i O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
modeling O
of O
the O
phase O
1 O
sad O
study O
data O
predicted O
that O
fixed O
doses O
would O
result O
in O
less O
var O
##iability O
in O
a O
##po O
##a O
- O
i O
exposure O
at O
extreme O
##s O
of O
the O
body O
weight O
range O
. O
19 O
consequently O
, O
fixed O
doses O
of O
c O
##s O
##l O
##11 O
##2 O
were O
used O
in O
the O
phase O
1 O
mad O
and O
phase O
2 O
##a O
studies O
. O
[SEP] O
[CLS] O
throughout O
the O
dose O
range O
in O
the O
current O
study O
and O
throughout O
the O
hours O
after O
in O
##fusion O
, O
a O
similar O
proportion O
of O
the O
in O
##fused O
a O
##po O
##a O
- O
i O
appeared O
as O
pre O
– O
β O
##1 O
- O
h O
##dl O
such O
that O
the O
relationship O
between O
a O
##po O
##a O
- O
i O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
and O
pre O
– O
β O
##1 O
- O
h O
##dl O
area O
under O
the O
effect O
curve O
0 O
to O
24 O
hours O
( O
au O
##ec O
##0 O
– O
24 O
) O
seems O
linear O
( O
figure O
1 O
##d O
) O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
the O
time B-PK
to I-PK
reach I-PK
the I-PK
maximum I-PK
plasma I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
obtained O
from O
the O
plasma O
concentration O
- O
time O
data O
. O
[SEP] O
[CLS] O
a O
and O
b O
: O
g O
– O
a O
plasma O
concentration O
in O
central O
and O
peripheral O
compartment O
, O
respectively O
; O
ka B-PK
: O
apparent B-PK
first I-PK
- I-PK
order I-PK
absorption I-PK
rate I-PK
constant I-PK
; O
k B-PK
##10 I-PK
: O
apparent B-PK
first I-PK
- I-PK
order I-PK
elimination I-PK
rate I-PK
constant I-PK
from I-PK
central I-PK
compartment I-PK
; O
k B-PK
##12 I-PK
: O
apparent B-PK
first I-PK
- I-PK
order I-PK
transfer I-PK
rate I-PK
constant I-PK
from I-PK
central I-PK
compartment I-PK
to I-PK
peripheral I-PK
compartment I-PK
; O
k B-PK
##21 I-PK
: O
apparent B-PK
first I-PK
- I-PK
order I-PK
transfer I-PK
rate I-PK
constant I-PK
from I-PK
peripheral I-PK
compartment I-PK
to I-PK
central I-PK
compartment I-PK
; O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
##ka I-PK
: O
absorption B-PK
half I-PK
time I-PK
; O
α O
and O
β O
: O
empirical O
constant O
##s O
corresponding O
to O
the O
coefficients O
of O
the O
ex O
##ponents O
of O
the O
values O
of O
a O
and O
b O
; O
v B-PK
/ I-PK
f I-PK
: O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
; O
c B-PK
##l I-PK
/ I-PK
f I-PK
: B-PK
apparent I-PK
clearance I-PK
; O
t B-PK
##max I-PK
: O
time B-PK
to I-PK
ma I-PK
##ximal I-PK
concentration I-PK
; O
cm B-PK
##ax I-PK
: O
ma B-PK
##ximal I-PK
concentration I-PK
; O
au B-PK
##c I-PK
##0 I-PK
##→ I-PK
##∞ I-PK
y O
au B-PK
##c I-PK
##0 I-PK
- I-PK
144 I-PK
##0 I-PK
min I-PK
: O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
curve I-PK
from I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
and I-PK
form I-PK
0 I-PK
to I-PK
144 I-PK
##0 I-PK
min I-PK
, O
respectively O
; O
m B-PK
##rt I-PK
: O
mean B-PK
residence I-PK
time I-PK
; O
s O
##s O
: O
sum O
of O
square O
; O
r O
##2 O
: O
correlation O
index O
; O
a O
##ic O
: O
aka O
##ike O
information O
criteria O
; O
s O
##c O
: O
s O
##ch O
##war O
##z O
criterion O
. O
[SEP] O
[CLS] O
however O
, O
the O
difference O
in O
t B-PK
##max I-PK
, O
v B-PK
##d I-PK
, O
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
between O
groups O
did O
not O
reach O
statistical O
significance O
, O
except O
c B-PK
##l I-PK
was O
significantly O
decreased O
to O
58 O
% O
by O
pre O
##tre O
##at O
##ment O
with O
20 O
mg O
/ O
kg O
of O
pipe O
##rine O
. O
[SEP] O
[CLS] O
the O
dose O
- O
dependent O
relationships O
of O
cm B-PK
##ax I-PK
, O
t B-PK
##max I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
are O
depicted O
in O
figure O
4 O
. O
[SEP] O
[CLS] O
in O
the O
control O
group O
given O
pu O
##era O
##rin O
only O
, O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
pu O
##era O
##rin O
in O
our O
study O
was O
partially O
consistent O
with O
the O
result O
of O
ji O
##ang O
et O
al O
. O
[ O
21 O
] O
, O
in O
which O
pu O
##era O
##rin O
also O
displayed O
a O
low O
cm B-PK
##ax I-PK
, O
short O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
and O
high O
c B-PK
##l I-PK
after O
oral O
administration O
. O
[SEP] O
[CLS] O
also O
, O
a O
2 O
- O
to O
4 O
- O
fold O
greater O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
peak I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
was O
observed O
for O
the O
dog O
compared O
to O
the O
other O
species O
as O
listed O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
mouse O
showed O
the O
highest O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
au I-PK
##c I-PK
, O
which O
was O
2 O
- O
fold O
greater O
than O
that O
for O
the O
rabbit O
and O
monkey O
both O
of O
which O
, O
by O
approximation O
showed O
the O
lowest O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
au I-PK
##c I-PK
value O
, O
as O
shown O
in O
table O
2 O
. O
[SEP] O
[CLS] O
the O
skin O
micro O
##dial O
##ys O
##is O
study O
indicated O
p O
##ae O
- O
l O
##c O
##n O
##ps O
have O
good O
trans O
##der O
##mal O
per B-PK
##me I-PK
##ability I-PK
and O
efficacy O
. O
[SEP] O
[CLS] O
modified O
dos O
##age O
formulation O
##s O
commonly O
cause O
flip O
- O
fl O
##op O
; O
however O
, O
formulation O
characteristics O
, O
such O
as O
the O
drugs O
per O
se O
or O
the O
ex O
##ci O
##pie O
##nts O
, O
can O
also O
trigger O
flip O
- O
fl O
##op O
. O
63 O
drugs O
, O
the O
oral O
absorption O
of O
which O
is O
limited O
by O
the O
per B-PK
##me I-PK
##ability I-PK
rate I-PK
, O
are O
most O
likely O
to O
exhibit O
flip O
- O
fl O
##op O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
64 O
thus O
, O
oral O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
would O
be O
expected O
to O
exhibit O
rapid O
onset O
action O
and O
a O
sustained O
therapeutic O
effect O
compared O
with O
i O
##v O
or O
oral O
pm O
##x O
alone O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
of O
a O
##can O
##th O
##op O
##ana O
##x O
sent O
##ico O
##sus O
p O
##oly O
##sa O
##cc O
##hari O
##des O
( O
as O
##ps O
) O
were O
significantly O
reduced O
in O
radiation O
- O
injured O
mice O
, O
suggesting O
that O
the O
blood B-PK
flow I-PK
of O
mouse O
was O
blocked O
or O
slowed O
, O
due O
to O
the O
path O
##ological O
state O
of O
is O
##che O
##mia O
and O
h O
##y O
##pox O
##ia O
, O
which O
are O
caused O
by O
radiation O
. O
[SEP] O
[CLS] O
average B-PK
concentrations I-PK
of O
da O
##ct O
in O
plasma O
, O
and O
to O
a O
greater O
extent O
in O
urine O
, O
were O
sensitive O
to O
v B-PK
##max I-PK
and O
km B-PK
for O
metabolism O
of O
de O
##a O
to O
da O
##ct O
. O
[SEP] O
[CLS] O
in O
general O
, O
the O
average B-PK
concentration I-PK
of O
at O
##z O
and O
its O
meta O
##bol O
##ites O
in O
plasma O
and O
urine O
was O
sensitive O
to O
the O
rate O
constant O
##s O
for O
metabolism O
or O
clearance B-PK
of O
each O
specific O
ch O
##lor O
##ot O
##ria O
##zine O
. O
[SEP] O
[CLS] O
corresponding O
##ly O
, O
the O
model O
‐ O
derived O
mean O
estimate O
of O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
24 I-PK
##h I-PK
at I-PK
steady I-PK
state I-PK
following O
last O
dose O
was O
higher O
in O
children O
compared O
with O
adolescent O
##s O
and O
adults O
( O
table O
4 O
) O
. O
[SEP] O
[CLS] O
in O
study O
part O
5 O
, O
dose O
proportional O
##ity O
for O
up O
##ada O
##ci O
##tin O
##ib O
exposure O
was O
tested O
for O
the O
natural O
log O
##ari O
##th O
##ms O
of O
dose B-PK
‐ I-PK
normal I-PK
##ized I-PK
cm I-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
after O
the O
last O
dose O
on O
day O
7 O
. O
[SEP] O
[CLS] O
the O
proportion O
of O
radio B-PK
##act I-PK
##ivity I-PK
for O
meta O
##bol O
##ite O
vs O
. O
total B-PK
radio I-PK
##act I-PK
##ivity I-PK
in O
the O
plasma O
samples O
was O
estimated O
and O
meta O
##bol O
##ite O
concentrations O
calculated O
and O
expressed O
in O
u O
##g O
e O
##qui O
##v O
/ O
m O
##l O
. O
au B-PK
##c I-PK
values O
for O
the O
meta O
##bol O
##ite O
( O
s O
) O
were O
estimated O
based O
on O
plasma B-PK
radio I-PK
##act I-PK
##ivity I-PK
vs O
. O
time O
data O
. O
[SEP] O
[CLS] O
do O
##ca O
is O
known O
to O
m O
##od O
##ulate O
or O
increase O
in O
##test O
##inal O
para O
##cellular O
per B-PK
##me I-PK
##ability I-PK
via O
e O
##pit O
##hel O
##ial O
growth O
factor O
receptor O
( O
e O
##g O
##f O
##r O
) O
auto O
- O
p O
##hos O
##ph O
##ory O
##lation O
, O
o O
##cc O
##lu O
##din O
de O
##ph O
##os O
##ph O
##ory O
##lation O
, O
and O
rear O
##rang O
##ement O
at O
the O
tight O
junction O
level O
. O
34 O
, O
51 O
it O
was O
also O
reported O
that O
p O
##18 O
##8 O
can O
change O
the O
lateral O
packing O
density O
of O
membrane O
##s O
by O
insertion O
into O
the O
lip O
##id O
layers O
. O
52 O
further O
##more O
, O
na O
##no O
##em O
##ul O
##sions O
en O
##tra O
##pping O
the O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
demonstrated O
a O
significant O
increase O
in O
p B-PK
##ap I-PK
##p I-PK
across O
a O
ca O
##co O
- O
2 O
cell O
mon O
##ola O
##yer O
by O
1 O
. O
15 O
- O
and O
9 O
. O
82 O
- O
fold O
compared O
with O
those O
of O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
and O
free O
pm O
##x O
, O
respectively O
, O
further O
implying O
enhanced O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
me O
##chan O
##istic O
study O
demonstrated O
that O
lab O
##ras O
##ol O
can O
disrupt O
tight O
junction O
##s O
at O
the O
molecular O
level O
, O
including O
the O
loss O
of O
junction O
integrity O
via O
changes O
in O
f O
- O
act O
##in O
ring O
and O
red O
##ist O
##ri O
##but O
##ion O
of O
z O
##on O
##ula O
o O
##cc O
##lude O
##ns O
- O
1 O
( O
z O
##o O
- O
1 O
) O
, O
leading O
them O
to O
act O
as O
potential O
absorption O
enhance O
##rs O
of O
h O
##ydro O
##phi O
##lic O
drugs O
. O
54 O
, O
55 O
based O
on O
the O
results O
of O
the O
in O
v O
##it O
##ro O
artificial O
in O
##test O
##inal O
membrane O
and O
ca O
##co O
- O
2 O
cell O
mon O
##ola O
##yer O
per B-PK
##me I-PK
##ability I-PK
analyses O
, O
further O
experiments O
, O
including O
those O
on O
the O
in O
v O
##ivo O
oral O
absorption O
in O
rats O
and O
tumor O
growth O
suppression O
efficacy O
in O
mice O
, O
were O
carried O
out O
using O
hp O
- O
beta O
- O
c O
##d O
/ O
pm O
##x O
/ O
d O
##ck O
/ O
p O
##18 O
##8 O
- O
ne O
. O
[SEP] O
[CLS] O
in O
male O
subjects O
, O
there O
were O
no O
significant O
changes O
in O
overall O
exposure O
( O
au B-PK
##c I-PK
) O
; O
however O
, O
there O
were O
significant O
increases O
in O
t B-PK
##max I-PK
and O
t B-PK
##½ I-PK
##β I-PK
, O
and O
a O
decrease O
in O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
the O
predicted O
free B-PK
au I-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
level O
was O
more O
sensitive O
to O
changes O
in O
free B-PK
fraction I-PK
levels O
when O
compared O
to O
the O
total B-PK
au I-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
( O
figure O
##6 O
##c O
, O
right O
) O
. O
[SEP] O
[CLS] O
to O
si O
##mu O
##late O
the O
terminal B-PK
clearance I-PK
of O
total B-PK
radio I-PK
##act I-PK
##ivity I-PK
from O
rat O
plasma O
, O
a O
rate O
of O
reaction O
with O
album O
##in O
was O
estimated O
to O
provide O
sufficient O
album O
##in O
- O
bound O
14 O
##c O
- O
at O
##z O
equivalent O
##s O
in O
plasma O
( O
t O
##im O
##chal O
##k O
et O
al O
. O
, O
1990 O
) O
, O
with O
the O
terminal B-PK
clearance I-PK
time I-PK
based O
on O
the O
turnover O
of O
serum O
album O
##in O
in O
rats O
. O
[SEP] O
[CLS] O
as O
expected O
, O
th O
##c O
, O
11 O
‐ O
oh O
‐ O
th O
##c O
, O
and O
11 O
‐ O
co O
##oh O
‐ O
th O
##c O
plasma O
concentrations O
were O
low O
or O
below O
the O
level O
of O
q O
##uant O
##ification O
throughout O
the O
trial O
and O
therefore O
the O
steady O
‐ O
state O
mean O
th O
##c O
exposure O
( O
cm B-PK
##ax I-PK
) O
was O
consistently O
low O
across O
co O
##hor O
##ts O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
c B-PK
##ss I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
and O
c B-PK
##ss I-PK
( I-PK
min I-PK
) I-PK
the O
maximum B-PK
and O
minimum B-PK
plasma I-PK
concentrations I-PK
at I-PK
steady I-PK
state I-PK
were O
calculated O
by O
the O
following O
equation O
by O
sub O
##stituting O
respective O
time O
points O
and O
rate O
constant O
##s O
. O
[SEP] O
[CLS] O
both O
peak O
exposure O
( O
cm B-PK
##ax I-PK
) O
and O
total O
exposure O
( O
au B-PK
##c I-PK
##last I-PK
) O
increased O
with O
increasing O
dose O
from O
0 O
. O
75 O
mg O
to O
9 O
mg O
, O
and O
the O
increases O
appeared O
to O
be O
dose O
proportional O
as O
evidenced O
by O
similar O
dose B-PK
- I-PK
normal I-PK
##ized I-PK
au I-PK
##c I-PK
##last I-PK
and O
cm B-PK
##ax I-PK
across O
all O
doses O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
, O
meant O
the O
targeted O
end O
##point O
for O
optimal O
efficacy O
; O
mi O
##c O
, O
meant O
minimum O
inhibitor O
##y O
concentration O
; O
c B-PK
##l I-PK
, O
meant O
clearance B-PK
per I-PK
day I-PK
; O
f B-PK
##u I-PK
, O
meant O
the O
free B-PK
fraction I-PK
of I-PK
drug I-PK
in I-PK
plasma I-PK
, O
ignoring O
if O
there O
was O
minimal O
binding O
; O
f B-PK
, O
meant O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
the O
radio B-PK
##act I-PK
##ivity I-PK
concentration O
in O
bi O
##le O
at O
0 O
. O
08 O
##3 O
h O
post O
##dos O
##e O
was O
100 O
- O
fold O
higher O
than O
that O
in O
blood O
( O
maximum B-PK
concentration I-PK
[ I-PK
cm I-PK
##ax I-PK
] I-PK
, O
1 O
, O
570 O
ng O
· O
e O
##q O
/ O
m O
##l O
) O
but O
was O
not O
me O
##as O
##urable O
at O
24 O
h O
. O
[SEP] O
[CLS] O
the O
radio B-PK
##act I-PK
##ivity I-PK
concentration O
in O
me O
##as O
##urable O
tissues O
was O
higher O
than O
in O
blood O
( O
cm B-PK
##ax I-PK
= O
125 O
ng O
· O
e O
##q O
/ O
m O
##l O
) O
, O
except O
in O
brain O
, O
spinal O
cord O
, O
and O
eyes O
( O
table O
2 O
and O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
tissue B-PK
- I-PK
to I-PK
- I-PK
blood I-PK
concentration I-PK
ratios I-PK
of O
1 O
. O
37 O
( O
based O
on O
cm B-PK
##ax I-PK
) O
and O
0 O
. O
37 O
( O
based O
on O
au B-PK
##c I-PK
) O
suggested O
moderate O
distribution O
of O
drug O
- O
related O
radio B-PK
##act I-PK
##ivity I-PK
to O
the O
test O
##is O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
the O
concentration O
profiles O
of O
the O
radio B-PK
##act I-PK
##ivity I-PK
of O
o O
##mada O
##cy O
##cline O
in O
blood O
and O
plasma O
were O
analyzed O
using O
win O
##non O
##lin O
and O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
curve I-PK
from I-PK
h I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
) I-PK
, O
and O
the O
terminal B-PK
half I-PK
- I-PK
lives I-PK
were O
estimated O
by O
a O
non O
##com O
##par O
##tment O
##al O
analysis O
. O
[SEP] O
[CLS] O
the O
fraction O
or O
percentage O
of O
the O
dose O
absorbed O
was O
calculated O
based O
on O
blood B-PK
or O
plasma B-PK
radio I-PK
##act I-PK
##ivity I-PK
data O
, O
assuming O
a O
proportional O
relationship O
between O
au B-PK
##c I-PK
and O
dose O
. O
[SEP] O
[CLS] O
next O
, O
as O
seen O
in O
fi O
##g O
. O
2d O
– O
f O
, O
i O
. O
p O
. O
injection O
of O
p O
##eg O
- O
t O
##ms O
- O
coated O
m O
##s O
##ns O
shows O
a O
pu O
##nc O
##tate O
bio O
##dis O
##tribution O
pattern O
throughout O
the O
abdomen O
at O
the O
initial O
time O
point O
of O
30 O
min O
that O
seems O
to O
map O
the O
abdominal O
l O
##ymph O
c O
##ir O
##cula O
##tory O
network O
##29 O
, O
with O
media O
##st O
##inal O
l O
##ymph O
nodes O
in O
the O
th O
##orax O
( O
see O
r O
##oi O
map O
fi O
##g O
. O
1 O
##c O
) O
being O
an O
important O
site O
of O
radio B-PK
##act I-PK
##ivity I-PK
( O
see O
fi O
##gs O
. O
2d O
– O
f O
, O
3 O
##b O
) O
. O
[SEP] O
[CLS] O
given O
that O
the O
i O
. O
v O
. O
injected O
m O
##s O
##ns O
are O
100 O
% O
bio O
##ava O
##ila O
##ble O
, O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
fraction I-PK
( O
calculated O
as O
the O
ratio O
of O
dose B-PK
normal I-PK
##ized I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
of O
i O
. O
p O
. O
to O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
of O
i O
. O
v O
. O
) O
of O
i O
. O
p O
. O
administered O
t O
##ms O
##25 O
, O
t O
##ms O
##50 O
, O
and O
t O
##ms O
##15 O
##0 O
m O
##s O
##ns O
is O
72 O
. O
8 O
, O
66 O
. O
6 O
, O
and O
79 O
. O
6 O
% O
, O
respectively O
, O
thus O
q O
##uant O
##ifying O
the O
incomplete O
absorption O
of O
m O
##s O
##ns O
from O
the O
per O
##ito O
##nea O
##l O
cavity O
into O
blood O
. O
[SEP] O
[CLS] O
for O
the O
p O
##ei O
##50 O
m O
##s O
##ns O
with O
surface O
- O
exposed O
am O
##ines O
, O
s O
##ple O
##en O
and O
liver O
are O
the O
prime O
sites O
of O
radio B-PK
##act I-PK
##ivity I-PK
, O
unlike O
the O
size O
- O
matched O
and O
z O
##eta O
potential O
- O
matched O
counterpart O
, O
q O
##a O
##50 O
, O
with O
o O
##bs O
##truct O
##ed O
am O
##ines O
( O
see O
fi O
##gs O
. O
3 O
##a O
, O
5 O
##e O
, O
f O
) O
. O
[SEP] O
[CLS] O
the O
presence O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
the O
u O
##rina O
##ry O
bladder O
r O
##oi O
indicates O
that O
some O
111 O
##in O
- O
d O
##t O
##pa O
is O
reaching O
the O
bladder O
( O
fi O
##gs O
. O
2 O
, O
3 O
, O
6 O
##b O
, O
e O
) O
. O
[SEP] O
[CLS] O
the O
effective B-PK
per I-PK
##me I-PK
##ability I-PK
coefficient I-PK
( I-PK
p I-PK
##ef I-PK
##f I-PK
) I-PK
was O
calculated O
with O
the O
following O
equation O
: O
p O
##ef O
##f O
= O
q O
##2 O
##π O
##rl O
##ln O
##co O
##ut O
##cin O
##where O
q O
represents O
the O
flow O
rate O
( O
0 O
. O
2 O
m O
##l O
/ O
min O
) O
, O
r O
and O
l O
denote O
the O
radius O
and O
length O
of O
the O
per O
##fused O
in O
##test O
##inal O
segment O
( O
cm O
) O
, O
c O
##in O
and O
co O
##ut O
are O
the O
inlet O
and O
outlet O
concentration O
of O
r O
##x O
##f O
, O
respectively O
. O
[SEP] O
[CLS] O
weight O
, O
height O
, O
and O
many O
physiological O
parameters O
, O
such O
as O
organ O
volumes O
, O
blood B-PK
flow I-PK
rates I-PK
, O
and O
gas O
##tro O
##int O
##est O
##inal O
characteristics O
, O
were O
varied O
according O
to O
published O
data O
##7 O
as O
implemented O
into O
the O
software O
. O
9 O
in O
addition O
to O
the O
var O
##iability O
in O
drug O
p O
##k O
that O
results O
from O
these O
physiological O
differences O
within O
the O
virtual O
populations O
, O
the O
expression O
levels O
of O
the O
implemented O
drug O
meta O
##bol O
##izing O
enzymes O
, O
transport O
##ers O
, O
and O
protein O
binding O
partners O
were O
varied O
around O
their O
reference O
values O
. O
[SEP] O
[CLS] O
to O
minimize O
an O
##eus O
##omy O
at O
the O
reference O
lo O
##ci O
, O
the O
reference O
lo O
##cus O
( O
r O
##pp O
##30 O
, O
c O
. O
16 O
_ O
c O
. O
77 O
, O
ch O
##r O
##10 O
##q O
##23 O
) O
was O
inter O
##rogate O
##d O
against O
two O
additional O
reference O
lo O
##ci O
( O
a O
##p O
##3 O
##b O
##1 O
, O
c O
. O
257 O
##8 O
– O
236 O
##0 O
##5 O
_ O
c O
. O
257 O
##8 O
_ O
235 O
##43 O
, O
ch O
##r O
##5 O
##q O
##14 O
; O
n O
##fa O
##t O
##5 O
, O
c O
. O
32 O
##7 O
_ O
c O
. O
395 O
, O
ch O
##r O
##16 O
##q O
##22 O
) O
such O
that O
each O
target O
lo O
##cus O
was O
normal O
##ized O
to O
the O
average B-PK
concentration I-PK
of O
the O
three O
reference O
lo O
##ci O
. O
[SEP] O
[CLS] O
drug O
- O
related O
radio B-PK
##act I-PK
##ivity I-PK
after O
a O
90 O
mg O
/ O
kg O
oral O
dose O
of O
14 O
##c O
- O
o O
##mada O
##cy O
##cline O
showed O
a O
low O
distribution O
to O
the O
central O
nervous O
system O
( O
brain O
and O
spinal O
cord O
) O
, O
since O
the O
concentrations O
were O
low O
( O
< O
80 O
ng O
· O
e O
##q O
/ O
g O
) O
and O
< O
ll O
##o O
##q O
for O
most O
time O
points O
, O
although O
the O
tissue B-PK
- I-PK
to I-PK
- I-PK
blood I-PK
concentration I-PK
ratios I-PK
were O
0 O
. O
62 O
( O
based O
on O
cm B-PK
##ax I-PK
) O
and O
[UNK] O
. O
19 O
( O
based O
on O
au B-PK
##c I-PK
) O
. O
[SEP] O
[CLS] O
the O
profile O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
each O
el O
##uted O
sample O
was O
obtained O
using O
a O
berth O
##old O
t O
##l O
##c O
linear O
analyze O
##r O
( O
model O
lb O
##28 O
##42 O
and O
lb O
##28 O
##32 O
; O
labor O
##ator O
##ium O
pro O
##f O
. O
d O
##r O
. O
berth O
##old O
, O
wild O
##bad O
, O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
blood O
loss O
volume O
( O
m O
##l O
) O
is O
measured O
in O
the O
surgical O
or O
cell O
- O
save O
##r O
as O
##piration O
bag O
, O
in O
the O
delivery O
bag O
collecting O
v B-PK
##agi I-PK
##nal I-PK
blood I-PK
flow I-PK
during O
c O
##s O
and O
by O
weighing O
d O
##rap O
##es O
and O
pads O
( O
conversion O
factor O
for O
blood O
density O
= O
1 O
. O
06 O
) O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
##0 I-PK
– I-PK
4 I-PK
( O
exposure O
before O
t B-PK
##max I-PK
for O
intact O
h O
##ydro O
##co O
##don O
##e O
er O
) O
was O
57 O
% O
lower O
for O
finely O
crushed O
h O
##ydro O
##co O
##don O
##e O
er O
than O
for O
h O
##ydro O
##co O
##don O
##e O
i O
##r O
. O
[SEP] O
[CLS] O
the O
study O
aims O
to O
determine O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
the O
le O
##vo O
##f O
##lo O
##xa O
##cin O
serum O
concentration O
in O
the O
24 O
hours O
after O
dos O
##ing O
divided O
by O
the O
minimal O
inhibitor O
##y O
concentration O
of O
the O
patient O
’ O
s O
my O
##co O
##ba O
##cter O
##ium O
tuberculosis O
is O
##olate O
that O
in O
##hibit O
##s O
> O
90 O
% O
of O
organisms O
( O
au B-PK
##c I-PK
/ I-PK
mi I-PK
##c I-PK
) O
that O
ma O
##xi O
##mize O
##s O
efficacy O
and O
the O
au B-PK
##c I-PK
that O
ma O
##xi O
##mize O
##s O
safety O
and O
to O
##ler O
##ability O
in O
the O
context O
of O
an O
m O
##dr O
- O
t O
##b O
treatment O
regime O
##n O
. O
[SEP] O
[CLS] O
the O
absorption B-PK
rate I-PK
constant I-PK
( I-PK
ka I-PK
) I-PK
data O
showed O
that O
the O
g O
##c O
##m O
trans O
- O
corn O
##eal O
per B-PK
##me I-PK
##ability I-PK
was O
enhanced O
and O
was O
statistical O
##ly O
significant O
than O
the O
g O
##an O
##ci O
##c O
##lov O
##ir O
solution O
. O
[SEP] O
[CLS] O
steady B-PK
- I-PK
state I-PK
im I-PK
##ati I-PK
##ni I-PK
##b I-PK
t I-PK
##rough I-PK
concentration I-PK
( I-PK
cm I-PK
##in I-PK
) I-PK
values O
in O
18 O
patients O
with O
g O
##ist O
who O
were O
taking O
300 O
mg O
/ O
d O
or O
400 O
mg O
/ O
d O
im O
##ati O
##ni O
##b O
were O
measured O
. O
[SEP] O
[CLS] O
distribution O
of O
im O
cm B-PK
##in I-PK
at I-PK
steady I-PK
state I-PK
for O
300 O
mg O
/ O
d O
and O
400 O
mg O
/ O
d O
are O
displayed O
in O
fi O
##g O
. O
1 O
. O
[SEP] O
[CLS] O
the O
dos O
##ing O
method O
based O
on O
clearance B-PK
values O
obtained O
by O
non O
##me O
##m O
analysis O
allowed O
the O
prediction O
of O
the O
steady B-PK
- I-PK
state I-PK
concentration I-PK
as O
a O
function O
of O
maintenance O
dose O
with O
acceptable O
error O
for O
therapeutic O
drug O
monitoring O
. O
[SEP] O
[CLS] O
greater O
que O
##rc O
##eti O
##n O
absorption O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
may O
be O
associated O
with O
poor O
vitamin O
c O
status O
and O
increased O
in O
##test O
##inal O
per B-PK
##me I-PK
##ability I-PK
in O
healthy O
adults O
. O
[SEP] O
[CLS] O
parameters O
were O
included O
into O
the O
analysis O
if O
they O
have O
been O
op O
##ti O
##mized O
, O
if O
they O
might O
have O
a O
strong O
influence O
due O
to O
calculation O
methods O
used O
in O
the O
model O
( O
e O
. O
g O
. O
, O
lip O
##op O
##hil O
##icit O
##y O
and O
fraction B-PK
un I-PK
##bound I-PK
) O
, O
if O
they O
are O
related O
to O
op O
##ti O
##mized O
parameters O
, O
or O
if O
they O
had O
significant O
impact O
in O
other O
models O
( O
e O
. O
g O
. O
, O
so O
##lub O
##ility O
and O
blood B-PK
/ I-PK
plasma I-PK
concentration I-PK
ratio I-PK
) O
. O
[SEP] O
[CLS] O
standard O
methods O
were O
used O
to O
determine O
the O
log O
of O
o O
##ct O
##ano O
##l O
/ O
water O
partition O
coefficient O
( O
log O
##p O
) O
, O
the O
blood B-PK
‐ I-PK
plasma I-PK
concentration I-PK
ratio I-PK
, O
and O
the O
fraction B-PK
un I-PK
##bound I-PK
in I-PK
plasma I-PK
. O
[SEP] O
[CLS] O
fraction B-PK
##s I-PK
escaping I-PK
gut I-PK
metabolism I-PK
in O
the O
presence O
and O
absence O
of O
inhibitor O
##s O
were O
set O
to O
unity O
for O
c O
##y O
##p O
##2 O
##b O
##6 O
and O
2d O
##6 O
, O
because O
expression O
of O
these O
enzymes O
in O
the O
gas O
##tro O
##int O
##est O
##inal O
tract O
is O
ne O
##gli O
##gible O
, O
36 O
and O
to O
unity O
and O
0 O
. O
57 O
for O
mid O
##az O
##ola O
##m O
in O
line O
with O
the O
prominent O
gut O
expression O
of O
c O
##y O
##p O
##3 O
##a O
. O
37 O
the O
static O
equation O
for O
a O
single O
c O
##y O
##p O
is O
##oz O
##yme O
si O
##mp O
##li O
##fies O
to O
: O
( O
1 O
) O
au O
##c O
′ O
au O
##c O
= O
f O
##gi O
##f O
##g O
##× O
##1 O
##f O
##m O
##cy O
##pi O
##1 O
+ O
i O
/ O
k O
##i O
+ O
1 O
##− O
##f O
##m O
##cy O
##pi O
##where O
[UNK] B-PK
and O
au B-PK
##c I-PK
are O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
time I-PK
curve I-PK
in O
the O
presence O
and O
absence O
of O
the O
inhibitor O
, O
f B-PK
##gi I-PK
and O
f B-PK
##g I-PK
are O
the O
fraction B-PK
##s I-PK
escaping I-PK
gut I-PK
metabolism I-PK
in O
the O
presence O
and O
absence O
of O
inhibitor O
, O
[ B-PK
i I-PK
] I-PK
is O
the O
estimated B-PK
un I-PK
##bound I-PK
inhibitor I-PK
concentration I-PK
as O
discussed O
below O
, O
k B-PK
##i I-PK
is O
the O
re B-PK
##versible I-PK
in I-PK
##hibition I-PK
constant I-PK
, O
and O
f B-PK
##m I-PK
##cy I-PK
##pi I-PK
represents O
the O
fraction B-PK
of I-PK
the I-PK
probe I-PK
drug I-PK
meta I-PK
##bol I-PK
##ized I-PK
by O
c O
##y O
##pi O
. O
[SEP] O
[CLS] O
the O
highest O
tissue B-PK
- I-PK
to I-PK
- I-PK
blood I-PK
concentration I-PK
ratios I-PK
( O
t O
/ O
b O
> O
5 O
) O
, O
calculated O
as O
values O
corresponding O
to O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
were O
observed O
in O
bone O
mineral O
, O
harder O
##ian O
g O
##land O
, O
liver O
, O
s O
##ple O
##en O
, O
and O
sa O
##liva O
##ry O
g O
##land O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
though O
the O
initial O
concentration O
and O
tumor B-PK
/ I-PK
blood I-PK
concentration I-PK
ratio I-PK
of O
5 O
- O
f O
##a O
were O
higher O
than O
5 O
- O
f O
##a O
- O
p O
##ae O
, O
a O
high O
elimination B-PK
rate I-PK
of O
5 O
- O
f O
##a O
severely O
limited O
its O
therapeutic O
effect O
in O
clinic O
. O
[SEP] O
[CLS] O
the O
results O
predicted O
e O
##vo O
##fo O
##s O
##fa O
##mi O
##de O
as O
a O
border O
##line O
weak O
inhibitor O
based O
on O
the O
maximum O
inhibitor O
concentration O
with O
a O
ratio O
of O
1 O
. O
32 O
, O
whereas O
the O
calculation O
based O
on O
the O
average B-PK
concentration I-PK
yielded O
an O
au B-PK
##c I-PK
ratio I-PK
of O
1 O
. O
00 O
##2 O
, O
making O
a O
clinical O
##ly O
relevant O
d O
##di O
again O
very O
unlikely O
. O
[SEP] O
[CLS] O
all O
other O
formulation O
##s O
produced O
similar O
exposure O
##s O
between O
11 O
– O
16 O
% O
of O
i O
##v O
and O
90 O
– O
129 O
% O
of O
re O
##ct O
##al O
suspension O
( O
as O
shown O
in O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##24 I-PK
h I-PK
, O
table O
3 O
) O
. O
[SEP] O
[CLS] O
other O
p O
##k O
parameters O
, O
including O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
0 I-PK
##− I-PK
##t I-PK
, O
au B-PK
##c I-PK
##0 I-PK
##− I-PK
##∞ I-PK
, O
clearance B-PK
( I-PK
c I-PK
##l I-PK
/ I-PK
f I-PK
) I-PK
, O
volume B-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##d I-PK
/ I-PK
f I-PK
) I-PK
, O
and O
mean B-PK
residence I-PK
time I-PK
( I-PK
m I-PK
##rt I-PK
) I-PK
, O
were O
calculated O
by O
a O
non O
- O
compartment O
##al O
model O
with O
win O
##non O
##lin O
v O
##6 O
. O
4 O
( O
p O
##har O
##sight O
co O
##rp O
. O
, O
mountain O
view O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
this O
difference O
, O
however O
, O
does O
not O
cause O
variation O
in O
the O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
two O
particles O
as O
indicated O
by O
similar O
values O
of O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
. O
[SEP] O
[CLS] O
since O
she O
##ta O
##2 O
has O
limited O
a O
##que O
##ous O
so O
##lub O
##ility O
, O
which O
may O
contribute O
to O
its O
low O
, O
dose O
- O
dependent O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
we O
compared O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
she O
##ta O
##2 O
with O
respect O
to O
doses O
across O
species O
and O
estimated O
the O
dose O
at O
which O
sat O
##uration O
in O
absorption O
may O
occur O
. O
[SEP] O
[CLS] O
i O
##ov O
was O
considered O
on O
c B-PK
##l I-PK
and O
v B-PK
. O
structural O
model O
selection O
was O
guided O
by O
objective O
function O
value O
( O
of O
##v O
) O
as O
com O
##puted O
by O
non O
##me O
##m O
, O
corresponding O
to O
minus O
twice O
the O
log O
- O
likelihood O
( O
a O
δ O
of O
− O
##3 O
. O
84 O
with O
1 O
degree O
of O
freedom O
, O
ch O
##i O
- O
squared O
distribution O
, O
corresponds O
to O
a O
significance O
level O
of O
p O
= O
0 O
. O
05 O
) O
goodness O
- O
of O
- O
fit O
plots O
and O
physiological O
p O
##laus O
##ibility O
. O
[SEP] O
[CLS] O
g O
##w O
##65 O
##46 O
##5 O
##2 O
was O
a O
potent O
inhibitor O
of O
the O
h O
##t O
##29 O
, O
h O
##ct O
##11 O
##6 O
and O
h O
##n O
##5 O
x O
##eno O
##gra O
##fts O
with O
an O
ed B-PK
##50 I-PK
ranging O
from O
20 O
to O
28 O
mg O
kg O
##− O
##1 O
. O
[SEP] O
[CLS] O
sex O
, O
age O
, O
and O
at O
##a O
status O
were O
tested O
as O
co O
##var O
##iate O
##s O
on O
k B-PK
##out I-PK
and O
k B-PK
. O
at O
##a O
status O
was O
not O
a O
statistical O
##ly O
significant O
co O
##var O
##iate O
for O
either O
k B-PK
##out I-PK
or O
k B-PK
. O
age O
was O
found O
to O
be O
a O
statistical O
##ly O
significant O
co O
##var O
##iate O
explaining O
inter O
##su O
##bject O
var O
##iability O
for O
both O
k B-PK
##out I-PK
( O
3 O
. O
6 O
% O
) O
and O
k B-PK
( O
7 O
. O
6 O
% O
) O
, O
whereas O
sex O
was O
a O
statistical O
##ly O
significant O
co O
##var O
##iate O
explaining O
inter O
##su O
##bject O
var O
##iability O
for O
k B-PK
##out I-PK
( O
11 O
. O
5 O
% O
) O
. O
[SEP] O
[CLS] O
log O
- O
log O
re O
##gression O
analysis O
( O
the O
power O
model O
) O
revealed O
that O
the O
steady B-PK
- I-PK
state I-PK
area I-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
( I-PK
s I-PK
##s I-PK
) I-PK
) I-PK
and O
the O
maximum B-PK
, O
minimum B-PK
, O
and O
average B-PK
concentrations I-PK
at I-PK
steady I-PK
state I-PK
( O
c B-PK
( I-PK
ma I-PK
##x I-PK
, I-PK
s I-PK
##s I-PK
) O
, O
c B-PK
( I-PK
min I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
, O
and O
c B-PK
( I-PK
a I-PK
##v I-PK
##g I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
, O
respectively O
) O
increased O
in O
a O
dose O
- O
proportional O
manner O
over O
the O
300 O
- O
to O
1 O
, O
200 O
- O
mg O
dose O
range O
. O
[SEP] O
[CLS] O
this O
study O
was O
approved O
by O
the O
may O
##o O
foundation O
institutional O
review O
board O
, O
and O
written O
informed O
consent O
was O
obtained O
from O
each O
patient O
prior O
to O
study O
participation O
. O
[SEP] O
[CLS] O
the O
con O
##stan O
##cy O
of O
the O
half B-PK
- I-PK
life I-PK
, O
c B-PK
##l I-PK
, O
and O
vs B-PK
##s I-PK
with O
increasing O
dose O
indicates O
dose O
- O
independent O
disposition O
for O
de O
##x O
##raz O
##ox O
##ane O
. O
[SEP] O
[CLS] O
tore O
##mi O
##fen O
##e O
c O
##it O
##rate O
in O
##hibit O
##ed O
e O
##bo O
##v O
replication O
with O
i B-PK
##c I-PK
##50 I-PK
##s I-PK
ranging O
from O
2 O
. O
1 O
to O
4 O
. O
5 O
μ O
##m O
( O
table O
1 O
) O
, O
and O
c O
##yt O
##oto O
##xi O
##city O
increased O
at O
doses O
of O
10 O
μ O
##m O
and O
above O
in O
the O
72 O
- O
h O
ass O
##ay O
( O
fi O
##g O
3 O
##f O
) O
. O
[SEP] O
[CLS] O
the O
inter O
##patient O
var O
##iability O
, O
however O
, O
supports O
the O
need O
for O
monitoring O
of O
plasma O
ch O
##lora O
##mp O
##hen O
##ico O
##l O
concentrations O
, O
especially O
in O
newborn O
infants O
, O
persons O
with O
liver O
disease O
, O
or O
those O
receiving O
other O
medications O
that O
alter O
ch O
##lora O
##mp O
##hen O
##ico O
##l O
metabolism O
. O
[SEP] O
[CLS] O
non O
- O
toxic O
doses O
in O
4 O
- O
week O
toxicity O
studies O
in O
rats O
are O
> O
or O
= O
3000 O
mg O
/ O
kg O
/ O
d O
and O
500 O
mg O
/ O
kg O
/ O
d O
for O
s O
- O
and O
r O
- O
p O
##azi O
##nac O
##lone O
, O
respectively O
; O
the O
corresponding O
doses O
in O
dogs O
are O
10 O
and O
4 O
mg O
/ O
kg O
/ O
d O
, O
respectively O
. O
[SEP] O
[CLS] O
ch O
##lor O
##o O
##quin O
##e O
( O
c O
##q O
) O
is O
an O
important O
anti O
##mal O
##aria O
##l O
drug O
for O
the O
treatment O
of O
special O
patient O
groups O
and O
as O
a O
com O
##par O
##ator O
for O
pre O
##c O
##lini O
##cal O
testing O
of O
new O
drugs O
. O
[SEP] O
[CLS] O
three O
of O
the O
20 O
patients O
documented O
to O
have O
progressive O
disease O
on O
p O
##ac O
##lit O
##ax O
##el O
alone O
had O
partial O
responses O
when O
high O
- O
dose O
pro O
##ges O
##tero O
##ne O
was O
added O
to O
the O
p O
##ac O
##lit O
##ax O
##el O
regime O
##n O
. O
[SEP] O
[CLS] O
pit O
##falls O
and O
valid O
approaches O
to O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
of O
mean O
concentration O
data O
following O
in O
##tra O
##ven O
##ous O
administration O
. O
[SEP] O
[CLS] O
the O
methods O
were O
also O
applied O
to O
q O
##uant O
##ification O
of O
t O
##ica O
##g O
##rel O
##or O
, O
a O
##r O
- O
c O
##12 O
##4 O
##9 O
##10 O
##x O
##x O
and O
a O
##r O
- O
c O
##13 O
##39 O
##13 O
##x O
##x O
in O
rabbit O
, O
rat O
, O
mouse O
and O
ma O
##rm O
##ose O
##t O
, O
using O
25 O
micro O
##l O
of O
animal O
plasma O
. O
[SEP] O
[CLS] O
ch O
##roma O
##to O
##graphic O
separation O
was O
operated O
on O
an O
ultimate O
##® O
x O
##b O
- O
c O
##18 O
column O
( O
2 O
. O
1 O
× O
50 O
mm O
, O
3 O
. O
5 O
μ O
##m O
, O
we O
##l O
##ch O
) O
with O
a O
flow O
rate O
of O
0 O
. O
400 O
m O
##l O
/ O
min O
, O
using O
a O
gradient O
el O
##ution O
with O
ace O
##ton O
##it O
##ril O
##e O
and O
water O
which O
contained O
2 O
mm O
am O
##mon O
##ium O
ace O
##tate O
and O
0 O
. O
1 O
% O
form O
##ic O
acid O
as O
the O
mobile O
phase O
. O
[SEP] O
[CLS] O
in O
first O
step O
, O
the O
model O
that O
gives O
the O
most O
drop O
of O
objective O
value O
is O
retained O
and O
taken O
forward O
to O
the O
next O
step O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
a O
single O
400 O
mg O
oral O
dose O
of O
fl O
##ero O
##xa O
##cin O
and O
p O
##ef O
##lo O
##xa O
##cin O
were O
evaluated O
in O
ten O
healthy O
male O
volunteers O
in O
a O
random O
##ized O
cross O
- O
over O
study O
. O
[SEP] O
[CLS] O
the O
resulting O
lower O
- O
than O
- O
expected O
magnitude O
of O
systemic O
a O
##z O
##d O
##31 O
##9 O
##9 O
exposure O
in O
cop O
##d O
patients O
was O
positively O
noteworthy O
from O
a O
to O
##ler O
##ability O
perspective O
, O
whereas O
differences O
v O
##is O
- O
a O
- O
v O
##is O
healthy O
ca O
##uca O
##sian O
volunteers O
were O
clinical O
##ly O
of O
minor O
importance O
with O
respect O
to O
the O
healthy O
j O
##apa O
##nese O
men O
and O
patients O
with O
as O
##th O
##ma O
( O
figure O
2 O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
degree O
of O
correlation O
across O
various O
regions O
was O
observed O
to O
vary O
( O
s O
##5 O
fi O
##g O
) O
. O
[SEP] O
[CLS] O
the O
second O
patient O
with O
low O
risk O
, O
stage O
4 O
##s O
ne O
##uro O
##blast O
##oma O
died O
prior O
to O
car O
##bo O
##p O
##lat O
##in O
treatment O
on O
day O
2 O
of O
the O
first O
course O
of O
treatment O
due O
to O
complications O
relating O
to O
t O
##umour O
burden O
. O
[SEP] O
[CLS] O
data O
were O
derived O
from O
a O
phase O
i O
study O
of O
26 O
patients O
receiving O
huh O
##m O
##f O
##g O
##1 O
at O
doses O
ranging O
from O
1 O
to O
16 O
mg O
kg O
##− O
##1 O
. O
[SEP] O
[CLS] O
the O
time O
duration O
at O
which O
the O
the O
##op O
##hyl O
##line O
plasma O
levels O
remain O
higher O
than O
75 O
% O
of O
the O
maximum B-PK
steady I-PK
- I-PK
state I-PK
levels I-PK
, O
following O
12 O
- O
h O
dos O
##ing O
interval O
, O
was O
evaluated O
: O
for O
the O
sustained O
- O
release O
micro O
##en O
##cap O
##sul O
##ated O
formulation O
##s O
this O
time O
duration O
reaches O
100 O
% O
of O
the O
dos O
##ing O
interval O
. O
[SEP] O
[CLS] O
[ O
re O
##ct O
##al O
fluid O
t O
##f O
##v O
] O
for O
predict O
##ing O
re O
##ct O
##al O
tissue O
t O
##f O
##v O
, O
β O
##1 O
, O
t O
##f O
##v O
= O
0 O
. O
63 O
##4 O
( O
± O
##0 O
. O
07 O
##7 O
##7 O
) O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
and O
β O
##0 O
, O
t O
##f O
##v O
= O
− O
##2 O
. O
43 O
( O
± O
##0 O
. O
335 O
) O
. O
[SEP] O
[CLS] O
patients O
for O
whom O
m O
##ri O
scanning O
is O
con O
##tra O
##ind O
##ica O
##ted O
( O
e O
. O
g O
. O
pace O
##maker O
, O
heart O
valve O
replacement O
) O
were O
also O
excluded O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
for O
total B-PK
radio I-PK
##act I-PK
##ivity I-PK
were O
higher O
in O
plasma O
compared O
with O
blood O
. O
[SEP] O
[CLS] O
the O
amount B-PK
of I-PK
total I-PK
radio I-PK
##act I-PK
##ivity I-PK
( I-PK
ng I-PK
##e I-PK
##q I-PK
) I-PK
in O
urine O
and O
f O
##ec O
##es O
was O
determined O
by O
multi O
##p O
##lying O
the O
volume O
or O
weight O
of O
the O
samples O
by O
the O
radio B-PK
##act I-PK
##ivity I-PK
concentration O
. O
[SEP] O
[CLS] O
tissue O
fraction O
##ation O
of O
liver O
, O
19 O
min O
after O
injection O
of O
labeled O
enzyme O
, O
indicated O
that O
the O
radio B-PK
##act I-PK
##ivity I-PK
was O
present O
both O
in O
end O
##oso O
##mes O
and O
in O
l O
##ys O
##oso O
##mes O
, O
suggesting O
up O
##take O
by O
end O
##oc O
##yt O
##osis O
, O
followed O
by O
breakdown O
in O
the O
l O
##ys O
##oso O
##mes O
. O
[SEP] O
[CLS] O
compared O
with O
( O
64 O
) O
cu O
- O
dot O
##a O
- O
r O
##g O
##d O
, O
this O
trace O
##r O
showed O
improved O
in O
v O
##ivo O
kinetic O
##s O
, O
with O
significantly O
reduced O
liver O
up O
##take O
( O
0 O
. O
99 O
+ O
- O
0 O
. O
08 O
% O
id O
/ O
g O
vs O
. O
1 O
. O
73 O
+ O
- O
0 O
. O
39 O
% O
id O
/ O
g O
at O
30 O
min O
after O
injection O
and O
0 O
. O
58 O
+ O
- O
0 O
. O
07 O
% O
id O
/ O
g O
vs O
. O
2 O
. O
57 O
+ O
- O
0 O
. O
49 O
% O
id O
/ O
g O
at O
4 O
h O
after O
injection O
) O
. O
[SEP] O
[CLS] O
the O
distribution O
of O
radio B-PK
##act I-PK
##ivity I-PK
into O
er O
##yt O
##hr O
##ocytes O
averaged O
from O
44 O
to O
36 O
% O
of O
the O
whole O
blood B-PK
radio I-PK
##act I-PK
##ivity I-PK
from O
0 O
. O
25 O
to O
12 O
h O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
on O
day O
1 O
, O
all O
patients O
had O
taken O
let O
##ro O
##zo O
##le O
for O
at O
least O
28 O
days O
and O
had O
steady B-PK
- I-PK
state I-PK
plasma I-PK
concentrations I-PK
. O
[SEP] O
[CLS] O
the O
tumors O
and O
various O
other O
tissues O
were O
removed O
, O
weighed O
, O
and O
assessed O
for O
radio B-PK
##act I-PK
##ivity I-PK
using O
a O
co O
##bra O
auto O
##gam O
##ma O
counter O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
tests O
in O
b O
##al O
##b O
/ O
c O
##j O
mice O
show O
blood O
d O
##t O
##g O
levels O
at O
, O
or O
above O
, O
its O
inhibitor O
##y O
concentration O
##90 O
of O
64 O
ng O
/ O
m O
##l O
for O
56 O
days O
, O
and O
tissue O
d O
##t O
##g O
levels O
for O
28 O
days O
. O
[SEP] O
[CLS] O
mean B-PK
serum I-PK
concentrations I-PK
exceeded O
a O
target O
peak O
of O
32 O
. O
0 O
micro O
##gram O
##s O
/ O
m O
##l O
and O
remained O
above O
an O
estimated O
inhibitor O
##y O
concentration O
of O
8 O
. O
0 O
micro O
##gram O
##s O
/ O
m O
##l O
for O
approximately O
12 O
h O
##r O
. O
[SEP] O
[CLS] O
after O
oral O
administration O
, O
n O
##b O
##d O
c O
##6 O
- O
c O
##era O
##mi O
##de O
rapidly O
rose O
to O
peak B-PK
plasma I-PK
concentrations I-PK
within O
the O
first O
90 O
min O
, O
distributed O
to O
tissues O
, O
and O
remained O
in O
v O
##ivo O
for O
more O
than O
24 O
h O
. O
t O
##iss O
##ular O
levels O
of O
n O
##b O
##d O
c O
##6 O
- O
c O
##era O
##mi O
##de O
from O
high O
to O
low O
were O
associated O
with O
heart O
, O
lung O
, O
c O
##ere O
##bell O
##um O
, O
test O
##icle O
, O
s O
##ple O
##en O
, O
liver O
, O
kidney O
, O
and O
brain O
. O
[SEP] O
[CLS] O
the O
low O
concentrations O
in O
serum O
were O
caused O
by O
more O
rapid O
u O
##rina O
##ry O
ex O
##cre O
##tion O
of O
the O
anti O
##biotic O
, O
with O
rates B-PK
of I-PK
re I-PK
##nal I-PK
clearance I-PK
averaging O
425 O
m O
##l O
/ O
min O
per O
1 O
. O
73 O
m O
##2 O
in O
the O
patients O
with O
c O
##f O
and O
36 O
##2 O
m O
##l O
/ O
min O
per O
1 O
. O
73 O
m O
##2 O
in O
the O
normal O
subjects O
. O
[SEP] O
[CLS] O
est O
##imating O
the O
var O
##iability O
in O
fraction B-PK
absorbed I-PK
as O
a O
paradigm O
for O
informing O
formulation O
development O
in O
early O
clinical O
drug O
development O
. O
[SEP] O
[CLS] O
the O
existence O
of O
one O
or O
two O
half B-PK
- I-PK
lives I-PK
for O
the O
rate B-PK
of I-PK
disappearance I-PK
was O
assessed O
. O
[SEP] O
[CLS] O
geometric O
mean O
( O
g O
##me O
##an O
) O
and O
coefficient O
of O
variation O
( O
c O
##v O
) O
are O
presented O
for O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
t I-PK
) I-PK
, O
au B-PK
##c I-PK
( I-PK
in I-PK
##f I-PK
) I-PK
, O
a B-PK
##i I-PK
_ I-PK
au I-PK
##c I-PK
, O
cm B-PK
##in I-PK
, O
and O
au B-PK
##c I-PK
( I-PK
ta I-PK
##u I-PK
) I-PK
; O
arithmetic O
mean O
and O
standard O
de O
##viation O
( O
s O
##d O
) O
are O
presented O
for O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
; O
and O
median O
and O
range O
are O
presented O
for O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
therefore O
, O
the O
decrease O
in O
dig O
##ox O
##in O
oral B-PK
clearance I-PK
previously O
observed O
in O
ch O
##f O
patients O
receiving O
e O
##pop O
##ros O
##ten O
##ol O
may O
be O
as O
##cribed O
to O
increases O
in O
dig O
##ox O
##in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
secondary O
to O
e O
##pop O
##ros O
##ten O
##ol O
- O
induced O
increases O
in O
q B-PK
##g I-PK
. O
[SEP] O
[CLS] O
during O
the O
continuous O
in O
##fusion O
##s O
, O
plateau B-PK
levels I-PK
of O
i O
##r O
- O
g O
##n O
##r O
##h O
between O
2 O
and O
6 O
h O
were O
34 O
% O
lower O
with O
s O
##c O
delivery O
( O
67 O
. O
5 O
vs O
. O
102 O
. O
4 O
p O
##g O
/ O
m O
##l O
) O
, O
indicating O
i O
##rre O
##versible O
losses O
of O
about O
one O
third O
of O
g O
##n O
##r O
##h O
injected O
s O
##c O
. O
[SEP] O
[CLS] O
to O
allow O
calculation O
of O
cell O
- O
to O
- O
medium O
met O
##f O
concentration O
ratios O
, O
average O
cell O
volume O
was O
determined O
in O
a O
separate O
series O
of O
experiments O
by O
simultaneous O
determination O
of O
cell O
number O
and O
packed O
cell O
volume O
using O
special O
cent O
##ri O
##fu O
##gation O
tubes O
( O
tech O
##no O
plastic O
products O
a O
##g O
, O
t O
##ras O
##ading O
##en O
, O
s O
##witz O
##erland O
) O
. O
[SEP] O
[CLS] O
however O
, O
respond O
##ers O
showed O
lower O
plasma O
concentrations O
of O
the O
parent O
compound O
r O
##is O
as O
well O
as O
lower O
metabolic B-PK
ratios I-PK
r O
##is O
/ O
9 O
- O
oh O
- O
r O
##is O
than O
non O
- O
respond O
##ers O
( O
p O
= O
0 O
. O
01 O
##7 O
and O
p O
= O
0 O
. O
03 O
##4 O
) O
. O
[SEP] O
[CLS] O
below O
500 O
micro O
##gram O
##s O
/ O
kg O
/ O
h O
the O
d O
##s O
and O
c O
##y O
216 O
plateau B-PK
concentrations I-PK
were O
higher O
than O
that O
of O
s O
##h O
while O
above O
this O
dose O
the O
s O
##h O
concentration O
was O
higher O
than O
that O
of O
d O
##s O
and O
c O
##y O
216 O
. O
[SEP] O
[CLS] O
ex B-PK
##cre I-PK
##ted I-PK
amount I-PK
of O
ca O
##de O
in O
urine O
constituted O
about O
1 O
. O
1 O
% O
after O
i O
##v O
in O
##fusion O
and O
4 O
. O
7 O
% O
after O
oral O
c O
##da O
treatment O
. O
[SEP] O
[CLS] O
the O
clearance B-PK
( O
studied O
in O
two O
groups O
) O
of O
org O
94 O
##8 O
##8 O
was O
1 O
. O
28 O
and O
1 O
. O
06 O
m O
##l O
x O
kg O
( O
- O
1 O
) O
x O
min O
( O
- O
1 O
) O
with O
an O
ex B-PK
##cre I-PK
##tion I-PK
fraction I-PK
in I-PK
the I-PK
urine I-PK
of O
51 O
. O
9 O
% O
and O
53 O
. O
5 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
a O
prolonged O
p O
##t O
and O
a O
r O
##iva O
##ro O
##xa O
##ban O
t B-PK
##rough I-PK
level I-PK
greater O
than O
eight O
times O
that O
predicted O
from O
p O
##har O
##ma O
##co O
##kin O
##etic O
modelling O
suggests O
that O
bleeding O
was O
due O
to O
increased O
exposure O
to O
r O
##iva O
##ro O
##xa O
##ban O
, O
probably O
due O
to O
an O
interaction O
with O
r O
##ito O
##na O
##vir O
and O
da O
##run O
##avi O
##r O
. O
[SEP] O
[CLS] O
in O
a O
model O
with O
log O
( O
doses O
per O
week O
) O
and O
log O
( O
au B-PK
##c I-PK
) O
as O
predict O
##ors O
, O
a O
log O
- O
linear O
relationship O
was O
seen O
between O
doses O
per O
week O
and O
t O
##f O
##v O
scalp O
hair O
level O
, O
with O
an O
estimated O
76 O
% O
( O
95 O
% O
c O
##i O
60 O
– O
93 O
% O
, O
p O
< O
0 O
. O
000 O
##1 O
) O
increase O
in O
hair O
level O
per O
2 O
- O
fold O
dose O
increase O
. O
[SEP] O
[CLS] O
the O
difference O
between O
the O
exit O
and O
input O
micro B-PK
##scopic I-PK
rate I-PK
constant I-PK
, I-PK
k I-PK
##12 I-PK
- I-PK
k I-PK
##21 I-PK
, O
was O
much O
larger O
in O
the O
young O
patients O
( O
p O
less O
than O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
the O
t B-PK
##max I-PK
of O
l O
##ume O
##fant O
##rine O
after O
oral O
administration O
was O
found O
to O
be O
in O
the O
range O
of O
2 O
- O
8 O
h O
. O
the O
reason O
for O
longer O
t B-PK
##max I-PK
seems O
to O
be O
the O
low O
a O
##que O
##ous O
so O
##lub O
##ility O
of O
l O
##ume O
##fant O
##rine O
since O
, O
l O
##ume O
##fant O
##rine O
displayed O
high O
per B-PK
##me I-PK
##ability I-PK
in O
the O
in O
- O
sit O
##u O
per B-PK
##me I-PK
##ability I-PK
study O
. O
[SEP] O
[CLS] O
68 O
##ga O
- O
dot O
##a O
- O
j O
##r O
##11 O
demonstrated O
rapid O
tumor O
up O
##take O
, O
high O
tumor B-PK
/ I-PK
background I-PK
ratios I-PK
, O
and O
rapid O
clearance B-PK
from I-PK
blood I-PK
. O
[SEP] O
[CLS] O
more O
detailed O
characteristics O
of O
this O
central O
alpha O
- O
ad O
##ren O
##oc O
##ept O
##or O
emerged O
from O
correlation O
studies O
in O
which O
new O
ed B-PK
##30 I-PK
values O
, O
associated O
with O
brain O
concentrations O
, O
were O
employed O
. O
[SEP] O
[CLS] O
co O
- O
administration O
of O
do O
##lut O
##eg O
##ra O
##vir O
with O
calcium O
carbon O
##ate O
or O
f O
##er O
##rous O
f O
##uma O
##rate O
had O
no O
effect O
on O
t B-PK
##max I-PK
of O
do O
##lut O
##eg O
##ra O
##vir O
( O
tables O
##2 O
and O
3 O
) O
. O
[SEP] O
[CLS] O
this O
analysis O
demonstrates O
the O
influence O
of O
the O
25 O
( O
oh O
) O
d O
reference O
value O
on O
the O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
as O
compared O
to O
oral O
administration O
, O
the O
su O
##pp O
##os O
##itor O
##ies O
produced O
a O
lower O
cm B-PK
##ax I-PK
and O
a O
delayed O
t B-PK
##max I-PK
, O
although O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
values O
were O
comparable O
. O
[SEP] O
[CLS] O
although O
0 O
. O
02 O
μ O
##g O
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
h O
##l O
and O
he O
##x O
##3 O
- O
l O
##h O
without O
the O
f O
##c O
region O
produced O
no O
substantial O
differences O
compared O
with O
the O
p O
##bs O
control O
, O
the O
same O
dose O
of O
he O
##x O
##3 O
- O
s O
##c O
##d O
##b O
- O
f O
##c O
- O
l O
##h O
significantly O
in O
##hibit O
##ed O
tumor O
growth O
in O
the O
s O
##cid O
mice O
( O
fi O
##g O
. O
8 O
##a O
) O
. O
[SEP] O

